<SEC-DOCUMENT>0001628908-23-000066.txt : 20230504
<SEC-HEADER>0001628908-23-000066.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230503194050
ACCESSION NUMBER:		0001628908-23-000066
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		23885954

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evh-20230331.htm
<DESCRIPTION>2022.03.31 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650,d:fd52120b191e4627a33957d67c68bb7f--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:evh="http://www.evolenthealth.com/20230331" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8xLTEtMS0xLTEwMTQyMA_4aa6ccd3-4cdd-4df8-b364-353bb9b0b76f">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8yLTEtMS0xLTEwNzQ0Ng_2775e8b3-6e50-4e38-af89-35bbf58ad361">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8yLTEtMS0xLTEwMTQyMA_f1feabee-cc6f-457a-a508-6d8159b95e54">false</ix:nonNumeric><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8zLTEtMS0xLTEwMTQyMA_c6119b32-91e0-4ff0-8cc8-39e469382477">2023</ix:nonNumeric><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV80LTEtMS0xLTEwMTQyMA_e035653e-2a15-42bd-9269-018553d508a9">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i0bba17d40adb43fc9d9eb09ba5b09080_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTAtMS0xLTEwNjk3MA_f4913bfc-ffb4-4cb0-b941-e38394874176">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i97d627a444fd4d149f0df76b556dd94e_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzItMS0xLTEtMTAxNDIw_efb0c71a-3abf-47e9-8532-0a475b3d4d85">9</ix:nonNumeric><ix:nonNumeric contextRef="i466c6c1cbb854e8f935205d90d504b4c_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzMtMS0xLTEtMTAxNDIw_c79faa51-51a4-4350-aa22-908bfc3bf078">21</ix:nonNumeric><ix:nonNumeric contextRef="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzQtMS0xLTEtMTAxNDIw_fa3f1929-a900-4734-8564-15b587afb36e">33</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i62777b414fb44723a0c931431d49303e_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDgvZnJhZzowZjQyMTRmMTZlODg0MGM1OGY2YWFkMTFmNzE5NmRhOS90ZXh0cmVnaW9uOjBmNDIxNGYxNmU4ODQwYzU4ZjZhYWQxMWY3MTk2ZGE5XzU_c8f90868-fbd9-4079-ae0f-6eafc18c6e24">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4308b13d2bc640e69e002f890872da68_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDgvZnJhZzowZjQyMTRmMTZlODg0MGM1OGY2YWFkMTFmNzE5NmRhOS90ZXh0cmVnaW9uOjBmNDIxNGYxNmU4ODQwYzU4ZjZhYWQxMWY3MTk2ZGE5XzIxNQ_e313e442-aea7-4012-8dd2-892631925b22">.0299135</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30be4b84e14a44928fadafc458cb5341_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i586e945bd60d49af85c5c42ff6511bc0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i86218da0e0884c94a088b193ed670843_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c7d4e62a4284394a63ec249572a7d1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0713ced519f3403194ba9f05d0b0292e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib743093d4bbc48e3a439e1657b566d11_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe93d2e31b3b4fa88abc8e17ae008f01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5cd6129ee464be1b32499eefeff761d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeeef40ff57344688c2de84656eb453b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9533fd157f36404db99df73e24250f17_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f39e0c2d9fa407cbb8bd38448014469_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide84d54410104b30956cb7ff55186ac5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa70195a0a874033a738fa36233fea32_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie506ce36e15348bc8daa8c1498a654d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77787921202e4fd4a18e90bf6cb87279_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8b41829710445a8d0f8c5817b4ec7e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed1265962b049e19122f05090afc707_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5eb55aee214a3a80aef01f773385a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia51a9c1f2e96457cb583435784fd8052_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df13d90a8c0400c9b19908332b563d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8683bc3116734882a3a6f338a1014c96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc2dc21792b4a4bae4ba077682310b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206feaffcac24ac0925bec2bf51079f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bba17d40adb43fc9d9eb09ba5b09080_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08d9338b291434896695b0967309848_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fbb53f36da458fbc7b7873ed9c53ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6afd820b04d04b58818736afa910bd99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecea63a0c33d40c59386cb36be688e7e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b76dfd95d14dbc9e21923faf1da208_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa8e880df0f4903b24f864bf0775ff3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a91ec36aed4015a6db0d978ab3355d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a846169eb64941a21068690d52a346_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1c9f37d4a9429f851ebf21526dc518_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b74bdff81224fc68d9ffbc419dfee68_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233880303bb34668b01e60bdc5f1cdd7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i34ce76b48a87457b99e7d1769a5aba81_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f69dd7282741df87449317463405fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3122c5fc961042ceb6802f6a1d99fef9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439908fc7be2410386d5bb54ff500846_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac3cc30824142c3b94108b50b60df21_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73d5d21a1a04f84babd13954429d25b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa977c28de4e47168b48e484eaede4c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ceb4458b7dc4a2dabf10c867a9c1a99_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2401b901664f83854b39254d8aae8d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06dde47fa30d4c54b76fc7b207080d9b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6712e972d4564a6a96307887c4567b00_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec6af2602a74fb0a0b69b149b991a9a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9ce60f6fab4cdfb829f791deb4e1a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="option_to_renew_lease"><xbrli:measure>evh:option_to_renew_lease</xbrli:measure></xbrli:unit><xbrli:context id="id8cbaa74b6e54164941327e9684444ae_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1713ff2a1e2e4416a51a05040c0a1b30_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08db4cba39da4c2daa8e8a98eec10995_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib604663c86e447178b86e5bd16de84b7_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb9822d76ab401a9b48a8fac6ca541c_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba5e6a382114572af38a8d1b8953795_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id25b028edfec49c187b6bb9961ecf387_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491e48a182e442f98c17a235d12252d7_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9c4ff54b524745a88b135d86bd443b_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1373bcac7934429293088da96849175b_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b6d6c6c553400a9d75350d6fa61da5_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91831d375a0845e7aa4af31f7b290c36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6cc900864834868948a404393a49a85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d6a8162061452483f3aa24db4d62d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6176d6981ea4c9b8d17bb71206e1cc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb36bbcf076422798e36c705ca489a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c51d30ca110417b9bc57ef158154a94_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60e2d87246f4a24b6e2e5c72158629a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if783561a665d46e194893a76d25beb3e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PerformanceSuiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ca0c0c1968494bbc67b02a9e28ff5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PerformanceSuiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef28bce40ea4047a5a04db3de0aadf1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:SpecialtyTechnologyAndServicesSuiteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129cce29425045eabdab581851009e0e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:SpecialtyTechnologyAndServicesSuiteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb47dcc6439a43fa8d4c19f2122b859a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f9f6fc9bd44f3fb6b41939fb533aca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4772da6b737d416fa93667acc7bec0e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:CasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a9c31ea4be40439865dcd7dc02302f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:CasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d627a444fd4d149f0df76b556dd94e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466c6c1cbb854e8f935205d90d504b4c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312025Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1142e9b4f22b41bb9861d40caedc8272_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409e1ed35fec45debbcfcdca8b668bc1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26be0edc14d47eb99b84495e133ece4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b0d3db141e42d9ba27945974ed98be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92fd7517b7e45d8a3a28cf15450d165_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5199740c894c7990588a57d16a827c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4d813436fe64f6cb913aa801cecded5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bfa3c9233e49a3885fdb8cd2d590db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21943cdf8a049d2a24adf36d3b79cd8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f46329635e4437b8068a2610a354f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15da874ddc524d2285a2fb1df7a7623c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if821daf7eb8c4bf3bcdc0fd5e08f4ed1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c753595d7f449f9388ce080153adee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab74d6cb3834527b8ae1fc110c1c9b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896c0f919a744ccdab15d963fb3c518e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909942c4cbc94b759e839fa9b4480c52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54563c905b50494cbe32a703a93fd3fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie224ebe8d58d426cbf7c6760029adacd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1064fdf19264fd6929844695005b91d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5928ba2c6c467daaf522ca8262ec8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3065bc9a90f4c3593d40da7cd173ea0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib551ddbba6244ae19cb603ed8c3a6e65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3f10e694c940868bd2594ab2017b6a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f15675963148d9b7c73a2c1b0ef222_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de16ded6120471a80302f91bbee7b2a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288455705c274ce2a2bd943c0f0704a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f561ad00b584a20ab6ac5a564705e71_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde355312eba4648bb0122ec21bd976e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bf39ef96634f3193ea5f32553d096d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868a181629a048b69538d93b32b52ff9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fae892598234158a4ae8ce37c46d1cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52491c9a83874a978dbed3b6892d4798_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56fee09db1334b68b2b6dbd706c21116_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99257a4824a4d16997f882b92ea6a96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b523dd4c194164ab39eb63ab1206c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b51a2db0824da5929aaac343723403_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia53c692cc90544f49ce6bab9b750a5d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e47ddf7af144c3bb65fd8dfd91cd016_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08da2b7f0d10418aab0845f0fb542546_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1b4ec02a7342fcb85559bcc229e583_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7598f678494d1aab584ad521987519_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff112cad23c4514bbfbb8c0655c94d0_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica07830c52aa4ce3a36a9196d7fd69c8_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f428993e84490da09219c15b871fd2_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>evh:day</xbrli:measure></xbrli:unit><xbrli:context id="i89ea6a7579f0498aaad68c4136be1a8e_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61f8c08dc6542cab575508067f47573_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d005b9b6f94895a2093108ec4023c1_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49c939410944f6892ee284ba7b362a4_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af1d7c94ffa4dfdb1daac49c0bdcc06_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0ccfb937d04787b9a2edcb589528a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c90a6284344462a51488ae0069e122_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie251d99bd74345e1bc9460f66244b376_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657a6cf3c44d4a4082d16bcf0b007b3e_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b77390117574b05b6853a2e6cdfd5a0_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0dbffb9cb44a82b9230fee7cbb2e8e_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09a99b6604145a39f0c6f2102806ba5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7820004852704049885c737ed680c6c8_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6487f01387746f0ba7463b6968f241d_D20220811-20220811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ba4e8ae10c4f378bae69514e2fe2bd_D20220817-20220818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-17</xbrli:startDate><xbrli:endDate>2022-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b149b5c258542fb966a78ac8c73abec_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dba2151c89f438db4f1b097c4343947_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b58c2da78614c1f968d97ed45d71235_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7659a2a5a47648a180caf848566c901e_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12584d85379426290b0c22a08b05259_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab32404962a644bdabfcb08801f645a6_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512e2046bfad40b18b8f73ffbb1a4ded_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be0a365f4f7429497792fd03ebd83c0_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7719930d21144dfb90251ca3af9cdb73_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb00e88f2384aedbcc301007edfb9e1_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16491b7341a141c18afc36d401c76145_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5726574012447b8981b087a4fceaa8e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d2ca0bd32c485ab1c987f756ff7c04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9845ada53344e68b0860c3e9255db86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0e4886fee54c19a088f62ee322a948_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9416432cd74f4712b91100ee7fbc1c94_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3eb67937fde4b28be9e30e00861878f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62777b414fb44723a0c931431d49303e_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4308b13d2bc640e69e002f890872da68_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fb4a8e6dd3437b85cca6d4d9569ea7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id016a79790b94258b28de85b550d8edd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507b0865bc8146928bbcd305853a7801_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2a5beda11b47868eb4cef319a84fbf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>evh:customer</xbrli:measure></xbrli:unit><xbrli:context id="ic0b19710891c484c82d272a4acf72ba5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice83adaf23a14ba0a5a83118b1a20fdb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637797ac467b47efa165f840c0332476_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f7148e093b474dadb164557530b7b8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae61262e7624b0d984871d542365619_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b6b23d17104a8e9b6c457000fbeea2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0832ebff07400ea476f7c58f11cc67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie192bdf6ff324e978b378295e4252596_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f62d774a64e46899704a37239c377c3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29e30cc2b08429d885dd5e19d4d420c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fc6c7947c34d74ac1f466cf78dbd92_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c68de8493844868847bcbb42b75777_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2494b7c3cda44bcb468b99115c25994_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1d9ed997744f43b91313620e282985_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f75598fe1bf467ca300361df6965225_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a9b81f7de640bfa0d4e787de30fe38_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab7706671c44c04b395a1bb53394e0c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88940471cab4b9f9504ec2ef053bed2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847f8c6b7dfb43bf822806907fa80330_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dfbe078bc7f430697d2a7b1b12e6204_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401ab859effb48808de07f4a1e3c6d16_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2add3c8d25f94736a9517cf9293a956c_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cca87e30358452e84669a73df40af76_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87668a6ea647431c972d8f8fa361cf97_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14b7cf7aca4447892720b9d169358bf_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id704c5c418084a8387e935db5922f100_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eba541d136f4310a4704831029d9705_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492d89de66e04f9b8c3db6a93fd81175_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476893462fa74bf58564ab53bd877692_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e4b979a9e74d449368aa622d2794fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a52a2247ce344d0bbdf4224e23b18a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede7c70b83d54696aa5c016fe07b1c1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddcae13946194fcaa1af1a86f752c869_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5af55fd09f6415f8a087fe94b7ac65b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c894fc3e14c4be68a1ebd94daafd420_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb4a2f5fe174475b5ce81a76c55e2b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96c354afa0c4e3c9db694479ca3a37d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d69bebdcc784d5d883a6d0f4540fe50_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70cae9e2b7d4e58b25f32a9c3d73a3b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6a4f64f12d41fc8e3d1bdb59b392cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33450827a3f4e9d919295348407f1bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c41447859d3478b9bf4c5cd97653cc5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9a2f209add49c28eaca381d3e00ea3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d01f3131ee44567b61845961fc57356_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b079f58e6d143e9bf0218c70cddb93a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02f997833034f13959b8d48cf3f413b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bafc71fd6ff4258ba1f07d59a2d2c26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6d740e3f65457ab486cd579e644ba8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c3f6529d1a407f9fb18c47de384547_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie128286c0dfa444dbd95773bf5ec6363_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ec04c66a434196a47081e73befb4d0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d66187bddab45d98d6021e00200a254_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0025cd927a74c64b32ed1f84552d804_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98252e4304374eba80127e9339ac00ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f37596d3fb4fd0b55345096a8d3ec5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea91b69217d4414bf3a0c1862b782c2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbfa8e87ea74767877c1bcb1ba75e70_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7838e8cce0d84e3c96376f68234721cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb07d39ed99e4b5493f3f1a76480c9b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i424e2672ed5c47d6a7f0e6908df8f4fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110024d501a54ed99a65ed852a158dd2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e0bc79b1d147a88d91c60dc1a05426_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35963def0f354878a0aee255acad57ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467 id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ifd52120b191e4627a33957d67c68bb7f_244"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTE_cd4859f7-ed66-47be-a792-a205cc2a3ed3">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTI_30f04c27-03ca-4987-b342-4759e9daf3ef">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIwNw_20d0baa4-168e-43c8-88ef-d260550ec54c">March&#160;31, 2023</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIxNw_489544d9-7cbd-4837-a6c7-20332b5294b5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzM5OQ_60d59b00-7f9d-4b38-8b34-0781eed76217">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzQyOQ_e7990506-02d8-4c94-a1e8-16f9cee7710d">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzAtMS0xLTEtMTAxNDIw_b939b6e8-2732-479b-a03a-d385a57438bd">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzAtOS0xLTEtMTAxNDIw_0d28eddd-a66e-40f2-a291-4699a4e0f109">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtMS0xLTEtMTAxNDIw_8be8640e-a9ae-4d1f-b737-7016377e17b3">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtMy0xLTEtMTAxNDIw_d57e1f25-104f-43ba-a24d-6e929e02d94e">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtNS0xLTEtMTAxNDIw_237bf411-9802-42fa-a6fc-78e2058d7a5a">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtNy0xLTEtMTAxNDIw_c147f930-ad71-45e4-8e9f-da3739c3150b">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtOS0xLTEtMTAxNDIw_adde4619-2509-4886-89cc-c6d8e646e899">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzUzNw_7e6dc651-a78b-481e-96f1-a33a1a14df23">571</ix:nonNumeric>) <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzU0MQ_f09a8210-bc55-41d7-a67b-3923fe2e5200">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMC0xLTEtMTAxNDIw_5d09370e-eb01-488e-8337-6efbc3c2e883">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMS0xLTEtMTAxNDIw_e157f83e-ff42-46bc-87f4-a145738716a5">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMi0xLTEtMTAxNDIw_6bd3c7af-a0c3-49c4-88fd-db75a03f6b51">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzEwNDI_2023c11f-a070-4ee5-ba24-df6049de6e8c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzEzNjQ_728cad44-8721-44f2-ae88-526b0c49eea4">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzE3MzE_0081dff4-3a5a-49c1-802a-a8458c9350fa">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzE4MTI_d38cf7e0-292e-4965-b172-62dc4091cdba">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTM_077b966a-bcaf-4c11-80c4-a7bf415a1f11">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTQ_11b69c76-4437-4739-b896-a64f914d39b4">S</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of April&#160;28, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i30be4b84e14a44928fadafc458cb5341_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIyNDg_f1f7dc4f-8a8a-4f2b-bac2-6456d39c207b">112,667,704</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_268"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_94">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_94">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_94">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_67">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_67">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_91">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_91">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_202">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_202">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_202">48</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_58">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_52">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_52">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_52">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_22">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_250">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_253">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_253">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_253">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_256">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_256">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_256">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_55">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_55">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_55">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_205">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_205">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_205">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_232">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_232">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_232">50</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_247">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifd52120b191e4627a33957d67c68bb7f_247">52</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_13"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to efficiently integrate NIA into our operations; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial information of NIA and the pro forma financial information of NIA may not be indicative of future results or our financial condition; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to terminate certain leases and recognize impairment charges in connection with our repositioning plan;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution of the healthcare regulatory and political framework;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners&#8217; needs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisitions of IPG and NIA, which could divert management resources, result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport to Molina Healthcare, Inc. may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including increasing inflationary pressures and economic and business conditions and the impact thereof on the economy resulting from public health emergencies, epidemics, pandemics or contagious diseases such as the COVID-19 pandemic;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to the failure of any bank in which we deposit our funds, which could reduce the amount of cash we have available to meet our cash commitments and make additional investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships and develop our partner relationships over time;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners could limit or negatively impact our profitability;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets for our services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts in some of our partner and founder contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to managing our offshore operations and cost reduction goals;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation proceedings, government inquiries, reviews, audits or investigations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to legal proceedings related to any alleged infringement, misappropriation or violation of third-party intellectual property rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2025 convertible notes, which, if triggered, could require us to settle the 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interest rate risk under the Credit Agreement and the terms of our Series A Preferred Stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our debt following the NIA acquisition and our ability to meet our obligations; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to service our debt and pay dividends on our Series A Preferred Stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale, including those issuable upon conversion of our Series A Preferred Stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our Series A Preferred Stock has rights, preferences and privileges that are not held by and are preferential to the rights of holders of our Class A common stock, and could in the future substantially dilute the ownership interest of holders of our Class A common stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.  Our Annual Report on Form 10-K for </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the year ended December 31, 2022 (the "2022 Form 10-K") and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.  New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_100"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:342.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzUtMS0xLTEtMTAxNDIw_0ae58ee1-6b72-43bf-bb57-cb6077c9ad01">157,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzUtMy0xLTEtMTAxNDIw_31f62249-1361-4dc5-9031-2db27b147a67">188,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzYtMS0xLTEtMTAxNDIw_af66dfc8-2974-4afa-9afb-6b8d47da6ed7">21,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzYtMy0xLTEtMTAxNDIw_cd328295-5c41-4b57-b413-fc9d02a4a55b">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff">262,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5">254,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe">33,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e">20,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzktMS0xLTEtMTAxNDIw_98be3407-ae4b-45ac-8609-446efdc821c2">475,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzktMy0xLTEtMTAxNDIw_961be97d-765c-4ea5-acd6-cd9e9f9736c9">478,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEwLTEtMS0xLTEwMTQyMA_230fc0ee-ab57-40d7-b85a-f89c80b60830">12,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEwLTMtMS0xLTEwMTQyMA_c492834c-828b-47c1-8b4a-f7d47a6e27a3">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzExLTEtMS0xLTEwMTQyMA_6ea25023-6106-45bc-a5d6-e144847438c3">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzExLTMtMS0xLTEwMTQyMA_a71472fc-c36c-4358-899c-6e8779477f33">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEyLTEtMS0xLTEwMTQyMA_f1cd89b2-1158-4a80-b1b1-565281b750ea">88,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEyLTMtMS0xLTEwMTQyMA_0d52ebad-7a37-4c5f-ac78-30abd8ba7cbb">87,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEzLTEtMS0xLTEwMTQyMA_eb89e978-4ee6-4172-a697-9ff21388b91d">44,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEzLTMtMS0xLTEwMTQyMA_33de2af0-923b-4b32-97d5-e17a595c8a45">49,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE1LTEtMS0xLTEwMTQyMA_22b748da-f149-4d0c-be0a-93f96d7ac243">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE1LTMtMS0xLTEwMTQyMA_b76f7b27-b313-44f5-b213-150cc0bbd9b9">17,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE2LTEtMS0xLTEwMTQyMA_041f315a-260d-4f12-b15c-a6fe24e6a9ae">825,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE2LTMtMS0xLTEwMTQyMA_2e474981-a43b-48c4-8924-93ef542ead86">442,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE3LTEtMS0xLTEwMTQyMA_62363328-560e-4766-99b4-421e62027951">1,117,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE3LTMtMS0xLTEwMTQyMA_55bf6452-cef8-4390-91ae-983f7f36a872">722,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE4LTEtMS0xLTEwMTQyMA_4b59a892-6fcb-4f12-a29c-70a118eb492b">2,589,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE4LTMtMS0xLTEwMTQyMA_87f5e741-8877-4109-bc25-76a36fe276a0">1,817,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754">51,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264">57,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002">170,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f">111,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI0LTEtMS0xLTEwMTQyMA_53f04736-43fd-4492-9d05-f8cdb09d4f94">4,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI0LTMtMS0xLTEwMTQyMA_bb74c89b-6e32-4aac-a991-e7af2c325c4d">7,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI1LTEtMS0xLTEwMTQyMA_f425a488-7acf-4733-ac74-d843d7eecc25">27,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI1LTMtMS0xLTEwMTQyMA_8630d4a2-a1b2-420c-b23a-780cda6ff613">52,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI2LTEtMS0xLTEwMTQyMA_30025483-9966-472a-8819-d4ef91ae48ed">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI2LTMtMS0xLTEwMTQyMA_e441030b-5021-4440-8aa7-1f05ac68d7b1">5,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600">197,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91">199,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI4LTEtMS0xLTEwMTQyMA_99536093-dcf1-4d34-a2ba-4c873f26ec4b">457,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI4LTMtMS0xLTEwMTQyMA_ce1922ea-4bfd-4231-8cde-93b4a4a1786c">433,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI5LTEtMS0xLTEwMTQyMA_f1d84a97-24fc-406d-acfe-4fb056aea6d4">632,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI5LTMtMS0xLTEwMTQyMA_6432778d-84a2-4c97-b11a-7a93085b5cc4">412,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMwLTEtMS0xLTEwMTQyMA_0dc48a0d-6014-4f60-b030-466d47c189ce">4,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMwLTMtMS0xLTEwMTQyMA_7033a92d-948d-48ac-9703-8ccc78c61f77">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMxLTEtMS0xLTEwMTQyMA_fa020a0f-8931-4e56-ba81-732f54bbd356">112,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMxLTMtMS0xLTEwMTQyMA_f7dd4e7f-677f-48aa-b546-930f090f0326">45,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMyLTEtMS0xLTEwMTQyMA_e425345b-20b2-4221-bf62-6c730d11c7ce">54,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMyLTMtMS0xLTEwMTQyMA_7d5222a7-5692-481f-b4d0-6785f1a3ed69">56,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMzLTEtMS0xLTEwMTQyMA_b0a28e0a-ca56-4b42-bf9d-4d75dfb0e266">36,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMzLTMtMS0xLTEwMTQyMA_63b93043-f49e-4325-a0a2-442391f185ed">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM0LTEtMS0xLTEwMTQyMA_4d7d5cba-77e6-4043-b631-c51395630542">1,297,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM0LTMtMS0xLTEwMTQyMA_7b369364-9411-4182-9e67-45aeb765005c">957,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM1LTEtMS0xLTEwMTQyMA_4ac6b262-9e2d-4020-b4c2-476c9402d1f3"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM1LTMtMS0xLTEwMTQyMA_17e12b39-3f58-413e-859f-6235d231db12"></ix:nonFraction></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mezzanine Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4Mjk_f7173833-0de5-4d17-bd8d-8d3d39ac4a6a">0.01</ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4MDA_270d7661-68d3-4e22-a053-bd8fb492eaba">50,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4MTA_095d19b6-824c-451b-8b52-54b3702d969f">175,000</ix:nonFraction> shares issued </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTEtMS0xLTEwODUwNQ_0582c30c-236a-4c76-bace-de9d269b68dd">170,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTMtMS0xLTEwODUwNQ_ccf32bf9-e41c-40b1-9b8c-510cdd842232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzI3_3b9988a2-7d78-4680-a3df-0d684acb9353"><ix:nonFraction unitRef="usdPerShare" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzI3_493b153d-2fbf-4649-b062-7bb768f7d7f5">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzQx_d60955c5-1224-4a0a-b475-77a90465e1ae"><ix:nonFraction unitRef="shares" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzQx_f85ff951-2257-440d-9445-06247304817c">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzYz_e9553c9e-7e63-4434-a4b7-3931d698850e">112,552,160</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0Xzcw_a86bd5a9-96a0-42e5-a263-d41e9ca7d3e0">101,500,558</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTEtMS0xLTEwMTQyMA_06e1e8cd-4281-45bd-9859-a1bd15cbd2e8">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTMtMS0xLTEwMTQyMA_e31caeb1-4005-41ed-9a65-0138c43bd0cd">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTEtMS0xLTEwMTQyMA_72e3cc23-38d5-4aa6-8bef-61261b5a777c">1,768,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTMtMS0xLTEwMTQyMA_c1b0496d-bdba-438b-8206-7779b4f4886c">1,486,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTEtMS0xLTEwMTQyMA_3c2eed9b-e179-4b0e-b255-365842b2437b">1,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTMtMS0xLTEwMTQyMA_2282cef7-cba5-4984-9a7b-b3e0a3bda2a9">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:342.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQwLTEtMS0xLTEwMTQyMA_960cc93d-0c4d-4018-be3a-99a8d8148487">626,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQwLTMtMS0xLTEwMTQyMA_2d9ad05e-1191-4193-a030-28c0bbe46361">606,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmJmZmNhM2RiOWZiMDQ4YzQ4YTc1MzIyMzg5N2UxNmZlXzI5_95e5de47-7cc9-49ee-afec-1675dee2ca55"><ix:nonFraction unitRef="shares" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmJmZmNhM2RiOWZiMDQ4YzQ4YTc1MzIyMzg5N2UxNmZlXzI5_fc0a7f5e-4f9e-4331-a73e-9683e7b08cee">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTEtMS0xLTEwMTQyMA_5e0443cd-7167-4c1c-8c2e-08a2da2bb500">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTMtMS0xLTEwMTQyMA_5437340a-80e7-41de-b60e-f48fa00275d2">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQyLTEtMS0xLTEwMTQyMA_f5f4d2bb-63ec-498a-9fc0-8431ea4e7763">1,121,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQyLTMtMS0xLTEwMTQyMA_df40f00c-6416-4fbf-aaa4-a06163155dbb">859,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, mezzanine equity and shareholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQzLTEtMS0xLTEwMTQyMA_c00f6e3e-24a5-46b6-b4f1-b10f07e5f306">2,589,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQzLTMtMS0xLTEwMTQyMA_a22ac73f-2425-480e-9d54-67f888571a70">1,817,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_103"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.<br/>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(unaudited, in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.00pt"><tr><td style="width:1.0pt"></td><td style="width:353.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558">427,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82">310,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796">219,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443">89,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5">58,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzctNS0xLTEtMTAxNDIw_693105f9-545e-40ed-8d38-6d609dfecb4a">29,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzctNy0xLTEtMTAxNDIw_22886571-b673-46d1-ac0a-95b61388997e">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEwLTUtMS0xLTEwMTQyMA_8b921870-289d-45d1-8096-e941a18cfdb4">8,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEwLTctMS0xLTEwMTQyMA_18366dfe-b679-4138-a696-045808be470b">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzExLTUtMS0xLTEwMTQyMA_1a9745bf-df17-41b2-87df-50382043aba7">438,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzExLTctMS0xLTEwMTQyMA_f79a0491-6dfa-41c8-b1ee-298e66d42418">299,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEyLTUtMS0xLTEwMTQyMA_ef16bc19-7426-4e7f-88c9-0c9f030316e4">10,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEyLTctMS0xLTEwMTQyMA_3a307de1-1381-4352-8798-00f2f317af19">2,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEzLTUtMS0xLTEwMTQyMA_bb849332-f1d6-4489-8e99-de0635015400">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEzLTctMS0xLTEwMTQyMA_d9230620-bb8c-4bc6-ade9-ecf890cc52cc">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE0LTUtMS0xLTEwMTQyMA_72fa3798-20e6-47ea-bc68-69f184d047d2">12,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE0LTctMS0xLTEwMTQyMA_55e4b711-391e-400a-8f84-11e11a5fd921">2,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE2LTUtMS0xLTEwMTQyMA_7db313d3-dd45-432e-b5f2-43e7811f9fb3">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE2LTctMS0xLTEwMTQyMA_47c4835b-eff3-479a-998e-8dba9c55ded7">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE5LTUtMS0xLTEwMTQyMA_63a5d696-b026-40ea-99a7-e4bd98e8f0a7">66,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE5LTctMS0xLTEwMTQyMA_05e009f0-b84e-49a5-86ae-27eea440b5db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIwLTUtMS0xLTEwMTQyMA_33c24bc7-acf1-42a5-9c37-656717798bc4">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIwLTctMS0xLTEwMTQyMA_97bd0e1b-9605-4747-9445-7205a95f28b3">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIxLTUtMS0xLTEwMTQyMA_6fd310d7-99b4-4a2f-b196-d34e6867b75c">88,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIxLTctMS0xLTEwMTQyMA_1e427a4b-1c45-4b7a-9a3c-d1ac9938d8c9">4,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIyLTUtMS0xLTEwMTQyMA_e1d0f425-17ea-4e31-a9bc-43aa2d886304">68,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIyLTctMS0xLTEwMTQyMA_ea243a20-30c1-4852-9ba2-9913729c8950">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before preferred dividends and accretion of Series A Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI2LTUtMS0xLTExNzA2OQ_44040c8c-6374-41dc-a366-6d682edcd60b">19,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI2LTctMS0xLTExNzA2OQ_fd07287e-18e4-4846-a58c-f8ba29abf2e3">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI3LTUtMS0xLTExNzA2OQ_cb6ffde3-f1f6-4c44-ae64-50eac866bd04">6,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI3LTctMS0xLTExNzA2OQ_74f647ad-417a-4207-80a7-103ce0509df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_c24049ed-f3ce-473f-90b1-4c8a63bdcd39"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_c84f3663-43a4-46fd-b1c1-95d6e2698772"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_e7c97b85-bbfe-4c04-b528-64ccc7462a6b"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_e987f5fa-6d07-42e6-9cc0-ba4138bd2c4f">26,258</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_1980d515-ef65-4c46-96a0-5dc3770d0a47"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_47d5cef9-3e2c-4522-b85f-2df07ec3bc4e"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_8185dac2-be1c-4f17-b3b3-c697c41afdbc"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_a50c1c3b-fe74-4cfa-924d-bae05b476b79">5,350</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTUtMS0xLTEwMTQyMA_a832f1ce-4f6e-4c9f-9657-58b10951bada"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTUtMS0xLTEwMTQyMA_b6527866-453d-4e92-a30a-4bf04344a6d7">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTctMS0xLTEwMTQyMA_4e751178-48c2-47e3-bffc-4aaf15ec3888"><ix:nonFraction unitRef="usdPerShare" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTctMS0xLTEwMTQyMA_90d78023-6930-4a04-99c9-2d97279d9b93">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTUtMS0xLTEwMTQyMA_7915880a-0cab-469c-baa5-041030907d3e"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTUtMS0xLTEwMTQyMA_bc51d071-7469-4cf4-8962-c45c089c02f7">107,783</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTctMS0xLTEwMTQyMA_3c84eed5-d87d-45a0-8d09-28bb088d1048"><ix:nonFraction unitRef="shares" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTctMS0xLTEwMTQyMA_6a850953-589b-406d-9a8b-bf62ff764231">89,509</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQyLTUtMS0xLTEwMTQyMA_5db6dd4b-3607-43bf-a6af-6573bb7c998c">26,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQyLTctMS0xLTEwMTQyMA_dcd1ff5a-5cf8-4053-b141-0d8b0155e798">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ0LTUtMS0xLTEwMTQyMA_f9ebf525-dbe2-4715-90c8-965d150b5261">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ0LTctMS0xLTEwMTQyMA_3071b3b0-c0d6-4429-933a-9f9668f8da45">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ1LTUtMS0xLTEwMTQyMA_8a249888-e6a1-42d9-ae7d-d02d01e99b4c">26,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ1LTctMS0xLTEwMTQyMA_42a60789-67d4-49dd-a8ff-9d89a3f3cca4">5,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_271"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mezzanine Equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A <br/>Preferred  Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzQtMS0xLTEtMTA4NTEy_7a320b7d-11a4-4507-b799-5a8227dc80dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzQtMy0xLTEtMTA4NTEy_5f127151-ac6d-46ab-8e6b-1c9d672354c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c7d4e62a4284394a63ec249572a7d1c_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMS0xLTEtMTAxNDIw_dbfb806d-eeb6-4ba9-afb5-3086f8006725">101,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7d4e62a4284394a63ec249572a7d1c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMy0xLTEtMTAxNDIw_9e24ed8f-7c77-4eb5-8500-71f7db573136">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0713ced519f3403194ba9f05d0b0292e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtNS0xLTEtMTAxNDIw_d0811867-4609-404b-b7e2-05fef7858f7d">1,486,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib743093d4bbc48e3a439e1657b566d11_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtNy0xLTEtMTAxNDIw_bfe27a5b-557c-4a93-a600-cc64ed895101">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe93d2e31b3b4fa88abc8e17ae008f01_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtOS0xLTEtMTAxNDIw_ec384391-8969-4f53-bfb0-accfe1a58023">606,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5cd6129ee464be1b32499eefeff761d_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMTEtMS0xLTEwMTQyMA_a457fcc9-b6dd-47a0-a824-98670e24fc91">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMTMtMS0xLTEwMTQyMA_44f83908-1625-40d1-bddc-c6cd85785a3d">859,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzUtNS0xLTEtMTAxNDIw_25242a63-4650-46f8-afd0-98741a04c1c3">10,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzUtMTMtMS0xLTEwMTQyMA_88242190-abd8-40e4-aa0c-4c5b2c1955da">10,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMS0xLTEtMTAxNDIw_4a47eabe-ba26-4b5b-aa63-f52a0bef506f">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMy0xLTEtMTAxNDIw_8ba62ab4-c08e-43d2-aeb1-0d38ddfd8eba">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtNS0xLTEtMTAxNDIw_6c5d1f95-8876-409f-87fb-8c14d050e6c0">1,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMTMtMS0xLTEwMTQyMA_776075a8-8d2c-4f91-9a72-4d662bd9071e">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMS0xLTEtMTAxNDIw_38e6f422-c5ad-470f-a3fa-f6ceec7744c8">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMy0xLTEtMTAxNDIw_09bcdedf-4e26-4d12-b374-24ed4769a9fe">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctNS0xLTEtMTAxNDIw_22b91911-e8b8-46b5-9d4e-de366cbbf164">8,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMTMtMS0xLTEwMTQyMA_32079d2d-1968-44ad-9fe0-03257bd65874">8,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMS0xLTEtMTA0NzA5_86541dcf-a5b6-4168-9cd7-ddfdcf6b8a79">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMy0xLTEtMTA0NzA5_2b79e493-3cb0-4925-b148-4f8d001a3bdc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeeef40ff57344688c2de84656eb453b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtNS0xLTEtMTA0NzA5_c5929e96-469c-4cf9-949c-1cb2d4d0093d">3,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMTMtMS0xLTEwNDcwOQ_b121681f-7621-466b-9309-db30c056d8c2">3,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9533fd157f36404db99df73e24250f17_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMS0xLTEtMTA0NzA5_ea816127-e8e6-44a8-95e4-319849204c06">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9533fd157f36404db99df73e24250f17_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMy0xLTEtMTA0NzA5_7fba5f0f-8919-4e38-b70e-144785ca622f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f39e0c2d9fa407cbb8bd38448014469_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktNS0xLTEtMTA0NzA5_8da4f2de-0eb3-488f-83df-6604b86e0236">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMTMtMS0xLTEwNDcwOQ_52565c71-b3fc-4e01-a927-8e2a6cb3129b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMS0xLTEtMTAxNDIw_25873e80-be32-469f-b6ac-9df68a1555c5">8,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMy0xLTEtMTAxNDIw_ccd6487b-6e6a-4305-8edb-36f3179bd87b">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktNS0xLTEtMTAxNDIw_cb528a68-5977-4a86-9fce-f30c0e37ce86">261,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMTMtMS0xLTEwMTQyMA_da0748cd-ff54-431f-8a48-1a7cb69cb265">261,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTUtMS0xLTEwODg4Nw_d993c809-99e3-4dea-a46b-eaba4f80356d">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTctMS0xLTEwODg4Nw_2dbdf6e3-8248-432c-9244-9248c37aac24">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTktMS0xLTEwODg5NQ_617b9061-183d-4e9d-ad83-5c2dae4fc3b7">27,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTE3LTEtMS0xMDg5MDM_758163f7-3937-42db-9d45-3476de257b57">27,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of series A preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEtMS0xLTEwODc0MQ_4b869289-9ba0-40bb-83c7-9610ae95449a">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTMtMS0xLTEwODc0MQ_623a230b-8f49-4a58-84a5-9f559a443a72">168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide84d54410104b30956cb7ff55186ac5_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEwLTctMS0xLTEwMTQyMA_dec8df6c-1f2f-4e89-b90a-5e817a9da387">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEwLTEzLTEtMS0xMDE0MjA_7a07a9fc-5cff-43d6-b24d-b4708cb26519">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE2LTMtMS0xLTEwODc0MQ_992e3ff3-b103-4840-a240-1f12b9b9caea">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTUtMS0xLTEwMTQyMA_7986d8bb-e84a-47f7-8d97-cc4fe93c5faf">6,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa70195a0a874033a738fa36233fea32_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTktMS0xLTEwMTQyMA_629aba2d-f93e-4cef-8f24-0549c65a31c1">19,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTEzLTEtMS0xMDE0MjA_ab5ed34b-50f5-41a4-a1e9-a748ea6e63e2">26,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:TemporaryEquitySharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE4LTEtMS0xLTEwODUxMg_f7f0db9f-37a4-4746-88e0-66464e1930a5">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE4LTMtMS0xLTEwODUxMg_89894898-b05f-4ee6-a744-463a731b639b">170,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEtMS0xLTEwMTQyMA_e364fe61-63c3-48d1-b391-55fa9a60c8aa">112,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTMtMS0xLTEwMTQyMA_03a73147-7ce7-45d7-8209-977ab9073f6e">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie506ce36e15348bc8daa8c1498a654d1_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTUtMS0xLTEwMTQyMA_48ec4910-1441-4a7c-be27-ef363d008a01">1,768,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77787921202e4fd4a18e90bf6cb87279_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTctMS0xLTEwMTQyMA_35037274-8812-4121-a121-b62c559bcdc8">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d8b41829710445a8d0f8c5817b4ec7e_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTktMS0xLTEwMTQyMA_c92c0df2-61e8-43bc-8bb8-6266795defcc">626,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ed1265962b049e19122f05090afc707_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTExLTEtMS0xMDE0MjA_0d1c8d35-f60c-4011-97b3-f807d354b7a1">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEzLTEtMS0xMDE0MjA_bdd18f38-0427-41ae-b6ff-ceddae1e5552">1,121,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mezzanine Equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A <br/>Preferred  Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd5eb55aee214a3a80aef01f773385a5_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTEtMS0xLTEwMTQyMA_83e6eab5-053f-4641-99e9-aaef19f17d0b">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5eb55aee214a3a80aef01f773385a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTMtMS0xLTEwMTQyMA_bd9de2c6-693b-475a-85e7-27f2d089c38f">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia51a9c1f2e96457cb583435784fd8052_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTUtMS0xLTEwMTQyMA_8a97e151-210c-4b03-8d43-f5c506305bae">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df13d90a8c0400c9b19908332b563d8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTctMS0xLTEwMTQyMA_5eed73d5-bdcd-423f-9903-a111e0bb54b3">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8683bc3116734882a3a6f338a1014c96_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTktMS0xLTEwMTQyMA_4bcfa629-3861-4a07-a820-1e31bdb84400">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cc2dc21792b4a4bae4ba077682310b7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTExLTEtMS0xMDE0MjA_e5f9b29c-2616-453b-bf28-cbea81483c47">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTEzLTEtMS0xMDE0MjA_84a3998d-638c-4967-b498-609fb11510ac">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTAtMS0xLTEwNjk3MA_f4913bfc-ffb4-4cb0-b941-e38394874176">Cumulative-effect adjustment from adoption of ASC 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08d9338b291434896695b0967309848_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTUtMS0xLTEwNjk2Mg_0204cbc3-c65d-4995-9afc-f07aad3ffcf0">106,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fbb53f36da458fbc7b7873ed9c53ee_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTktMS0xLTEwNjk1OQ_a5b62ae0-8d6e-4c1e-af9a-307704002c17">39,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6afd820b04d04b58818736afa910bd99_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEzLTEtMS0xMDY5NTk_929021de-b1f0-41b1-b8e1-b02addeb7e4b">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIxLTUtMS0xLTEwMTQyMA_3fa21b6f-a222-45c3-8268-e6f016e5ef7e">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIxLTEzLTEtMS0xMDE0MjA_8e87cc34-213b-4b47-bae7-93dbb30a1a06">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTEtMS0xLTEwMTQyMA_59edce6f-0835-40da-a29e-003df6ba032b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTUtMS0xLTEwMTQyMA_598c8aaa-a518-4efc-ac9f-331105607f4c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTEzLTEtMS0xMDE0MjA_d2bb9c7c-812f-4569-92e5-1400cd3e83aa">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEtMS0xLTEwMTQyMA_8d95215e-49c1-4f59-97e4-c503cf3c3b5e">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTMtMS0xLTEwMTQyMA_3bd2a98d-92e0-4d50-b4c4-ff0454081023">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTUtMS0xLTEwMTQyMA_c08cbc58-cee0-4425-9719-6bdbe88d8648">4,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEzLTEtMS0xMDE0MjA_ba1ef793-1294-4e66-b9f7-d9fc6388c90f">4,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEtMS0xLTEwNjk1Mg_250cbf5a-b735-4ce4-ba84-a1b23f04993a">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTMtMS0xLTEwNjk1Mg_b1e99d7e-d2de-4acd-a424-200bc92d31f2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTUtMS0xLTEwNjk1Mg_23838839-1887-4a2b-b3e6-10bf15108948">11,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEzLTEtMS0xMDY5NTY_21bd16aa-a768-410b-8e95-f256225bf834">11,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecea63a0c33d40c59386cb36be688e7e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI0LTctMS0xLTEwMTQyMA_f33cad7b-ebf0-494d-b16e-bda93c2570af">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI0LTEzLTEtMS0xMDE0MjA_fd98f9c4-ae63-401f-ba17-112fe3b11b01">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62b76dfd95d14dbc9e21923faf1da208_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI1LTktMS0xLTEwMTQyMA_31c5ba11-61e7-4498-a0a5-a32c75c2caec">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI1LTEzLTEtMS0xMDE0MjA_31321250-90a6-4fc5-a484-d02d9a4f25fb">5,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaa8e880df0f4903b24f864bf0775ff3_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEtMS0xLTEwMTQyMA_cbd084ec-a82d-420b-bf97-c5276f41c446">91,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa8e880df0f4903b24f864bf0775ff3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTMtMS0xLTEwMTQyMA_e1740ad2-ff8e-4fdf-8136-3e41ea1c8d92">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a91ec36aed4015a6db0d978ab3355d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTUtMS0xLTEwMTQyMA_d9a7c0db-a865-43ae-b09a-33ce2c6dfa74">1,224,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65a846169eb64941a21068690d52a346_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTctMS0xLTEwMTQyMA_90fe4d6d-1b9d-40cc-a080-ee7fdd6cfd15">494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1c9f37d4a9429f851ebf21526dc518_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTktMS0xLTEwMTQyMA_57421962-1d72-4bfd-a2b6-1fbd9e896422">592,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b74bdff81224fc68d9ffbc419dfee68_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTExLTEtMS0xMDE0MjA_2924f2e2-9355-42c6-a540-9f02f24c7da9">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEzLTEtMS0xMDE0MjA_a4becc9b-01f9-4244-8a3f-bcf62d6b9143">611,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:524.25pt"><tr><td style="width:1.0pt"></td><td style="width:340.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:87.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:87.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before dividends declared and accretion of Series A preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMtMS0xLTEtMTAxNDIw_9bc8ff97-9536-418a-b6c6-f2824651f272">19,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMtMy0xLTEtMTAxNDIw_5af1dc08-e540-458f-9b74-d0c546e17637">5,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUtMS0xLTEtMTAxNDIw_79c1a2e6-17c1-4ae8-9ace-771d9fbc46e9">8,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUtMy0xLTEtMTAxNDIw_a149716b-0033-404d-9775-b92bac48786f">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzctMS0xLTEtMTAxNDIw_8685fdce-ec4d-49c2-879d-6cb5016992e6">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzctMy0xLTEtMTAxNDIw_f44a150c-5efa-481a-963b-f7abebce4921">596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzgtMS0xLTEtMTAxNDIw_c2717e38-76d0-4dce-b1f0-4ab8000828b1">29,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzgtMy0xLTEtMTAxNDIw_530aa69f-f9e0-43c9-af3e-4505a76c0d1f">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEwLTEtMS0xLTEwMTQyMA_cd14494d-b6c6-497e-b5fa-104c05a24192">10,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEwLTMtMS0xLTEwMTQyMA_8c0820d6-8523-49e4-8a10-4d2bae500dd2">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzExLTEtMS0xLTEwMTQyMA_24cf0f73-5212-418b-bb6a-27557b40269d">68,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzExLTMtMS0xLTEwMTQyMA_449cc689-983e-49fc-b55b-5d75bef35af5">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEyLTEtMS0xLTEwMTQyMA_aff28f70-4ebd-415b-badf-4a0a53454678">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEyLTMtMS0xLTEwMTQyMA_a9bb8ad2-a77b-4cbd-8dcc-1580cfc29374">11,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEzLTEtMS0xLTEwMTQyMA_6b48d56b-6b76-4976-9cd1-3ece46476168">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEzLTMtMS0xLTEwMTQyMA_b36caed3-0b9c-47ef-9b27-83ef90195e61">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE3LTEtMS0xLTEwMTQyMA_3dadab86-95a5-4133-8a17-372ed2c83c6c">66,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE3LTMtMS0xLTEwMTQyMA_9b231d1c-c30b-47ba-8905-032cc8fbd32e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTEtMS0xLTExNDE5OQ_8a76322c-f0cb-42ba-b3f8-b69129089bdc">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTMtMS0xLTExNDE5OQ_84f622f9-6fc6-4385-9322-2f8234a32bac">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE5LTEtMS0xLTExNDM3OA_1af22dcd-5b58-4705-88d7-c018216424cd">4,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE5LTMtMS0xLTExNDM3OA_bd71ec88-4562-4c56-a600-3ca2d1afdc73">1,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash outflows, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTEtMS0xLTEwMTQyMA_707ead46-83a3-4fef-9b20-9fb455cc7c6d">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTMtMS0xLTEwMTQyMA_334af38b-ecd0-434b-812d-c1fe2aee4ebe">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIwLTEtMS0xLTEwMTQyMA_9a500d3c-3f93-4576-9882-88e8e7eefa8e">19,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIwLTMtMS0xLTEwMTQyMA_030f29cb-7c74-4b2e-8cd7-3cb37bc024e6">46,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIxLTEtMS0xLTEwMTQyMA_b431de44-bba1-4388-a7b2-174e0bac2311">13,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIxLTMtMS0xLTEwMTQyMA_1f416b72-7274-4a7e-af00-3a9d53aa9e88">6,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIyLTEtMS0xLTEwMTQyMA_40ae30a1-d64f-4159-8a75-b479463cee3b">1,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIyLTMtMS0xLTEwMTQyMA_d5ab0a38-9414-4c99-b2b1-acb5ec506891">1,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIzLTEtMS0xLTEwMTQyMA_b9f7b014-abe1-417e-a6e4-894629901747">13,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIzLTMtMS0xLTEwMTQyMA_0081636e-465f-4b2d-b064-d8fb1ef6b68f">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI0LTEtMS0xLTEwMTQyMA_b37e87aa-0e4f-4dc7-b8ad-e547f8dfbe92">4,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI0LTMtMS0xLTEwMTQyMA_718075af-9a37-4df6-b028-013fa24477bd">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI1LTEtMS0xLTEwMTQyMA_65a191d8-1c09-4d92-9180-2c3a2f385666">31,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI1LTMtMS0xLTEwMTQyMA_3279b08f-68d9-463b-9341-212aad45f0bb">32,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI2LTEtMS0xLTEwMTQyMA_32fba995-5f90-4905-bf3a-f60da7d2f9fa">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI2LTMtMS0xLTEwMTQyMA_11bf905b-8ee3-41f0-b434-5fb14d22558b">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI3LTEtMS0xLTEwMTQyMA_8080eab5-685a-43c3-9791-330d7a60896a">2,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI3LTMtMS0xLTEwMTQyMA_6aa6d4e0-9b92-41d4-9daa-88dbaf298f0e">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMwLTEtMS0xLTEwMTQyMA_c15b0837-ddb4-40b8-aa93-3494e1c9584d">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMwLTMtMS0xLTEwMTQyMA_5e662702-6b0e-448c-80cc-8101c7ff4344">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMxLTEtMS0xLTEwMTQyMA_174e09de-df66-40dd-9813-76b3c2541f28">7,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMxLTMtMS0xLTEwMTQyMA_fa2f23c6-2d32-486b-9367-411409b3926e">57,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMzLTEtMS0xLTEwMTQyMA_28fcedf9-92dc-41d7-956c-ba05f0660189">386,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMzLTMtMS0xLTEwMTQyMA_37192ba9-480c-448f-b904-1b869a8cde69">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM1LTEtMS0xLTEwMTQyMA_24767e11-9257-4293-901a-26027b680034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM1LTMtMS0xLTEwMTQyMA_44d8b50c-5715-49d5-8d46-a6daa5dd17b1">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM3LTEtMS0xLTEwMTQyMA_788c83c5-b929-4831-bf5a-0c7f4261b9c4">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM3LTMtMS0xLTEwMTQyMA_5e17429c-f22a-47b3-8927-830406c6111a">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQxLTEtMS0xLTEwMTQyMA_efdbfb01-1097-4eb1-8718-85b04fc9a63f">9,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQxLTMtMS0xLTEwMTQyMA_d1d0c8cb-a7e0-4e35-85ae-aa7e4f96a5f8">8,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQzLTEtMS0xLTEwMTQyMA_bc3940da-c954-43e9-9366-11ddd22459d8">394,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQzLTMtMS0xLTEwMTQyMA_91a944e7-0620-46a1-8011-d1e9e9520d1d">16,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ1LTEtMS0xLTEwMTQyMA_73590846-9adf-4b3c-984a-d1e56f20476e">7,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ1LTMtMS0xLTEwMTQyMA_fbe27a92-d45f-4eda-82e2-833726a7806e">34,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ3LTEtMS0xLTEwMTQyMA_924f81fd-1120-417c-9a4a-e6d3d64c21a4">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ3LTMtMS0xLTEwMTQyMA_056d354e-3c9e-461d-83c0-00171c36fc3c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ4LTEtMS0xLTEwMTQyMA_1d689dfc-d4e5-4dc9-8595-64d606cc593e">256,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ4LTMtMS0xLTEwMTQyMA_2cac7a3a-fbca-48fa-9eae-26431b5f64ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTEtMS0xLTExMjEyMA_34f948fd-fb0d-4b66-a459-3ae39d2d2404">37,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTMtMS0xLTExMjEyMA_7e0c3060-d9e7-46ed-a72c-f43ee30e6c66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTEtMS0xLTEwMTQyMA_5d3c2a6b-a1fe-4869-8b8b-cac657626992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTMtMS0xLTEwMTQyMA_c09d038d-1dac-4067-adbf-722f4de9fcb3">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of preferred stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTEtMS0xLTExMTcwOQ_4149beba-8b09-47b1-af8d-8618c90b4498">168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTMtMS0xLTExMTcwOQ_eef8955b-b436-48e3-a1b2-d58e939a5b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of preferred dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTEtMS0xLTExMTcwOQ_a71ea143-aad8-45d8-a753-e34aaa5014dc">3,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTMtMS0xLTExMTcwOQ_f39afb7d-aa30-43dc-acc7-3bbec9ed6818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTEtMS0xLTEwMTQyMA_fe205f34-f986-41a6-8d1a-38f3e9d3428e">12,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTMtMS0xLTEwMTQyMA_a5ec733f-60cd-44b2-81b0-341092f9af86">16,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTEtMS0xLTEwMTQyMA_8b2bead4-37c4-4add-a923-c73e48b10bd9">379,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTMtMS0xLTEwMTQyMA_da9d312b-9641-4295-bc03-ea18a5679b80">51,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUzLTEtMS0xLTEwMTQyMA_16dbe0ab-aa03-4581-932d-cbb03206fc5f">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUzLTMtMS0xLTEwMTQyMA_057aa4a3-d5f1-40f5-9358-139075a2b2df">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU0LTEtMS0xLTEwMTQyMA_62bbb8f0-c088-46a6-b7b3-1c27843e05fb">23,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU0LTMtMS0xLTEwMTQyMA_e3506b0a-fab3-47f7-aa87-39c119630787">92,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:524.25pt"><tr><td style="width:1.0pt"></td><td style="width:340.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:87.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:87.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU1LTEtMS0xLTEwMTQyMA_5aed919c-9524-4818-806a-e4c7a6fb198d">215,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU1LTMtMS0xLTEwMTQyMA_c311332c-e446-4fa1-b1c2-f962be9f2bae">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU2LTEtMS0xLTEwMTQyMA_0796eed9-b53d-4c98-ab49-6fb14bb29cc8">191,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU2LTMtMS0xLTEwMTQyMA_f4a5b4e5-aec4-4536-b3d9-f2d634d413e4">262,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="ifd52120b191e4627a33957d67c68bb7f_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzEwMDk_c9187bdc-c8fb-4fc1-a812-2f141eeec456" continuedAt="icc28ba7b303d48289f8af21663baadb0" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icc28ba7b303d48289f8af21663baadb0" continuedAt="i058f8d5c87644076a2585ffc9b40a70a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports healthcare entities to improve the quality of care delivered for people with complex conditions through proven solutions that make health care simpler and more affordable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made organizational changes, including re-evaluating its reportable segments, as a result of growth in our value-based specialty care business, both organically and through acquisitions. Effective during the three months ended March 31, 2023, the Company changed its reportable segments to reflect changes in the way its chief operating decision maker evaluates the performance of its operations, develops strategy and allocates capital resources. Specifically, the Company collapsed its previous Evolent Health Services and Clinical Solutions segments into <ix:nonFraction unitRef="segment" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzE2NDkyNjc0NDQwODY_711b0d39-bb3e-4dfc-ac70-f4b0f963ceef">one</ix:nonFraction> segment. The Company's historical disclosures have been recast to be consistent with the current presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzQ2Nw_d16bdac6-9ddf-4e05-be7e-1431f0895162">157.5</ix:nonFraction> million. The Company believes it has sufficient liquidity for at least the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i058f8d5c87644076a2585ffc9b40a70a">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTkw_11a031ac-2911-42d6-afdc-b56908f5de2d" continuedAt="iee59c8ab31034a8ba1780e908191720a" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iee59c8ab31034a8ba1780e908191720a" continuedAt="i4b0c672e18fb443e8f31ba5f2eeaea59"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjU5_3cc82259-6da5-4a78-8de0-6b042f829be1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2022 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjIw_5738ccd4-c6f4-4a15-984b-704df6b9203f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4b0c672e18fb443e8f31ba5f2eeaea59" continuedAt="ie886f3df042444a3ab6154034ac88ee7"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzMyOTg1MzQ5MjUxODY_feb2b562-670c-4951-9a19-98968edd0575" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjQ2_f8ceacb0-74ab-4036-832a-a8b3f36eea28" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjM2_64f0e839-6075-4a9f-9602-0ab8bf5da0ce" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjAz_e5d3db7c-7196-4c24-82cb-5ca0616b5b8f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ce76b48a87457b99e7d1769a5aba81_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzItMS0xLTEtMTAxNDIw_b83e924e-5907-42dc-8c92-3b633fb178a6">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f69dd7282741df87449317463405fc_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzItMy0xLTEtMTAxNDIw_7a6dddda-f818-41ae-8d0e-a30554a842e3">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3122c5fc961042ceb6802f6a1d99fef9_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzMtMS0xLTEtMTAxNDIw_833494e2-9f2e-4ab9-b92e-0ebeb908b1e3">10,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439908fc7be2410386d5bb54ff500846_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzMtMy0xLTEtMTAxNDIw_f824eb5e-ef8d-4664-9055-a2969736d979">10,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac3cc30824142c3b94108b50b60df21_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzQtMS0xLTEtMTAxNDIw_83e0627b-9f6a-43dc-8289-da5d5cf72411">21,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73d5d21a1a04f84babd13954429d25b_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzQtMy0xLTEtMTAxNDIw_36d8321f-88fd-4f71-bf89-e91f7e7f2b59">13,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzYtMS0xLTEtMTAxNDIw_83e7f67b-bbe0-4895-ba3b-541014cf5528">34,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzYtMy0xLTEtMTAxNDIw_19883d70-0094-4c76-811f-93347a64df68">26,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzgtMS0xLTEtMTAxNDIw_8c45dac1-4a0c-4080-bffd-c31926f2eff1">21,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzgtMy0xLTEtMTAxNDIw_9cd719a8-85ba-4d91-8004-b294e4073c12">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzktMS0xLTEtMTAxNDIw_7599e53e-2e21-4a03-9d4e-1b8714fbfac6">21,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzktMy0xLTEtMTAxNDIw_27cc590c-155c-422d-8301-4fa6a8a526ce">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzExLTEtMS0xLTEwMTQyMA_e33e3de5-d68d-4f28-9a82-ee06447b0feb">12,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzExLTMtMS0xLTEwMTQyMA_c8b1320e-172b-4330-bc35-b3e7aeab07fb">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzEyLTEtMS0xLTEwMTQyMA_12574e41-2e5b-4c0d-961b-fb1b6e9db3f8">12,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzEyLTMtMS0xLTEwMTQyMA_d72bf05a-8b3c-46ab-9d1a-7deab189bb7b">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjEx_14af6903-277f-48b5-a2e8-8cb79bfaba78" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzItMS0xLTEtMTAxNDIw_84751895-44cd-4a1b-bbe7-d2053eaf40fa">157,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzItMy0xLTEtMTAxNDIw_918175c0-c547-429e-983a-7fc631febbef">210,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzMtMS0xLTEtMTAxNDIw_0a3f12a2-406c-41a3-966d-2b0573b628b0">34,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzMtMy0xLTEtMTAxNDIw_ac0fcde2-55e4-44a0-9204-17c84ae6236a">52,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzQtMS0xLTEtMTAxNDIw_4a34706b-9227-43a5-a4c8-ee599db0da05">191,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzQtMy0xLTEtMTAxNDIw_25155334-72a5-4bdc-8df4-8712a0b8b78e">262,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTg2_def680e1-ec54-4431-ac24-a0affaf7690f" continuedAt="i78e115cd0cf24156ab27ce40ee651dcb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie886f3df042444a3ab6154034ac88ee7" continuedAt="i663b68ce380f43f2b19f4555dee729ac"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78e115cd0cf24156ab27ce40ee651dcb" continuedAt="iadd845a90967460b80c9891712150bf3">determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iadd845a90967460b80c9891712150bf3">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</ix:continuation> See Note 4 for additional discussion regarding business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjMx_17693bb8-be69-41b4-aa8d-375a2348c5e5" continuedAt="i42014561806d4844b899b678748468de" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42014561806d4844b899b678748468de">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</ix:continuation> See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2022.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjM4_8b7904f6-fab9-49f4-9436-ab7a52daf9bd" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjQx_7d8a49fc-d28d-4ede-bfed-8ec017ca6a28" continuedAt="i38ac17e08cde4b38a018689a54c5ef42" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa977c28de4e47168b48e484eaede4c5_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzAtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Mjc1YzhmYTkyZmE3NDFiNGJmOGE3YTQxMzk0ZWFiZTRfNA_479de001-f640-49b9-884a-e62cd6c61ad0">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i4ceb4458b7dc4a2dabf10c867a9c1a99_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzAtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Mjc1YzhmYTkyZmE3NDFiNGJmOGE3YTQxMzk0ZWFiZTRfOQ_f60b383a-fdd7-4466-ae7b-01732767592b">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f2401b901664f83854b39254d8aae8d_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzEtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Yjg2NGM0ODM2ZmFkNDlhZThkNTUxZTZiMTRmMTBiMjZfNA_de56902f-1a35-409a-808f-fdf486f03412">11</ix:nonNumeric> - <ix:nonNumeric contextRef="i06dde47fa30d4c54b76fc7b207080d9b_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzEtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Yjg2NGM0ODM2ZmFkNDlhZThkNTUxZTZiMTRmMTBiMjZfOQ_dccd6556-77ad-4e1f-99ea-3ba7cbedf094">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6712e972d4564a6a96307887c4567b00_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzItMS0xLTEtMTAxNDIw_f6e0bcc0-e2e3-4c0f-8218-3ce3e66e57c0">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idec6af2602a74fb0a0b69b149b991a9a_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzMtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246ZDdmZDU4OTVjMzg3NDgxN2EwMTk4YjVjMTdhNDc0OWJfNA_e599da08-354f-4950-9a9c-fb11876870fe">3</ix:nonNumeric> - <ix:nonNumeric contextRef="ice9ce60f6fab4cdfb829f791deb4e1a1_I20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzMtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246ZDdmZDU4OTVjMzg3NDgxN2EwMTk4YjVjMTdhNDc0OWJfOQ_a36bd4eb-7e4d-47dc-8a5d-7b21064e4e91">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTg3_73aa79c6-deaa-4f6a-8a8c-990eaf0d644a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i663b68ce380f43f2b19f4555dee729ac" continuedAt="i0f146aa2c6374503b99447d9113e3d18"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjE3_a703155d-7bb6-42c9-b4ce-566e11986981" continuedAt="i66a9756dd41944aa855b9674aae7c1d0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i66a9756dd41944aa855b9674aae7c1d0">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</ix:continuation> See Note 19 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjA4_8752622e-d94d-415d-8cf3-fb60ef3a83c1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both March&#160;31, 2023 and December 31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3MzUx_21ca165e-4b73-491e-a4ee-209c0447010b"><ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3MzUx_85d1b0dd-c69e-4875-94f4-83799358c5ff">47</ix:nonFraction></ix:nonFraction>% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2023, approximately <ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3NDk5_d0279784-4469-457c-88c6-80636595136d">20</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjE0_38085c59-1e2d-4297-ba9c-c7c7e0957948" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE4Nzc0_72f74173-0259-49ed-8682-d20851ce83e8">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjU3_c7529ea9-ada5-408e-86bf-43962664bc6c" continuedAt="ibf4ae740f83542ac870dbfe22344634d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 for further discussion of our policies related to revenue recognition. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0f146aa2c6374503b99447d9113e3d18"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE2NDkyNjc0ODUxMjg_ea18ff43-baf9-4f6d-8a8c-d66dd53956d5" continuedAt="iea0e7d65d8dc4afab6b4111c6ce4db26" escape="true">Series A Senior Convertible Preferred Shares</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea0e7d65d8dc4afab6b4111c6ce4db26">In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company&#8217;s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares.</ix:continuation> Refer to Note 12 - Series A Senior Convertible Preferred Shares for further discussion.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzIyNzc_d33bfb64-cb9f-4632-b27c-9ada14da8786" continuedAt="i1d6f5990d0ae4253b8e55686ae5f83ee" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1d6f5990d0ae4253b8e55686ae5f83ee" continuedAt="idd1a7d4dc20e419a8b565387ec0d1817"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzIyNzE_6ac3ba78-3013-4aec-a765-a93559c03dea" continuedAt="i7941de2351414a16bbeb1f37bec696ca" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $<ix:nonFraction unitRef="usd" contextRef="id8cbaa74b6e54164941327e9684444ae_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE0NzE_41a35a57-7207-4151-b3df-014ff9284ed5">39.8</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i1713ff2a1e2e4416a51a05040c0a1b30_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1MTM_ded9b478-9e4c-4964-a00e-2751c054c1bd">106.2</ix:nonFraction>&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $<ix:nonFraction unitRef="usd" contextRef="i08db4cba39da4c2daa8e8a98eec10995_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1ODQ_c2b63661-6270-42d3-b6a1-9f9128344bc3">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib604663c86e447178b86e5bd16de84b7_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1OTE_557612ad-18b1-4266-a726-9c9c31734fb4">41.3</ix:nonFraction>&#160;million, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd1a7d4dc20e419a8b565387ec0d1817"><ix:continuation id="i7941de2351414a16bbeb1f37bec696ca">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzc4OTM_bdb2e00e-cb45-436f-b512-0ca0907b0553" continuedAt="i6806879bd8a7415c824cc0c5fe0b629b" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6806879bd8a7415c824cc0c5fe0b629b" continuedAt="i7ca9e8aaf50546aab0d1309964100783"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Imaging Associates Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, the Company completed its acquisition of NIA, including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (&#8220;Magellan&#8221;) and certain of its subsidiaries that were used in the Magellan Specialty Health Division. NIA is a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI1OTU_937bba63-c36a-4ec2-a62e-02261617a360">715.7</ix:nonFraction>&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on January 20, 2023. The acquisition consideration consisted of approximately $<ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2NTY_68b1e8c9-f743-4b5e-988b-f11659dee93c">387.8</ix:nonFraction>&#160;million of cash consideration (inclusive of certain post-closing adjustments), <ix:nonFraction unitRef="shares" contextRef="i3eb9822d76ab401a9b48a8fac6ca541c_D20230120-20230120" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2Mjc_04e78239-a404-45f4-9e44-ad7f58d85102">8,474,576</ix:nonFraction> shares of the Company&#8217;s Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2MTE_b27ad20e-8626-4cb6-9b3d-b2cd4728769f">261.3</ix:nonFraction>&#160;million as of January 20, 2023, and an earn-out consisting of additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2NDA_b630e97f-074a-45e6-93bd-68ee4d99a605">150.0</ix:nonFraction>&#160;million payable in cash and, at the Company&#8217;s election, up to <ix:nonFraction unitRef="number" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="INF" name="evh:BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE2NDkyNjc0Nzc3Njc_cb223538-42f3-43e6-bcb5-2e1b14b4c0ef">50</ix:nonFraction>% in shares of the Company&#8217;s Class A common stock (the &#8220;Contingent Consideration&#8221;). As of January 20, 2023, the Contingent Consideration is fair valued at $<ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3OTM_0c3dede1-3d72-4a43-bad4-fa2ebc375c23">66.6</ix:nonFraction>&#160;million. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MDkxMTg_0f11c285-b739-4fbe-9ac0-0854445f794c" continuedAt="ia7af765baa464742a6ebc3c1d06767a0" escape="true"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MDkxMTg_0f66f960-d9b0-413d-82e5-79b72a80d40f" continuedAt="ia268e57fddf840dea3dd5d3339c77a9a" escape="true">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ca9e8aaf50546aab0d1309964100783" continuedAt="i2a443932a5894ba4b4acb94581e7984d"><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="ia7af765baa464742a6ebc3c1d06767a0" continuedAt="ifc7867fbd89646c18e9e1b04bf45214f"><ix:continuation id="ia268e57fddf840dea3dd5d3339c77a9a" continuedAt="ib0428e28893641c3b2ddcf487fd6ef8c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEtMS0xLTEtMTA4NTM1_24c5fc2a-4ad3-41e7-9ecf-cd228d9446fe">387,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzItMS0xLTEtMTA4NTM1_4c9bd5ad-7437-4716-a6a3-57be7e98729b">261,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzMtMS0xLTEtMTA4NTM1_bb0da24f-9d25-461f-92e3-ca03cf9af18a">66,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzQtMS0xLTEtMTA4NTM1_2521765d-4924-4529-abf8-088b650fd980">715,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzctMS0xLTEtMTA4NTM1_79e2bfba-82bc-43c3-abd9-636ace18b827">28,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzgtMS0xLTEtMTA4NTM1_0db16dee-da52-43bc-8942-79f604f11dc9">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEwLTEtMS0xLTEwODUzNQ_c68bf3c5-4798-4eeb-8ab1-29efb3ab3a8e">28,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba5e6a382114572af38a8d1b8953795_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEzLTEtMS0xLTEwODUzNQ_3bf5cded-3e35-4f1d-8829-58a53342a47d">345,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE0LTEtMS0xLTEwODUzNQ_5fee0d98-2a92-4071-9fe8-1590c3aae30a">50,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25b028edfec49c187b6bb9961ecf387_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE1LTEtMS0xLTEwODUzNQ_71f395ce-f416-4a10-af30-79335676c6e2">8,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE2LTEtMS0xLTEwODUzNQ_c32f3959-2107-4778-b5be-72b8a8cad4ea">404,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIwLTEtMS0xLTEwODUzNQ_a866b848-e8d7-4651-ab9b-495cc789ee2e">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIxLTEtMS0xLTEwODUzNQ_1921386e-d883-4778-8159-63b709566da8">6,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIyLTEtMS0xLTEwODUzNQ_6e42c3fb-2ada-4b07-a8bc-dcd5dbea8be3">100,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIzLTEtMS0xLTEwODUzNQ_62c529c0-ade0-4b0a-a995-f9c3acbe58f6">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI1LTEtMS0xLTEwODUzNQ_9b3d97ee-d162-441d-be6b-1865af2f9799">112,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI3LTEtMS0xLTEwODUzOA_ea3a9fdb-2219-47d0-bbf9-0bd78e8cc4e5">395,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI4LTEtMS0xLTEwODUzOA_f923162b-7474-4273-8a43-8493b8011da9">715,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="iaba5e6a382114572af38a8d1b8953795_I20230120" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDE_0dad9b5a-359f-4cc9-acc8-fb9beb15dd5e">15</ix:nonNumeric> years, <ix:nonNumeric contextRef="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDA_106c26ca-0a06-4ab7-8d19-29787975587b">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="id25b028edfec49c187b6bb9961ecf387_I20230120" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2OTk_2b641dba-057f-4663-b71c-0fd8dfca05e9">2</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of proprietary software that supports NIA&#8217;s core business applications and specialty business. The corporate trade name reflects the value that we believe the NIA brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is <ix:nonFraction unitRef="usd" contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDY_c4996ebe-fd43-40d5-8ebc-2019e8c04e54">not</ix:nonFraction> deductible for tax purposes. Additionally, a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MjI_b19c6a35-9e94-4f43-b2c9-04973f2b2ee0">56.1</ix:nonFraction>&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2023, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2a443932a5894ba4b4acb94581e7984d" continuedAt="iaa2db7d499f1448aa6c6cea350f47f4f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the financial results of NIA in our consolidated financial statements from January 20, 2023. The consolidated statements of operations and comprehensive income (loss) include $<ix:nonFraction unitRef="usd" contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTgyOTk_d72bf7de-83eb-4780-a4d9-54fec6f7b93c">48.5</ix:nonFraction>&#160;million of revenues and $(<ix:nonFraction unitRef="usd" contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTgzMTQ_8b590d2f-d917-416d-b938-757e515e6a36">5.5</ix:nonFraction>)&#160;million of net loss attributable to NIA for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including <ix:nonFraction unitRef="number" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE1Mg_e0287f2d-2a7e-4d7c-962b-a6b61ca3cf33">100</ix:nonFraction>% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzcxNA_92a206a7-ab67-4de6-a979-7aa9fa001ab6">461.7</ix:nonFraction>&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzg1Nw_99442a7a-a78f-433b-a596-35a6c5861694">256.5</ix:nonFraction>&#160;million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzg4Mw_9a533820-9d6f-4906-8e5d-5b60ed1bac2c">3.7</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzkzMw_edb20e98-2da2-4378-a256-c876d394a507">130.2</ix:nonFraction>&#160;million as of August 1, 2022, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzk4Mw_997c2351-f09b-41f4-9b39-d0c66767998a">87.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwMDI_5246d33f-5bf6-4da4-b4c8-2b34469bea11">75.0</ix:nonFraction>&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><ix:continuation id="ifc7867fbd89646c18e9e1b04bf45214f" continuedAt="if95e107a74bc4ef9a029bbfb652041e6"><ix:continuation id="ib0428e28893641c3b2ddcf487fd6ef8c" continuedAt="i5bc5d406ecd7418cb165a535de65a2a4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEtMS0xLTEtMTAxNDIw_3add17ea-2cf7-4d51-ac08-7b454385beeb">256,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzItMS0xLTEtMTAxNDIw_2356eab8-b065-479c-bee9-4d158caf2ad7">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzMtMS0xLTEtMTAxNDIw_644cae6b-69b9-438c-9558-149f0a8ee943">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzQtMS0xLTEtMTAxNDIw_5da54a23-6da5-454e-9755-6b04567214d5">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzctMS0xLTEtMTAxNDIw_1699792d-1bbb-4f42-a2de-9760d875c0e5">34,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzgtMS0xLTEtMTAxNDIw_8b58f47d-b9ea-4c92-8324-2b63fa2470a5">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzktMS0xLTEtMTAxNDIw_60bcc170-f42c-4fc5-bdb3-9f0f7c7f42d4">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEwLTEtMS0xLTEwMTQyMA_efbd74fd-5215-45ff-b63f-8e91d898bf3d">36,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c4ff54b524745a88b135d86bd443b_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEzLTEtMS0xLTEwMTQyMA_31ba5271-79ca-45b0-9558-d3d28c634541">154,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1373bcac7934429293088da96849175b_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE0LTEtMS0xLTEwMTQyMA_48f5ab59-7440-4805-8ec9-627eeca6f957">23,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b6d6c6c553400a9d75350d6fa61da5_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE1LTEtMS0xLTEwMTQyMA_ccac5ab7-f68d-4463-9569-de7375563ea0">17,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE2LTEtMS0xLTEwMTQyMA_c8de5914-f305-4f02-9cc0-0b4bf3c2b1e9">195,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE5LTEtMS0xLTEwMTQyMA_fdd2e5ae-14a3-45d0-913e-9b877476e151">7,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIwLTEtMS0xLTEwMTQyMA_0d936f2f-d740-4967-b1af-d406c1e9cdf7">8,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIxLTEtMS0xLTEwMTQyMA_b1131aab-345e-44a3-9889-2709902d8944">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIyLTEtMS0xLTEwMTQyMA_fdbebbe5-35bd-4ea8-974d-3a56fb5790e3">48,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIzLTEtMS0xLTEwMTQyMA_e0b062c0-c273-49c8-9bb1-dba1ad6e1031">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI0LTEtMS0xLTEwMTQyMA_8d296b82-7245-42e4-8165-3f5313cc0337">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI1LTEtMS0xLTEwMTQyMA_0cdaa65c-f282-427c-8d45-31d8262993b1">66,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaa2db7d499f1448aa6c6cea350f47f4f"><div><ix:continuation id="if95e107a74bc4ef9a029bbfb652041e6"><ix:continuation id="i5bc5d406ecd7418cb165a535de65a2a4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI3LTEtMS0xLTEwMTQyMA_17c19710-7d81-4c66-9f06-9c6bf0ac75de">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI4LTEtMS0xLTEwMTQyMA_4f5b0118-f77e-4f3d-8878-b83117bd6347">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i2d9c4ff54b524745a88b135d86bd443b_I20220801" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5Mjc_63af5a75-6e09-465b-b503-380cbb6e0a38">20</ix:nonNumeric> years, <ix:nonNumeric contextRef="i1373bcac7934429293088da96849175b_I20220801" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5MzE_6463d872-5ad8-45bd-8222-40586609ac43">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i57b6d6c6c553400a9d75350d6fa61da5_I20220801" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5Mzk_9a269433-4025-4f41-a37b-1e0140d13117">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is <ix:nonFraction unitRef="usd" contextRef="i491e48a182e442f98c17a235d12252d7_I20220801" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzM2MTg_36b8584d-ad30-427e-a181-ddb3de9d1eee">no</ix:nonFraction>t deductible for tax purposes. Additionally, a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i91831d375a0845e7aa4af31f7b290c36_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzM2OTE_1b6fcfca-6ad1-49d0-b2b4-5033eec9ae74">46.8</ix:nonFraction>&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pro forma financial information (unaudited)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited condensed pro forma information presents combined financial information as if the acquisition of NIA had been effective as of January 1, 2022, the beginning of the 2022 fiscal year. The unaudited pro forma financial information includes adjustments to historical amounts including amortization of acquired intangible assets, depreciation of acquired property and equipment, interest expense for the financing of the transaction, alignment of NIA&#8217;s revenue recognition policy, and the associated income tax effects as if NIA had been included in the Company&#8217;s results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTY1NDg_dc1a25e8-12a6-443e-a8d4-be3212e58413" continuedAt="i0dfb576af86f4bcb8a27a90d4a59352e" escape="true">The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company&#8217;s historical financial information on a pro forma basis (in thousands).</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i0dfb576af86f4bcb8a27a90d4a59352e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzItMS0xLTEtMTEzMTAx_92a23613-e223-4c71-b560-b7e89f10aaca">446,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzItMy0xLTEtMTEzMTAx_57d68250-c394-4f5b-8de6-5f10c3079d77">362,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzQtMS0xLTEtMTEzMTAx_366e3533-f1f2-43eb-84fd-d5e0a0139d91">15,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzQtMy0xLTEtMTEzMTAx_dfb6edb8-c16d-4180-a404-3a71b539f15f">10,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#8217;s interim consolidated financial statements was not material.</span></div></ix:continuation><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NTI_1a5f3273-9a26-4656-9bc6-f26475a933fa" continuedAt="ib42b32079fdd4a4999e69bd2d08e80d3" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibf4ae740f83542ac870dbfe22344634d" continuedAt="i394c585773b14497a00fcdae08e50f26"><ix:continuation id="ib42b32079fdd4a4999e69bd2d08e80d3" continuedAt="ic87e01b998454298884edcd135c2c3e0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic87e01b998454298884edcd135c2c3e0" continuedAt="i6685689f66d04ef6b8e3f948c302fa07"><ix:continuation id="i394c585773b14497a00fcdae08e50f26"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NDg_fbf96939-6eb4-416b-8de0-49d8bd59e57b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by end-market and product type:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:358.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cc900864834868948a404393a49a85_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzMtOS0xLTEtMTAxNDIw_9d295f84-7dc3-42c0-94f3-29e400709535">183,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d6a8162061452483f3aa24db4d62d8_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzMtMTEtMS0xLTEwMTQyMA_5165c754-0dc8-44c4-9ae1-6e71c5bad28a">130,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6176d6981ea4c9b8d17bb71206e1cc2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzQtOS0xLTEtMTAxNDIw_6782ce75-bf75-4327-8521-d16c4dec578e">127,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb36bbcf076422798e36c705ca489a5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzQtMTEtMS0xLTEwMTQyMA_1de5659c-09ad-4314-83a9-48f0951bc6c1">104,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c51d30ca110417b9bc57ef158154a94_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzUtOS0xLTEtMTAxNDIw_20a318cd-46da-41ff-98fa-156a0dd3bc80">116,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60e2d87246f4a24b6e2e5c72158629a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzUtMTEtMS0xLTEwMTQyMA_aa2cd3eb-4686-4bc6-9cbf-93ccf62a1a19">62,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzYtOS0xLTEtMTAxNDIw_a47a2df2-d286-4bcb-aab0-3cc386b26854">427,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzYtMTEtMS0xLTEwMTQyMA_a364eb76-7d0f-45e2-8b59-910a26e19c95">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if783561a665d46e194893a76d25beb3e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzctOS0xLTEtMTE1ODgw_80f97a03-4e11-4f7e-98e0-b09afe9036dc">239,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ca0c0c1968494bbc67b02a9e28ff5c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzctMTEtMS0xLTExNTg4NQ_eedcd616-0094-4f6a-a2e3-58d762a141ca">171,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef28bce40ea4047a5a04db3de0aadf1_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzgtOS0xLTEtMTE1ODgw_da3d3708-4ab5-4001-866c-124b8b577b3e">65,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129cce29425045eabdab581851009e0e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzgtMTEtMS0xLTExNTg4NQ_0d6c9f45-6739-469f-9a98-d9bdc34deb44">13,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb47dcc6439a43fa8d4c19f2122b859a_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzktOS0xLTEtMTE1ODgw_e14ef60a-1ed4-48de-87a0-209585617df5">83,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f9f6fc9bd44f3fb6b41939fb533aca_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzktMTEtMS0xLTExNTg4NQ_f70966c5-428e-4ee3-a03c-d331dc927a4d">106,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4772da6b737d416fa93667acc7bec0e6_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzEwLTktMS0xLTExNTg4MA_4ce17f58-5883-47bd-a177-759b4bfeecd3">39,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8a9c31ea4be40439865dcd7dc02302f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzEwLTExLTEtMS0xMTU4ODU_a2731141-ec44-442a-af9a-6ce862e8cdf1">5,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzExLTktMS0xLTExNTg4MA_1679f189-b508-46e6-9579-a4e15a11e1f9">427,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzExLTExLTEtMS0xMTU4ODU_95b37874-2e20-4680-a8bd-417253bab961">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQyOTk_286026d1-e5c6-4f38-aabe-185a2cf165ce">43.8</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2023. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="i97d627a444fd4d149f0df76b556dd94e_I20230331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5MTg_0b2bb198-f791-442d-9ea6-edc0763c76b0">69</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i466c6c1cbb854e8f935205d90d504b4c_I20230331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5MjI_599e45b9-e1f8-4158-a563-b45d94febfc2">92</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5Mjk_8b785cb7-73b7-49c2-b659-1d4bdd22131e">100</ix:nonFraction>% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6685689f66d04ef6b8e3f948c302fa07" continuedAt="i955d8c13fa4740b38696561004c8dbaa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NTA_66fc9a4a-ff77-48bf-982b-71323d926de5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzItMS0xLTEtMTAxNDIw_27a17d97-8b60-4865-998d-37d31d5377cb">261,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzItMy0xLTEtMTAxNDIw_20fdf1b1-56fa-4155-82d3-25c716e7ccd3">246,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzQtMS0xLTEtMTAxNDIw_a0ed615b-6a2a-4931-afe4-8d06b9bcf094">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzQtMy0xLTEtMTAxNDIw_2eb495d9-78fd-4249-aa9f-dd23434dd205">5,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzUtMS0xLTEtMTAxNDIw_b24f2e30-9bac-4e63-b703-0efe1160003b">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzUtMy0xLTEtMTAxNDIw_a24dc325-ed19-4e1e-a2dc-5fb6a0bbe6a1">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzEtMS0xLTEtMTAxNDIw_90853979-a276-4dc5-8efa-36e44cd125c9">8,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzItMS0xLTEtMTAxNDIw_df6f14d7-a804-4310-be73-0f97aec2eed2">3,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzMtMS0xLTEtMTAxNDIw_139b795c-d337-4a24-ad92-f5b9fc3a0b5c">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzQtMS0xLTEtMTAxNDIw_8c190932-6f43-472b-b9f8-840a4a6df0c4">9,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue, excluding customer discounts of $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="evh:CustomerDiscountsFromPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzY1OTcwNjk3ODE3OTI_2e501436-1644-4146-89b6-12ee6a5192f4">1.5</ix:nonFraction>&#160;million, recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzcwOTM_a3f0b852-bde0-4be0-8702-60260615fbd6">4.8</ix:nonFraction>&#160;million for the three months ended March 31, 2023, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i1142e9b4f22b41bb9861d40caedc8272_I20230331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzc3ODQ_8f4390a5-72fc-42f5-9b48-b6f995cceb65">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i409e1ed35fec45debbcfcdca8b668bc1_I20220331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzc3OTE_09b0c647-ee43-41d7-917f-bd6d823805bb">3.9</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $<ix:nonFraction unitRef="usd" contextRef="ie26be0edc14d47eb99b84495e133ece4_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzgwMDU_22686917-6dab-4f70-809c-acf13beba6f1">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70b0d3db141e42d9ba27945974ed98be_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzgwMDk_9a7e5c42-71dc-434d-be71-bab3763a0746">1.4</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our revenue contracts, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib92fd7517b7e45d8a3a28cf15450d165_I20230331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzg3ODc_3cb2b2c2-80a0-488e-bd31-d45bcf3c0fe4">13.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a5199740c894c7990588a57d16a827c_I20220331" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzg3OTQ_cee4bf22-20bf-4023-a867-d7b1dd54d9dd">18.1</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $<ix:nonFraction unitRef="usd" contextRef="ib4d813436fe64f6cb913aa801cecded5_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkwOTE_0906913e-26fa-4241-b632-e41f5a856e8d">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia8bfa3c9233e49a3885fdb8cd2d590db_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkwOTU_689c5340-69c4-41fd-b20d-5377fb82cfa7">10.3</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i955d8c13fa4740b38696561004c8dbaa">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkzMzQ_5b275c2f-bd46-4f48-ac83-95d6e033563a">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzMzMTU_11d7d4c5-ffe3-4983-b0f9-b767fc1f9163" continuedAt="i06a7b3b2b42041d5bd95d8b216e0a996" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i06a7b3b2b42041d5bd95d8b216e0a996"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2023. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, we did not record material changes in our allowances during the three months ended March 31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2023,&#160;<ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzIzNDI_9bc02185-6538-491e-8431-67e94af96568">70</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="ic21943cdf8a049d2a24adf36d3b79cd8_I20230331" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzIzNTk_307ee511-f2a2-44ce-a783-d03151fd79b2">23</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i70f46329635e4437b8068a2610a354f6_I20230331" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0MDA_0f0d29c0-74f3-48c8-8730-6362a6859d0f">26</ix:nonFraction>% past due less than 120 days and at December 31, 2022, <ix:nonFraction unitRef="number" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0NTc_ed56937d-d56e-425b-a99d-3faf5abd8b59">67</ix:nonFraction>% was current, <ix:nonFraction unitRef="number" contextRef="i15da874ddc524d2285a2fb1df7a7623c_I20221231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0NzM_6727208d-92df-4a3c-ad11-63ba785cf0a4">21</ix:nonFraction>% was past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="if821daf7eb8c4bf3bcdc0fd5e08f4ed1_I20221231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI1MTM_4d36ef4b-12e9-4370-ae03-4abd872546f3">29</ix:nonFraction>% past due less than 120 days. As of&#160;March&#160;31, 2023 and December 31, 2022, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI2MzI_08bfbc45-0342-4640-b5fc-a89c83a4325e">284.7</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI2Mzk_67f5a672-c325-4b35-a98b-ae67112f180c">269.1</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI3ODA_f471cfc4-8131-4f64-9d04-a4e6f1484de4">15.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI3ODc_4e599237-769d-475b-8f5d-f7524ccc5385">10.2</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzMzMTY_420e5157-7564-46fd-83aa-60bb6f2cddf1" continuedAt="i53020e1b2e51406ab6e2800727038a03" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i53020e1b2e51406ab6e2800727038a03"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzItMS0xLTEtMTAxNDIw_017dea71-6a67-4507-952b-cd935904e275">10,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzItMy0xLTEtMTAxNDIw_1176280c-555b-4eec-aa8c-e0d96ee76b26">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIA acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzMtMS0xLTEtMTAxNDIw_247886df-d313-446c-aacf-232c9ff02132">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzMtMy0xLTEtMTAxNDIw_ba15cb0e-d84b-4115-bf18-92c54de8373a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzQtMS0xLTEtMTAxNDIw_099a8730-2f02-4103-97e4-23920141c86d">5,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzQtMy0xLTEtMTAxNDIw_3058302f-f773-49c8-ac05-a530d2b67145">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzUtMS0xLTEtMTAxNDIw_669610a8-c5f6-4982-ac21-779bd229328b">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzUtMy0xLTEtMTAxNDIw_802db86a-0983-4365-8140-79d079f382ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzYtMS0xLTEtMTAxNDIw_1cd1156a-b647-4094-b999-ed21d2e907fc">15,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzYtMy0xLTEtMTAxNDIw_6cd9cc53-b611-448f-bd14-687b09efbc15">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzcxOQ_615b6593-7ddb-4a1c-93c9-f59a587c93b3" continuedAt="ia4fbff98f2234faf9a44acf3d3b8d72e" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia4fbff98f2234faf9a44acf3d3b8d72e" continuedAt="i382a8e527d2b4d0881479ed3b67183bc"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzcyMQ_26b34986-8deb-4bc5-8e2e-3f7fe43835c1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c753595d7f449f9388ce080153adee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzMtMS0xLTEtMTAxNDIw_18c36ca7-786a-405f-99d8-c0859b4ee7b5">30,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab74d6cb3834527b8ae1fc110c1c9b8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzMtMy0xLTEtMTAxNDIw_e9d017bd-715a-43a5-bfde-3c9be42942fb">30,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896c0f919a744ccdab15d963fb3c518e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzQtMS0xLTEtMTAxNDIw_760f9ea6-acb9-4b95-a13e-45177bf071c9">4,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909942c4cbc94b759e839fa9b4480c52_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzQtMy0xLTEtMTAxNDIw_f117e306-967c-4fd6-b40c-41efcb488173">4,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54563c905b50494cbe32a703a93fd3fc_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzUtMS0xLTEtMTAxNDIw_4fe4c29b-76be-45f8-8362-f0c965dc20a4">197,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie224ebe8d58d426cbf7c6760029adacd_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzUtMy0xLTEtMTAxNDIw_4240b7af-d4a7-4531-a6af-791aa221d8c0">189,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1064fdf19264fd6929844695005b91d_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzYtMS0xLTEtMTAxNDIw_fd9facfb-0b2c-4d8a-bac2-bf676200552c">15,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5928ba2c6c467daaf522ca8262ec8f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzYtMy0xLTEtMTAxNDIw_8eec1c08-6413-4ad2-94c9-040c4d1b3687">14,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzctMS0xLTEtMTAxNDIw_abeb8126-7218-4d3c-9b2e-889bdb7d1e30">247,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzctMy0xLTEtMTAxNDIw_ae9bca61-1909-4ebf-993c-2851b7c8bb3a">238,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzgtMS0xLTEtMTAxNDIw_46b911d3-5476-4bf5-a45d-c9013ff15b92">158,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzgtMy0xLTEtMTAxNDIw_1d77ff36-8920-4079-8e0e-1f01cf3895a1">150,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzktMS0xLTEtMTAxNDIw_80ee099e-285f-4072-aca9-e0259f7fbba6">88,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzktMy0xLTEtMTAxNDIw_a490f050-47b5-44fa-ab8d-a6d842126297">87,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i382a8e527d2b4d0881479ed3b67183bc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="ic3065bc9a90f4c3593d40da7cd173ea0_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzEzOA_138c6b5a-1160-4601-bf4b-9cc205b49eb6">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib551ddbba6244ae19cb603ed8c3a6e65_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzE0Mg_6745908f-2a60-42b5-a96a-88365f4dbcb4">6.4</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzM0Mg_c4b3c34e-96e1-4b93-bf6d-90ea5a55ecb3">75.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzM0OQ_43435e7d-0d26-4656-9776-e2d644b92485">73.7</ix:nonFraction> million as of March&#160;31, 2023 and December 31, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzQ1OQ_8ba00afe-c222-4c7f-af74-a296c4003224">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzQ2Mw_880747c8-8a27-4b01-b80a-b75e8f825037">7.6</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzYzOA_25e2950d-7136-460b-9e58-7b01a9a2e750"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzYzOA_bdfee8af-7c7d-43e5-a9bf-c6e2cf0d33d0">6.7</ix:nonFraction></ix:nonFraction> million for both the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5NDA_1299d00a-9480-4f02-8fdf-a65e7787372e" continuedAt="ib56079e19f28486b8921b31bb7531564" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib56079e19f28486b8921b31bb7531564" continuedAt="ib9bb006c5f034a1383795694e36548d3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test of October 31, 2023.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib9bb006c5f034a1383795694e36548d3" continuedAt="iaab8f893ef8d4e709c4246423a8655ac"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceeded directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzM4MTU_6acc0a99-602e-40cb-bfdb-93adab8adaf5">no</ix:nonFraction> impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5NDY_bc8825b6-4fbc-4ce8-82b9-ccb2f4184bca" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzEtNS0xLTEtMTAxNDIw_6aa43c6d-8a65-4e7d-aa40-364ff4d30890">722,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzItNS0xLTEtMTAxNDIw_b533599b-c531-4db7-9d70-664ad1f0c6a6">395,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzMtNS0xLTEtMTAxNDIw_6d2359fe-8dad-4453-aa23-64fd57896d41">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzQtNS0xLTEtMTAxNDIw_6f503a04-a927-4fc1-a78b-5ae34f172a7d">1,117,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzktNS0xLTEtMTAxNDIw_d34cd44d-a3c5-49fa-b960-7b076164c883">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzExLTUtMS0xLTEwMTQyMA_f6ea9eb5-0176-4cab-99ac-3a6e54a5c759">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzEyLTUtMS0xLTEwMTQyMA_99f66228-5b86-41f6-b835-444fa3acf24d">426,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUwMzA_0a6695d5-15ba-4577-b659-887b163bf970"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUwMzA_1bf6e9fa-303d-4453-aa27-d8ca754f8e74">575.5</ix:nonFraction></ix:nonFraction> million as of December 31, 2022 and 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of NIA in January 2023.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="iaab8f893ef8d4e709c4246423a8655ac"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i38ac17e08cde4b38a018689a54c5ef42"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide3f10e694c940868bd2594ab2017b6a_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMS0xLTEtMTAxNDIw_e80d595c-25ad-4cb5-acac-aefb59d88ee7">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMy0xLTEtMTAxNDIw_dc06656d-6784-44a9-9303-ef25c8e84f4f">51,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItNS0xLTEtMTAxNDIw_deac7d1c-ad19-4d67-ab77-f70ceb9fc496">16,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItNy0xLTEtMTAxNDIw_ae308293-cf84-437c-8c20-c83190e93999">34,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6de16ded6120471a80302f91bbee7b2a_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItOS0xLTEtMTAxNDIw_a8bbe564-4160-44a6-b1a2-fee5495e4f8f">12.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTEtMS0xLTEwMTQyMA_71ee6891-7bc8-450a-80e6-13d39a6a38f0">43,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTMtMS0xLTEwMTQyMA_44f3cef7-e486-41dd-b34e-3614a5921c0a">11,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTUtMS0xLTEwMTQyMA_d758b72f-72fb-4139-a1bb-48b3c230b110">31,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f561ad00b584a20ab6ac5a564705e71_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMS0xLTEtMTAxNDIw_a1358115-da51-4798-a059-9cc473eeda52">15.2</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMy0xLTEtMTAxNDIw_b27cc0f2-a8b2-4349-a973-eb4480eb709c">810,119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtNS0xLTEtMTAxNDIw_a02334fc-e346-44c5-afeb-5edc99218944">103,694</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtNy0xLTEtMTAxNDIw_86f29afb-d8a6-40cc-9d44-6522cc6262ea">706,425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67bf39ef96634f3193ea5f32553d096d_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtOS0xLTEtMTAxNDIw_c9401f24-582f-4ea4-8fa1-74889d11fe26">15.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868a181629a048b69538d93b32b52ff9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTEtMS0xLTEwMTQyMA_9d323b4c-5cab-4349-9f8d-1b1f5389b4f6">465,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868a181629a048b69538d93b32b52ff9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTMtMS0xLTEwMTQyMA_73555fe7-de38-4961-856b-b6f07581aa9b">92,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868a181629a048b69538d93b32b52ff9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTUtMS0xLTEwMTQyMA_9f827445-6295-48ee-b68b-4278aa2aa4a0">372,259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8fae892598234158a4ae8ce37c46d1cb_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMS0xLTEtMTAxNDIw_5473bad9-bd0b-42cd-a1db-eba15a468f67">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6712e972d4564a6a96307887c4567b00_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMy0xLTEtMTAxNDIw_2a82a16b-ca5a-4d42-913d-38785466cd39">162,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6712e972d4564a6a96307887c4567b00_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtNS0xLTEtMTAxNDIw_8ddf04af-3ec1-42b8-8f66-8e9f1cc19781">83,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6712e972d4564a6a96307887c4567b00_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtNy0xLTEtMTAxNDIw_e28e1ba5-9a15-4db6-bb77-2ea24cb8559d">78,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52491c9a83874a978dbed3b6892d4798_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtOS0xLTEtMTAxNDIw_449c8ffa-d1e3-41df-8636-c686984732cc">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTEtMS0xLTEwMTQyMA_8566e62f-4a60-4624-93bf-a8c795a420b5">111,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTMtMS0xLTEwMTQyMA_d1d33baf-8107-4375-8640-51cd619775b5">80,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTUtMS0xLTEwMTQyMA_d6af5cbd-4c64-46a2-a0a2-ef7d053a71bb">31,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56fee09db1334b68b2b6dbd706c21116_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMS0xLTEtMTAxNDIw_c3cbd56e-7a7e-4c14-9685-f379810ff1d8">0.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMy0xLTEtMTAxNDIw_cfadc440-11ec-4419-87ff-dcbf482b5c9d">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtNS0xLTEtMTAxNDIw_916a3022-1b27-4ce0-a443-711cd77c2b38">1,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtNy0xLTEtMTAxNDIw_4e255b90-d0f2-437c-9bbb-ef7339ede337">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85b523dd4c194164ab39eb63ab1206c2_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtOS0xLTEtMTAxNDIw_924ae75d-a14e-4e5a-8962-1fbe1efa5221">0.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b51a2db0824da5929aaac343723403_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTEtMS0xLTEwMTQyMA_ddc48bce-c5db-47c9-babb-227a33387e0b">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b51a2db0824da5929aaac343723403_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTMtMS0xLTEwMTQyMA_86b46f77-1c64-45f4-b1c5-5ba3afd84f11">1,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b51a2db0824da5929aaac343723403_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTUtMS0xLTEwMTQyMA_9d14408c-3041-44ee-a8df-a48fd2d37989">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia53c692cc90544f49ce6bab9b750a5d9_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMS0xLTEtMTAxNDIw_96004a4c-4332-4113-9507-4cae88602f18">1.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMy0xLTEtMTAxNDIw_e467c76f-7af1-48f4-bd3f-bec0d7c36038">18,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtNS0xLTEtMTAxNDIw_d739b160-3e8f-4138-85c0-08d9aba7bb74">12,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtNy0xLTEtMTAxNDIw_45e9db64-241b-4573-8aa8-96eed4860d00">5,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e47ddf7af144c3bb65fd8dfd91cd016_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtOS0xLTEtMTAxNDIw_fb5936b6-e5c9-4566-811a-6ce32c16fb4d">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTEtMS0xLTEwMTQyMA_1e96b0e5-ca4a-4f5f-a182-f347c419ca17">18,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTMtMS0xLTEwMTQyMA_b3823eac-21b0-4a31-8c63-14d545d396f0">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTUtMS0xLTEwMTQyMA_0b0a869d-7c7b-4d15-af5a-28aea8d699da">7,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMy0xLTEtMTAxNDIw_85edabd0-88d0-4fe2-b9ff-fa7d1e92da24">1,044,685</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctNS0xLTEtMTAxNDIw_4c7c1903-e96f-4b92-86bf-7a71edd65d89">218,828</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctNy0xLTEtMTAxNDIw_ed6586a4-dbb8-4ca9-b4ab-a30981ac6162">825,857</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTEtMS0xLTEwMTQyMA_ac867a72-3b08-4f9a-9bf6-a3013e46ba89">640,510</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTMtMS0xLTEwMTQyMA_2fdea8a0-f439-4792-84d4-faf228866137">197,726</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTUtMS0xLTEwMTQyMA_e4427901-9972-4721-8ab6-38a8054c0f24">442,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUzMjg_eae7bb01-e997-400e-b9c0-19d1ca5dacad">21.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUzMzI_2f14b509-c4e3-46ab-907e-991881925e99">7.5</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5MzI_2c37c676-89de-4c8d-b9d0-249669032514" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzAtMS0xLTEtMTAxNDIw_cf8719d4-6f98-441e-b166-54aa98cbe12d">69,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzEtMS0xLTEtMTAxNDIw_dde4f547-47f5-44dd-9134-ecf9ba7593e2">87,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzItMS0xLTEtMTAxNDIw_1dabd3e7-a64c-4179-bb5a-7dc072d8ce5b">63,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzMtMS0xLTEtMTAxNDIw_1f6c97e5-6e90-42a5-bdf5-83b0719c0815">63,293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzQtMS0xLTEtMTAxNDIw_2a1fac6a-a8a5-4bdb-a632-11242d640d25">60,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzUtMS0xLTEtMTAxNDIw_89f9617d-8822-45d4-bf46-4d9c1cde07fb">480,897</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzYtMS0xLTEtMTAxNDIw_c344d95c-db79-452f-946f-e2deb10a6b61">825,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2023, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIzNDYy_d52cb4ae-2c71-4020-8cf3-7dd149c582b5" continuedAt="i96ec909ae051414e958823cfc7d5574c" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i96ec909ae051414e958823cfc7d5574c" continuedAt="ibd89bcc5edcc4678abc27726e2e6940c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;IPG Closing Date&#8221;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, collateral agent and revolver agent (the &#8220;Existing Credit Agreement&#8221; and as modified by the Amendment (defined below), the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) initial term loans in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i3f1b4ec02a7342fcb85559bcc229e583_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzYxMQ_9178f13d-70c8-42e6-b0c8-d280f27e0c47">175.0</ix:nonFraction>&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) revolving credit commitments in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i2b7598f678494d1aab584ad521987519_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY5NA_4d25f711-8b1a-4bab-a5a3-4d7ca3f72a67">50.0</ix:nonFraction>&#160;million (the &#8220;Initial Revolving Facility&#8221;), the availability of which shall be determined by reference to the lesser of $<ix:nonFraction unitRef="usd" contextRef="i2b7598f678494d1aab584ad521987519_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzc0NQ_f80d6aa3-4e7b-4d67-bf66-fbe459c245d5">50.0</ix:nonFraction>&#160;million and a borrowing base calculation. The Borrowers borrowed full amount under the Initial Term Loan Facility and the Initial Revolving Facility on the IPG Closing Date. A closing fee of (a) <ix:nonFraction unitRef="number" contextRef="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801" decimals="4" name="evh:DebtInstrumentClosingFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1Njc_68337f1e-e838-4041-b189-d0aa623fe5fe">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Initial Term Loan Facility and (b) <ix:nonFraction unitRef="number" contextRef="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801" decimals="4" name="evh:DebtInstrumentClosingFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1NzQ_699a3c9c-d776-4c6d-8f9b-c776c28b6838">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Initial Revolving Facility was paid as of the IPG Closing Date.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibd89bcc5edcc4678abc27726e2e6940c" continuedAt="ia89e3107e8d142e79a58cb3d7416f8c5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, (&#8220;the NIA Closing Date&#8221;), the Company entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) additional revolving commitments in an aggregate principal amount equal to $<ix:nonFraction unitRef="usd" contextRef="i8ff112cad23c4514bbfbb8c0655c94d0_I20230120" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMTAw_032d6af8-1403-437f-9ec9-c0d231abbbd2">25.0</ix:nonFraction>&#160;million (the &#8220;Incremental Revolving Facility&#8221; and together with the Initial Revolving Facility, the Revolving Facility&#8221;), and (ii) additional term loans in an aggregate principal amount equal to $<ix:nonFraction unitRef="usd" contextRef="ica07830c52aa4ce3a36a9196d7fd69c8_I20230120" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMTA0_563752e5-52ad-421c-af6a-5de54f0acf62">240.0</ix:nonFraction>&#160;million, (the &#8220;Incremental Term Loan Facility&#8221; and together with the Initial Term Loan Facility, the &#8220;Term Loan Facility&#8221;; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the &#8220;Credit Facilities&#8221;). The Borrowers borrowed the full amount under the Incremental Term Loan Facility and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) <ix:nonFraction unitRef="number" contextRef="id3f428993e84490da09219c15b871fd2_D20230120-20230120" decimals="4" name="evh:DebtInstrumentClosingFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1ODE_947832e3-fd3d-4c78-8e72-f43f5a018b3b">3.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) <ix:nonFraction unitRef="number" contextRef="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120" decimals="4" name="evh:DebtInstrumentClosingFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1ODg_a7173abe-5812-4d26-b11c-27164ee57275">3.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain customary exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain customary exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All loans under the Credit Facilities will mature on the date that is the earliest of (a) the sixth anniversary of the NIA Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (<ix:nonFraction unitRef="day" contextRef="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyOTg1MzQ5MTk4OTM_8220c4e0-b397-4896-97b3-836e7653ef31">91</ix:nonFraction>) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate for the Loans is calculated, at the option of the Borrowers, (a) in the case of the Term Loan Facility, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="i89ea6a7579f0498aaad68c4136be1a8e_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI1Mjc_1af6002c-9f66-42bb-a947-1d8500408006">6.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="ie61f8c08dc6542cab575508067f47573_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI1NTM_772aa22f-39f0-4cf0-96bf-b54b97cc2182">5.00</ix:nonFraction>% and (b) in the case of the Revolving Facility, at either the Adjusted Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="if0d005b9b6f94895a2093108ec4023c1_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2NDA_b1d0ad1a-6cd9-4253-9008-bab1e553af8e">4.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="ic49c939410944f6892ee284ba7b362a4_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2NjY_7a604f8c-69ef-487c-80bc-cae98ab3507b">3.00</ix:nonFraction>%. A closing fee of (a) <ix:nonFraction unitRef="number" contextRef="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2OTQ_324185ae-2b11-4c86-bfb4-9f87cbbe8d35">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) <ix:nonFraction unitRef="number" contextRef="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI4MDM_a5b953b9-8db6-4c35-b2c3-8f1f1f754db7">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI5MzU_618f9f1a-db4e-430a-8ea5-c176f3a2185e">11.1</ix:nonFraction>&#160;million in interest expense related to our Credit Agreement for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facilities may be prepaid at the option of the Company, subject to the following prepayment premium (the &#8220;Prepayment Premium&#8221;): (1) <ix:nonFraction unitRef="number" contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMjI_8cab52a4-d522-4069-8c76-eb7178eab564">3.00</ix:nonFraction>% of the principal amount so prepaid after the NIA Closing Date but prior to the first anniversary of the NIA Closing Date; (2) <ix:nonFraction unitRef="number" contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMzNDI_688abcbf-aecf-402f-9897-c2a558cef48b">2.00</ix:nonFraction>% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the NIA Closing Date; (3) <ix:nonFraction unitRef="number" contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzM0ODg_236b018c-f731-4ef9-882e-9eb7b07c1306">1.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the NIA Closing Date but prior to the third anniversary of the NIA Closing Date; and (4) <ix:nonFraction unitRef="number" contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzM2Mzg_753a2c50-a653-494c-9732-f75fd36fd66b">0.00</ix:nonFraction>% of the principal amount so prepaid on or after the third anniversary of the NIA Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction, in each case, subject to application of the Prepayment Premium. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Loans. We incurred $<ix:nonFraction unitRef="usd" contextRef="i6af1d7c94ffa4dfdb1daac49c0bdcc06_I20220801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzQ3NTA_38e851bd-e3ec-486f-8725-ee442d8eba61">14.4</ix:nonFraction>&#160;million of debt issuance costs in connection with the Loans, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the Credit Agreement. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzQ5OTY_b61eaa3d-6389-4bf3-bc83-b6bce9fa5ae0">0.5</ix:nonFraction>&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="iee0ccfb937d04787b9a2edcb589528a9_D20230101-20230331" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyOTg1MzQ5MTgwNTE_89f85cfe-cc2a-4ba0-8b2e-3acde0dbec2b">37.5</ix:nonFraction>&#160;million under the Revolving Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzUxNDc_4e042835-d1c4-417e-a9cc-3a549df7992c">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzUxODQ_493307d4-3217-450c-8499-d0ae2fb69351">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0MDI_426d5ca9-b5aa-4731-b823-19d4f493770f">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i86c90a6284344462a51488ae0069e122_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0NzA_d2be7773-a942-4648-b0bc-4dadc4931e28">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="ie251d99bd74345e1bc9460f66244b376_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU1NTk_994bb731-c735-4ff7-b644-54d1cb20ee6f">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="i657a6cf3c44d4a4082d16bcf0b007b3e_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU1NzQ_031dca44-a369-425b-a818-32bef8d8e838">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU2NTQ_df55fef4-4ce0-49a8-8afb-25d25f68e216">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia89e3107e8d142e79a58cb3d7416f8c5" continuedAt="iba36245d480f43068805cf0604fb10ec"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzYyMTA_d4e21623-2fdb-495e-a0d2-737c7fa953a8">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY1MTg_27b028dc-1086-43d2-9619-683174caecdc">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY1MjM_576d9f95-9aa2-4413-8957-bb1a51908650">1.0</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY5ODU_06307783-1c19-44bb-98d6-33a3b32d565d">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzcxMDE_62e40106-f049-43e5-acf7-4c5332a8f5f8">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgwMTY_8abff5b2-cce4-40af-9814-787382462883">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgxNjU_c122eaf5-0835-4218-9f78-e72e40789079">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgyNjA_a09e0db5-a67a-4008-b6f2-a79cd2c81ce9">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6b77390117574b05b6853a2e6cdfd5a0_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgyNjc_9c25516a-2e6c-486e-ada9-ab5b6a687285">1.3</ix:nonFraction>&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgzOTk_f355e21f-5504-4779-8d3e-751d012b0498">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzg0MDM_8691ea7b-caee-4efb-a1cb-22002e4b9a52">1.7</ix:nonFraction>&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i5e0dbffb9cb44a82b9230fee7cbb2e8e_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkwODI_101fe3d2-1a0c-4033-8f42-ca2b523bf244">38.1</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="id09a99b6604145a39f0c6f2102806ba5_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkxMzA_a2e041c0-7324-4204-8423-6af8071dc57d">1.3</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $<ix:nonFraction unitRef="usd" contextRef="i7820004852704049885c737ed680c6c8_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkyNzE_a77b28cb-7d61-44ba-b9f6-b130b7e0322b">11.7</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i08db4cba39da4c2daa8e8a98eec10995_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzk1NTM_c2b63661-6270-42d3-b6a1-9f9128344bc3">25.1</ix:nonFraction>&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMDI2_36656f7b-df7a-48d8-bdb4-8ade822fe3ce"><ix:nonFraction unitRef="usd" contextRef="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMDI2_40ee3e1e-9ecb-41d7-9e77-34a83bd1a225">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMzc0_90285e3f-8d48-4891-b01f-cf9dcc1ce3eb">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwNzk1_90232ecf-3379-438f-8215-84c22be6a836">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwODUw_d7fb41dc-9ddc-477c-9e33-6b0d7529b5e0">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwOTA2_30ca3350-038d-4352-8ad8-ab9827807034">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExMTQ0_8caf042c-9e05-4f3a-b65f-a34e21fa61b2">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $<ix:nonFraction unitRef="usd" contextRef="ib6487f01387746f0ba7463b6968f241d_D20220811-20220811" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNDMx_a6d4d44c-dacb-4d09-8ffe-c81bffd034f4">92.8</ix:nonFraction>&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i97ba4e8ae10c4f378bae69514e2fe2bd_D20220817-20220818" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNjIw_0b9e2577-ba28-4759-8163-635c194e29c5">5,394,165</ix:nonFraction> shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $<ix:nonFraction unitRef="usd" contextRef="i4b149b5c258542fb966a78ac8c73abec_D20220801-20220831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNzU0_e022a39e-3757-45eb-9555-4e5bdb94e37b">10.2</ix:nonFraction>&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iba36245d480f43068805cf0604fb10ec" continuedAt="i20625cdcac04497c9e28b9fe59688254"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE0Nzk3_afe41d61-84b8-47a1-ac8c-f0dd0f5dd75e">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE0ODM0_069f7de9-0e7e-487a-a785-b5261fe41ccc">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MTAy_6f35ed9f-b6e9-4921-9446-43919459c390">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i8b58c2da78614c1f968d97ed45d71235_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MTE4_b73a02ac-c7d7-4f32-a16a-a4018d5cd5b7">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="i7659a2a5a47648a180caf848566c901e_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MjE5_e9cf8351-69a4-4543-9e8c-bbd22361b523">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="ic12584d85379426290b0c22a08b05259_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MzQ3_92d7bcf2-9cec-407d-b4cb-538172013a22">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1Njg3_069f7de9-0e7e-487a-a785-b5261fe41ccc">1.50</ix:nonFraction>%&#160;per annum. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0OTc1NTg0MjMyMA_450cdc4c-6a35-42e9-841c-66ed25ada687"><ix:nonFraction unitRef="usd" contextRef="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0OTc1NTg0MjMyMA_57ef5737-54de-476b-9197-59e0f19580ed">0.6</ix:nonFraction></ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2Njcz_f39986c3-d6c8-4591-926d-0ed2dc3f81d1">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2Nzg5_10163995-c4b1-49c6-b8f4-55d5ffe1d553">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE3Njk3_35621025-6a71-456f-ad27-0e2854827de9">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="iab32404962a644bdabfcb08801f645a6_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE3ODQ2_d81fa645-69d3-46d9-ba4f-4c6a1fe2d846">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MDU3_0ce2078e-6521-49ed-92e3-6554bac00253">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i512e2046bfad40b18b8f73ffbb1a4ded_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MDY0_2bbfc03a-9ac9-4973-b136-d9d04065bd6b">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="iab32404962a644bdabfcb08801f645a6_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MTk1_d81fa645-69d3-46d9-ba4f-4c6a1fe2d846">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MTk5_0ce2078e-6521-49ed-92e3-6554bac00253">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i2be0a365f4f7429497792fd03ebd83c0_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4OTI1_316f0c69-4f1e-441e-9069-8be6891c5455">71.8</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="i7719930d21144dfb90251ca3af9cdb73_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4OTcz_f947e75d-1185-4676-b1f0-5cec6aab3fff">2.5</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i4eb00e88f2384aedbcc301007edfb9e1_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5MTEz_5c1cb48e-dcc2-451f-896b-fbbf2c79915b">28.1</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="ib604663c86e447178b86e5bd16de84b7_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5Mzk1_557612ad-18b1-4266-a726-9c9c31734fb4">41.3</ix:nonFraction>&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5ODY4_14a17087-ff23-46c9-a705-b155dca5811e"><ix:nonFraction unitRef="usd" contextRef="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5ODY4_e546ae68-f4a1-4f48-a03b-f24c618b10cb">0.3</ix:nonFraction></ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwMjE2_b064df25-dc60-497d-93c9-0686c93e5f83">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNjE1_47d27ddf-f850-4c9b-9118-b900cef88799">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNjcw_55d49d11-e3ee-4dac-9842-a4b619391a16">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNzI2_3a02ca0e-256a-4974-b0f7-12aa646b60f1">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i20625cdcac04497c9e28b9fe59688254"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption price equal to <ix:nonFraction unitRef="number" contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwOTY0_56db02c7-2f74-4140-91bd-17dc463b99dd">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2023. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIzNDYw_10ba2491-5a92-48dc-a3a2-e440d78eef60" continuedAt="i125a5b5e163240a2b8220d7e89883134" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2023 and December 31, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i125a5b5e163240a2b8220d7e89883134"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzMtMS0xLTEtMTAxNDIw_65856fd4-df31-4535-a718-03fbd599ae5f">23,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16491b7341a141c18afc36d401c76145_I20221231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzMtMy0xLTEtMTAxNDIw_e740536f-4128-4f47-b331-c460eb5465e9">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzQtMS0xLTEtMTAxNDIw_9fce5ec3-0253-4aa8-b1b2-0dd3f60a7410">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16491b7341a141c18afc36d401c76145_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzQtMy0xLTEtMTAxNDIw_f9a17b95-dff8-4f2a-99bd-11169b6ea36b">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzUtMS0xLTEtMTAxNDIw_0ae3e7d4-8df5-4c3f-94b6-f515032ff583">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16491b7341a141c18afc36d401c76145_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzUtMy0xLTEtMTAxNDIw_e99d1709-632d-478b-b13c-d641ed4af1bc">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzYtMS0xLTEtMTAxNDIw_0a8edc9f-db9d-4857-985b-e658f2cd6698">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16491b7341a141c18afc36d401c76145_I20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzYtMy0xLTEtMTAxNDIw_b80f6398-71c8-4ee6-b968-63247922458b">1.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5726574012447b8981b087a4fceaa8e_I20230331" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzctMS0xLTEtMTAxNDIw_296283fa-f271-482f-bda4-ca1956294d94">38,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2ca0bd32c485ab1c987f756ff7c04_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzctMy0xLTEtMTAxNDIw_70a53efc-3634-4bd0-810e-a41fd5c74ad6">38,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9845ada53344e68b0860c3e9255db86_I20230331" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEwLTEtMS0xLTEwMTQyMA_02144640-1419-4124-bf50-2ee38945f267">169,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEwLTMtMS0xLTEwMTQyMA_7d841c27-f0dd-4876-bbb8-c169ba08352b">168,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9845ada53344e68b0860c3e9255db86_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzExLTEtMS0xLTEwMTQyMA_bf8ecfff-5787-495c-8bbd-1f78fc4a23a1">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzExLTMtMS0xLTEwMTQyMA_0f27b4f9-d274-4094-987c-8a1a3042d6e4">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9845ada53344e68b0860c3e9255db86_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEyLTEtMS0xLTEwMTQyMA_bf9b9f6e-2f7d-4da4-8794-88e8cb227726">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEyLTMtMS0xLTEwMTQyMA_c6311bd4-d57a-460b-a676-4a4035e24a08">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9845ada53344e68b0860c3e9255db86_I20230331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEzLTEtMS0xLTEwMTQyMA_ae90f837-d0dc-4adc-85c1-7dee36c206bb">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEzLTMtMS0xLTEwMTQyMA_8d09b6e4-8170-4274-a4c2-bb5bbdf218b2">2.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9416432cd74f4712b91100ee7fbc1c94_I20230331" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzE0LTEtMS0xLTEwMTQyMA_2f5d6e66-4521-4f02-8482-413aa38e90b2">192,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3eb67937fde4b28be9e30e00861878f_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzE0LTMtMS0xLTEwMTQyMA_d98525d6-ff25-45fe-9dc4-fb98cda12e7a">185,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODA2_dbe0593a-4dac-4453-ad0b-9af0dd8fabd2" continuedAt="if861d11ae0b34910909e828873251824" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if861d11ae0b34910909e828873251824" continuedAt="ibbd6477f6c09489fa61b9329ef093d7b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2023 and December&#160;31, 2022, the Company was party to irrevocable standby letters of credit&#160;with a bank for $<ix:nonFraction unitRef="usd" contextRef="i27fb4a8e6dd3437b85cca6d4d9569ea7_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE3NA_5274bd9f-734a-4fab-b8fd-08f7befb5b57"><ix:nonFraction unitRef="usd" contextRef="id016a79790b94258b28de85b550d8edd_I20221231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE3NA_e174498f-fa20-4210-8d3f-3444befbd0f3">13.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="i507b0865bc8146928bbcd305853a7801_I20230331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzMwMA_54606c36-69cd-43c7-9007-f233624ce99a"><ix:nonFraction unitRef="usd" contextRef="i2e2a5beda11b47868eb4cef319a84fbf_I20220331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzMwMA_db30049f-9ec9-4cc6-9da9-388708f5bedf">13.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2023 and 2022, respectively. The letters of credit have current expiration dates between April 2023 and March 2032 and will automatically extend without amendment for an additional <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="evh:LineOfCreditFacilityAutomaticExtensionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODA4_991e3427-bdd3-4135-baa4-823164522b76">one-year</ix:nonNumeric> period and will continue to automatically extend after each <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODE0_698d0cc8-0f4a-40d1-b6b4-de20003f1bca">one-year</ix:nonNumeric> term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying interim consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibbd6477f6c09489fa61b9329ef093d7b" continuedAt="if6b4e7ee3eae45138742215039e07619"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2023, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of <ix:nonFraction unitRef="customer" contextRef="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331" decimals="INF" name="evh:NumberOfCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY0MzM_d7e4e216-d4c6-40a2-b290-c2d0523b76b1">20</ix:nonFraction> of the Company&#8217;s customers. There were <ix:nonFraction unitRef="usd" contextRef="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE2NDkyNjc0NjU2NjM_345297f4-5fb2-4c14-84a5-8a6195f38b8c">no</ix:nonFraction> expenses associated with the UPMC Reseller Agreement for the three months ended March 31, 2023, and $<ix:nonFraction unitRef="usd" contextRef="ic0b19710891c484c82d272a4acf72ba5_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY1Nzc_59cd8638-c18b-4a09-88e1-420c51bc8db2">0.6</ix:nonFraction>&#160;million for the three months ended March 31, 2022. The contract is currently being wound down. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="INF" name="evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY4ODE_e91925bb-a381-4d92-9a69-ddaf65d8ad69">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the NIA acquisition, the Company has recorded the remaining TRA liability of $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzczMzg_a1f66602-dc46-424a-8139-3073f6de6f6d">66.2</ix:nonFraction>&#160;million for the three months ended March 31, 2023, resulting in a total TRA liability of $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE2NDkyNjc0NjU3MDE_8974d18c-0347-4e16-b623-a45630f2945f">112.1</ix:nonFraction> million as of March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if6b4e7ee3eae45138742215039e07619" continuedAt="ia813c75c98624e658bcae0f3182c905e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2023, approximately <ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExMzMy_7a03a41d-dd29-445b-bb4d-0794191e805a">99.1</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExMzQy_15a86276-bbcd-4818-84d5-573972949e24">192.0</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExNDkz_af9c4294-3195-4330-a72e-d6144c1e71f6">0.9</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company has not experienced any realized losses on cash and cash equivalents to date; however, no assurances can be provided.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODE1_d57006c4-8707-49aa-8270-5645de47779c" continuedAt="i810a347e8125428d9aeef54960246b23" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i810a347e8125428d9aeef54960246b23" continuedAt="i0822f1a6c8e640af94151ce45e3fc301"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice83adaf23a14ba0a5a83118b1a20fdb_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzItMS0xLTEtMTAxNDIw_8419abe9-77a5-4467-8543-20bccf7d0c92">34.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i637797ac467b47efa165f840c0332476_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzItMy0xLTEtMTAxNDIw_a37fd754-ec93-4263-be1e-3911cb04d06d">42.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25f7148e093b474dadb164557530b7b8_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzQtMS0xLTEtMTAxNDIw_154dc9d4-3cb8-4c89-9a90-b6db52677466">17.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae61262e7624b0d984871d542365619_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzQtMy0xLTEtMTAxNDIw_dee25749-e34c-4312-ac45-72972b6e8bdd">12.0</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12b6b23d17104a8e9b6c457000fbeea2_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzUtMy0xLTEtMTAxNDIw_9ecb730f-c917-4d7b-a078-e8934a592187">11.3</ix:nonFraction>%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0822f1a6c8e640af94151ce45e3fc301"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:86.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:86.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c0832ebff07400ea476f7c58f11cc67_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzItNS0xLTEtMTAxNDIw_94e29f4a-c528-4980-a879-102e645aec37">17.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie192bdf6ff324e978b378295e4252596_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzItNy0xLTEtMTAxNDIw_d6f4ff6a-8384-4b3c-8a2d-337b7e6322b0">23.9</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f62d774a64e46899704a37239c377c3_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzMtNS0xLTEtMTAxNDIw_bc9f28c0-4390-48dd-bc7a-71ea1472fe95">11.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib29e30cc2b08429d885dd5e19d4d420c_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzMtNy0xLTEtMTAxNDIw_14aa7156-f362-4691-9ede-bac941564197">11.9</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34fc6c7947c34d74ac1f466cf78dbd92_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzQtNS0xLTEtMTExMTQx_53a34e91-42fd-4989-ac20-aab9ccf77425">13.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia813c75c98624e658bcae0f3182c905e">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzM_756e6225-740d-4076-be00-6ac52a346c85" continuedAt="ib7ff52cd4abf475e97ca2e3dda7e736b" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib7ff52cd4abf475e97ca2e3dda7e736b" continuedAt="i5d66d585103b486aa5df240636fc6609"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzQyNg_8ee093da-7f25-4eca-a8c0-03fb1abbd553">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="i23c68de8493844868847bcbb42b75777_I20230331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI2NjE_5ee25ddc-13a3-4c5a-ae7a-e8d144e6b58d"><ix:nonFraction unitRef="usd" contextRef="ic2494b7c3cda44bcb468b99115c25994_I20221231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI2NjE_f99e75b3-a8d9-4248-b2ec-ab825802fde9">2.1</ix:nonFraction></ix:nonFraction> million in letters of credit as of both March&#160;31, 2023 and December 31, 2022, respectively. As of March&#160;31, 2023 and December 31, 2022, the Company held $<ix:nonFraction unitRef="usd" contextRef="i23c68de8493844868847bcbb42b75777_I20230331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI3NjE_4630a26e-192d-4e6c-b2d8-341453e532c0">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic2494b7c3cda44bcb468b99115c25994_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzU0OTc1NTgxNzMyMQ_69b4022b-8c90-421a-90b1-3d9acd025329">2.3</ix:nonFraction>&#160;million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzQ_a987717a-c670-4bea-afe4-a57573b11dbe" continuedAt="i2f842d6c3ebd4ff88381d49d977948ea" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2023 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d1d9ed997744f43b91313620e282985_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtMi0xLTEtMTAxNDIw_fac2157a-52c0-4e09-a879-bfc13a7451a1">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1d9ed997744f43b91313620e282985_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtNC0xLTEtMTAxNDIw_78bfa117-8eaa-466c-9e1e-90a0b015b0d3">28,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1d9ed997744f43b91313620e282985_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtNi0xLTEtMTAxNDIw_0a142a0d-aa9c-4147-98ee-e9b857b909a4">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f75598fe1bf467ca300361df6965225_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItMi0xLTEtMTAxNDIw_55e462e3-cb70-4092-8e63-098ef9bd0e63">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f75598fe1bf467ca300361df6965225_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItNC0xLTEtMTAxNDIw_6070a337-3662-4b2e-88d1-791f7fc0919b">37,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f75598fe1bf467ca300361df6965225_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItNi0xLTEtMTAxNDIw_21b4de9f-8ae6-4684-b7c3-4ae9cb237fbe">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtMi0xLTEtMTAxNDIw_d5a86232-d82f-4919-8451-2d9ca74e867e">3.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtNC0xLTEtMTAxNDIw_a958b947-1984-4e69-af08-553b5dbc16bb">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtNi0xLTEtMTAxNDIw_1e87d46a-cb53-421b-a98f-995c220a5694">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtMi0xLTEtMTAxNDIw_a54ec528-d7bf-4eb0-93f7-cba84a54086d">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtNC0xLTEtMTAxNDIw_3d249412-7431-4c59-b461-db68ae213ab6">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtNi0xLTEtMTAxNDIw_86dd7f2b-8a46-4b35-a2be-6f71626c0a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtMi0xLTEtMTAxNDIw_717648e6-4211-4514-8de6-b3d9b9430ae2">0.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtNC0xLTEtMTAxNDIw_182ba6bd-b48a-401f-8582-127157108a33">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtNi0xLTEtMTAxNDIw_074d381c-3274-452c-9ac3-1fbf472915ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtMi0xLTEtMTAxNDIw_8a7b365e-184e-4696-9ed4-8e2867de0c48">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtNC0xLTEtMTAxNDIw_d4612793-3d83-4c8f-86b6-d040b533f7d0">4,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtNi0xLTEtMTAxNDIw_f8a73708-796e-47b2-805c-433b0a3dcd44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzU_fb23a18b-81e8-473c-b3f9-c3ca227ebea9" continuedAt="ie98da254f1984b68bc5f55176d5a432d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"></td><td style="width:65.238%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.380%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzItNS0xLTEtMTAxNDIw_e317acd7-6427-4f5c-86f9-e2f1fb6eb862">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzItNy0xLTEtMTAxNDIw_5e851c26-8b26-4a6a-a5b5-81105eb78136">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzUtNS0xLTEtMTAxNDIw_8e5ea141-fe10-4831-8566-fe55a1f63700">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzUtNy0xLTEtMTAxNDIw_8858c49b-b5a6-4d4c-afd5-24936e4493ec">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzYtNS0xLTEtMTAxNDIw_af653e21-1223-4d17-8a15-57cef4149801">3,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzYtNy0xLTEtMTAxNDIw_98824367-9b29-471d-9569-b52038402fde">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5d66d585103b486aa5df240636fc6609"><ix:continuation id="i2f842d6c3ebd4ff88381d49d977948ea"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzEtMS0xLTEtMTAxNDIw_f619179c-89b4-4f10-9f82-0188f28dbd9e">5,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzItMS0xLTEtMTAxNDIw_00d9dc44-facd-4847-8539-09df76c86ba2">10,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzMtMS0xLTEtMTAxNDIw_f8acf4f4-5948-4756-9ce5-9b000c7746fb">10,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzQtMS0xLTEtMTAxNDIw_4e80fb59-6d83-4800-96bb-37c5fb739eac">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzUtMS0xLTEtMTAxNDIw_2c218a40-8f28-4f28-a542-024b6e46ace9">8,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="evh:LesseeOperatingLeaseLiabilityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzYtMS0xLTEtMTAxNDIw_7fee020d-ff49-4e66-a8a1-13d82a15ec0f">31,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzctMS0xLTEtMTAxNDIw_bdda429b-8f6e-476c-a870-1da091c4b922">75,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzktMS0xLTEtMTAxNDIw_263b74d4-5a6e-42d1-9b0f-c9b362b505aa">16,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzEwLTEtMS0xLTEwMTQyMA_c1a1230d-bb80-4b16-b1c8-ca16ff83e6aa">58,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie98da254f1984b68bc5f55176d5a432d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTphOGEyMDU1MDkxY2E0MDc0OGJkNGUwM2Q5MGVkMGVjOC90YWJsZXJhbmdlOmE4YTIwNTUwOTFjYTQwNzQ4YmQ0ZTAzZDkwZWQwZWM4XzItMS0xLTEtMTAxNDIw_5d28cddc-2bab-401d-90b6-b9298c0dae8c">6.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTphOGEyMDU1MDkxY2E0MDc0OGJkNGUwM2Q5MGVkMGVjOC90YWJsZXJhbmdlOmE4YTIwNTUwOTFjYTQwNzQ4YmQ0ZTAzZDkwZWQwZWM4XzMtMS0xLTEtMTAxNDIw_7eef5592-e4dc-48d7-8578-ee549e6d0ba2">8.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_2483"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="evh:TemporaryEquityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl8zMjk4NTM0ODkyNjAz_4ff00ee0-89f9-4b63-988d-7742c1b15c1e" continuedAt="i915d2c6bf502470386b3a7a45cd22d3d" escape="true">Convertible Preferred Equity</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i915d2c6bf502470386b3a7a45cd22d3d" continuedAt="i0ca8c154dbc04000a9dcfe91cbf1eed2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company offered and sold to the Purchasers an aggregate <ix:nonFraction unitRef="shares" contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120" decimals="-3" name="evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85MzU5_afe2cb1f-6514-464e-9c8b-dcc50bd8540d">175,000</ix:nonFraction> shares of the Company&#8217;s newly created Cumulative Series A Preferred Shares, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85MzY5_3ff66c82-22b7-4cdc-b36d-7dc866a33770">0.01</ix:nonFraction> (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120" decimals="2" name="evh:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzcz_b1a22038-e575-43c0-aef3-47ba6ea23d36">960.00</ix:nonFraction> per share, resulting in total gross proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzc3_2e6518c3-c12e-4370-9929-904c36073f58">168.0</ix:nonFraction>&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#8217;s Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i1dfbe078bc7f430697d2a7b1b12e6204_I20230120" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzgx_0f1f9067-8354-4dc5-ac87-d68dc545b251">0.01</ix:nonFraction> per share and all future series of the Company&#8217;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzg1_beee4743-7084-47f4-972c-3aed3a466578">1,000.00</ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus <ix:nonFraction unitRef="number" contextRef="i401ab859effb48808de07f4a1e3c6d16_I20230120" decimals="4" name="evh:TemporaryEquityVariableDividendRateBasisSpread" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzg5_227f6027-7bf0-4508-8b36-d179cf4fd008">6.00</ix:nonFraction>%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by <ix:nonFraction unitRef="number" contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120" decimals="3" name="evh:TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzkz_2f904258-dd90-42e7-a348-fa756d40fd50">2.0</ix:nonFraction>% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#8217;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120" decimals="2" name="evh:TemporaryEquityConvertibleConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzk3_d64c28f1-e68d-4c7f-8417-3e5fc97f1195">40.00</ix:nonFraction> of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="i2add3c8d25f94736a9517cf9293a956c_I20230120" decimals="4" name="evh:TemporaryEquityRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDAx_647e6484-598a-4a18-887d-458bfff522b9">165.00</ix:nonFraction>% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0ca8c154dbc04000a9dcfe91cbf1eed2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="i9cca87e30358452e84669a73df40af76_I20230120" decimals="4" name="evh:TemporaryEquityRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDA1_2b1934f9-d808-4a1c-bbc4-b82a4cb4b79b">150.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="i87668a6ea647431c972d8f8fa361cf97_I20230120" decimals="INF" name="evh:TemporaryEquityRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDA5_49dfb49f-054c-4be1-a3c0-790b68b5f0cf">165.00</ix:nonFraction>% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Change of Control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) <ix:nonFraction unitRef="number" contextRef="ie14b7cf7aca4447892720b9d169358bf_I20230120" decimals="INF" name="evh:TemporaryEquityRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDEz_95098fbb-9c53-428b-aba5-24bddefc28b3">150.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and <ix:nonFraction unitRef="number" contextRef="id704c5c418084a8387e935db5922f100_I20230120" decimals="INF" name="evh:TemporaryEquityRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDE3_d679472e-1107-4825-a877-b65a39020006">135.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, the Company entered into an Investors Rights Agreement with the Purchasers named in Schedule I thereto (the &#8220;Investors Rights Agreement&#8221;). The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Investors Rights Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders named in Schedule I thereto, which granted certain registration rights to Ares in respect of the shares of the Company&#8217;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl82NTk3MDY5Nzc2OTI3_3dcfad11-ad4e-4674-8eef-b9bcde6c3cb6">3.7</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331" decimals="2" name="evh:TemporaryEquityDividendRatePerDollarAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl81NDk3NTU4MjQ1Mzg_6e62df11-87f9-4684-80bb-b5593807e8a7">20.86</ix:nonFraction> per share of Series A Preferred Stock, and accreted $<ix:nonFraction unitRef="usd" contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331" decimals="-5" name="evh:TemporaryEquityAccretionToRedemptionValueAndDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl81NDk3NTU4MjM5MzI_61fd419f-f82c-4f4e-aa90-ae51d9b23b43">2.6</ix:nonFraction>&#160;million of deferred issuance costs in additional paid-in-capital on the consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_157"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4Nw_21431bb3-1340-4ae6-b3aa-86c7ad95d692" continuedAt="i0ac943f49ca245beb89e67c12885a6f6" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0ac943f49ca245beb89e67c12885a6f6"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4Ng_3516f18e-c526-4c90-bfa6-237212f26ece" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_c24049ed-f3ce-473f-90b1-4c8a63bdcd39"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_c84f3663-43a4-46fd-b1c1-95d6e2698772"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_e7c97b85-bbfe-4c04-b528-64ccc7462a6b"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_e987f5fa-6d07-42e6-9cc0-ba4138bd2c4f">26,258</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_1980d515-ef65-4c46-96a0-5dc3770d0a47"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_47d5cef9-3e2c-4522-b85f-2df07ec3bc4e"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_8185dac2-be1c-4f17-b3b3-c697c41afdbc"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_a50c1c3b-fe74-4cfa-924d-bae05b476b79">5,350</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNS0xLTEtMTAxNDIw_713b7515-df01-4066-a235-37cc819d23e6"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNS0xLTEtMTAxNDIw_9c316804-1f36-45f2-beb9-2b2bc60d99aa">107,783</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNy0xLTEtMTAxNDIw_3c84eed5-d87d-45a0-8d09-28bb088d1048"><ix:nonFraction unitRef="shares" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNy0xLTEtMTAxNDIw_6a850953-589b-406d-9a8b-bf62ff764231">89,509</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTUtMS0xLTEwMTQyMA_a832f1ce-4f6e-4c9f-9657-58b10951bada"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTUtMS0xLTEwMTQyMA_b6527866-453d-4e92-a30a-4bf04344a6d7">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTctMS0xLTEwMTQyMA_4e751178-48c2-47e3-bffc-4aaf15ec3888"><ix:nonFraction unitRef="usdPerShare" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTctMS0xLTEwMTQyMA_90d78023-6930-4a04-99c9-2d97279d9b93">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4OA_fc457ac4-25f2-4998-9ade-5305e9007081" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2eba541d136f4310a4704831029d9705_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzItNS0xLTEtMTAxNDIw_059f7e85-eb69-4613-b970-47698759b07c">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i492d89de66e04f9b8c3db6a93fd81175_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzItNy0xLTEtMTAxNDIw_acb05358-7ccd-45c3-9ff9-cbe8caf6a1aa">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i476893462fa74bf58564ab53bd877692_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzMtNS0xLTEtMTAxNDIw_b2ee6b56-0a93-4661-b848-4671a2c8b4e2">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83e4b979a9e74d449368aa622d2794fe_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzMtNy0xLTEtMTAxNDIw_e9dd949f-9087-483f-baac-2832cb52e9ac">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a52a2247ce344d0bbdf4224e23b18a3_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNS0xLTEtMTA3NTU2_5e53241e-c487-4a80-be14-ecf6ad997dc8">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iede7c70b83d54696aa5c016fe07b1c1b_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNy0xLTEtMTA3NTU2_39a8d8e1-2641-4055-ad4e-24ac996e65c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddcae13946194fcaa1af1a86f752c869_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNS0xLTEtMTAxNDIw_8b04686f-7aad-4ba6-826a-1bc0cf876662">6,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5af55fd09f6415f8a087fe94b7ac65b_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNy0xLTEtMTAxNDIw_56aee0f0-4257-4095-ad85-cd89d29586a6">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzUtNS0xLTEtMTAxNDIw_45549b25-a124-478d-bb28-ec1207eb177e">13,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzUtNy0xLTEtMTAxNDIw_1c776f40-b36a-41df-9eb8-e0f6ff915555">15,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_274"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyMw_c83454c8-656b-4cdb-a5bd-3a210182ce04" continuedAt="i0a710bf365164a3ea904885d558262bc" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0a710bf365164a3ea904885d558262bc" continuedAt="i3a7975acfad64ab4b39c988dfc63f2b2"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyNA_8bee4e66-7d40-46ed-8cac-e7d24c0814ec" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:414.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c894fc3e14c4be68a1ebd94daafd420_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzMtNS0xLTEtMTAxNDIw_793520c9-2cf9-4b5a-b0b0-6001a7a1b72a">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb4a2f5fe174475b5ce81a76c55e2b3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzMtNy0xLTEtMTAxNDIw_5d19b182-8930-4cd8-a0e4-a5f286d6b3e2">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzQtNS0xLTEtMTAxNDIw_e8267bc4-43a3-46f3-9514-6aa4ce5c8148">7,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzQtNy0xLTEtMTAxNDIw_f51b3bcb-2d8f-48e4-9fd4-6458dde951b5">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzUtNS0xLTEtMTAxNDIw_12f6396c-bcc6-4c44-92dc-d9e43cefe587">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96c354afa0c4e3c9db694479ca3a37d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzUtNy0xLTEtMTAxNDIw_3646119a-de05-4530-b3b0-1a9edc5eea1b">775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzYtNS0xLTEtMTAxNDIw_82c1712d-868b-44e8-b3f6-401a06bc18e4">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzYtNy0xLTEtMTAxNDIw_49bcd88d-be80-4cc2-93aa-59df1765cecf">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzctNS0xLTEtMTAxNDIw_6ea49f50-b177-450e-a3f9-d14d57ad2c61">10,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzctNy0xLTEtMTAxNDIw_72455d30-3400-41d6-b4e6-0ec3ed97a50b">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d69bebdcc784d5d883a6d0f4540fe50_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEwLTUtMS0xLTEwMTQyMA_ea24988b-e6be-474c-86b7-91d682b71877">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70cae9e2b7d4e58b25f32a9c3d73a3b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEwLTctMS0xLTEwMTQyMA_adc6cf0b-36ae-4410-9c88-b6427730908b">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6a4f64f12d41fc8e3d1bdb59b392cc_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzExLTUtMS0xLTEwMTQyMA_f704b26c-ea99-4854-aa89-53d168b4acea">9,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33450827a3f4e9d919295348407f1bf_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzExLTctMS0xLTEwMTQyMA_e5a4e706-e45b-4ae9-809c-0bb1edc10285">4,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEyLTUtMS0xLTEwMTQyMA_371fab01-d07f-448a-81c8-f4a0e0bbfd46">10,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEyLTctMS0xLTEwMTQyMA_72455d30-3400-41d6-b4e6-0ec3ed97a50b">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3a7975acfad64ab4b39c988dfc63f2b2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_139149f2-8752-4b6b-b9be-a8d90a46c34b"><ix:nonFraction unitRef="usd" contextRef="i6c41447859d3478b9bf4c5cd97653cc5_D20210101-20210331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_70703995-6201-4ec2-bfd3-6b8d3413b041"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_985d2e98-807e-4335-804f-482904d652a4">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyNQ_636ac72d-0b72-4fb4-83ac-b37d28eb9023" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:358.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzItNS0xLTEtMTAxNDIw_cefeb6bd-12f2-4be2-a9a4-553d41f4ec63">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzItNy0xLTEtMTAxNDIw_c2b7f11a-8c66-4714-a75a-c6e50b01fa0a">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzMtNS0xLTEtMTAxNDIw_0722ee10-ee04-4791-a5f4-a9547cea13ff">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzMtNy0xLTEtMTAxNDIw_233c9225-e242-4da1-9f7c-08ffd41d9bf0">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_277"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzIyMDQ_e707b6d6-3446-44fb-92fd-6ea9ffe05d03" continuedAt="i1cac64004f1042b8949479241bfbc077" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1cac64004f1042b8949479241bfbc077"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An income tax provision (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzQ1Mw_8e59020b-aea3-4d3a-8f71-e7c316215e9b">68.2</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0OTc1NTgxNjA5Ng_b2962c5b-4d5c-46ed-8368-1986f716c866">1.2</ix:nonFraction>&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively, which resulted in effective tax rates of <ix:nonFraction unitRef="number" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0NQ_e861366d-5d23-42f7-a27c-713800aac9e9">77.3</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU1Mg_8d3660a4-b480-4064-9973-d57591c9dea4">29.0</ix:nonFraction>)%, respectively. The income tax benefit recorded during the three months ended March 31, 2023, primarily relates to $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzk0Mg_20160b9c-e6af-41de-ac98-1aa760ef02be">56.1</ix:nonFraction>&#160;million for the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the NIA acquisition accounting and $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="evh:TaxReceivablesAgreementTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0OTc1NTgxODIyNg_81c9a88d-4cf5-46b2-8f19-db283bb92bcd">8.3</ix:nonFraction>&#160;million for the TRA liabilities that will create current and future tax benefits upon settlement. The income tax expense recorded during the three months ended March 31, 2022, primarily related to state and foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzE1MTg_12edeb26-8dc6-4508-8928-91440e3c9fa5">1.6</ix:nonFraction>&#160;million that, if recognized, would affect the overall effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="INF" name="evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzE5MDg_3cf9f670-ab78-4302-ba1e-3fc55a8d6e01">85</ix:nonFraction>% of the amount of the tax benefits that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above for discussion of our TRA.</span></div></ix:continuation><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_172"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIyMTk_9708b7bf-f79c-4abe-8542-87c7c76a1fd8" continuedAt="i1705d2465f984dce88220752a9b6d042" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1705d2465f984dce88220752a9b6d042"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2023 and December&#160;31, 2022, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i0b9a2f209add49c28eaca381d3e00ea3_I20230331" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNDM_4a973c5d-c542-4115-aebb-76803f6744ac"><ix:nonFraction unitRef="number" contextRef="i3d01f3131ee44567b61845961fc57356_I20221231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNDM_8fe09248-046e-4c25-885e-8f98ffb54b94">4</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3b079f58e6d143e9bf0218c70cddb93a_I20221231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNTA_64809e21-96b0-46c8-a492-8aada77e8aa6"><ix:nonFraction unitRef="number" contextRef="ib02f997833034f13959b8d48cf3f413b_I20230331" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNTA_aa3e14d1-59d5-4b0b-ad6f-61cf858d8194">38</ix:nonFraction></ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i3d01f3131ee44567b61845961fc57356_I20221231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTE_7599d5da-773b-456b-beec-3f263f5278e0"><ix:nonFraction unitRef="number" contextRef="i0b9a2f209add49c28eaca381d3e00ea3_I20230331" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTE_c93450bc-3629-40fe-8134-e750fa4029c8">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib02f997833034f13959b8d48cf3f413b_I20230331" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTg_00f39cc7-9ac8-4b3f-9e2b-d52ef3e60f08"><ix:nonFraction unitRef="number" contextRef="i3b079f58e6d143e9bf0218c70cddb93a_I20221231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTg_24b72873-43a5-4c81-992d-3c1d4b702985">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzE4MDA_d4cb1d82-1d07-4ebe-bbe4-a48199583f12">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzE4MDU_ef75abe3-3ca9-414c-8a16-28fb0817b0ac">0.6</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="i0bafc71fd6ff4258ba1f07d59a2d2c26_D20230101-20230331" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIxMzM_132f8dff-7302-4859-8038-d52a732f9aa8">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6a6d740e3f65457ab486cd579e644ba8_D20220101-20220331" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIxMzg_944542cd-f022-42f7-989f-555e7f5a8978">3.6</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_175"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODY_2b2d43a6-34eb-4bcc-9ed5-4a3a4b4fcd2b" continuedAt="i5e4d7316be2a4ee18e42e52f4e547559" escape="true"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODc_ccc2f4d7-bed0-44ab-b49a-06cb06e2d7e3" continuedAt="i1c3000dcc83649f09d118723d8c89af2" escape="true">Fair Value Measurement</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1c3000dcc83649f09d118723d8c89af2" continuedAt="ia7c3b19a1d6e40e4854a14d920aabbf3"><ix:continuation id="i5e4d7316be2a4ee18e42e52f4e547559" continuedAt="i567c026cf4314fc49fbf7758f2150c2a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODg_b51ca5fb-edf7-4807-84ab-6bb2ff8dee62" continuedAt="i09d8313f997c42658e2b4f523542889f" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i09d8313f997c42658e2b4f523542889f" continuedAt="i9acc6ee2ad23456bb4b8ddb2935ab905"> </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9acc6ee2ad23456bb4b8ddb2935ab905"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c3f6529d1a407f9fb18c47de384547_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtMS0xLTEtMTAxNDIw_fef7104d-4ffe-4172-8d09-6ed05bf09735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie128286c0dfa444dbd95773bf5ec6363_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtMy0xLTEtMTAxNDIw_cd63ec13-244e-4d20-9097-7d8426626a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtNS0xLTEtMTAxNDIw_e15d5103-3103-4951-be23-981594e337b5">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtNy0xLTEtMTAxNDIw_05141f62-5f62-4f08-b940-605a35c15308">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c3f6529d1a407f9fb18c47de384547_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtMS0xLTEtMTAxNDIw_a021c609-df88-4e23-9a80-acb38035f589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie128286c0dfa444dbd95773bf5ec6363_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtMy0xLTEtMTAxNDIw_1ad30491-92c8-43f2-a3a8-cbfe6ddf7918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtNS0xLTEtMTAxNDIw_dcd2e02f-44ee-43d8-a993-076a4c1065fa">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtNy0xLTEtMTAxNDIw_c6f5cf51-6b88-495d-bcf4-617c400119fc">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d66187bddab45d98d6021e00200a254_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtMS0xLTEtMTAxNDIw_b64d5fb0-f179-45cf-9c06-84dc26b885fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtMy0xLTEtMTAxNDIw_274d70e2-70ec-4365-82ab-9f6e5c4fe1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtNS0xLTEtMTAxNDIw_95155a57-1010-4944-ad04-3e8f8f2803bc">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98252e4304374eba80127e9339ac00ca_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtNy0xLTEtMTAxNDIw_6d570f88-4744-4034-a531-0b96966af654">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d66187bddab45d98d6021e00200a254_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtMS0xLTEtMTAxNDIw_db7b5b63-0fe1-4ad3-b488-3a56562aa0c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtMy0xLTEtMTAxNDIw_715fda90-787a-446b-895f-3fcef1a76302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtNS0xLTEtMTAxNDIw_ea3bcee1-a754-4368-a7ef-c19bae046549">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98252e4304374eba80127e9339ac00ca_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtNy0xLTEtMTAxNDIw_3547ada1-9991-4bc3-8005-7dc25a640442">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.</span></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions of NIA and IPG include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the NIA contingent consideration is the year ending December 31, 2023, and the earnout period for IPG is the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the NIA and IPG contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia7c3b19a1d6e40e4854a14d920aabbf3"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODk_7fc9fb8c-5215-4628-aa72-aa3a487d9868" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzItMS0xLTEtMTAxNDIw_ec016f1d-2875-40d9-adf5-1eb5bd0f5ee9">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzItMy0xLTEtMTAxNDIw_dc09371f-9106-49fd-9e79-8e93bb6d849b">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzMtMS0xLTEtMTAxNDIw_124efe9a-fdcf-4f6b-8124-de828819eea8">69,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzMtMy0xLTEtMTAxNDIw_58e78e9d-7f21-4805-bf76-75d336d366f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzQtMS0xLTEtMTAxNDIw_4d2686b8-29c1-416b-a9fd-8a161c8dd385">29,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzQtMy0xLTEtMTAxNDIw_75bbc39d-a9a1-4304-b73e-2a2225114838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" name="evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMC0xLTEtMTAxNDIw_6680a014-a447-4ee0-882e-987f2070330e"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMC0xLTEtMTAxNDIw_a077718b-bb01-4bc0-8853-d4daa5dcac90">Unrealized (gain) loss, net</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMS0xLTEtMTAxNDIw_0f0e1443-cbc5-4ec2-aad5-04445649a3a7">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMy0xLTEtMTAxNDIw_9fbb7939-f1a7-4eaf-a19b-0428b40bdcdb">3,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzYtMS0xLTEtMTAxNDIw_1a7c2443-aa8f-4a5b-903a-8ae6e78c8c5c">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzYtMy0xLTEtMTAxNDIw_2b5076f1-c7c1-4e4c-8657-7b7df2f4eeb2">32,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyOTA_afd182d4-9a62-4175-85e0-38887bc301af" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzMtMS0xLTEtMTAxNDIw_1ca51577-56b0-4972-a54b-163a2f47f1a4">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f37596d3fb4fd0b55345096a8d3ec5_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzMtNy0xLTEtMTAxNDIw_b2308ebe-403b-41f7-a05d-6a534b633938">122,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ea91b69217d4414bf3a0c1862b782c2_I20230331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246ZTlkZDI1NGE3ODBmNGVjYTg1MWMxODBmMmY3NDM5ZDFfNA_8ddf9734-a044-48c7-abfe-116e01d8a2ee">8.80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iefbfa8e87ea74767877c1bcb1ba75e70_I20230331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246ZTlkZDI1NGE3ODBmNGVjYTg1MWMxODBmMmY3NDM5ZDFfOQ_c885d51b-8528-4862-af50-f69869f90c38">16.64</ix:nonFraction>%</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzMtMS0xLTEtMTAxNDIw_4f2960b6-7c33-400e-bb9f-b881df5694fd">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7838e8cce0d84e3c96376f68234721cc_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzMtNy0xLTEtMTAxNDIw_3af5377b-dffe-41a6-9419-5108b7fbda29">77,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb07d39ed99e4b5493f3f1a76480c9b4_I20221231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246YzI0M2ZlNzYyZDY5NDkxODhjNzBhYjMyM2VlZjI5NDRfMTY0OTI2NzQ0MTY4Ng_ca507cbf-5105-46a6-82e4-bfb1e7821fd9">9.85</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i424e2672ed5c47d6a7f0e6908df8f4fa_I20221231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246YzI0M2ZlNzYyZDY5NDkxODhjNzBhYjMyM2VlZjI5NDRfMTY0OTI2NzQ0MTcwMg_2c5e2181-05a8-46ab-8abe-3ed486c755ed">10.01</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i567c026cf4314fc49fbf7758f2150c2a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90ZXh0cmVnaW9uOmQxNWMwMjJiMjdhMDQyYWI5NDliNzIxN2VlZjg3ODgwXzExNzc_68dbaa93-1d6d-48fd-86c2-7d9225cab91b" continuedAt="ie0a7c19c42b042338cea4a4cde393ad6" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0a7c19c42b042338cea4a4cde393ad6" continuedAt="i8cbdbcdd2b9b42b892cd0fd15e596a16"> </ix:continuation></span></div><ix:continuation id="i8cbdbcdd2b9b42b892cd0fd15e596a16" continuedAt="iee9a61551b1342e79d4d6abba66f70a7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our interim consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee9a61551b1342e79d4d6abba66f70a7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90ZXh0cmVnaW9uOmQxNWMwMjJiMjdhMDQyYWI5NDliNzIxN2VlZjg3ODgwXzExNzQ_a51396ea-e880-4646-9f21-566e1e3fe689" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzQtMS0xLTEtMTAxNDIw_bf292416-de58-4981-aa9a-40d38e64825d">9,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzQtMy0xLTEtMTAxNDIw_3e321c85-7677-4a46-b20f-aac591615190">8,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzktMS0xLTEtMTAxNDIw_f374bd85-ca7b-4d01-b3d7-76f1fcc56d80">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzktMy0xLTEtMTAxNDIw_4c177473-41d2-4a18-b5ed-563bb2977e16">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzEwLTEtMS0xLTEwMTQyMA_f6958d7d-fc0f-4fa7-87ed-fe83cf42d03e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzEwLTMtMS0xLTEwMTQyMA_e72b7eaf-3f44-4757-8441-0d483f12a439">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:358.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzItNS0xLTEtMTAxNDIw_55d965be-3292-4217-bc3d-5fa7293571ec">54,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzItNy0xLTEtMTAxNDIw_47f6d7a2-6db0-4e35-a091-bc35f995ca96">32,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzUtNS0xLTEtMTAxNDIw_84fd8430-407e-4d07-ace6-174a592ebd69">47,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzUtNy0xLTEtMTAxNDIw_193eb81b-7839-4500-9650-b4dd70e02cee">26,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzYtNS0xLTEtMTAxNDIw_2ebed1e7-18af-481d-a7a7-6164d9102ef4">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzYtNy0xLTEtMTAxNDIw_f9772122-1ef7-48eb-82cf-5d58a2e48cea">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_187"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90ZXh0cmVnaW9uOmM0ZjQ4M2Q1NjFiYzRmM2I4OTk4NmIxZGVhN2Y1NjRhXzQ0OTc_f4ef5420-4df3-44ae-92b3-1bd72d05a1ba" continuedAt="i82179e96563d47638ca55d056ac41f9a" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i82179e96563d47638ca55d056ac41f9a" continuedAt="ifd21757738d04647862ebd3c5e880f4a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 10.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifd21757738d04647862ebd3c5e880f4a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90ZXh0cmVnaW9uOmM0ZjQ4M2Q1NjFiYzRmM2I4OTk4NmIxZGVhN2Y1NjRhXzQ0OTk_e728b932-7910-4aae-82c2-a66532b21913" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzMtNS0xLTEtMTAxNDIw_8ea43cff-d5c5-418c-9900-64c1fb7d11f0">199,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzMtMTEtMS0xLTEwMTQyMA_0dff02ac-f8d0-41e8-b526-5003557fc852">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzUtNS0xLTEtMTAxNDIw_35e42b51-7dd1-46af-87aa-334282a03ddd">180,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzUtMTEtMS0xLTEwMTQyMA_ef2434a5-9430-4038-97c6-1d6cde52e9eb">102,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzYtNS0xLTEtMTAxNDIw_7488469a-905f-42d8-adb6-c430da2ea2db">19,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzYtMTEtMS0xLTEwMTQyMA_d4d8b47a-1b12-4b15-9038-d0faa40bc402">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzctNS0xLTEtMTAxNDIw_5faec6e6-d463-4d94-a393-fbf263628202">160,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzctMTEtMS0xLTEwMTQyMA_7dced8d5-d71a-4b69-82ee-b3935f945264">109,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzktNS0xLTEtMTAxNDIw_f5008dc7-af3f-47e9-be2f-2ae3eafb902b">64,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzktMTEtMS0xLTEwMTQyMA_bcc2445d-89a0-458a-a58e-ba17d3950883">47,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEwLTUtMS0xLTEwMTQyMA_da281773-caac-4ebf-b4ee-58f4891776ad">98,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEwLTExLTEtMS0xMDE0MjA_4502d1e2-7ea8-4074-a57e-2186a07d5b75">59,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTUtMS0xLTEwMTQyMA_fc8fdf44-8290-489a-b136-b4de2b1f449d">163,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTExLTEtMS0xMDE0MjA_f6d78775-344d-4667-9b52-754a95d9fd1c">107,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTEtMS0xLTExMzY5MQ_8ff2a094-855a-4d85-bb2b-44ae00ec7aee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTMtMS0xLTExMzY5MQ_0b00429b-1c64-4538-9912-01d2d8774611">9,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEyLTUtMS0xLTEwMTQyMA_c11e6499-dc6f-4dad-b953-319e94c32cd0">197,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEyLTExLTEtMS0xMDE0MjA_52c6bb76-49cf-49bc-9f6e-daf28a7fd596">164,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_193"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90ZXh0cmVnaW9uOmY0ZDUzZTgwMTNmMDQzZjhhY2RkNGU4YmEzNWNlNDllXzEyOA_ce96d356-a5b3-4aaa-ba71-3ea55ec1f2a8" continuedAt="i4ee509896dc04e4f919843a8047e78a3" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4ee509896dc04e4f919843a8047e78a3"><ix:nonNumeric contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90ZXh0cmVnaW9uOmY0ZDUzZTgwMTNmMDQzZjhhY2RkNGU4YmEzNWNlNDllXzEzMA_a8c4c907-8b4d-4ae0-a6f8-0774cf1df323" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:358.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzMtMS0xLTEtMTAxNDIw_78ecb15d-cce1-43a7-9a81-ca7e10fe5b0c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzMtMy0xLTEtMTAxNDIw_8118d72e-3220-40c2-85eb-b404a9b576a7">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzgtMS0xLTEtMTAxNDIw_f728943b-a9f5-423a-83d1-74f681e8c593">261,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzgtMy0xLTEtMTAxNDIw_f5a21860-80f9-4875-b2cb-573bd4fbc798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzExLTEtMS0xLTEwMTQyMA_4b2df67c-7758-4f61-8d37-d0e86db6daf8">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzExLTMtMS0xLTEwMTQyMA_2afa8789-1948-4a7e-a2e3-770b8262df39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzEzLTEtMS0xLTEwMTQyMA_e4510555-39fd-4936-8884-128c885e9661">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzEzLTMtMS0xLTEwMTQyMA_6ea401cd-9f1c-4e68-bd10-b0a6c0841310">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzE0LTEtMS0xLTEwMTQyMA_7d06583c-4bac-4669-a0bb-83776c879521">3,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzE0LTMtMS0xLTEwMTQyMA_00ceb68f-ba72-482e-8523-2548f2429381">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with our interim consolidated financial statements and the accompanying notes to our interim consolidated financial statements presented in &#8220;Part I &#8211; Item 1. Financial Statements&#8221; of this Form 10-Q; our 2022 Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; and our current reports on Form 8-K filed in 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_73"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models. We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Update</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 2020 and 2022, we significantly grew our value-based specialty care business, both organically and through acquisitions. Given the pace of our growth, what we believe to be our high level of competitive differentiation, and the size of potential opportunities in the specialty care market, we began a process in 2023 of revising the way we manage the business, evaluate performance and allocate resources, resulting in an updated segment structure comprised of one segment. We now provide a broad spectrum of specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care improvement along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. We began reporting under this new segment structure as of January 1, 2023. Prior year information has been adjusted to reflect the change in segment reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net income during the year ended March&#160;31, 2023. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:86.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:86.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquisition of NIA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 17, 2022, Evolent Health LLC, a wholly owned subsidiary of the Company, and the Company entered into a definitive agreement for the Company to acquire NIA. On January 20, 2023, we consummated the acquisition of NIA for $387.8&#160;million in cash, $265.0 million in debt financing provided by Ares Capital Corporation and the issuance of 8.5 million shares of Class A common </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stock. NIA reports into Evolent&#8217;s specialty care management offering, New Century Health. Refer to &#8220;Part I - Item 1. Financial Statements - Note 4&#8221; for additional discussion regarding the NIA acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Credit Agreement Amendment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, (&#8220;the NIA Closing Date&#8221;), the Company entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form (i) additional revolving commitments in an aggregate principal amount equal to $25.0 million (the &#8220;Incremental Revolving Facility&#8221; and together with the Initial Revolving Facility, the &#8220;Revolving Facility&#8221;), and (ii) additional term loans in an aggregate principal amount equal to $240.0 million (the &#8220;Incremental Term Loan Facility&#8221; and together with the Initial Term Loan Facility, the &#8220;Term Loan Facility&#8221;; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the &#8220;Credit Facilities&#8221;). The Borrowers borrowed full amount under the Incremental Term Loan Facility  and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) 3.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 3.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. Refer to &#8220;Part I - Item 1. Financial Statements - Note 9&#8221; for additional discussion regarding the amendment to the Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the acquisition of NIA, on January 20, 2023, we entered into a Securities Purchase Agreement pursuant to which the Company offered and sold an aggregate 175,000 shares of Series A Preferred Stock, at a purchase price of $960.00 per share, resulting in total gross proceeds to us of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable for the acquisition of NIA and pay transaction fees and expenses. Refer to &#8220;Part II - Item 8. Financial Statements - Note 12&#8221; for additional discussion regarding the sale of Series A Preferred Stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repositioning Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. In the first quarter of 2023, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. During 2023, we expect to terminate certain leases and recognize impairment charges in connection with the Repositioning Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2022 Form 10-K for a complete summary of our significant accounting policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended March 31, 2023. We will perform our annual impairment test of October 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2&#160;million and increased retained earnings by $39.8&#160;million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1&#160;million and $41.3&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and ongoing services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of claims expense, employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Lives on Platform are calculated by summing monthly members covered for oncology and cardiology specialty care services for contracts not under ASO arrangements, plus members managed by Evolent Care Partners in risk arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">musculoskeletal, advanced imaging and other diagnostics specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for EHS implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our IPG and Vital Decisions programs in a given period. Members covered for more than one category are counted in each category. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Average PMPM fee is defined as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to IPG and Vital Decisions divided by the number of cases for a given period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where clients cross between multiple products, we only capture members from the product with the maximum number of members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has changed its calculation of Lives on Platform to more accurately reflect the membership that corresponds to quarterly revenue.  The Company has recast prior periods to reflect the current presentation of Lives on Platform, PMPM fees, Cases and Revenue per Case.  The current Performance Suite maps to the prior disclosure of the Clinical Solutions Performance Suite. The current Specialty Technology and Services Suite maps to the prior disclosure of the Clinical Solutions New Century Health Technology and Services Suite. The current Administrative Services maps to the prior disclosure of Evolent Health Services segment. There has been no change in the presentation of Cases from prior period.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.8%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.1%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,557)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270.1)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for Three Months Ended March&#160;31, 2023 to 2022 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $130.6 million, or 44.0%, to $427.7 million for the three months ended March 31, 2023, as compared to 2022. This increase is primarily due to $82.5 million from our acquisitions of and launches of new integrated products with NIA, IPG and Vital Decisions, and $48.1 million from the addition of new partners and expansion with existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by end-market (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:434.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s Lives on Platform, Cases, PMPM fees and revenue per case for the three months ended March&#160;31, 2023 and 2022 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Lives on Platform/ Cases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees / Revenue per Case </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Unique Members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $90.7 million, or 41.3%, to $310.5 million for the three months ended March 31, 2023, as compared to 2022, principally as a result of the growth in our revenue. The increase included approximately $56.8 million from higher claims cost from acquisitions and transition from ASO to risk based contracts for certain customers, $25.8 million of higher personnel costs due to increased headcount, employee benefit, bonus accruals for employees and severance payments to former employees and $25.5 million of surgical management costs at IPG. These increases were offset in part by a decrease of $8.1 million in professional fees due primarily to lower costs incurred for contracts that went live during the quarter and third-party service fees for existing customers and a decrease of $8.4 million for the acceleration of amortization of contract costs for certain customers. Approximately $1.5 million and $0.8 million of total personnel costs in costs of revenue was attributable to stock-based compensation expense for the three months ended March 31, 2023, and 2022, respectively. Cost of revenue represented 72.6% and 74.0% of total revenue for the three months ended March 31, 2023, and 2022, respectively. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $30.8 million, or 52.3%, to $89.7 million for the three months ended March 31, 2023, as compared to 2022, principally as a result of the IPG and NIA acquisitions and employee costs across all business units. The increase was primarily driven by higher personnel fees due to increased headcount and expected benefit accruals to employees of $3.8 million, higher stock compensation of $4.6 million due to the achievement and change in projected achievement of certain performance measurements, higher bad debt expense of $4.6 million due to collection timing from our customers, technology services due to higher headcount of $1.4 million, $0.6 million of higher insurance costs, $0.3 million of severance costs and acquisition costs of $11.3 million, offset, in part by lower professional fees from cost savings initiatives of $1.5 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately $9.2 million and $4.5 million of total personnel costs were attributable to stock-based compensation expense for the three months ended March 31, 2023, and 2022, respectively. Acquisition and severance costs accounted for approximately $12.3&#160;million and $0.5&#160;million of total selling, general and administrative expenses for the three months ended March 31, 2023, and 2022, respectively. Selling, general and administrative expenses represented 21.0% and 19.8% of total revenue for the three months ended March 31, 2023, as compared to 2022, respectively. While our selling, general and administrative expenses are expected to grow as we integrate NIA operations, we expect them to decrease as a percentage of our total revenue over the long-term due to cost saving initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $14.2 million, or 93.8%, to $29.3 million for the three months ended March 31, 2023, as compared to 2022 due primarily to amortization of intangible assets acquired through our acquisitions. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a loss on change in fair value of contingent consideration of&#160;$8.6 million&#160;for the three months ended March 31, 2023, related to the liabilities acquired as a result of the acquisitions of NIA in January 2023 and IPG in August 2022, and&#160;$6.1 million for the three months ended March 31, 2022, related to liabilities acquired as a result of the acquisition of Vital Decisions.  See &#8220;Part I - Item 1. Financial Statements - Note 17&#8221; in this Form 10-Q for more information related to changes in the fair value of contingent consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest expense is primarily attributable to our Credit Agreement with Ares Capital Corporation as well as the 2024 Notes and 2025 Convertible Notes. We recorded interest expense (including amortization of deferred financing costs) of approximately $12.9 million and $2.2 million for the three months ended March 31, 2023, and 2022, respectively. The increase in interest expense is driven primarily by the interest expense incurred on our Loans. We expect interest expense to increase during 2023, however, we are focused </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on deleveraging the balance sheet in the long-term thereby decreasing interest expense. See &#8220;Part I - Item 1. Financial Statements - Note 9&#8221; in this Form 10-Q for more information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Tax Receivable Agreement Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the NIA acquisition, the Company has recorded the remaining TRA liability of $66.2&#160;million for the three months ended March 31, 2023, resulting in a total TRA liability of $112.1&#160;million as of March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A provision for (benefit from) income taxes of $(68.2) million and $1.2 million was recognized for the three months ended March 31, 2023, and 2022, respectively, which resulted in effective tax rates of 77.3% and (29.0)%, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_85"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_88"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported operating losses of $(10.4) million and $(2.8) million for the three months ended March 31, 2023, and 2022, respectively. Net cash and restricted cash used in operating activities was $(8.0) million and $(57.4) million for the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had $157.5 million of cash and cash equivalents and $34.5 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies, which may require us to seek sources of financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part I - Item 1. Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:408.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $8.0 million for the three months ended March 31, 2023 were primarily due to our net loss of $20.0 million, non-cash items including depreciation and amortization expenses of $29.3 million, stock-based compensation expense of $10.7 million, deferred tax benefit of $(68.7) million, amortization of contract cost assets of $2.3 million, change in fair value of contingent consideration of $8.6 million and change in our tax receivable liability of $66.2 million. Our operating cash outflows were affected by the timing of our customer and vendor payments primarily driven by cash receipts from certain customers of approximately $39.8 million and a reduction of our accrued compensation and employee benefits due to end of year bonus payments and severance of $31.4 million, offset in part by increases in accounts receivable from our acquisition of NIA of $28.1 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $57.4 million for the three months ended March 31, 2022 were primarily due to our net loss of $5.4 million, non-cash items including depreciation and amortization expenses of $15.1 million, stock-based compensation expense of $5.3 million amortization of contract cost assets of $11.7 million and change in fair value of contingent consideration of $6.1 million. Our operating cash inflows were affected by the timing of our customer and vendor payments driven by increases in accounts receivables and prepaid expenses and other assets and reductions in reserves for claims and performance-based arrangements and accrued compensation and employee benefits contributed approximately $91.9 million to our cash outflows.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $395.0 million in the three months ended March 31, 2023 were primarily attributable to $386.7 million paid for acquisitions and $9.1 million of investments in internal-use software and purchases of property and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $16.8 million in the three months ended March 31, 2022 were primarily attributable to $23.0 million from the transfer of membership and release of Passport escrow offset, in part by, $8.5 million of investments in internal-use software and purchases of property and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by financing activities of $379.7 million in the three months ended March 31, 2023, were primarily related to $256.3 million received from our Acquisition Facilities in connection with our Credit Agreement and $168.0 million from the issuance of preferred equity, offset in part, by $37.5 million of cash outflows related to the payment on our Revolving Facility, $3.7 million of preferred dividends paid on our Series A Preferred Stock and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.6 million from taxes withheld for restricted stock unit vesting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $51.4 million in the three months ended March 31, 2022 were primarily related to a $34.4 million decrease in net working capital balances held on behalf of our partners for claims processing services and $16.2 million from taxes withheld for restricted stock unit vesting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual and Other Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2023. Our estimated contractual obligations (in thousands) as of March&#160;31, 2023, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024-2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026-2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2028+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes interest payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,851&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Operating leases for facilities includes $392 thousand and $1.1 million and $1.2 million of leases not yet commenced for the 2023, 2024-2025 and 2026-2027 time periods, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $415.0 million of aggregate principal amount in a secured term loan, $37.5 million of aggregate principal amount in a secured revolving credit facility. All Loans under the Credit Agreement will mature in 2029. The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as of March&#160;31, 2023, we had 175,000 shares of the Company&#8217;s newly created Cumulative Series A Convertible Preferred Shares. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations) plus 6.00%. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the three months ended March 31, 2023, accounts receivable, net, increased due primarily to the timing of cash receipts from certain customers combined with $28.1 million of receivables acquired as part of the IPG acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $34.5 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $21.4 million, collateral for letters of credit required as security deposits for facility leases of $2.1 million, amounts held with financial institutions for risk-sharing arrangements of $11.0 million as of March&#160;31, 2023. See &#8220;Part I - Item 1. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets are carried at cost and includes prepaid expenses and non-trade accounts receivable. During the three months ended March 31, 2023, prepaid insurance increased as a result of higher premiums and acquisition of NIA.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. As part of our acquisition of NIA in January 2023 we added $404.0 million of intangible assets and $395.2 million of goodwill. As part of our acquisition of IPG in August 2022, we added $195.7 million of intangible assets and $296.6 million of goodwill. See &#8220;Part I - Item 1. Financial Statements - Note 4&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. Payments under the TRA are due within 100 days of filing the Company&#8217;s annual U.S. Federal income tax return. The Company has recorded a TRA liability of $112.1&#160;million as of March 31, 2023. See &#8220;Part I - Item 1. Financial Statements - Note 15&#8221; for further details of the Company&#8217;s TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business, payment of interest on our convertible debt and secured borrowings and payment of preferred dividends. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had cash and cash equivalents and restricted cash and restricted investments of $192.0 million, which consisted of bank deposits with FDIC participating banks of $190.3 million and bank deposits in international banks of $1.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $196.8 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. In addition, as of March&#160;31, 2023, we had $415.0 million of aggregate principal amount in a secured term loan, $37.5 million of aggregate principal amount in a secured revolving credit facility and $175.0 million of Series A Preferred Stock outstanding, all of which are floating rate instruments based on the SOFR and subject to fluctuations in interest rates. In the case of (a) the term loan, interest is calculated at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00%, (b) in the case of a revolving loan, interest is calculated at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00% and (c) in the case of the Series A Preferred Stock, dividends are to be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designation) plus 6.00%. For every 1% increase in SOFR, the Company would record additional interest expense of $4.5 million per annum and preferred dividends of $1.8 million per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the discussion in &#8220;Part I - Item 1. Financial Statements - Note 9&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have foreign currency risks related to our operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee and the Philippine Peso. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation income (loss) of $0.1 million and $(0.1) million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_202"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (&#8220;CEO&#8221;) and the Chief Financial Officer (&#8220;CFO&#8221;), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of March 31, 2023, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 and January 20, 2023, we completed the acquisitions of IPG and NIA, respectively. Under guidelines established by the SEC, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. In conducting our evaluation of the effectiveness of our internal control over financial reporting, we excluded IPG and NIA from our evaluation for the period ended March 31, 2023. We are in the process of integrating IPG and NIA into our system of internal control over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the foregoing, there have been no changes in our internal control over financial reporting that occurred in the quarterly period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Inherent Limitations of Internal Controls</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of legal proceedings included within &#8220;Part I &#8211; Item 1. Financial Statements and Supplementary Data - Note 10 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_250"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;2022 Form 10-K&#8221;). These risk factors are supplemented for the items described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services involve the collection, storage and analysis of confidential information, including intellectual property and personal information of employees, health providers and others, as well as protected health information of our partners&#8217; patients. Because of the extreme sensitivity of this information, the security and privacy features of our computer, network, and communications systems infrastructure are very important. In certain cases, we provide such information to third parties, for example, to the service providers who provide hosting services for our technology platform, and we may be unable to control the use of such information or the security and privacy protections employed by such third parties. We may be required to expend significant capital and other resources to protect against security breaches and/or privacy incidents or to alleviate problems caused by security breaches and/or privacy incidents. Despite our implementation of security and privacy measures designed to help ensure data security and compliance with applicable laws and rules, our facilities and systems, and those of our third-party providers, are vulnerable to threats. Furthermore, our increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic, has heightened these cybersecurity and privacy risks, including risks from cyber-attacks such as phishing, spam emails, hacking, social engineering, and malicious software including harmful malware and ransomware. Threat actors regularly attempt to gain access to our information and infrastructure through various techniques. These threats include cyber-attacks, the use of harmful malware or ransomware, security breaches, acts of vandalism or theft (including by employees), computer viruses, misplaced or lost data, programming and/or human errors, power outages, protected health information leakage from implementing third-party technology to process and share data, hardware failures or other similar events. To date we have not experienced a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cybersecurity incident that has resulted in any material impact on our business, operations or financial results or on our ability to service our partners or run our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, past and future incidents, including if we are unable to effectively resolve breaches in a timely manner, could result in damage to the market perception of the effectiveness of our security and privacy measures and we could lose sales and partners, which could have a material adverse effect on our business, operations, and financial results. A cyber-attack that bypasses our, or our third-party providers&#8217;, security systems successfully could require us to expend significant resources to remediate any damage, and prevent future occurrences, interrupt our operations, damage our reputation and our relationship with our partners, expose us or other third parties to a risk of loss or misuse of confidential information, reduce demand for our products and services or subject us to significant liability through litigation as well as regulatory action. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks continue to evolve in sophistication and volume and may remain undetected for an extended period. In addition, techniques used to obtain unauthorized access to information or to sabotage information technology systems change frequently. We have seen, and will continue to see, industry-wide vulnerabilities, such as the Log4j vulnerability reported in December 2021, which have and could in the future affect our or other parties&#8217; systems. We expect to continue to experience such vulnerabilities in the future. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of attempting to protect against cybersecurity risks and the costs of responding to cyber-attacks are significant. This could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New data security and privacy laws and regulations are being implemented rapidly and are evolving, and we may not be able to timely comply with such requirements, and such requirements may not be compatible with our current processes. For example, regulators in the United States and globally are also inquiring more about and imposing greater monetary fines for privacy violations. In the last year, the FTC has announced that it will begin enforcing the Health Breach Notification Rule, and entered into a consent order with a $1.5 million fine. The FTC and many states (including California, Utah, Colorado, Virginia and Connecticut) have specific </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements for collecting and processing certain data including data minimization, data de-identification, opt out rights, deletion and sharing. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could subject us to liability for non-compliance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of any bank in which we deposit our funds could reduce the amount of cash we have available to pay distributions and make additional investments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Deposit Insurance Corporation only insures amounts up to $250,000 per depositor. It is likely that we will have cash and cash equivalents and restricted cash deposited in certain financial institutions in excess of federally insured levels. Recently, we have seen the abrupt failure of more than one regional bank. Although we did not experience any loss related to these failures, if any of the banking institutions in which we deposit funds ultimately fails, we may lose any amounts of our deposits over federally insured levels. The loss of our deposits could reduce the amount of cash we have available to distribute or invest and could result in a decline in our value. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_253"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, we issued 8,474,576 shares of our Class A common stock in connection with the purchase of NIA. The issuance was exempt from registration under the Securities Act in reliance upon Section 4(a)(2) and Rule 506(b) of the Securities Act as a transaction by an issuer not involving a public offering. We determined that the purchasers of shares of Class A common stock in the transaction were accredited investors. The Company did not engage in a general solicitation or advertising with regard to the issuance and contribution of the Class A common stock issued in connection with the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we issued 849,715 shares of our Class A common stock in connection with a contingent consideration earn-out provision pursuant to the terms of an agreement between the Company and the previous owners of IPG. The issuance was exempt from registration under the Securities Act in reliance upon Section 4(a)(2) and Rule 506(b) of the Securities Act as a transaction by an issuer not involving a public offering. We determined that the purchasers of shares of Class A common stock in the transaction were accredited investors. The Company did not engage in a general solicitation or advertising with regard to the issuance and contribution of the Class A common stock issued in connection with the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_256"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_205"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_232"></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifd52120b191e4627a33957d67c68bb7f_235"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">Amendment No. 1 to Stock and Asset Purchase Agreement dated January 20, 2023, by and among Evolent Health, Inc., Evolent Health LLC, and Magellan Health, Inc. which was filed as Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">.6 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit26.htm">, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit27.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit27.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit27.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890823000029/a123122exhibit27.htm">Amendment No. 2 to Stock and Asset Purchase Agreement dated February 17, 2023, by and among Evolent Health, Inc., Evolent Health LLC, and Magellan Health, Inc. which was filed as Exhibit 2.7 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 24, 2023, and incorporated herein by reference.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm">3.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm">1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Company, dated as of January 19, 2023, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex102.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex102.htm">1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex102.htm">Securities Purchase Agreement, dated as of January 20, 2023, by and among the Purchasers listed on Schedule I thereto and the Company, filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">Investors Rights Agreement, dated as of January 20, 2023, by and among the Purchasers listed on Schedule I thereto and the Company, filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex104.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex104.htm">3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex104.htm">Registration Rights Agreement, dated as of January 20, 2023, by and among the Stockholders named in Schedule I thereto and the Company, filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex105.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex105.htm">4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex105.htm">Registration Rights Agreement, dated as of January 20, 2023, by and between Magellan Health, Inc. and the Company, filed as Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">10.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">Amendment No. 1, dated as of January 20, 2023, to the Credit Agreement, dated as of August 1, 2022, by the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the Company, as the Parent, each other Guarantor party thereto, Ares Capital Corporation, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106.htm">6+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106.htm">Amended and Restated Performance Stock Unit Award Agreement under the Evolent Health, Inc 2015 Omnibus Incentive Compensation Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a33123exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">+ Constitutes a management contract or other compensatory plan or arrangement. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ifd52120b191e4627a33957d67c68bb7f_247"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Accounting Officer and Controller</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  May&#160;3, 2023 </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>exhibit106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2385f1b55901412f9a47fb89893b8937_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.6</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2015 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDED AND RESTATED<br>PERFORMANCE STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of &#91;DATE&#93; between EVOLENT HEALTH, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and ____________.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Stock Unit Award Agreement, as amended and restated effective April &#160;3, 2023 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth the terms and conditions of an award for a target number of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">______</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (such number, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) performance stock units (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (each such performance stock unit, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that are granted to you under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Award constitutes an unfunded and unsecured promise of the Company to deliver (or to cause to be delivered ) to you, subject to the terms of this Award Agreement, one share of the Company&#8217;s Class A Common Stock, $0.01 par value (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or cash equal to the Fair Market Value of one Share, for each PSU ultimately earned by you, as set forth in this Award Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS AWARD IS SUBJECT TO ALL TERMS AND CONDITIONS OF THE PLAN AND THIS AWARD AGREEMENT, INCLUDING THE DISPUTE RESOLUTION PROVISIONS SET FORTH IN SECTION&#160;13 OF THIS AWARD AGREEMENT.  BY SIGNING YOUR NAME BELOW, YOU SHALL HAVE CONFIRMED YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AWARD AGREEMENT.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">The Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award is made pursuant to the Plan, all the terms of which are hereby incorporated in this Award Agreement.  In the event of any conflict between the terms of the Plan and the terms of this Award Agreement, the terms of the Plan shall govern.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Capitalized terms used in this Award Agreement that are not defined in this Award Agreement have the meanings as used or defined in the Plan.  As used in this Award Agreement, the following terms have the meanings set forth below&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3(c).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a day that is not a Saturday, a Sunday or a day on which banking institutions are legally permitted to be closed in the City of New York.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3 (b) and (c). </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Adjusted EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for the Performance Period means the Company&#8217;s cumulative earnings for the applicable Performance Period before interest, taxes, depreciation and amortization, and before stock-based compensation, acquisition expenses and similar non-recurring items, in a manner consistent with the Company&#8217;s publicly-reported adjusted EBITDA.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence, without your written consent, of any of the events or circumstances set forth in clauses (a) through (d) below&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;a material reduction in your annual base salary or target bonus opportunity as the same may be increased from time to time&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;your assignment to duties inconsistent in any material respect with your position, authority or responsibilities with the Company, or any other action or omission by the Company, which results in each case in a material diminution of your position, authority or responsibilities&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;a relocation of your principal work location by more than 50 miles from such location as of immediately prior to the Change of Control&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;any material breach of this Award Agreement by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Good Reason shall not exist unless you give the Company notice of the event giving rise to Good Reason within 60 days of the date you have knowledge of such event.  Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within 90 days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) after such notice is given in accordance with Section&#160;15 of this Award Agreement.  If such breach is not so cured (or is not curable), you may resign for Good Reason within three months following the end of the Cure Period.  If such breach is cured within the Cure Period or if such breach is not cured but you do not resign for Good Reason within three months following the end of the Cure Period, Good Reason shall not exist hereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on &#91;.&#93; and ending on &#91;.&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Replacement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#160;means an award, which, upon a Change of Control, is provided to you as a replacement or substitution for this Award and which&#58; (i) is of the same type as this Award (or a different type from this Award, provided that the Committee, as constituted immediately prior to the Change of Control, finds such type acceptable)&#59; (ii) has an intrinsic value at least equal to the value of this Award&#59; (iii) relates to publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control&#59; (iv) has terms and conditions that comply with the provisions of Section 6(c) of this Agreement&#59; (v) has vesting conditions that continue on the same terms as set forth in this Award&#59; and (vi) has other terms and conditions that are not less favorable to you than the terms and conditions of this Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, a Replacement Award may take the form of a continuation of this Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions set forth in clauses (i) through (vi) are satisfied shall be made by the Committee, as constituted immediately before the Change of Control, in its sole discretion. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s total recognized revenue from customers in a calendar year associated with the Company&#8217;s customer contracts, in a manner consistent with the Company&#8217;s publicly-reported financials. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revenue Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the lesser of (i) &#91;.&#93; and (ii) the Revenue of the Company for the Company&#8217;s &#91;.&#93; fiscal year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">divided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Revenue of the Company for the Company&#8217;s &#91;.&#93; fiscal year.  The Revenue of the Company for the &#91;.&#93; fiscal year was &#91;.&#93;.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section&#160;409A of the Code and the regulations and other interpretive guidance promulgated thereunder, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Subject to the service-vesting provisions set forth in Section 4 of this Award Agreement, the total number of PSUs you earn will be determined at the end of the Performance Period based on the Company Value, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Except as set forth in Section 3(c), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the product of (i) the Cumulative Adjusted EBITDA for the Performance Period, (ii) the Revenue Ratio, and (iii) &#91;.&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;In determining the portion of the Company Value attributable to any business that is acquired by the Company and becomes part of the Company during the Performance Period (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the following rules shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The Company Value shall first be determined without regard to the Acquired Business based on the Cumulative Adjusted EBITDA and Revenue Ratio for the Company (without taking the Acquired Business into account) in accordance with Section 3(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The value of the Acquired Business shall be determined as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;The Cumulative Adjusted EBITDA attributable to the Acquired Business shall be determined by adding all Adjusted EBITDA referable to the Acquired Business from the date of acquisition by the Company through to &#91;.&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;The Revenue Ratio for the Acquired Business shall be the lesser of (i) &#91;.&#93; and (ii) the Revenue attributable to the Acquired Business for the &#91;.&#93; fiscal year of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">divided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the annualized revenue of the Acquired Business for the most recent completed fiscal year of the Acquired Business prior to the date of acquisition by the Company. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;Multiply the product of (A) and (B) above by &#91;.&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;The value determined in (C) shall be reduced by the product of (1) the purchase price to the Company of the Acquired Business and the (2) fraction obtained by dividing the number of full months in the Performance Period that follow the date of the acquisition of the Acquired Business by &#91;.&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The Company Value, including the value of the Acquired Company, for the Performance Period shall be the sum of the amounts in Section 3(c)(i) and Section 3(c)(ii)(D).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;In the event of a Change of Control following the date of the Company&#8217;s acquisition of the Acquired Business and prior to the last day of the Performance Period, the value attributable to the Acquired Business (prior to reduction for a portion of the purchase price to the Company of the Acquired Business in accordance with Section 3(c)(ii)(D)), shall be determined in accordance with Section 6(b)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided however that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the target Cumulative Adjusted EBITDA and the target Revenue for the Acquired Business for any fiscal quarter that has not been completed through the date of the Change of Control shall be determined by the Committee in good faith, taking into account, among other things, the internal business targets for the Acquired Business established by the Company for the Performance Period in connection with the acquisition of the Acquired Business. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;No later than 50 days following the end of the Performance Period, the Committee will review and certify in writing (i) the level of Cumulative Adjusted EBITDA achieved for the Performance Period, (ii) the Revenue Ratio, (iii) the Company Value, and (iv) the number of PSUs that you have earned, if any, for the Performance Period.  The Committee&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certification shall be final, conclusive and binding on you, and on all other persons, to the maximum extent permitted by law.   </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Committee shall, to the extent and in such manner as it deems appropriate, adjust or modify the Performance Goals set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the Performance Period (i) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development affecting the Company, or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), (ii) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or the financial statements of the Company or any of its Affiliates, Subsidiaries, divisions or operating units (to the extent applicable to such Performance Goal), or (iii) in recognition of changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange, accounting principles, law or business conditions.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   The PSUs are subject to forfeiture until vested, as described in this Award Agreement. Except as otherwise provided in Section 6 below, your PSUs will vest and become nonforfeitable on &#91;.&#93;, provided that you remain continuously employed by the Company or any of its Subsidiaries from the grant date of this Award through such vesting date.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeiture of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in Section 6, if your service with the Company and all of its Subsidiaries terminates for any reason before &#91;.&#93;, all of your PSUs shall be immediately forfeited and you shall be entitled to no further payments or benefits with respect thereto.  Further, if you breach any restrictive covenant contained in any arrangements with the Company or a Subsidiary (including this Award Agreement) to which you are subject, all your PSUs shall be immediately forfeited, and you shall be entitled to no further payments or benefits with respect thereto.  Furthermore, any PSUs awarded pursuant to this Award Agreement and any Shares issued to you or cash paid to you under this Award Agreement upon settlement of such PSUs shall be subject to any recoupment or clawback policy the Company maintains, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;If a Change of Control occurs during the Performance Period, and your Award does not remain outstanding following the Change of Control and the acquiror or successor entity neither assumes nor provides a substitute for your Award that meets the requirements of a Replacement Award, then you will be deemed to have earned that number of PSUs as described in Section 6(b) below, effective as of the date of the Change of Control, and your Award shall become vested and nonforfeitable pursuant to Section 4 on &#91;.&#93;, provided that, except as set forth in Section 6(c) or (d) below, you remain continuously employed by the Company or any of its Subsidiaries through &#91;.&#93;.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The number of PSUs earned shall be the determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, based on the Company Value determined as of the date of the Change of Control, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has been completed as of the date of the Change of Control, Cumulative Adjusted EBITDA shall be determined based on the actual Adjusted EBITDA for such quarter&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;For any fiscal quarter in the Performance Period that has not been completed as of the date of the Change of Control, Cumulative Adjusted EBITDA shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be determined based on the target Adjusted EBITDA for each such quarter, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The Revenue Ratio shall be determined by using the target Revenue of the Company for any quarter in &#91;.&#93; which has not been completed as of the Change of Control, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto, and the actual Revenue of the Company for any quarter in &#91;.&#93; that has been completed prior to the Change of Control.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;If you are not subject to a Severance and Change-in-Control Agreement with the Company, and if, within twelve (12) months following the date of the Change of Control but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, the service vesting requirements of Section 4 shall automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;If you are subject to a Severance and Change-in-Control Agreement with the Company and, within the Change in Control Protection Period, as defined in your Severance and Change-in-Control Agreement, but prior to &#91;.&#93;, your employment is terminated by the Company or the acquiror or successor entity without Cause or by you for Good Reason, as those terms are defined in your Severance and Change-in-Control Agreement, then, subject to satisfaction of the release and other requirements of your Severance and Change-in-Control Agreement, the service vesting requirements of Section 4 shall automatically be deemed satisfied, and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination.  For the avoidance of doubt, notwithstanding anything in your Severance and Change-in-Control Agreement to the contrary, any PSUs not earned at the time of the Change of Control pursuant to Section 6(b) above shall be forfeited at the time of the Change of Control.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Settlement of PSUs earned under this Award Agreement shall be, at the Committee&#8217;s sole discretion, either (i) in Shares, which the Company shall deliver to you or your legal representative, (ii) in an amount in cash equal to the Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) of the Shares to be delivered in satisfaction of the PSUs, or (iii) in a combination of Shares and cash.  Settlement shall take place within sixty (60) days following the end of the Performance Period, or, in the event of a termination of employment described in Section 6(c) or (d), within sixty (60) days following your termination date.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall not have any rights or privileges of a stockholder with respect to the PSUs subject to this Award Agreement unless and until certificates representing such Shares are actually issued to you or your legal representative or an entry is recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator) in settlement of this Award.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Transferability of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless otherwise provided by the Committee in its discretion, PSUs may not be sold, assigned, alienated, transferred, pledged, attached or otherwise encumbered except as provided in Section&#160;9(a) of the Plan.  Any purported sale, assignment, alienation, transfer, pledge, attachment or other encumbrance of PSUs in violation of the provisions of this Section&#160;9 and Section&#160;9(a) of the Plan shall be void.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding, Consents and Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The delivery of Shares or cash pursuant to Section&#160;7 of this Award Agreement is conditioned on satisfaction of any applicable withholding taxes in accordance with this Section&#160;10 and Section&#160;9(d) of the Plan.  No later than the date as of which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an amount first becomes includible in your gross income for Federal, state, local or foreign income tax purposes with respect to any PSUs you shall pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any Federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld with respect to such amount.  In the event that there is withholding tax liability in connection with the settlement of the PSUs you may satisfy, in whole or in part, any withholding tax liability by having the Company withhold from the number of Shares or cash you would be entitled to receive upon settlement of the PSUs an amount in cash or a number of Shares having a Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Committee in accordance with applicable withholding requirements) equal to such withholding tax liability.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your rights in respect of the PSUs are conditioned on the receipt to the full satisfaction of the Committee of any required consents that the Committee may determine to be necessary or advisable (including your consent to the Company&#8217;s supplying to any third-party recordkeeper of the Plan such personal information as the Committee deems advisable to administer the Plan).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may affix to certificates for Shares issued pursuant to this Award Agreement any legend that the Committee determines to be necessary or advisable (including to reflect any restrictions to which you may be subject under any applicable securities laws).  The Company may advise the transfer agent to place a stop order against any legended Shares.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms and conditions of this Award Agreement shall be binding upon and shall inure to the benefit of the Company and its successors and assigns.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee shall have full and plenary discretion with respect to any actions to be taken or determinations to be made in connection with this Award Agreement, and its determinations shall be final, binding and conclusive.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the Eastern District of Virginia and (ii) the courts of the State of Virginia for the purposes of any suit, action or other proceeding arising out of this Award Agreement or the Plan.  You and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the Eastern District of Virginia or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Virginia.  You and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party&#8217;s address set forth below shall be effective service of process for any action, suit or proceeding in Virginia with respect to any matters to which you have submitted to jurisdiction in this Section&#160;13(a).  You and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Award Agreement or the Plan in (A) the United States District Court for the Eastern District of Virginia or (B) the courts of the State of Virginia, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of you may have to a trial by jury in respect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any litigation directly or indirectly arising out of, under or in connection with this Award Agreement or the Plan.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby agree to keep confidential the existence of, and any information concerning, a dispute described in this Section&#160;13, except that you may disclose information concerning such dispute to the court that is considering such dispute or to your legal counsel (provided that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the grant of PSUs under this Award Agreement and as a condition to the receipt of the PSUs pursuant to this Award Agreement, you agree that&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;You acknowledge that the Company and its Affiliates continually develop Confidential Information (as defined below), that you may develop Confidential Information for the Company or its Affiliates and that you may learn of Confidential Information during the course of your employment.  You will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by applicable law or for the proper performance of your duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by you incident to your employment or other association with the Company or any of its Affiliates.  You understand that this restriction shall continue to apply after your employment terminates, regardless of the reason for such termination.  The confidentiality obligation under this Section&#160;14 shall not apply to information which is generally known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of you or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Award Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whether or not prepared by the you, shall be the sole and exclusive property of the Company and its Affiliates.  You shall safeguard all Documents and shall surrender to the Company at the time your employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in your possession or control.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business, and any and all information, whether or not publicly known in whole or in part, which, if disclosed by the Company or any of its Affiliates, would assist in competition against them.  Confidential Information includes without limitation such information relating to (A) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (B) the products and services of the Company and its Affiliates, (C) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates, (D) the identity and special needs of the customers of the Company and its Affiliates and (E) the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships.  Confidential Information also includes any information that the Company or any of its Affiliates has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;You agree and acknowledge that the business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which you are or were involved on or prior to your date of termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;You agree that, except as the Company expressly agrees in writing, during your employment with the Company and for the 12-month period following termination of your employment for any reason, you shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever, of or for any person or entity (other than for the Company)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (1) the Business or (2) if you have provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the twelve-month period preceding the termination of your employment with the Company, such customer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding this Section&#160;14(b)(ii)(A), you may accept employment with a Competitor whose business is diversified, provided that (I) such employment is with a portion of the Competitor&#8217;s business that does not provide products or services that are the same as, are similar to, or compete with the Company&#8217;s products or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competing Products or Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (II) prior to your acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from you that you will not provide any Competing Products or Services&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, for a purpose that is competitive with the Business&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;contact, recruit, solicit, hire, retain, or employ (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the 6-month period prior to your date of termination had been, employed or engaged by the Company, or induce or take any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States of America and any other country with respect to which you have been involved on behalf of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in Section&#160;14(b)(ii) of this Award Agreement, you are permitted to own, individually, as a passive investor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;You shall disclose in writing all of your relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or other business entity, to the Company for the 12-month period after your date of termination. You shall not disparage the Company or any of its officers, directors, or employees&#59; provided, however, that this Section&#160;14(b)(iv) shall not prohibit or constrain truthful testimony by you compelled by any valid legal process or valid legal dispute resolution process.  Notwithstanding anything herein to the contrary, nothing in this Section&#160;14 shall prevent either party hereto from enforcing such party&#8217;s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;During the 12-month period following your date of termination, you shall notify in writing any prospective new employer or entity otherwise seeking to engage you that the provisions of this Section&#160;14 exist prior to accepting employment or such other engagement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Section&#160;14 are reasonable and necessary in light of your position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests of the parties hereto.  In addition, any breach of the covenants contained in this Section&#160;14 would cause irreparable harm to the Company, its Subsidiaries and Affiliates, and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Rights&#59; Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, this Award Agreement is not intended to, and shall be interpreted in a manner that does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Exchange Act).  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Under the Defend Trade Secrets Act&#58; (A) no person will be held criminally or civilly liable under federal or state trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is&#58; (1) made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law, or, (2) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public, and (B) a person who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the person and use the trade secret information in the court proceeding, if the person files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices, requests, demands and other communications required or permitted to be given under the terms of this Award Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three Business Days after they have been mailed by U.S. certified or registered mail, return receipt requested, postage prepaid, addressed to the other party as set forth below&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:71.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:34.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800 N. Glebe Road, Suite 500</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arlington, VA 22203 </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to you&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To your address as most recently supplied to the Company and set forth in the Company&#8217;s records</font></td></tr></table></div><div style="text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties may change the address to which notices under this Award Agreement shall be sent by providing written notice to the other in the manner specified above.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award Agreement shall be deemed to be made in the State of Delaware, and the validity, construction and effect of this Award Agreement in all respects shall be determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings and Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Headings are given to the Sections and subsections of this Award Agreement solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Award Agreement or any provision thereof.  Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Award Agreement, they shall be deemed to be followed by the words &#8220;but not limited to&#8221;.  The term &#8220;or&#8221; is not exclusive.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment of this Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate this Award Agreement prospectively or retroactively&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, except as set forth in Section&#160;19(d) of this Award Agreement, any such waiver, amendment, alteration, suspension, discontinuance, cancelation or termination that would impair your rights under this Award Agreement shall not to that extent be effective without your consent (it being understood, notwithstanding the foregoing proviso, that this Award Agreement and the PSUs shall be subject to the provisions of Section&#160;7(c) of the Plan).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;It is intended that the provisions of this Award Agreement be exempt from or comply with Section&#160;409A, and all provisions of this Award Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Neither you nor any of your creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section&#160;409A) payable under this Award Agreement to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section&#160;409A, any deferred compensation (within the meaning of Section&#160;409A) payable to you or for your benefit under this Award Agreement may not be reduced by, or offset against, any amount owing by you to the Company or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;If, at the time of your separation from service (within the meaning of Section&#160;409A), (i) you shall be a specified employee (within the meaning of Section&#160;409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of Section&#160;409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section&#160;409A in order to avoid taxes or penalties under Section&#160;409A, then the Company shall not pay such amount on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise scheduled payment date but shall instead pay it, without interest, on the first Business Day after such six-month period.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Notwithstanding any provision of this Award Agreement to the contrary, in light of the uncertainty with respect to the proper application of Section&#160;409A, the Company reserves the right to make amendments to this Award Agreement as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Section&#160;409A. In any case, you shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on you or for your account in connection with this Award Agreement (including any taxes and penalties under Section&#160;409A), and neither the Company nor any of its Affiliates shall have any obligation to indemnify or otherwise hold you harmless from any or all of such taxes or penalties.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  You and the Company hereby acknowledge and agree that signatures delivered by facsimile or electronic means (including by &#8220;pdf&#8221;) shall be deemed effective for all purposes.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div id="i2385f1b55901412f9a47fb89893b8937_47"></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="i2385f1b55901412f9a47fb89893b8937_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a33123exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5e21877639ef47ffbe6c5ee8570713a3_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a33123exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i097ac3c22dfd4b7bbfba48559700fed3_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a33123exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie709056a706f4ffd89c6ea4ce27e6c60_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a33123exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0fb2603125ec4625943c925d7d3939fc_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-K of the Company for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>evh-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolenthealth.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>0000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>0000008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>0000009 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>0000010 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>0000011 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>0000012 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>0000013 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>0000015 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>0000017 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredEquity" roleURI="http://www.evolenthealth.com/role/ConvertiblePreferredEquity">
        <link:definition>0000018 - Disclosure - Convertible Preferred Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.evolenthealth.com/role/LossPerCommonShare">
        <link:definition>0000019 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>0000020 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>0000022 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>0000023 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>0000024 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>0000025 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>0000026 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>0000027 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>0000028 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>0000029 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>0000030 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>0000031 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000032 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>0000033 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>0000034 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>0000036 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables">
        <link:definition>0000037 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>0000038 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>0000039 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>0000040 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>0000041 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>0000042 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>0000043 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>0000044 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails">
        <link:definition>0000045 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails">
        <link:definition>0000046 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>0000047 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>0000048 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsNarrativeDetails" roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails">
        <link:definition>0000049 - Disclosure - Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsAllocationofAcquisitionCostDetails" roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails">
        <link:definition>0000050 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsProFormaInformationDetails" roleURI="http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails">
        <link:definition>0000051 - Disclosure - Transactions - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000052 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>0000053 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>0000053 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>0000054 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>0000055 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>0000056 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>0000057 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000058 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>0000059 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>0000060 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>0000061 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>0000062 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2022CreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails">
        <link:definition>0000063 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>0000064 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>0000065 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>0000066 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>0000067 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000068 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesCreditandConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails">
        <link:definition>0000069 - Disclosure - Commitments and Contingencies - Credit and Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>0000070 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>0000071 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000072 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>0000073 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>0000073 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>0000074 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredEquityDetails" roleURI="http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails">
        <link:definition>0000075 - Disclosure - Convertible Preferred Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>0000076 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>0000077 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>0000078 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>0000079 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails">
        <link:definition>0000080 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesDetails">
        <link:definition>0000081 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>0000082 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>0000083 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>0000084 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>0000085 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>0000086 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>0000087 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>0000088 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>0000089 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" abstract="false" name="TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_ImplantableProviderGroupIMPMember" abstract="true" name="ImplantableProviderGroupIMPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" abstract="false" name="BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_SpecialtyTechnologyAndServicesSuiteMember" abstract="true" name="SpecialtyTechnologyAndServicesSuiteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_December312023Member" abstract="true" name="December312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossFromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodThreeMember" abstract="true" name="TemporaryEquityRedemptionPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TemporaryEquityDisclosureTextBlock" abstract="false" name="TemporaryEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_TemporaryEquityConvertibleConversionPrice" abstract="false" name="TemporaryEquityConvertibleConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_A2022CreditFacilitiesMember" abstract="true" name="A2022CreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementLiability" abstract="false" name="TaxReceivableAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" abstract="false" name="TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodAxis" abstract="true" name="TemporaryEquityRedemptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_NumberOfOptionsToRenewLeases" abstract="false" name="NumberOfOptionsToRenewLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_EquityComponentOfLongTermDebtMember" abstract="true" name="EquityComponentOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_UPMCResellerAgreementMember" abstract="true" name="UPMCResellerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" abstract="false" name="TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BrightHealthManagementIncMember" abstract="true" name="BrightHealthManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TemporaryEquityVariableDividendRateBasisSpread" abstract="false" name="TemporaryEquityVariableDividendRateBasisSpread" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_LineOfCreditFacilityAutomaticExtensionPeriod" abstract="false" name="LineOfCreditFacilityAutomaticExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_CustomerDiscountsFromPerformanceObligations" abstract="false" name="CustomerDiscountsFromPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_LesseeOperatingLeaseLiabilityAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PerformanceSuiteMember" abstract="true" name="PerformanceSuiteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodValueEarnOuts" abstract="false" name="StockIssuedDuringPeriodValueEarnOuts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" abstract="false" name="AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodFiveMember" abstract="true" name="TemporaryEquityRedemptionPeriodFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_December312024Member" abstract="true" name="December312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TemporaryEquityDividendRatePerDollarAmount" abstract="false" name="TemporaryEquityDividendRatePerDollarAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" abstract="false" name="DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementTaxExpenseBenefit" abstract="false" name="TaxReceivablesAgreementTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" abstract="false" name="LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NationalImagingAssociatesIncNIAMember" abstract="true" name="NationalImagingAssociatesIncNIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_December312025Member" abstract="true" name="December312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodOnePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodOneMember" abstract="true" name="TemporaryEquityRedemptionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodTwoMember" abstract="true" name="TemporaryEquityRedemptionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodSharesEarnOuts" abstract="false" name="StockIssuedDuringPeriodSharesEarnOuts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_DebtInstrumentClosingFeePercent" abstract="false" name="DebtInstrumentClosingFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_ChangesInTaxReceivablesAgreementLiability" abstract="false" name="ChangesInTaxReceivablesAgreementLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_WeightedAverageCommonSharesOutstandingAbstract" abstract="true" name="WeightedAverageCommonSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPricePercentage" abstract="false" name="TemporaryEquityRedemptionPricePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_CasesMember" abstract="true" name="CasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodDomain" abstract="true" name="TemporaryEquityRedemptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_TemporaryEquityRedemptionPeriodFourMember" abstract="true" name="TemporaryEquityRedemptionPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_TemporaryEquityAccretionToRedemptionValueAndDividends" abstract="false" name="TemporaryEquityAccretionToRedemptionValueAndDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="evh_DeferredFinancingFeesMember" abstract="true" name="DeferredFinancingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>evh-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_14885dfe-27e5-4d4b-a512-2068148a28cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_us-gaap_LiabilitiesCurrent_14885dfe-27e5-4d4b-a512-2068148a28cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_38595eea-d311-497c-9d04-9d8c31b2ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_38595eea-d311-497c-9d04-9d8c31b2ec38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1708ee9f-5feb-4fd1-a8ab-e2437b18aa31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1708ee9f-5feb-4fd1-a8ab-e2437b18aa31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e672fe3-e014-4e49-a8ff-11e8faf36005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e672fe3-e014-4e49-a8ff-11e8faf36005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_21423b00-78ee-4649-97c3-f6475cd63d56" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_evh_TaxReceivableAgreementLiability_21423b00-78ee-4649-97c3-f6475cd63d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6be4d2a4-4e65-47cb-baf2-0fa0fc2d95f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef2deb8-ad14-403b-a539-2e5f3e96dc9e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6be4d2a4-4e65-47cb-baf2-0fa0fc2d95f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_9aee2630-360f-484a-8da4-9ccce709bee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_9aee2630-360f-484a-8da4-9ccce709bee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d128eda7-2755-4ae8-bc02-0752abb415f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_AssetsCurrent_d128eda7-2755-4ae8-bc02-0752abb415f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a100645-ad8f-4a2e-87dd-6249ad50b067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a100645-ad8f-4a2e-87dd-6249ad50b067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5c5c85b-638c-4355-a7e4-54bb61977866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5c5c85b-638c-4355-a7e4-54bb61977866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_40a20364-11a2-47b8-b9c0-6f417bf1d807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_40a20364-11a2-47b8-b9c0-6f417bf1d807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e03bca84-b6c0-487c-ba10-d7e65d2b6ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e03bca84-b6c0-487c-ba10-d7e65d2b6ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c8464e52-c538-43a7-b66e-ae0aa0d39b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c8464e52-c538-43a7-b66e-ae0aa0d39b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e6017b2-3045-4d96-9d61-98e09b39d052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_Goodwill_3e6017b2-3045-4d96-9d61-98e09b39d052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_678e78ca-dbf0-44fb-8f8d-cc53c9b866d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_80c4db1f-2b9e-4a35-a37b-1dffc3ae9a8e" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_678e78ca-dbf0-44fb-8f8d-cc53c9b866d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_875c9ebb-e8ea-4896-9b1b-0b4a677c893c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffa8141a-b8eb-496e-bc17-a282b57e6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_875c9ebb-e8ea-4896-9b1b-0b4a677c893c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffa8141a-b8eb-496e-bc17-a282b57e6e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ebed8618-f7a6-4c51-bab0-a888ca134e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_875c9ebb-e8ea-4896-9b1b-0b4a677c893c" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_ebed8618-f7a6-4c51-bab0-a888ca134e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9f38808-c620-447d-b7c9-ef0ff8137998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_875c9ebb-e8ea-4896-9b1b-0b4a677c893c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9f38808-c620-447d-b7c9-ef0ff8137998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019ce677-0f2b-449f-b09c-0ad64269e7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_875c9ebb-e8ea-4896-9b1b-0b4a677c893c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019ce677-0f2b-449f-b09c-0ad64269e7d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6cf55016-902a-41d5-b335-2a58d77a444a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6cf55016-902a-41d5-b335-2a58d77a444a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9eff97a6-09f2-4d46-be70-e5b9b9b61091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9eff97a6-09f2-4d46-be70-e5b9b9b61091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0930eebc-9fa3-4863-b539-5130c5af6b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0930eebc-9fa3-4863-b539-5130c5af6b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6a5ca281-b679-4b27-aa66-23cb9ec036a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:to="loc_us-gaap_CommonStockValue_6a5ca281-b679-4b27-aa66-23cb9ec036a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_859287f8-d855-4d27-b0e3-a56f181c53b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0477c804-199f-4045-9f58-08779150ff3f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_859287f8-d855-4d27-b0e3-a56f181c53b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f2f401ca-fdf6-4439-b47c-0fdfa6b0cfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f0637196-8dbe-41b8-b293-11a2a76a5bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f2f401ca-fdf6-4439-b47c-0fdfa6b0cfe3" xlink:to="loc_us-gaap_Liabilities_f0637196-8dbe-41b8-b293-11a2a76a5bb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8caae95f-1254-444a-9610-5030207215fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f2f401ca-fdf6-4439-b47c-0fdfa6b0cfe3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8caae95f-1254-444a-9610-5030207215fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f86034a6-417e-45b9-b997-55c858246fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f2f401ca-fdf6-4439-b47c-0fdfa6b0cfe3" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f86034a6-417e-45b9-b997-55c858246fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d32db06-8127-4233-ad44-2f613cb23efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f2f401ca-fdf6-4439-b47c-0fdfa6b0cfe3" xlink:to="loc_us-gaap_StockholdersEquity_1d32db06-8127-4233-ad44-2f613cb23efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cb4b007b-4315-4288-ab64-b816fb8506cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_us-gaap_AccountsPayableCurrent_cb4b007b-4315-4288-ab64-b816fb8506cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b560eef-d4db-4904-b890-bfb02159a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b560eef-d4db-4904-b890-bfb02159a08d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_b2a0ef53-27ff-4af8-b4aa-3c771e1f8abc" xlink:href="evh-20230331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_b2a0ef53-27ff-4af8-b4aa-3c771e1f8abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_961e2439-d73f-41a7-8afd-6027d163e057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_961e2439-d73f-41a7-8afd-6027d163e057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6bb08d8d-3d91-4877-bdcf-cf5136a038f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6bb08d8d-3d91-4877-bdcf-cf5136a038f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c423dde-398c-4593-873d-d93d5eefa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b3faaee2-37c7-424c-af4c-b212dd1b22f1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c423dde-398c-4593-873d-d93d5eefa31a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_efef7999-5fbb-48c2-a693-c1a950cec0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_35e3d723-414a-4ba0-a8b1-0ad265e80407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_efef7999-5fbb-48c2-a693-c1a950cec0db" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_35e3d723-414a-4ba0-a8b1-0ad265e80407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1ba85031-2a1b-409a-9359-c4df9781aeef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_efef7999-5fbb-48c2-a693-c1a950cec0db" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1ba85031-2a1b-409a-9359-c4df9781aeef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f81264c-022d-4e10-8134-4f591188ef0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7469ddb8-a92f-4f20-9416-4b42195eda40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f81264c-022d-4e10-8134-4f591188ef0d" xlink:to="loc_us-gaap_NetIncomeLoss_7469ddb8-a92f-4f20-9416-4b42195eda40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1c8f871d-59f9-4403-85cc-6208c3939dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f81264c-022d-4e10-8134-4f591188ef0d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1c8f871d-59f9-4403-85cc-6208c3939dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_78160360-be55-408b-8540-b829cd81801f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_47bac765-12e9-4cd4-bf71-6e13bda9b94e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_78160360-be55-408b-8540-b829cd81801f" xlink:to="loc_us-gaap_CostOfRevenue_47bac765-12e9-4cd4-bf71-6e13bda9b94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_148781b6-75e4-4ff0-bd19-f10bb9dd621b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_78160360-be55-408b-8540-b829cd81801f" xlink:to="loc_us-gaap_DepreciationAndAmortization_148781b6-75e4-4ff0-bd19-f10bb9dd621b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cd485592-ce16-4220-984c-20693b374a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_78160360-be55-408b-8540-b829cd81801f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cd485592-ce16-4220-984c-20693b374a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_010cc078-c223-4e83-b222-870648f55555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_78160360-be55-408b-8540-b829cd81801f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_010cc078-c223-4e83-b222-870648f55555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e1061e53-2679-4644-930d-97965e0e7d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d069d8aa-d9fa-4bbf-bb21-83e92805d211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e1061e53-2679-4644-930d-97965e0e7d2d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d069d8aa-d9fa-4bbf-bb21-83e92805d211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_5136e20f-d746-4af7-b60c-5db4ea5e5b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e1061e53-2679-4644-930d-97965e0e7d2d" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_5136e20f-d746-4af7-b60c-5db4ea5e5b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c966e61b-c3e8-4f3a-9ec7-ca9e39e20770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1a4c706-71a9-4140-92a8-57cd8a343169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c966e61b-c3e8-4f3a-9ec7-ca9e39e20770" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1a4c706-71a9-4140-92a8-57cd8a343169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1907fe9e-2c10-4380-adb3-1542b819a821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c966e61b-c3e8-4f3a-9ec7-ca9e39e20770" xlink:to="loc_us-gaap_CostsAndExpenses_1907fe9e-2c10-4380-adb3-1542b819a821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69f938c8-0a28-4869-9fbb-3527b9b441b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_us-gaap_OperatingIncomeLoss_69f938c8-0a28-4869-9fbb-3527b9b441b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_7d0eec9a-d37b-47a1-b65e-062421dff5ad" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_7d0eec9a-d37b-47a1-b65e-062421dff5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d824759d-fd32-4a55-aab0-9db01fd9c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_us-gaap_InterestExpense_d824759d-fd32-4a55-aab0-9db01fd9c3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6862f754-6e30-4763-a3b8-7eb2970483f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6862f754-6e30-4763-a3b8-7eb2970483f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_04f6ac84-9125-4f3e-be4d-3c96028f9cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_04f6ac84-9125-4f3e-be4d-3c96028f9cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a1013288-8318-45a2-9685-367ef9dd3710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_439a61c2-7766-4443-aa07-439511ec6f69" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a1013288-8318-45a2-9685-367ef9dd3710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_f08c9ea8-d768-44f0-b511-d578a1bd2326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7543dcb7-83b2-4e63-8ede-8ed423474a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_f08c9ea8-d768-44f0-b511-d578a1bd2326" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7543dcb7-83b2-4e63-8ede-8ed423474a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_485809e5-f7ac-458c-94af-00d89d30255a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_f08c9ea8-d768-44f0-b511-d578a1bd2326" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_485809e5-f7ac-458c-94af-00d89d30255a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_e181eac6-e801-4559-83aa-bdecacfea318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_e181eac6-e801-4559-83aa-bdecacfea318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0ccd9e7e-090e-45eb-a531-a15d06c4d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_ShareBasedCompensation_0ccd9e7e-090e-45eb-a531-a15d06c4d0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7b23d237-84b3-4f63-bffb-a8b29af21177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7b23d237-84b3-4f63-bffb-a8b29af21177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4d191795-c46c-4bbe-9243-fa60fb19b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4d191795-c46c-4bbe-9243-fa60fb19b4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e1291443-054b-46f8-b838-206f15f8b2e9" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e1291443-054b-46f8-b838-206f15f8b2e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c11898c0-3e8a-49d4-8333-1244c7e2cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c11898c0-3e8a-49d4-8333-1244c7e2cd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_3cb76ce5-61ff-4262-9b21-187794796a0f" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_3cb76ce5-61ff-4262-9b21-187794796a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c408e2d8-fd71-4157-8069-e619e93881c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c408e2d8-fd71-4157-8069-e619e93881c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_61f388d4-3905-43f1-92f1-2a07c6ada59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_61f388d4-3905-43f1-92f1-2a07c6ada59e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0a152f3b-833a-406a-9436-840e65921dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0a152f3b-833a-406a-9436-840e65921dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bc85e04b-f6bf-4241-b84a-e1bce2f67d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bc85e04b-f6bf-4241-b84a-e1bce2f67d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a90887f0-3112-4540-94a7-f494311234c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a90887f0-3112-4540-94a7-f494311234c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b8b5412d-b875-432d-a314-ea1f48b93a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b8b5412d-b875-432d-a314-ea1f48b93a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_765f3311-3ad9-4128-91b6-93300129dca1" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_765f3311-3ad9-4128-91b6-93300129dca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_cf5ff88c-124c-43f2-911e-86391605f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_cf5ff88c-124c-43f2-911e-86391605f8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_01f9f40b-b755-47a5-976d-ebd8f0189eff" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_01f9f40b-b755-47a5-976d-ebd8f0189eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5cd413ae-b0c8-433e-909c-73819028c43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5cd413ae-b0c8-433e-909c-73819028c43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_700d3fb1-24af-46b0-994f-1e887df3b9b6" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_700d3fb1-24af-46b0-994f-1e887df3b9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_400bc581-3aec-4a6e-bf2b-e156e1012077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_400bc581-3aec-4a6e-bf2b-e156e1012077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5325031c-c3a4-465e-a0e7-5e4197acb579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5325031c-c3a4-465e-a0e7-5e4197acb579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee2b1491-308e-43e5-b097-ec0ccfb0f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4f10df6-75f6-4d92-99f2-4e5ba3af6109" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ee2b1491-308e-43e5-b097-ec0ccfb0f94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3a578e61-4a40-4cc3-9645-39a068d9d355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3a578e61-4a40-4cc3-9645-39a068d9d355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29000ff3-e122-47ce-afe5-49781860fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29000ff3-e122-47ce-afe5-49781860fd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_c4309b7d-34b3-49e8-84f8-dc3002ca24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_c4309b7d-34b3-49e8-84f8-dc3002ca24fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7423ac5-5026-4182-b7de-5a9cc543f1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7423ac5-5026-4182-b7de-5a9cc543f1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_16af5b13-cfd8-4461-84fd-8e977ec0bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_16af5b13-cfd8-4461-84fd-8e977ec0bac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_9085c23e-b7b0-4a80-bfdb-0e7699f62487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_9085c23e-b7b0-4a80-bfdb-0e7699f62487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a1d3eae9-985e-47f3-ac3e-882387d56359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a1d3eae9-985e-47f3-ac3e-882387d56359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_fce74856-8b32-4bed-88b0-3e3f875e108c" xlink:href="evh-20230331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe97e413-9b4b-4985-a28d-fb8e634a9836" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_fce74856-8b32-4bed-88b0-3e3f875e108c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5c5d144-a17d-470f-a9bd-d7f9cbb9f652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_13a346d0-054a-4c13-a3a7-07d2c8c81394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5c5d144-a17d-470f-a9bd-d7f9cbb9f652" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_13a346d0-054a-4c13-a3a7-07d2c8c81394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_af546ac4-84f7-4f8f-99ec-4e50d39737ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5c5d144-a17d-470f-a9bd-d7f9cbb9f652" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_af546ac4-84f7-4f8f-99ec-4e50d39737ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_11c9c2b0-e6c3-4d3d-ad7f-6eb611dce843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5c5d144-a17d-470f-a9bd-d7f9cbb9f652" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_11c9c2b0-e6c3-4d3d-ad7f-6eb611dce843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d595c5d1-cf92-4876-8d3f-768196ed96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5c5d144-a17d-470f-a9bd-d7f9cbb9f652" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d595c5d1-cf92-4876-8d3f-768196ed96b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1311531e-ec2e-4926-8dd0-2e178d3c3fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02ecd92c-7a6b-48ab-92e5-3e5609f2fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1311531e-ec2e-4926-8dd0-2e178d3c3fe6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02ecd92c-7a6b-48ab-92e5-3e5609f2fb9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_420720d5-63ce-41b3-9e7d-55ab489427a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1311531e-ec2e-4926-8dd0-2e178d3c3fe6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_420720d5-63ce-41b3-9e7d-55ab489427a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9e0e838-aac8-4be9-ba75-222f1daf2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1311531e-ec2e-4926-8dd0-2e178d3c3fe6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9e0e838-aac8-4be9-ba75-222f1daf2c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9bdd798-09af-4f43-8723-d02a9d59becd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1311531e-ec2e-4926-8dd0-2e178d3c3fe6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9bdd798-09af-4f43-8723-d02a9d59becd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_11c86417-99dc-48b7-8bda-503d3db7745a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e3795f4-31ee-48a3-b763-9fdfd6b80388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_11c86417-99dc-48b7-8bda-503d3db7745a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e3795f4-31ee-48a3-b763-9fdfd6b80388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ea7c482e-bd61-428d-b930-341841142ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64e47832-ae19-4725-b9a3-3e5e83c5b672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ea7c482e-bd61-428d-b930-341841142ede" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64e47832-ae19-4725-b9a3-3e5e83c5b672" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3dfae88-84d7-48d0-a25d-b9fe3554e494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_fe9520a9-23db-4375-86e9-5d64a3f79260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3dfae88-84d7-48d0-a25d-b9fe3554e494" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_fe9520a9-23db-4375-86e9-5d64a3f79260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2489636f-3f65-48ad-89b9-0ec98b05ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3dfae88-84d7-48d0-a25d-b9fe3554e494" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2489636f-3f65-48ad-89b9-0ec98b05ea83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_091ca25f-4234-4ccb-9a6f-2bafc9c9ed15" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_18b3e752-73d2-41ed-9d84-1c82a0ef5e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_091ca25f-4234-4ccb-9a6f-2bafc9c9ed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_18b3e752-73d2-41ed-9d84-1c82a0ef5e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4ffb6a49-4d5c-4f02-b1d7-191a1d902675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_091ca25f-4234-4ccb-9a6f-2bafc9c9ed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4ffb6a49-4d5c-4f02-b1d7-191a1d902675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d7f4b0ec-1677-4310-85d4-eda36b8eed3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_091ca25f-4234-4ccb-9a6f-2bafc9c9ed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d7f4b0ec-1677-4310-85d4-eda36b8eed3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_1ddbcdf3-0e2f-43a8-b774-7f2ab09d48d4" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_1ddbcdf3-0e2f-43a8-b774-7f2ab09d48d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0c265278-d262-4c2c-b7f4-a8e064e46710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0c265278-d262-4c2c-b7f4-a8e064e46710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eb08e8c9-7461-4675-81a5-3d8c2bc95848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eb08e8c9-7461-4675-81a5-3d8c2bc95848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_02d27076-3f80-4a8e-a13d-3d5ab6c288d2" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_02d27076-3f80-4a8e-a13d-3d5ab6c288d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d1bd51f0-2dff-4e99-9922-b2616bb20fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d1bd51f0-2dff-4e99-9922-b2616bb20fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_72ee21de-2283-45bb-b6cc-11b3ec32eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2fafb3f7-ef88-40b2-b574-915185a061b5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_72ee21de-2283-45bb-b6cc-11b3ec32eaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_370cbbd3-a885-4bea-a7e5-72c0f68457c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8c6f0de0-2ba9-46c2-918f-c075678ce06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_370cbbd3-a885-4bea-a7e5-72c0f68457c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8c6f0de0-2ba9-46c2-918f-c075678ce06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_50481ec1-74bf-450a-a0fd-d7f6987ebb05" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_370cbbd3-a885-4bea-a7e5-72c0f68457c9" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_50481ec1-74bf-450a-a0fd-d7f6987ebb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9c693140-364e-4a72-a37c-932976b7f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_370cbbd3-a885-4bea-a7e5-72c0f68457c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9c693140-364e-4a72-a37c-932976b7f1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b741b342-d58e-413f-866a-d126e3caa903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_370cbbd3-a885-4bea-a7e5-72c0f68457c9" xlink:to="loc_us-gaap_Goodwill_b741b342-d58e-413f-866a-d126e3caa903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bdda0b95-3917-415e-945e-3e748ce2daa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cfeb4161-1f4a-4a24-bad1-3debcb8b8d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bdda0b95-3917-415e-945e-3e748ce2daa1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cfeb4161-1f4a-4a24-bad1-3debcb8b8d24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bf2bfbb1-c051-418b-a8eb-48df2209ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bdda0b95-3917-415e-945e-3e748ce2daa1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bf2bfbb1-c051-418b-a8eb-48df2209ce1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8395293c-402c-4d88-9621-ea0bff8b2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bdda0b95-3917-415e-945e-3e748ce2daa1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8395293c-402c-4d88-9621-ea0bff8b2c14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd1b784f-d669-4ef3-b946-ab2ca13f28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a57aee22-b7ad-4c25-b28c-9d912eebc92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fd1b784f-d669-4ef3-b946-ab2ca13f28ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a57aee22-b7ad-4c25-b28c-9d912eebc92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b85943db-801e-4c76-afcf-0a0fd0b1d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fd1b784f-d669-4ef3-b946-ab2ca13f28ca" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b85943db-801e-4c76-afcf-0a0fd0b1d18b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2be6160c-f0c3-45de-b573-b88ec583df4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_31eaf4c1-ee6f-4450-8159-a79d509ea6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2be6160c-f0c3-45de-b573-b88ec583df4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_31eaf4c1-ee6f-4450-8159-a79d509ea6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0fe77dbe-40f9-4b0a-bfee-5e1c215c4264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2be6160c-f0c3-45de-b573-b88ec583df4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0fe77dbe-40f9-4b0a-bfee-5e1c215c4264" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_54dc7b07-c184-405e-b19a-0ef249761f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_54dc7b07-c184-405e-b19a-0ef249761f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_de626f0b-62aa-4cfe-bd5f-f7c76800fa29" xlink:href="evh-20230331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_de626f0b-62aa-4cfe-bd5f-f7c76800fa29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_619aad29-6bc5-434b-83c1-6b6589a73da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_619aad29-6bc5-434b-83c1-6b6589a73da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d7f9e02b-5b39-4faf-9ed9-ba8ccf7073fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d7f9e02b-5b39-4faf-9ed9-ba8ccf7073fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_07006201-5be8-46a1-8017-b84c6de5eaba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_07006201-5be8-46a1-8017-b84c6de5eaba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_40466b03-fe62-4d0c-921b-866930094c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8855106-fc17-4d5a-8cf0-d2bf1a1ab6e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_40466b03-fe62-4d0c-921b-866930094c15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_3f458beb-b61e-468f-9800-545c1381419a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7c51f24e-cbbf-4efc-9a8f-31b3cc8f167c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_3f458beb-b61e-468f-9800-545c1381419a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7c51f24e-cbbf-4efc-9a8f-31b3cc8f167c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4bc6d0c8-dd9c-422f-b73f-456870ee10db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_3f458beb-b61e-468f-9800-545c1381419a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4bc6d0c8-dd9c-422f-b73f-456870ee10db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5b63fb01-83b2-443a-ba24-4830c25fe4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_df59f6d0-6a62-401e-9886-d90fb68be8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5b63fb01-83b2-443a-ba24-4830c25fe4f8" xlink:to="loc_us-gaap_VariableLeaseCost_df59f6d0-6a62-401e-9886-d90fb68be8f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5fba9f93-13b7-4b31-8c54-e22a2d6bb186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5b63fb01-83b2-443a-ba24-4830c25fe4f8" xlink:to="loc_us-gaap_OperatingLeaseCost_5fba9f93-13b7-4b31-8c54-e22a2d6bb186" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dacb90b8-9573-4f12-b428-22dc155a4d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76ad6162-978a-4166-a53b-06526eb367a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dacb90b8-9573-4f12-b428-22dc155a4d2f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76ad6162-978a-4166-a53b-06526eb367a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_408561e3-623f-4d6b-b4f8-04a9e5d4db35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dacb90b8-9573-4f12-b428-22dc155a4d2f" xlink:to="loc_us-gaap_OperatingLeaseLiability_408561e3-623f-4d6b-b4f8-04a9e5d4db35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_18047e26-839c-4600-b775-23c1470a7862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_18047e26-839c-4600-b775-23c1470a7862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour_b82e5e04-5cbe-49f2-9e5b-6d892e6e8479" xlink:href="evh-20230331.xsd#evh_LesseeOperatingLeaseLiabilityAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour_b82e5e04-5cbe-49f2-9e5b-6d892e6e8479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5b06bc73-9636-4bb7-92b2-5515f65b1513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5b06bc73-9636-4bb7-92b2-5515f65b1513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f510867-c194-48bc-9938-784e3b3b3362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f510867-c194-48bc-9938-784e3b3b3362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2431f2d-d40c-4605-b1ed-d65fc62181d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2431f2d-d40c-4605-b1ed-d65fc62181d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a73f6dda-0b0b-4f73-9bb6-59ed4652a9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4e9321f-dcb2-4932-91ab-82eed26f260a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a73f6dda-0b0b-4f73-9bb6-59ed4652a9a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_31bcb64d-1142-4245-add5-53030202532a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_55b79d39-8214-46b3-9153-d7c1684e7c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_31bcb64d-1142-4245-add5-53030202532a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_55b79d39-8214-46b3-9153-d7c1684e7c64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_f70306f0-69da-4eaa-b512-c24c7d00fa01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5922d76d-1dd0-4113-bbca-d2bf85bbaf96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_f70306f0-69da-4eaa-b512-c24c7d00fa01" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5922d76d-1dd0-4113-bbca-d2bf85bbaf96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0c846678-d544-471f-9e68-cf44c5939019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_f70306f0-69da-4eaa-b512-c24c7d00fa01" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0c846678-d544-471f-9e68-cf44c5939019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5e3befc7-d733-4bc4-80f0-44e9cee8445c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_520d6585-08f3-4c4f-9a61-58615b750170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5e3befc7-d733-4bc4-80f0-44e9cee8445c" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_520d6585-08f3-4c4f-9a61-58615b750170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_571a43b1-18df-4dde-b532-ae3afe595ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5e3befc7-d733-4bc4-80f0-44e9cee8445c" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_571a43b1-18df-4dde-b532-ae3afe595ee4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>evh-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY" xlink:type="extended" id="i89e230052fc642e69490f353ca0fa373_CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_fb1538e0-4607-4228-b633-4222e308c69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_fb1538e0-4607-4228-b633-4222e308c69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_63cbb1d4-bf2c-49ec-99a7-c5d956bfaceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_63cbb1d4-bf2c-49ec-99a7-c5d956bfaceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_5acc6741-de6d-4723-9c2f-35d3841f951b" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_5acc6741-de6d-4723-9c2f-35d3841f951b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b584bdb1-c270-42c8-b6ba-4a8e5a2a46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b584bdb1-c270-42c8-b6ba-4a8e5a2a46d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_d25ed673-2f65-4873-a037-277cf3a53e7c" xlink:href="evh-20230331.xsd#evh_TemporaryEquityAccretionToRedemptionValueAndDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_d25ed673-2f65-4873-a037-277cf3a53e7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_2d673c9a-c5c6-486a-836e-a14546daa5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_2d673c9a-c5c6-486a-836e-a14546daa5eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_6c3194aa-58e7-4123-a0fe-cebc50da9d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b9e3682b-e1cf-4af2-9d30-96d8072b703d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f3e96038-6807-4e7e-af13-9ae05f6480fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_SharesIssued_f3e96038-6807-4e7e-af13-9ae05f6480fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73c041fd-5dec-451e-9efc-8b1de015044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockholdersEquity_73c041fd-5dec-451e-9efc-8b1de015044b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ce7efd5e-3503-4ffb-94ed-9f9c106fdf79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ce7efd5e-3503-4ffb-94ed-9f9c106fdf79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ff6b1ee-82ab-4b50-b092-5f1776e5f2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ff6b1ee-82ab-4b50-b092-5f1776e5f2fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52ea7a8f-292b-4609-b5f3-c1e63c2c2883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52ea7a8f-292b-4609-b5f3-c1e63c2c2883" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9602019f-3b08-4de5-bcee-058b3fcc8109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9602019f-3b08-4de5-bcee-058b3fcc8109" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a0a9c158-c6df-4a79-8bb3-4b3b9aca192e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a0a9c158-c6df-4a79-8bb3-4b3b9aca192e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_91347863-d6f8-42a4-b9d6-98055764e514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_91347863-d6f8-42a4-b9d6-98055764e514" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81a708b9-e31e-426d-9d0f-c84658431a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81a708b9-e31e-426d-9d0f-c84658431a39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_378ce940-b831-4e12-b8fc-f7d57f25ad49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_378ce940-b831-4e12-b8fc-f7d57f25ad49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7a9a479e-6fcc-4c3d-8561-713e635d1316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7a9a479e-6fcc-4c3d-8561-713e635d1316" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1508717a-a7d4-46ec-9176-4bdf0c307708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1508717a-a7d4-46ec-9176-4bdf0c307708" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_f34f8204-05de-4f87-aab9-be9316aa83b9" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_f34f8204-05de-4f87-aab9-be9316aa83b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_c95d84c0-c083-4e40-9230-fae2a98b7bf1" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_c95d84c0-c083-4e40-9230-fae2a98b7bf1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f71ad8e2-0564-4244-a7c0-5018655e38d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f71ad8e2-0564-4244-a7c0-5018655e38d0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb91f9f1-9e5e-4c9d-8d4f-04b1db2064d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_NetIncomeLoss_cb91f9f1-9e5e-4c9d-8d4f-04b1db2064d2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c8cf9624-1035-4a90-8519-f7ae46d07794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dbea2b69-f02a-4f1a-bc60-14bdf5a17fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:to="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_123c3ecf-e166-4cd3-b66d-065c36b11ed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:to="loc_us-gaap_EquityComponentDomain_123c3ecf-e166-4cd3-b66d-065c36b11ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:to="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_864a65c7-c87f-4a28-8508-de06b9f1c470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_CommonStockMember_864a65c7-c87f-4a28-8508-de06b9f1c470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_00636d48-aa0f-4c10-bd79-af4d53972a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_00636d48-aa0f-4c10-bd79-af4d53972a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf731a4-e932-4bbb-b20a-1f96cc23f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf731a4-e932-4bbb-b20a-1f96cc23f4c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_23a294f1-b8dd-4562-95cb-e4561582da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_RetainedEarningsMember_23a294f1-b8dd-4562-95cb-e4561582da5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_96c35ad5-09c7-4a77-ad47-5683c0368cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_96c35ad5-09c7-4a77-ad47-5683c0368cf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e71a0c76-890c-49c4-b701-943eba35b346_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e71a0c76-890c-49c4-b701-943eba35b346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_354f9cd0-c584-4139-971c-39599e450b74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_354f9cd0-c584-4139-971c-39599e450b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83a0da3b-691a-4f4d-84d0-b39d69fff0a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83a0da3b-691a-4f4d-84d0-b39d69fff0a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_b8ab5ca5-0e18-47ec-8bd6-9aea29d83783" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_b8ab5ca5-0e18-47ec-8bd6-9aea29d83783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c34223ac-a305-4e3d-b016-38f970c47a25" xlink:href="evh-20230331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c34223ac-a305-4e3d-b016-38f970c47a25" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="i657a132b875b4f9590b698a70adb09e0_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_6a5665f0-df9a-492e-a613-cd10be5963d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_6a5665f0-df9a-492e-a613-cd10be5963d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_617f015d-759a-4ef8-bf68-ec47e08098be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_617f015d-759a-4ef8-bf68-ec47e08098be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_a9a572ae-5c78-462d-8cb5-998e7ef327b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_a9a572ae-5c78-462d-8cb5-998e7ef327b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6173dce2-f1b8-4b30-a1e9-4f2d0d2d254c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6173dce2-f1b8-4b30-a1e9-4f2d0d2d254c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ee5714aa-8e3f-4bf2-b0b7-8d928fdc210a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ee5714aa-8e3f-4bf2-b0b7-8d928fdc210a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2d50fb64-2168-4813-b13c-842cfcddffc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2d50fb64-2168-4813-b13c-842cfcddffc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_d091002c-076d-4f0e-8851-6bce0d14fa90" xlink:href="evh-20230331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_d091002c-076d-4f0e-8851-6bce0d14fa90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_39697418-010c-4fc2-867d-51e9cf5ac7b1" xlink:href="evh-20230331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_39697418-010c-4fc2-867d-51e9cf5ac7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_b53cac64-d869-4336-8e43-22e11580ea7e" xlink:href="evh-20230331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_b53cac64-d869-4336-8e43-22e11580ea7e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="ib3bc237819f44f1d9d6e04e33cffe0a4_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e3a3eac-7e42-4073-aa6c-bbfaa43abb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e3a3eac-7e42-4073-aa6c-bbfaa43abb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a9152e2-e3be-4246-93f9-f58c681a9cf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a9152e2-e3be-4246-93f9-f58c681a9cf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_815dbb26-6ad2-4365-a629-c18a34784d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_TradeNamesMember_815dbb26-6ad2-4365-a629-c18a34784d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_098241d3-bceb-4d04-91d1-160d64f32cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_098241d3-bceb-4d04-91d1-160d64f32cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5f30004e-8999-431c-af23-819f80e57aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5f30004e-8999-431c-af23-819f80e57aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_b6b98cb1-7c25-4721-bb6b-9498c2b323e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_b6b98cb1-7c25-4721-bb6b-9498c2b323e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:to="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98556fd7-b245-477d-9105-097c535bb4be_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:to="loc_srt_RangeMember_98556fd7-b245-477d-9105-097c535bb4be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:to="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cea5d065-4db4-4c45-9c98-00eed773164a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:to="loc_srt_MinimumMember_cea5d065-4db4-4c45-9c98-00eed773164a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac86eeee-a207-4869-9207-523f83460813" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:to="loc_srt_MaximumMember_ac86eeee-a207-4869-9207-523f83460813" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="idcc6e40a54984d85a789a2d0c47854c4_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1032260a-3b47-4d00-82ae-e9156f4b4fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:to="loc_us-gaap_StockholdersEquity_1032260a-3b47-4d00-82ae-e9156f4b4fec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93ea76ba-f45f-4c8b-9631-af10a2940a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:to="loc_us-gaap_LongTermDebt_93ea76ba-f45f-4c8b-9631-af10a2940a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1e3c7fec-1aa4-40b3-bc04-724409742305_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1e3c7fec-1aa4-40b3-bc04-724409742305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_12d37cde-325e-42f1-8dc9-be385a2c2859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_12d37cde-325e-42f1-8dc9-be385a2c2859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60ef93ab-fcad-4fab-b11d-509b8684796b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:to="loc_us-gaap_EquityComponentDomain_60ef93ab-fcad-4fab-b11d-509b8684796b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:to="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_69457199-b97b-4307-9b58-aeef56dc6503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:to="loc_us-gaap_RetainedEarningsMember_69457199-b97b-4307-9b58-aeef56dc6503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f724ba1-acf1-4d99-a182-c87bcfc90eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f724ba1-acf1-4d99-a182-c87bcfc90eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4af49a77-88a8-42ff-98ad-f34dd9b5bebc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4af49a77-88a8-42ff-98ad-f34dd9b5bebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2fe64646-5419-48d1-bbcd-1b4ddf7e9950" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2fe64646-5419-48d1-bbcd-1b4ddf7e9950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1065caba-9fc7-49fb-802c-ac6a15c67dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1065caba-9fc7-49fb-802c-ac6a15c67dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_4c3639f2-d80c-4c21-ac2b-f60540dd54e9" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_4c3639f2-d80c-4c21-ac2b-f60540dd54e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_9ad88318-5da1-4188-b4ca-701e827249db" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_9ad88318-5da1-4188-b4ca-701e827249db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1acf9467-72b6-4839-a583-cd927a0134c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1acf9467-72b6-4839-a583-cd927a0134c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d93d29cb-6492-43c6-bb62-c47b67d7be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:to="loc_us-gaap_SeniorNotesMember_d93d29cb-6492-43c6-bb62-c47b67d7be4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended" id="i6a2df7bfcf29491582bec906ac13557f_TransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03efe08f-2d9b-4f98-9e62-cf34373a8692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03efe08f-2d9b-4f98-9e62-cf34373a8692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_29057f48-d62a-4499-b48e-2a3d667b7483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_29057f48-d62a-4499-b48e-2a3d667b7483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3a7a25a0-6bc5-480a-9134-be132662d649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3a7a25a0-6bc5-480a-9134-be132662d649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9204f78-2541-4f7c-a807-dd4742575a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9204f78-2541-4f7c-a807-dd4742575a17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b429aac-701d-4724-8ac9-fb6ade9a247b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b429aac-701d-4724-8ac9-fb6ade9a247b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_5b58dc47-2774-4389-abb5-a5f31a93b3ea" xlink:href="evh-20230331.xsd#evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_5b58dc47-2774-4389-abb5-a5f31a93b3ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4abf0487-3652-4c83-a948-7b196c5af3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4abf0487-3652-4c83-a948-7b196c5af3a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7958d440-3426-47f0-81c5-26d505ff89e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7958d440-3426-47f0-81c5-26d505ff89e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b4dc0527-e7bf-4be7-bf2c-211beac87509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b4dc0527-e7bf-4be7-bf2c-211beac87509" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_997a3225-3367-4e90-a381-c5eb42248bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_997a3225-3367-4e90-a381-c5eb42248bb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f42a8e47-771b-4a8d-b2f3-a7ef43d0cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f42a8e47-771b-4a8d-b2f3-a7ef43d0cdf7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_746eac46-af3b-4fe8-b4d1-3a5aa3694901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_NetIncomeLoss_746eac46-af3b-4fe8-b4d1-3a5aa3694901" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cc4fe874-1a93-40e2-b7df-5a4a9a33c315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cc4fe874-1a93-40e2-b7df-5a4a9a33c315" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddbba390-e7a9-4f38-a289-450246431817_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddbba390-e7a9-4f38-a289-450246431817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_808cc90e-2b96-4760-99c6-f8e60cbb424c" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_808cc90e-2b96-4760-99c6-f8e60cbb424c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_f7a43406-1434-48f5-8585-0868e40070ec" xlink:href="evh-20230331.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_f7a43406-1434-48f5-8585-0868e40070ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8f1fc780-2663-4f46-83bd-066bc54e3f80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8f1fc780-2663-4f46-83bd-066bc54e3f80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_50e452e2-4ddb-48ae-ad4e-9e69161d1140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_50e452e2-4ddb-48ae-ad4e-9e69161d1140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_3d202472-253b-4533-88db-244ca0832a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_3d202472-253b-4533-88db-244ca0832a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_81452bca-8efe-48da-902e-5e9c80573d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_TradeNamesMember_81452bca-8efe-48da-902e-5e9c80573d61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c36d0476-2f71-49b3-879d-a719381dc862_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:to="loc_us-gaap_ClassOfStockDomain_c36d0476-2f71-49b3-879d-a719381dc862_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:to="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7f9e2c39-b38c-4b04-9e17-ffcf607a7386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:to="loc_us-gaap_CommonClassAMember_7f9e2c39-b38c-4b04-9e17-ffcf607a7386" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended" id="if274da82cd2c40bd95cc10e24fce59ec_TransactionsAllocationofAcquisitionCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ea14c3e-6731-4f6b-a1cd-5e2a7a844756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ea14c3e-6731-4f6b-a1cd-5e2a7a844756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7b8ce66f-4587-433c-a391-fad30b9c989e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7b8ce66f-4587-433c-a391-fad30b9c989e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0aaf51f0-41aa-41b4-b1f3-5dc11504ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0aaf51f0-41aa-41b4-b1f3-5dc11504ef9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_01df205b-e4b0-4906-8e64-fce929f6ea86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_01df205b-e4b0-4906-8e64-fce929f6ea86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c48da8d4-f74f-43b3-a36a-f9c69fa7546c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c48da8d4-f74f-43b3-a36a-f9c69fa7546c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5b537273-d73c-444d-94f7-79ff4e1cb901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5b537273-d73c-444d-94f7-79ff4e1cb901" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1f3c8bd8-50db-4cef-a7f4-9c1d8de36d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1f3c8bd8-50db-4cef-a7f4-9c1d8de36d40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e7823d59-434b-4f60-8c82-e19469d8e332" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e7823d59-434b-4f60-8c82-e19469d8e332" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ead8c31a-f8d5-41f0-ad75-f8da97b4591a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ead8c31a-f8d5-41f0-ad75-f8da97b4591a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_181f4332-5016-43c5-ad02-ecb5fc6ad297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_181f4332-5016-43c5-ad02-ecb5fc6ad297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_da78e8a2-31ea-41a1-a551-42aa7a4bdfaf" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_da78e8a2-31ea-41a1-a551-42aa7a4bdfaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f632eb4f-8595-49f0-abe4-1c91d080814b" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f632eb4f-8595-49f0-abe4-1c91d080814b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bdceb0af-f506-476a-9549-e226e41e0c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bdceb0af-f506-476a-9549-e226e41e0c8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_18925626-2fe7-450a-9c9a-b049ff350d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_18925626-2fe7-450a-9c9a-b049ff350d70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_814f0355-a468-4d4a-be31-cb640c1053dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_814f0355-a468-4d4a-be31-cb640c1053dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_949d5f37-36f7-4afa-bc5e-f32291859a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_949d5f37-36f7-4afa-bc5e-f32291859a33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3730ec15-c13c-4db2-be11-dd436f41fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_Goodwill_3730ec15-c13c-4db2-be11-dd436f41fcaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a023934f-5c07-4430-b8a2-b46552e4bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a023934f-5c07-4430-b8a2-b46552e4bad7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c149d5c7-afab-4d56-b1e0-f3144d3764c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c149d5c7-afab-4d56-b1e0-f3144d3764c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_085ac7f2-ce8d-4c4b-b345-6278baa013ff" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_085ac7f2-ce8d-4c4b-b345-6278baa013ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_d56f6d6e-f127-4f4a-9946-06e183dddefa" xlink:href="evh-20230331.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_d56f6d6e-f127-4f4a-9946-06e183dddefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e61982f8-fb18-4be6-b4a4-2ff725243d6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e61982f8-fb18-4be6-b4a4-2ff725243d6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c06c49d2-9ac3-433f-acc9-52b22e92bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c06c49d2-9ac3-433f-acc9-52b22e92bad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7a52d048-ac7b-4d36-abf4-ebee6033412c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7a52d048-ac7b-4d36-abf4-ebee6033412c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4e0ade8b-32bc-4e3f-8b6d-2e41771d37c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_TradeNamesMember_4e0ade8b-32bc-4e3f-8b6d-2e41771d37c4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails" xlink:type="extended" id="i159a467a5fdf4d9aa12d8479c56b7e01_TransactionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_70b670ab-99cb-449b-ad92-07a0d87eb9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_70b670ab-99cb-449b-ad92-07a0d87eb9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7b7c596c-81d2-42ec-8b63-556cea7ae2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7b7c596c-81d2-42ec-8b63-556cea7ae2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_f7ec316f-03ec-4416-be4c-0608e820fcdf" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_f7ec316f-03ec-4416-be4c-0608e820fcdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i31fa5076fd024772baebac351d5156f3_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6431a7f4-b599-4319-a6f3-2ded4c996a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6431a7f4-b599-4319-a6f3-2ded4c996a12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_09327964-2a99-4155-aea5-ed22007386dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:to="loc_us-gaap_SegmentDomain_09327964-2a99-4155-aea5-ed22007386dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:to="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_5b737a82-33fc-4b8f-b088-62c690e3ce19" xlink:href="evh-20230331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_5b737a82-33fc-4b8f-b088-62c690e3ce19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c9b07d7b-3f69-48aa-8141-9278be2341ee_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_c9b07d7b-3f69-48aa-8141-9278be2341ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_c1c2bc6d-84d7-41c0-95ac-f601bafe7c37" xlink:href="evh-20230331.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_MedicaidCustomersMember_c1c2bc6d-84d7-41c0-95ac-f601bafe7c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_a246c248-62aa-48c8-83e6-f50f32db7055" xlink:href="evh-20230331.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_MedicareCustomersMember_a246c248-62aa-48c8-83e6-f50f32db7055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_805248a9-6c45-429b-975f-307c005e0fa2" xlink:href="evh-20230331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_CommercialAndOtherCustomersMember_805248a9-6c45-429b-975f-307c005e0fa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ed3781c-18d1-43ee-b01d-f9e497779009_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:to="loc_srt_ProductsAndServicesDomain_7ed3781c-18d1-43ee-b01d-f9e497779009_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:to="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceSuiteMember_e1a16aca-83df-4e29-857b-745072ae5621" xlink:href="evh-20230331.xsd#evh_PerformanceSuiteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_PerformanceSuiteMember_e1a16aca-83df-4e29-857b-745072ae5621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SpecialtyTechnologyAndServicesSuiteMember_4fb09efd-8aae-4274-b38e-478e93152da8" xlink:href="evh-20230331.xsd#evh_SpecialtyTechnologyAndServicesSuiteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_SpecialtyTechnologyAndServicesSuiteMember_4fb09efd-8aae-4274-b38e-478e93152da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeServiceMember_fcb11bbd-0d35-4ee5-a01d-128512331ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_us-gaap_AdministrativeServiceMember_fcb11bbd-0d35-4ee5-a01d-128512331ad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CasesMember_fb91044a-8b49-49b5-925a-052295722c38" xlink:href="evh-20230331.xsd#evh_CasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_CasesMember_fb91044a-8b49-49b5-925a-052295722c38" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="i039a4018db8b4ec1b6d6108dc7c56903_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c44eaf63-6ac9-4bad-afaa-0374b7a94725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c44eaf63-6ac9-4bad-afaa-0374b7a94725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3fea6a42-9e52-4304-af58-ed34d79d6f3c_default" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3fea6a42-9e52-4304-af58-ed34d79d6f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:href="evh-20230331.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:href="evh-20230331.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:href="evh-20230331.xsd#evh_December312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="i6693fa2bdfad41fc92a476ed5aea477d_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3fea6a42-9e52-4304-af58-ed34d79d6f3c_default" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3fea6a42-9e52-4304-af58-ed34d79d6f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:href="evh-20230331.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:href="evh-20230331.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:href="evh-20230331.xsd#evh_December312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="icd475f3a7ae34a16bb338d5a0d9f46b3_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_80af6263-c8e4-463d-a73a-b070a7c415c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostNet_80af6263-c8e4-463d-a73a-b070a7c415c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_577b7b58-d6c2-4dfa-b37f-d64e3b745dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_577b7b58-d6c2-4dfa-b37f-d64e3b745dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_feade6db-23b8-4b6e-9eb2-f2d1eb3ef7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_feade6db-23b8-4b6e-9eb2-f2d1eb3ef7a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_ad3c0511-d67f-46d9-bbaf-49ea315e12d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_ad3c0511-d67f-46d9-bbaf-49ea315e12d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_4d7b7260-d7d3-480f-a4ca-529474162b95" xlink:href="evh-20230331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:to="loc_evh_BonusesAndCommissionsMember_4d7b7260-d7d3-480f-a4ca-529474162b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_8260a9ee-3333-4a42-8aa7-e3c8ffbdda44" xlink:href="evh-20230331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:to="loc_evh_ContractFulfillmentCostsMember_8260a9ee-3333-4a42-8aa7-e3c8ffbdda44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="ia4d66dc1cd9f475fb53813ffb3123866_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_eafb2945-deac-4d09-874d-6620bab6a26a" xlink:href="evh-20230331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_eafb2945-deac-4d09-874d-6620bab6a26a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_3704686a-c6bc-4e4d-a6f7-baca1be784bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_3704686a-c6bc-4e4d-a6f7-baca1be784bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_fbadd429-05da-45c1-b6bd-662f8c50887a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_AccountsReceivableNet_fbadd429-05da-45c1-b6bd-662f8c50887a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a5b0c614-0bd0-4282-a7d1-4a5713553f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a5b0c614-0bd0-4282-a7d1-4a5713553f51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_bb93d4d5-ea15-44a4-8399-268f57e45ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_bb93d4d5-ea15-44a4-8399-268f57e45ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_81632cf3-68d0-4e80-a86f-316bfb3f096c" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_81632cf3-68d0-4e80-a86f-316bfb3f096c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_e527ea40-72c5-4c41-8106-101ae1b22f8b" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_e527ea40-72c5-4c41-8106-101ae1b22f8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i894bf032d255444cac6ff10b6db9f0f8_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55ae8685-5d08-443c-b0d3-ef6bb3982f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55ae8685-5d08-443c-b0d3-ef6bb3982f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_068c6944-c90e-4838-aca9-e909f4024918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_068c6944-c90e-4838-aca9-e909f4024918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1d64d508-444b-4fe3-a0e2-47e561dd766c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1d64d508-444b-4fe3-a0e2-47e561dd766c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9157d60a-5abf-401f-bfb0-130e32fd2e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9157d60a-5abf-401f-bfb0-130e32fd2e74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_4d9ca9be-b7e4-41e6-a93c-a53c1e01084c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_4d9ca9be-b7e4-41e6-a93c-a53c1e01084c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_06dfb637-8b40-45e2-bc9c-b0f021a507b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_Depreciation_06dfb637-8b40-45e2-bc9c-b0f021a507b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9b046cfe-242a-4c8c-b306-270618a0a403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9b046cfe-242a-4c8c-b306-270618a0a403" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_037ab50b-216b-4c5b-9f77-d6811d74820e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_037ab50b-216b-4c5b-9f77-d6811d74820e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_687c7616-3251-4203-b680-092e867847cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_ComputerEquipmentMember_687c7616-3251-4203-b680-092e867847cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_44f1e3a6-c752-4d1e-8b11-b5657a6d3e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_44f1e3a6-c752-4d1e-8b11-b5657a6d3e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2f6e0a84-c293-44de-a58b-4f754b919e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2f6e0a84-c293-44de-a58b-4f754b919e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e3dee78c-a068-4b0f-b3a2-616f4a961dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e3dee78c-a068-4b0f-b3a2-616f4a961dd3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="i0d8340c13a674c9189da064e297b9d6a_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_524dcd08-e5f0-48ad-8963-6eaccfb99c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_524dcd08-e5f0-48ad-8963-6eaccfb99c7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19690042-1eb6-4239-8a05-1321e831c166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19690042-1eb6-4239-8a05-1321e831c166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da4b4a92-c9f9-45e8-85a3-cd6a4d88ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da4b4a92-c9f9-45e8-85a3-cd6a4d88ccb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ca322-2e91-4f1b-8084-3ed850c389eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ca322-2e91-4f1b-8084-3ed850c389eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2994a8d6-903a-479c-ab5f-ef949b81dfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2994a8d6-903a-479c-ab5f-ef949b81dfc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b6b953d0-7578-442f-8da5-13cc362811e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_TradeNamesMember_b6b953d0-7578-442f-8da5-13cc362811e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8232dac7-a595-49a2-af46-f4e3686cfc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8232dac7-a595-49a2-af46-f4e3686cfc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f3fb5447-b3bf-4384-899c-5f9720891bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f3fb5447-b3bf-4384-899c-5f9720891bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_4c405042-750a-480d-8527-82e2daec00bd" xlink:href="evh-20230331.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_evh_BelowMarketLeasesMember_4c405042-750a-480d-8527-82e2daec00bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_1c4c6332-0b13-43ff-825b-b4e8d1f7dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_1c4c6332-0b13-43ff-825b-b4e8d1f7dab0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended" id="i1026cb11aa5b456f9b73489ceab86cec_LongtermDebt2022CreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8150054-3ecc-4adb-965c-4cc2dc85cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8150054-3ecc-4adb-965c-4cc2dc85cdd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentClosingFeePercent_7d3dbe36-a8fa-490b-a5ab-e832ae407b31" xlink:href="evh-20230331.xsd#evh_DebtInstrumentClosingFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentClosingFeePercent_7d3dbe36-a8fa-490b-a5ab-e832ae407b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_669e75a6-e3a2-42b9-b66d-e166cffe977b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_669e75a6-e3a2-42b9-b66d-e166cffe977b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_887ffc03-c5c6-410f-aa13-965dd85d7780" xlink:href="evh-20230331.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_887ffc03-c5c6-410f-aa13-965dd85d7780" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_663e770a-d114-4d65-a5da-82149352963f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_663e770a-d114-4d65-a5da-82149352963f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_aef33b11-501e-421d-8e63-becbd16984d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_aef33b11-501e-421d-8e63-becbd16984d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b85ba99a-ddd2-4bb3-90bf-4777cf225cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_InterestExpenseDebt_b85ba99a-ddd2-4bb3-90bf-4777cf225cba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_d18c9c1c-0204-4f92-b899-34679de34212" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_d18c9c1c-0204-4f92-b899-34679de34212" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_99300e77-df95-48a2-8c04-db755fea2905" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_99300e77-df95-48a2-8c04-db755fea2905" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_f5523ed2-06db-4feb-911e-76ce7907100e" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_f5523ed2-06db-4feb-911e-76ce7907100e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_e419be5b-3b60-4356-8426-84b8a13106bc" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_e419be5b-3b60-4356-8426-84b8a13106bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_050fc6e0-b40d-4ccc-97de-d3f0a04a82d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_050fc6e0-b40d-4ccc-97de-d3f0a04a82d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf863ddb-2a87-4668-ab9e-64f21c762326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf863ddb-2a87-4668-ab9e-64f21c762326" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b778f2db-941f-49b3-a8cf-15dfd25a6843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b778f2db-941f-49b3-a8cf-15dfd25a6843" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_416cb6b5-c41b-49aa-bb74-7a40ca8e2682_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:to="loc_us-gaap_CreditFacilityDomain_416cb6b5-c41b-49aa-bb74-7a40ca8e2682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:to="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e1c1d040-204f-441b-941e-b929c3de2e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_us-gaap_SecuredDebtMember_e1c1d040-204f-441b-941e-b929c3de2e16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dd4503e5-b6a4-4dcb-82b6-dbf72249148c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dd4503e5-b6a4-4dcb-82b6-dbf72249148c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_49f5cfe9-bf73-4062-b1ec-4926f1a001c3" xlink:href="evh-20230331.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_evh_A2022CreditFacilitiesMember_49f5cfe9-bf73-4062-b1ec-4926f1a001c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_348c8deb-fbb1-497c-84d3-f6fc5dea2888_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_348c8deb-fbb1-497c-84d3-f6fc5dea2888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d008d7a9-e4b1-403b-98e1-9994ad094091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:to="loc_us-gaap_LineOfCreditMember_d008d7a9-e4b1-403b-98e1-9994ad094091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_81335245-70a5-42ff-85a3-8b25b0975a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:to="loc_us-gaap_SecuredDebtMember_81335245-70a5-42ff-85a3-8b25b0975a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8d1d3bab-9431-427c-a3c9-982ec3b06cde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:to="loc_us-gaap_VariableRateDomain_8d1d3bab-9431-427c-a3c9-982ec3b06cde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:to="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_52cf9e6c-37c0-478b-93d2-ed9f78aef7c9" xlink:href="evh-20230331.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_52cf9e6c-37c0-478b-93d2-ed9f78aef7c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_2197f6ca-6fe1-4fc2-9e0a-6fdda07f1740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:to="loc_us-gaap_BaseRateMember_2197f6ca-6fe1-4fc2-9e0a-6fdda07f1740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80da7bea-44c1-4851-ad32-45d37e40db74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80da7bea-44c1-4851-ad32-45d37e40db74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_d18a3eda-ef51-4907-aee8-6b0e8392dff7" xlink:href="evh-20230331.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:to="loc_evh_A2022CreditFacilitiesMember_d18a3eda-ef51-4907-aee8-6b0e8392dff7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="ib57aa25ccd6541cb92eb785fc3862f99_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8a027ea-cffa-429e-a480-d8d171eac7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8a027ea-cffa-429e-a480-d8d171eac7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a2ad75e-5a36-45b4-9def-be69d702a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a2ad75e-5a36-45b4-9def-be69d702a2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_462204e7-e4d8-4868-abe8-b93850e5ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_462204e7-e4d8-4868-abe8-b93850e5ce4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_4ef512f2-3dbc-4dfc-994f-d3c4e7a86707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_4ef512f2-3dbc-4dfc-994f-d3c4e7a86707" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b5499923-7e38-440b-9743-eeec6cca1a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b5499923-7e38-440b-9743-eeec6cca1a47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d71c9492-e994-437f-aa73-757466ad2b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d71c9492-e994-437f-aa73-757466ad2b0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3050fc3a-5270-4882-8847-124e7ebe45cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_InterestExpenseDebt_3050fc3a-5270-4882-8847-124e7ebe45cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2ee6c1ac-03a3-4822-bc2f-3e2f34dc35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2ee6c1ac-03a3-4822-bc2f-3e2f34dc35c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b7519686-18e0-4a16-848b-032f1fe7dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b7519686-18e0-4a16-848b-032f1fe7dbce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b1921828-0745-40df-b657-01c3fa7bc9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b1921828-0745-40df-b657-01c3fa7bc9bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d837cb8e-d949-4db6-99be-125751096561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_LongTermDebt_d837cb8e-d949-4db6-99be-125751096561" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_347d3b29-fd81-4592-8337-842c2f694f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_347d3b29-fd81-4592-8337-842c2f694f32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_536e4f8d-a153-4e50-8d9c-37aad923e9a6" xlink:href="evh-20230331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_536e4f8d-a153-4e50-8d9c-37aad923e9a6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a328c7d-0908-4cf4-bde1-82b4d8859f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_StockholdersEquity_3a328c7d-0908-4cf4-bde1-82b4d8859f75" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c7c1e384-7026-4785-b80e-1d5612767216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c7c1e384-7026-4785-b80e-1d5612767216" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_81052ab2-47e6-436e-97f6-3bef67a3bd3c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_81052ab2-47e6-436e-97f6-3bef67a3bd3c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_c5e1e4b9-9fbd-4ce3-9327-fad6824c600e" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_c5e1e4b9-9fbd-4ce3-9327-fad6824c600e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_29b4ca11-291a-4745-bd88-bbe69050fc4c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_29b4ca11-291a-4745-bd88-bbe69050fc4c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_f8e947cb-61c5-4c84-bb34-1d45c5673ae7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_f8e947cb-61c5-4c84-bb34-1d45c5673ae7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_7cb1577a-4990-431f-8cad-e24010134442" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_7cb1577a-4990-431f-8cad-e24010134442" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8b05304-2eda-48e9-9777-12b6fe952c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8b05304-2eda-48e9-9777-12b6fe952c0c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b98299f8-2f65-493b-b433-6dfe1598d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b98299f8-2f65-493b-b433-6dfe1598d2c2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e859421e-5d09-43db-acd3-f2d5aba59b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e859421e-5d09-43db-acd3-f2d5aba59b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_86bd8438-557e-4c9d-8bbf-356595c6ff34" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_86bd8438-557e-4c9d-8bbf-356595c6ff34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_a5cb213e-cedd-4497-bd17-4a8a40b8e387" xlink:href="evh-20230331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_a5cb213e-cedd-4497-bd17-4a8a40b8e387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_86ecab3f-190c-4720-81a0-0fe229e5fe3d" xlink:href="evh-20230331.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_NewNotesMember_86ecab3f-190c-4720-81a0-0fe229e5fe3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da35c10d-1d64-4956-9892-f155fc17e1ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da35c10d-1d64-4956-9892-f155fc17e1ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f6604143-e76b-4ccc-8c65-b0c1f52f976d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:to="loc_us-gaap_SeniorNotesMember_f6604143-e76b-4ccc-8c65-b0c1f52f976d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_984cb31a-1da4-4669-88c2-68731d4f6eb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:to="loc_us-gaap_EquityComponentDomain_984cb31a-1da4-4669-88c2-68731d4f6eb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:to="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_92f2f0bd-a725-464b-9800-c2867acacc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_CommonStockMember_92f2f0bd-a725-464b-9800-c2867acacc58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f0a65d44-75f4-4d03-a64b-7cabaf99254e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f0a65d44-75f4-4d03-a64b-7cabaf99254e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c59e9088-3b36-423b-b807-b05f7498002b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_RetainedEarningsMember_c59e9088-3b36-423b-b807-b05f7498002b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a5ef1e04-5148-469e-ba65-019a83f096a3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a5ef1e04-5148-469e-ba65-019a83f096a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_36cbae45-8f2b-46ea-8151-766fbcdd9a77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_36cbae45-8f2b-46ea-8151-766fbcdd9a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8ff5d6fb-e315-4bab-9c17-18fefa02b476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8ff5d6fb-e315-4bab-9c17-18fefa02b476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a404625b-c554-456b-a77b-aa9975a57c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a404625b-c554-456b-a77b-aa9975a57c66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b14d577d-cd12-4de9-82d1-51fb90ceee0a" xlink:href="evh-20230331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b14d577d-cd12-4de9-82d1-51fb90ceee0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_a3054d3e-ccea-488c-8ca3-6de282692bca" xlink:href="evh-20230331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:to="loc_evh_DeferredFinancingFeesMember_a3054d3e-ccea-488c-8ca3-6de282692bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_214c5d67-38a9-4ecb-af71-607381bffbbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:to="loc_us-gaap_ClassOfStockDomain_214c5d67-38a9-4ecb-af71-607381bffbbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:to="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_481cda3f-0294-47ea-8182-7d8ee357887e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:to="loc_us-gaap_CommonClassAMember_481cda3f-0294-47ea-8182-7d8ee357887e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="iedc7c14f54064ebd9ca0c55daff0be5a_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2a6a6dec-bd23-4500-b7b0-c6790b8494cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2a6a6dec-bd23-4500-b7b0-c6790b8494cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d716ed16-da20-49dc-a00b-b3006b0590c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d716ed16-da20-49dc-a00b-b3006b0590c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_be5d777d-d242-4667-95af-b77aae7606e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_InterestExpenseDebt_be5d777d-d242-4667-95af-b77aae7606e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_03647704-b1df-4ac9-bd2c-0c792aaf7af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_03647704-b1df-4ac9-bd2c-0c792aaf7af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_107494a8-f2f7-4a90-aa97-b56a9d56e5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_107494a8-f2f7-4a90-aa97-b56a9d56e5b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e95b8051-d511-4538-8c97-14177b1bc4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e95b8051-d511-4538-8c97-14177b1bc4b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ecaad84f-18f0-4853-a5c6-7e68a560bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_LongTermDebt_ecaad84f-18f0-4853-a5c6-7e68a560bb59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_58c7afc2-e8d4-4c87-a2ee-ea70571fd14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_58c7afc2-e8d4-4c87-a2ee-ea70571fd14c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ed4be37d-5974-4e2f-a053-d5e80a59d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ed4be37d-5974-4e2f-a053-d5e80a59d00b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef779106-9bc3-4d86-be86-f2cb438c4fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_StockholdersEquity_ef779106-9bc3-4d86-be86-f2cb438c4fd4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_57f3e576-6401-4438-8b2c-8f8d845dcba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_57f3e576-6401-4438-8b2c-8f8d845dcba0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_9c0ed4ae-f043-4572-b856-3f57647a2082" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_9c0ed4ae-f043-4572-b856-3f57647a2082" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5d18dd9e-f140-4287-b974-7047650de5b7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5d18dd9e-f140-4287-b974-7047650de5b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_1b30a961-b3bf-4e9d-bc90-d82f811be1e9" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_1b30a961-b3bf-4e9d-bc90-d82f811be1e9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_113395ab-c361-4400-ae7e-ed89321d967c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_113395ab-c361-4400-ae7e-ed89321d967c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_0c45b13f-e809-49b4-9600-a8333f1844d7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_0c45b13f-e809-49b4-9600-a8333f1844d7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_689c6c41-9e17-4124-98b7-636d4bfe8e4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_689c6c41-9e17-4124-98b7-636d4bfe8e4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_79879036-dc40-468a-aa04-2901883062e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:to="loc_us-gaap_SeniorNotesMember_79879036-dc40-468a-aa04-2901883062e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d02414b-74df-446c-8693-e49511fa3243_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d02414b-74df-446c-8693-e49511fa3243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_de600e54-7a56-4aa3-a62f-75c2e23898fa" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_de600e54-7a56-4aa3-a62f-75c2e23898fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_892f6a45-a697-4fca-8533-e9327108c9f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:to="loc_us-gaap_EquityComponentDomain_892f6a45-a697-4fca-8533-e9327108c9f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:to="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adffa07b-e400-4af5-a7a0-42a6e4c8a86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_CommonStockMember_adffa07b-e400-4af5-a7a0-42a6e4c8a86a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f242426f-60ad-4696-bd3c-469c13bbe088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f242426f-60ad-4696-bd3c-469c13bbe088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_177c20ae-58b0-4813-887b-565911190af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_RetainedEarningsMember_177c20ae-58b0-4813-887b-565911190af3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92b8bd74-328a-4d22-93df-06ddb043b983_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92b8bd74-328a-4d22-93df-06ddb043b983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_630197d0-25cb-4096-b376-4d192ae738dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_630197d0-25cb-4096-b376-4d192ae738dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_48573273-36f0-43f0-8a2c-aff51703e337_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_48573273-36f0-43f0-8a2c-aff51703e337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_ebf09d4a-eebd-4781-b7b9-fc13c6479f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_ebf09d4a-eebd-4781-b7b9-fc13c6479f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_be0d02aa-1b39-4eb3-aa5a-3900da56063b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_be0d02aa-1b39-4eb3-aa5a-3900da56063b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_593e0dfe-cc1e-4a28-9802-339ddde216ba" xlink:href="evh-20230331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_593e0dfe-cc1e-4a28-9802-339ddde216ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_c7cef379-606e-435d-b3b1-b75b5b7d1275" xlink:href="evh-20230331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:to="loc_evh_DeferredFinancingFeesMember_c7cef379-606e-435d-b3b1-b75b5b7d1275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66e05204-f330-4b7b-bca9-10296135f2e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:to="loc_us-gaap_ClassOfStockDomain_66e05204-f330-4b7b-bca9-10296135f2e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:to="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_219ea8ed-b535-4544-ac9a-0db0fd8c94d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:to="loc_us-gaap_CommonClassAMember_219ea8ed-b535-4544-ac9a-0db0fd8c94d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i04226c00110d458fa3dfdbe11e098c7b_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9c1c1109-af0b-4442-bac4-279a54c8c276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9c1c1109-af0b-4442-bac4-279a54c8c276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4ebb88ff-22eb-4323-8e6f-51eb7bb6742c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4ebb88ff-22eb-4323-8e6f-51eb7bb6742c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f82683f3-1a32-451a-aa75-c0ac87a5ec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f82683f3-1a32-451a-aa75-c0ac87a5ec2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9e9487bd-9507-4a93-aebf-58806ff0a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9e9487bd-9507-4a93-aebf-58806ff0a56c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15376ec3-4b0b-48d3-b288-f6b1095e4851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15376ec3-4b0b-48d3-b288-f6b1095e4851" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_01426d36-c168-4ee1-b398-58e13520c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_01426d36-c168-4ee1-b398-58e13520c8b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa36ef45-fa08-4a1d-ad2e-ce8d2e431134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa36ef45-fa08-4a1d-ad2e-ce8d2e431134" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b0c888c-d671-422a-94ef-2369dd4cbd91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b0c888c-d671-422a-94ef-2369dd4cbd91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_caabd48e-a071-4ce4-b5c9-a9ce68a41756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:to="loc_us-gaap_SeniorNotesMember_caabd48e-a071-4ce4-b5c9-a9ce68a41756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_9087b654-7d23-4a68-ab83-5036ae929059" xlink:href="evh-20230331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_9087b654-7d23-4a68-ab83-5036ae929059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_4124c36b-0210-4391-9102-84b4f1b53840" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_4124c36b-0210-4391-9102-84b4f1b53840" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="i9a0614b807f14cea85df387075a07b53_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_99cd806f-8037-4627-83a9-e7bd5db48a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_ConvertibleDebt_99cd806f-8037-4627-83a9-e7bd5db48a44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_77abfc09-b397-4cb0-a93c-4397187cd7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_77abfc09-b397-4cb0-a93c-4397187cd7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_aa023fc3-ac9f-4d95-ba31-ad735d5468f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_aa023fc3-ac9f-4d95-ba31-ad735d5468f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_ebcef1a9-1c7f-4d24-8ec0-2300b4ee7f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_ebcef1a9-1c7f-4d24-8ec0-2300b4ee7f1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6e698c48-c5bb-49ab-adf2-262189c81ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_LongTermDebtFairValue_6e698c48-c5bb-49ab-adf2-262189c81ff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e3963dd-a642-46a7-9cb5-bb472312a821_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e3963dd-a642-46a7-9cb5-bb472312a821_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_63d30eaa-7cd8-4d30-9d9f-cb46420d018f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:to="loc_us-gaap_SeniorNotesMember_63d30eaa-7cd8-4d30-9d9f-cb46420d018f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e66e5549-e044-4aa9-9142-28062f138030_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e66e5549-e044-4aa9-9142-28062f138030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_deddbf8e-010b-47e5-801f-66da7175bd26" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_deddbf8e-010b-47e5-801f-66da7175bd26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_595ad70e-d824-4b89-be14-62eea78ce585" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_595ad70e-d824-4b89-be14-62eea78ce585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_244df77e-9186-4469-b829-3170be314d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_244df77e-9186-4469-b829-3170be314d51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i5191acc9673c45cdb1403af11a38ad64_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20389a37-0f3a-4269-828d-471e39fabcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20389a37-0f3a-4269-828d-471e39fabcdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc9cac8-7fc1-4d4f-991e-de7acbff0a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc9cac8-7fc1-4d4f-991e-de7acbff0a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_e6aca37b-5baa-4820-90a0-468187256373" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_e6aca37b-5baa-4820-90a0-468187256373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_52918dcb-ddf1-4f1f-a3ee-65f1a3ba68cd" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_52918dcb-ddf1-4f1f-a3ee-65f1a3ba68cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_b0e86b3b-b3f8-444a-8b0d-8288f95fd8bb" xlink:href="evh-20230331.xsd#evh_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_NumberOfCustomers_b0e86b3b-b3f8-444a-8b0d-8288f95fd8bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8b18b471-7cba-4f34-9031-9a6c48f41f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_Revenues_8b18b471-7cba-4f34-9031-9a6c48f41f1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_fce640fa-b068-4b88-8f56-ee713bc63d60" xlink:href="evh-20230331.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_fce640fa-b068-4b88-8f56-ee713bc63d60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_668a78ad-eede-41b1-8d45-17848b62283d" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_668a78ad-eede-41b1-8d45-17848b62283d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_21faf8e4-e98d-4a15-b9c4-1e03495be3c0" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_TaxReceivableAgreementLiability_21faf8e4-e98d-4a15-b9c4-1e03495be3c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d8841fa0-7fe6-4a31-b0ca-e027df672d85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:to="loc_us-gaap_CreditFacilityDomain_d8841fa0-7fe6-4a31-b0ca-e027df672d85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:to="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f07b848f-0da3-44d5-b56f-d81626af527e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:to="loc_us-gaap_LetterOfCreditMember_f07b848f-0da3-44d5-b56f-d81626af527e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4e59d5c0-6255-4d9d-a6ae-51498b6edf94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4e59d5c0-6255-4d9d-a6ae-51498b6edf94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_473060b9-6d3a-4cff-82f2-9e1603a19a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:to="loc_us-gaap_LineOfCreditMember_473060b9-6d3a-4cff-82f2-9e1603a19a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5f9e68cf-b452-4191-9087-9668f46e6b0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5f9e68cf-b452-4191-9087-9668f46e6b0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_3dd69995-54a2-404c-a45b-1c2cf3b48712" xlink:href="evh-20230331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_3dd69995-54a2-404c-a45b-1c2cf3b48712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_7b786d5a-e521-41f0-bda1-eee62abd01c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_7b786d5a-e521-41f0-bda1-eee62abd01c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_c445a5a6-de6d-4c24-903c-5eabcdfdbc9c" xlink:href="evh-20230331.xsd#evh_UPMCResellerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:to="loc_evh_UPMCResellerAgreementMember_c445a5a6-de6d-4c24-903c-5eabcdfdbc9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingenciesCreditandConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails" xlink:type="extended" id="ia69a62cd4189429ab31df386218ddd9a_CommitmentsandContingenciesCreditandConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_972d89e0-1dc0-4c38-a71f-9099930c8fb0" xlink:href="evh-20230331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_972d89e0-1dc0-4c38-a71f-9099930c8fb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89927b2c-e5d1-49f5-a685-78bbad4979a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89927b2c-e5d1-49f5-a685-78bbad4979a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_59b18bcc-d30d-4559-a298-dda5c2acb8ae" xlink:href="evh-20230331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_59b18bcc-d30d-4559-a298-dda5c2acb8ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_06fcb5e2-aad3-4e28-a70d-c2337495e066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_06fcb5e2-aad3-4e28-a70d-c2337495e066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ece05b95-20ec-4fa5-ae98-4b700a58bf51_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:to="loc_srt_NameOfMajorCustomerDomain_ece05b95-20ec-4fa5-ae98-4b700a58bf51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:to="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_e3ea9a9b-d01a-4590-b83b-65efab16fcb1" xlink:href="evh-20230331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_e3ea9a9b-d01a-4590-b83b-65efab16fcb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_418f92ad-265a-4544-a325-e40cc25d70a7" xlink:href="evh-20230331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_FloridaBlueMedicareIncMember_418f92ad-265a-4544-a325-e40cc25d70a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_4902a912-531b-4c74-a33b-2466eefd88e9" xlink:href="evh-20230331.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_MolinaHealthcareMember_4902a912-531b-4c74-a33b-2466eefd88e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_15c0a2dd-1c3a-48e4-8796-abb7d58c1ed0" xlink:href="evh-20230331.xsd#evh_BrightHealthManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_BrightHealthManagementIncMember_15c0a2dd-1c3a-48e4-8796-abb7d58c1ed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_656b7179-3323-4ca0-94b6-505533a05e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_656b7179-3323-4ca0-94b6-505533a05e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1284f23-cbd4-4292-9d15-422361e5a5b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1284f23-cbd4-4292-9d15-422361e5a5b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_29f80672-3eb6-48f1-81d1-70188cc00aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:to="loc_us-gaap_AccountsReceivableMember_29f80672-3eb6-48f1-81d1-70188cc00aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_54d5932c-fce9-4c19-b585-71ec6dc50f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_54d5932c-fce9-4c19-b585-71ec6dc50f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d872fc22-ac01-4ace-84ad-affee889a042_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:to="loc_us-gaap_ReceivableTypeDomain_d872fc22-ac01-4ace-84ad-affee889a042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:to="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_127c68f2-61f4-4c77-b3dc-404fc151a467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_127c68f2-61f4-4c77-b3dc-404fc151a467" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i65b999eaea684822935bd3ff01eb23f2_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_a8406ec9-987a-410c-a43f-7d022d7e89a3" xlink:href="evh-20230331.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_a8406ec9-987a-410c-a43f-7d022d7e89a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_83fd58ef-a7ef-41ab-93da-9b7672b795bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_83fd58ef-a7ef-41ab-93da-9b7672b795bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1129ef01-0f13-4caf-a389-8ae688379a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1129ef01-0f13-4caf-a389-8ae688379a81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:to="loc_us-gaap_OtherCommitmentsDomain_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:to="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_0e858a02-992a-4a7c-841e-f3759b4a0aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:to="loc_us-gaap_LeaseAgreementsMember_0e858a02-992a-4a7c-841e-f3759b4a0aa7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="ie7d26b4bec954665b574d605ef33ede9_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_87d53d6b-9458-49d6-9c91-04cce818fd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_87d53d6b-9458-49d6-9c91-04cce818fd59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df367082-0925-45b0-8231-85e3b3b71efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df367082-0925-45b0-8231-85e3b3b71efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0de9f571-82bf-4a28-88ad-bb1c228c9821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0de9f571-82bf-4a28-88ad-bb1c228c9821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:to="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_603e5c31-0a74-4306-a9e9-fd2031305630_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:to="loc_srt_SegmentGeographicalDomain_603e5c31-0a74-4306-a9e9-fd2031305630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:to="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_14d37e7d-fdaa-4896-8a1a-6959076d0575" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_VA_14d37e7d-fdaa-4896-8a1a-6959076d0575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_1091ec1e-fa21-49d7-9a8a-51b3daffe46a" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_IL_1091ec1e-fa21-49d7-9a8a-51b3daffe46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_84a47590-b020-409b-a6e8-7abf5664583d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_NJ_84a47590-b020-409b-a6e8-7abf5664583d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_e9b77dc9-189a-46fd-8421-2b75db4b83f1" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_GA_e9b77dc9-189a-46fd-8421-2b75db4b83f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_3c9fe571-537d-4eec-bb14-750d59a762f5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_country_IN_3c9fe571-537d-4eec-bb14-750d59a762f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_939a6f74-1942-4ef3-a891-f9953232dfc8" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_CA_939a6f74-1942-4ef3-a891-f9953232dfc8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#ConvertiblePreferredEquityDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails" xlink:type="extended" id="ief75a75944c543e8bdd762f0ff017dad_ConvertiblePreferredEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c5637e6a-2850-4d23-b8ea-69b662533dcc" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c5637e6a-2850-4d23-b8ea-69b662533dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7fb3b8b0-adad-4115-9b35-39b2e1f29d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7fb3b8b0-adad-4115-9b35-39b2e1f29d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_e3358cb6-bcc2-49a3-a03c-009f05c59605" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_e3358cb6-bcc2-49a3-a03c-009f05c59605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8578f4a8-2cf9-4b72-aa7f-14da791f07da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8578f4a8-2cf9-4b72-aa7f-14da791f07da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f95551e-c916-4f0d-a6a7-8be4dd7e5767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f95551e-c916-4f0d-a6a7-8be4dd7e5767" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_7eb24db6-0f87-4a59-acbb-61557cd25188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_7eb24db6-0f87-4a59-acbb-61557cd25188" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityVariableDividendRateBasisSpread_d007fb68-7b6d-411d-8ea0-cd1c232221b3" xlink:href="evh-20230331.xsd#evh_TemporaryEquityVariableDividendRateBasisSpread"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityVariableDividendRateBasisSpread_d007fb68-7b6d-411d-8ea0-cd1c232221b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_4cd08afa-657d-4284-9b58-1ed23b641980" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_4cd08afa-657d-4284-9b58-1ed23b641980" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityConvertibleConversionPrice_b8fdb817-092c-4a85-bf4c-8a302cca3ff8" xlink:href="evh-20230331.xsd#evh_TemporaryEquityConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityConvertibleConversionPrice_b8fdb817-092c-4a85-bf4c-8a302cca3ff8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPricePercentage_b0496076-043a-453d-88fc-8a942530af2d" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityRedemptionPricePercentage_b0496076-043a-453d-88fc-8a942530af2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_68af34fb-a8d5-43e2-abb3-7845457ff99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_68af34fb-a8d5-43e2-abb3-7845457ff99e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePerDollarAmount_0c9286c8-93f9-43bf-b06b-81c71e4530f7" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePerDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityDividendRatePerDollarAmount_0c9286c8-93f9-43bf-b06b-81c71e4530f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_205d8bac-7249-42e0-b82b-c8c82c93e391" xlink:href="evh-20230331.xsd#evh_TemporaryEquityAccretionToRedemptionValueAndDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_205d8bac-7249-42e0-b82b-c8c82c93e391" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6c00a77-cb89-4226-aac6-b4b332e066cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:to="loc_us-gaap_ClassOfStockDomain_c6c00a77-cb89-4226-aac6-b4b332e066cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:to="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_cfe8e030-de9e-449a-b583-89c22b95338a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_cfe8e030-de9e-449a-b583-89c22b95338a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_becf4750-35e9-4536-87d6-da42a0b3eec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:to="loc_us-gaap_CommonClassAMember_becf4750-35e9-4536-87d6-da42a0b3eec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2c105518-e2c9-4c97-a5e6-0c559680e9f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:to="loc_us-gaap_VariableRateDomain_2c105518-e2c9-4c97-a5e6-0c559680e9f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:to="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_81a4fcb6-1130-46ce-909e-bca99821b527" xlink:href="evh-20230331.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_81a4fcb6-1130-46ce-909e-bca99821b527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodDomain_652ac7e4-ba0b-45eb-9416-9b8c04d1a239_default" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodDomain_652ac7e4-ba0b-45eb-9416-9b8c04d1a239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodOneMember_0a8e8ef0-741c-4771-8465-0c6be3e1a9ee" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodOneMember_0a8e8ef0-741c-4771-8465-0c6be3e1a9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodTwoMember_8df144c7-74ac-4e34-b1d6-e5afc5562de0" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodTwoMember_8df144c7-74ac-4e34-b1d6-e5afc5562de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodThreeMember_356f7e24-50ad-4109-b211-00d7b9c2bc23" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodThreeMember_356f7e24-50ad-4109-b211-00d7b9c2bc23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFourMember_99fcccfd-74e2-4df8-8319-6995e554e4b5" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodFourMember_99fcccfd-74e2-4df8-8319-6995e554e4b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFiveMember_2493bdd6-d960-4349-9318-2a5d385abbd9" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodFiveMember_2493bdd6-d960-4349-9318-2a5d385abbd9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i01d590904008467881bccf4bd84d2c80_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5abca312-057d-4fd7-a64b-515ce8323fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5abca312-057d-4fd7-a64b-515ce8323fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f85b911-d459-4a3e-9d3a-30a3cfffee33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f85b911-d459-4a3e-9d3a-30a3cfffee33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_57e5d7b4-c353-4842-a6da-01ed52883011" xlink:href="evh-20230331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_57e5d7b4-c353-4842-a6da-01ed52883011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ec938ea-42e5-49b0-a4aa-249e1b521230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ec938ea-42e5-49b0-a4aa-249e1b521230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_d971c423-4b0c-4cb2-bb36-5b79049352c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_PreferredClassAMember_d971c423-4b0c-4cb2-bb36-5b79049352c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_36ee0b97-12da-404b-83a4-4d5be1b00779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_ConvertibleDebtMember_36ee0b97-12da-404b-83a4-4d5be1b00779" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="ia04257f5833f4b8d9a2bb2a80cd735a1_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a31ca9b-62ee-4996-b1bd-0dfea5c09fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a31ca9b-62ee-4996-b1bd-0dfea5c09fa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:to="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8932346e-47cc-4f74-9aa3-93cda31d299f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8932346e-47cc-4f74-9aa3-93cda31d299f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_69271868-c49d-4382-9857-900d6b79f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_69271868-c49d-4382-9857-900d6b79f91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_332d0667-1e54-4271-a887-e176925f97a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_332d0667-1e54-4271-a887-e176925f97a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_ac2b77b6-8b36-4872-91c2-bbc66234e5cd" xlink:href="evh-20230331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_ac2b77b6-8b36-4872-91c2-bbc66234e5cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_c2df0175-73bc-44a0-b581-1bcafc808b0b" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_c2df0175-73bc-44a0-b581-1bcafc808b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b7e9421-9499-4988-9a10-ef4d6dd4104a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b7e9421-9499-4988-9a10-ef4d6dd4104a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_622033ec-0c88-411e-8f0f-d0bb653b596b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:to="loc_us-gaap_CostOfSalesMember_622033ec-0c88-411e-8f0f-d0bb653b596b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef5def0f-6272-4c93-90a6-5eb382a7c998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef5def0f-6272-4c93-90a6-5eb382a7c998" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails" xlink:type="extended" id="i04d362d0f67542c38ec7b1c19bee9501_StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfb1e46a-fe67-4e53-b9ab-ad92c8086005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfb1e46a-fe67-4e53-b9ab-ad92c8086005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:to="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94a9d84b-529b-417d-ab11-60c77b1ef5fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94a9d84b-529b-417d-ab11-60c77b1ef5fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79700baa-f4bc-4403-9657-978f85bd22be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79700baa-f4bc-4403-9657-978f85bd22be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_6d781c6c-8d29-4be3-9a37-ff9932c28984" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_6d781c6c-8d29-4be3-9a37-ff9932c28984" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="i00ce4e3d872b4f9b834ea7ec8254677f_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d1f948bb-eb14-417d-ba72-5a305852f705" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d1f948bb-eb14-417d-ba72-5a305852f705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_2fd5e7b9-f41c-459e-b811-4424da79a006" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_2fd5e7b9-f41c-459e-b811-4424da79a006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf77c110-a528-43d7-9466-afb3eeb1e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf77c110-a528-43d7-9466-afb3eeb1e6ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_afff268a-9174-489c-9664-51f1280b69bc" xlink:href="evh-20230331.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_afff268a-9174-489c-9664-51f1280b69bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6aafaae-4219-4156-bb14-fb6d736beccf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:to="loc_srt_RangeMember_f6aafaae-4219-4156-bb14-fb6d736beccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:to="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf5bea61-7e96-40aa-ab24-902295167240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:to="loc_srt_MinimumMember_bf5bea61-7e96-40aa-ab24-902295167240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_513ee556-e7c2-45fe-a666-6f1fa3088189" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:to="loc_srt_MaximumMember_513ee556-e7c2-45fe-a666-6f1fa3088189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_42699088-414b-469b-af0f-264b8afb6140_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:to="loc_us-gaap_RelatedPartyDomain_42699088-414b-469b-af0f-264b8afb6140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:to="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_16213ef3-2453-47dd-9adb-df6d9d160e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_16213ef3-2453-47dd-9adb-df6d9d160e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3e30dd09-f7fd-4040-91ea-d781b44fea4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3e30dd09-f7fd-4040-91ea-d781b44fea4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_2d1db547-9562-43c5-a071-b509b906383c" xlink:href="evh-20230331.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:to="loc_evh_ServicesAgreementsMember_2d1db547-9562-43c5-a071-b509b906383c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i33a711ede77a4c70ade766d48add201f_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c290f0a-4342-4972-ada8-cdf0f52b4586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c290f0a-4342-4972-ada8-cdf0f52b4586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0698df6f-5b37-4d13-b791-ce7ae3660e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0698df6f-5b37-4d13-b791-ce7ae3660e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b2d2fd86-5f99-4028-8d9e-b9572199adce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b2d2fd86-5f99-4028-8d9e-b9572199adce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_954cd7b3-de84-4988-ae4f-b733fc40367a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_954cd7b3-de84-4988-ae4f-b733fc40367a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6ed60e6-bffe-4030-a471-b61c99d93636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6ed60e6-bffe-4030-a471-b61c99d93636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e559af4b-a496-4a9f-a2ca-28847153c971_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e559af4b-a496-4a9f-a2ca-28847153c971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8975246d-32b6-4a52-84e7-c34c49992851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8975246d-32b6-4a52-84e7-c34c49992851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i3198729494b343df975957f8aadecb0b_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9cd226b1-4efb-4b5c-8821-68a395c8a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9cd226b1-4efb-4b5c-8821-68a395c8a5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_14e2a41e-28c6-4e33-8cad-7585e7c76cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_14e2a41e-28c6-4e33-8cad-7585e7c76cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a1d7b078-1777-4ccf-8cf7-f0f9073514d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a1d7b078-1777-4ccf-8cf7-f0f9073514d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75839f76-306a-4736-95f7-ce02fa698355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75839f76-306a-4736-95f7-ce02fa698355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f65fab8-02e6-4f46-881d-c421f4cec100_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f65fab8-02e6-4f46-881d-c421f4cec100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b711aa94-5561-4c9b-aa16-35d10c702304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b711aa94-5561-4c9b-aa16-35d10c702304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e6368779-c679-492c-9247-11765711334b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e6368779-c679-492c-9247-11765711334b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_b45c34b9-e45a-42dc-a25e-ae7ba1d287de" xlink:href="evh-20230331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_b45c34b9-e45a-42dc-a25e-ae7ba1d287de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_5283208d-4a68-4efc-8afb-39cdf25b7859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_5283208d-4a68-4efc-8afb-39cdf25b7859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_80aa7185-a9eb-4b6e-807c-c5586db34c16_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:to="loc_srt_RangeMember_80aa7185-a9eb-4b6e-807c-c5586db34c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:to="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7d1043a-04ac-4413-b119-d6df1ebb8866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:to="loc_srt_MinimumMember_b7d1043a-04ac-4413-b119-d6df1ebb8866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8faacfc4-65a0-4b2c-8482-52b9406186f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:to="loc_srt_MaximumMember_8faacfc4-65a0-4b2c-8482-52b9406186f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="i4f0eafbf726c433e86aec0e914d4d9cf_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:to="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fda6f8ef-a892-42bf-80c1-c834c3a87f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fda6f8ef-a892-42bf-80c1-c834c3a87f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:to="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_79c9775a-b25a-4a5e-bfaf-bc3cb1e8fa96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:to="loc_us-gaap_AccountsPayableCurrent_79c9775a-b25a-4a5e-bfaf-bc3cb1e8fa96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3c5401c-f57e-41f0-9557-d885efd968bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e3c5401c-f57e-41f0-9557-d885efd968bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_baa7c50d-c71f-44e9-b13d-dcab7d36471d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:to="loc_us-gaap_RelatedPartyDomain_baa7c50d-c71f-44e9-b13d-dcab7d36471d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:to="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0a7281e1-02db-40ca-9a2f-d953bbeffc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:to="loc_us-gaap_RelatedPartyMember_0a7281e1-02db-40ca-9a2f-d953bbeffc63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="id2f91307497b4317bba49cbb083714a5_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b7b9e24b-dd76-44bd-8696-12120ecf28a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:to="loc_us-gaap_Revenues_b7b9e24b-dd76-44bd-8696-12120ecf28a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7c32dc6d-d2e5-4cf8-ad58-e67c6c3ee74b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7c32dc6d-d2e5-4cf8-ad58-e67c6c3ee74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75be6d16-8ad9-4e42-9da3-535f8fc82900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75be6d16-8ad9-4e42-9da3-535f8fc82900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3e0ab2a1-24dc-4b3c-8038-32470b6af834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:to="loc_us-gaap_RelatedPartyDomain_3e0ab2a1-24dc-4b3c-8038-32470b6af834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:to="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_13668db1-1384-4c5e-ba65-920471eb2459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:to="loc_us-gaap_RelatedPartyMember_13668db1-1384-4c5e-ba65-920471eb2459" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>evh-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_81189b0b-8e47-400c-b8cf-651a2bbd7246_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e20c508c-c0b6-45ae-b575-cba8ac1670fb_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_dd7d7c00-e33b-468e-8448-12c0dad26366_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_9c85587e-b35f-41c6-a488-0da8a980cb3f_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3a2bbb56-ad39-4904-bafa-7503acaf79b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_557d14a7-935e-4161-9ef3-c1387b3f322e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_49b3d723-cb83-4cbf-a5ec-8ae278477a02_verboseLabel_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to services agreements</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20230331.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8e13c854-a303-418a-84c1-d31fedfb9a77_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d737b5a4-71ea-4817-a794-b4c205cb893d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2804d187-0e03-4833-be5d-7a63b1c6a912_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b921b0b8-fe21-4fe4-88b5-cfd3026e6e43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_14b03eaa-b796-41b3-a1e2-3c8723546a22_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodThreeMember_e7cdf862-1910-4d4a-acf1-863da747edba_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refinancing or replacement of debt</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Three [Member]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodThreeMember_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12b4e773-d791-4d00-8a28-45cdc9f416c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_41095fd2-2016-4497-acc2-2c9094beb137_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a7fb13d9-9600-4a1c-859d-cec770a5cb45_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_52be5a3b-8829-4e7c-a660-c90973588321_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of series A preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_91e5b8ca-f34b-4e57-9214-b6989a027271_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_def96811-6c55-4ba1-a068-d8c9b220713d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1ddf4735-711f-4352-8f7a-4e925649d500_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_72bb77dd-5a63-453a-a7a7-4f7d8a546c0a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f16f2698-51d4-446b-8ca6-9216421f9837_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_9f59aee7-448d-4a31-b753-2636d35d82fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ded177b7-af2a-4b3b-b0c3-a0b9ab65c749_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_5c5f2efb-6885-4bd0-8f40-53c6332c8b52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends and accretion of Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f67e19be-4c96-47b5-b180-62e25d52356d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_32eb2c20-da76-4223-9646-c6dc3c35fd37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d2a93acf-fafe-453e-bb02-43ba8d3a3a5a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cb9c57b6-1f1c-455d-8c02-b30d138a647d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b24921af-30b6-4b0a-be6a-9790e94e5f99_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_bbfb0d91-db87-4dff-b049-ca690be701cb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b897f71-4068-454c-8ec6-c97c33ee1dbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_220d923f-b1c3-40f7-ae5c-976e5169e943_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_877e4c51-ea93-4896-b258-1f7b83b76401_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a5229877-82cf-4ae9-949e-7d15feeb7b91_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_73b1d83c-f23f-49d7-98a6-c0ec1cb73d48_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d641fafb-8c50-41de-9c2f-5f8a0650ece3_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6f4834be-f7ff-428b-8152-019b6a216835_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_534b64a3-cecf-429c-a15d-f98b0c0e02be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_58512f6f-4d48-4742-b036-bf52481ffe84_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9bfa5df8-0f8c-4182-b524-5402538f84c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_90fe8a51-1a1e-4486-bd2c-66d4711aa8e1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b1848d73-eaf6-461b-8d85-79cc00ff4d05_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_183a23c7-d662-48cb-91cc-6439c038f74a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3df40922-e2b8-4fba-b98a-eed23d5abafc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3904da7b-7351-442f-88bd-c70880915efc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodOneMember_55e57e38-deab-458a-a915-9f16e2f0f14b_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Called by company on or after January 20, 2025</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodOneMember_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period One [Member]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodOneMember_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d9afd98c-1b23-4216-8a1c-e6570bffc4c0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6938abb2-a290-4436-b604-6ee8e192fb03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f153ec2e-3cc5-4cde-b831-33cf69abeec0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04955acc-7e7d-4b84-843d-605b970320e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9dcdaf92-526d-40e4-91c6-2b0df8870a5c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_159b1c2b-a219-4a7c-87a6-d6fb3abafe7b_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_7c40c527-e885-4a22-ac7a-5cab8d876119_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_0f39f36d-d135-4ef0-848d-0a6ede4f8933_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_671b6375-c5e4-494a-93c9-35b367792995_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_3c6e2233-5bb2-4ddb-aa86-d30dc4c76dcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_9e4dc527-7bd1-4561-9ecd-62bcbbe1a3ad_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of Series A preferred stock</link:label>
    <link:label id="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_label_en-US" xlink:label="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion To Redemption Value And Dividends</link:label>
    <link:label id="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_documentation_en-US" xlink:label="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion To Redemption Value And Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:href="evh-20230331.xsd#evh_TemporaryEquityAccretionToRedemptionValueAndDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:to="lab_evh_TemporaryEquityAccretionToRedemptionValueAndDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f1f62cfd-c847-4d79-a474-6dec254b1818_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_1f358d99-38df-4991-975e-82c13ac9c090_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares issued</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ac621fde-e263-423a-87b3-3eff78876db6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03baa540-2beb-48d2-8f7a-540ebacf2f42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9bcf5f00-6619-439e-a3c0-d3fe373ab23d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_9d4cdc2e-c55d-428d-8fa1-2b121afe9c52_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_bf7be500-c74c-4ee1-aad2-f7e6644e46ac_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_0352445f-9458-4ee5-82b6-4a222d7a9511_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_693c3d42-b96f-4c59-bcfb-f83e387a48f3_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_638841f7-d105-44e7-8a49-b0185649347d_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_d76ca668-0e10-4bcd-aa9d-a0760236c79e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c24dc71-015a-4ce2-a8a5-bb5244759e37_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1cfabe72-8ee4-4f6c-8e44-9a13f97af428_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ed5035a5-db5b-4d23-8d28-a83a6cb1aeca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e878d9f3-f1af-4d01-b070-293b2f6b33b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_ffa9d6a3-adc0-4cd8-a3b0-143f4df7f58f_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_af1eb0d2-4987-4a88-bc6c-e4927ed9ad4c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1f35a828-932b-4298-8ecd-6851138b7318_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2736782f-a427-4b7a-a058-3a522145de0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFiveMember_fb6144e2-9876-471e-bc1c-3658d654a0e3_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change of control after January 20, 2025</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFiveMember_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Five [Member]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFiveMember_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_a54d2957-9851-45c2-a734-824dacfd4f7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_2f6ce700-307e-43f2-b163-0f2f433d4820_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_db682cb1-4d28-418e-91f0-c163668b7be1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1b20606d-4d1a-4c1a-ad71-850a9f8a0ad5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_399597b4-396e-4f52-b2d8-22da883a18c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8ea4ea4a-901f-47ec-a30f-fd1300a25abd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_8003bcc6-19d0-4488-bca3-8634f1b8c3b0_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20230331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_713026d5-6a74-4fb0-bf4c-0de512d1c9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_66d9ff86-1fe1-40b1-b5fa-4c325714b83e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9560a7e9-cde6-4dfb-9657-bdb47c71e345_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_547a279f-3dd0-40ac-9537-e6701a2c00b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c55b1f72-2773-4394-ad1f-d5eaccbce414_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_d12c74d9-99de-4fec-b2d3-8f0bebbc6682_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20230331.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4b20641a-b6dd-4ffb-8471-d8d33a226f33_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2886766f-7c83-40a0-9ed4-d548bbd00580_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b5f6efac-7a9f-4df8-b542-1aa994325b51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_14017b58-aa1d-41f0-af75-f263fbebb272_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3625666d-4486-4d7d-b5cb-fe6329dbf4a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_31b6548d-439d-491b-a2f9-e9ba5c14eff8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bd53d382-8b4f-4e0d-bcee-365d842722f0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e640bfaf-89d4-4cb5-be77-72040659f35c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e809d98b-eb96-40b9-acc1-5c2779bc0c9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_5a6ab406-11c9-4c97-aa18-84cf47c8f106_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20230331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_26d02812-2fd3-4982-8687-8f64d574123c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_6391086b-220a-4248-b282-eeae59b03059_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_15802425-669b-4a43-94dd-77ec678d45d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a9cb39d3-eb14-4e6b-96fa-e08da4ca29fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_41470bf2-88fd-445f-8e06-f83660cec977_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94204da6-fd9d-40b2-8416-57a3296d29f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_45f16fda-c25d-4db3-953c-3852893176f6_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20230331.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9b323b46-f639-4caf-b5e9-039791603cbe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_5216625b-eb68-4f5c-9be6-9f0c35fae162_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a94d7376-963a-4838-a58c-fd61a7f68952_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_5534aa55-de6b-42fc-b520-1f56af5a9ebf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_a4668843-cd1d-4c5c-9aa7-cd5d9201ca66_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8713135a-22b6-47e6-b16c-9822d5886c01_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8688f086-a4cd-4bff-aadd-4947e87c883e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ed1c6c85-f38b-4ae2-bd04-8048453ae98e_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9a779a63-6137-458c-b138-fbfac38e61fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cbf3e89a-229f-4a3e-989e-7efcde125cc2_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dffc6d2b-8a6b-4ec2-a211-db9be2f752a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4afd21d7-9d31-4f30-8361-909bb642852e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred health care costs:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_8eeaf881-45a0-42e6-8b5f-e72ef5c891e6_terseLabel_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss, net</link:label>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="evh-20230331.xsd#evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_de46b182-573b-49c0-8363-6be5134da08f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a935de1b-508c-4891-9729-ec9c0dfcfee0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_94948439-3d58-45a9-ac44-cd6c84731978_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785b7e28-4165-498d-a380-4cda67b4c843_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cb3bb063-a79d-4142-bcee-32a27e24aee1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ed5fccd9-5af6-4f4d-ac37-13b6af623cd3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_3445a733-c090-4a30-a378-9091ae3a9b44_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:href="evh-20230331.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_11a3c8ca-05b9-44bc-8ebc-7c7edbf9e247_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3527ae14-84f5-471a-b99b-d165a37fce3e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment from adoption of ASC 2020-06</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_12d2a336-efca-4816-9e87-044fa48ec16b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ec6e2df0-173a-4007-a4ab-c4e648412749_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_92b631c3-bd2f-4d46-9332-95cbe87e5218_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_61432928-78c9-4151-abe7-620e425ead3a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_9b2be557-d767-4405-8e6e-b8a7b8bdfb67_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_ada9e7c4-c769-4c1a-aa7d-f7109a214b3b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4b169530-b2ab-435f-bae2-4932765e96eb_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_500b582b-a2ce-4bf5-a5ba-30d62313845c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Primary Office Leases and Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityDividendRatePerDollarAmount_1055e5b5-da06-48de-a709-c2f8d5994239_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid (in dollars per share)</link:label>
    <link:label id="lab_evh_TemporaryEquityDividendRatePerDollarAmount_label_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:label id="lab_evh_TemporaryEquityDividendRatePerDollarAmount_documentation_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePerDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:to="lab_evh_TemporaryEquityDividendRatePerDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_6e675f65-cf21-4308-940b-e753fa6c3d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Purchase Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit_592f1326-1058-409f-a2ab-8861be17d22b_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit) from TRA</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Tax Expense (Benefit)</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:href="evh-20230331.xsd#evh_TaxReceivablesAgreementTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:to="lab_evh_TaxReceivablesAgreementTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_459259bf-38d3-4752-a713-ccf24bbbbf17_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_6417751b-bc1f-462c-b2ea-fe1dc7308056_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty prior to first anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4ba98d6e-fabd-4547-b5ed-ad3662624611_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_73551bff-7886-41a0-baea-0cc7600a8c93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ad67ba22-66c0-47ac-9429-8745e46a1205_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_50483f6c-d4e8-49c6-b734-e187d8f6a638_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8c87fb84-3319-414b-9845-395b95eff42d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0c20b615-ff56-4c29-8ffc-244dbff1b43b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_4689c279-f1a8-4b4a-b3ff-511a3df1f0c6_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e9ca38bf-c538-4cf7-9fb9-89dfd1cff221_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a0d167b-31f7-4ad7-ba80-529c6d3b4596_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b99ee57-1397-4728-ac52-40ee1b5bf6a3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e6cfcdac-728b-44a1-b467-34b5fbb14d4c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6adb468-3c83-489f-9a23-f8ee3f716d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_28bd25be-2489-46bd-b8cf-97e40426470d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_92753d0f-d766-4e31-8877-6c28e7291ad6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_15e3f516-f2e3-4da9-90a5-f02c6f4b29d4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_afd300fc-f73c-456a-8a10-8a5779855314_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdd42b3f-dfa1-4fea-9257-1f5123073852_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_94f84bb0-7193-41f5-9d17-6bbcf84897e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_97ec6a3f-cf69-4adf-97a8-ec7a2938abe7_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_0f10dc50-dbe3-4f19-8635-b50fcbe84036_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3fecf819-47fa-4475-b728-a9e9ff400f06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_65913d5a-fea4-4082-a1d2-c32bbf316fea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2118c5d6-3583-4f5c-b0f4-5c342fb85c3a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_49883163-c05b-4e77-b16b-1708e0377924_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7eb31574-f281-4860-a937-0d45f88e175a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a26ea2b5-f962-491d-a152-f530c2fa2564_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or input ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b1fcd3e0-a32f-4cfd-9c1f-004301f4de91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8f20e119-e517-4814-b0a2-0118c232901c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5b9b5506-1a05-4beb-8269-7e724b451b7f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ab9ecb74-e130-4d4d-96bc-bfa6f4fdb9bc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_d567e93a-69bb-4998-853d-b37d6f44932a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9c11c120-1dba-4c80-80a6-5e6be88abb6e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec2317c-64d9-4402-a792-9415051907f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityDisclosureTextBlock_e2b41d7c-0156-48d3-a746-2645e7a1ccca_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Equity</link:label>
    <link:label id="lab_evh_TemporaryEquityDisclosureTextBlock_label_en-US" xlink:label="lab_evh_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_evh_TemporaryEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_evh_TemporaryEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDisclosureTextBlock" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityDisclosureTextBlock" xlink:to="lab_evh_TemporaryEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_58b47770-908d-4715-bbf9-6f4cc70c6b4f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a2fe81f2-a497-4a62-be5c-bd91e6ed011e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312023Member_cb76f28e-9aa2-44ad-b737-4bfc957d049e_terseLabel_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_evh_December312023Member_label_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023 [Member]</link:label>
    <link:label id="lab_evh_December312023Member_documentation_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member" xlink:href="evh-20230331.xsd#evh_December312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312023Member" xlink:to="lab_evh_December312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f937aed0-9829-4094-8516-85e88c719bdf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cfb5ca7a-974d-4c5f-a66a-915917762d1d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0e7d2cfd-b9ac-44c1-8aea-ccbe42bcba78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_db411473-9c4e-463b-a233-4b457803b742_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e77daa6b-febf-4d68-9bb8-57eae4001d86_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4d2506c7-20a3-4453-bcc6-3212ff3184a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3093e699-2850-434d-a168-5f5b9ff989d8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_5e4291d2-c6ca-45af-a65f-e29ff6a8f3f5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_34428676-f7bf-46d7-8e59-ada85797a8ce_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20230331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_ab165f1d-042d-4185-815c-119c0f1b88c2_terseLabel_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_label_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt [Member]</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_documentation_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember" xlink:href="evh-20230331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityComponentOfLongTermDebtMember" xlink:to="lab_evh_EquityComponentOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df499a0c-d2bd-4965-aa34-46f29afe5d41_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efcf6c32-da98-4a74-abea-67718a2b8819_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_648d9af4-3f83-4d06-9912-307863873ff7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe9dec83-b08d-44e7-9344-6b65361f5ec6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_27112621-b765-4fa7-a827-b265b19869fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2743683e-edd9-4ec1-824e-1128725f13d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityConvertibleConversionPrice_f2706e6b-7889-419a-ba52-3a6cc299424c_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollar per share)</link:label>
    <link:label id="lab_evh_TemporaryEquityConvertibleConversionPrice_label_en-US" xlink:label="lab_evh_TemporaryEquityConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Convertible, Conversion Price</link:label>
    <link:label id="lab_evh_TemporaryEquityConvertibleConversionPrice_documentation_en-US" xlink:label="lab_evh_TemporaryEquityConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityConvertibleConversionPrice" xlink:href="evh-20230331.xsd#evh_TemporaryEquityConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityConvertibleConversionPrice" xlink:to="lab_evh_TemporaryEquityConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_2af5c1e2-17a4-4b55-a0d5-6be3c1c71663_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_cb470512-8df5-4679-96b4-f30563c9d139_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_72457305-e474-4315-bb63-2603cceb3bf0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_233f4224-7e2a-4106-9d9e-ec5b37d7b7e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fc89cf36-4640-401e-b13e-92951c63c08f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b95c779f-96e5-4485-9940-c488825e33fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a71e9c1a-2e4e-4914-83bd-7444656dbcdc_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_30837ffe-1698-48bc-ac45-6b05bc5bd8e4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5f31f332-c972-4b57-8a74-98988d61b4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e03b502d-c625-4591-a5f2-c6a9b32e259f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_3ffe1c98-8de0-4a2b-9d3c-f7080fc0caa7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred class A common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_de2dec84-859c-430a-8a89-63f404c7a116_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a9d4bbb9-d924-4c6e-851f-5a35d1ccccf3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_06c3a11f-56c5-4d6d-847f-6cb08ad99cae_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_d6510ba4-2c5c-4dd0-972a-f46ce3d5f3bd_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e429172f-eada-4160-a45d-c8156819f664_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d9308b68-e604-420a-92f0-d51070a09e97_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e1f51144-4457-4df6-9c8b-f573cf24a05f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e1a4a0b3-d634-4cb0-a4c0-3d9b4f04c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_4bd29df9-6639-47f5-aa70-37983df992a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4343db99-f825-43de-8bbe-8053430289b4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2ea73a6d-be20-4cd2-90bf-c3aa0f34a90f_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_d1b33adb-24ab-44f8-8fa4-9801e496ed3a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9b9b58b8-4dc9-4141-bfd1-a3f83d206b42_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ebf80468-c1c5-4b39-a29e-2ee0cd00c5fa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_9f0c2e38-5c9a-4701-a868-aa0d2312e1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b2072c86-c6fb-4158-bfbc-52a3c866e508_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_d1142194-edbb-49f5-b1d8-74855e7cf0a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0c0f0f30-b116-45bd-9d8c-723db8c1e93e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6919ff7f-ab84-47ce-be0a-3df9c36635c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9bf07922-b8a9-46c6-9d9f-ca6f49897536_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6cd28598-719d-4644-8257-8d1fe05ae734_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_44cd5e48-de9a-4dd4-8e5d-59d90a5bf7d9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_695abbb4-3212-47ad-a1fc-55f5e63ce0db_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UPMCResellerAgreementMember_3a3e82ed-77ee-4807-922c-248a40a18dbb_terseLabel_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_label_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement [Member]</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_documentation_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember" xlink:href="evh-20230331.xsd#evh_UPMCResellerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UPMCResellerAgreementMember" xlink:to="lab_evh_UPMCResellerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1cd1fc17-bdb2-45d0-b794-c76bd5a9c2c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_406af1b9-5e34-4ab8-a950-c964d0c89cd2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_79145850-0ae4-47b6-a0a0-da28ce0141a2_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_689c060b-ce40-4778-ba45-79b14a947b97_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_8124dae9-6e00-455c-ba61-903370d61e5e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d32f6205-e610-4b5d-bba2-333c687d2245_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_eaaf53c9-64a2-4127-9a96-7a26f218e1e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash outflows, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_be0ca581-80da-4094-9dc1-bf7d784b7fb1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_2e5deb1f-8b25-43de-b4a7-15ff588adb3e_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20230331.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_ec3bc8d3-0a32-4f47-841d-62a6b519a3cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of preferred dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_fc9fc39f-746e-4a90-b647-1f4d5a8ee55d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of preferred dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_da715a7b-6089-4c15-a015-064eaaae59f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d9cce1dc-0a2a-41bd-aedc-1f59e1d8fb09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_5aa80917-9091-4cc3-98b9-f60c864a907a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_04057635-d030-4270-b927-7977eba487a0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_154a436d-4271-4ee4-b335-146b5a60e025_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c49a859b-d638-47a3-9862-fbdd8655f2e3_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_01961a03-4b2a-4beb-8fdd-477f5f78ff07_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_9628c681-d7c8-438e-8b23-c5a021721366_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_379ddb61-521e-4bd7-a57a-721d1f2eedec_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs (in shares)</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_191d49ef-edd7-4102-9992-4f29f764cb01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f74f934f-da3a-471f-a4c0-7b032a8b4ac4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_83cd5d62-54f2-4cef-8bd7-9033287ed942_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312024Member_5e8086c7-544b-4b9e-8d47-f893665acca6_terseLabel_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_evh_December312024Member_label_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024 [Member]</link:label>
    <link:label id="lab_evh_December312024Member_documentation_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member" xlink:href="evh-20230331.xsd#evh_December312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312024Member" xlink:to="lab_evh_December312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_55d56ca2-d9fc-49a1-8cbd-72aac8e6f3dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e7df5130-23b8-41d5-83d3-7154d0176f8f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_60a5d221-8f2c-45ec-8e92-eafda6465ffb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_e16fa69f-3c50-4f5f-9ec2-dcfb48dfa056_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_869a1ec3-9a46-4ba4-ae12-62db63ffeb27_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_adc10ad5-810c-477f-ac16-6350117ca2ee_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfCustomers_93531a58-eba7-443b-b0dd-e5187a769e96_terseLabel_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_label_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_documentation_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers" xlink:href="evh-20230331.xsd#evh_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfCustomers" xlink:to="lab_evh_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_66ecbb39-1b4a-4a10-9212-b029e49b14c6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_88c64e17-a1b9-42e3-bb70-dd798278e6e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17416303-c5fc-4d90-b7eb-4372c474e358_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e6ba961c-dca5-4d17-8308-baa7db3265fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_6f5ffc4f-6bcd-4a4b-ab55-5bb33f44426d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a2445f65-268e-4f7b-825c-18a7324b394a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_0727dcfe-f075-4532-b9b3-cb895ae04444_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity in Claims Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2246cb1-ee77-47a9-bc6f-00c35e92954a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_93ed5ccc-2edf-4d11-8acb-8013c1ecb8fa_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty on or after third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d628441d-f4db-4963-8c2e-6ce43b87abbf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_9cc04ac5-d52b-4d55-a054-cab90a54482b_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5df9feeb-f0ec-40e1-8f98-b4ed8dced8cf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_4ac70ac8-4846-4cd4-bf51-d37c52cdef45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour_e26e7446-af38-4f4e-832f-23e73865b23f_terseLabel_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour_label_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, After Year Four</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour_documentation_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:href="evh-20230331.xsd#evh_LesseeOperatingLeaseLiabilityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:to="lab_evh_LesseeOperatingLeaseLiabilityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_f1692cf0-6772-41dd-b825-9dec724ba1ba_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_301e4fb8-9a38-461f-b747-2f81b568e40e_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_655e7026-9392-41e8-a67a-6bd030773c4f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a100928b-77fe-4aa4-8593-31073acfd7c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion issued (in share)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_33d52597-459a-4b93-869c-7fe176f5b86a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7c1988ce-6e26-4967-9ad0-d3ae6d2d9075_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9bd8fd01-1d17-4de0-b2eb-3ba9b5069f3b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_f162604d-210d-4103-85f0-0f68a34a7f57_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_90cb27b7-b43d-4232-8845-609378382549_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_d105c6d7-e9c9-4547-99ac-9a56ddd6d5d9_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance - based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20230331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6e07e4ae-7b3e-4858-926d-069424f4b6d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_44997336-8cd7-4b46-bf4d-6d93d6f0cb0a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_a7f30d37-0cd4-4043-b84c-8553dcdb682c_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20230331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_c4066a00-13ba-46d5-95fd-02966e8f3094_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="evh-20230331.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_3c2a63ff-2b9b-4490-abc7-80b37d571c99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_48ac0e16-b6b8-4237-beeb-d483d9757f8e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67702a11-7132-40c8-8df6-8a6cdebb6b71_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_8f61c6b5-b23e-4d09-a531-ca80440f2a4e_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_645da24c-79ad-4a0b-a4a5-4667647ab4d7_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4f3ef9b8-98e7-4500-867b-b8649397043e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3928bffc-8245-48c3-89cc-24082a7f2230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cba63e0-4145-4ddf-b0e4-e98ab9d12baf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5acbc315-70eb-483f-9287-11ec98983d59_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_04dc79dc-6cb6-4ce4-b972-7f49b92de416_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3e0f07f9-e7ca-4fb6-be2f-5b7714325a07_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_7d769489-7483-4ae7-a9d7-c4f43b1c8466_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3e66e1c2-1c24-417c-825d-a41b9cd0673e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fe6cc32d-6205-4b2c-b7ed-5c2aaecacd70_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bcf84b6c-ddd8-4538-81d8-a5296229944d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8450ba5e-14e3-4fe9-9813-a44cd3e0d687_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a5727ee8-d6c9-4fcc-ad25-314f06f831e5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_b38dfd4e-80cc-46e1-a7f7-6cf2fb498e11_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0a3a00b7-042a-4754-820e-456d1101fe12_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0eb91dc3-8cc3-48ac-9bab-d189f7b03787_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8663e5df-fadc-4073-8bef-e800f4ac79f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e76bffaa-040c-4bac-b80c-30ef35dcd195_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b94f8f71-bfc9-4a17-963b-8baeb1f4bbf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6088585c-bffb-4725-aa52-6c82424c9d86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_77d3fe0b-1aa8-47ce-85ac-9cd3c841fb3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fdb7570f-0359-4683-9d0a-513b997c9381_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_657a7715-352a-4f86-9ba2-4ff4e3f81ea6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_d891e444-5c30-4c09-b205-ae103387f683_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_7c00f52a-1d78-4f4c-97df-b2ba63936d2c_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20230331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_21bde897-2401-4c64-b84e-b703cbbb227d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_a9251210-a038-4a83-9239-fb3c349c69f6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NationalImagingAssociatesIncNIAMember_4d219fcf-4c48-467b-8028-36b1079ed615_terseLabel_en-US" xlink:label="lab_evh_NationalImagingAssociatesIncNIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIA</link:label>
    <link:label id="lab_evh_NationalImagingAssociatesIncNIAMember_label_en-US" xlink:label="lab_evh_NationalImagingAssociatesIncNIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Imaging Associates Inc. (NIA) [Member]</link:label>
    <link:label id="lab_evh_NationalImagingAssociatesIncNIAMember_documentation_en-US" xlink:label="lab_evh_NationalImagingAssociatesIncNIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Imaging Associates Inc. (NIA)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NationalImagingAssociatesIncNIAMember" xlink:to="lab_evh_NationalImagingAssociatesIncNIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_b8e73aa1-6bac-4be3-8812-4fc4b870c9c6_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52a37b20-3e35-472d-85f1-baa0f623be5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdministrativeServiceMember_614dab80-a261-4eec-a874-b341b164b6ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdministrativeServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Services</link:label>
    <link:label id="lab_us-gaap_AdministrativeServiceMember_label_en-US" xlink:label="lab_us-gaap_AdministrativeServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdministrativeServiceMember" xlink:to="lab_us-gaap_AdministrativeServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6ae41fd5-5533-46b0-bf37-3ae8e7645cf8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_953ec51d-4604-48fa-8b53-d4708acf9616_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:to="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ebb6891c-8e19-42de-b92c-df3ad616ad72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_948519cd-3db8-4ef3-95c8-0b1fddc59fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbbc505b-8024-441a-a21d-76a634dba2b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f0576eb4-231b-464b-ae9d-4f50dbfb5195_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4c9c0b1c-7526-462f-81b0-c8192d79da7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a308a424-4dd6-498c-a95a-824cd6c47447_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_4cf01323-f8b5-4d58-9b88-751352332744_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20230331.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CasesMember_f15265b5-e765-4727-a2af-5a224d6bd051_terseLabel_en-US" xlink:label="lab_evh_CasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases</link:label>
    <link:label id="lab_evh_CasesMember_label_en-US" xlink:label="lab_evh_CasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases [Member]</link:label>
    <link:label id="lab_evh_CasesMember_documentation_en-US" xlink:label="lab_evh_CasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CasesMember" xlink:href="evh-20230331.xsd#evh_CasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CasesMember" xlink:to="lab_evh_CasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_759d93cc-7086-4757-ac7e-9d1a50caca24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_5f565eff-b167-42d5-9e52-65cccfadc333_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before preferred dividends and accretion of Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_1d789978-921c-4595-926a-0e9122c75c3d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before dividends declared and accretion of Series A preferred stock</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f380c776-bbc6-42e8-8b30-d15f1ed18d92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ec9a90cf-6e47-49e9-ace3-cd800bc7a7d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_debf5815-fdba-4e9b-9401-0383944e21fd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c0101a94-b877-4dcb-ab3a-a387acce62e5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_41c0aa5e-bb4b-4e84-8699-21f757ce79d2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_27781e00-9936-4ac3-9280-4e1772ff6464_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Awards Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2f294d97-77b7-4de3-b3e3-a8ddbe9a87f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bf2baf1e-2a3c-4ba3-b1f7-5d352157bb6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56ebe755-5a63-4dc5-be2d-9b7839aca2db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_a5e70837-941b-4e99-879d-16bae764e17c_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20230331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_be62c1c6-2a58-4cf8-9e7f-75ee0ab27505_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_129aaeb1-150b-42f5-b452-a86fa2565007_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e685ab5c-10e3-4186-83d7-cfa075f306ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4af12410-d74a-4aa7-87a4-1cf330ed9500_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_6c2eedb9-1c59-4ea3-9763-f07dbe24723b_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension after each period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:to="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_1910891c-ca2a-46f5-ac68-4664b8fbff22_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repaid under the revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5a68b745-bfd3-4ed6-8d05-06f810eadd40_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_0f709eb0-32da-4c1f-ae03-ee308d0e6480_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_0ebe29a8-eb7c-4749-be44-264806f04cd2_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20230331.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_21e5a705-42e7-4b56-9e80-6cc412161284_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_97cc9575-d3eb-4c8c-9c65-3fc35898b861_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_f6f63094-16e3-4f0b-b6c8-a0d86ec7c5dc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7e6b32bd-e2d7-4011-9b58-1768c63121db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_77e71125-be19-4674-8eaa-dc6bf555caab_negatedTerseLabel_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIA acquisition</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_label_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_documentation_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:href="evh-20230331.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:to="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_26df2899-f662-4882-9e84-a68cb2ec8ef2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d1fa583d-425a-4991-8fdc-daf3e441f5aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8b3411b8-e1e1-4b6c-ace4-ac0ff90f048e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 112,552,160 and 101,500,558 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_2e569d39-2522-4d25-b7ec-d0979b8b0a86_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7879f75-9f42-4f11-b83f-7a075321b275_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_5cb1ecef-f5e6-43ef-81ed-3395d084f77e_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_7706b594-1ef4-427e-a7c1-38535101e529_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpharetta, GA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_7d30feb5-c969-47db-a881-63a423c8843e_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_622a7dc0-d030-4550-8e04-6fb9dbd71bf3_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of series A preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_82f71837-c268-4d56-9398-5906e044d750_verboseLabel_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate shares of preferred stock sold (in shares)</link:label>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_260af0e2-4b13-4146-a0c9-89232484c877_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a5166ad0-04bb-4dca-8e23-15306e950837_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredFinancingFeesMember_a4cff841-e312-4441-9b1b-4ed14af499ee_terseLabel_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_label_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees [Member]</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_documentation_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember" xlink:href="evh-20230331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredFinancingFeesMember" xlink:to="lab_evh_DeferredFinancingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_124ed6f0-4082-4e96-a4a3-8bcbbc8b78d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodTwoMember_ca617704-f28c-4fac-8454-b52f17c8625c_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Called by holder on or after January 20, 2030</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Two [Member]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodTwoMember_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_b69c81db-87f2-478a-937c-22c39fa0c946_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_138065f9-b28a-4e8c-9471-2a764ab85434_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a425bd6f-6156-43cc-b391-77ffd8718e49_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_44f96dab-d1c8-4b75-9c76-dfd5e4b6a426_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_85a1de6c-54ad-4dc4-8044-4886f7c2b583_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentClosingFeePercent_238d79a3-3182-4d84-84a8-eaa32cd0ba3b_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentClosingFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee percentage</link:label>
    <link:label id="lab_evh_DebtInstrumentClosingFeePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentClosingFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentClosingFeePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentClosingFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentClosingFeePercent" xlink:href="evh-20230331.xsd#evh_DebtInstrumentClosingFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentClosingFeePercent" xlink:to="lab_evh_DebtInstrumentClosingFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da0714c5-a86d-4a39-bfaa-f3abf4ac2154_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8aaccc33-4e2e-46c5-be52-911c7387085b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6b31a2ec-b2cc-4e07-91c8-21ba9654ac4a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_01f4ed2e-eba9-41b6-bcba-4e0cf1859a02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a2fabcf2-b7e9-41ab-85be-be8b74537b51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_38579657-e966-4f3c-9719-70f1c7bfd2da_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_9f07701f-d550-4680-a95c-8ed42bd89ba5_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20230331.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_92fe81b1-e4e7-4a00-a3e3-0c224635dcdf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_76fdd48e-7c5c-4ac2-940b-f780e4baf2f3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cd730a57-a81c-4e9d-9f83-ecc8a3f446e2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_09f3d16c-ea4b-4e7b-8bb3-cc619091bf16_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20230331.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b9590434-e624-45e2-b171-e5d44d35cd1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23348c7a-d2c1-4f8d-8fab-67457431e28a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_020eee26-1bdf-4547-95fc-d9c50613ad10_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_1f688b5c-7f28-41a9-bac5-87533f6a1a42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_94b30936-7fcc-4a03-87bb-24445c5fb7d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1f5299c4-4985-49d9-959d-f183886e5ebc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of preferred stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_29b8d079-e3a8-4548-81a6-07733ccabafe_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3e1398f3-ce08-4203-8700-d5e68e8da27f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_703b53c0-27d5-4a37-a341-3c3e0e8b4ebc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1e4c16b4-eb23-4244-ae50-1e4c4e30cde1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_05fbfd24-4401-45d7-ae3f-a66dc3214726_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_c09d9686-d708-47c8-8a15-8d741878ef49_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4acaec16-e700-4e1f-b369-9fe22b759579_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_57bf6766-7410-4431-a086-1733398f358d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_b78635e3-33a1-43d8-a1f5-e350974c2d5d_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20230331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4eaf112f-816a-432f-b2fb-cee5a1e6436b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_86694581-4030-4bf1-a146-d28ec0e3ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_977c5bf5-671e-414a-b253-72077ec16afd_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc60f1be-5468-49a4-98b0-9e9f1d44c2db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5ed74bf1-ba6f-433b-b28b-805ba23ee3ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_15abaec0-b125-49b4-8a57-082cfe6cde41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fdcc09a5-18da-4a28-a784-8c79cc75d2a7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d7bb2537-65b1-4d8c-ba6d-b74db16da8c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d43f0ef6-0d1a-4b33-af03-32ef3fc5bf90_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_564e93fc-a421-46a0-882a-0670ebf1c91e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_df2b1e50-f537-478c-b369-c0e195d3b083_terseLabel_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_label_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember" xlink:href="evh-20230331.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_A2022CreditFacilitiesMember" xlink:to="lab_evh_A2022CreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dcef29d4-3801-47ae-89ce-cdca24bf6f69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_e2587efb-18d1-456f-9f2e-cfbd91d2d612_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_8314987a-131f-4898-a9c3-033f85c23ea5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_e8e9fe49-6087-4154-af8f-598d3d090884_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0b7171db-702b-4b7a-a224-a4aca5e2e360_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dedefc3-6d85-4b30-a217-2afaf325c4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_01f22f27-7844-4ae5-8795-ec4874c30dc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Techniques and Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_48a7fa78-35d6-4470-b82f-8fb47b323067_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in dividend rate</link:label>
    <link:label id="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_label_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage, Annual Increase In Rate</link:label>
    <link:label id="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_documentation_en-US" xlink:label="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage, Annual Increase In Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:to="lab_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8660fb8e-a9ad-4c8a-8111-607c20af4202_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_dc27be38-5c5d-4373-9d36-98e75bba6e46_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_902b0d19-399d-4590-851d-48885fa15f7a_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20230331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1aaab6a-7689-492c-ad48-36de08fed003_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e68d0c97-77c2-4173-a98a-57da226a9856_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d62b05c-0960-4cd6-838b-5133970483e2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b078e9b0-0456-4cc6-bda2-a5c1b414340a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFourMember_94df569e-2feb-4a0a-8587-d582a1a8735d_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change of control prior to January 20, 2025</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFourMember_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Four [Member]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodFourMember_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bc36b862-a8a7-4914-9d41-b36fc7faa2ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75e4d908-e75b-4f07-a822-84eb4d3b6e8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_c34780ae-9f5d-413b-8d17-3c5f7de22e56_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_39fb7515-f1d5-41fa-9a5c-87ba3d18a107_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8818c4b9-acda-49cc-96cd-43cdf711ee40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_67851cbb-1a3b-489f-b063-374e1077f7e9_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_59c77e55-73fc-40bd-bedb-38588f70e5af_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_04af3d8e-8e3a-4aca-898e-99bfa8b181d6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_95aeb798-254e-4fb9-b679-9960a0986384_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_bfc6b1a8-e0f9-452f-8923-0bc1c3b87aac_terseLabel_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPG</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_label_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP") [Member]</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_documentation_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember" xlink:href="evh-20230331.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ImplantableProviderGroupIMPMember" xlink:to="lab_evh_ImplantableProviderGroupIMPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_42f003b0-9b70-46e6-8796-e3ed42f418ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_0d55751d-6f15-42f3-a352-4a27b5d29ff4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_fe1e2ad7-bad7-43fe-8f36-99a80316b051_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Senior Convertible Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_10547da1-9b53-43d0-9352-3e7f4b0ca427_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20230331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2bed9b75-169f-4ae1-bbdc-063b0dc1b1c1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_90f99a48-a005-465f-9fb3-504a196127f7_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20230331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_a827fce3-5acd-444b-a932-2704d0c2ed25_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_109fe9e1-a7d5-439f-b0dd-a5f7053cb5de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SpecialtyTechnologyAndServicesSuiteMember_23d81845-50bc-4c85-beea-e4c10271d766_terseLabel_en-US" xlink:label="lab_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Technology and Services Suite</link:label>
    <link:label id="lab_evh_SpecialtyTechnologyAndServicesSuiteMember_label_en-US" xlink:label="lab_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Technology And Services Suite [Member]</link:label>
    <link:label id="lab_evh_SpecialtyTechnologyAndServicesSuiteMember_documentation_en-US" xlink:label="lab_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Technology And Services Suite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:href="evh-20230331.xsd#evh_SpecialtyTechnologyAndServicesSuiteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:to="lab_evh_SpecialtyTechnologyAndServicesSuiteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9a6b8a25-a776-4e71-a1ff-575289e68ba6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_af4938a7-222d-4ec0-b172-485f026d32e1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_db1ffd34-867d-4b6f-b3b9-9d68aacdb3d6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_e646d6c1-17d6-46b4-9e0a-32ec995da76a_terseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs)</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_eaafe36f-ecf9-42ac-9693-e953db34b9e3_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20230331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_15ad5a04-a82f-4c77-9456-0dc087e22be2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bf8d4a8a-4541-4420-8646-fe9a680f9217_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_381b3248-1af3-4f9f-bca5-5ab91a92253b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f5e56079-d188-4050-953a-8fa26a946d92_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_829a384b-9e8f-48ef-9c9f-73908f1813f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e4a1fdcd-2d4e-40d4-8978-06ecbbee2fa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_bce152e0-8522-4242-b40a-85347a2b9ce0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fa450c6c-0762-47e4-a013-370929696bb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_9dc58f02-fba2-4901-b8ed-759b51ca023c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from sale of temporary equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_de41d874-368e-4356-9390-a3c28a25a82d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_57a29718-3d28-4690-92c3-9eda2acbba71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_6ff58fb6-42dd-40e0-aca7-8442ba0c1e30_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_89547914-8a82-42be-bdde-ed9bad9899bf_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0fa11179-1d8b-45a2-8439-93b0f81e68bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3fa4d415-eb91-4179-9c43-48eb25bb0d7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9fd8cdd5-1521-4979-aaa7-3ec14495e422_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contingent Consideration Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b7a7a392-3110-4fd8-8f31-de9ace43e2c2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0c42af1d-72a9-4eb0-88db-ceffc1433e7f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_9633949f-60c0-4857-940d-882458c5f693_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_8b3171c9-bc69-4059-849a-fb0b7d919b2d_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0c5e8903-7c13-414d-9f7c-e3521d3e601b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_dd149c3d-78dd-4cf4-ad76-6bd178b2607c_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_d6fdd753-9410-405c-be62-39cda57980f5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4ef0a284-7499-4432-b6fc-b74865e23eea_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_a7052051-5f5d-48f3-9e59-d97a659eaf39_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days prior to any junior debt maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_label_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_documentation_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:href="evh-20230331.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:to="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_41f9bd1f-de55-46b5-8c7a-7dfe348cb3c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d70cbaf7-43a4-4f61-87d3-db19fececebf_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_950ff582-e99d-4c18-99a1-0ba8c3e7eee3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7e47168a-8f80-48d1-8418-13435f8c9347_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments_061c2393-b68b-40d0-af84-e7e7b7ddd176_negatedTerseLabel_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments_label_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Other Adjustments</link:label>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments_documentation_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:href="evh-20230331.xsd#evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:to="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ccc8a3cd-a783-4f78-8310-5452b9acd1d0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b267b3ec-c68a-496f-8fc9-ac21f44c15d4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_88adfe5f-f6ef-4c0f-9e82-759b5c2ccbf2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2cf74694-ffe7-411d-8db6-70f2cbbd9e77_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d5068d2-b257-4f34-8173-1620f093fe4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_125daac6-8f5b-4a83-9378-e689c465cca2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_17e7e5db-72e2-4591-a5ab-a0b241ac134c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_5a917f63-b6bf-4fbe-94a4-8f159c5690a6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_08461752-aeb8-4a38-9e69-13059fd5e15f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f8b7abbe-bd88-4b67-9f53-ce1bc4dfdaf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_ac8a5f24-5126-4da0-8e61-f9e6bafe49b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_98514cbb-c961-4a1a-a8e9-eb38c0323b32_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_63dbf018-2a80-4d14-9907-b9ef10c1ed34_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20230331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_04b47982-a7bf-42ae-95d5-c889b17a27f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_111dd0a6-43be-4870-a65a-91a4195f9885_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_c329c265-7778-43a5-82e9-f4db9e36f450_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20230331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312025Member_0f2261ef-ac59-49f6-932e-87d7742daebb_terseLabel_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_evh_December312025Member_label_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025 [Member]</link:label>
    <link:label id="lab_evh_December312025Member_documentation_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member" xlink:href="evh-20230331.xsd#evh_December312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312025Member" xlink:to="lab_evh_December312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e3ce39ff-fe75-460e-a1b8-a18bc34e5784_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d7a11b8c-3d59-46fc-b339-5f0f1c041858_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a57b1e66-3338-4fa5-8f1f-f783e6360345_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ca4c5543-3ab8-4ab6-ba58-b8c84cbd7097_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eb9c6007-a92a-4678-abbf-86f2d14fc658_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_07e2929d-b3ce-481f-8c13-d1b1061e3da5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_92fbb445-ab60-4ad4-a35d-6590de33c15f_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_ab4a7174-c28b-4c2f-880e-0066f2748847_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a7655a1e-f39f-48b4-8640-e0748b4f5dd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_1139d16c-03e5-42d4-8465-1460a07c801b_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_label_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</link:label>
    <link:label id="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_documentation_en-US" xlink:label="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:to="lab_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ad27139b-54c1-4c66-b8fc-9924b6702ab9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_56d7c248-46d8-4a81-bc7a-c4a99fa7f4fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_c51936fa-d27b-4167-9365-a1c90bd6841f_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20230331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_93a9da8e-1b51-4d05-9cfc-977ef829b9e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4f9fd1f5-c28c-48d9-909b-0579480247e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c5585bb5-9bdc-47af-89f3-08685bae676f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_3f2c85a3-c86f-4a40-b3bc-01c962c2765b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ed8e4cac-68c0-49d0-80fa-2a89d98ed5b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3b114e7f-0a47-4a9b-a590-56de14284d72_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_c44560ca-cae1-4897-8830-3dbc3d72169a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_a0f26f11-3d53-4e10-8c5d-fcc5a8a3df63_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20230331.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_05c9fd3a-5cb0-4f29-afe0-8703352b6c0d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4b60c627-5a46-4048-9e27-765a0ecd9fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_33e14c7a-d695-4935-93fd-f5231694fc0b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_65248cfe-2171-4b91-b7dc-58a94a019903_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_d5851d10-3df8-4236-b1f0-535a24579e2f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_a2e36694-607a-4e20-899d-939fb8c5d6c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with business combinations</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_d7ae18ed-4ad4-4190-ab63-e9ba11922411_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_1a359169-52c6-43c3-9984-72feafda6991_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_543f8955-a411-4c29-b525-b3e2e3f56f15_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a85a8155-26db-4e71-8115-edd4d9a9ef47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_8e8f7868-c1eb-443c-bd94-da20df414b7a_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_e7d894b1-2cd1-40b9-a3fe-44274f775c99_terseLabel_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:href="evh-20230331.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_df5340c9-65f3-436a-bd21-3e6219696c6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_493f0c3a-73c9-4067-a6a9-4752944ab097_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_7c68744b-90e6-4bda-9020-7e3b411612ad_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_5126b324-06fa-4977-96d7-715cc3e388f3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims paid related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_11f59456-91e7-4a03-b4e5-26167b4e75ba_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_c2ccc562-79aa-443e-9de3-54a384abe6e5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_69544224-29fd-4c7d-a0ab-1e10fc910cf3_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_45e434a0-b10d-41f2-8a38-c053f9d9c4fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_724987e7-b379-426c-ab71-ad983cee2f1f_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_602fe11b-6287-42fa-996a-fa8135e9760b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3ecc2cfd-f135-4151-8a54-c82629fd40ad_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5056ef05-66da-4cf0-ae47-2acaa389e7b6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_11fa26ff-7299-4065-a6b3-46d13f704f2a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Restricted Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceSuiteMember_06034693-1bd3-44a8-a6dc-126032e9856c_terseLabel_en-US" xlink:label="lab_evh_PerformanceSuiteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Suite</link:label>
    <link:label id="lab_evh_PerformanceSuiteMember_label_en-US" xlink:label="lab_evh_PerformanceSuiteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Suite [Member]</link:label>
    <link:label id="lab_evh_PerformanceSuiteMember_documentation_en-US" xlink:label="lab_evh_PerformanceSuiteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Suite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceSuiteMember" xlink:href="evh-20230331.xsd#evh_PerformanceSuiteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceSuiteMember" xlink:to="lab_evh_PerformanceSuiteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_9ea4234f-b5b8-4c39-a7c1-a5fbfb886f23_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20230331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_24422622-b3cf-4a6d-93e5-d5f5ded5008d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_58b3cdca-21b0-4956-a601-f09b6ed15493_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_b10e9346-b52a-4caa-ade4-188001ca53a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_24b8d0a4-4e1e-43db-ae80-703f97105805_negatedTerseLabel_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_43e304b3-53da-4f8d-8cb7-e8e9b222e959_verboseLabel_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_2cdd214b-b5f6-4ca9-bf6f-d58bee8adc79_terseLabel_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of remaining TRA liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_label_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_documentation_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:to="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_abfbf59d-9307-4b18-b9ed-86ec948e313d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_eadfa43d-a94d-4291-8b5a-406da6f23108_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_7c68b6d7-e3ec-41f0-98e3-a7bdbf20f137_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6ee41d6b-8fc6-4208-94c7-8e3c1a90fc37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_da51e159-1f02-4b09-83d3-1b0ed67d38a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_ece9617e-e713-4a3a-abb1-52a5ffcbeb52_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1fa33673-e37c-46f3-adb3-b10f79141a94_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e4207cec-2218-4e3b-b671-7701e45ac136_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a855fd3a-51f2-4fe8-be63-e4c402dde3f0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_c763503d-cbfb-484c-b14f-ceee94dcae6e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_2faf1ebf-e1f2-4452-9ebe-e2a08b0177b0_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPricePercentage_dcca38f9-7f7e-45d3-b16b-d8132e073576_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPricePercentage_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption Price Percentage</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPricePercentage_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption Price Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPricePercentage" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPricePercentage" xlink:to="lab_evh_TemporaryEquityRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30953b52-82fe-4386-a87d-335842330710_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a60c3d93-f444-4f95-b1ab-dc42168fa64f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_657f5a67-0395-471a-b73e-29df7d54fe12_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_de21cf25-fb78-4859-ae66-8ba9c0972758_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_5f72a4b1-354e-447c-aa5c-67713288c5e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_cd5886a6-9e48-49e9-93df-fda40f659abb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d1e2fb4f-971c-49fe-884e-1f5af412a4f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ef9f405a-41e1-49c1-bb45-c7d6aec0ed2a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be06571c-458a-4058-ab8c-daeff15259b9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a5c6d5e2-f773-41fb-a6c4-66444bff459c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b10bce06-c8eb-408d-ae37-54bf817fde1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_74f7642f-6b94-488d-a29b-e157be17e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_6168ad3d-f703-49eb-b1b1-13ebaee80455_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_a6a36c9f-6920-4d2d-a716-ed2e25e3748f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4474cdbd-fa6f-436a-899c-06ccfff934e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_26a40bed-a263-4d53-822d-81442dc654a9_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementLiability" xlink:to="lab_evh_TaxReceivableAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_1e0d64f0-3cb7-4cec-82e7-343e5cd3ab97_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Allowance for Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_917e7d9b-8f75-47bc-9212-58a8853a37be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Adjustments</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_d92dde68-7315-4f1e-8c46-db09334e7581_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dc041098-d9d1-4bb9-bc6e-20f4ed20531b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_04103c09-aaed-4743-acfc-d050d00843d5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of the debt discount and the issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_3980c322-927d-4025-a239-95563fe337d0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bb10e826-69d4-485c-ba23-56bb39d6921c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BrightHealthManagementIncMember_4258ee3a-85db-4eff-96b3-06db4660b75d_terseLabel_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc.</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_label_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc [Member]</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_documentation_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember" xlink:href="evh-20230331.xsd#evh_BrightHealthManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BrightHealthManagementIncMember" xlink:to="lab_evh_BrightHealthManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e2eb0e99-e65a-4fbc-9051-de664ec4f298_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation expense by financial statement line item</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_2807d30f-d4f9-406c-bc0d-e7dfac349c83_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_ca7c2d8f-d6e2-4630-9a7c-7e8e150a3446_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39a6f30a-9806-4102-94a3-eb46c36248b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f1011206-dc62-4d92-b00b-e87a1e6bdb5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c9c4bdc4-c085-4fd2-b4fc-58eb10ea263f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_a8af657c-8ea5-4584-b2f1-8c9af6de3516_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred class A common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_eb957b63-364e-4085-87ef-a3e51a57a8e1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0420b964-deb3-4e15-9845-ba27df70d842_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_8b5dac90-d5e3-4679-a78d-e669e8552a2e_terseLabel_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="evh-20230331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_371e11ff-687b-4d68-9af5-3c28a2d01657_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_118a2ded-2cea-4048-bd00-c570eacb642c_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4f503d7e-1ef3-4bc3-871b-83beec6a1422_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9f40973f-659a-41f2-8cc2-4bc3be34601c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityVariableDividendRateBasisSpread_43884719-0be9-4dbf-9561-58b22da03c96_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly dividend rate, basis spread on variable rate</link:label>
    <link:label id="lab_evh_TemporaryEquityVariableDividendRateBasisSpread_label_en-US" xlink:label="lab_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Variable Dividend Rate, Basis Spread</link:label>
    <link:label id="lab_evh_TemporaryEquityVariableDividendRateBasisSpread_documentation_en-US" xlink:label="lab_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Variable Dividend Rate, Basis Spread</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:href="evh-20230331.xsd#evh_TemporaryEquityVariableDividendRateBasisSpread"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:to="lab_evh_TemporaryEquityVariableDividendRateBasisSpread" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9ec2aaa5-7b0e-49b6-9517-98ad13bb752b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_5c6f8046-20bb-491d-9d65-7e26ec9326f3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c8de4bb8-b9ef-4234-9157-7a26a33d134a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_083d1123-269c-42c3-a0b8-812bad563f94_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39f1a236-2d6b-44fa-84c3-d9709d8e396f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de6b810d-8c6c-40ac-8d64-58b288437456_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_813f1369-0a61-4c86-a771-1893ae03531e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_40b79fff-bca7-4bf0-b8d2-41ede03f73ca_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredClassAMember_673697cd-9429-443f-97e3-a2e45163f520_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredClassAMember_label_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_66687881-2070-4ee3-ad61-fc9637d46ad1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_d7336456-b6db-4442-bc28-4a9433b5f4e7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_49d8d3fc-b8e1-4b46-ba12-6d5e9ac83ea8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b329c3ec-0bd2-4bd4-b464-ed4ce25ed971_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1f43cff0-4b26-4860-8916-2ed044a10668_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_7806b5fc-0bb7-4d0b-8489-32cf1768dc2e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred class A common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_14144ddb-d59c-4c02-a74e-70a87c676504_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_3bd451be-68f0-4751-a285-415e32950f9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b7cb577c-c860-4b8b-bab0-660691f021af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_537b9dc0-0a15-406d-88e5-8b3527f523d7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_cc57a90f-322a-453c-8685-750129fef3f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a6a19bb2-dabd-4222-8b72-43463616adf5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3fb2665f-688e-43d0-9dfd-3a471385b710_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_84eeb8f9-bfe9-4d81-a73c-0736f9d9c523_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94f794f5-30f5-4ab9-ac3d-b6df43714c9e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d85378c9-d06f-46bc-8147-3d3ecff78662_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_f0ca23ad-a8cc-4123-bf66-d746746894c2_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_374bcda8-6791-46d4-a241-ca4e77fa57da_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodAxis_0ed6cba1-a6a6-43ff-b449-148ae8f7a3c4_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Axis]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodAxis_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Redemption Period [Axis]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodAxis_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Redemption Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodAxis" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodAxis" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_2aaa41fe-b31f-42c6-b11a-8edf68f93886_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20230331.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6800171f-3bcd-4799-8283-646d84778014_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_bbc42e80-4239-4a9d-bad3-7b635f90fce7_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6a2f2c30-919a-483c-8829-db7134a82d27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f608c67f-d4b1-46f0-90be-021a7016b9c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_64e06fe8-b8b5-4a73-92d5-8178d818bb63_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a11687c4-edbb-4a5d-8d56-ca708acfb9b0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a889e6a3-750a-4772-8675-fdcc4c8e95e8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7f9bb67b-a74c-4ca2-b788-b2b7566212d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b6530cfb-72d7-4765-8c6e-d9cf52c8c757_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9026b088-d30b-41cf-a21a-8217116640cb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_9eebf20f-d173-4eea-bb0f-bd609393f7b0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued net working capital adjustment with business combinations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7b6c3cf-f479-45ab-bec4-75c71abdcae7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_204c9081-d021-4d2e-a652-9d1664c1beec_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_785a61b3-9d03-476f-bca9-e58bad5ecf58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7aa2325b-a64c-41b5-b2f5-0076cf9a61ca_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_025b327e-09dc-4e07-b74c-b1f662ad3920_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b76a4ac7-9ddf-43f7-99e8-ebbf0b56e2ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_aa3c9b1a-1c15-4470-bb28-f938a009235a_verboseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs)</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d2a9b907-8a10-4d01-a524-4ef47ae9ab9c_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_35bbf42e-39df-428f-8805-4eb1b3cc22c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4cb4b575-21a8-4fed-9601-893adf2651b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cafb59af-0099-491d-b36c-a5cbc2e018bc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_d253de20-0fb7-4e8a-83e2-fa8623c573c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_382f7200-63f7-45d2-92ee-3b564b784bc6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_4d25de96-5e5f-48ad-9827-ab42c5f3130f_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20230331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ee4199c1-12bd-42d7-a42c-92fc4fc7e089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodDomain_3b2145dc-e823-40dc-af06-1d880c66bf1a_terseLabel_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Domain]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodDomain_label_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Redemption Period [Domain]</link:label>
    <link:label id="lab_evh_TemporaryEquityRedemptionPeriodDomain_documentation_en-US" xlink:label="lab_evh_TemporaryEquityRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodDomain" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain" xlink:to="lab_evh_TemporaryEquityRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_9ef01aef-a6c4-49e1-8f90-44ec9c9014e2_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20230331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_050d093d-62aa-4e9b-924a-7056544091d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e3cd154-45f0-4a5d-a12b-4c510aa53b37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_7b03edca-c4d1-4bfd-a2e4-8b2ffef6c7a2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0c35b7ad-c36e-44af-b522-165d92dd1fa5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_a41e80e0-f2df-4e1c-9b9d-fb691ed5caf2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f7a24b5-1d04-4544-a101-3f487ed598d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_37630204-3359-464b-a30c-638b1444d322_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ec2dedc-ea30-4328-9562-dc3f9f0c88b7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_880fd6ee-ba44-4f66-92d2-b75304e0d919_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_10e31ec8-608d-4a34-9d39-337f525d700c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1efb58a8-afe5-4d10-9814-f2e80861cb1c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_65216c0a-acee-40bc-bc65-0b9bfcf80a69_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_dc6817eb-0f4b-4ab6-a726-94799f064a0c_terseLabel_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases option</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_label_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_documentation_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases" xlink:href="evh-20230331.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfOptionsToRenewLeases" xlink:to="lab_evh_NumberOfOptionsToRenewLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3610b091-d4bb-4b6b-b9cc-4afa6e8cda4e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f68c9139-f570-4921-a2cb-0ef918ff4091_verboseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_f8fd937e-34bb-493d-bf75-768090b06cd0_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contingent consideration allowed to be paid in equity interest (up to)</link:label>
    <link:label id="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_label_en-US" xlink:label="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Percentage Allowed To Be Paid In Equity</link:label>
    <link:label id="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_documentation_en-US" xlink:label="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Percentage Allowed To Be Paid In Equity Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:href="evh-20230331.xsd#evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:to="lab_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_29eaf057-d4df-40df-88cf-b2c212d40f5c_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20230331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_09eda44f-9c54-4d28-a934-229a04345db4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CustomerDiscountsFromPerformanceObligations_f3bcfda4-d460-4191-bd83-0d8173206724_terseLabel_en-US" xlink:label="lab_evh_CustomerDiscountsFromPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_evh_CustomerDiscountsFromPerformanceObligations_label_en-US" xlink:label="lab_evh_CustomerDiscountsFromPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Discounts From Performance Obligations</link:label>
    <link:label id="lab_evh_CustomerDiscountsFromPerformanceObligations_documentation_en-US" xlink:label="lab_evh_CustomerDiscountsFromPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Discounts From Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CustomerDiscountsFromPerformanceObligations" xlink:href="evh-20230331.xsd#evh_CustomerDiscountsFromPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CustomerDiscountsFromPerformanceObligations" xlink:to="lab_evh_CustomerDiscountsFromPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_8ee1b359-c977-4363-9353-43daf5bb829e_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_27f83ae4-8a2f-4e45-ad94-cca6af678dc8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_44bc51ad-c71f-4426-bc1d-b06f7de2e58b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f7ca267b-74b9-472c-91fe-7774f97e3b4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1ac30fd9-5367-49aa-a446-2d8d03b6dafc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_73b93faa-ffa5-412e-88a9-e1b9ffdbb807_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_9729decf-bd13-4202-8f09-c36e2b5524cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7e49accd-0873-4a79-bd49-0944101b437f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_15a2d964-f7bc-4c7e-af5f-d57680a6aaa1_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0492ed9b-d020-4153-98b7-62fc68fd9044_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_7b51b1fc-012c-4b0a-9719-b5f089307272_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax benefit percent</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_04a5c42e-d507-42a2-bc88-99046eff10e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_7fb38d7e-5e9f-457b-9a81-1ebfc81b84ed_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_f5021d42-7425-4555-9d1e-07350eaab871_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net capitalized internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>evh-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e5837711-4759-4721-9d6c-b9090b9824a7,g:5a7952fd-c7d9-4bcd-8103-8d2299d37650-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Cover" xlink:type="simple" xlink:href="evh-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1df49766-b579-4cd4-ad8e-137ed7975c05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentType_1df49766-b579-4cd4-ad8e-137ed7975c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_901d278d-9dcb-40a2-95d9-34b67e8cc96c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentQuarterlyReport_901d278d-9dcb-40a2-95d9-34b67e8cc96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2fdf1c86-fd61-44ce-8ff2-427f3cc7461e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentPeriodEndDate_2fdf1c86-fd61-44ce-8ff2-427f3cc7461e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a08d52a0-fa09-41bc-86b9-ef56e7ffd5bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentTransitionReport_a08d52a0-fa09-41bc-86b9-ef56e7ffd5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b5d771fc-48ab-4a94-80cf-30ee6b5f2382" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityFileNumber_b5d771fc-48ab-4a94-80cf-30ee6b5f2382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2a0c3202-0817-4b46-b32a-2fa94f07186d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityRegistrantName_2a0c3202-0817-4b46-b32a-2fa94f07186d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b4d6fd10-192c-4479-80e1-4f78941fc200" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b4d6fd10-192c-4479-80e1-4f78941fc200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2a6c598d-ecb4-40c2-acd6-1a8fe0c2093a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityTaxIdentificationNumber_2a6c598d-ecb4-40c2-acd6-1a8fe0c2093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b46a7508-8890-4ffe-a71b-c807d929e40a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityAddressAddressLine1_b46a7508-8890-4ffe-a71b-c807d929e40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ededc166-53e5-441f-9049-df880fa18341" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityAddressAddressLine2_ededc166-53e5-441f-9049-df880fa18341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_406dbeae-8be9-4549-a7ca-afd20de2fc98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityAddressCityOrTown_406dbeae-8be9-4549-a7ca-afd20de2fc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d3fb2f8-9194-4b9f-907e-28b7993a361b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityAddressStateOrProvince_0d3fb2f8-9194-4b9f-907e-28b7993a361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b2d6c907-cb26-478b-a958-17de956528b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityAddressPostalZipCode_b2d6c907-cb26-478b-a958-17de956528b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d4e3a100-e777-40e3-939b-27e79f9cd5c7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_CityAreaCode_d4e3a100-e777-40e3-939b-27e79f9cd5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de01e8b3-99ea-49f9-b923-7524a337c0a6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_LocalPhoneNumber_de01e8b3-99ea-49f9-b923-7524a337c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_87889919-bf24-4dca-9f78-9ec9e918d8d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_Security12bTitle_87889919-bf24-4dca-9f78-9ec9e918d8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_612dd907-edcc-4847-ab31-9d270755dd61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_TradingSymbol_612dd907-edcc-4847-ab31-9d270755dd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_49ddaf32-ffb6-4e58-83eb-5ed921809406" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_SecurityExchangeName_49ddaf32-ffb6-4e58-83eb-5ed921809406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_22f8d9c4-7c0d-43b5-9995-a873a66f951a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityCurrentReportingStatus_22f8d9c4-7c0d-43b5-9995-a873a66f951a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_33187425-56c6-43cd-9329-ab41d37ff0ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityInteractiveDataCurrent_33187425-56c6-43cd-9329-ab41d37ff0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c4e449a5-4db1-46d1-9091-44e30079fbc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityFilerCategory_c4e449a5-4db1-46d1-9091-44e30079fbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5ee394c8-dc17-446a-8fa7-34588a26f463" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntitySmallBusiness_5ee394c8-dc17-446a-8fa7-34588a26f463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c565bfc1-5417-47ee-9e26-eea6e4f8f036" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityEmergingGrowthCompany_c565bfc1-5417-47ee-9e26-eea6e4f8f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_aca77177-89a2-4044-bd42-2e44ce2d4070" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityShellCompany_aca77177-89a2-4044-bd42-2e44ce2d4070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cc3285a9-fdb9-473e-beff-312b62e25941" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cc3285a9-fdb9-473e-beff-312b62e25941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f0185104-157a-4a88-9042-25b4767acb11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_EntityCentralIndexKey_f0185104-157a-4a88-9042-25b4767acb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b6b3132e-43d5-4fda-900f-e9ac44e16391" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_CurrentFiscalYearEndDate_b6b3132e-43d5-4fda-900f-e9ac44e16391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_02a7a31d-24a8-49e6-8cf0-1293c9564b81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_AmendmentFlag_02a7a31d-24a8-49e6-8cf0-1293c9564b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9b35cadb-a4d0-4e27-b22c-47e077d11765" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentFiscalYearFocus_9b35cadb-a4d0-4e27-b22c-47e077d11765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c7d6f90f-24c0-44ff-a155-3cb1aa897d21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee8400fc-f5ec-436e-bf41-c7b1feb35b96" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c7d6f90f-24c0-44ff-a155-3cb1aa897d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d4207488-b339-4b8e-8e42-1c2384014970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4207488-b339-4b8e-8e42-1c2384014970" xlink:to="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fd561a8-f775-41c5-a69b-657c4d64befb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fd561a8-f775-41c5-a69b-657c4d64befb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_8453f25d-1266-4c88-b69b-d54f0fd7b564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_8453f25d-1266-4c88-b69b-d54f0fd7b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_81e0a610-3773-4286-b692-2f2edd97e186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_81e0a610-3773-4286-b692-2f2edd97e186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8509f39d-b24f-41e3-bae6-3af62103fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8509f39d-b24f-41e3-bae6-3af62103fd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d5b6ed67-23f6-4440-ae35-218e079b7e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1ea9544-d8b2-45c1-91a9-ee5676d3f0b4" xlink:to="loc_us-gaap_AssetsCurrent_d5b6ed67-23f6-4440-ae35-218e079b7e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0df90af4-7be1-45cb-bde3-e282d9f87398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0df90af4-7be1-45cb-bde3-e282d9f87398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4120f1e3-2af0-42e1-b491-8804272e31d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4120f1e3-2af0-42e1-b491-8804272e31d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2da18511-137a-4e90-bc07-d5ff6ad946ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2da18511-137a-4e90-bc07-d5ff6ad946ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b6ec7b14-85fd-4f5f-97a4-71df0977e954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b6ec7b14-85fd-4f5f-97a4-71df0977e954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_46c2fe64-8dcf-4ba2-a2f1-59805d7f7449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_46c2fe64-8dcf-4ba2-a2f1-59805d7f7449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_342ba19d-a3cf-4f41-afca-3c18da70a618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_342ba19d-a3cf-4f41-afca-3c18da70a618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e73d41cb-46c0-4995-bac8-c33084f86e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e73d41cb-46c0-4995-bac8-c33084f86e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_33d4fe27-7964-48c4-bede-ae505fd1b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_Goodwill_33d4fe27-7964-48c4-bede-ae505fd1b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c9de57e4-8485-41aa-b4e8-1038995b95d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a756ed0-a572-44ee-a949-2691cf4ecb1b" xlink:to="loc_us-gaap_Assets_c9de57e4-8485-41aa-b4e8-1038995b95d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4207488-b339-4b8e-8e42-1c2384014970" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:to="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4b08b72f-01b0-4e1a-9779-eb963e09528d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_AccountsPayableCurrent_4b08b72f-01b0-4e1a-9779-eb963e09528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d77aed57-2142-4eaa-9b2f-16dec7d8ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d77aed57-2142-4eaa-9b2f-16dec7d8ee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1baa2ac0-7413-4ba6-aac4-d21775c3140a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1baa2ac0-7413-4ba6-aac4-d21775c3140a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d67a730-9757-4809-b0d3-c9585be532d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d67a730-9757-4809-b0d3-c9585be532d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_38b91a83-9a94-4d42-bb60-144899a58c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_38b91a83-9a94-4d42-bb60-144899a58c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_bf0e8977-f1ae-44a5-84f3-1d9645a16fb3" xlink:href="evh-20230331.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_bf0e8977-f1ae-44a5-84f3-1d9645a16fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b32cf167-7b2e-41b2-a000-852e85c0b06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d492ea-b6a1-4eab-b1a8-7783193aa9a7" xlink:to="loc_us-gaap_LiabilitiesCurrent_b32cf167-7b2e-41b2-a000-852e85c0b06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_40170e90-2e08-4290-9f57-f0fd51876603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_40170e90-2e08-4290-9f57-f0fd51876603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7da37fcd-69e7-402a-ba52-94504050e5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7da37fcd-69e7-402a-ba52-94504050e5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_317a2cde-b1f0-44e6-a218-a7efde410a72" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_evh_TaxReceivableAgreementLiability_317a2cde-b1f0-44e6-a218-a7efde410a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deee2232-8397-4951-86a5-5ec0dc975363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deee2232-8397-4951-86a5-5ec0dc975363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8dd74c0f-fd9b-4004-b2ca-0761f0ffd1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8dd74c0f-fd9b-4004-b2ca-0761f0ffd1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e1a9280-caba-488c-a3a5-2232f51b2227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_26d3d392-f79b-44d0-b49d-99ce0cee000f" xlink:to="loc_us-gaap_Liabilities_0e1a9280-caba-488c-a3a5-2232f51b2227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c0cb9755-31a2-466c-9812-4adc621a4713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c0cb9755-31a2-466c-9812-4adc621a4713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_71fdd7b1-8c78-4433-87f6-e2abc7e96495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:to="loc_us-gaap_TemporaryEquityAbstract_71fdd7b1-8c78-4433-87f6-e2abc7e96495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ba452a35-ac2e-4c83-a388-39382ef7ce31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_71fdd7b1-8c78-4433-87f6-e2abc7e96495" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ba452a35-ac2e-4c83-a388-39382ef7ce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_68d54df6-ab12-4881-9bfd-7655a06272bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_CommonStockValue_68d54df6-ab12-4881-9bfd-7655a06272bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7bb1f5a2-92d6-4335-87ab-923cc81a0b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7bb1f5a2-92d6-4335-87ab-923cc81a0b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d64f506a-8c0b-4ab7-886e-f8849e9f8773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d64f506a-8c0b-4ab7-886e-f8849e9f8773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03061d60-625f-4cdd-a083-6f4581bd5f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03061d60-625f-4cdd-a083-6f4581bd5f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_96066123-2eda-4efe-8e06-d5c513e5aeac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_TreasuryStockCommonValue_96066123-2eda-4efe-8e06-d5c513e5aeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7894e6c-68af-4867-91a7-e13ec2f9081a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_db1ab608-4825-427a-a470-0c7e668d69de" xlink:to="loc_us-gaap_StockholdersEquity_d7894e6c-68af-4867-91a7-e13ec2f9081a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85b8aae7-57e3-4bca-a288-8a57839ab2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_315920c0-b6e4-4b0e-84a2-7f8efe59fc10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_85b8aae7-57e3-4bca-a288-8a57839ab2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8523e141-8182-4733-8ef7-1d3eda015ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_30a58622-a0ec-4658-83c4-f0876ded2bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8523e141-8182-4733-8ef7-1d3eda015ea7" xlink:to="loc_us-gaap_TemporaryEquityAbstract_30a58622-a0ec-4658-83c4-f0876ded2bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_768bb698-4a09-4903-a6dc-48dfba854f22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_30a58622-a0ec-4658-83c4-f0876ded2bce" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_768bb698-4a09-4903-a6dc-48dfba854f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_82328b33-cf24-4247-8843-d08195db9094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_30a58622-a0ec-4658-83c4-f0876ded2bce" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_82328b33-cf24-4247-8843-d08195db9094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_c6afba72-a667-4b36-8218-e61994df8f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_30a58622-a0ec-4658-83c4-f0876ded2bce" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_c6afba72-a667-4b36-8218-e61994df8f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8523e141-8182-4733-8ef7-1d3eda015ea7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9bbc339-3f1f-44ab-bf7c-a417b36cbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9bbc339-3f1f-44ab-bf7c-a417b36cbad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bf3e009e-0bff-42f5-90a3-46d60341952c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bf3e009e-0bff-42f5-90a3-46d60341952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3f9a15b1-2063-4195-bcc8-196fa370c889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:to="loc_us-gaap_CommonStockSharesIssued_3f9a15b1-2063-4195-bcc8-196fa370c889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f2277039-2e31-454e-afa2-c08549d9c04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11c53961-bb93-4cf8-aed9-e968bee09466" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f2277039-2e31-454e-afa2-c08549d9c04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_82a2d10c-baed-4b3a-ae85-eb30a9fbbc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_82a2d10c-baed-4b3a-ae85-eb30a9fbbc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_3dc70eda-2a67-457e-af27-a9c5b00f89a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:to="loc_us-gaap_CostOfRevenue_3dc70eda-2a67-457e-af27-a9c5b00f89a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_88480ce2-e47d-440c-8052-b984a290e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_88480ce2-e47d-440c-8052-b984a290e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_efa07846-3f6b-4a10-8649-b34d09488b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:to="loc_us-gaap_DepreciationAndAmortization_efa07846-3f6b-4a10-8649-b34d09488b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_951fdddf-1417-4e60-8ea0-b0a4d8987ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_951fdddf-1417-4e60-8ea0-b0a4d8987ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7a1c42da-9b08-4403-a3ea-e9b9f3e91eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_448e8916-461e-451b-a39f-ed194c5a2a89" xlink:to="loc_us-gaap_CostsAndExpenses_7a1c42da-9b08-4403-a3ea-e9b9f3e91eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c34fbb1-e865-4909-9e64-01fc848bfc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_OperatingIncomeLoss_1c34fbb1-e865-4909-9e64-01fc848bfc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_db78d980-7808-475a-9747-e7a0ad5b8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_InvestmentIncomeInterest_db78d980-7808-475a-9747-e7a0ad5b8f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_440131f5-3a9d-4d23-9b74-345b05541ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_InterestExpense_440131f5-3a9d-4d23-9b74-345b05541ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_29085f2e-fa2f-4377-8374-2b96d4be3a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_29085f2e-fa2f-4377-8374-2b96d4be3a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_61657d61-5d43-4f47-883e-68552f24fb9d" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_61657d61-5d43-4f47-883e-68552f24fb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c9d5a13a-cd62-4bce-bfd4-c0e60274de19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c9d5a13a-cd62-4bce-bfd4-c0e60274de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6daec84e-d387-4073-8a2c-82ae234bd88e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6daec84e-d387-4073-8a2c-82ae234bd88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92574b87-66e2-4ab5-9f92-b88243f47cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92574b87-66e2-4ab5-9f92-b88243f47cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e38f930a-e709-48cd-ad87-f9fc5820e601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e38f930a-e709-48cd-ad87-f9fc5820e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_fc535310-0707-4350-81fd-93a1cde40cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_fc535310-0707-4350-81fd-93a1cde40cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fd708053-d83e-4d16-860c-f8eb72b85a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fd708053-d83e-4d16-860c-f8eb72b85a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff16a1ed-0d80-4b6f-aa13-657b62997ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff16a1ed-0d80-4b6f-aa13-657b62997ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_90349e0b-27ec-4f28-9f09-6cecc880e05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_EarningsPerShareAbstract_90349e0b-27ec-4f28-9f09-6cecc880e05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7ca9d6e5-5445-4f02-ae41-7b12515d372b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_90349e0b-27ec-4f28-9f09-6cecc880e05b" xlink:to="loc_us-gaap_EarningsPerShareBasic_7ca9d6e5-5445-4f02-ae41-7b12515d372b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_436fe488-398f-4794-8f65-af35e0eae2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_90349e0b-27ec-4f28-9f09-6cecc880e05b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_436fe488-398f-4794-8f65-af35e0eae2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_a42b8cab-2cd1-4e14-8c56-e4b226f5ce61" xlink:href="evh-20230331.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_a42b8cab-2cd1-4e14-8c56-e4b226f5ce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_895709bc-7a5b-4e7a-b897-e17df1112a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_a42b8cab-2cd1-4e14-8c56-e4b226f5ce61" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_895709bc-7a5b-4e7a-b897-e17df1112a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f506871-2112-4480-a9a2-e392c1aebb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_a42b8cab-2cd1-4e14-8c56-e4b226f5ce61" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f506871-2112-4480-a9a2-e392c1aebb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_26bb71ac-81b5-4277-89ac-9d0541bdc6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6588922e-431f-4b31-8ec4-729a957753ca" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_26bb71ac-81b5-4277-89ac-9d0541bdc6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4dd7e6d1-1814-4004-a60b-6a9f6582fdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_26bb71ac-81b5-4277-89ac-9d0541bdc6d6" xlink:to="loc_us-gaap_NetIncomeLoss_4dd7e6d1-1814-4004-a60b-6a9f6582fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1b0a277a-a9c6-493a-96b0-4a849e828b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_26bb71ac-81b5-4277-89ac-9d0541bdc6d6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1b0a277a-a9c6-493a-96b0-4a849e828b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c3dc9aad-79d8-4e02-a26a-c6d3b3eabd57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1b0a277a-a9c6-493a-96b0-4a849e828b80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c3dc9aad-79d8-4e02-a26a-c6d3b3eabd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdae27aa-c56e-48d9-a241-3a31dd3e964d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_26bb71ac-81b5-4277-89ac-9d0541bdc6d6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bdae27aa-c56e-48d9-a241-3a31dd3e964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3612e23e-16b9-42c2-bf81-d0903e1e4a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3612e23e-16b9-42c2-bf81-d0903e1e4a55" xlink:to="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123c3ecf-e166-4cd3-b66d-065c36b11ed8" xlink:to="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_864a65c7-c87f-4a28-8508-de06b9f1c470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_CommonStockMember_864a65c7-c87f-4a28-8508-de06b9f1c470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_00636d48-aa0f-4c10-bd79-af4d53972a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_00636d48-aa0f-4c10-bd79-af4d53972a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf731a4-e932-4bbb-b20a-1f96cc23f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf731a4-e932-4bbb-b20a-1f96cc23f4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_23a294f1-b8dd-4562-95cb-e4561582da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_RetainedEarningsMember_23a294f1-b8dd-4562-95cb-e4561582da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_96c35ad5-09c7-4a77-ad47-5683c0368cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb50f9ba-9c5b-410c-8689-961acb3f738f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_96c35ad5-09c7-4a77-ad47-5683c0368cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e71a0c76-890c-49c4-b701-943eba35b346" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_354f9cd0-c584-4139-971c-39599e450b74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3cadb2b8-5f4f-4eec-8cec-398e310fac28" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_354f9cd0-c584-4139-971c-39599e450b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83a0da3b-691a-4f4d-84d0-b39d69fff0a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_b8ab5ca5-0e18-47ec-8bd6-9aea29d83783" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_b8ab5ca5-0e18-47ec-8bd6-9aea29d83783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c34223ac-a305-4e3d-b016-38f970c47a25" xlink:href="evh-20230331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdade630-d80c-430e-ab39-927c57c18e3c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c34223ac-a305-4e3d-b016-38f970c47a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1c339a6-6d92-478b-9baf-e77adebdb525" xlink:to="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_fb1538e0-4607-4228-b633-4222e308c69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_fb1538e0-4607-4228-b633-4222e308c69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_63cbb1d4-bf2c-49ec-99a7-c5d956bfaceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_63cbb1d4-bf2c-49ec-99a7-c5d956bfaceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_5acc6741-de6d-4723-9c2f-35d3841f951b" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_5acc6741-de6d-4723-9c2f-35d3841f951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b584bdb1-c270-42c8-b6ba-4a8e5a2a46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b584bdb1-c270-42c8-b6ba-4a8e5a2a46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_d25ed673-2f65-4873-a037-277cf3a53e7c" xlink:href="evh-20230331.xsd#evh_TemporaryEquityAccretionToRedemptionValueAndDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_d25ed673-2f65-4873-a037-277cf3a53e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_2d673c9a-c5c6-486a-836e-a14546daa5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_2d673c9a-c5c6-486a-836e-a14546daa5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_6c3194aa-58e7-4123-a0fe-cebc50da9d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_6c3194aa-58e7-4123-a0fe-cebc50da9d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b9e3682b-e1cf-4af2-9d30-96d8072b703d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_846de673-053e-43a1-b8bc-2d964b0db578" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b9e3682b-e1cf-4af2-9d30-96d8072b703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9486a91-8e7f-47dc-8a2e-c310045cb5b4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f3e96038-6807-4e7e-af13-9ae05f6480fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_SharesIssued_f3e96038-6807-4e7e-af13-9ae05f6480fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73c041fd-5dec-451e-9efc-8b1de015044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockholdersEquity_73c041fd-5dec-451e-9efc-8b1de015044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ce7efd5e-3503-4ffb-94ed-9f9c106fdf79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_ce7efd5e-3503-4ffb-94ed-9f9c106fdf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ff6b1ee-82ab-4b50-b092-5f1776e5f2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ff6b1ee-82ab-4b50-b092-5f1776e5f2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52ea7a8f-292b-4609-b5f3-c1e63c2c2883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52ea7a8f-292b-4609-b5f3-c1e63c2c2883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9602019f-3b08-4de5-bcee-058b3fcc8109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9602019f-3b08-4de5-bcee-058b3fcc8109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a0a9c158-c6df-4a79-8bb3-4b3b9aca192e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a0a9c158-c6df-4a79-8bb3-4b3b9aca192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_91347863-d6f8-42a4-b9d6-98055764e514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_91347863-d6f8-42a4-b9d6-98055764e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81a708b9-e31e-426d-9d0f-c84658431a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81a708b9-e31e-426d-9d0f-c84658431a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_378ce940-b831-4e12-b8fc-f7d57f25ad49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_378ce940-b831-4e12-b8fc-f7d57f25ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7a9a479e-6fcc-4c3d-8561-713e635d1316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7a9a479e-6fcc-4c3d-8561-713e635d1316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1508717a-a7d4-46ec-9176-4bdf0c307708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1508717a-a7d4-46ec-9176-4bdf0c307708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_f34f8204-05de-4f87-aab9-be9316aa83b9" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_f34f8204-05de-4f87-aab9-be9316aa83b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_c95d84c0-c083-4e40-9230-fae2a98b7bf1" xlink:href="evh-20230331.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_c95d84c0-c083-4e40-9230-fae2a98b7bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f71ad8e2-0564-4244-a7c0-5018655e38d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f71ad8e2-0564-4244-a7c0-5018655e38d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb91f9f1-9e5e-4c9d-8d4f-04b1db2064d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_NetIncomeLoss_cb91f9f1-9e5e-4c9d-8d4f-04b1db2064d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c8cf9624-1035-4a90-8519-f7ae46d07794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_SharesIssued_c8cf9624-1035-4a90-8519-f7ae46d07794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dbea2b69-f02a-4f1a-bc60-14bdf5a17fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a39a2fe9-20e4-4061-9e4c-1752f748bcff" xlink:to="loc_us-gaap_StockholdersEquity_dbea2b69-f02a-4f1a-bc60-14bdf5a17fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b266574e-d3f5-426f-a751-7472a354a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b266574e-d3f5-426f-a751-7472a354a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_064a204b-7901-4cfe-9d94-4f771de00a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b266574e-d3f5-426f-a751-7472a354a61b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_064a204b-7901-4cfe-9d94-4f771de00a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b266574e-d3f5-426f-a751-7472a354a61b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7bbb8423-8020-465b-bbdf-e150784be5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7bbb8423-8020-465b-bbdf-e150784be5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_54989566-cac3-4bec-9f62-8fdc1825d514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_54989566-cac3-4bec-9f62-8fdc1825d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9f9da432-53bb-4819-9f35-c05452d318fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9f9da432-53bb-4819-9f35-c05452d318fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_35cb55d1-0349-4152-9ee1-161c9145ce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_ShareBasedCompensation_35cb55d1-0349-4152-9ee1-161c9145ce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_60cfc22b-def1-4ab2-93fc-f0ba4070258e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_60cfc22b-def1-4ab2-93fc-f0ba4070258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_3d31273b-ff94-45d3-80fa-8c16fe05fe14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_3d31273b-ff94-45d3-80fa-8c16fe05fe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5b5129c7-2121-4eee-8c69-948985193992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5b5129c7-2121-4eee-8c69-948985193992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_3dbb7a8a-ce68-46bf-9d4a-d7883f601ee8" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_3dbb7a8a-ce68-46bf-9d4a-d7883f601ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9a166a98-1c7d-4451-95e8-a33d01de1e88" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9a166a98-1c7d-4451-95e8-a33d01de1e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8a060e33-77cd-4480-8c0a-3b01c9cbd76c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8a060e33-77cd-4480-8c0a-3b01c9cbd76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fc4fdcc6-3df2-462b-8025-d67230ac6d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fc4fdcc6-3df2-462b-8025-d67230ac6d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c2b17bb9-1f6a-4bd8-a643-8bb9de6cf351" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c2b17bb9-1f6a-4bd8-a643-8bb9de6cf351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7cdbbe5-c584-4528-97de-b12ce3dd40be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7cdbbe5-c584-4528-97de-b12ce3dd40be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_c9ba4722-62a9-47b6-87e1-1b4d1d3bd666" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_c9ba4722-62a9-47b6-87e1-1b4d1d3bd666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34ba1f96-d470-437c-a257-49d16352b189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34ba1f96-d470-437c-a257-49d16352b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_41268e2d-8c31-4610-bdb5-49e60310c542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_41268e2d-8c31-4610-bdb5-49e60310c542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c2c30826-65a6-4ca7-950a-4801bee18d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c2c30826-65a6-4ca7-950a-4801bee18d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_21c74d39-d3db-45f4-8a9d-cab48e5aa2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_21c74d39-d3db-45f4-8a9d-cab48e5aa2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_13a1cf62-fb8e-4d01-859d-559f88961613" xlink:href="evh-20230331.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_13a1cf62-fb8e-4d01-859d-559f88961613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_465fa755-750c-486d-9897-d37375ae8b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ee60032-f132-4072-a488-388faf439b5f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_465fa755-750c-486d-9897-d37375ae8b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e141aa3-62fc-47be-9573-d840018d4622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7c824df2-5206-422d-af42-e12186074e32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e141aa3-62fc-47be-9573-d840018d4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_74939996-d316-4001-b3e9-b207e5d5397e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_74939996-d316-4001-b3e9-b207e5d5397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c13f24dd-82a4-42c2-a19e-cb9a83a510bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c13f24dd-82a4-42c2-a19e-cb9a83a510bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_226c1528-2227-4cb1-8da9-2652400e80f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_226c1528-2227-4cb1-8da9-2652400e80f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_bc8c5513-50ef-41fb-8e6b-1faceedca343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_bc8c5513-50ef-41fb-8e6b-1faceedca343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8fa02d2-31f3-48ec-831b-3d439fb29388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f315f82e-6fe0-4c5b-9a27-43b9ff43fe9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8fa02d2-31f3-48ec-831b-3d439fb29388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_96526bf6-4e4f-409b-9128-6309b2586dac" xlink:href="evh-20230331.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_96526bf6-4e4f-409b-9128-6309b2586dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b10b0224-377b-4947-876f-890b4e402d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b10b0224-377b-4947-876f-890b4e402d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93c20673-cc01-4fcf-bbfd-3b75fb4b9798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93c20673-cc01-4fcf-bbfd-3b75fb4b9798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0d08cd4c-782f-40b8-b1c3-d9cc14f5f162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0d08cd4c-782f-40b8-b1c3-d9cc14f5f162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_3bb7b9c5-f766-47b7-8c37-c7f13b7ffac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_3bb7b9c5-f766-47b7-8c37-c7f13b7ffac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3bd21c94-c40c-47bb-8ab0-0569f63cf8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3bd21c94-c40c-47bb-8ab0-0569f63cf8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_d9abccf6-99b9-47ce-902a-b7e329dcb380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_d9abccf6-99b9-47ce-902a-b7e329dcb380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b7e1f4a-40be-4752-bd30-b390264f32b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b7e1f4a-40be-4752-bd30-b390264f32b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6034ea3-b256-402f-a8f3-afd0f43f20d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ae6adc2-96fe-4a5d-8a95-79f1fc0034ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6034ea3-b256-402f-a8f3-afd0f43f20d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70ad9573-3863-42be-b77b-56cd1c549a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70ad9573-3863-42be-b77b-56cd1c549a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0216e1d-16eb-40fb-864f-623c17ada9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0216e1d-16eb-40fb-864f-623c17ada9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715eaf46-aed1-4073-bc02-c4952976d631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715eaf46-aed1-4073-bc02-c4952976d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c3e3546-d07a-43d5-880d-69ce9ded2403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19d7b14b-3dd7-4be3-a233-33309ffddf9e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c3e3546-d07a-43d5-880d-69ce9ded2403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20230331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce69dd9c-93e1-4331-a9b0-f2885eeb4852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_65771a07-66bb-4cdb-ba96-97fbf3096795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce69dd9c-93e1-4331-a9b0-f2885eeb4852" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_65771a07-66bb-4cdb-ba96-97fbf3096795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76b71597-3d23-4afd-88db-8e42cc4fe7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f901e00f-f794-4cba-a8af-b3be23461311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76b71597-3d23-4afd-88db-8e42cc4fe7d4" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f901e00f-f794-4cba-a8af-b3be23461311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20230331.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1857f627-2c2d-4331-979d-9b9062e8fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5b7de5a9-ff71-4361-90fd-39c4d2e148a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1857f627-2c2d-4331-979d-9b9062e8fae4" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5b7de5a9-ff71-4361-90fd-39c4d2e148a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20230331.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5f961f57-2e65-4156-8b64-d60008f83134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d0e71acb-0c6a-439a-a5a4-478a1fb9a6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5f961f57-2e65-4156-8b64-d60008f83134" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d0e71acb-0c6a-439a-a5a4-478a1fb9a6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ffe874f3-e6eb-4c28-9a85-bd6e1a278e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_945ac977-1ccd-49ea-b34d-3754f9d86483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ffe874f3-e6eb-4c28-9a85-bd6e1a278e3e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_945ac977-1ccd-49ea-b34d-3754f9d86483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20230331.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_41559fbb-b529-4346-847e-25b70ec4af8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_61a357b9-f565-4302-949c-e529f5e2fd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_41559fbb-b529-4346-847e-25b70ec4af8f" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_61a357b9-f565-4302-949c-e529f5e2fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20230331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d437ab88-3740-4e89-84f8-bcd57d8c47f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f83ef6be-eb04-41df-94dd-4562c6599681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d437ab88-3740-4e89-84f8-bcd57d8c47f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f83ef6be-eb04-41df-94dd-4562c6599681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b0d613b-a48d-4ed5-87e8-7a680d78eafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6d8e758b-7747-41c5-b5c3-465ae31968cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b0d613b-a48d-4ed5-87e8-7a680d78eafe" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6d8e758b-7747-41c5-b5c3-465ae31968cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_39acc59b-7af7-4d66-9bcb-97526f4f2039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4cc662af-face-4512-ab6e-b700f839679e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39acc59b-7af7-4d66-9bcb-97526f4f2039" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4cc662af-face-4512-ab6e-b700f839679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc59f1c5-2aca-49c5-bbc8-d3a7b782ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f5ace3a3-7a5c-4e93-b85d-ea3afebcc4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc59f1c5-2aca-49c5-bbc8-d3a7b782ef1f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f5ace3a3-7a5c-4e93-b85d-ea3afebcc4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_67042fa3-c6d7-47c3-89af-24cfd20021dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_520f8e50-f483-4167-9668-f4d8482355fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67042fa3-c6d7-47c3-89af-24cfd20021dd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_520f8e50-f483-4167-9668-f4d8482355fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ConvertiblePreferredEquity" xlink:type="simple" xlink:href="evh-20230331.xsd#ConvertiblePreferredEquity"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ConvertiblePreferredEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_74fb3138-613e-42ac-8061-87552e81627c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDisclosureTextBlock_e523e926-25b0-4bed-9d13-6b19dbf8b717" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_74fb3138-613e-42ac-8061-87552e81627c" xlink:to="loc_evh_TemporaryEquityDisclosureTextBlock_e523e926-25b0-4bed-9d13-6b19dbf8b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="evh-20230331.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_964a2484-9bfa-4826-b071-091a192b6427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b207877f-9b5f-46a8-991a-3e8b70895cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_964a2484-9bfa-4826-b071-091a192b6427" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b207877f-9b5f-46a8-991a-3e8b70895cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0c254b2-0552-443f-a850-cba7fdf8f377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d7939e8f-b3ea-46d5-8c64-5ab3ca9f751a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0c254b2-0552-443f-a850-cba7fdf8f377" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d7939e8f-b3ea-46d5-8c64-5ab3ca9f751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21bdce26-9437-4105-b529-8ffb64830e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5751bc5-89a1-4794-ad8e-e8c4aa44a728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21bdce26-9437-4105-b529-8ffb64830e40" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5751bc5-89a1-4794-ad8e-e8c4aa44a728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20230331.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f1dd847f-2c0f-49a8-a389-dfda29fe7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b494136c-da40-46cf-95fa-acde81e079c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f1dd847f-2c0f-49a8-a389-dfda29fe7bdd" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b494136c-da40-46cf-95fa-acde81e079c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_880ddc27-3f5e-4802-8ea6-ffdcab9c6dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_11dd95aa-4110-401d-bc0d-7a2113305be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_880ddc27-3f5e-4802-8ea6-ffdcab9c6dbf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_11dd95aa-4110-401d-bc0d-7a2113305be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8da49fd6-95c5-4d5c-83c2-8796c6cdfec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f12b485d-23fa-489e-9522-dced4e5b06e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8da49fd6-95c5-4d5c-83c2-8796c6cdfec0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f12b485d-23fa-489e-9522-dced4e5b06e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20230331.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_944be863-9101-4af8-bcf4-ee70c75f0f68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_e193fb93-95c9-46c9-a64a-96e128d34230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_944be863-9101-4af8-bcf4-ee70c75f0f68" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_e193fb93-95c9-46c9-a64a-96e128d34230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20230331.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_20cc37a5-41e7-4b7b-a9e5-030b546842d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_6333ae81-2def-4a39-93cb-003295e18fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_20cc37a5-41e7-4b7b-a9e5-030b546842d2" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_6333ae81-2def-4a39-93cb-003295e18fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_320e8ad1-cc82-4da2-bc2e-c949e78c3f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_320e8ad1-cc82-4da2-bc2e-c949e78c3f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_289075a4-36d5-4fa4-980d-d6ca7e685f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_UseOfEstimates_289075a4-36d5-4fa4-980d-d6ca7e685f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_34f1e1fa-5c48-4349-90e6-ae8f2ffd9837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_34f1e1fa-5c48-4349-90e6-ae8f2ffd9837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_19672a79-8a2b-4591-9fb2-0533e2e92d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_19672a79-8a2b-4591-9fb2-0533e2e92d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_10d6b11a-2b75-424f-a22d-0c88147d5822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_10d6b11a-2b75-424f-a22d-0c88147d5822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_a9c6e526-3faa-4f62-9a7f-3a740114a710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_a9c6e526-3faa-4f62-9a7f-3a740114a710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5384b09b-7f4d-4cb5-85d4-ad13bb83699e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5384b09b-7f4d-4cb5-85d4-ad13bb83699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_d7e20138-74ef-4f05-a60c-df78b058fefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_d7e20138-74ef-4f05-a60c-df78b058fefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0626f5d0-eb2b-4f16-a6a2-49f740529740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0626f5d0-eb2b-4f16-a6a2-49f740529740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_be033a12-c948-4312-882e-788d698e73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_be033a12-c948-4312-882e-788d698e73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_9028d279-0309-4293-9e2a-68e14ef89dac" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_9028d279-0309-4293-9e2a-68e14ef89dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a50727d-a885-423f-a735-9d827a93b402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a50727d-a885-423f-a735-9d827a93b402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_66ef6bc1-1e5f-418c-b2a9-a20a88154018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_66ef6bc1-1e5f-418c-b2a9-a20a88154018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_4ba8d418-6eee-4917-b642-fc3554f98802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_4ba8d418-6eee-4917-b642-fc3554f98802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0b33e983-010c-423b-85f3-5c91e7039baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0b33e983-010c-423b-85f3-5c91e7039baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7c6d9a87-3ad8-4726-b9f8-e6dd2bcc776f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24ee5a21-7c57-417c-94dc-6996b0d21453" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7c6d9a87-3ad8-4726-b9f8-e6dd2bcc776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1ddf39a8-dfe5-4968-a1ce-e8260919af77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d15022d7-e6dc-4a31-832b-bd816cd4e782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ddf39a8-dfe5-4968-a1ce-e8260919af77" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d15022d7-e6dc-4a31-832b-bd816cd4e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c18d98c4-e65f-4582-87d3-c180934e1669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ddf39a8-dfe5-4968-a1ce-e8260919af77" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c18d98c4-e65f-4582-87d3-c180934e1669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a7a32a37-c880-4935-9f0d-835f850f75f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ddf39a8-dfe5-4968-a1ce-e8260919af77" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a7a32a37-c880-4935-9f0d-835f850f75f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_706bf1b6-3c8e-4adf-a041-1caa72149274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_5a2cfb0f-36a6-4e1c-9374-bb0d10f3ad4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_706bf1b6-3c8e-4adf-a041-1caa72149274" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_5a2cfb0f-36a6-4e1c-9374-bb0d10f3ad4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c0690f3d-3eb3-4931-9d31-e69212a97910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_706bf1b6-3c8e-4adf-a041-1caa72149274" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c0690f3d-3eb3-4931-9d31-e69212a97910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_cd0ea06e-677c-40d2-bef7-242277a7f877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_706bf1b6-3c8e-4adf-a041-1caa72149274" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_cd0ea06e-677c-40d2-bef7-242277a7f877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cf2861bb-d03d-4a2f-a712-5ee7ce8ed902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_111b5544-227d-411a-bf22-a81ef39a1d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cf2861bb-d03d-4a2f-a712-5ee7ce8ed902" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_111b5544-227d-411a-bf22-a81ef39a1d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e63b4ecd-6363-49ff-8460-352b75afd064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cf2861bb-d03d-4a2f-a712-5ee7ce8ed902" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e63b4ecd-6363-49ff-8460-352b75afd064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20230331.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_16d7e3f3-4905-4a25-9640-5652d0bd3921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_acec9c5c-2c31-46cf-9e5d-34300ecca238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_16d7e3f3-4905-4a25-9640-5652d0bd3921" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_acec9c5c-2c31-46cf-9e5d-34300ecca238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20230331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b3294632-3817-4395-97c0-daa3e903d127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0ded996e-963d-4901-8f6e-af6548a1c2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b3294632-3817-4395-97c0-daa3e903d127" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0ded996e-963d-4901-8f6e-af6548a1c2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4a2be46-8f13-4c6c-867a-e2d5fb166dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_69ff51c7-9b6e-4270-92d3-6ccdf77843fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4a2be46-8f13-4c6c-867a-e2d5fb166dd5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_69ff51c7-9b6e-4270-92d3-6ccdf77843fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a650f9a2-9f8d-4e2a-bed9-55f134df5f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4a2be46-8f13-4c6c-867a-e2d5fb166dd5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a650f9a2-9f8d-4e2a-bed9-55f134df5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_65813c06-6d73-448b-8baf-50a1d08fa88f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4a2be46-8f13-4c6c-867a-e2d5fb166dd5" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_65813c06-6d73-448b-8baf-50a1d08fa88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_679a75cd-c1d2-4c32-a68f-0394167e8f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_ed501942-c7f5-465b-b763-96cb5fd1b9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_679a75cd-c1d2-4c32-a68f-0394167e8f97" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_ed501942-c7f5-465b-b763-96cb5fd1b9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ac66744-bd83-4d85-b946-36a9dec21b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3873c1c7-1c4a-40a7-9b91-ee48f13bbb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ac66744-bd83-4d85-b946-36a9dec21b01" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3873c1c7-1c4a-40a7-9b91-ee48f13bbb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_407c6ceb-7782-4929-af15-b86d7529c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6eec6cbd-c24a-449a-84dd-ffe35e967af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_407c6ceb-7782-4929-af15-b86d7529c5a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6eec6cbd-c24a-449a-84dd-ffe35e967af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c998c494-1a92-48f4-ac7f-1ae107ecaf33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_407c6ceb-7782-4929-af15-b86d7529c5a5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c998c494-1a92-48f4-ac7f-1ae107ecaf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20230331.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df09acf5-2df2-4f16-bb7d-82018c0145be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_490fe63c-abc1-47f5-8bd3-081e8eba9211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df09acf5-2df2-4f16-bb7d-82018c0145be" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_490fe63c-abc1-47f5-8bd3-081e8eba9211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22283722-91c2-42bb-8e76-4d867f5e7f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df09acf5-2df2-4f16-bb7d-82018c0145be" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22283722-91c2-42bb-8e76-4d867f5e7f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dc18de-d9c4-4e64-ba7f-7468a87caea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_871217f7-60b4-42ba-81a2-14b1982e8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dc18de-d9c4-4e64-ba7f-7468a87caea1" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_871217f7-60b4-42ba-81a2-14b1982e8c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_16eb96ff-c756-4f6f-af7b-2dbbe49f1509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dc18de-d9c4-4e64-ba7f-7468a87caea1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_16eb96ff-c756-4f6f-af7b-2dbbe49f1509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6276449d-5929-49b4-8ace-3305c3e90c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_d0cb21b1-d889-4869-85f3-d8b73a9c00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6276449d-5929-49b4-8ace-3305c3e90c4d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_d0cb21b1-d889-4869-85f3-d8b73a9c00d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9e6c205f-7ca8-4c61-b80a-930fb16c47b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6276449d-5929-49b4-8ace-3305c3e90c4d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9e6c205f-7ca8-4c61-b80a-930fb16c47b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9e61f5de-8e07-4409-bc4f-f51e495113c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6276449d-5929-49b4-8ace-3305c3e90c4d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9e61f5de-8e07-4409-bc4f-f51e495113c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_40d1c561-8e2f-4f6b-8735-19ad1d0e0b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fa273f25-8119-4f45-b784-83631273f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_40d1c561-8e2f-4f6b-8735-19ad1d0e0b4e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fa273f25-8119-4f45-b784-83631273f2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20230331.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_c820002b-84a9-460a-b73e-899789da9af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_16600fd8-52b7-4bf1-906e-af6b1f26851f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_c820002b-84a9-460a-b73e-899789da9af3" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_16600fd8-52b7-4bf1-906e-af6b1f26851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20230331.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_923bf7ed-0c40-4e8a-854f-04f1cc3e7ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a2789049-9bfa-4828-bcda-a41346b95cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_923bf7ed-0c40-4e8a-854f-04f1cc3e7ebe" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a2789049-9bfa-4828-bcda-a41346b95cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_590bf952-3005-416f-a789-1844c8df6e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d0ffb440-3ac9-40b3-94e3-0be3a1fe178c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_590bf952-3005-416f-a789-1844c8df6e1a" xlink:to="loc_us-gaap_NumberOfReportableSegments_d0ffb440-3ac9-40b3-94e3-0be3a1fe178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a85e96d-b9ec-4e44-8063-6d9970774d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_590bf952-3005-416f-a789-1844c8df6e1a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a85e96d-b9ec-4e44-8063-6d9970774d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e516efea-c235-4536-bb3a-b0ada4ae8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e516efea-c235-4536-bb3a-b0ada4ae8d39" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2d50fb64-2168-4813-b13c-842cfcddffc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_d091002c-076d-4f0e-8851-6bce0d14fa90" xlink:href="evh-20230331.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_d091002c-076d-4f0e-8851-6bce0d14fa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_39697418-010c-4fc2-867d-51e9cf5ac7b1" xlink:href="evh-20230331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_39697418-010c-4fc2-867d-51e9cf5ac7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_b53cac64-d869-4336-8e43-22e11580ea7e" xlink:href="evh-20230331.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7b7d8abb-bc9b-42fe-a8d7-ea373cc283c0" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_b53cac64-d869-4336-8e43-22e11580ea7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9bd53bb8-8960-4b1d-b615-b5aed212446f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_6a5665f0-df9a-492e-a613-cd10be5963d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_6a5665f0-df9a-492e-a613-cd10be5963d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_617f015d-759a-4ef8-bf68-ec47e08098be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_617f015d-759a-4ef8-bf68-ec47e08098be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_a9a572ae-5c78-462d-8cb5-998e7ef327b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_a9a572ae-5c78-462d-8cb5-998e7ef327b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6173dce2-f1b8-4b30-a1e9-4f2d0d2d254c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6173dce2-f1b8-4b30-a1e9-4f2d0d2d254c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ee5714aa-8e3f-4bf2-b0b7-8d928fdc210a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2ae24642-1cfb-4e1b-8f35-f4656a7a9a80" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ee5714aa-8e3f-4bf2-b0b7-8d928fdc210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4444560f-1e4b-407e-9fb1-ffa5bf74ff76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ad2ce87-8929-48a1-8f6f-d0cbe3775f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4444560f-1e4b-407e-9fb1-ffa5bf74ff76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ad2ce87-8929-48a1-8f6f-d0cbe3775f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_aa4c253d-154b-482d-9652-1e2f40863a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4444560f-1e4b-407e-9fb1-ffa5bf74ff76" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_aa4c253d-154b-482d-9652-1e2f40863a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_523a784b-b751-4d00-a8b7-68944a8b532a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4444560f-1e4b-407e-9fb1-ffa5bf74ff76" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_523a784b-b751-4d00-a8b7-68944a8b532a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f66b48a7-7051-4ef1-88ce-a0ad00359982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_2872c317-0700-4c31-be06-8afbbe4fec69" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f66b48a7-7051-4ef1-88ce-a0ad00359982" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_2872c317-0700-4c31-be06-8afbbe4fec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_3394a815-12a2-4c5f-afd0-c81dedefc01f" xlink:href="evh-20230331.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f66b48a7-7051-4ef1-88ce-a0ad00359982" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_3394a815-12a2-4c5f-afd0-c81dedefc01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_ef0eac40-4333-4906-8342-1ba3fbd05f6e" xlink:href="evh-20230331.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f66b48a7-7051-4ef1-88ce-a0ad00359982" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_ef0eac40-4333-4906-8342-1ba3fbd05f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e70b48a-4210-477e-b76d-57444b82bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e70b48a-4210-477e-b76d-57444b82bf16" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a9152e2-e3be-4246-93f9-f58c681a9cf9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_815dbb26-6ad2-4365-a629-c18a34784d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_TradeNamesMember_815dbb26-6ad2-4365-a629-c18a34784d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_098241d3-bceb-4d04-91d1-160d64f32cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_098241d3-bceb-4d04-91d1-160d64f32cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5f30004e-8999-431c-af23-819f80e57aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5f30004e-8999-431c-af23-819f80e57aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_b6b98cb1-7c25-4721-bb6b-9498c2b323e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59a3ade9-a0a5-4498-a286-b53ace912c4b" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_b6b98cb1-7c25-4721-bb6b-9498c2b323e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:to="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98556fd7-b245-477d-9105-097c535bb4be" xlink:to="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cea5d065-4db4-4c45-9c98-00eed773164a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:to="loc_srt_MinimumMember_cea5d065-4db4-4c45-9c98-00eed773164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac86eeee-a207-4869-9207-523f83460813" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb0de9a3-f5e2-467d-85eb-1923134aa873" xlink:to="loc_srt_MaximumMember_ac86eeee-a207-4869-9207-523f83460813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b27e8ee3-8534-4a2e-a5a7-c49bf11be8d8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e3a3eac-7e42-4073-aa6c-bbfaa43abb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57adb98a-28a9-4593-8103-63c784baccae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e3a3eac-7e42-4073-aa6c-bbfaa43abb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_684767bd-e4fa-46c9-9e71-783d4da9bcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_684767bd-e4fa-46c9-9e71-783d4da9bcb5" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1e3c7fec-1aa4-40b3-bc04-724409742305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_12d37cde-325e-42f1-8dc9-be385a2c2859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ebe3b9d8-e3ef-4941-9763-a6d60dadac47" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_12d37cde-325e-42f1-8dc9-be385a2c2859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60ef93ab-fcad-4fab-b11d-509b8684796b" xlink:to="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_69457199-b97b-4307-9b58-aeef56dc6503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:to="loc_us-gaap_RetainedEarningsMember_69457199-b97b-4307-9b58-aeef56dc6503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f724ba1-acf1-4d99-a182-c87bcfc90eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6ed44e1-aef9-432e-a79a-cdf5fb1eca46" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f724ba1-acf1-4d99-a182-c87bcfc90eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4af49a77-88a8-42ff-98ad-f34dd9b5bebc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2fe64646-5419-48d1-bbcd-1b4ddf7e9950" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_65d24261-9cdc-49f0-9432-4aa7491e0352" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2fe64646-5419-48d1-bbcd-1b4ddf7e9950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1065caba-9fc7-49fb-802c-ac6a15c67dc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_4c3639f2-d80c-4c21-ac2b-f60540dd54e9" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_4c3639f2-d80c-4c21-ac2b-f60540dd54e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_9ad88318-5da1-4188-b4ca-701e827249db" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17f92db9-9177-4c53-a3e0-bbbdbe1e09e7" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_9ad88318-5da1-4188-b4ca-701e827249db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1acf9467-72b6-4839-a583-cd927a0134c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d93d29cb-6492-43c6-bb62-c47b67d7be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ffaeb436-d1dd-47ed-a15c-dc5b6bdfb45f" xlink:to="loc_us-gaap_SeniorNotesMember_d93d29cb-6492-43c6-bb62-c47b67d7be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_20c49683-d20d-4400-b324-62fce01b9f0d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1032260a-3b47-4d00-82ae-e9156f4b4fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:to="loc_us-gaap_StockholdersEquity_1032260a-3b47-4d00-82ae-e9156f4b4fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93ea76ba-f45f-4c8b-9631-af10a2940a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1ca2d815-e2b5-4462-9990-d4f764e47a41" xlink:to="loc_us-gaap_LongTermDebt_93ea76ba-f45f-4c8b-9631-af10a2940a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d0022c0-a77f-4b2d-af1d-1b64fb8b0618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d0022c0-a77f-4b2d-af1d-1b64fb8b0618" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddbba390-e7a9-4f38-a289-450246431817" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_808cc90e-2b96-4760-99c6-f8e60cbb424c" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_808cc90e-2b96-4760-99c6-f8e60cbb424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_f7a43406-1434-48f5-8585-0868e40070ec" xlink:href="evh-20230331.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99e99c06-2aa3-4742-9438-e87dc2681d1e" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_f7a43406-1434-48f5-8585-0868e40070ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8f1fc780-2663-4f46-83bd-066bc54e3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_50e452e2-4ddb-48ae-ad4e-9e69161d1140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_50e452e2-4ddb-48ae-ad4e-9e69161d1140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_3d202472-253b-4533-88db-244ca0832a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_3d202472-253b-4533-88db-244ca0832a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_81452bca-8efe-48da-902e-5e9c80573d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41ad086f-0b9d-4398-ab2e-a9d0d5fcada1" xlink:to="loc_us-gaap_TradeNamesMember_81452bca-8efe-48da-902e-5e9c80573d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c36d0476-2f71-49b3-879d-a719381dc862" xlink:to="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7f9e2c39-b38c-4b04-9e17-ffcf607a7386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8de3649c-13d4-49a6-a41c-256d6de653fb" xlink:to="loc_us-gaap_CommonClassAMember_7f9e2c39-b38c-4b04-9e17-ffcf607a7386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_846e8b24-ae97-472b-b44c-5824cf3e794e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03efe08f-2d9b-4f98-9e62-cf34373a8692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03efe08f-2d9b-4f98-9e62-cf34373a8692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_29057f48-d62a-4499-b48e-2a3d667b7483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_29057f48-d62a-4499-b48e-2a3d667b7483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3a7a25a0-6bc5-480a-9134-be132662d649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3a7a25a0-6bc5-480a-9134-be132662d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9204f78-2541-4f7c-a807-dd4742575a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b9204f78-2541-4f7c-a807-dd4742575a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b429aac-701d-4724-8ac9-fb6ade9a247b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b429aac-701d-4724-8ac9-fb6ade9a247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_5b58dc47-2774-4389-abb5-a5f31a93b3ea" xlink:href="evh-20230331.xsd#evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity_5b58dc47-2774-4389-abb5-a5f31a93b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4abf0487-3652-4c83-a948-7b196c5af3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4abf0487-3652-4c83-a948-7b196c5af3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7958d440-3426-47f0-81c5-26d505ff89e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7958d440-3426-47f0-81c5-26d505ff89e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b4dc0527-e7bf-4be7-bf2c-211beac87509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b4dc0527-e7bf-4be7-bf2c-211beac87509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_997a3225-3367-4e90-a381-c5eb42248bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_997a3225-3367-4e90-a381-c5eb42248bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f42a8e47-771b-4a8d-b2f3-a7ef43d0cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f42a8e47-771b-4a8d-b2f3-a7ef43d0cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_746eac46-af3b-4fe8-b4d1-3a5aa3694901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_NetIncomeLoss_746eac46-af3b-4fe8-b4d1-3a5aa3694901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cc4fe874-1a93-40e2-b7df-5a4a9a33c315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db01cc9c-241c-436f-86f1-b0300410712c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cc4fe874-1a93-40e2-b7df-5a4a9a33c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d3df47bf-8c8b-4cb4-add6-c696851dd929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d3df47bf-8c8b-4cb4-add6-c696851dd929" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c149d5c7-afab-4d56-b1e0-f3144d3764c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_085ac7f2-ce8d-4c4b-b345-6278baa013ff" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_085ac7f2-ce8d-4c4b-b345-6278baa013ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_d56f6d6e-f127-4f4a-9946-06e183dddefa" xlink:href="evh-20230331.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db67849f-a3f8-4ebb-add0-5475303bd504" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_d56f6d6e-f127-4f4a-9946-06e183dddefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61982f8-fb18-4be6-b4a4-2ff725243d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c06c49d2-9ac3-433f-acc9-52b22e92bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c06c49d2-9ac3-433f-acc9-52b22e92bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7a52d048-ac7b-4d36-abf4-ebee6033412c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7a52d048-ac7b-4d36-abf4-ebee6033412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4e0ade8b-32bc-4e3f-8b6d-2e41771d37c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c6cdee-fc4e-4892-b613-6487401d1b01" xlink:to="loc_us-gaap_TradeNamesMember_4e0ade8b-32bc-4e3f-8b6d-2e41771d37c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6896d5f-9039-456e-bdd3-c50d8546842c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ea14c3e-6731-4f6b-a1cd-5e2a7a844756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ea14c3e-6731-4f6b-a1cd-5e2a7a844756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7b8ce66f-4587-433c-a391-fad30b9c989e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7b8ce66f-4587-433c-a391-fad30b9c989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0aaf51f0-41aa-41b4-b1f3-5dc11504ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0aaf51f0-41aa-41b4-b1f3-5dc11504ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_01df205b-e4b0-4906-8e64-fce929f6ea86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d722504e-4e9a-4acc-8d39-9aac6b26b7cb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_01df205b-e4b0-4906-8e64-fce929f6ea86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c48da8d4-f74f-43b3-a36a-f9c69fa7546c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c48da8d4-f74f-43b3-a36a-f9c69fa7546c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5b537273-d73c-444d-94f7-79ff4e1cb901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5b537273-d73c-444d-94f7-79ff4e1cb901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1f3c8bd8-50db-4cef-a7f4-9c1d8de36d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1f3c8bd8-50db-4cef-a7f4-9c1d8de36d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e7823d59-434b-4f60-8c82-e19469d8e332" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_e08f1421-ac67-4114-a5fd-12cd6140302a" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e7823d59-434b-4f60-8c82-e19469d8e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ead8c31a-f8d5-41f0-ad75-f8da97b4591a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_fcc2276e-9bd8-4dbb-b6e9-b6ba5f5b0c09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ead8c31a-f8d5-41f0-ad75-f8da97b4591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_181f4332-5016-43c5-ad02-ecb5fc6ad297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_181f4332-5016-43c5-ad02-ecb5fc6ad297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_da78e8a2-31ea-41a1-a551-42aa7a4bdfaf" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_da78e8a2-31ea-41a1-a551-42aa7a4bdfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f632eb4f-8595-49f0-abe4-1c91d080814b" xlink:href="evh-20230331.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f632eb4f-8595-49f0-abe4-1c91d080814b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bdceb0af-f506-476a-9549-e226e41e0c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bdceb0af-f506-476a-9549-e226e41e0c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_18925626-2fe7-450a-9c9a-b049ff350d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_18925626-2fe7-450a-9c9a-b049ff350d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_814f0355-a468-4d4a-be31-cb640c1053dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_814f0355-a468-4d4a-be31-cb640c1053dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_949d5f37-36f7-4afa-bc5e-f32291859a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_90020342-ee12-46fd-940a-df89dbc26ba6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_949d5f37-36f7-4afa-bc5e-f32291859a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3730ec15-c13c-4db2-be11-dd436f41fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_Goodwill_3730ec15-c13c-4db2-be11-dd436f41fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a023934f-5c07-4430-b8a2-b46552e4bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4133e6f6-584f-47cd-b892-01cbb8e9f2d9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a023934f-5c07-4430-b8a2-b46552e4bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#TransactionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9afbac06-90f7-4983-bb47-b28e10efb4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9afbac06-90f7-4983-bb47-b28e10efb4d8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bd72f04-41a1-4bbc-aaac-1d9f6667a36e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesIncNIAMember_f7ec316f-03ec-4416-be4c-0608e820fcdf" xlink:href="evh-20230331.xsd#evh_NationalImagingAssociatesIncNIAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61443688-f914-4eb2-b995-f3ae56e23648" xlink:to="loc_evh_NationalImagingAssociatesIncNIAMember_f7ec316f-03ec-4416-be4c-0608e820fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75b5568e-4654-4fe0-bf69-c58569ee21ee" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_70b670ab-99cb-449b-ad92-07a0d87eb9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_70b670ab-99cb-449b-ad92-07a0d87eb9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7b7c596c-81d2-42ec-8b63-556cea7ae2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c62c5669-9feb-44bc-a8e2-ada6df4786bc" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7b7c596c-81d2-42ec-8b63-556cea7ae2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c56f1493-a67d-4ca7-9186-803d055a1c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c56f1493-a67d-4ca7-9186-803d055a1c36" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09327964-2a99-4155-aea5-ed22007386dd" xlink:to="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_5b737a82-33fc-4b8f-b088-62c690e3ce19" xlink:href="evh-20230331.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cc56217d-7d21-4b5a-a378-f1279612e259" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_5b737a82-33fc-4b8f-b088-62c690e3ce19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c9b07d7b-3f69-48aa-8141-9278be2341ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_c1c2bc6d-84d7-41c0-95ac-f601bafe7c37" xlink:href="evh-20230331.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_MedicaidCustomersMember_c1c2bc6d-84d7-41c0-95ac-f601bafe7c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_a246c248-62aa-48c8-83e6-f50f32db7055" xlink:href="evh-20230331.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_MedicareCustomersMember_a246c248-62aa-48c8-83e6-f50f32db7055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_805248a9-6c45-429b-975f-307c005e0fa2" xlink:href="evh-20230331.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e09190d-ede0-4eb6-957f-46de962a51df" xlink:to="loc_evh_CommercialAndOtherCustomersMember_805248a9-6c45-429b-975f-307c005e0fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7ed3781c-18d1-43ee-b01d-f9e497779009" xlink:to="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceSuiteMember_e1a16aca-83df-4e29-857b-745072ae5621" xlink:href="evh-20230331.xsd#evh_PerformanceSuiteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_PerformanceSuiteMember_e1a16aca-83df-4e29-857b-745072ae5621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SpecialtyTechnologyAndServicesSuiteMember_4fb09efd-8aae-4274-b38e-478e93152da8" xlink:href="evh-20230331.xsd#evh_SpecialtyTechnologyAndServicesSuiteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_SpecialtyTechnologyAndServicesSuiteMember_4fb09efd-8aae-4274-b38e-478e93152da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeServiceMember_fcb11bbd-0d35-4ee5-a01d-128512331ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_us-gaap_AdministrativeServiceMember_fcb11bbd-0d35-4ee5-a01d-128512331ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CasesMember_fb91044a-8b49-49b5-925a-052295722c38" xlink:href="evh-20230331.xsd#evh_CasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdf1a92-ddf9-41c6-a2a2-6b3a11863318" xlink:to="loc_evh_CasesMember_fb91044a-8b49-49b5-925a-052295722c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d44dd2d3-4eb5-4ac5-8732-0749a7966e9e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6431a7f4-b599-4319-a6f3-2ded4c996a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3ad728c6-3921-40c2-88c5-059beacf47aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6431a7f4-b599-4319-a6f3-2ded4c996a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6205383-72d6-4164-ba2a-8a651ff10b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_2b5444d9-a2d7-4126-864c-0fce89640d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6205383-72d6-4164-ba2a-8a651ff10b5b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_2b5444d9-a2d7-4126-864c-0fce89640d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6205383-72d6-4164-ba2a-8a651ff10b5b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c44eaf63-6ac9-4bad-afaa-0374b7a94725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c44eaf63-6ac9-4bad-afaa-0374b7a94725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:href="evh-20230331.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_3fea6a42-9e52-4304-af58-ed34d79d6f3c" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:href="evh-20230331.xsd#evh_December312023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312023Member_d73b584a-3647-41bc-84e9-e447e18ec846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:href="evh-20230331.xsd#evh_December312024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312024Member_ff63a1ed-b0fd-4d4c-912b-8316479a72a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:href="evh-20230331.xsd#evh_December312025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_c841810e-3dff-48dd-b97f-f81498175d2c" xlink:to="loc_evh_December312025Member_61663982-6cd6-418b-934a-0ceac287255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_65ce8c84-dd95-4410-9d04-7cee90ef0826" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c3d0b90d-15dc-47a8-a41e-1cc74e6ae440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_32589d99-9a4b-4224-953a-1812968674f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b3f63007-ce55-4267-a781-0f1460a899b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_ad6ee8bd-8207-42da-8b42-51e249757f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_ad6ee8bd-8207-42da-8b42-51e249757f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5bd23512-7725-48d8-b7d7-085d67b49c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5bd23512-7725-48d8-b7d7-085d67b49c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_608d8421-23f4-4bb1-888a-26a2ad250533" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_608d8421-23f4-4bb1-888a-26a2ad250533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:href="evh-20230331.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5577a95e-3519-419d-831b-5ea4ff436d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5577a95e-3519-419d-831b-5ea4ff436d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_436768e2-2fd4-437e-bbdd-1ba728022f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_436768e2-2fd4-437e-bbdd-1ba728022f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_17b8ddeb-7c14-4df6-9a85-b02659e15de7" xlink:href="evh-20230331.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_17b8ddeb-7c14-4df6-9a85-b02659e15de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0fc6f5e5-a627-402a-b275-8d2b95c6d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_725f34c5-0c90-4d61-b16d-7c6f4b031c87" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0fc6f5e5-a627-402a-b275-8d2b95c6d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CustomerDiscountsFromPerformanceObligations_671c9d6e-8ca7-4081-8944-e9ef52e81be4" xlink:href="evh-20230331.xsd#evh_CustomerDiscountsFromPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_evh_CustomerDiscountsFromPerformanceObligations_671c9d6e-8ca7-4081-8944-e9ef52e81be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_09d99ed4-5110-489d-bcf9-b7fc5c2674be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61be6b32-2d1a-4b75-bcc4-3672667dda4c" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_09d99ed4-5110-489d-bcf9-b7fc5c2674be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb8ab7f2-e4d0-445a-af1b-a697e6306b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb8ab7f2-e4d0-445a-af1b-a697e6306b27" xlink:to="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_ad3c0511-d67f-46d9-bbaf-49ea315e12d2" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_4d7b7260-d7d3-480f-a4ca-529474162b95" xlink:href="evh-20230331.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:to="loc_evh_BonusesAndCommissionsMember_4d7b7260-d7d3-480f-a4ca-529474162b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_8260a9ee-3333-4a42-8aa7-e3c8ffbdda44" xlink:href="evh-20230331.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_433dd765-4a16-497a-94b3-6704323442a5" xlink:to="loc_evh_ContractFulfillmentCostsMember_8260a9ee-3333-4a42-8aa7-e3c8ffbdda44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_3369b3a7-c0b7-4295-93a4-3f413c266167" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_80af6263-c8e4-463d-a73a-b070a7c415c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostNet_80af6263-c8e4-463d-a73a-b070a7c415c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_577b7b58-d6c2-4dfa-b37f-d64e3b745dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_577b7b58-d6c2-4dfa-b37f-d64e3b745dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_feade6db-23b8-4b6e-9eb2-f2d1eb3ef7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_b655a53f-9d9b-4626-a9f0-d60e5ec57c94" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_feade6db-23b8-4b6e-9eb2-f2d1eb3ef7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_7ac1e5da-1b45-444c-83b2-2d12b280c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_7ac1e5da-1b45-444c-83b2-2d12b280c0f9" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb93d4d5-ea15-44a4-8399-268f57e45ae7" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_81632cf3-68d0-4e80-a86f-316bfb3f096c" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_81632cf3-68d0-4e80-a86f-316bfb3f096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_e527ea40-72c5-4c41-8106-101ae1b22f8b" xlink:href="evh-20230331.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_970a6709-8ebf-4cac-bebc-8359e3fa9be0" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_e527ea40-72c5-4c41-8106-101ae1b22f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_37e8efe6-39ce-42cb-a8df-022880590223" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_eafb2945-deac-4d09-874d-6620bab6a26a" xlink:href="evh-20230331.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_eafb2945-deac-4d09-874d-6620bab6a26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_3704686a-c6bc-4e4d-a6f7-baca1be784bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_3704686a-c6bc-4e4d-a6f7-baca1be784bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_fbadd429-05da-45c1-b6bd-662f8c50887a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_AccountsReceivableNet_fbadd429-05da-45c1-b6bd-662f8c50887a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a5b0c614-0bd0-4282-a7d1-4a5713553f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_a7c5aedb-1443-4b02-b1fb-e66e0e921f41" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a5b0c614-0bd0-4282-a7d1-4a5713553f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_ab92c443-d0de-448d-984d-c9165a316c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_ab92c443-d0de-448d-984d-c9165a316c32" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3ac65cc0-3b6f-4d01-a650-b0d449f08a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3ac65cc0-3b6f-4d01-a650-b0d449f08a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_10d17eed-72c1-4c56-b58e-f6aa7d50aab9" xlink:href="evh-20230331.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:to="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_10d17eed-72c1-4c56-b58e-f6aa7d50aab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e8f22e13-894f-4b1b-8aa8-a877e9892bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e8f22e13-894f-4b1b-8aa8-a877e9892bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8a45f1bc-0be1-436c-9ef8-53add8a82bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8a45f1bc-0be1-436c-9ef8-53add8a82bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_94ef4176-7e9b-4963-adca-7b524c4cd230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_af1017dc-cea0-402b-a979-4e56f7232697" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_94ef4176-7e9b-4963-adca-7b524c4cd230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0107131d-9372-4496-9505-cc737318a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0107131d-9372-4496-9505-cc737318a97c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037ab50b-216b-4c5b-9f77-d6811d74820e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_687c7616-3251-4203-b680-092e867847cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_ComputerEquipmentMember_687c7616-3251-4203-b680-092e867847cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_44f1e3a6-c752-4d1e-8b11-b5657a6d3e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_44f1e3a6-c752-4d1e-8b11-b5657a6d3e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2f6e0a84-c293-44de-a58b-4f754b919e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2f6e0a84-c293-44de-a58b-4f754b919e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e3dee78c-a068-4b0f-b3a2-616f4a961dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_729dbaa7-9c9c-47cc-aebf-ffcad85fd66e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e3dee78c-a068-4b0f-b3a2-616f4a961dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9b93eb77-2c75-46d2-a615-658625f82c69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55ae8685-5d08-443c-b0d3-ef6bb3982f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55ae8685-5d08-443c-b0d3-ef6bb3982f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_068c6944-c90e-4838-aca9-e909f4024918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_068c6944-c90e-4838-aca9-e909f4024918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1d64d508-444b-4fe3-a0e2-47e561dd766c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1d64d508-444b-4fe3-a0e2-47e561dd766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9157d60a-5abf-401f-bfb0-130e32fd2e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9157d60a-5abf-401f-bfb0-130e32fd2e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_4d9ca9be-b7e4-41e6-a93c-a53c1e01084c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_4d9ca9be-b7e4-41e6-a93c-a53c1e01084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_06dfb637-8b40-45e2-bc9c-b0f021a507b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_Depreciation_06dfb637-8b40-45e2-bc9c-b0f021a507b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9b046cfe-242a-4c8c-b306-270618a0a403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4e10537f-6844-4a4f-b306-77122e9a1bc9" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9b046cfe-242a-4c8c-b306-270618a0a403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_794d226a-a186-4ced-a8b2-74cd5984b7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_48957359-0092-45de-8cd7-a12f63e8ab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_794d226a-a186-4ced-a8b2-74cd5984b7fc" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_48957359-0092-45de-8cd7-a12f63e8ab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd4d9e7f-5a3a-4c8a-8c66-8f1ab9321b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd4d9e7f-5a3a-4c8a-8c66-8f1ab9321b78" xlink:to="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_74551c8d-f305-468a-b4fc-a6000457f818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:to="loc_us-gaap_Goodwill_74551c8d-f305-468a-b4fc-a6000457f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e936981a-4d9e-4fec-ba57-6c0202a60789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e936981a-4d9e-4fec-ba57-6c0202a60789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7d35814e-02ed-4787-9d8f-fe1d9179b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7d35814e-02ed-4787-9d8f-fe1d9179b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9298c3b-5174-470c-a12f-1a8fe003b66d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bbb8c4da-af98-4c16-8675-fcd0c0da3f07" xlink:to="loc_us-gaap_Goodwill_d9298c3b-5174-470c-a12f-1a8fe003b66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b9ec8b3a-2113-4fe0-91f1-902a1833acba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd4d9e7f-5a3a-4c8a-8c66-8f1ab9321b78" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b9ec8b3a-2113-4fe0-91f1-902a1833acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e217a245-dc77-4fb2-9ce3-e681fd992ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e217a245-dc77-4fb2-9ce3-e681fd992ece" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_398c4bf1-9790-4aa5-b3f7-ab63b019e9c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b6b953d0-7578-442f-8da5-13cc362811e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_TradeNamesMember_b6b953d0-7578-442f-8da5-13cc362811e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8232dac7-a595-49a2-af46-f4e3686cfc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8232dac7-a595-49a2-af46-f4e3686cfc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f3fb5447-b3bf-4384-899c-5f9720891bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f3fb5447-b3bf-4384-899c-5f9720891bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_4c405042-750a-480d-8527-82e2daec00bd" xlink:href="evh-20230331.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_evh_BelowMarketLeasesMember_4c405042-750a-480d-8527-82e2daec00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_1c4c6332-0b13-43ff-825b-b4e8d1f7dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e37a806-2a8c-4996-b4b8-842e710e8b8e" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_1c4c6332-0b13-43ff-825b-b4e8d1f7dab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c57669ae-b68c-41cc-b071-4f788a2d36f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_524dcd08-e5f0-48ad-8963-6eaccfb99c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_524dcd08-e5f0-48ad-8963-6eaccfb99c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19690042-1eb6-4239-8a05-1321e831c166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_19690042-1eb6-4239-8a05-1321e831c166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da4b4a92-c9f9-45e8-85a3-cd6a4d88ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da4b4a92-c9f9-45e8-85a3-cd6a4d88ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ca322-2e91-4f1b-8084-3ed850c389eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ca322-2e91-4f1b-8084-3ed850c389eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2994a8d6-903a-479c-ab5f-ef949b81dfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0d017af-cc50-4bb6-8f27-504d9efb5149" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2994a8d6-903a-479c-ab5f-ef949b81dfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ac15740c-07fc-4177-9f6c-9cac47a05354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ac15740c-07fc-4177-9f6c-9cac47a05354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_22c2ac78-b87f-4b00-a394-dd24cbf6a614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_22c2ac78-b87f-4b00-a394-dd24cbf6a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ec442b8-bb34-4880-a788-6aa2f2a59fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ec442b8-bb34-4880-a788-6aa2f2a59fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ed71f6cf-1564-460b-80be-d4f91b7a1dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ed71f6cf-1564-460b-80be-d4f91b7a1dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d1a56c31-ea7c-468c-8400-61e93af6c052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d1a56c31-ea7c-468c-8400-61e93af6c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0d78a0d2-5d24-48c3-bdc8-4fe81758c205" xlink:href="evh-20230331.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0d78a0d2-5d24-48c3-bdc8-4fe81758c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf29c61b-c358-487e-8b26-057e41dde27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e07664-dd87-491d-b638-b26589f6a166" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf29c61b-c358-487e-8b26-057e41dde27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9b79901a-1646-4f6f-b0f1-8d72fd9ef674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b79901a-1646-4f6f-b0f1-8d72fd9ef674" xlink:to="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_416cb6b5-c41b-49aa-bb74-7a40ca8e2682" xlink:to="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e1c1d040-204f-441b-941e-b929c3de2e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_us-gaap_SecuredDebtMember_e1c1d040-204f-441b-941e-b929c3de2e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dd4503e5-b6a4-4dcb-82b6-dbf72249148c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dd4503e5-b6a4-4dcb-82b6-dbf72249148c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_49f5cfe9-bf73-4062-b1ec-4926f1a001c3" xlink:href="evh-20230331.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_db38f9e7-f148-491c-a6fc-83c1be7d14a7" xlink:to="loc_evh_A2022CreditFacilitiesMember_49f5cfe9-bf73-4062-b1ec-4926f1a001c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_348c8deb-fbb1-497c-84d3-f6fc5dea2888" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d008d7a9-e4b1-403b-98e1-9994ad094091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:to="loc_us-gaap_LineOfCreditMember_d008d7a9-e4b1-403b-98e1-9994ad094091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_81335245-70a5-42ff-85a3-8b25b0975a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b0792e0-dee3-424c-a1ed-e9baae4a5f4e" xlink:to="loc_us-gaap_SecuredDebtMember_81335245-70a5-42ff-85a3-8b25b0975a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8d1d3bab-9431-427c-a3c9-982ec3b06cde" xlink:to="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_52cf9e6c-37c0-478b-93d2-ed9f78aef7c9" xlink:href="evh-20230331.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_52cf9e6c-37c0-478b-93d2-ed9f78aef7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_2197f6ca-6fe1-4fc2-9e0a-6fdda07f1740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c3e275e6-6a10-404c-9cd5-08f59540a5e9" xlink:to="loc_us-gaap_BaseRateMember_2197f6ca-6fe1-4fc2-9e0a-6fdda07f1740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_80da7bea-44c1-4851-ad32-45d37e40db74" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_d18a3eda-ef51-4907-aee8-6b0e8392dff7" xlink:href="evh-20230331.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dd0bfd1e-8409-45b7-a53a-ba93ebf4e154" xlink:to="loc_evh_A2022CreditFacilitiesMember_d18a3eda-ef51-4907-aee8-6b0e8392dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_077cc76e-4608-4c19-9093-358e238c910b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8150054-3ecc-4adb-965c-4cc2dc85cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8150054-3ecc-4adb-965c-4cc2dc85cdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentClosingFeePercent_7d3dbe36-a8fa-490b-a5ab-e832ae407b31" xlink:href="evh-20230331.xsd#evh_DebtInstrumentClosingFeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentClosingFeePercent_7d3dbe36-a8fa-490b-a5ab-e832ae407b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_669e75a6-e3a2-42b9-b66d-e166cffe977b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_669e75a6-e3a2-42b9-b66d-e166cffe977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_887ffc03-c5c6-410f-aa13-965dd85d7780" xlink:href="evh-20230331.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_887ffc03-c5c6-410f-aa13-965dd85d7780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_663e770a-d114-4d65-a5da-82149352963f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_663e770a-d114-4d65-a5da-82149352963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_aef33b11-501e-421d-8e63-becbd16984d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_aef33b11-501e-421d-8e63-becbd16984d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b85ba99a-ddd2-4bb3-90bf-4777cf225cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_InterestExpenseDebt_b85ba99a-ddd2-4bb3-90bf-4777cf225cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_d18c9c1c-0204-4f92-b899-34679de34212" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_d18c9c1c-0204-4f92-b899-34679de34212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_99300e77-df95-48a2-8c04-db755fea2905" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_99300e77-df95-48a2-8c04-db755fea2905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_f5523ed2-06db-4feb-911e-76ce7907100e" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_f5523ed2-06db-4feb-911e-76ce7907100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_e419be5b-3b60-4356-8426-84b8a13106bc" xlink:href="evh-20230331.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_e419be5b-3b60-4356-8426-84b8a13106bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_050fc6e0-b40d-4ccc-97de-d3f0a04a82d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_050fc6e0-b40d-4ccc-97de-d3f0a04a82d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf863ddb-2a87-4668-ab9e-64f21c762326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf863ddb-2a87-4668-ab9e-64f21c762326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b778f2db-941f-49b3-a8cf-15dfd25a6843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aca2d062-7f73-4692-af7a-0d514cb3866c" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b778f2db-941f-49b3-a8cf-15dfd25a6843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bbb50d5a-a0ff-4283-b175-8eefea228166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bbb50d5a-a0ff-4283-b175-8eefea228166" xlink:to="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e859421e-5d09-43db-acd3-f2d5aba59b3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_86bd8438-557e-4c9d-8bbf-356595c6ff34" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_86bd8438-557e-4c9d-8bbf-356595c6ff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_a5cb213e-cedd-4497-bd17-4a8a40b8e387" xlink:href="evh-20230331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_a5cb213e-cedd-4497-bd17-4a8a40b8e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_86ecab3f-190c-4720-81a0-0fe229e5fe3d" xlink:href="evh-20230331.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18c9c261-7239-4586-8f43-b1c14e5ca6ef" xlink:to="loc_evh_NewNotesMember_86ecab3f-190c-4720-81a0-0fe229e5fe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da35c10d-1d64-4956-9892-f155fc17e1ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f6604143-e76b-4ccc-8c65-b0c1f52f976d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_de2afef7-4751-4400-ba6e-2c8b5196b2b8" xlink:to="loc_us-gaap_SeniorNotesMember_f6604143-e76b-4ccc-8c65-b0c1f52f976d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_984cb31a-1da4-4669-88c2-68731d4f6eb9" xlink:to="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_92f2f0bd-a725-464b-9800-c2867acacc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_CommonStockMember_92f2f0bd-a725-464b-9800-c2867acacc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f0a65d44-75f4-4d03-a64b-7cabaf99254e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f0a65d44-75f4-4d03-a64b-7cabaf99254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c59e9088-3b36-423b-b807-b05f7498002b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0b22c26d-4f99-4672-aee5-f8c1428ea282" xlink:to="loc_us-gaap_RetainedEarningsMember_c59e9088-3b36-423b-b807-b05f7498002b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a5ef1e04-5148-469e-ba65-019a83f096a3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_36cbae45-8f2b-46ea-8151-766fbcdd9a77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8618263a-991e-4b7f-84d5-9375a7f02f86" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_36cbae45-8f2b-46ea-8151-766fbcdd9a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8ff5d6fb-e315-4bab-9c17-18fefa02b476" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a404625b-c554-456b-a77b-aa9975a57c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_fb4b1d1e-c653-440e-8edd-4f2322567029" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a404625b-c554-456b-a77b-aa9975a57c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c2f14e4e-209b-4ab9-b8c9-cf7658e02b60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b14d577d-cd12-4de9-82d1-51fb90ceee0a" xlink:href="evh-20230331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b14d577d-cd12-4de9-82d1-51fb90ceee0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_a3054d3e-ccea-488c-8ca3-6de282692bca" xlink:href="evh-20230331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2648e898-c94f-458f-a600-43e50f5e27ee" xlink:to="loc_evh_DeferredFinancingFeesMember_a3054d3e-ccea-488c-8ca3-6de282692bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_214c5d67-38a9-4ecb-af71-607381bffbbf" xlink:to="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_481cda3f-0294-47ea-8182-7d8ee357887e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5268d4c4-9fbe-4da6-9de8-b919641a7396" xlink:to="loc_us-gaap_CommonClassAMember_481cda3f-0294-47ea-8182-7d8ee357887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd116c62-db93-448b-976a-8ae637dcb7db" xlink:to="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8a027ea-cffa-429e-a480-d8d171eac7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8a027ea-cffa-429e-a480-d8d171eac7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a2ad75e-5a36-45b4-9def-be69d702a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a2ad75e-5a36-45b4-9def-be69d702a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_462204e7-e4d8-4868-abe8-b93850e5ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_462204e7-e4d8-4868-abe8-b93850e5ce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_4ef512f2-3dbc-4dfc-994f-d3c4e7a86707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_4ef512f2-3dbc-4dfc-994f-d3c4e7a86707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b5499923-7e38-440b-9743-eeec6cca1a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b5499923-7e38-440b-9743-eeec6cca1a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d71c9492-e994-437f-aa73-757466ad2b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d71c9492-e994-437f-aa73-757466ad2b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3050fc3a-5270-4882-8847-124e7ebe45cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_InterestExpenseDebt_3050fc3a-5270-4882-8847-124e7ebe45cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2ee6c1ac-03a3-4822-bc2f-3e2f34dc35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2ee6c1ac-03a3-4822-bc2f-3e2f34dc35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b7519686-18e0-4a16-848b-032f1fe7dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b7519686-18e0-4a16-848b-032f1fe7dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b1921828-0745-40df-b657-01c3fa7bc9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b1921828-0745-40df-b657-01c3fa7bc9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d837cb8e-d949-4db6-99be-125751096561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_LongTermDebt_d837cb8e-d949-4db6-99be-125751096561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_347d3b29-fd81-4592-8337-842c2f694f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_347d3b29-fd81-4592-8337-842c2f694f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_536e4f8d-a153-4e50-8d9c-37aad923e9a6" xlink:href="evh-20230331.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_536e4f8d-a153-4e50-8d9c-37aad923e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a328c7d-0908-4cf4-bde1-82b4d8859f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_StockholdersEquity_3a328c7d-0908-4cf4-bde1-82b4d8859f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c7c1e384-7026-4785-b80e-1d5612767216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c7c1e384-7026-4785-b80e-1d5612767216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_81052ab2-47e6-436e-97f6-3bef67a3bd3c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_81052ab2-47e6-436e-97f6-3bef67a3bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_c5e1e4b9-9fbd-4ce3-9327-fad6824c600e" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_c5e1e4b9-9fbd-4ce3-9327-fad6824c600e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_29b4ca11-291a-4745-bd88-bbe69050fc4c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_29b4ca11-291a-4745-bd88-bbe69050fc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_f8e947cb-61c5-4c84-bb34-1d45c5673ae7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_f8e947cb-61c5-4c84-bb34-1d45c5673ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_7cb1577a-4990-431f-8cad-e24010134442" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_7cb1577a-4990-431f-8cad-e24010134442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8b05304-2eda-48e9-9777-12b6fe952c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8b05304-2eda-48e9-9777-12b6fe952c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b98299f8-2f65-493b-b433-6dfe1598d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_593b2c08-4fbd-461a-bec1-beaaf625e737" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b98299f8-2f65-493b-b433-6dfe1598d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_648dc003-d1a4-454d-b409-028e1c719a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_648dc003-d1a4-454d-b409-028e1c719a83" xlink:to="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_689c6c41-9e17-4124-98b7-636d4bfe8e4f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_79879036-dc40-468a-aa04-2901883062e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1674408b-f63e-4d8e-9945-42310ebf3f00" xlink:to="loc_us-gaap_SeniorNotesMember_79879036-dc40-468a-aa04-2901883062e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d02414b-74df-446c-8693-e49511fa3243" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_de600e54-7a56-4aa3-a62f-75c2e23898fa" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9dcef967-bce8-468a-9bc9-7cdce8509d34" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_de600e54-7a56-4aa3-a62f-75c2e23898fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_892f6a45-a697-4fca-8533-e9327108c9f3" xlink:to="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adffa07b-e400-4af5-a7a0-42a6e4c8a86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_CommonStockMember_adffa07b-e400-4af5-a7a0-42a6e4c8a86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f242426f-60ad-4696-bd3c-469c13bbe088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f242426f-60ad-4696-bd3c-469c13bbe088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_177c20ae-58b0-4813-887b-565911190af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060fe27d-56e4-4374-9211-0d9bdc93ad5d" xlink:to="loc_us-gaap_RetainedEarningsMember_177c20ae-58b0-4813-887b-565911190af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_92b8bd74-328a-4d22-93df-06ddb043b983" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_630197d0-25cb-4096-b376-4d192ae738dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cc6ec30e-e342-480b-b1d6-41d8bdb0f30e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_630197d0-25cb-4096-b376-4d192ae738dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_48573273-36f0-43f0-8a2c-aff51703e337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_ebf09d4a-eebd-4781-b7b9-fc13c6479f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_106b4853-3350-46b8-b947-258f4e622810" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_ebf09d4a-eebd-4781-b7b9-fc13c6479f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_be0d02aa-1b39-4eb3-aa5a-3900da56063b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_593e0dfe-cc1e-4a28-9802-339ddde216ba" xlink:href="evh-20230331.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_593e0dfe-cc1e-4a28-9802-339ddde216ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_c7cef379-606e-435d-b3b1-b75b5b7d1275" xlink:href="evh-20230331.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b52995a4-27c8-43f2-85df-82a1da614422" xlink:to="loc_evh_DeferredFinancingFeesMember_c7cef379-606e-435d-b3b1-b75b5b7d1275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66e05204-f330-4b7b-bca9-10296135f2e6" xlink:to="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_219ea8ed-b535-4544-ac9a-0db0fd8c94d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d3f25ffa-2fb0-4435-9b6f-d0491d9116ce" xlink:to="loc_us-gaap_CommonClassAMember_219ea8ed-b535-4544-ac9a-0db0fd8c94d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55ffb324-8389-4812-8807-9d699462f561" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2a6a6dec-bd23-4500-b7b0-c6790b8494cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2a6a6dec-bd23-4500-b7b0-c6790b8494cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d716ed16-da20-49dc-a00b-b3006b0590c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d716ed16-da20-49dc-a00b-b3006b0590c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_be5d777d-d242-4667-95af-b77aae7606e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_InterestExpenseDebt_be5d777d-d242-4667-95af-b77aae7606e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_03647704-b1df-4ac9-bd2c-0c792aaf7af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_03647704-b1df-4ac9-bd2c-0c792aaf7af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_107494a8-f2f7-4a90-aa97-b56a9d56e5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_107494a8-f2f7-4a90-aa97-b56a9d56e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e95b8051-d511-4538-8c97-14177b1bc4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e95b8051-d511-4538-8c97-14177b1bc4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ecaad84f-18f0-4853-a5c6-7e68a560bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_LongTermDebt_ecaad84f-18f0-4853-a5c6-7e68a560bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_58c7afc2-e8d4-4c87-a2ee-ea70571fd14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_58c7afc2-e8d4-4c87-a2ee-ea70571fd14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ed4be37d-5974-4e2f-a053-d5e80a59d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ed4be37d-5974-4e2f-a053-d5e80a59d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef779106-9bc3-4d86-be86-f2cb438c4fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_StockholdersEquity_ef779106-9bc3-4d86-be86-f2cb438c4fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_57f3e576-6401-4438-8b2c-8f8d845dcba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_57f3e576-6401-4438-8b2c-8f8d845dcba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_9c0ed4ae-f043-4572-b856-3f57647a2082" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_9c0ed4ae-f043-4572-b856-3f57647a2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5d18dd9e-f140-4287-b974-7047650de5b7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5d18dd9e-f140-4287-b974-7047650de5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_1b30a961-b3bf-4e9d-bc90-d82f811be1e9" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_1b30a961-b3bf-4e9d-bc90-d82f811be1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_113395ab-c361-4400-ae7e-ed89321d967c" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_113395ab-c361-4400-ae7e-ed89321d967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_0c45b13f-e809-49b4-9600-a8333f1844d7" xlink:href="evh-20230331.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdf93a2b-a6eb-47de-bdae-3d8b8e8457a8" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_0c45b13f-e809-49b4-9600-a8333f1844d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6028ef08-4d02-4bd6-adb2-e5e67c2e941d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6028ef08-4d02-4bd6-adb2-e5e67c2e941d" xlink:to="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8b0c888c-d671-422a-94ef-2369dd4cbd91" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_caabd48e-a071-4ce4-b5c9-a9ce68a41756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ff81bea-a87f-44f6-bfb6-564ed54fad6c" xlink:to="loc_us-gaap_SeniorNotesMember_caabd48e-a071-4ce4-b5c9-a9ce68a41756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d86ef3c-6fce-4786-9e6f-e2e29d4aa518" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_9087b654-7d23-4a68-ab83-5036ae929059" xlink:href="evh-20230331.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_9087b654-7d23-4a68-ab83-5036ae929059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_4124c36b-0210-4391-9102-84b4f1b53840" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_50c08f36-c05e-457a-b645-7ea43c8d811c" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_4124c36b-0210-4391-9102-84b4f1b53840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a31d8d08-6332-422a-b6f0-a764065acb8d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9c1c1109-af0b-4442-bac4-279a54c8c276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9c1c1109-af0b-4442-bac4-279a54c8c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4ebb88ff-22eb-4323-8e6f-51eb7bb6742c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4ebb88ff-22eb-4323-8e6f-51eb7bb6742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f82683f3-1a32-451a-aa75-c0ac87a5ec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f82683f3-1a32-451a-aa75-c0ac87a5ec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9e9487bd-9507-4a93-aebf-58806ff0a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9e9487bd-9507-4a93-aebf-58806ff0a56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15376ec3-4b0b-48d3-b288-f6b1095e4851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15376ec3-4b0b-48d3-b288-f6b1095e4851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_01426d36-c168-4ee1-b398-58e13520c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_01426d36-c168-4ee1-b398-58e13520c8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa36ef45-fa08-4a1d-ad2e-ce8d2e431134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41cec87b-8485-48aa-a6a9-62b30cb129ee" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa36ef45-fa08-4a1d-ad2e-ce8d2e431134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1f941b88-4a29-4ccb-8639-11b770b2b70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1f941b88-4a29-4ccb-8639-11b770b2b70d" xlink:to="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e3963dd-a642-46a7-9cb5-bb472312a821" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_63d30eaa-7cd8-4d30-9d9f-cb46420d018f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4e5b86fa-ec89-4f4c-aede-6e480a374e04" xlink:to="loc_us-gaap_SeniorNotesMember_63d30eaa-7cd8-4d30-9d9f-cb46420d018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e66e5549-e044-4aa9-9142-28062f138030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_deddbf8e-010b-47e5-801f-66da7175bd26" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_deddbf8e-010b-47e5-801f-66da7175bd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_595ad70e-d824-4b89-be14-62eea78ce585" xlink:href="evh-20230331.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_099e5a23-0d7b-4452-81c8-04248acab596" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_595ad70e-d824-4b89-be14-62eea78ce585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d87425a-bdd7-4f6a-a35c-12feb9bd94d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_244df77e-9186-4469-b829-3170be314d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f243e34-962b-4757-a915-2d60c7d15aef" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_244df77e-9186-4469-b829-3170be314d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8a3380c-1319-4ab8-9d97-66700e15efeb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_99cd806f-8037-4627-83a9-e7bd5db48a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_ConvertibleDebt_99cd806f-8037-4627-83a9-e7bd5db48a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_77abfc09-b397-4cb0-a93c-4397187cd7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_77abfc09-b397-4cb0-a93c-4397187cd7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_aa023fc3-ac9f-4d95-ba31-ad735d5468f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_aa023fc3-ac9f-4d95-ba31-ad735d5468f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_ebcef1a9-1c7f-4d24-8ec0-2300b4ee7f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_ebcef1a9-1c7f-4d24-8ec0-2300b4ee7f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6e698c48-c5bb-49ab-adf2-262189c81ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_055ba293-27bb-4c9b-8476-147238a5fdb7" xlink:to="loc_us-gaap_LongTermDebtFairValue_6e698c48-c5bb-49ab-adf2-262189c81ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0555ae0-6373-4d95-8e74-40960fdafa81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0555ae0-6373-4d95-8e74-40960fdafa81" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d8841fa0-7fe6-4a31-b0ca-e027df672d85" xlink:to="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f07b848f-0da3-44d5-b56f-d81626af527e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_70af895a-fe33-464d-86e9-14ff864d5baf" xlink:to="loc_us-gaap_LetterOfCreditMember_f07b848f-0da3-44d5-b56f-d81626af527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4e59d5c0-6255-4d9d-a6ae-51498b6edf94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_473060b9-6d3a-4cff-82f2-9e1603a19a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d876a85f-5b26-48b3-8dc9-52d2aaed3603" xlink:to="loc_us-gaap_LineOfCreditMember_473060b9-6d3a-4cff-82f2-9e1603a19a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5f9e68cf-b452-4191-9087-9668f46e6b0b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_3dd69995-54a2-404c-a45b-1c2cf3b48712" xlink:href="evh-20230331.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4e38533-c613-44ec-8b60-2e5ba5bb7157" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_3dd69995-54a2-404c-a45b-1c2cf3b48712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_7b786d5a-e521-41f0-bda1-eee62abd01c0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_c445a5a6-de6d-4c24-903c-5eabcdfdbc9c" xlink:href="evh-20230331.xsd#evh_UPMCResellerAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b7ed5e17-4a16-4eb8-aa31-dbbe7d39d0a6" xlink:to="loc_evh_UPMCResellerAgreementMember_c445a5a6-de6d-4c24-903c-5eabcdfdbc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1f4fc49d-5211-40a3-bb2f-3bc5fbecb94c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20389a37-0f3a-4269-828d-471e39fabcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20389a37-0f3a-4269-828d-471e39fabcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc9cac8-7fc1-4d4f-991e-de7acbff0a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc9cac8-7fc1-4d4f-991e-de7acbff0a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_e6aca37b-5baa-4820-90a0-468187256373" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_e6aca37b-5baa-4820-90a0-468187256373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_52918dcb-ddf1-4f1f-a3ee-65f1a3ba68cd" xlink:href="evh-20230331.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_52918dcb-ddf1-4f1f-a3ee-65f1a3ba68cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_b0e86b3b-b3f8-444a-8b0d-8288f95fd8bb" xlink:href="evh-20230331.xsd#evh_NumberOfCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_NumberOfCustomers_b0e86b3b-b3f8-444a-8b0d-8288f95fd8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8b18b471-7cba-4f34-9031-9a6c48f41f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_us-gaap_Revenues_8b18b471-7cba-4f34-9031-9a6c48f41f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_fce640fa-b068-4b88-8f56-ee713bc63d60" xlink:href="evh-20230331.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_fce640fa-b068-4b88-8f56-ee713bc63d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_668a78ad-eede-41b1-8d45-17848b62283d" xlink:href="evh-20230331.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_668a78ad-eede-41b1-8d45-17848b62283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_21faf8e4-e98d-4a15-b9c4-1e03495be3c0" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2b471af0-753c-4662-8438-3cca8cdc9af4" xlink:to="loc_evh_TaxReceivableAgreementLiability_21faf8e4-e98d-4a15-b9c4-1e03495be3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#CommitmentsandContingenciesCreditandConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f05d3306-ec82-46d1-996a-93c760bde299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f05d3306-ec82-46d1-996a-93c760bde299" xlink:to="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ece05b95-20ec-4fa5-ae98-4b700a58bf51" xlink:to="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_e3ea9a9b-d01a-4590-b83b-65efab16fcb1" xlink:href="evh-20230331.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_e3ea9a9b-d01a-4590-b83b-65efab16fcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_418f92ad-265a-4544-a325-e40cc25d70a7" xlink:href="evh-20230331.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_FloridaBlueMedicareIncMember_418f92ad-265a-4544-a325-e40cc25d70a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_4902a912-531b-4c74-a33b-2466eefd88e9" xlink:href="evh-20230331.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_MolinaHealthcareMember_4902a912-531b-4c74-a33b-2466eefd88e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_15c0a2dd-1c3a-48e4-8796-abb7d58c1ed0" xlink:href="evh-20230331.xsd#evh_BrightHealthManagementIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_368624a7-276d-43dc-ab43-2077b74fd38f" xlink:to="loc_evh_BrightHealthManagementIncMember_15c0a2dd-1c3a-48e4-8796-abb7d58c1ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dbfca1bb-ae91-43ba-bfe9-f067cf71cf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_656b7179-3323-4ca0-94b6-505533a05e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3445ea41-4b95-4a41-b2a6-f5888d3ac8a5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_656b7179-3323-4ca0-94b6-505533a05e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1284f23-cbd4-4292-9d15-422361e5a5b4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_29f80672-3eb6-48f1-81d1-70188cc00aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:to="loc_us-gaap_AccountsReceivableMember_29f80672-3eb6-48f1-81d1-70188cc00aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_54d5932c-fce9-4c19-b585-71ec6dc50f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a068e47-3c03-435f-8a61-ebb50b809465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_54d5932c-fce9-4c19-b585-71ec6dc50f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d872fc22-ac01-4ace-84ad-affee889a042" xlink:to="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_127c68f2-61f4-4c77-b3dc-404fc151a467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_aa05af8c-a072-4d5f-9de1-086367f85803" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_127c68f2-61f4-4c77-b3dc-404fc151a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_43d26f76-6a9c-46a5-b812-2522f4f74534" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_972d89e0-1dc0-4c38-a71f-9099930c8fb0" xlink:href="evh-20230331.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_972d89e0-1dc0-4c38-a71f-9099930c8fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89927b2c-e5d1-49f5-a685-78bbad4979a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89927b2c-e5d1-49f5-a685-78bbad4979a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_59b18bcc-d30d-4559-a298-dda5c2acb8ae" xlink:href="evh-20230331.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_59b18bcc-d30d-4559-a298-dda5c2acb8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_06fcb5e2-aad3-4e28-a70d-c2337495e066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9849113-8721-4461-90a9-ef8ec1cecdf0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_06fcb5e2-aad3-4e28-a70d-c2337495e066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b59543d-cde9-4f67-bbbc-6fb38958d6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b59543d-cde9-4f67-bbbc-6fb38958d6fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b111f8c-6cd3-4a63-b8b3-00db7536c1d2" xlink:to="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_0e858a02-992a-4a7c-841e-f3759b4a0aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_f3d22cfe-923d-4a4b-ba3b-286d10aa070d" xlink:to="loc_us-gaap_LeaseAgreementsMember_0e858a02-992a-4a7c-841e-f3759b4a0aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5217eb0e-ea3a-4955-a846-ff00130a8bfa" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_a8406ec9-987a-410c-a43f-7d022d7e89a3" xlink:href="evh-20230331.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_a8406ec9-987a-410c-a43f-7d022d7e89a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_83fd58ef-a7ef-41ab-93da-9b7672b795bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_83fd58ef-a7ef-41ab-93da-9b7672b795bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1129ef01-0f13-4caf-a389-8ae688379a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f97c4bb8-9c5f-4021-a016-73315d9541cb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1129ef01-0f13-4caf-a389-8ae688379a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_75113c3e-58f6-4fee-9d3b-4e1624da84a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_75113c3e-58f6-4fee-9d3b-4e1624da84a4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:to="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_603e5c31-0a74-4306-a9e9-fd2031305630" xlink:to="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_14d37e7d-fdaa-4896-8a1a-6959076d0575" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_VA_14d37e7d-fdaa-4896-8a1a-6959076d0575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_1091ec1e-fa21-49d7-9a8a-51b3daffe46a" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_IL_1091ec1e-fa21-49d7-9a8a-51b3daffe46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_84a47590-b020-409b-a6e8-7abf5664583d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_NJ_84a47590-b020-409b-a6e8-7abf5664583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_e9b77dc9-189a-46fd-8421-2b75db4b83f1" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_GA_e9b77dc9-189a-46fd-8421-2b75db4b83f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_3c9fe571-537d-4eec-bb14-750d59a762f5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_country_IN_3c9fe571-537d-4eec-bb14-750d59a762f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_939a6f74-1942-4ef3-a891-f9953232dfc8" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d430b6b5-ebdb-4e13-ad11-f147b098a834" xlink:to="loc_stpr_CA_939a6f74-1942-4ef3-a891-f9953232dfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_09c7569e-f570-4da5-986d-1f51f6eda417" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_87d53d6b-9458-49d6-9c91-04cce818fd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_87d53d6b-9458-49d6-9c91-04cce818fd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df367082-0925-45b0-8231-85e3b3b71efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df367082-0925-45b0-8231-85e3b3b71efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0de9f571-82bf-4a28-88ad-bb1c228c9821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_672cd144-aedf-4850-8b9f-0aed157da4ac" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0de9f571-82bf-4a28-88ad-bb1c228c9821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4a2b9538-90fb-45af-a4a1-e32ca0b67675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_700d9058-03ad-44b4-9e9c-0672b9a4c674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a2b9538-90fb-45af-a4a1-e32ca0b67675" xlink:to="loc_us-gaap_OperatingLeaseCost_700d9058-03ad-44b4-9e9c-0672b9a4c674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f0a759bb-abdb-4865-887f-4ec591adc913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a2b9538-90fb-45af-a4a1-e32ca0b67675" xlink:to="loc_us-gaap_VariableLeaseCost_f0a759bb-abdb-4865-887f-4ec591adc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c23f7aa0-0688-4484-92ad-3b1ab2c642df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a2b9538-90fb-45af-a4a1-e32ca0b67675" xlink:to="loc_us-gaap_LeaseCost_c23f7aa0-0688-4484-92ad-3b1ab2c642df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cef15a22-02b4-4668-a1c7-4f36346c214d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cef15a22-02b4-4668-a1c7-4f36346c214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4aca1402-6428-41d9-8447-969746b71b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4aca1402-6428-41d9-8447-969746b71b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6fcb5cd9-217b-417d-81a2-f9931dd14066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6fcb5cd9-217b-417d-81a2-f9931dd14066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3efca52-72fd-4aca-890d-ed75aec95790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3efca52-72fd-4aca-890d-ed75aec95790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0564e4dc-499c-473b-9f63-e329cae9ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0564e4dc-499c-473b-9f63-e329cae9ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour_139f7c86-35de-434b-a51b-027a94552d90" xlink:href="evh-20230331.xsd#evh_LesseeOperatingLeaseLiabilityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityAfterYearFour_139f7c86-35de-434b-a51b-027a94552d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a54dde5-ebbc-4d49-a1e8-82f70d789c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a54dde5-ebbc-4d49-a1e8-82f70d789c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_aff1cfa7-b0ad-4061-bb42-666432d7b800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_aff1cfa7-b0ad-4061-bb42-666432d7b800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_212d5dda-e847-4411-9027-67005bbe686f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_aff1cfa7-b0ad-4061-bb42-666432d7b800" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_212d5dda-e847-4411-9027-67005bbe686f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5502cd19-f87d-480e-91a8-0c9a7efbd9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc259512-f4fc-4840-9542-c23ce2b4d688" xlink:to="loc_us-gaap_OperatingLeaseLiability_5502cd19-f87d-480e-91a8-0c9a7efbd9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_17900a29-fe1b-4264-96a1-605da895549c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e8db18af-a315-44ee-ad46-8535cd9ad8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_17900a29-fe1b-4264-96a1-605da895549c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e8db18af-a315-44ee-ad46-8535cd9ad8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3ad97203-a994-41b5-bd2a-68ea4705cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_17900a29-fe1b-4264-96a1-605da895549c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3ad97203-a994-41b5-bd2a-68ea4705cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#ConvertiblePreferredEquityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_443eab40-cafe-4dc4-a1ed-831df00374b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_443eab40-cafe-4dc4-a1ed-831df00374b3" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c00a77-cb89-4226-aac6-b4b332e066cd" xlink:to="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_cfe8e030-de9e-449a-b583-89c22b95338a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_cfe8e030-de9e-449a-b583-89c22b95338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_becf4750-35e9-4536-87d6-da42a0b3eec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_19681e8d-3443-4b9e-bda6-d1da172e3c17" xlink:to="loc_us-gaap_CommonClassAMember_becf4750-35e9-4536-87d6-da42a0b3eec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2c105518-e2c9-4c97-a5e6-0c559680e9f3" xlink:to="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_81a4fcb6-1130-46ce-909e-bca99821b527" xlink:href="evh-20230331.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b5b88f60-b115-4742-9f2f-4a8ca786041b" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_81a4fcb6-1130-46ce-909e-bca99821b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodAxis_652ac7e4-ba0b-45eb-9416-9b8c04d1a239" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodOneMember_0a8e8ef0-741c-4771-8465-0c6be3e1a9ee" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodOneMember_0a8e8ef0-741c-4771-8465-0c6be3e1a9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodTwoMember_8df144c7-74ac-4e34-b1d6-e5afc5562de0" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodTwoMember_8df144c7-74ac-4e34-b1d6-e5afc5562de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodThreeMember_356f7e24-50ad-4109-b211-00d7b9c2bc23" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodThreeMember_356f7e24-50ad-4109-b211-00d7b9c2bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFourMember_99fcccfd-74e2-4df8-8319-6995e554e4b5" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodFourMember_99fcccfd-74e2-4df8-8319-6995e554e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPeriodFiveMember_2493bdd6-d960-4349-9318-2a5d385abbd9" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPeriodFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_TemporaryEquityRedemptionPeriodDomain_9b604110-a57e-4547-bb99-e37d54d9b50a" xlink:to="loc_evh_TemporaryEquityRedemptionPeriodFiveMember_2493bdd6-d960-4349-9318-2a5d385abbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_581ca3a3-70b7-4d80-8368-77b18384b8aa" xlink:to="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c5637e6a-2850-4d23-b8ea-69b662533dcc" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c5637e6a-2850-4d23-b8ea-69b662533dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7fb3b8b0-adad-4115-9b35-39b2e1f29d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7fb3b8b0-adad-4115-9b35-39b2e1f29d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_e3358cb6-bcc2-49a3-a03c-009f05c59605" xlink:href="evh-20230331.xsd#evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare_e3358cb6-bcc2-49a3-a03c-009f05c59605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8578f4a8-2cf9-4b72-aa7f-14da791f07da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8578f4a8-2cf9-4b72-aa7f-14da791f07da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f95551e-c916-4f0d-a6a7-8be4dd7e5767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f95551e-c916-4f0d-a6a7-8be4dd7e5767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_7eb24db6-0f87-4a59-acbb-61557cd25188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_7eb24db6-0f87-4a59-acbb-61557cd25188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityVariableDividendRateBasisSpread_d007fb68-7b6d-411d-8ea0-cd1c232221b3" xlink:href="evh-20230331.xsd#evh_TemporaryEquityVariableDividendRateBasisSpread"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityVariableDividendRateBasisSpread_d007fb68-7b6d-411d-8ea0-cd1c232221b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_4cd08afa-657d-4284-9b58-1ed23b641980" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate_4cd08afa-657d-4284-9b58-1ed23b641980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityConvertibleConversionPrice_b8fdb817-092c-4a85-bf4c-8a302cca3ff8" xlink:href="evh-20230331.xsd#evh_TemporaryEquityConvertibleConversionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityConvertibleConversionPrice_b8fdb817-092c-4a85-bf4c-8a302cca3ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityRedemptionPricePercentage_b0496076-043a-453d-88fc-8a942530af2d" xlink:href="evh-20230331.xsd#evh_TemporaryEquityRedemptionPricePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityRedemptionPricePercentage_b0496076-043a-453d-88fc-8a942530af2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_68af34fb-a8d5-43e2-abb3-7845457ff99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_68af34fb-a8d5-43e2-abb3-7845457ff99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityDividendRatePerDollarAmount_0c9286c8-93f9-43bf-b06b-81c71e4530f7" xlink:href="evh-20230331.xsd#evh_TemporaryEquityDividendRatePerDollarAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityDividendRatePerDollarAmount_0c9286c8-93f9-43bf-b06b-81c71e4530f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_205d8bac-7249-42e0-b82b-c8c82c93e391" xlink:href="evh-20230331.xsd#evh_TemporaryEquityAccretionToRedemptionValueAndDividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_0013d008-3bd3-4c44-9467-666eb05133a4" xlink:to="loc_evh_TemporaryEquityAccretionToRedemptionValueAndDividends_205d8bac-7249-42e0-b82b-c8c82c93e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cc82203-7952-4a0c-a81c-75d4f8562322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cc82203-7952-4a0c-a81c-75d4f8562322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_34b2665d-829c-41b7-9e93-aeb6a18f8524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_34b2665d-829c-41b7-9e93-aeb6a18f8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8191d2-0754-4a97-9094-da6a22f0c7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8191d2-0754-4a97-9094-da6a22f0c7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07179215-b192-4f62-bd04-d51c0cf7365f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07179215-b192-4f62-bd04-d51c0cf7365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_7ab2a09c-11be-4fce-8701-90ce814145ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fccb02a9-86a9-40a7-8f43-efcf93eaa17b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_7ab2a09c-11be-4fce-8701-90ce814145ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_255b6423-02ff-4bcf-a35c-9a536f18aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7ab2a09c-11be-4fce-8701-90ce814145ac" xlink:to="loc_us-gaap_EarningsPerShareBasic_255b6423-02ff-4bcf-a35c-9a536f18aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_756425ce-7336-4de9-a5b9-0569e9edb0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7ab2a09c-11be-4fce-8701-90ce814145ac" xlink:to="loc_us-gaap_EarningsPerShareDiluted_756425ce-7336-4de9-a5b9-0569e9edb0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_363b71cb-c47b-403b-86a0-912ee81d9f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_363b71cb-c47b-403b-86a0-912ee81d9f4d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f85b911-d459-4a3e-9d3a-30a3cfffee33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_57e5d7b4-c353-4842-a6da-01ed52883011" xlink:href="evh-20230331.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_57e5d7b4-c353-4842-a6da-01ed52883011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ec938ea-42e5-49b0-a4aa-249e1b521230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ec938ea-42e5-49b0-a4aa-249e1b521230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_d971c423-4b0c-4cb2-bb36-5b79049352c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_PreferredClassAMember_d971c423-4b0c-4cb2-bb36-5b79049352c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_36ee0b97-12da-404b-83a4-4d5be1b00779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54c1a61c-daf0-4c54-913f-2849d6867d3c" xlink:to="loc_us-gaap_ConvertibleDebtMember_36ee0b97-12da-404b-83a4-4d5be1b00779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d2554f9-2759-4785-94a6-b30c4c2c3016" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5abca312-057d-4fd7-a64b-515ce8323fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33705079-e970-41a6-83d3-ef7a9ce340bf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5abca312-057d-4fd7-a64b-515ce8323fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d7e4a9-e710-48a1-9cf4-13d015eb1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d7e4a9-e710-48a1-9cf4-13d015eb1b1f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:to="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8932346e-47cc-4f74-9aa3-93cda31d299f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_69271868-c49d-4382-9857-900d6b79f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_69271868-c49d-4382-9857-900d6b79f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_332d0667-1e54-4271-a887-e176925f97a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_332d0667-1e54-4271-a887-e176925f97a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_ac2b77b6-8b36-4872-91c2-bbc66234e5cd" xlink:href="evh-20230331.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_ac2b77b6-8b36-4872-91c2-bbc66234e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_c2df0175-73bc-44a0-b581-1bcafc808b0b" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5ae9fc-e84d-41c6-9b53-48c8c35cecf6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_c2df0175-73bc-44a0-b581-1bcafc808b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b7e9421-9499-4988-9a10-ef4d6dd4104a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_622033ec-0c88-411e-8f0f-d0bb653b596b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:to="loc_us-gaap_CostOfSalesMember_622033ec-0c88-411e-8f0f-d0bb653b596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef5def0f-6272-4c93-90a6-5eb382a7c998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67a3743e-1970-4af8-8efc-4f1f8ddc7856" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef5def0f-6272-4c93-90a6-5eb382a7c998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_686fa8a3-9466-487b-be81-015ddf487d19" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a31ca9b-62ee-4996-b1bd-0dfea5c09fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43cec5be-57a8-498f-b1bb-52b49139fd91" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a31ca9b-62ee-4996-b1bd-0dfea5c09fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86365557-a737-4df9-a137-18c6ed999fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6c576bee-8cfb-4b59-8ef4-8e2a97de8ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86365557-a737-4df9-a137-18c6ed999fa0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6c576bee-8cfb-4b59-8ef4-8e2a97de8ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0b5e569-6dd9-4ff8-97d4-928cb555a1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0b5e569-6dd9-4ff8-97d4-928cb555a1a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:to="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_94a9d84b-529b-417d-ab11-60c77b1ef5fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79700baa-f4bc-4403-9657-978f85bd22be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79700baa-f4bc-4403-9657-978f85bd22be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_6d781c6c-8d29-4be3-9a37-ff9932c28984" xlink:href="evh-20230331.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c945d06-b25c-479b-9e1d-0c5bdcbc4edd" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_6d781c6c-8d29-4be3-9a37-ff9932c28984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cb3f3d9-7187-4407-b52c-10261f62cfbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfb1e46a-fe67-4e53-b9ab-ad92c8086005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a14b2846-4a09-4bf4-97c2-e9c8365e4f8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfb1e46a-fe67-4e53-b9ab-ad92c8086005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ba322109-60e7-45da-a54d-c0a6a83aae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ba322109-60e7-45da-a54d-c0a6a83aae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_77960d77-0e02-4b52-ba90-9519f51f320e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_77960d77-0e02-4b52-ba90-9519f51f320e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9dc412b5-93d8-4cab-9d10-f6ac7e30bef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9dc412b5-93d8-4cab-9d10-f6ac7e30bef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementTaxExpenseBenefit_3d611b67-3944-4f5f-b96b-93ded2cfc666" xlink:href="evh-20230331.xsd#evh_TaxReceivablesAgreementTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_evh_TaxReceivablesAgreementTaxExpenseBenefit_3d611b67-3944-4f5f-b96b-93ded2cfc666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_88525c38-749e-498e-ad16-858f5b7211cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_88525c38-749e-498e-ad16-858f5b7211cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_1344772b-fe50-49f3-95d8-ba8373170b05" xlink:href="evh-20230331.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc324216-234a-42fb-b130-bb79e517660d" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_1344772b-fe50-49f3-95d8-ba8373170b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b6ec1950-7f1f-415f-9a64-f5c968b46ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b6ec1950-7f1f-415f-9a64-f5c968b46ab9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6aafaae-4219-4156-bb14-fb6d736beccf" xlink:to="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf5bea61-7e96-40aa-ab24-902295167240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:to="loc_srt_MinimumMember_bf5bea61-7e96-40aa-ab24-902295167240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_513ee556-e7c2-45fe-a666-6f1fa3088189" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28eaa818-8fb4-4d61-af7e-339e59601faa" xlink:to="loc_srt_MaximumMember_513ee556-e7c2-45fe-a666-6f1fa3088189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_42699088-414b-469b-af0f-264b8afb6140" xlink:to="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_16213ef3-2453-47dd-9adb-df6d9d160e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2bb3fc4f-d1e5-4001-b301-163b55f1e5d3" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_16213ef3-2453-47dd-9adb-df6d9d160e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3e30dd09-f7fd-4040-91ea-d781b44fea4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_2d1db547-9562-43c5-a071-b509b906383c" xlink:href="evh-20230331.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_22c380bd-e708-497b-816a-875128b1d1f9" xlink:to="loc_evh_ServicesAgreementsMember_2d1db547-9562-43c5-a071-b509b906383c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7d6054ea-3814-4352-b932-2cb04adcd0d8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d1f948bb-eb14-417d-ba72-5a305852f705" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d1f948bb-eb14-417d-ba72-5a305852f705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_2fd5e7b9-f41c-459e-b811-4424da79a006" xlink:href="evh-20230331.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_2fd5e7b9-f41c-459e-b811-4424da79a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf77c110-a528-43d7-9466-afb3eeb1e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf77c110-a528-43d7-9466-afb3eeb1e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_afff268a-9174-489c-9664-51f1280b69bc" xlink:href="evh-20230331.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_97fe9e41-8800-4bfe-a975-0f9bb300bb7e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_afff268a-9174-489c-9664-51f1280b69bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f2ca6c42-ffb6-4754-a8de-bf88eecd7d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2ca6c42-ffb6-4754-a8de-bf88eecd7d49" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bbc2abd-5a22-43b7-b3ad-b60ba3a872bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b2d2fd86-5f99-4028-8d9e-b9572199adce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b2d2fd86-5f99-4028-8d9e-b9572199adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_954cd7b3-de84-4988-ae4f-b733fc40367a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_954cd7b3-de84-4988-ae4f-b733fc40367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6ed60e6-bffe-4030-a471-b61c99d93636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3f708f2-121b-4650-94e5-22198fd14705" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6ed60e6-bffe-4030-a471-b61c99d93636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e559af4b-a496-4a9f-a2ca-28847153c971" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8975246d-32b6-4a52-84e7-c34c49992851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9b5003e0-f7f8-47ee-a7a2-514bd80b4ee1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8975246d-32b6-4a52-84e7-c34c49992851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3c0a7835-81e8-44a8-a52e-703723b1a3ea" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6c1ce02c-be0c-4c10-8913-48876c1afa38" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c290f0a-4342-4972-ada8-cdf0f52b4586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c290f0a-4342-4972-ada8-cdf0f52b4586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0698df6f-5b37-4d13-b791-ce7ae3660e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ea0f3bba-e8bc-48e9-873d-5038af4c1212" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0698df6f-5b37-4d13-b791-ce7ae3660e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_811a3d71-15e2-494b-b437-bdab6c42a9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_811a3d71-15e2-494b-b437-bdab6c42a9a6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_01f04a87-d6fe-4be0-8e54-175150773955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_01f04a87-d6fe-4be0-8e54-175150773955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8b12b7ac-0c3d-4750-8ea5-772beafa11fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8b12b7ac-0c3d-4750-8ea5-772beafa11fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_d334a4e0-3759-4eb0-b035-2b717a9f850e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_d334a4e0-3759-4eb0-b035-2b717a9f850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_2a4ff130-a0d7-4784-b32f-041737707e98" xlink:href="evh-20230331.xsd#evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_2a4ff130-a0d7-4784-b32f-041737707e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a900ed14-9f05-47b6-aa76-ad5e40afc875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a900ed14-9f05-47b6-aa76-ad5e40afc875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0f89f552-ef8e-4c48-9de9-415267416b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4894a818-38f5-4d04-b6aa-b13fe3e0cac8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0f89f552-ef8e-4c48-9de9-415267416b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4406abe9-6532-4f01-8384-2ddbeebc81ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4406abe9-6532-4f01-8384-2ddbeebc81ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1d7b078-1777-4ccf-8cf7-f0f9073514d9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75839f76-306a-4736-95f7-ce02fa698355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5c93f68-3e0b-426b-9098-256283d0396a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75839f76-306a-4736-95f7-ce02fa698355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f65fab8-02e6-4f46-881d-c421f4cec100" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b711aa94-5561-4c9b-aa16-35d10c702304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f0aa04f-ad9a-4df0-8e1a-a77599ad5543" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b711aa94-5561-4c9b-aa16-35d10c702304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e6368779-c679-492c-9247-11765711334b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_b45c34b9-e45a-42dc-a25e-ae7ba1d287de" xlink:href="evh-20230331.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_b45c34b9-e45a-42dc-a25e-ae7ba1d287de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_5283208d-4a68-4efc-8afb-39cdf25b7859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ae2a2371-b1f1-421b-8acd-5b2a2531e344" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_5283208d-4a68-4efc-8afb-39cdf25b7859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_80aa7185-a9eb-4b6e-807c-c5586db34c16" xlink:to="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7d1043a-04ac-4413-b119-d6df1ebb8866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:to="loc_srt_MinimumMember_b7d1043a-04ac-4413-b119-d6df1ebb8866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8faacfc4-65a0-4b2c-8482-52b9406186f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_822e2856-1255-4c7b-8fd3-6e7136e6f723" xlink:to="loc_srt_MaximumMember_8faacfc4-65a0-4b2c-8482-52b9406186f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2b59aeb0-aefe-4f42-8e44-892ca2494b74" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9cd226b1-4efb-4b5c-8821-68a395c8a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9cd226b1-4efb-4b5c-8821-68a395c8a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_14e2a41e-28c6-4e33-8cad-7585e7c76cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0c00a3c6-0b0d-4686-b385-c5d4f6165673" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_14e2a41e-28c6-4e33-8cad-7585e7c76cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_63ca85d7-4076-41a5-92fd-82a56aa07610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_63ca85d7-4076-41a5-92fd-82a56aa07610" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baa7c50d-c71f-44e9-b13d-dcab7d36471d" xlink:to="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0a7281e1-02db-40ca-9a2f-d953bbeffc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_fb49ff52-3343-4270-812f-13948e461e9c" xlink:to="loc_us-gaap_RelatedPartyMember_0a7281e1-02db-40ca-9a2f-d953bbeffc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_29c3144a-0aff-434c-9a62-4d8d74f54660" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:to="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fda6f8ef-a892-42bf-80c1-c834c3a87f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3a91923-f138-4e45-b03a-118f05749308" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fda6f8ef-a892-42bf-80c1-c834c3a87f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_06c26731-7fcb-4b33-8418-01b76ccb963f" xlink:to="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_79c9775a-b25a-4a5e-bfaf-bc3cb1e8fa96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:to="loc_us-gaap_AccountsPayableCurrent_79c9775a-b25a-4a5e-bfaf-bc3cb1e8fa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3c5401c-f57e-41f0-9557-d885efd968bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c761ca0a-f5d3-411e-85dc-2ec5862d4f0d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e3c5401c-f57e-41f0-9557-d885efd968bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bdc39bd3-2f4b-4cd8-9449-0ec6c35c85db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bdc39bd3-2f4b-4cd8-9449-0ec6c35c85db" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3e0ab2a1-24dc-4b3c-8038-32470b6af834" xlink:to="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_13668db1-1384-4c5e-ba65-920471eb2459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ea8c3221-2e65-4320-9417-a4ee5a4132ef" xlink:to="loc_us-gaap_RelatedPartyMember_13668db1-1384-4c5e-ba65-920471eb2459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a5c1ddf-0441-429f-9f36-4d80dca91eb0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b7b9e24b-dd76-44bd-8696-12120ecf28a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:to="loc_us-gaap_Revenues_b7b9e24b-dd76-44bd-8696-12120ecf28a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_47582965-a106-4b98-ab41-78a3d347446f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7c32dc6d-d2e5-4cf8-ad58-e67c6c3ee74b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7c32dc6d-d2e5-4cf8-ad58-e67c6c3ee74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75be6d16-8ad9-4e42-9da3-535f8fc82900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_21ce0b0d-f20d-4dd9-bcc6-92b3e8d614bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75be6d16-8ad9-4e42-9da3-535f8fc82900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_4eb93f6e-ba95-42a6-9f63-fc249de81a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_4eb93f6e-ba95-42a6-9f63-fc249de81a8a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fe5d89d2-1b72-4f19-953a-ad7643352be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fe5d89d2-1b72-4f19-953a-ad7643352be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_275d022c-984c-4f7a-8ed6-e531966df7df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_275d022c-984c-4f7a-8ed6-e531966df7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ecaf25bc-4b6a-42fa-916b-c6d287cc0e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_275d022c-984c-4f7a-8ed6-e531966df7df" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ecaf25bc-4b6a-42fa-916b-c6d287cc0e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_614d5ce8-7c60-43d3-87a7-2c610557c770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_275d022c-984c-4f7a-8ed6-e531966df7df" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_614d5ce8-7c60-43d3-87a7-2c610557c770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_b024c5f2-6803-407d-9024-78f8044c28cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_275d022c-984c-4f7a-8ed6-e531966df7df" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_b024c5f2-6803-407d-9024-78f8044c28cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_65787040-429f-4e7c-88d0-510dccbb3eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_65787040-429f-4e7c-88d0-510dccbb3eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1b3ffae6-7535-4c2b-baed-648b8c108525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_65787040-429f-4e7c-88d0-510dccbb3eb1" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1b3ffae6-7535-4c2b-baed-648b8c108525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f45777bf-f3ad-4c3f-b95c-de548c552311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_65787040-429f-4e7c-88d0-510dccbb3eb1" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f45777bf-f3ad-4c3f-b95c-de548c552311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bd3011c4-4aac-4515-82bf-e60af9e44905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_65787040-429f-4e7c-88d0-510dccbb3eb1" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bd3011c4-4aac-4515-82bf-e60af9e44905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments_7ec23b11-c70c-4c50-b247-264e9dc185cf" xlink:href="evh-20230331.xsd#evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:to="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments_7ec23b11-c70c-4c50-b247-264e9dc185cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_737e00c3-3fe3-4d73-a3ad-1e0e6a5d88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_cb340e67-481e-488a-bd46-ebd95643fbd8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_737e00c3-3fe3-4d73-a3ad-1e0e6a5d88cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20230331.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_15f62757-5faf-45c7-8a3e-c65e09fef7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69d25835-05b8-4795-b52e-44dbfe9b48e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_15f62757-5faf-45c7-8a3e-c65e09fef7ab" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69d25835-05b8-4795-b52e-44dbfe9b48e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d337bff2-2c19-4e50-8c9f-730893bed61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69d25835-05b8-4795-b52e-44dbfe9b48e3" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d337bff2-2c19-4e50-8c9f-730893bed61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_1c4ea696-840f-48ac-ad93-303a1fe4cb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69d25835-05b8-4795-b52e-44dbfe9b48e3" xlink:to="loc_us-gaap_StockIssued1_1c4ea696-840f-48ac-ad93-303a1fe4cb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_5e5e16ea-705e-4f4b-aa65-ad48b3ea00b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69d25835-05b8-4795-b52e-44dbfe9b48e3" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_5e5e16ea-705e-4f4b-aa65-ad48b3ea00b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_6996a7b3-c7f3-4be8-912e-ceaaceb8fa59" xlink:href="evh-20230331.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_15f62757-5faf-45c7-8a3e-c65e09fef7ab" xlink:to="loc_evh_CashFlowLesseeAbstract_6996a7b3-c7f3-4be8-912e-ceaaceb8fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f94b668d-048c-4098-abf1-17e489ab8176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_6996a7b3-c7f3-4be8-912e-ceaaceb8fa59" xlink:to="loc_us-gaap_OperatingLeasePayments_f94b668d-048c-4098-abf1-17e489ab8176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_93e4ab5a-a60b-4196-bf8a-c4ed18b934e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_6996a7b3-c7f3-4be8-912e-ceaaceb8fa59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_93e4ab5a-a60b-4196-bf8a-c4ed18b934e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790108208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,667,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791188896">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 157,519<span></span>
</td>
<td class="nump">$ 188,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,932<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">262,764<span></span>
</td>
<td class="nump">254,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,757<span></span>
</td>
<td class="nump">20,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">475,972<span></span>
</td>
<td class="nump">478,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">12,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88,606<span></span>
</td>
<td class="nump">87,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,408<span></span>
</td>
<td class="nump">49,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,543<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,497<span></span>
</td>
<td class="nump">17,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">825,857<span></span>
</td>
<td class="nump">442,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,117,945<span></span>
</td>
<td class="nump">722,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,589,459<span></span>
</td>
<td class="nump">1,817,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,012<span></span>
</td>
<td class="nump">57,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">170,236<span></span>
</td>
<td class="nump">111,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,608<span></span>
</td>
<td class="nump">7,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,527<span></span>
</td>
<td class="nump">52,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">5,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance - based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">197,197<span></span>
</td>
<td class="nump">199,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">457,649<span></span>
</td>
<td class="nump">433,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">632,277<span></span>
</td>
<td class="nump">412,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,473<span></span>
</td>
<td class="nump">4,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112,134<span></span>
</td>
<td class="nump">45,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,274<span></span>
</td>
<td class="nump">56,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,284<span></span>
</td>
<td class="nump">4,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,297,091<span></span>
</td>
<td class="nump">957,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 10)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 112,552,160 and 101,500,558 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,768,999<span></span>
</td>
<td class="nump">1,486,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,122)<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(626,136)<span></span>
</td>
<td class="num">(606,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,121,743<span></span>
</td>
<td class="nump">859,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,589,459<span></span>
</td>
<td class="nump">$ 1,817,293<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790021360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred class A common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred class A common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred class A common stock, shares issued</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Class A common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Class A common stock, shares authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Class A common stock, shares issued</a></td>
<td class="nump">112,552,160<span></span>
</td>
<td class="nump">101,500,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares issued</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659885598544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 427,690<span></span>
</td>
<td class="nump">$ 297,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">310,475<span></span>
</td>
<td class="nump">219,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">89,726<span></span>
</td>
<td class="nump">58,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,275<span></span>
</td>
<td class="nump">15,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,569<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">438,045<span></span>
</td>
<td class="nump">299,855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,355)<span></span>
</td>
<td class="num">(2,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,895)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">423<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66,184)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(220)<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(88,171)<span></span>
</td>
<td class="num">(4,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68,189)<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss before preferred dividends and accretion of Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,982)<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Dividends and accretion of Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,276)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,258)<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (26,258)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageCommonSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,783<span></span>
</td>
<td class="nump">89,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,783<span></span>
</td>
<td class="nump">89,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (26,258)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (26,202)<span></span>
</td>
<td class="num">$ (5,482)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageCommonSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageCommonSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659785539200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Performance-Based Restricted Stock Units (PSUs)</div></th>
<th class="th"><div>Leveraged Stock Units (LSUs)</div></th>
<th class="th"><div>Cumulative-effect adjustment from adoption of ASC 2020-06</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th">
<div>Class A Common Stock </div>
<div>Performance-Based Restricted Stock Units (PSUs)</div>
</th>
<th class="th">
<div>Class A Common Stock </div>
<div>Leveraged Stock Units (LSUs)</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Performance-Based Restricted Stock Units (PSUs)</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Leveraged Stock Units (LSUs)</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative-effect adjustment from adoption of ASC 2020-06</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative-effect adjustment from adoption of ASC 2020-06</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,340,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(4,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(11,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(5,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of series A preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of series A preferred stock, net of issuance costs</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income (loss)</a></td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 170,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">859,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(606,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(8,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock units vested, net of shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,975)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,977)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">261,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">27,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(26,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,121,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,768,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,122)<span></span>
</td>
<td class="num">$ (626,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodSharesEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodSharesEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodValueEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodValueEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659789898480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Used In Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss before dividends declared and accretion of Series A preferred stock</a></td>
<td class="num">$ (19,982)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">8,569<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="num">(423)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">29,275<span></span>
</td>
<td class="nump">15,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,710<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax provision</a></td>
<td class="num">(68,728)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">11,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="nump">66,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right-of-use operating assets</a></td>
<td class="num">(4,620)<span></span>
</td>
<td class="num">(1,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(4,250)<span></span>
</td>
<td class="num">(1,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash outflows, net</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="nump">19,832<span></span>
</td>
<td class="num">(46,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(13,758)<span></span>
</td>
<td class="num">(6,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(13,585)<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">4,785<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(31,401)<span></span>
</td>
<td class="num">(32,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="num">(2,533)<span></span>
</td>
<td class="num">(7,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash used in operating activities</a></td>
<td class="num">(7,974)<span></span>
</td>
<td class="num">(57,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="num">(386,724)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="num">(9,055)<span></span>
</td>
<td class="num">(8,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by (used in) investing activities</a></td>
<td class="num">(394,993)<span></span>
</td>
<td class="nump">16,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="nump">7,576<span></span>
</td>
<td class="num">(34,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="nump">256,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(37,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of offering costs</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred dividends</a></td>
<td class="num">(3,651)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of equity awards</a></td>
<td class="num">(12,607)<span></span>
</td>
<td class="num">(16,214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash provided by (used in) financing activities</a></td>
<td class="nump">379,729<span></span>
</td>
<td class="num">(51,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="num">(23,188)<span></span>
</td>
<td class="num">(92,156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="nump">215,158<span></span>
</td>
<td class="nump">354,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="nump">$ 191,970<span></span>
</td>
<td class="nump">$ 262,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796646112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports healthcare entities to improve the quality of care delivered for people with complex conditions through proven solutions that make health care simpler and more affordable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made organizational changes, including re-evaluating its reportable segments, as a result of growth in our value-based specialty care business, both organically and through acquisitions. Effective during the three months ended March 31, 2023, the Company changed its reportable segments to reflect changes in the way its chief operating decision maker evaluates the performance of its operations, develops strategy and allocates capital resources. Specifically, the Company collapsed its previous Evolent Health Services and Clinical Solutions segments into one segment. The Company's historical disclosures have been recast to be consistent with the current presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had unrestricted cash and cash equivalents of $157.5 million. The Company believes it has sufficient liquidity for at least the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796671376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2022 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 19 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both March&#160;31, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2023, approximately 20% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Senior Convertible Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company&#8217;s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares. Refer to Note 12 - Series A Senior Convertible Preferred Shares for further discussion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659900188624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div>In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796624800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Imaging Associates Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, the Company completed its acquisition of NIA, including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (&#8220;Magellan&#8221;) and certain of its subsidiaries that were used in the Magellan Specialty Health Division. NIA is a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $715.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on January 20, 2023. The acquisition consideration consisted of approximately $387.8&#160;million of cash consideration (inclusive of certain post-closing adjustments), 8,474,576 shares of the Company&#8217;s Class A common stock, fair valued at $261.3&#160;million as of January 20, 2023, and an earn-out consisting of additional consideration of up to $150.0&#160;million payable in cash and, at the Company&#8217;s election, up to 50% in shares of the Company&#8217;s Class A common stock (the &#8220;Contingent Consideration&#8221;). As of January 20, 2023, the Contingent Consideration is fair valued at $66.6&#160;million. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 15 years, 5 years, and 2 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of proprietary software that supports NIA&#8217;s core business applications and specialty business. The corporate trade name reflects the value that we believe the NIA brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $56.1&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2023, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the financial results of NIA in our consolidated financial statements from January 20, 2023. The consolidated statements of operations and comprehensive income (loss) include $48.5&#160;million of revenues and $(5.5)&#160;million of net loss attributable to NIA for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pro forma financial information (unaudited)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited condensed pro forma information presents combined financial information as if the acquisition of NIA had been effective as of January 1, 2022, the beginning of the 2022 fiscal year. The unaudited pro forma financial information includes adjustments to historical amounts including amortization of acquired intangible assets, depreciation of acquired property and equipment, interest expense for the financing of the transaction, alignment of NIA&#8217;s revenue recognition policy, and the associated income tax effects as if NIA had been included in the Company&#8217;s results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company&#8217;s historical financial information on a pro forma basis (in thousands).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#8217;s interim consolidated financial statements was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793020848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by end-market and product type:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $43.8 million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2023. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 69%, 92% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue, excluding customer discounts of $1.5&#160;million, recognized from performance obligations satisfied (or partially satisfied) in a previous period was $4.8&#160;million for the three months ended March 31, 2023, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $3.4 million and $3.9 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $0.3 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our revenue contracts, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $13.1 million and $18.1 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $2.0 million and $10.3 million for the three months ended March 31, 2023 and 2022, respectively.</span></div>These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793010304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2023. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, we did not record material changes in our allowances during the three months ended March 31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2023,&#160;70% were current, 23%&#160;were past due less than 60 days, with 26% past due less than 120 days and at December 31, 2022, 67% was current, 21% was past due less than 60 days, with 29% past due less than 120 days. As of&#160;March&#160;31, 2023 and December 31, 2022, in total we reported on the consolidated balance sheet&#160;$284.7 million&#160;and $269.1&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$15.1 million and $10.2 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIA acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-42<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 44<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-44<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796531760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $8.1 million and $6.4 million for the three months ended March 31, 2023 and 2022, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $75.1 million and $73.7 million as of March&#160;31, 2023 and December 31, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $8.1 million and $7.6 million for the three months ended March 31, 2023 and 2022, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.7 million for both the three months ended March 31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790036224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test of October 31, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceeded directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of NIA in January 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,694&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044,685&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,828&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $21.1 million and $7.5 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2023, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793038912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;IPG Closing Date&#8221;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, collateral agent and revolver agent (the &#8220;Existing Credit Agreement&#8221; and as modified by the Amendment (defined below), the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) initial term loans in an aggregate principal amount of $175.0&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) revolving credit commitments in an aggregate principal amount of $50.0&#160;million (the &#8220;Initial Revolving Facility&#8221;), the availability of which shall be determined by reference to the lesser of $50.0&#160;million and a borrowing base calculation. The Borrowers borrowed full amount under the Initial Term Loan Facility and the Initial Revolving Facility on the IPG Closing Date. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Initial Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Initial Revolving Facility was paid as of the IPG Closing Date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, (&#8220;the NIA Closing Date&#8221;), the Company entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) additional revolving commitments in an aggregate principal amount equal to $25.0&#160;million (the &#8220;Incremental Revolving Facility&#8221; and together with the Initial Revolving Facility, the Revolving Facility&#8221;), and (ii) additional term loans in an aggregate principal amount equal to $240.0&#160;million, (the &#8220;Incremental Term Loan Facility&#8221; and together with the Initial Term Loan Facility, the &#8220;Term Loan Facility&#8221;; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the &#8220;Credit Facilities&#8221;). The Borrowers borrowed the full amount under the Incremental Term Loan Facility and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) 3.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 3.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain customary exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain customary exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All loans under the Credit Facilities will mature on the date that is the earliest of (a) the sixth anniversary of the NIA Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate for the Loans is calculated, at the option of the Borrowers, (a) in the case of the Term Loan Facility, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of the Revolving Facility, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. The Company recorded $11.1&#160;million in interest expense related to our Credit Agreement for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facilities may be prepaid at the option of the Company, subject to the following prepayment premium (the &#8220;Prepayment Premium&#8221;): (1) 3.00% of the principal amount so prepaid after the NIA Closing Date but prior to the first anniversary of the NIA Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the NIA Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the NIA Closing Date but prior to the third anniversary of the NIA Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the NIA Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction, in each case, subject to application of the Prepayment Premium. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Loans. We incurred $14.4&#160;million of debt issuance costs in connection with the Loans, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the Credit Agreement. The Company recorded $0.5&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company repaid $37.5&#160;million under the Revolving Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $0.2 million, $1.0 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.2 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. The Company recorded interest expense of $0.6 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.3 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2023. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796541344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2023 and December&#160;31, 2022, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2023 and 2022, respectively. The letters of credit have current expiration dates between April 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying interim consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2023, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers. There were no expenses associated with the UPMC Reseller Agreement for the three months ended March 31, 2023, and $0.6&#160;million for the three months ended March 31, 2022. The contract is currently being wound down. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the NIA acquisition, the Company has recorded the remaining TRA liability of $66.2&#160;million for the three months ended March 31, 2023, resulting in a total TRA liability of $112.1 million as of March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2023, approximately 99.1% of our $192.0 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.9% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company has not experienced any realized losses on cash and cash equivalents to date; however, no assurances can be provided.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:357.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:86.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:86.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790036224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $2.1 million in letters of credit as of both March&#160;31, 2023 and December 31, 2022, respectively. As of March&#160;31, 2023 and December 31, 2022, the Company held $2.1 million and $2.3&#160;million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2023 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:65.238%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.380%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793038912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityDisclosureTextBlock', window );">Convertible Preferred Equity</a></td>
<td class="text">Convertible Preferred Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company&#8217;s newly created Cumulative Series A Preferred Shares, par value $0.01 (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of  $960.00 per share, resulting in total gross proceeds to the Company of $168.0&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#8217;s Class A common stock, par value $0.01 per share and all future series of the Company&#8217;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000.00 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#8217;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Change of Control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, the Company entered into an Investors Rights Agreement with the Purchasers named in Schedule I thereto (the &#8220;Investors Rights Agreement&#8221;). The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Investors Rights Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the NIA closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders named in Schedule I thereto, which granted certain registration rights to Ares in respect of the shares of the Company&#8217;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company paid dividends of $3.7&#160;million, or $20.86 per share of Series A Preferred Stock, and accreted $2.6&#160;million of deferred issuance costs in additional paid-in-capital on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796508032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793716880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,710&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796531760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An income tax provision (benefit) of $(68.2)&#160;million and $1.2&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively, which resulted in effective tax rates of 77.3% and (29.0)%, respectively. The income tax benefit recorded during the three months ended March 31, 2023, primarily relates to $56.1&#160;million for the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the NIA acquisition accounting and $8.3&#160;million for the TRA liabilities that will create current and future tax benefits upon settlement. The income tax expense recorded during the three months ended March 31, 2022, primarily related to state and foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, the Company had unrecognized tax benefits of $1.6&#160;million that, if recognized, would affect the overall effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above for discussion of our TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796514208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2023 and December&#160;31, 2022, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $0.4 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $4.8 million and $3.6 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796634560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions of NIA and IPG include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the NIA contingent consideration is the year ending December 31, 2023, and the earnout period for IPG is the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the NIA and IPG contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.80% - 16.64%</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.85% - 10.01%</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796543776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our interim consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796506032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 10.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:357.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,294)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(4)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(4)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796570304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659785516624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Restricted Investments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div>determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div>Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div>The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both March&#160;31, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2023, approximately 20% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Series A Senior Convertible Preferred Shares</a></td>
<td class="text">Series A Senior Convertible Preferred SharesIn accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company&#8217;s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div>In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659785503872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,694&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044,685&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,828&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791592672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Allocation of Purchase Price</a></td>
<td class="text">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired</a></td>
<td class="text">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Adjustments</a></td>
<td class="text">The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company&#8217;s historical financial information on a pro forma basis (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793625696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by end-market and product type:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796577600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Changes in Allowance for Accounts Receivable</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIA acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796559712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659797564016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of NIA in January 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,694&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044,685&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,828&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,857&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793038912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2023 and December 31, 2022 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796506032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:357.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:86.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:86.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793664096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Primary Office Leases and Maturity of Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of March&#160;31, 2023 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of March&#160;31, 2023, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:65.238%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.380%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790003200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791185952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:414.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,710&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-Based Awards Granted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791320320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets and Liabilities on Recurring Basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration Measured at Fair Value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Valuation Techniques and Significant Unobservable Inputs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.80% - 16.64%</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.85% - 10.01%</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796508032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796699552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Activity in Claims Reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:357.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,294)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796624800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:358.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659787277056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="nump">$ 157,519<span></span>
</td>
<td class="nump">$ 188,200<span></span>
</td>
<td class="nump">$ 210,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791270480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 34,451<span></span>
</td>
<td class="nump">$ 26,958<span></span>
</td>
<td class="nump">$ 52,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="nump">21,932<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="nump">21,932<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">12,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">12,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="nump">10,966<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 21,353<span></span>
</td>
<td class="nump">$ 13,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791583456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 157,519<span></span>
</td>
<td class="nump">$ 188,200<span></span>
</td>
<td class="nump">$ 210,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="nump">34,451<span></span>
</td>
<td class="nump">26,958<span></span>
</td>
<td class="nump">52,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 191,970<span></span>
</td>
<td class="nump">$ 215,158<span></span>
</td>
<td class="nump">$ 262,786<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659885564928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details) - option_to_renew_lease<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Accounts receivable netted against claims payable</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Accounts receivable, net eligible for net basis settlement</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791377088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786689408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,121,743<span></span>
</td>
<td class="nump">$ 859,417<span></span>
</td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="num">(626,136)<span></span>
</td>
<td class="num">(606,154)<span></span>
</td>
<td class="num">(592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,768,999<span></span>
</td>
<td class="nump">$ 1,486,857<span></span>
</td>
<td class="nump">$ 1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786382784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Transactions - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2023</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386,724,000<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Discrete tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,189,000<span></span>
</td>
<td class="num">(1,202,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,690,000<span></span>
</td>
<td class="nump">297,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,258,000)<span></span>
</td>
<td class="num">$ (5,350,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 715,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">387,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">261,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity', window );">Percentage of contingent consideration allowed to be paid in equity interest (up to)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Discrete tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Common Class A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,474,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Customer relationships</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Corporate trade name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 461,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Discrete tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Percentage Allowed To Be Paid In Equity Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659787049584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Allocation of Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2023</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386,724<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,117,945<span></span>
</td>
<td class="nump">$ 426,274<span></span>
</td>
<td class="nump">$ 722,774<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 387,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">261,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">715,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">28,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">28,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">5,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">6,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">100,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">112,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">395,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">715,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">345,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">50,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember', window );">NIA | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total identifiable intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659787343920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Pro Forma Information (Details) - NIA - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 446,740<span></span>
</td>
<td class="nump">$ 362,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="num">$ (15,730)<span></span>
</td>
<td class="num">$ (10,240)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesIncNIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790450320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 427,690<span></span>
</td>
<td class="nump">$ 297,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,690<span></span>
</td>
<td class="nump">297,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Performance Suite</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,873<span></span>
</td>
<td class="nump">171,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Specialty Technology and Services Suite</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65,316<span></span>
</td>
<td class="nump">13,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Administrative Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,067<span></span>
</td>
<td class="nump">106,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Cases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,434<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,034<span></span>
</td>
<td class="nump">130,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127,669<span></span>
</td>
<td class="nump">104,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services Segment | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 116,987<span></span>
</td>
<td class="nump">$ 62,157<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PerformanceSuiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PerformanceSuiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_SpecialtyTechnologyAndServicesSuiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_SpecialtyTechnologyAndServicesSuiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_AdministrativeServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_AdministrativeServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_CasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_CasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786140800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 43.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">21 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">33 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791355376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 261,875<span></span>
</td>
<td class="nump">$ 246,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">5,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="nump">8,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="num">(3,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">9,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CustomerDiscountsFromPerformanceObligations', window );">Revenue</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CustomerDiscountsFromPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer Discounts From Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CustomerDiscountsFromPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786142288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 2,290<span></span>
</td>
<td class="nump">$ 11,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">18,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -SubTopic 40<br> -Topic 340<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659787240944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 284,700<span></span>
</td>
<td class="nump">$ 269,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 15,073<span></span>
</td>
<td class="nump">$ 10,180<span></span>
</td>
<td class="nump">$ 2,171<span></span>
</td>
<td class="nump">$ 3,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790877072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (10,180)<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod', window );">NIA acquisition</a></td>
<td class="num">(240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(5,482)<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Charge-offs</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">$ (15,073)<span></span>
</td>
<td class="num">$ (2,171)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Acquired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791283936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 247,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(158,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,477)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">88,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Net capitalized internal-use software development costs</a></td>
<td class="nump">75,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">197,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 15,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -SubTopic 20<br> -Topic 985<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793924864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774826000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 722,774<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">395,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">$ 1,117,945<span></span>
</td>
<td class="nump">$ 426,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791492688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,044,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">218,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">825,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 21,100<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 51,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">16,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 34,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">15 years 2 months 12 days<span></span>
</td>
<td class="text">15 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 810,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">103,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 706,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 162,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">83,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 78,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 18,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">12,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 5,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786943520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 69,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">87,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">63,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">63,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">60,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">480,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 825,857<span></span>
</td>
<td class="nump">$ 442,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791762976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2022 Credit Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2023 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,330<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of the debt discount and the issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentClosingFeePercent', window );">Closing fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentClosingFeePercent', window );">Closing fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | 2022 Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repaid under the revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember', window );">2022 Credit Facilities | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent', window );">Prepayment penalty prior to first anniversary of closing date (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent', window );">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent', window );">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent', window );">Prepayment penalty on or after third anniversary of closing date (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentClosingFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentClosingFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Four, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period One, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Three, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Two, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659784715472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121,743<span></span>
</td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="nump">$ 859,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,999<span></span>
</td>
<td class="nump">1,224,250<span></span>
</td>
<td class="nump">1,486,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,172)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,136)<span></span>
</td>
<td class="num">(592,340)<span></span>
</td>
<td class="num">(606,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100<span></span>
</td>
<td class="nump">24,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Class A Common Stock | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion issued (in share) | shares</a></td>
<td class="nump">5,394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659777121888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121,743,000<span></span>
</td>
<td class="nump">$ 611,209,000<span></span>
</td>
<td class="nump">$ 859,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911,000<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="nump">916,000<span></span>
</td>
<td class="nump">1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,999,000<span></span>
</td>
<td class="nump">1,224,250,000<span></span>
</td>
<td class="nump">1,486,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,172,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,136,000)<span></span>
</td>
<td class="num">(592,340,000)<span></span>
</td>
<td class="num">(606,154,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Class A Common Stock | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659778321808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details) - Senior Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">$ 92,800<span></span>
</td>
<td class="nump">84,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100<span></span>
</td>
<td class="nump">$ 24,281<span></span>
</td>
<td class="nump">$ 24,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659785456688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">$ 23,971,000<span></span>
</td>
<td class="nump">$ 23,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">169,205,000<span></span>
</td>
<td class="nump">168,885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">3,295,000<span></span>
</td>
<td class="nump">3,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 192,605,000<span></span>
</td>
<td class="nump">$ 185,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659789898592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod', window );">Automatic extension period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension', window );">Automatic extension after each period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid', window );">Percent of tax savings to be paid</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Recognition of remaining TRA liability</a></td>
<td class="nump">$ 66,184<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="nump">$ 112,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember', window );">UPMC Reseller Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfCustomers', window );">Number of customers | customer</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Automatic Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityAutomaticExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Period Before Each Automatic Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659784167072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Credit and Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="nump">99.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="nump">$ 191,970<span></span>
</td>
<td class="nump">$ 262,786<span></span>
</td>
<td class="nump">$ 215,158<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">34.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">23.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">17.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember', window );">Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793764976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>option_to_renew_lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option | option_to_renew_lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659791477968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 75,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 28,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 37,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_GA', window );">Alpharetta, GA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 4,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774838080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 2,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,496<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786286032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 5,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">10,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">10,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">8,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">8,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LesseeOperatingLeaseLiabilityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">31,692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">75,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">16,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 58,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LesseeOperatingLeaseLiabilityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LesseeOperatingLeaseLiabilityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659796570304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659787009152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Equity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Aggregate shares of preferred stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred class A common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Class A common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Aggregate shares of preferred stock sold (in shares)</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred class A common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 960.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of temporary equity</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate', window );">Annual increase in dividend rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityConvertibleConversionPrice', window );">Conversion price (in dollar per share)</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityDividendRatePerDollarAmount', window );">Dividends paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityAccretionToRedemptionValueAndDividends', window );">Accretion of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Called by company on or after January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Called by holder on or after January 20, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Refinancing or replacement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Change of control prior to January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Change of control after January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TemporaryEquityVariableDividendRateBasisSpread', window );">Quarterly dividend rate, basis spread on variable rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Class A common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityAccretionToRedemptionValueAndDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Accretion To Redemption Value And Dividends</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityAccretionToRedemptionValueAndDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Convertible, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Per-Dollar-Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Percentage, Annual Increase In Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Redemption Price Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityVariableDividendRateBasisSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Variable Dividend Rate, Basis Spread</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityVariableDividendRateBasisSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TemporaryEquityRedemptionPeriodAxis=evh_TemporaryEquityRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793319152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</a></td>
<td class="num">$ (26,258)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="num">$ (26,258)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">107,783<span></span>
</td>
<td class="nump">89,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">107,783<span></span>
</td>
<td class="nump">89,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774790720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">13,746<span></span>
</td>
<td class="nump">15,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">11,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659784156528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">$ 10,710<span></span>
</td>
<td class="nump">$ 5,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">9,170<span></span>
</td>
<td class="nump">4,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">7,489<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation expense by financial statement line item</a></td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659797353872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793708224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">996<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793336752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (68,189)<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">77.30%<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance</a></td>
<td class="nump">$ 56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivablesAgreementTaxExpenseBenefit', window );">Tax expense (benefit) from TRA</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders', window );">Amount of tax benefit percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659786962096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement', window );">Revenue related to services agreements</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774819120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 122,100<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">122,100<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">122,100<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 122,100<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774909280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">69,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">$ (29,961)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Unrealized (gain) loss, net</a></td>
<td class="text">Unrealized (gain) loss, net<span></span>
</td>
<td class="text">Unrealized (gain) loss, net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss, net</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 122,100<span></span>
</td>
<td class="nump">$ 32,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659774790368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 122,100<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 122,100<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">122,100<span></span>
</td>
<td class="nump">77,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">0.0880<span></span>
</td>
<td class="nump">0.0985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">0.1664<span></span>
</td>
<td class="nump">0.1001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793373920">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 262,764<span></span>
</td>
<td class="nump">$ 254,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,012<span></span>
</td>
<td class="nump">57,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">170,236<span></span>
</td>
<td class="nump">111,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,360<span></span>
</td>
<td class="nump">8,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659790468016">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 89,726<span></span>
</td>
<td class="nump">$ 58,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,721<span></span>
</td>
<td class="nump">32,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,506<span></span>
</td>
<td class="nump">26,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659793349264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">$ 199,730<span></span>
</td>
<td class="nump">$ 171,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">180,675<span></span>
</td>
<td class="nump">102,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(19,914)<span></span>
</td>
<td class="nump">6,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="nump">160,761<span></span>
</td>
<td class="nump">109,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="num">(64,870)<span></span>
</td>
<td class="num">(47,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(98,424)<span></span>
</td>
<td class="num">(59,491)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(163,294)<span></span>
</td>
<td class="num">(107,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,016)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">$ 197,197<span></span>
</td>
<td class="nump">$ 164,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659789687760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Class A common stock issued in connection with business combinations</a></td>
<td class="nump">261,271<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Accrued net working capital adjustment with business combinations</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="num">$ (3,076)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140659794282848">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>evh-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:evh="http://www.evolenthealth.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20230331.xsd" xlink:type="simple"/>
    <context id="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30be4b84e14a44928fadafc458cb5341_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i586e945bd60d49af85c5c42ff6511bc0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iedeac599ed134eeeb0c936f4c013dbc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86218da0e0884c94a088b193ed670843_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4c7d4e62a4284394a63ec249572a7d1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0713ced519f3403194ba9f05d0b0292e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib743093d4bbc48e3a439e1657b566d11_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe93d2e31b3b4fa88abc8e17ae008f01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5cd6129ee464be1b32499eefeff761d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieeeef40ff57344688c2de84656eb453b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9533fd157f36404db99df73e24250f17_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f39e0c2d9fa407cbb8bd38448014469_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide84d54410104b30956cb7ff55186ac5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifa70195a0a874033a738fa36233fea32_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie506ce36e15348bc8daa8c1498a654d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i77787921202e4fd4a18e90bf6cb87279_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d8b41829710445a8d0f8c5817b4ec7e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ed1265962b049e19122f05090afc707_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd5eb55aee214a3a80aef01f773385a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia51a9c1f2e96457cb583435784fd8052_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df13d90a8c0400c9b19908332b563d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8683bc3116734882a3a6f338a1014c96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cc2dc21792b4a4bae4ba077682310b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i206feaffcac24ac0925bec2bf51079f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bba17d40adb43fc9d9eb09ba5b09080_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id08d9338b291434896695b0967309848_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74fbb53f36da458fbc7b7873ed9c53ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6afd820b04d04b58818736afa910bd99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecea63a0c33d40c59386cb36be688e7e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i62b76dfd95d14dbc9e21923faf1da208_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icaa8e880df0f4903b24f864bf0775ff3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib4a91ec36aed4015a6db0d978ab3355d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65a846169eb64941a21068690d52a346_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7b1c9f37d4a9429f851ebf21526dc518_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1b74bdff81224fc68d9ffbc419dfee68_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i233880303bb34668b01e60bdc5f1cdd7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i34ce76b48a87457b99e7d1769a5aba81_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16f69dd7282741df87449317463405fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3122c5fc961042ceb6802f6a1d99fef9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i439908fc7be2410386d5bb54ff500846_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ac3cc30824142c3b94108b50b60df21_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia73d5d21a1a04f84babd13954429d25b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa977c28de4e47168b48e484eaede4c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ceb4458b7dc4a2dabf10c867a9c1a99_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f2401b901664f83854b39254d8aae8d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06dde47fa30d4c54b76fc7b207080d9b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6712e972d4564a6a96307887c4567b00_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idec6af2602a74fb0a0b69b149b991a9a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice9ce60f6fab4cdfb829f791deb4e1a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id8cbaa74b6e54164941327e9684444ae_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i1713ff2a1e2e4416a51a05040c0a1b30_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i08db4cba39da4c2daa8e8a98eec10995_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ib604663c86e447178b86e5bd16de84b7_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i3eb9822d76ab401a9b48a8fac6ca541c_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ib409c87cf89b4073a5635cf8c0a310ba_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="iaba5e6a382114572af38a8d1b8953795_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="id25b028edfec49c187b6bb9961ecf387_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i491e48a182e442f98c17a235d12252d7_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i2d9c4ff54b524745a88b135d86bd443b_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i1373bcac7934429293088da96849175b_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i57b6d6c6c553400a9d75350d6fa61da5_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i91831d375a0845e7aa4af31f7b290c36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesIncNIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6cc900864834868948a404393a49a85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i38d6a8162061452483f3aa24db4d62d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6176d6981ea4c9b8d17bb71206e1cc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6cb36bbcf076422798e36c705ca489a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c51d30ca110417b9bc57ef158154a94_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia60e2d87246f4a24b6e2e5c72158629a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if783561a665d46e194893a76d25beb3e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PerformanceSuiteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic6ca0c0c1968494bbc67b02a9e28ff5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PerformanceSuiteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifef28bce40ea4047a5a04db3de0aadf1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:SpecialtyTechnologyAndServicesSuiteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i129cce29425045eabdab581851009e0e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:SpecialtyTechnologyAndServicesSuiteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb47dcc6439a43fa8d4c19f2122b859a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88f9f6fc9bd44f3fb6b41939fb533aca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4772da6b737d416fa93667acc7bec0e6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:CasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8a9c31ea4be40439865dcd7dc02302f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:CasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97d627a444fd4d149f0df76b556dd94e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i466c6c1cbb854e8f935205d90d504b4c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1142e9b4f22b41bb9861d40caedc8272_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i409e1ed35fec45debbcfcdca8b668bc1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie26be0edc14d47eb99b84495e133ece4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70b0d3db141e42d9ba27945974ed98be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib92fd7517b7e45d8a3a28cf15450d165_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a5199740c894c7990588a57d16a827c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib4d813436fe64f6cb913aa801cecded5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia8bfa3c9233e49a3885fdb8cd2d590db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic21943cdf8a049d2a24adf36d3b79cd8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70f46329635e4437b8068a2610a354f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i15da874ddc524d2285a2fb1df7a7623c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if821daf7eb8c4bf3bcdc0fd5e08f4ed1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3c753595d7f449f9388ce080153adee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ab74d6cb3834527b8ae1fc110c1c9b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i896c0f919a744ccdab15d963fb3c518e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i909942c4cbc94b759e839fa9b4480c52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54563c905b50494cbe32a703a93fd3fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie224ebe8d58d426cbf7c6760029adacd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1064fdf19264fd6929844695005b91d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d5928ba2c6c467daaf522ca8262ec8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3065bc9a90f4c3593d40da7cd173ea0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib551ddbba6244ae19cb603ed8c3a6e65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ide3f10e694c940868bd2594ab2017b6a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i45f15675963148d9b7c73a2c1b0ef222_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6de16ded6120471a80302f91bbee7b2a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i288455705c274ce2a2bd943c0f0704a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f561ad00b584a20ab6ac5a564705e71_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibde355312eba4648bb0122ec21bd976e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i67bf39ef96634f3193ea5f32553d096d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i868a181629a048b69538d93b32b52ff9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8fae892598234158a4ae8ce37c46d1cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i52491c9a83874a978dbed3b6892d4798_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56fee09db1334b68b2b6dbd706c21116_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie99257a4824a4d16997f882b92ea6a96_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i85b523dd4c194164ab39eb63ab1206c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i30b51a2db0824da5929aaac343723403_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia53c692cc90544f49ce6bab9b750a5d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e47ddf7af144c3bb65fd8dfd91cd016_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08da2b7f0d10418aab0845f0fb542546_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f1b4ec02a7342fcb85559bcc229e583_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i2b7598f678494d1aab584ad521987519_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i8ff112cad23c4514bbfbb8c0655c94d0_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="ica07830c52aa4ce3a36a9196d7fd69c8_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="id3f428993e84490da09219c15b871fd2_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i89ea6a7579f0498aaad68c4136be1a8e_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ie61f8c08dc6542cab575508067f47573_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="if0d005b9b6f94895a2093108ec4023c1_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ic49c939410944f6892ee284ba7b362a4_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i6af1d7c94ffa4dfdb1daac49c0bdcc06_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="iee0ccfb937d04787b9a2edcb589528a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idee11c2ef7d44c05b143e3c697bfe00b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i86c90a6284344462a51488ae0069e122_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ie251d99bd74345e1bc9460f66244b376_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i657a6cf3c44d4a4082d16bcf0b007b3e_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i6b77390117574b05b6853a2e6cdfd5a0_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5e0dbffb9cb44a82b9230fee7cbb2e8e_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="id09a99b6604145a39f0c6f2102806ba5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7820004852704049885c737ed680c6c8_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ib6487f01387746f0ba7463b6968f241d_D20220811-20220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="i97ba4e8ae10c4f378bae69514e2fe2bd_D20220817-20220818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="i4b149b5c258542fb966a78ac8c73abec_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i8dba2151c89f438db4f1b097c4343947_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i8b58c2da78614c1f968d97ed45d71235_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i7659a2a5a47648a180caf848566c901e_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="ic12584d85379426290b0c22a08b05259_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab32404962a644bdabfcb08801f645a6_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i512e2046bfad40b18b8f73ffbb1a4ded_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i2be0a365f4f7429497792fd03ebd83c0_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7719930d21144dfb90251ca3af9cdb73_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i4eb00e88f2384aedbcc301007edfb9e1_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16491b7341a141c18afc36d401c76145_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5726574012447b8981b087a4fceaa8e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32d2ca0bd32c485ab1c987f756ff7c04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9845ada53344e68b0860c3e9255db86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b0e4886fee54c19a088f62ee322a948_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9416432cd74f4712b91100ee7fbc1c94_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie3eb67937fde4b28be9e30e00861878f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62777b414fb44723a0c931431d49303e_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4308b13d2bc640e69e002f890872da68_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i27fb4a8e6dd3437b85cca6d4d9569ea7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id016a79790b94258b28de85b550d8edd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i507b0865bc8146928bbcd305853a7801_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e2a5beda11b47868eb4cef319a84fbf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic0b19710891c484c82d272a4acf72ba5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice83adaf23a14ba0a5a83118b1a20fdb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i637797ac467b47efa165f840c0332476_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25f7148e093b474dadb164557530b7b8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7ae61262e7624b0d984871d542365619_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12b6b23d17104a8e9b6c457000fbeea2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7c0832ebff07400ea476f7c58f11cc67_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie192bdf6ff324e978b378295e4252596_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f62d774a64e46899704a37239c377c3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib29e30cc2b08429d885dd5e19d4d420c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i34fc6c7947c34d74ac1f466cf78dbd92_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i23c68de8493844868847bcbb42b75777_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2494b7c3cda44bcb468b99115c25994_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d1d9ed997744f43b91313620e282985_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8f75598fe1bf467ca300361df6965225_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id3a9b81f7de640bfa0d4e787de30fe38_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idab7706671c44c04b395a1bb53394e0c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib88940471cab4b9f9504ec2ef053bed2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i847f8c6b7dfb43bf822806907fa80330_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i1dfbe078bc7f430697d2a7b1b12e6204_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i401ab859effb48808de07f4a1e3c6d16_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i2add3c8d25f94736a9517cf9293a956c_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i9cca87e30358452e84669a73df40af76_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i87668a6ea647431c972d8f8fa361cf97_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="ie14b7cf7aca4447892720b9d169358bf_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="id704c5c418084a8387e935db5922f100_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:TemporaryEquityRedemptionPeriodAxis">evh:TemporaryEquityRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2eba541d136f4310a4704831029d9705_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i492d89de66e04f9b8c3db6a93fd81175_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i476893462fa74bf58564ab53bd877692_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83e4b979a9e74d449368aa622d2794fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a52a2247ce344d0bbdf4224e23b18a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iede7c70b83d54696aa5c016fe07b1c1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddcae13946194fcaa1af1a86f752c869_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib5af55fd09f6415f8a087fe94b7ac65b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c894fc3e14c4be68a1ebd94daafd420_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6eb4a2f5fe174475b5ce81a76c55e2b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if96c354afa0c4e3c9db694479ca3a37d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d69bebdcc784d5d883a6d0f4540fe50_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id70cae9e2b7d4e58b25f32a9c3d73a3b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e6a4f64f12d41fc8e3d1bdb59b392cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie33450827a3f4e9d919295348407f1bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c41447859d3478b9bf4c5cd97653cc5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0b9a2f209add49c28eaca381d3e00ea3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d01f3131ee44567b61845961fc57356_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b079f58e6d143e9bf0218c70cddb93a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib02f997833034f13959b8d48cf3f413b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0bafc71fd6ff4258ba1f07d59a2d2c26_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a6d740e3f65457ab486cd579e644ba8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4c3f6529d1a407f9fb18c47de384547_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie128286c0dfa444dbd95773bf5ec6363_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7ec04c66a434196a47081e73befb4d0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2d66187bddab45d98d6021e00200a254_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0025cd927a74c64b32ed1f84552d804_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98252e4304374eba80127e9339ac00ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15f37596d3fb4fd0b55345096a8d3ec5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ea91b69217d4414bf3a0c1862b782c2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iefbfa8e87ea74767877c1bcb1ba75e70_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7838e8cce0d84e3c96376f68234721cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb07d39ed99e4b5493f3f1a76480c9b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i424e2672ed5c47d6a7f0e6908df8f4fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i110024d501a54ed99a65ed852a158dd2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i95e0bc79b1d147a88d91c60dc1a05426_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i35963def0f354878a0aee255acad57ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="option_to_renew_lease">
        <measure>evh:option_to_renew_lease</measure>
    </unit>
    <unit id="day">
        <measure>evh:day</measure>
    </unit>
    <unit id="customer">
        <measure>evh:customer</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8xLTEtMS0xLTEwMTQyMA_4aa6ccd3-4cdd-4df8-b364-353bb9b0b76f">0001628908</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8yLTEtMS0xLTEwNzQ0Ng_2775e8b3-6e50-4e38-af89-35bbf58ad361">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8yLTEtMS0xLTEwMTQyMA_f1feabee-cc6f-457a-a508-6d8159b95e54">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV8zLTEtMS0xLTEwMTQyMA_c6119b32-91e0-4ff0-8cc8-39e469382477">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl80L2ZyYWc6M2QwZDNjMDcxM2E4NGU2ZmFiYmU1MzVjM2ExMzIyNjAvdGFibGU6NjNkOGJmNmQxNmVlNDY3ZmFiOTYyYjNmNTRjZGIxMjUvdGFibGVyYW5nZTo2M2Q4YmY2ZDE2ZWU0NjdmYWI5NjJiM2Y1NGNkYjEyNV80LTEtMS0xLTEwMTQyMA_e035653e-2a15-42bd-9269-018553d508a9">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i0bba17d40adb43fc9d9eb09ba5b09080_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTAtMS0xLTEwNjk3MA_f4913bfc-ffb4-4cb0-b941-e38394874176">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i97d627a444fd4d149f0df76b556dd94e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzItMS0xLTEtMTAxNDIw_efb0c71a-3abf-47e9-8532-0a475b3d4d85">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i466c6c1cbb854e8f935205d90d504b4c_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzMtMS0xLTEtMTAxNDIw_c79faa51-51a4-4350-aa22-908bfc3bf078">P21M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzMvZnJhZzo3NTg5MGM5NGVhNzA0MDk4ODY3NmNkZTZjNjI4ZWIyYi90YWJsZTozM2EzNzVmNzFhNmM0ZTkyODZlYjIwNDY0OTU4NmNjZi90YWJsZXJhbmdlOjMzYTM3NWY3MWE2YzRlOTI4NmViMjA0NjQ5NTg2Y2NmXzQtMS0xLTEtMTAxNDIw_fa3f1929-a900-4734-8564-15b587afb36e">P33M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i62777b414fb44723a0c931431d49303e_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDgvZnJhZzowZjQyMTRmMTZlODg0MGM1OGY2YWFkMTFmNzE5NmRhOS90ZXh0cmVnaW9uOjBmNDIxNGYxNmU4ODQwYzU4ZjZhYWQxMWY3MTk2ZGE5XzU_c8f90868-fbd9-4079-ae0f-6eafc18c6e24"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4308b13d2bc640e69e002f890872da68_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDgvZnJhZzowZjQyMTRmMTZlODg0MGM1OGY2YWFkMTFmNzE5NmRhOS90ZXh0cmVnaW9uOjBmNDIxNGYxNmU4ODQwYzU4ZjZhYWQxMWY3MTk2ZGE5XzIxNQ_e313e442-aea7-4012-8dd2-892631925b22"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTE_cd4859f7-ed66-47be-a792-a205cc2a3ed3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTI_30f04c27-03ca-4987-b342-4759e9daf3ef">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIwNw_20d0baa4-168e-43c8-88ef-d260550ec54c">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIxNw_489544d9-7cbd-4837-a6c7-20332b5294b5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzM5OQ_60d59b00-7f9d-4b38-8b34-0781eed76217">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzQyOQ_e7990506-02d8-4c94-a1e8-16f9cee7710d">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzAtMS0xLTEtMTAxNDIw_b939b6e8-2732-479b-a03a-d385a57438bd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzAtOS0xLTEtMTAxNDIw_0d28eddd-a66e-40f2-a291-4699a4e0f109">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtMS0xLTEtMTAxNDIw_8be8640e-a9ae-4d1f-b737-7016377e17b3">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtMy0xLTEtMTAxNDIw_d57e1f25-104f-43ba-a24d-6e929e02d94e">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtNS0xLTEtMTAxNDIw_237bf411-9802-42fa-a6fc-78e2058d7a5a">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtNy0xLTEtMTAxNDIw_c147f930-ad71-45e4-8e9f-da3739c3150b">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZToyODkwY2Y5YWUzZWQ0Y2MwOGM0ZDRhZTNlODE3MTZhZS90YWJsZXJhbmdlOjI4OTBjZjlhZTNlZDRjYzA4YzRkNGFlM2U4MTcxNmFlXzMtOS0xLTEtMTAxNDIw_adde4619-2509-4886-89cc-c6d8e646e899">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzUzNw_7e6dc651-a78b-481e-96f1-a33a1a14df23">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzU0MQ_f09a8210-bc55-41d7-a67b-3923fe2e5200">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMC0xLTEtMTAxNDIw_5d09370e-eb01-488e-8337-6efbc3c2e883">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMS0xLTEtMTAxNDIw_e157f83e-ff42-46bc-87f4-a145738716a5">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90YWJsZTpmMDdhZTllMTkwMDE0YTE1ODlkY2MyNjVlZDBiMTIyYi90YWJsZXJhbmdlOmYwN2FlOWUxOTAwMTRhMTU4OWRjYzI2NWVkMGIxMjJiXzEtMi0xLTEtMTAxNDIw_6bd3c7af-a0c3-49c4-88fd-db75a03f6b51">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzEwNDI_2023c11f-a070-4ee5-ba24-df6049de6e8c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzEzNjQ_728cad44-8721-44f2-ae88-526b0c49eea4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzE3MzE_0081dff4-3a5a-49c1-802a-a8458c9350fa">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzE4MTI_d38cf7e0-292e-4965-b172-62dc4091cdba">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTM_077b966a-bcaf-4c11-80c4-a7bf415a1f11">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIzMTQ_11b69c76-4437-4739-b896-a64f914d39b4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i30be4b84e14a44928fadafc458cb5341_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDQvZnJhZzo4ZTAwNGM1NTVjYzc0OWMxYjVjZjJlMWY5NmJmYWY5OC90ZXh0cmVnaW9uOjhlMDA0YzU1NWNjNzQ5YzFiNWNmMmUxZjk2YmZhZjk4XzIyNDg_f1f7dc4f-8a8a-4f2b-bac2-6456d39c207b"
      unitRef="shares">112667704</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzUtMS0xLTEtMTAxNDIw_0ae58ee1-6b72-43bf-bb57-cb6077c9ad01"
      unitRef="usd">157519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzUtMy0xLTEtMTAxNDIw_31f62249-1361-4dc5-9031-2db27b147a67"
      unitRef="usd">188200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzYtMS0xLTEtMTAxNDIw_af66dfc8-2974-4afa-9afb-6b8d47da6ed7"
      unitRef="usd">21932000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzYtMy0xLTEtMTAxNDIw_cd328295-5c41-4b57-b413-fc9d02a4a55b"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff"
      unitRef="usd">262764000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5"
      unitRef="usd">254684000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe"
      unitRef="usd">33757000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e"
      unitRef="usd">20678000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzktMS0xLTEtMTAxNDIw_98be3407-ae4b-45ac-8609-446efdc821c2"
      unitRef="usd">475972000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzktMy0xLTEtMTAxNDIw_961be97d-765c-4ea5-acd6-cd9e9f9736c9"
      unitRef="usd">478054000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEwLTEtMS0xLTEwMTQyMA_230fc0ee-ab57-40d7-b85a-f89c80b60830"
      unitRef="usd">12519000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEwLTMtMS0xLTEwMTQyMA_c492834c-828b-47c1-8b4a-f7d47a6e27a3"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzExLTEtMS0xLTEwMTQyMA_6ea25023-6106-45bc-a5d6-e144847438c3"
      unitRef="usd">4112000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzExLTMtMS0xLTEwMTQyMA_a71472fc-c36c-4358-899c-6e8779477f33"
      unitRef="usd">4475000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEyLTEtMS0xLTEwMTQyMA_f1cd89b2-1158-4a80-b1b1-565281b750ea"
      unitRef="usd">88606000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEyLTMtMS0xLTEwMTQyMA_0d52ebad-7a37-4c5f-ac78-30abd8ba7cbb"
      unitRef="usd">87874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEzLTEtMS0xLTEwMTQyMA_eb89e978-4ee6-4172-a697-9ff21388b91d"
      unitRef="usd">44408000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzEzLTMtMS0xLTEwMTQyMA_33de2af0-923b-4b32-97d5-e17a595c8a45"
      unitRef="usd">49027000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865"
      unitRef="usd">3543000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467"
      unitRef="usd">2378000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE1LTEtMS0xLTEwMTQyMA_22b748da-f149-4d0c-be0a-93f96d7ac243"
      unitRef="usd">16497000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE1LTMtMS0xLTEwMTQyMA_b76f7b27-b313-44f5-b213-150cc0bbd9b9"
      unitRef="usd">17461000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE2LTEtMS0xLTEwMTQyMA_041f315a-260d-4f12-b15c-a6fe24e6a9ae"
      unitRef="usd">825857000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE2LTMtMS0xLTEwMTQyMA_2e474981-a43b-48c4-8924-93ef542ead86"
      unitRef="usd">442784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE3LTEtMS0xLTEwMTQyMA_62363328-560e-4766-99b4-421e62027951"
      unitRef="usd">1117945000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE3LTMtMS0xLTEwMTQyMA_55bf6452-cef8-4390-91ae-983f7f36a872"
      unitRef="usd">722774000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE4LTEtMS0xLTEwMTQyMA_4b59a892-6fcb-4f12-a29c-70a118eb492b"
      unitRef="usd">2589459000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE4LTMtMS0xLTEwMTQyMA_87f5e741-8877-4109-bc25-76a36fe276a0"
      unitRef="usd">1817293000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754"
      unitRef="usd">51012000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264"
      unitRef="usd">57174000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002"
      unitRef="usd">170236000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f"
      unitRef="usd">111198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI0LTEtMS0xLTEwMTQyMA_53f04736-43fd-4492-9d05-f8cdb09d4f94"
      unitRef="usd">4608000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI0LTMtMS0xLTEwMTQyMA_bb74c89b-6e32-4aac-a991-e7af2c325c4d"
      unitRef="usd">7122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI1LTEtMS0xLTEwMTQyMA_f425a488-7acf-4733-ac74-d843d7eecc25"
      unitRef="usd">27527000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI1LTMtMS0xLTEwMTQyMA_8630d4a2-a1b2-420c-b23a-780cda6ff613"
      unitRef="usd">52460000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI2LTEtMS0xLTEwMTQyMA_30025483-9966-472a-8819-d4ef91ae48ed"
      unitRef="usd">7069000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI2LTMtMS0xLTEwMTQyMA_e441030b-5021-4440-8aa7-1f05ac68d7b1"
      unitRef="usd">5758000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600"
      unitRef="usd">197197000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91"
      unitRef="usd">199730000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI4LTEtMS0xLTEwMTQyMA_99536093-dcf1-4d34-a2ba-4c873f26ec4b"
      unitRef="usd">457649000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI4LTMtMS0xLTEwMTQyMA_ce1922ea-4bfd-4231-8cde-93b4a4a1786c"
      unitRef="usd">433442000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI5LTEtMS0xLTEwMTQyMA_f1d84a97-24fc-406d-acfe-4fb056aea6d4"
      unitRef="usd">632277000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI5LTMtMS0xLTEwMTQyMA_6432778d-84a2-4c97-b11a-7a93085b5cc4"
      unitRef="usd">412986000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMwLTEtMS0xLTEwMTQyMA_0dc48a0d-6014-4f60-b030-466d47c189ce"
      unitRef="usd">4473000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMwLTMtMS0xLTEwMTQyMA_7033a92d-948d-48ac-9703-8ccc78c61f77"
      unitRef="usd">4744000</us-gaap:OtherLiabilitiesNoncurrent>
    <evh:TaxReceivableAgreementLiability
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMxLTEtMS0xLTEwMTQyMA_fa020a0f-8931-4e56-ba81-732f54bbd356"
      unitRef="usd">112134000</evh:TaxReceivableAgreementLiability>
    <evh:TaxReceivableAgreementLiability
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMxLTMtMS0xLTEwMTQyMA_f7dd4e7f-677f-48aa-b546-930f090f0326"
      unitRef="usd">45950000</evh:TaxReceivableAgreementLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMyLTEtMS0xLTEwMTQyMA_e425345b-20b2-4221-bf62-6c730d11c7ce"
      unitRef="usd">54274000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMyLTMtMS0xLTEwMTQyMA_7d5222a7-5692-481f-b4d0-6785f1a3ed69"
      unitRef="usd">56010000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMzLTEtMS0xLTEwMTQyMA_b0a28e0a-ca56-4b42-bf9d-4d75dfb0e266"
      unitRef="usd">36284000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzMzLTMtMS0xLTEwMTQyMA_63b93043-f49e-4325-a0a2-442391f185ed"
      unitRef="usd">4744000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM0LTEtMS0xLTEwMTQyMA_4d7d5cba-77e6-4043-b631-c51395630542"
      unitRef="usd">1297091000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM0LTMtMS0xLTEwMTQyMA_7b369364-9411-4182-9e67-45aeb765005c"
      unitRef="usd">957876000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM1LTEtMS0xLTEwMTQyMA_4ac6b262-9e2d-4020-b4c2-476c9402d1f3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM1LTMtMS0xLTEwMTQyMA_17e12b39-3f58-413e-859f-6235d231db12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4Mjk_f7173833-0de5-4d17-bd8d-8d3d39ac4a6a"
      unitRef="usdPerShare">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4MDA_270d7661-68d3-4e22-a053-bd8fb492eaba"
      unitRef="shares">50000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTAtMS0xLTEwODM0Mi90ZXh0cmVnaW9uOjZhNGZkNDMzZTgzMDQ1MzRiMDEwYTRiYzhkZjc2NTdkXzE2NDkyNjc0NDE4MTA_095d19b6-824c-451b-8b52-54b3702d969f"
      unitRef="shares">175000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTEtMS0xLTEwODUwNQ_0582c30c-236a-4c76-bace-de9d269b68dd"
      unitRef="usd">170625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTMtMS0xLTEwODUwNQ_ccf32bf9-e41c-40b1-9b8c-510cdd842232"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzI3_3b9988a2-7d78-4680-a3df-0d684acb9353"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzI3_493b153d-2fbf-4649-b062-7bb768f7d7f5"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzQx_d60955c5-1224-4a0a-b475-77a90465e1ae"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzQx_f85ff951-2257-440d-9445-06247304817c"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0XzYz_e9553c9e-7e63-4434-a4b7-3931d698850e"
      unitRef="shares">112552160</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmVhZTVlYWE2YmMyMjRiNDFiNzA0NjY3ZTVjNGQ5MGI0Xzcw_a86bd5a9-96a0-42e5-a263-d41e9ca7d3e0"
      unitRef="shares">101500558</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTEtMS0xLTEwMTQyMA_06e1e8cd-4281-45bd-9859-a1bd15cbd2e8"
      unitRef="usd">1125000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM3LTMtMS0xLTEwMTQyMA_e31caeb1-4005-41ed-9a65-0138c43bd0cd"
      unitRef="usd">1015000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTEtMS0xLTEwMTQyMA_72e3cc23-38d5-4aa6-8bef-61261b5a777c"
      unitRef="usd">1768999000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM4LTMtMS0xLTEwMTQyMA_c1b0496d-bdba-438b-8206-7779b4f4886c"
      unitRef="usd">1486857000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTEtMS0xLTEwMTQyMA_3c2eed9b-e179-4b0e-b255-365842b2437b"
      unitRef="usd">-1122000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzM5LTMtMS0xLTEwMTQyMA_2282cef7-cba5-4984-9a7b-b3e0a3bda2a9"
      unitRef="usd">-1178000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQwLTEtMS0xLTEwMTQyMA_960cc93d-0c4d-4018-be3a-99a8d8148487"
      unitRef="usd">-626136000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQwLTMtMS0xLTEwMTQyMA_2d9ad05e-1191-4193-a030-28c0bbe46361"
      unitRef="usd">-606154000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmJmZmNhM2RiOWZiMDQ4YzQ4YTc1MzIyMzg5N2UxNmZlXzI5_95e5de47-7cc9-49ee-afec-1675dee2ca55"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTAtMS0xLTEwMTQyMC90ZXh0cmVnaW9uOmJmZmNhM2RiOWZiMDQ4YzQ4YTc1MzIyMzg5N2UxNmZlXzI5_fc0a7f5e-4f9e-4331-a73e-9683e7b08cee"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTEtMS0xLTEwMTQyMA_5e0443cd-7167-4c1c-8c2e-08a2da2bb500"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQxLTMtMS0xLTEwMTQyMA_5437340a-80e7-41de-b60e-f48fa00275d2"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQyLTEtMS0xLTEwMTQyMA_f5f4d2bb-63ec-498a-9fc0-8431ea4e7763"
      unitRef="usd">1121743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQyLTMtMS0xLTEwMTQyMA_df40f00c-6416-4fbf-aaa4-a06163155dbb"
      unitRef="usd">859417000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQzLTEtMS0xLTEwMTQyMA_c00f6e3e-24a5-46b6-b4f1-b10f07e5f306"
      unitRef="usd">2589459000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzQzLTMtMS0xLTEwMTQyMA_a22ac73f-2425-480e-9d54-67f888571a70"
      unitRef="usd">1817293000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558"
      unitRef="usd">427690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82"
      unitRef="usd">310475000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796"
      unitRef="usd">219739000</us-gaap:CostOfRevenue>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443"
      unitRef="usd">89726000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5"
      unitRef="usd">58932000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzctNS0xLTEtMTAxNDIw_693105f9-545e-40ed-8d38-6d609dfecb4a"
      unitRef="usd">29275000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzctNy0xLTEtMTAxNDIw_22886571-b673-46d1-ac0a-95b61388997e"
      unitRef="usd">15106000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEwLTUtMS0xLTEwMTQyMA_8b921870-289d-45d1-8096-e941a18cfdb4"
      unitRef="usd">8569000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEwLTctMS0xLTEwMTQyMA_18366dfe-b679-4138-a696-045808be470b"
      unitRef="usd">6078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzExLTUtMS0xLTEwMTQyMA_1a9745bf-df17-41b2-87df-50382043aba7"
      unitRef="usd">438045000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzExLTctMS0xLTEwMTQyMA_f79a0491-6dfa-41c8-b1ee-298e66d42418"
      unitRef="usd">299855000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEyLTUtMS0xLTEwMTQyMA_ef16bc19-7426-4e7f-88c9-0c9f030316e4"
      unitRef="usd">-10355000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEyLTctMS0xLTEwMTQyMA_3a307de1-1381-4352-8798-00f2f317af19"
      unitRef="usd">-2798000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEzLTUtMS0xLTEwMTQyMA_bb849332-f1d6-4489-8e99-de0635015400"
      unitRef="usd">1060000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzEzLTctMS0xLTEwMTQyMA_d9230620-bb8c-4bc6-ade9-ecf890cc52cc"
      unitRef="usd">117000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE0LTUtMS0xLTEwMTQyMA_72fa3798-20e6-47ea-bc68-69f184d047d2"
      unitRef="usd">12895000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE0LTctMS0xLTEwMTQyMA_55e4b711-391e-400a-8f84-11e11a5fd921"
      unitRef="usd">2241000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE2LTUtMS0xLTEwMTQyMA_7db313d3-dd45-432e-b5f2-43e7811f9fb3"
      unitRef="usd">423000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE2LTctMS0xLTEwMTQyMA_47c4835b-eff3-479a-998e-8dba9c55ded7"
      unitRef="usd">596000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE5LTUtMS0xLTEwMTQyMA_63a5d696-b026-40ea-99a7-e4bd98e8f0a7"
      unitRef="usd">66184000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzE5LTctMS0xLTEwMTQyMA_05e009f0-b84e-49a5-86ae-27eea440b5db"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIwLTUtMS0xLTEwMTQyMA_33c24bc7-acf1-42a5-9c37-656717798bc4"
      unitRef="usd">-220000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIwLTctMS0xLTEwMTQyMA_97bd0e1b-9605-4747-9445-7205a95f28b3"
      unitRef="usd">178000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIxLTUtMS0xLTEwMTQyMA_6fd310d7-99b4-4a2f-b196-d34e6867b75c"
      unitRef="usd">-88171000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIxLTctMS0xLTEwMTQyMA_1e427a4b-1c45-4b7a-9a3c-d1ac9938d8c9"
      unitRef="usd">-4148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIyLTUtMS0xLTEwMTQyMA_e1d0f425-17ea-4e31-a9bc-43aa2d886304"
      unitRef="usd">-68189000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzIyLTctMS0xLTEwMTQyMA_ea243a20-30c1-4852-9ba2-9913729c8950"
      unitRef="usd">1202000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI2LTUtMS0xLTExNzA2OQ_44040c8c-6374-41dc-a366-6d682edcd60b"
      unitRef="usd">-19982000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI2LTctMS0xLTExNzA2OQ_fd07287e-18e4-4846-a58c-f8ba29abf2e3"
      unitRef="usd">-5350000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI3LTUtMS0xLTExNzA2OQ_cb6ffde3-f1f6-4c44-ae64-50eac866bd04"
      unitRef="usd">6276000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI3LTctMS0xLTExNzA2OQ_74f647ad-417a-4207-80a7-103ce0509df1"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_c24049ed-f3ce-473f-90b1-4c8a63bdcd39"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_c84f3663-43a4-46fd-b1c1-95d6e2698772"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_e7c97b85-bbfe-4c04-b528-64ccc7462a6b"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTUtMS0xLTEwMTQyMA_e987f5fa-6d07-42e6-9cc0-ba4138bd2c4f"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_1980d515-ef65-4c46-96a0-5dc3770d0a47"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_47d5cef9-3e2c-4522-b85f-2df07ec3bc4e"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_8185dac2-be1c-4f17-b3b3-c697c41afdbc"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzI1LTctMS0xLTEwMTQyMA_a50c1c3b-fe74-4cfa-924d-bae05b476b79"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTUtMS0xLTEwMTQyMA_a832f1ce-4f6e-4c9f-9657-58b10951bada"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTUtMS0xLTEwMTQyMA_b6527866-453d-4e92-a30a-4bf04344a6d7"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTctMS0xLTEwMTQyMA_4e751178-48c2-47e3-bffc-4aaf15ec3888"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMxLTctMS0xLTEwMTQyMA_90d78023-6930-4a04-99c9-2d97279d9b93"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTUtMS0xLTEwMTQyMA_7915880a-0cab-469c-baa5-041030907d3e"
      unitRef="shares">107783000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTUtMS0xLTEwMTQyMA_bc51d071-7469-4cf4-8962-c45c089c02f7"
      unitRef="shares">107783000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTctMS0xLTEwMTQyMA_3c84eed5-d87d-45a0-8d09-28bb088d1048"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzM4LTctMS0xLTEwMTQyMA_6a850953-589b-406d-9a8b-bf62ff764231"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQyLTUtMS0xLTEwMTQyMA_5db6dd4b-3607-43bf-a6af-6573bb7c998c"
      unitRef="usd">-26258000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQyLTctMS0xLTEwMTQyMA_dcd1ff5a-5cf8-4053-b141-0d8b0155e798"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ0LTUtMS0xLTEwMTQyMA_f9ebf525-dbe2-4715-90c8-965d150b5261"
      unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ0LTctMS0xLTEwMTQyMA_3071b3b0-c0d6-4429-933a-9f9668f8da45"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ1LTUtMS0xLTEwMTQyMA_8a249888-e6a1-42d9-ae7d-d02d01e99b4c"
      unitRef="usd">-26202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzQ1LTctMS0xLTEwMTQyMA_42a60789-67d4-49dd-a8ff-9d89a3f3cca4"
      unitRef="usd">-5482000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzQtMS0xLTEtMTA4NTEy_7a320b7d-11a4-4507-b799-5a8227dc80dc"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzQtMy0xLTEtMTA4NTEy_5f127151-ac6d-46ab-8e6b-1c9d672354c1"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i4c7d4e62a4284394a63ec249572a7d1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMS0xLTEtMTAxNDIw_dbfb806d-eeb6-4ba9-afb5-3086f8006725"
      unitRef="shares">101501000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4c7d4e62a4284394a63ec249572a7d1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMy0xLTEtMTAxNDIw_9e24ed8f-7c77-4eb5-8500-71f7db573136"
      unitRef="usd">1015000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0713ced519f3403194ba9f05d0b0292e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtNS0xLTEtMTAxNDIw_d0811867-4609-404b-b7e2-05fef7858f7d"
      unitRef="usd">1486857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib743093d4bbc48e3a439e1657b566d11_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtNy0xLTEtMTAxNDIw_bfe27a5b-557c-4a93-a600-cc64ed895101"
      unitRef="usd">-1178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe93d2e31b3b4fa88abc8e17ae008f01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtOS0xLTEtMTAxNDIw_ec384391-8969-4f53-bfb0-accfe1a58023"
      unitRef="usd">-606154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5cd6129ee464be1b32499eefeff761d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMTEtMS0xLTEwMTQyMA_a457fcc9-b6dd-47a0-a824-98670e24fc91"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzMtMTMtMS0xLTEwMTQyMA_44f83908-1625-40d1-bddc-c6cd85785a3d"
      unitRef="usd">859417000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzUtNS0xLTEtMTAxNDIw_25242a63-4650-46f8-afd0-98741a04c1c3"
      unitRef="usd">10710000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzUtMTMtMS0xLTEwMTQyMA_88242190-abd8-40e4-aa0c-4c5b2c1955da"
      unitRef="usd">10710000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMS0xLTEtMTAxNDIw_4a47eabe-ba26-4b5b-aa63-f52a0bef506f"
      unitRef="shares">330000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMy0xLTEtMTAxNDIw_8ba62ab4-c08e-43d2-aeb1-0d38ddfd8eba"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtNS0xLTEtMTAxNDIw_6c5d1f95-8876-409f-87fb-8c14d050e6c0"
      unitRef="usd">1578000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzYtMTMtMS0xLTEwMTQyMA_776075a8-8d2c-4f91-9a72-4d662bd9071e"
      unitRef="usd">1581000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMS0xLTEtMTAxNDIw_38e6f422-c5ad-470f-a3fa-f6ceec7744c8"
      unitRef="shares">434000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMy0xLTEtMTAxNDIw_09bcdedf-4e26-4d12-b374-24ed4769a9fe"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctNS0xLTEtMTAxNDIw_22b91911-e8b8-46b5-9d4e-de366cbbf164"
      unitRef="usd">-8636000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzctMTMtMS0xLTEwMTQyMA_32079d2d-1968-44ad-9fe0-03257bd65874"
      unitRef="usd">-8632000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMS0xLTEtMTA0NzA5_86541dcf-a5b6-4168-9cd7-ddfdcf6b8a79"
      unitRef="shares">202000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5ba4196151d347619ca059a369a32dcc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMy0xLTEtMTA0NzA5_2b79e493-3cb0-4925-b148-4f8d001a3bdc"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieeeef40ff57344688c2de84656eb453b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtNS0xLTEtMTA0NzA5_c5929e96-469c-4cf9-949c-1cb2d4d0093d"
      unitRef="usd">-3977000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzgtMTMtMS0xLTEwNDcwOQ_b121681f-7621-466b-9309-db30c056d8c2"
      unitRef="usd">-3975000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9533fd157f36404db99df73e24250f17_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMS0xLTEtMTA0NzA5_ea816127-e8e6-44a8-95e4-319849204c06"
      unitRef="shares">760000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9533fd157f36404db99df73e24250f17_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMy0xLTEtMTA0NzA5_7fba5f0f-8919-4e38-b70e-144785ca622f"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6f39e0c2d9fa407cbb8bd38448014469_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktNS0xLTEtMTA0NzA5_8da4f2de-0eb3-488f-83df-6604b86e0236"
      unitRef="usd">-8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMTMtMS0xLTEwNDcwOQ_52565c71-b3fc-4e01-a927-8e2a6cb3129b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMS0xLTEtMTAxNDIw_25873e80-be32-469f-b6ac-9df68a1555c5"
      unitRef="shares">8475000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMy0xLTEtMTAxNDIw_ccd6487b-6e6a-4305-8edb-36f3179bd87b"
      unitRef="usd">85000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktNS0xLTEtMTAxNDIw_cb528a68-5977-4a86-9fce-f30c0e37ce86"
      unitRef="usd">261186000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzktMTMtMS0xLTEwMTQyMA_da0748cd-ff54-431f-8a48-1a7cb69cb265"
      unitRef="usd">261271000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTUtMS0xLTEwODg4Nw_d993c809-99e3-4dea-a46b-eaba4f80356d"
      unitRef="shares">850000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i270ca9e7bb06493c82d54ee5ab2b6df9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTctMS0xLTEwODg4Nw_2dbdf6e3-8248-432c-9244-9248c37aac24"
      unitRef="usd">8000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTktMS0xLTEwODg5NQ_617b9061-183d-4e9d-ad83-5c2dae4fc3b7"
      unitRef="usd">27565000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTE3LTEtMS0xMDg5MDM_758163f7-3937-42db-9d45-3476de257b57"
      unitRef="usd">27573000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEtMS0xLTEwODc0MQ_4b869289-9ba0-40bb-83c7-9610ae95449a"
      unitRef="shares">175000</evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTMtMS0xLTEwODc0MQ_623a230b-8f49-4a58-84a5-9f559a443a72"
      unitRef="usd">168000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide84d54410104b30956cb7ff55186ac5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEwLTctMS0xLTEwMTQyMA_dec8df6c-1f2f-4e89-b90a-5e817a9da387"
      unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEwLTEzLTEtMS0xMDE0MjA_7a07a9fc-5cff-43d6-b24d-b4708cb26519"
      unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE2LTMtMS0xLTEwODc0MQ_992e3ff3-b103-4840-a240-1f12b9b9caea"
      unitRef="usd">2625000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLoss
      contextRef="id7d22c2fdd114d1fa1c4b46d5e8429af_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTUtMS0xLTEwMTQyMA_7986d8bb-e84a-47f7-8d97-cc4fe93c5faf"
      unitRef="usd">-6276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa70195a0a874033a738fa36233fea32_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTktMS0xLTEwMTQyMA_629aba2d-f93e-4cef-8f24-0549c65a31c1"
      unitRef="usd">-19982000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzExLTEzLTEtMS0xMDE0MjA_ab5ed34b-50f5-41a4-a1e9-a748ea6e63e2"
      unitRef="usd">-26258000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE4LTEtMS0xLTEwODUxMg_f7f0db9f-37a4-4746-88e0-66464e1930a5"
      unitRef="shares">175000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE4LTMtMS0xLTEwODUxMg_89894898-b05f-4ee6-a744-463a731b639b"
      unitRef="usd">170625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEtMS0xLTEwMTQyMA_e364fe61-63c3-48d1-b391-55fa9a60c8aa"
      unitRef="shares">112552000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i829aa62eee8247c4b73f9990e5d0bfb2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTMtMS0xLTEwMTQyMA_03a73147-7ce7-45d7-8209-977ab9073f6e"
      unitRef="usd">1125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie506ce36e15348bc8daa8c1498a654d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTUtMS0xLTEwMTQyMA_48ec4910-1441-4a7c-be27-ef363d008a01"
      unitRef="usd">1768999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77787921202e4fd4a18e90bf6cb87279_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTctMS0xLTEwMTQyMA_35037274-8812-4121-a121-b62c559bcdc8"
      unitRef="usd">-1122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d8b41829710445a8d0f8c5817b4ec7e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTktMS0xLTEwMTQyMA_c92c0df2-61e8-43bc-8bb8-6266795defcc"
      unitRef="usd">-626136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ed1265962b049e19122f05090afc707_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTExLTEtMS0xMDE0MjA_0d1c8d35-f60c-4011-97b3-f807d354b7a1"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzEzLTEzLTEtMS0xMDE0MjA_bdd18f38-0427-41ae-b6ff-ceddae1e5552"
      unitRef="usd">1121743000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="icd5eb55aee214a3a80aef01f773385a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTEtMS0xLTEwMTQyMA_83e6eab5-053f-4641-99e9-aaef19f17d0b"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="icd5eb55aee214a3a80aef01f773385a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTMtMS0xLTEwMTQyMA_bd9de2c6-693b-475a-85e7-27f2d089c38f"
      unitRef="usd">908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia51a9c1f2e96457cb583435784fd8052_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTUtMS0xLTEwMTQyMA_8a97e151-210c-4b03-8d43-f5c506305bae"
      unitRef="usd">1340989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1df13d90a8c0400c9b19908332b563d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTctMS0xLTEwMTQyMA_5eed73d5-bdcd-423f-9903-a111e0bb54b3"
      unitRef="usd">-362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8683bc3116734882a3a6f338a1014c96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTktMS0xLTEwMTQyMA_4bcfa629-3861-4a07-a820-1e31bdb84400"
      unitRef="usd">-626779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8cc2dc21792b4a4bae4ba077682310b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTExLTEtMS0xMDE0MjA_e5f9b29c-2616-453b-bf28-cbea81483c47"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzE5LTEzLTEtMS0xMDE0MjA_84a3998d-638c-4967-b498-609fb11510ac"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id08d9338b291434896695b0967309848_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTUtMS0xLTEwNjk2Mg_0204cbc3-c65d-4995-9afc-f07aad3ffcf0"
      unitRef="usd">-106172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74fbb53f36da458fbc7b7873ed9c53ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTktMS0xLTEwNjk1OQ_a5b62ae0-8d6e-4c1e-af9a-307704002c17"
      unitRef="usd">39789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6afd820b04d04b58818736afa910bd99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEzLTEtMS0xMDY5NTk_929021de-b1f0-41b1-b8e1-b02addeb7e4b"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIxLTUtMS0xLTEwMTQyMA_3fa21b6f-a222-45c3-8268-e6f016e5ef7e"
      unitRef="usd">5346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIxLTEzLTEtMS0xMDE0MjA_8e87cc34-213b-4b47-bae7-93dbb30a1a06"
      unitRef="usd">5346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTEtMS0xLTEwMTQyMA_59edce6f-0835-40da-a29e-003df6ba032b"
      unitRef="shares">37000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTUtMS0xLTEwMTQyMA_598c8aaa-a518-4efc-ac9f-331105607f4c"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIyLTEzLTEtMS0xMDE0MjA_d2bb9c7c-812f-4569-92e5-1400cd3e83aa"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEtMS0xLTEwMTQyMA_8d95215e-49c1-4f59-97e4-c503cf3c3b5e"
      unitRef="shares">334000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTMtMS0xLTEwMTQyMA_3bd2a98d-92e0-4d50-b4c4-ff0454081023"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTUtMS0xLTEwMTQyMA_c08cbc58-cee0-4425-9719-6bdbe88d8648"
      unitRef="usd">-4986000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzIzLTEzLTEtMS0xMDE0MjA_ba1ef793-1294-4e66-b9f7-d9fc6388c90f"
      unitRef="usd">-4983000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEtMS0xLTEwNjk1Mg_250cbf5a-b735-4ce4-ba84-a1b23f04993a"
      unitRef="shares">458000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5e7c11f2f9c4442eae53858efef639a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTMtMS0xLTEwNjk1Mg_b1e99d7e-d2de-4acd-a424-200bc92d31f2"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i93cd92f4929640c6a9f8d6e47d530f73_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTUtMS0xLTEwNjk1Mg_23838839-1887-4a2b-b3e6-10bf15108948"
      unitRef="usd">-11236000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEzLTEtMS0xMDY5NTY_21bd16aa-a768-410b-8e95-f256225bf834"
      unitRef="usd">-11231000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iecea63a0c33d40c59386cb36be688e7e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI0LTctMS0xLTEwMTQyMA_f33cad7b-ebf0-494d-b16e-bda93c2570af"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI0LTEzLTEtMS0xMDE0MjA_fd98f9c4-ae63-401f-ba17-112fe3b11b01"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i62b76dfd95d14dbc9e21923faf1da208_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI1LTktMS0xLTEwMTQyMA_31c5ba11-61e7-4498-a0a5-a32c75c2caec"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI1LTEzLTEtMS0xMDE0MjA_31321250-90a6-4fc5-a484-d02d9a4f25fb"
      unitRef="usd">-5350000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="icaa8e880df0f4903b24f864bf0775ff3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEtMS0xLTEwMTQyMA_cbd084ec-a82d-420b-bf97-c5276f41c446"
      unitRef="shares">91588000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="icaa8e880df0f4903b24f864bf0775ff3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTMtMS0xLTEwMTQyMA_e1740ad2-ff8e-4fdf-8136-3e41ea1c8d92"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4a91ec36aed4015a6db0d978ab3355d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTUtMS0xLTEwMTQyMA_d9a7c0db-a865-43ae-b09a-33ce2c6dfa74"
      unitRef="usd">1224250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65a846169eb64941a21068690d52a346_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTctMS0xLTEwMTQyMA_90fe4d6d-1b9d-40cc-a080-ee7fdd6cfd15"
      unitRef="usd">-494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b1c9f37d4a9429f851ebf21526dc518_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTktMS0xLTEwMTQyMA_57421962-1d72-4bfd-a2b6-1fbd9e896422"
      unitRef="usd">-592340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b74bdff81224fc68d9ffbc419dfee68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTExLTEtMS0xMDE0MjA_2924f2e2-9355-42c6-a540-9f02f24c7da9"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzEvZnJhZzphOWNlZWNhMGEwZmE0MjE5OGI5YzViOTMxMzNhODM3NS90YWJsZTo3NzAxMDA4YWM5NDY0NjIxOGY3MTBjZmJjYWExYjk4YS90YWJsZXJhbmdlOjc3MDEwMDhhYzk0NjQ2MjE4ZjcxMGNmYmNhYTFiOThhXzI3LTEzLTEtMS0xMDE0MjA_a4becc9b-01f9-4244-8a3f-bcf62d6b9143"
      unitRef="usd">611209000</us-gaap:StockholdersEquity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMtMS0xLTEtMTAxNDIw_9bc8ff97-9536-418a-b6c6-f2824651f272"
      unitRef="usd">-19982000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMtMy0xLTEtMTAxNDIw_5af1dc08-e540-458f-9b74-d0c546e17637"
      unitRef="usd">-5350000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUtMS0xLTEtMTAxNDIw_79c1a2e6-17c1-4ae8-9ace-771d9fbc46e9"
      unitRef="usd">8569000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUtMy0xLTEtMTAxNDIw_a149716b-0033-404d-9775-b92bac48786f"
      unitRef="usd">6078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzctMS0xLTEtMTAxNDIw_8685fdce-ec4d-49c2-879d-6cb5016992e6"
      unitRef="usd">423000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzctMy0xLTEtMTAxNDIw_f44a150c-5efa-481a-963b-f7abebce4921"
      unitRef="usd">596000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzgtMS0xLTEtMTAxNDIw_c2717e38-76d0-4dce-b1f0-4ab8000828b1"
      unitRef="usd">29275000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzgtMy0xLTEtMTAxNDIw_530aa69f-f9e0-43c9-af3e-4505a76c0d1f"
      unitRef="usd">15106000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEwLTEtMS0xLTEwMTQyMA_cd14494d-b6c6-497e-b5fa-104c05a24192"
      unitRef="usd">10710000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEwLTMtMS0xLTEwMTQyMA_8c0820d6-8523-49e4-8a10-4d2bae500dd2"
      unitRef="usd">5346000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzExLTEtMS0xLTEwMTQyMA_24cf0f73-5212-418b-bb6a-27557b40269d"
      unitRef="usd">-68728000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzExLTMtMS0xLTEwMTQyMA_449cc689-983e-49fc-b55b-5d75bef35af5"
      unitRef="usd">-132000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEyLTEtMS0xLTEwMTQyMA_aff28f70-4ebd-415b-badf-4a0a53454678"
      unitRef="usd">2290000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEyLTMtMS0xLTEwMTQyMA_a9bb8ad2-a77b-4cbd-8dcc-1580cfc29374"
      unitRef="usd">11689000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEzLTEtMS0xLTEwMTQyMA_6b48d56b-6b76-4976-9cd1-3ece46476168"
      unitRef="usd">911000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzEzLTMtMS0xLTEwMTQyMA_b36caed3-0b9c-47ef-9b27-83ef90195e61"
      unitRef="usd">539000</us-gaap:AmortizationOfFinancingCosts>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE3LTEtMS0xLTEwMTQyMA_3dadab86-95a5-4133-8a17-372ed2c83c6c"
      unitRef="usd">66184000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE3LTMtMS0xLTEwMTQyMA_9b231d1c-c30b-47ba-8905-032cc8fbd32e"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTEtMS0xLTExNDE5OQ_8a76322c-f0cb-42ba-b3f8-b69129089bdc"
      unitRef="usd">-4620000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTMtMS0xLTExNDE5OQ_84f622f9-6fc6-4385-9322-2f8234a32bac"
      unitRef="usd">-1718000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE5LTEtMS0xLTExNDM3OA_1af22dcd-5b58-4705-88d7-c018216424cd"
      unitRef="usd">-4250000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE5LTMtMS0xLTExNDM3OA_bd71ec88-4562-4c56-a600-3ca2d1afdc73"
      unitRef="usd">-1992000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTEtMS0xLTEwMTQyMA_707ead46-83a3-4fef-9b20-9fb455cc7c6d"
      unitRef="usd">56000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzE4LTMtMS0xLTEwMTQyMA_334af38b-ecd0-434b-812d-c1fe2aee4ebe"
      unitRef="usd">357000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIwLTEtMS0xLTEwMTQyMA_9a500d3c-3f93-4576-9882-88e8e7eefa8e"
      unitRef="usd">-19832000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIwLTMtMS0xLTEwMTQyMA_030f29cb-7c74-4b2e-8cd7-3cb37bc024e6"
      unitRef="usd">46299000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIxLTEtMS0xLTEwMTQyMA_b431de44-bba1-4388-a7b2-174e0bac2311"
      unitRef="usd">13758000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIxLTMtMS0xLTEwMTQyMA_1f416b72-7274-4a7e-af00-3a9d53aa9e88"
      unitRef="usd">6071000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIyLTEtMS0xLTEwMTQyMA_40ae30a1-d64f-4159-8a75-b479463cee3b"
      unitRef="usd">1326000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIyLTMtMS0xLTEwMTQyMA_d5ab0a38-9414-4c99-b2b1-acb5ec506891"
      unitRef="usd">1106000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIzLTEtMS0xLTEwMTQyMA_b9f7b014-abe1-417e-a6e4-894629901747"
      unitRef="usd">-13585000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzIzLTMtMS0xLTEwMTQyMA_0081636e-465f-4b2d-b064-d8fb1ef6b68f"
      unitRef="usd">426000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI0LTEtMS0xLTEwMTQyMA_b37e87aa-0e4f-4dc7-b8ad-e547f8dfbe92"
      unitRef="usd">4785000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI0LTMtMS0xLTEwMTQyMA_718075af-9a37-4df6-b028-013fa24477bd"
      unitRef="usd">2220000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI1LTEtMS0xLTEwMTQyMA_65a191d8-1c09-4d92-9180-2c3a2f385666"
      unitRef="usd">-31401000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI1LTMtMS0xLTEwMTQyMA_3279b08f-68d9-463b-9341-212aad45f0bb"
      unitRef="usd">-32435000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI2LTEtMS0xLTEwMTQyMA_32fba995-5f90-4905-bf3a-f60da7d2f9fa"
      unitRef="usd">1169000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI2LTMtMS0xLTEwMTQyMA_11bf905b-8ee3-41f0-b434-5fb14d22558b"
      unitRef="usd">1344000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI3LTEtMS0xLTEwMTQyMA_8080eab5-685a-43c3-9791-330d7a60896a"
      unitRef="usd">-2533000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzI3LTMtMS0xLTEwMTQyMA_6aa6d4e0-9b92-41d4-9daa-88dbaf298f0e"
      unitRef="usd">-7056000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMwLTEtMS0xLTEwMTQyMA_c15b0837-ddb4-40b8-aa93-3494e1c9584d"
      unitRef="usd">-277000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMwLTMtMS0xLTEwMTQyMA_5e662702-6b0e-448c-80cc-8101c7ff4344"
      unitRef="usd">-514000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMxLTEtMS0xLTEwMTQyMA_174e09de-df66-40dd-9813-76b3c2541f28"
      unitRef="usd">-7974000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMxLTMtMS0xLTEwMTQyMA_fa2f23c6-2d32-486b-9367-411409b3926e"
      unitRef="usd">-57442000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMzLTEtMS0xLTEwMTQyMA_28fcedf9-92dc-41d7-956c-ba05f0660189"
      unitRef="usd">386724000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzMzLTMtMS0xLTEwMTQyMA_37192ba9-480c-448f-b904-1b869a8cde69"
      unitRef="usd">70000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM1LTEtMS0xLTEwMTQyMA_24767e11-9257-4293-901a-26027b680034"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM1LTMtMS0xLTEwMTQyMA_44d8b50c-5715-49d5-8d46-a6daa5dd17b1"
      unitRef="usd">22969000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM3LTEtMS0xLTEwMTQyMA_788c83c5-b929-4831-bf5a-0c7f4261b9c4"
      unitRef="usd">786000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzM3LTMtMS0xLTEwMTQyMA_5e17429c-f22a-47b3-8927-830406c6111a"
      unitRef="usd">2375000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQxLTEtMS0xLTEwMTQyMA_efdbfb01-1097-4eb1-8718-85b04fc9a63f"
      unitRef="usd">9055000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQxLTMtMS0xLTEwMTQyMA_d1d0c8cb-a7e0-4e35-85ae-aa7e4f96a5f8"
      unitRef="usd">8508000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQzLTEtMS0xLTEwMTQyMA_bc3940da-c954-43e9-9366-11ddd22459d8"
      unitRef="usd">-394993000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQzLTMtMS0xLTEwMTQyMA_91a944e7-0620-46a1-8011-d1e9e9520d1d"
      unitRef="usd">16766000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ1LTEtMS0xLTEwMTQyMA_73590846-9adf-4b3c-984a-d1e56f20476e"
      unitRef="usd">-7576000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ1LTMtMS0xLTEwMTQyMA_fbe27a92-d45f-4eda-82e2-833726a7806e"
      unitRef="usd">34371000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ3LTEtMS0xLTEwMTQyMA_924f81fd-1120-417c-9a4a-e6d3d64c21a4"
      unitRef="usd">1581000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ3LTMtMS0xLTEwMTQyMA_056d354e-3c9e-461d-83c0-00171c36fc3c"
      unitRef="usd">309000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ4LTEtMS0xLTEwMTQyMA_1d689dfc-d4e5-4dc9-8595-64d606cc593e"
      unitRef="usd">256330000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzQ4LTMtMS0xLTEwMTQyMA_2cac7a3a-fbca-48fa-9eae-26431b5f64ab"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTEtMS0xLTExMjEyMA_34f948fd-fb0d-4b66-a459-3ae39d2d2404"
      unitRef="usd">37500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTMtMS0xLTExMjEyMA_7e0c3060-d9e7-46ed-a72c-f43ee30e6c66"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTEtMS0xLTEwMTQyMA_5d3c2a6b-a1fe-4869-8b8b-cac657626992"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUwLTMtMS0xLTEwMTQyMA_c09d038d-1dac-4067-adbf-722f4de9fcb3"
      unitRef="usd">1100000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTEtMS0xLTExMTcwOQ_4149beba-8b09-47b1-af8d-8618c90b4498"
      unitRef="usd">168000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTMtMS0xLTExMTcwOQ_eef8955b-b436-48e3-a1b2-d58e939a5b05"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTEtMS0xLTExMTcwOQ_a71ea143-aad8-45d8-a753-e34aaa5014dc"
      unitRef="usd">3651000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTMtMS0xLTExMTcwOQ_f39afb7d-aa30-43dc-acc7-3bbec9ed6818"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTEtMS0xLTEwMTQyMA_fe205f34-f986-41a6-8d1a-38f3e9d3428e"
      unitRef="usd">12607000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUxLTMtMS0xLTEwMTQyMA_a5ec733f-60cd-44b2-81b0-341092f9af86"
      unitRef="usd">16214000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTEtMS0xLTEwMTQyMA_8b2bead4-37c4-4add-a923-c73e48b10bd9"
      unitRef="usd">379729000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUyLTMtMS0xLTEwMTQyMA_da9d312b-9641-4295-bc03-ea18a5679b80"
      unitRef="usd">-51376000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUzLTEtMS0xLTEwMTQyMA_16dbe0ab-aa03-4581-932d-cbb03206fc5f"
      unitRef="usd">50000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzUzLTMtMS0xLTEwMTQyMA_057aa4a3-d5f1-40f5-9358-139075a2b2df"
      unitRef="usd">-104000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU0LTEtMS0xLTEwMTQyMA_62bbb8f0-c088-46a6-b7b3-1c27843e05fb"
      unitRef="usd">-23188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU0LTMtMS0xLTEwMTQyMA_e3506b0a-fab3-47f7-aa87-39c119630787"
      unitRef="usd">-92156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU1LTEtMS0xLTEwMTQyMA_5aed919c-9524-4818-806a-e4c7a6fb198d"
      unitRef="usd">215158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU1LTMtMS0xLTEwMTQyMA_c311332c-e446-4fa1-b1c2-f962be9f2bae"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU2LTEtMS0xLTEwMTQyMA_0796eed9-b53d-4c98-ab49-6fb14bb29cc8"
      unitRef="usd">191970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDkvZnJhZzpmMDg1MGY3YjkxZTM0ZDlkYjg2N2RjMzBjNzQ3NWE0ZC90YWJsZTozMzNmZjQ2ODBlNDk0OWFiYjYwMWFmMjQ1MTk5N2Q5Yi90YWJsZXJhbmdlOjMzM2ZmNDY4MGU0OTQ5YWJiNjAxYWYyNDUxOTk3ZDliXzU2LTMtMS0xLTEwMTQyMA_f4a5b4e5-aec4-4536-b3d9-f2d634d413e4"
      unitRef="usd">262786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzEwMDk_c9187bdc-c8fb-4fc1-a812-2f141eeec456">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports healthcare entities to improve the quality of care delivered for people with complex conditions through proven solutions that make health care simpler and more affordable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made organizational changes, including re-evaluating its reportable segments, as a result of growth in our value-based specialty care business, both organically and through acquisitions. Effective during the three months ended March 31, 2023, the Company changed its reportable segments to reflect changes in the way its chief operating decision maker evaluates the performance of its operations, develops strategy and allocates capital resources. Specifically, the Company collapsed its previous Evolent Health Services and Clinical Solutions segments into one segment. The Company's historical disclosures have been recast to be consistent with the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had unrestricted cash and cash equivalents of $157.5 million. The Company believes it has sufficient liquidity for at least the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzE2NDkyNjc0NDQwODY_711b0d39-bb3e-4dfc-ac70-f4b0f963ceef"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTUvZnJhZzphODVjOTA2NTg0MDg0MzFiOWFiY2JlMjg3ZjEyN2RmMS90ZXh0cmVnaW9uOmE4NWM5MDY1ODQwODQzMWI5YWJjYmUyODdmMTI3ZGYxXzQ2Nw_d16bdac6-9ddf-4e05-be7e-1431f0895162"
      unitRef="usd">157500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTkw_11a031ac-2911-42d6-afdc-b56908f5de2d">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#x201d; in our 2022 Form 10-K for a complete summary of our significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 19 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both March&#160;31, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2023, approximately 20% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 11 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 5 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Senior Convertible Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company&#x2019;s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares. Refer to Note 12 - Series A Senior Convertible Preferred Shares for further discussion.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjU5_3cc82259-6da5-4a78-8de0-6b042f829be1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjIw_5738ccd4-c6f4-4a15-984b-704df6b9203f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzMyOTg1MzQ5MjUxODY_feb2b562-670c-4951-9a19-98968edd0575">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjQ2_f8ceacb0-74ab-4036-832a-a8b3f36eea28">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjM2_64f0e839-6075-4a9f-9602-0ab8bf5da0ce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjAz_e5d3db7c-7196-4c24-82cb-5ca0616b5b8f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i34ce76b48a87457b99e7d1769a5aba81_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzItMS0xLTEtMTAxNDIw_b83e924e-5907-42dc-8c92-3b633fb178a6"
      unitRef="usd">2132000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i16f69dd7282741df87449317463405fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzItMy0xLTEtMTAxNDIw_7a6dddda-f818-41ae-8d0e-a30554a842e3"
      unitRef="usd">2269000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i3122c5fc961042ceb6802f6a1d99fef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzMtMS0xLTEtMTAxNDIw_833494e2-9f2e-4ab9-b92e-0ebeb908b1e3"
      unitRef="usd">10966000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i439908fc7be2410386d5bb54ff500846_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzMtMy0xLTEtMTAxNDIw_f824eb5e-ef8d-4664-9055-a2969736d979"
      unitRef="usd">10912000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i1ac3cc30824142c3b94108b50b60df21_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzQtMS0xLTEtMTAxNDIw_83e0627b-9f6a-43dc-8289-da5d5cf72411"
      unitRef="usd">21353000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="ia73d5d21a1a04f84babd13954429d25b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzQtMy0xLTEtMTAxNDIw_36d8321f-88fd-4f71-bf89-e91f7e7f2b59"
      unitRef="usd">13777000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzYtMS0xLTEtMTAxNDIw_83e7f67b-bbe0-4895-ba3b-541014cf5528"
      unitRef="usd">34451000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzYtMy0xLTEtMTAxNDIw_19883d70-0094-4c76-811f-93347a64df68"
      unitRef="usd">26958000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzgtMS0xLTEtMTAxNDIw_8c45dac1-4a0c-4080-bffd-c31926f2eff1"
      unitRef="usd">21932000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzgtMy0xLTEtMTAxNDIw_9cd719a8-85ba-4d91-8004-b294e4073c12"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzktMS0xLTEtMTAxNDIw_7599e53e-2e21-4a03-9d4e-1b8714fbfac6"
      unitRef="usd">21932000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzktMy0xLTEtMTAxNDIw_27cc590c-155c-422d-8301-4fa6a8a526ce"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzExLTEtMS0xLTEwMTQyMA_e33e3de5-d68d-4f28-9a82-ee06447b0feb"
      unitRef="usd">12519000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzExLTMtMS0xLTEwMTQyMA_c8b1320e-172b-4330-bc35-b3e7aeab07fb"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzEyLTEtMS0xLTEwMTQyMA_12574e41-2e5b-4c0d-961b-fb1b6e9db3f8"
      unitRef="usd">12519000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTpkMWUzOGU0MGRlMTQ0MzU2YTgwYzBmOWRjNGEzZmY4My90YWJsZXJhbmdlOmQxZTM4ZTQwZGUxNDQzNTZhODBjMGY5ZGM0YTNmZjgzXzEyLTMtMS0xLTEwMTQyMA_d72bf05a-8b3c-46ab-9d1a-7deab189bb7b"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjEx_14af6903-277f-48b5-a2e8-8cb79bfaba78">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzItMS0xLTEtMTAxNDIw_84751895-44cd-4a1b-bbe7-d2053eaf40fa"
      unitRef="usd">157519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzItMy0xLTEtMTAxNDIw_918175c0-c547-429e-983a-7fc631febbef"
      unitRef="usd">210158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzMtMS0xLTEtMTAxNDIw_0a3f12a2-406c-41a3-966d-2b0573b628b0"
      unitRef="usd">34451000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzMtMy0xLTEtMTAxNDIw_ac0fcde2-55e4-44a0-9204-17c84ae6236a"
      unitRef="usd">52628000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzQtMS0xLTEtMTAxNDIw_4a34706b-9227-43a5-a4c8-ee599db0da05"
      unitRef="usd">191970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5MGRmYzlmODdiNDc0ODFiYTJhNGQ5MTA4YzQyODMwNC90YWJsZXJhbmdlOjkwZGZjOWY4N2I0NzQ4MWJhMmE0ZDkxMDhjNDI4MzA0XzQtMy0xLTEtMTAxNDIw_25155334-72a5-4bdc-8df4-8712a0b8b78e"
      unitRef="usd">262786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTg2_def680e1-ec54-4431-ac24-a0affaf7690f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final &lt;/span&gt;&lt;/div&gt;determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjMx_17693bb8-be69-41b4-aa8d-375a2348c5e5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjM4_8b7904f6-fab9-49f4-9436-ab7a52daf9bd">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjQx_7d8a49fc-d28d-4ede-bfed-8ec017ca6a28">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifa977c28de4e47168b48e484eaede4c5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzAtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Mjc1YzhmYTkyZmE3NDFiNGJmOGE3YTQxMzk0ZWFiZTRfNA_479de001-f640-49b9-884a-e62cd6c61ad0">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4ceb4458b7dc4a2dabf10c867a9c1a99_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzAtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Mjc1YzhmYTkyZmE3NDFiNGJmOGE3YTQxMzk0ZWFiZTRfOQ_f60b383a-fdd7-4466-ae7b-01732767592b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7f2401b901664f83854b39254d8aae8d_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzEtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Yjg2NGM0ODM2ZmFkNDlhZThkNTUxZTZiMTRmMTBiMjZfNA_de56902f-1a35-409a-808f-fdf486f03412">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i06dde47fa30d4c54b76fc7b207080d9b_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzEtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246Yjg2NGM0ODM2ZmFkNDlhZThkNTUxZTZiMTRmMTBiMjZfOQ_dccd6556-77ad-4e1f-99ea-3ba7cbedf094">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6712e972d4564a6a96307887c4567b00_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzItMS0xLTEtMTAxNDIw_f6e0bcc0-e2e3-4c0f-8218-3ce3e66e57c0">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idec6af2602a74fb0a0b69b149b991a9a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzMtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246ZDdmZDU4OTVjMzg3NDgxN2EwMTk4YjVjMTdhNDc0OWJfNA_e599da08-354f-4950-9a9c-fb11876870fe">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ice9ce60f6fab4cdfb829f791deb4e1a1_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90YWJsZTo5YjU1MDM4NWQ0MzE0ZDc3OWZhZDRlZDViYmE1ZGI4NC90YWJsZXJhbmdlOjliNTUwMzg1ZDQzMTRkNzc5ZmFkNGVkNWJiYTVkYjg0XzMtMS0xLTEtMTAxNDIwL3RleHRyZWdpb246ZDdmZDU4OTVjMzg3NDgxN2EwMTk4YjVjMTdhNDc0OWJfOQ_a36bd4eb-7e4d-47dc-8a5d-7b21064e4e91">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NTg3_73aa79c6-deaa-4f6a-8a8c-990eaf0d644a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjE3_a703155d-7bb6-42c9-b4ce-566e11986981">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjA4_8752622e-d94d-415d-8cf3-fb60ef3a83c1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both March&#160;31, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of March&#160;31, 2023, approximately 20% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3MzUx_21ca165e-4b73-491e-a4ee-209c0447010b"
      unitRef="number">0.47</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3MzUx_85d1b0dd-c69e-4875-94f4-83799358c5ff"
      unitRef="number">0.47</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE3NDk5_d0279784-4469-457c-88c6-80636595136d"
      unitRef="number">0.20</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjE0_38085c59-1e2d-4297-ba9c-c7c7e0957948">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE4Nzc0_72f74173-0259-49ed-8682-d20851ce83e8"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzI2NjU3_c7529ea9-ada5-408e-86bf-43962664bc6c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMTgvZnJhZzpjOGY2NjVhMDQ1YzI0YjI4YTkwMWE0MDQ2Yjc4MTgzZS90ZXh0cmVnaW9uOmM4ZjY2NWEwNDVjMjRiMjhhOTAxYTQwNDZiNzgxODNlXzE2NDkyNjc0ODUxMjg_ea18ff43-baf9-4f6d-8a8c-d66dd53956d5">Series A Senior Convertible Preferred SharesIn accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company&#x2019;s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares.</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzIyNzc_d33bfb64-cb9f-4632-b27c-9ada14da8786">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzIyNzE_6ac3ba78-3013-4aec-a765-a93559c03dea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The Company adopted this standard starting in the first quarter of 2023, which did not have a material impact on our consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="id8cbaa74b6e54164941327e9684444ae_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE0NzE_41a35a57-7207-4151-b3df-014ff9284ed5"
      unitRef="usd">39800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1713ff2a1e2e4416a51a05040c0a1b30_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1MTM_ded9b478-9e4c-4964-a00e-2751c054c1bd"
      unitRef="usd">106200000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i08db4cba39da4c2daa8e8a98eec10995_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1ODQ_c2b63661-6270-42d3-b6a1-9f9128344bc3"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib604663c86e447178b86e5bd16de84b7_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjEvZnJhZzoxZmQ3YTkxODczN2M0OTIyYTNmOGYyZDI4YzZlNTFhZS90ZXh0cmVnaW9uOjFmZDdhOTE4NzM3YzQ5MjJhM2Y4ZjJkMjhjNmU1MWFlXzE1OTE_557612ad-18b1-4266-a726-9c9c31734fb4"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzc4OTM_bdb2e00e-cb45-436f-b512-0ca0907b0553">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;National Imaging Associates Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2023, the Company completed its acquisition of NIA, including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (&#x201c;Magellan&#x201d;) and certain of its subsidiaries that were used in the Magellan Specialty Health Division. NIA is a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total acquisition consideration, net of cash on hand and certain closing adjustments, was $715.7&#160;million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on January 20, 2023. The acquisition consideration consisted of approximately $387.8&#160;million of cash consideration (inclusive of certain post-closing adjustments), 8,474,576 shares of the Company&#x2019;s Class A common stock, fair valued at $261.3&#160;million as of January 20, 2023, and an earn-out consisting of additional consideration of up to $150.0&#160;million payable in cash and, at the Company&#x2019;s election, up to 50% in shares of the Company&#x2019;s Class A common stock (the &#x201c;Contingent Consideration&#x201d;). As of January 20, 2023, the Contingent Consideration is fair valued at $66.6&#160;million. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 15 years, 5 years, and 2 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of proprietary software that supports NIA&#x2019;s core business applications and specialty business. The corporate trade name reflects the value that we believe the NIA brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $56.1&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2023, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have included the financial results of NIA in our consolidated financial statements from January 20, 2023. The consolidated statements of operations and comprehensive income (loss) include $48.5&#160;million of revenues and $(5.5)&#160;million of net loss attributable to NIA for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Implantable Provider Group&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#x2019;s Class A Common Stock, at the Company&#x2019;s option. See Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of March 31, 2023, we had not finalized the determination of fair values allocated to the deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pro forma financial information (unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited condensed pro forma information presents combined financial information as if the acquisition of NIA had been effective as of January 1, 2022, the beginning of the 2022 fiscal year. The unaudited pro forma financial information includes adjustments to historical amounts including amortization of acquired intangible assets, depreciation of acquired property and equipment, interest expense for the financing of the transaction, alignment of NIA&#x2019;s revenue recognition policy, and the associated income tax effects as if NIA had been included in the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company&#x2019;s historical financial information on a pro forma basis (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#x2019;s interim consolidated financial statements was not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI1OTU_937bba63-c36a-4ec2-a62e-02261617a360"
      unitRef="usd">715700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2NTY_68b1e8c9-f743-4b5e-988b-f11659dee93c"
      unitRef="usd">387800000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i3eb9822d76ab401a9b48a8fac6ca541c_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2Mjc_04e78239-a404-45f4-9e44-ad7f58d85102"
      unitRef="shares">8474576</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2MTE_b27ad20e-8626-4cb6-9b3d-b2cd4728769f"
      unitRef="usd">261300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2NDA_b630e97f-074a-45e6-93bd-68ee4d99a605"
      unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <evh:BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE2NDkyNjc0Nzc3Njc_cb223538-42f3-43e6-bcb5-2e1b14b4c0ef"
      unitRef="number">0.50</evh:BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3OTM_0c3dede1-3d72-4a43-bad4-fa2ebc375c23"
      unitRef="usd">66600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MDkxMTg_0f11c285-b739-4fbe-9ac0-0854445f794c">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MDkxMTg_0f66f960-d9b0-413d-82e5-79b72a80d40f">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEtMS0xLTEtMTA4NTM1_24c5fc2a-4ad3-41e7-9ecf-cd228d9446fe"
      unitRef="usd">387823000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzItMS0xLTEtMTA4NTM1_4c9bd5ad-7437-4716-a6a3-57be7e98729b"
      unitRef="usd">261271000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzMtMS0xLTEtMTA4NTM1_bb0da24f-9d25-461f-92e3-ca03cf9af18a"
      unitRef="usd">66600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzQtMS0xLTEtMTA4NTM1_2521765d-4924-4529-abf8-088b650fd980"
      unitRef="usd">715694000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzctMS0xLTEtMTA4NTM1_79e2bfba-82bc-43c3-abd9-636ace18b827"
      unitRef="usd">28065000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzgtMS0xLTEtMTA4NTM1_0db16dee-da52-43bc-8942-79f604f11dc9"
      unitRef="usd">675000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEwLTEtMS0xLTEwODUzNQ_c68bf3c5-4798-4eeb-8ab1-29efb3ab3a8e"
      unitRef="usd">28740000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iaba5e6a382114572af38a8d1b8953795_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzEzLTEtMS0xLTEwODUzNQ_3bf5cded-3e35-4f1d-8829-58a53342a47d"
      unitRef="usd">345100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE0LTEtMS0xLTEwODUzNQ_5fee0d98-2a92-4071-9fe8-1590c3aae30a"
      unitRef="usd">50700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id25b028edfec49c187b6bb9961ecf387_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE1LTEtMS0xLTEwODUzNQ_71f395ce-f416-4a10-af30-79335676c6e2"
      unitRef="usd">8200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzE2LTEtMS0xLTEwODUzNQ_c32f3959-2107-4778-b5be-72b8a8cad4ea"
      unitRef="usd">404000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIwLTEtMS0xLTEwODUzNQ_a866b848-e8d7-4651-ab9b-495cc789ee2e"
      unitRef="usd">5409000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIxLTEtMS0xLTEwODUzNQ_1921386e-d883-4778-8159-63b709566da8"
      unitRef="usd">6173000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIyLTEtMS0xLTEwODUzNQ_6e42c3fb-2ada-4b07-a8bc-dcd5dbea8be3"
      unitRef="usd">100486000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzIzLTEtMS0xLTEwODUzNQ_62c529c0-ade0-4b0a-a995-f9c3acbe58f6"
      unitRef="usd">142000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI1LTEtMS0xLTEwODUzNQ_9b3d97ee-d162-441d-be6b-1865af2f9799"
      unitRef="usd">112210000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI3LTEtMS0xLTEwODUzOA_ea3a9fdb-2219-47d0-bbf9-0bd78e8cc4e5"
      unitRef="usd">395164000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTpkYzBiMjlkOGJmNzU0NGU2OWE0ZGI5NWVlMTFhYzJhMi90YWJsZXJhbmdlOmRjMGIyOWQ4YmY3NTQ0ZTY5YTRkYjk1ZWUxMWFjMmEyXzI4LTEtMS0xLTEwODUzOA_f923162b-7474-4273-8a43-8493b8011da9"
      unitRef="usd">715694000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iaba5e6a382114572af38a8d1b8953795_I20230120"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDE_0dad9b5a-359f-4cc9-acc8-fb9beb15dd5e">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0ab13671a8f24f42ae2f394e346fc8a5_I20230120"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDA_106c26ca-0a06-4ab7-8d19-29787975587b">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id25b028edfec49c187b6bb9961ecf387_I20230120"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI2OTk_2b641dba-057f-4663-b71c-0fd8dfca05e9">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ib409c87cf89b4073a5635cf8c0a310ba_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MDY_c4996ebe-fd43-40d5-8ebc-2019e8c04e54"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwOTk1MTE2NTI3MjI_b19c6a35-9e94-4f43-b2c9-04973f2b2ee0"
      unitRef="usd">-56100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTgyOTk_d72bf7de-83eb-4780-a4d9-54fec6f7b93c"
      unitRef="usd">48500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTgzMTQ_8b590d2f-d917-416d-b938-757e515e6a36"
      unitRef="usd">-5500000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE1Mg_e0287f2d-2a7e-4d7c-962b-a6b61ca3cf33"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzcxNA_92a206a7-ab67-4de6-a979-7aa9fa001ab6"
      unitRef="usd">461700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzg1Nw_99442a7a-a78f-433b-a596-35a6c5861694"
      unitRef="usd">256500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzg4Mw_9a533820-9d6f-4906-8e5d-5b60ed1bac2c"
      unitRef="shares">3700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzkzMw_edb20e98-2da2-4378-a256-c876d394a507"
      unitRef="usd">130200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzk4Mw_997c2351-f09b-41f4-9b39-d0c66767998a"
      unitRef="usd">87000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzEwMDI_5246d33f-5bf6-4da4-b4c8-2b34469bea11"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEtMS0xLTEtMTAxNDIw_3add17ea-2cf7-4d51-ac08-7b454385beeb"
      unitRef="usd">256488000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzItMS0xLTEtMTAxNDIw_2356eab8-b065-479c-bee9-4d158caf2ad7"
      unitRef="usd">130175000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzMtMS0xLTEtMTAxNDIw_644cae6b-69b9-438c-9558-149f0a8ee943"
      unitRef="usd">75000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i70db4d4fbb824193a828dae02cc23751_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzQtMS0xLTEtMTAxNDIw_5da54a23-6da5-454e-9755-6b04567214d5"
      unitRef="usd">461663000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzctMS0xLTEtMTAxNDIw_1699792d-1bbb-4f42-a2de-9760d875c0e5"
      unitRef="usd">34155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzgtMS0xLTEtMTAxNDIw_8b58f47d-b9ea-4c92-8324-2b63fa2470a5"
      unitRef="usd">636000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzktMS0xLTEtMTAxNDIw_60bcc170-f42c-4fc5-bdb3-9f0f7c7f42d4"
      unitRef="usd">1393000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEwLTEtMS0xLTEwMTQyMA_efbd74fd-5215-45ff-b63f-8e91d898bf3d"
      unitRef="usd">36184000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i2d9c4ff54b524745a88b135d86bd443b_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzEzLTEtMS0xLTEwMTQyMA_31ba5271-79ca-45b0-9558-d3d28c634541"
      unitRef="usd">154000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1373bcac7934429293088da96849175b_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE0LTEtMS0xLTEwMTQyMA_48f5ab59-7440-4805-8ec9-627eeca6f957"
      unitRef="usd">23900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i57b6d6c6c553400a9d75350d6fa61da5_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE1LTEtMS0xLTEwMTQyMA_ccac5ab7-f68d-4463-9569-de7375563ea0"
      unitRef="usd">17800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE2LTEtMS0xLTEwMTQyMA_c8de5914-f305-4f02-9cc0-0b4bf3c2b1e9"
      unitRef="usd">195700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzE5LTEtMS0xLTEwMTQyMA_fdd2e5ae-14a3-45d0-913e-9b877476e151"
      unitRef="usd">7997000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIwLTEtMS0xLTEwMTQyMA_0d936f2f-d740-4967-b1af-d406c1e9cdf7"
      unitRef="usd">8083000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIxLTEtMS0xLTEwMTQyMA_b1131aab-345e-44a3-9889-2709902d8944"
      unitRef="usd">423000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIyLTEtMS0xLTEwMTQyMA_fdbebbe5-35bd-4ea8-974d-3a56fb5790e3"
      unitRef="usd">48671000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzIzLTEtMS0xLTEwMTQyMA_e0b062c0-c273-49c8-9bb1-dba1ad6e1031"
      unitRef="usd">321000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI0LTEtMS0xLTEwMTQyMA_8d296b82-7245-42e4-8165-3f5313cc0337"
      unitRef="usd">1323000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI1LTEtMS0xLTEwMTQyMA_0cdaa65c-f282-427c-8d45-31d8262993b1"
      unitRef="usd">66818000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI3LTEtMS0xLTEwMTQyMA_17c19710-7d81-4c66-9f06-9c6bf0ac75de"
      unitRef="usd">296597000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphN2ZhNjM5MjdlZWQ0MGE4YmNkM2EwMGYyYzkyMDlkMC90YWJsZXJhbmdlOmE3ZmE2MzkyN2VlZDQwYThiY2QzYTAwZjJjOTIwOWQwXzI4LTEtMS0xLTEwMTQyMA_4f5b0118-f77e-4f3d-8878-b83117bd6347"
      unitRef="usd">461663000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2d9c4ff54b524745a88b135d86bd443b_I20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5Mjc_63af5a75-6e09-465b-b503-380cbb6e0a38">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1373bcac7934429293088da96849175b_I20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5MzE_6463d872-5ad8-45bd-8222-40586609ac43">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i57b6d6c6c553400a9d75350d6fa61da5_I20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzE5Mzk_9a269433-4025-4f41-a37b-1e0140d13117">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i491e48a182e442f98c17a235d12252d7_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzM2MTg_36b8584d-ad30-427e-a181-ddb3de9d1eee"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91831d375a0845e7aa4af31f7b290c36_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzM2OTE_1b6fcfca-6ad1-49d0-b2b4-5033eec9ae74"
      unitRef="usd">-46800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90ZXh0cmVnaW9uOmQ2MWE4YWI2MmFlNDQ5MmI5Mjg4NWNjZDg1YTVlNWRhXzMyOTg1MzQ5MTY1NDg_dc1a25e8-12a6-443e-a8d4-be3212e58413">The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company&#x2019;s historical financial information on a pro forma basis (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzItMS0xLTEtMTEzMTAx_92a23613-e223-4c71-b560-b7e89f10aaca"
      unitRef="usd">446740000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzItMy0xLTEtMTEzMTAx_57d68250-c394-4f5b-8de6-5f10c3079d77"
      unitRef="usd">362827000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzQtMS0xLTEtMTEzMTAx_366e3533-f1f2-43eb-84fd-d5e0a0139d91"
      unitRef="usd">-15730000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i9403ccefb23147b28f89b6a847f5da86_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMjQvZnJhZzpkNjFhOGFiNjJhZTQ0OTJiOTI4ODVjY2Q4NWE1ZTVkYS90YWJsZTphYWJjMGE1MTdkOTk0MjFhYmNkYjI5MjZkOTQ0NzllMy90YWJsZXJhbmdlOmFhYmMwYTUxN2Q5OTQyMWFiY2RiMjkyNmQ5NDQ3OWUzXzQtMy0xLTEtMTEzMTAx_dfb6edb8-c16d-4180-a404-3a71b539f15f"
      unitRef="usd">-10240000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NTI_1a5f3273-9a26-4656-9bc6-f26475a933fa">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue contracts are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by end-market and product type:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance Suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Technology and Services Suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Administrative Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $43.8 million of transaction price to performance obligations that are unsatisfied as of March&#160;31, 2023. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 69%, 92% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue, excluding customer discounts of $1.5&#160;million, recognized from performance obligations satisfied (or partially satisfied) in a previous period was $4.8&#160;million for the three months ended March 31, 2023, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $3.4 million and $3.9 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of $0.3 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our revenue contracts, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of March&#160;31, 2023 and 2022, the Company had $13.1 million and $18.1 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $2.0 million and $10.3 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NDg_fbf96939-6eb4-416b-8de0-49d8bd59e57b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by end-market and product type:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance Suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Technology and Services Suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Administrative Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6cc900864834868948a404393a49a85_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzMtOS0xLTEtMTAxNDIw_9d295f84-7dc3-42c0-94f3-29e400709535"
      unitRef="usd">183034000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38d6a8162061452483f3aa24db4d62d8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzMtMTEtMS0xLTEwMTQyMA_5165c754-0dc8-44c4-9ae1-6e71c5bad28a"
      unitRef="usd">130501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6176d6981ea4c9b8d17bb71206e1cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzQtOS0xLTEtMTAxNDIw_6782ce75-bf75-4327-8521-d16c4dec578e"
      unitRef="usd">127669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cb36bbcf076422798e36c705ca489a5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzQtMTEtMS0xLTEwMTQyMA_1de5659c-09ad-4314-83a9-48f0951bc6c1"
      unitRef="usd">104399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c51d30ca110417b9bc57ef158154a94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzUtOS0xLTEtMTAxNDIw_20a318cd-46da-41ff-98fa-156a0dd3bc80"
      unitRef="usd">116987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia60e2d87246f4a24b6e2e5c72158629a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzUtMTEtMS0xLTEwMTQyMA_aa2cd3eb-4686-4bc6-9cbf-93ccf62a1a19"
      unitRef="usd">62157000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzYtOS0xLTEtMTAxNDIw_a47a2df2-d286-4bcb-aab0-3cc386b26854"
      unitRef="usd">427690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzYtMTEtMS0xLTEwMTQyMA_a364eb76-7d0f-45e2-8b59-910a26e19c95"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if783561a665d46e194893a76d25beb3e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzctOS0xLTEtMTE1ODgw_80f97a03-4e11-4f7e-98e0-b09afe9036dc"
      unitRef="usd">239873000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6ca0c0c1968494bbc67b02a9e28ff5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzctMTEtMS0xLTExNTg4NQ_eedcd616-0094-4f6a-a2e3-58d762a141ca"
      unitRef="usd">171164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifef28bce40ea4047a5a04db3de0aadf1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzgtOS0xLTEtMTE1ODgw_da3d3708-4ab5-4001-866c-124b8b577b3e"
      unitRef="usd">65316000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i129cce29425045eabdab581851009e0e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzgtMTEtMS0xLTExNTg4NQ_0d6c9f45-6739-469f-9a98-d9bdc34deb44"
      unitRef="usd">13580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb47dcc6439a43fa8d4c19f2122b859a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzktOS0xLTEtMTE1ODgw_e14ef60a-1ed4-48de-87a0-209585617df5"
      unitRef="usd">83067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88f9f6fc9bd44f3fb6b41939fb533aca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzktMTEtMS0xLTExNTg4NQ_f70966c5-428e-4ee3-a03c-d331dc927a4d"
      unitRef="usd">106859000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4772da6b737d416fa93667acc7bec0e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzEwLTktMS0xLTExNTg4MA_4ce17f58-5883-47bd-a177-759b4bfeecd3"
      unitRef="usd">39434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8a9c31ea4be40439865dcd7dc02302f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzEwLTExLTEtMS0xMTU4ODU_a2731141-ec44-442a-af9a-6ce862e8cdf1"
      unitRef="usd">5454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzExLTktMS0xLTExNTg4MA_1679f189-b508-46e6-9579-a4e15a11e1f9"
      unitRef="usd">427690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id43b4f490aa146abbdc3a9429e13f8aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZToyMzAwZmM5NzcyY2Y0OGNkOTUzN2Q3M2ZiNjM5OTAxZi90YWJsZXJhbmdlOjIzMDBmYzk3NzJjZjQ4Y2Q5NTM3ZDczZmI2Mzk5MDFmXzExLTExLTEtMS0xMTU4ODU_95b37874-2e20-4680-a8bd-417253bab961"
      unitRef="usd">297057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQyOTk_286026d1-e5c6-4f38-aabe-185a2cf165ce"
      unitRef="usd">43800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i97d627a444fd4d149f0df76b556dd94e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5MTg_0b2bb198-f791-442d-9ea6-edc0763c76b0"
      unitRef="number">0.69</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i466c6c1cbb854e8f935205d90d504b4c_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5MjI_599e45b9-e1f8-4158-a563-b45d94febfc2"
      unitRef="number">0.92</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="ib48ab736f158463982ae6d2fd4bb0ef6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzQ5Mjk_8b785cb7-73b7-49c2-b659-1d4bdd22131e"
      unitRef="number">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzk0NTA_66fc9a4a-ff77-48bf-982b-71323d926de5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March&#160;31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzItMS0xLTEtMTAxNDIw_27a17d97-8b60-4865-998d-37d31d5377cb"
      unitRef="usd">261875000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzItMy0xLTEtMTAxNDIw_20fdf1b1-56fa-4155-82d3-25c716e7ccd3"
      unitRef="usd">246209000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzQtMS0xLTEtMTAxNDIw_a0ed615b-6a2a-4931-afe4-8d06b9bcf094"
      unitRef="usd">7069000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzQtMy0xLTEtMTAxNDIw_2eb495d9-78fd-4249-aa9f-dd23434dd205"
      unitRef="usd">5758000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzUtMS0xLTEtMTAxNDIw_b24f2e30-9bac-4e63-b703-0efe1160003b"
      unitRef="usd">2193000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTozMWEwZjVmMGIxZjI0OWVmYWIzOWMwZmI4ZDIzZTE5OC90YWJsZXJhbmdlOjMxYTBmNWYwYjFmMjQ5ZWZhYjM5YzBmYjhkMjNlMTk4XzUtMy0xLTEtMTAxNDIw_a24dc325-ed19-4e1e-a2dc-5fb6a0bbe6a1"
      unitRef="usd">2533000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzEtMS0xLTEtMTAxNDIw_90853979-a276-4dc5-8efa-36e44cd125c9"
      unitRef="usd">8291000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzItMS0xLTEtMTAxNDIw_df6f14d7-a804-4310-be73-0f97aec2eed2"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzMtMS0xLTEtMTAxNDIw_139b795c-d337-4a24-ad92-f5b9fc3a0b5c"
      unitRef="usd">4958000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90YWJsZTpmYjQxMWE3ZDhmZTQ0OGEyOTM1MDRhN2JhNzg2ZjMzZS90YWJsZXJhbmdlOmZiNDExYTdkOGZlNDQ4YTI5MzUwNGE3YmE3ODZmMzNlXzQtMS0xLTEtMTAxNDIw_8c190932-6f43-472b-b9f8-840a4a6df0c4"
      unitRef="usd">9262000</us-gaap:ContractWithCustomerLiability>
    <evh:CustomerDiscountsFromPerformanceObligations
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzY1OTcwNjk3ODE3OTI_2e501436-1644-4146-89b6-12ee6a5192f4"
      unitRef="usd">1500000</evh:CustomerDiscountsFromPerformanceObligations>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzcwOTM_a3f0b852-bde0-4be0-8702-60260615fbd6"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i1142e9b4f22b41bb9861d40caedc8272_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzc3ODQ_8f4390a5-72fc-42f5-9b48-b6f995cceb65"
      unitRef="usd">3400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i409e1ed35fec45debbcfcdca8b668bc1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzc3OTE_09b0c647-ee43-41d7-917f-bd6d823805bb"
      unitRef="usd">3900000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ie26be0edc14d47eb99b84495e133ece4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzgwMDU_22686917-6dab-4f70-809c-acf13beba6f1"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i70b0d3db141e42d9ba27945974ed98be_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzgwMDk_9a7e5c42-71dc-434d-be71-bab3763a0746"
      unitRef="usd">1400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="ib92fd7517b7e45d8a3a28cf15450d165_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzg3ODc_3cb2b2c2-80a0-488e-bd31-d45bcf3c0fe4"
      unitRef="usd">13100000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i3a5199740c894c7990588a57d16a827c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2Xzg3OTQ_cee4bf22-20bf-4023-a867-d7b1dd54d9dd"
      unitRef="usd">18100000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ib4d813436fe64f6cb913aa801cecded5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkwOTE_0906913e-26fa-4241-b632-e41f5a856e8d"
      unitRef="usd">2000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia8bfa3c9233e49a3885fdb8cd2d590db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkwOTU_689c5340-69c4-41fd-b20d-5377fb82cfa7"
      unitRef="usd">10300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzAvZnJhZzozYjAxYmQ2NmFlMzY0NjRjYmZjMTcwOTA1M2RmMWJhNi90ZXh0cmVnaW9uOjNiMDFiZDY2YWUzNjQ2NGNiZmMxNzA5MDUzZGYxYmE2XzkzMzQ_5b275c2f-bd46-4f48-ac83-95d6e033563a">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzMzMTU_11d7d4c5-ffe3-4983-b0f9-b767fc1f9163">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, current inflationary pressures on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the three months ended March 31, 2023. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, we did not record material changes in our allowances during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;March&#160;31, 2023,&#160;70% were current, 23%&#160;were past due less than 60 days, with 26% past due less than 120 days and at December 31, 2022, 67% was current, 21% was past due less than 60 days, with 29% past due less than 120 days. As of&#160;March&#160;31, 2023 and December 31, 2022, in total we reported on the consolidated balance sheet&#160;$284.7 million&#160;and $269.1&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$15.1 million and $10.2 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NIA acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzIzNDI_9bc02185-6538-491e-8431-67e94af96568"
      unitRef="number">0.70</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="ic21943cdf8a049d2a24adf36d3b79cd8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzIzNTk_307ee511-f2a2-44ce-a783-d03151fd79b2"
      unitRef="number">0.23</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i70f46329635e4437b8068a2610a354f6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0MDA_0f0d29c0-74f3-48c8-8730-6362a6859d0f"
      unitRef="number">0.26</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0NTc_ed56937d-d56e-425b-a99d-3faf5abd8b59"
      unitRef="number">0.67</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i15da874ddc524d2285a2fb1df7a7623c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI0NzM_6727208d-92df-4a3c-ad11-63ba785cf0a4"
      unitRef="number">0.21</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="if821daf7eb8c4bf3bcdc0fd5e08f4ed1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI1MTM_4d36ef4b-12e9-4370-ae03-4abd872546f3"
      unitRef="number">0.29</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI2MzI_08bfbc45-0342-4640-b5fc-a89c83a4325e"
      unitRef="usd">284700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI2Mzk_67f5a672-c325-4b35-a98b-ae67112f180c"
      unitRef="usd">269100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI3ODA_f471cfc4-8131-4f64-9d04-a4e6f1484de4"
      unitRef="usd">15100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzI3ODc_4e599237-769d-475b-8f5d-f7524ccc5385"
      unitRef="usd">10200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90ZXh0cmVnaW9uOjE1MWUxYTY5M2VkMTQwMGI4ODYwMzFiMTExMDNkYTJlXzMzMTY_420e5157-7564-46fd-83aa-60bb6f2cddf1">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NIA acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzItMS0xLTEtMTAxNDIw_017dea71-6a67-4507-952b-cd935904e275"
      unitRef="usd">10180000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzItMy0xLTEtMTAxNDIw_1176280c-555b-4eec-aa8c-e0d96ee76b26"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzMtMS0xLTEtMTAxNDIw_247886df-d313-446c-aacf-232c9ff02132"
      unitRef="usd">240000</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzMtMy0xLTEtMTAxNDIw_ba15cb0e-d84b-4115-bf18-92c54de8373a"
      unitRef="usd">0</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzQtMS0xLTEtMTAxNDIw_099a8730-2f02-4103-97e4-23920141c86d"
      unitRef="usd">5482000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzQtMy0xLTEtMTAxNDIw_3058302f-f773-49c8-ac05-a530d2b67145"
      unitRef="usd">-1203000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzUtMS0xLTEtMTAxNDIw_669610a8-c5f6-4982-ac21-779bd229328b"
      unitRef="usd">829000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzUtMy0xLTEtMTAxNDIw_802db86a-0983-4365-8140-79d079f382ed"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzYtMS0xLTEtMTAxNDIw_1cd1156a-b647-4094-b999-ed21d2e907fc"
      unitRef="usd">15073000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzYvZnJhZzoxNTFlMWE2OTNlZDE0MDBiODg2MDMxYjExMTAzZGEyZS90YWJsZTpjY2FiYzQ1YmJiYjE0MzJiYjJhNGFjMzA5Yjg3YWY3Ny90YWJsZXJhbmdlOmNjYWJjNDViYmJiMTQzMmJiMmE0YWMzMDliODdhZjc3XzYtMy0xLTEtMTAxNDIw_6cd9cc53-b611-448f-bd14-687b09efbc15"
      unitRef="usd">2171000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzcxOQ_615b6593-7ddb-4a1c-93c9-f59a587c93b3">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $8.1 million and $6.4 million for the three months ended March 31, 2023 and 2022, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $75.1 million and $73.7 million as of March&#160;31, 2023 and December 31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $8.1 million and $7.6 million for the three months ended March 31, 2023 and 2022, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.7 million for both the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzcyMQ_26b34986-8deb-4bc5-8e2e-3f7fe43835c1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3c753595d7f449f9388ce080153adee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzMtMS0xLTEtMTAxNDIw_18c36ca7-786a-405f-99d8-c0859b4ee7b5"
      unitRef="usd">30441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ab74d6cb3834527b8ae1fc110c1c9b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzMtMy0xLTEtMTAxNDIw_e9d017bd-715a-43a5-bfde-3c9be42942fb"
      unitRef="usd">30092000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i896c0f919a744ccdab15d963fb3c518e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzQtMS0xLTEtMTAxNDIw_760f9ea6-acb9-4b95-a13e-45177bf071c9"
      unitRef="usd">4246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i909942c4cbc94b759e839fa9b4480c52_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzQtMy0xLTEtMTAxNDIw_f117e306-967c-4fd6-b40c-41efcb488173"
      unitRef="usd">4214000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i54563c905b50494cbe32a703a93fd3fc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzUtMS0xLTEtMTAxNDIw_4fe4c29b-76be-45f8-8362-f0c965dc20a4"
      unitRef="usd">197174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie224ebe8d58d426cbf7c6760029adacd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzUtMy0xLTEtMTAxNDIw_4240b7af-d4a7-4531-a6af-791aa221d8c0"
      unitRef="usd">189119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1064fdf19264fd6929844695005b91d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzYtMS0xLTEtMTAxNDIw_fd9facfb-0b2c-4d8a-bac2-bf676200552c"
      unitRef="usd">15390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7d5928ba2c6c467daaf522ca8262ec8f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzYtMy0xLTEtMTAxNDIw_8eec1c08-6413-4ad2-94c9-040c4d1b3687"
      unitRef="usd">14926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzctMS0xLTEtMTAxNDIw_abeb8126-7218-4d3c-9b2e-889bdb7d1e30"
      unitRef="usd">247251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzctMy0xLTEtMTAxNDIw_ae9bca61-1909-4ebf-993c-2851b7c8bb3a"
      unitRef="usd">238351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzgtMS0xLTEtMTAxNDIw_46b911d3-5476-4bf5-a45d-c9013ff15b92"
      unitRef="usd">158645000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzgtMy0xLTEtMTAxNDIw_1d77ff36-8920-4079-8e0e-1f01cf3895a1"
      unitRef="usd">150477000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzktMS0xLTEtMTAxNDIw_80ee099e-285f-4072-aca9-e0259f7fbba6"
      unitRef="usd">88606000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90YWJsZTo1ZjYxMzc5NjA0MWQ0NzM1OTExMzc1YjYzZDExMzUwMC90YWJsZXJhbmdlOjVmNjEzNzk2MDQxZDQ3MzU5MTEzNzViNjNkMTEzNTAwXzktMy0xLTEtMTAxNDIw_a490f050-47b5-44fa-ab8d-a6d842126297"
      unitRef="usd">87874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ic3065bc9a90f4c3593d40da7cd173ea0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzEzOA_138c6b5a-1160-4601-bf4b-9cc205b49eb6"
      unitRef="usd">8100000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ib551ddbba6244ae19cb603ed8c3a6e65_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzE0Mg_6745908f-2a60-42b5-a96a-88365f4dbcb4"
      unitRef="usd">6400000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzM0Mg_c4b3c34e-96e1-4b93-bf6d-90ea5a55ecb3"
      unitRef="usd">75100000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzM0OQ_43435e7d-0d26-4656-9776-e2d644b92485"
      unitRef="usd">73700000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:Depreciation
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzQ1OQ_8ba00afe-c222-4c7f-af74-a296c4003224"
      unitRef="usd">8100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzQ2Mw_880747c8-8a27-4b01-b80a-b75e8f825037"
      unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzYzOA_25e2950d-7136-460b-9e58-7b01a9a2e750"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMzkvZnJhZzo2NTUwZjRkYjRhZjI0ZDcwOTBiMDhkMjQ5MDc2MTcwOS90ZXh0cmVnaW9uOjY1NTBmNGRiNGFmMjRkNzA5MGIwOGQyNDkwNzYxNzA5XzYzOA_bdfee8af-7c7d-43e5-a9bf-c6e2cf0d33d0"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5NDA_1299d00a-9480-4f02-8fdf-a65e7787372e">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2023&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We will perform our annual impairment test of October 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#x2019;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceeded directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#x2019;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of NIA in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets was $21.1 million and $7.5 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2023, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the organizational changes as a result of growth in our value-based specialty care business, we re-evaluated the useful lives of our intangible assets. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the three months ended March 31, 2023, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzM4MTU_6acc0a99-602e-40cb-bfdb-93adab8adaf5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5NDY_bc8825b6-4fbc-4ce8-82b9-ccb2f4184bca">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of NIA in January 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzEtNS0xLTEtMTAxNDIw_6aa43c6d-8a65-4e7d-aa40-364ff4d30890"
      unitRef="usd">722774000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzItNS0xLTEtMTAxNDIw_b533599b-c531-4db7-9d70-664ad1f0c6a6"
      unitRef="usd">395164000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzMtNS0xLTEtMTAxNDIw_6d2359fe-8dad-4453-aa23-64fd57896d41"
      unitRef="usd">7000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzQtNS0xLTEtMTAxNDIw_6f503a04-a927-4fc1-a78b-5ae34f172a7d"
      unitRef="usd">1117945000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzktNS0xLTEtMTAxNDIw_d34cd44d-a3c5-49fa-b960-7b076164c883"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzExLTUtMS0xLTEwMTQyMA_f6ea9eb5-0176-4cab-99ac-3a6e54a5c759"
      unitRef="usd">-23000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTpmYzk5YzY1NzAxOWM0ZGVkODI1NmI0ODg0Y2ZjMGI0NS90YWJsZXJhbmdlOmZjOTljNjU3MDE5YzRkZWQ4MjU2YjQ4ODRjZmMwYjQ1XzEyLTUtMS0xLTEwMTQyMA_99f66228-5b86-41f6-b835-444fa3acf24d"
      unitRef="usd">426274000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUwMzA_0a6695d5-15ba-4577-b659-887b163bf970"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUwMzA_1bf6e9fa-303d-4453-aa27-d8ca754f8e74"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ide3f10e694c940868bd2594ab2017b6a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMS0xLTEtMTAxNDIw_e80d595c-25ad-4cb5-acac-aefb59d88ee7">P1Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMy0xLTEtMTAxNDIw_dc06656d-6784-44a9-9303-ef25c8e84f4f"
      unitRef="usd">51965000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItNS0xLTEtMTAxNDIw_deac7d1c-ad19-4d67-ab77-f70ceb9fc496"
      unitRef="usd">16967000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i45f15675963148d9b7c73a2c1b0ef222_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItNy0xLTEtMTAxNDIw_ae308293-cf84-437c-8c20-c83190e93999"
      unitRef="usd">34998000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6de16ded6120471a80302f91bbee7b2a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItOS0xLTEtMTAxNDIw_a8bbe564-4160-44a6-b1a2-fee5495e4f8f">P12Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTEtMS0xLTEwMTQyMA_71ee6891-7bc8-450a-80e6-13d39a6a38f0"
      unitRef="usd">43600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTMtMS0xLTEwMTQyMA_44f3cef7-e486-41dd-b34e-3614a5921c0a"
      unitRef="usd">11726000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i288455705c274ce2a2bd943c0f0704a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzItMTUtMS0xLTEwMTQyMA_d758b72f-72fb-4139-a1bb-48b3c230b110"
      unitRef="usd">31874000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3f561ad00b584a20ab6ac5a564705e71_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMS0xLTEtMTAxNDIw_a1358115-da51-4798-a059-9cc473eeda52">P15Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMy0xLTEtMTAxNDIw_b27cc0f2-a8b2-4349-a973-eb4480eb709c"
      unitRef="usd">810119000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtNS0xLTEtMTAxNDIw_a02334fc-e346-44c5-afeb-5edc99218944"
      unitRef="usd">103694000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibde355312eba4648bb0122ec21bd976e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtNy0xLTEtMTAxNDIw_86f29afb-d8a6-40cc-9d44-6522cc6262ea"
      unitRef="usd">706425000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i67bf39ef96634f3193ea5f32553d096d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtOS0xLTEtMTAxNDIw_c9401f24-582f-4ea4-8fa1-74889d11fe26">P15Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i868a181629a048b69538d93b32b52ff9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTEtMS0xLTEwMTQyMA_9d323b4c-5cab-4349-9f8d-1b1f5389b4f6"
      unitRef="usd">465019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i868a181629a048b69538d93b32b52ff9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTMtMS0xLTEwMTQyMA_73555fe7-de38-4961-856b-b6f07581aa9b"
      unitRef="usd">92760000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i868a181629a048b69538d93b32b52ff9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzMtMTUtMS0xLTEwMTQyMA_9f827445-6295-48ee-b68b-4278aa2aa4a0"
      unitRef="usd">372259000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8fae892598234158a4ae8ce37c46d1cb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMS0xLTEtMTAxNDIw_5473bad9-bd0b-42cd-a1db-eba15a468f67">P2Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6712e972d4564a6a96307887c4567b00_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMy0xLTEtMTAxNDIw_2a82a16b-ca5a-4d42-913d-38785466cd39"
      unitRef="usd">162522000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6712e972d4564a6a96307887c4567b00_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtNS0xLTEtMTAxNDIw_8ddf04af-3ec1-42b8-8f66-8e9f1cc19781"
      unitRef="usd">83970000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6712e972d4564a6a96307887c4567b00_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtNy0xLTEtMTAxNDIw_e28e1ba5-9a15-4db6-bb77-2ea24cb8559d"
      unitRef="usd">78552000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i52491c9a83874a978dbed3b6892d4798_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtOS0xLTEtMTAxNDIw_449c8ffa-d1e3-41df-8636-c686984732cc">P2Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTEtMS0xLTEwMTQyMA_8566e62f-4a60-4624-93bf-a8c795a420b5"
      unitRef="usd">111822000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTMtMS0xLTEwMTQyMA_d1d33baf-8107-4375-8640-51cd619775b5"
      unitRef="usd">80255000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8ea0fcfe4caf4ea787ab931809c49aaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzQtMTUtMS0xLTEwMTQyMA_d6af5cbd-4c64-46a2-a0a2-ef7d053a71bb"
      unitRef="usd">31567000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i56fee09db1334b68b2b6dbd706c21116_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMS0xLTEtMTAxNDIw_c3cbd56e-7a7e-4c14-9685-f379810ff1d8">P0Y1M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMy0xLTEtMTAxNDIw_cfadc440-11ec-4419-87ff-dcbf482b5c9d"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtNS0xLTEtMTAxNDIw_916a3022-1b27-4ce0-a443-711cd77c2b38"
      unitRef="usd">1200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie99257a4824a4d16997f882b92ea6a96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtNy0xLTEtMTAxNDIw_4e255b90-d0f2-437c-9bbb-ef7339ede337"
      unitRef="usd">18000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i85b523dd4c194164ab39eb63ab1206c2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtOS0xLTEtMTAxNDIw_924ae75d-a14e-4e5a-8962-1fbe1efa5221">P0Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30b51a2db0824da5929aaac343723403_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTEtMS0xLTEwMTQyMA_ddc48bce-c5db-47c9-babb-227a33387e0b"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30b51a2db0824da5929aaac343723403_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTMtMS0xLTEwMTQyMA_86b46f77-1c64-45f4-b1c5-5ba3afd84f11"
      unitRef="usd">1151000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30b51a2db0824da5929aaac343723403_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzUtMTUtMS0xLTEwMTQyMA_9d14408c-3041-44ee-a8df-a48fd2d37989"
      unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia53c692cc90544f49ce6bab9b750a5d9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMS0xLTEtMTAxNDIw_96004a4c-4332-4113-9507-4cae88602f18">P1Y1M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMy0xLTEtMTAxNDIw_e467c76f-7af1-48f4-bd3f-bec0d7c36038"
      unitRef="usd">18861000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtNS0xLTEtMTAxNDIw_d739b160-3e8f-4138-85c0-08d9aba7bb74"
      unitRef="usd">12997000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i06d9de3c22fb4970a3e79ed7c60971ba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtNy0xLTEtMTAxNDIw_45e9db64-241b-4573-8aa8-96eed4860d00"
      unitRef="usd">5864000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8e47ddf7af144c3bb65fd8dfd91cd016_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtOS0xLTEtMTAxNDIw_fb5936b6-e5c9-4566-811a-6ce32c16fb4d">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTEtMS0xLTEwMTQyMA_1e96b0e5-ca4a-4f5f-a182-f347c419ca17"
      unitRef="usd">18851000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTMtMS0xLTEwMTQyMA_b3823eac-21b0-4a31-8c63-14d545d396f0"
      unitRef="usd">11834000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i08da2b7f0d10418aab0845f0fb542546_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzYtMTUtMS0xLTEwMTQyMA_0b0a869d-7c7b-4d15-af5a-28aea8d699da"
      unitRef="usd">7017000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMy0xLTEtMTAxNDIw_85edabd0-88d0-4fe2-b9ff-fa7d1e92da24"
      unitRef="usd">1044685000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctNS0xLTEtMTAxNDIw_4c7c1903-e96f-4b92-86bf-7a71edd65d89"
      unitRef="usd">218828000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctNy0xLTEtMTAxNDIw_ed6586a4-dbb8-4ca9-b4ab-a30981ac6162"
      unitRef="usd">825857000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTEtMS0xLTEwMTQyMA_ac867a72-3b08-4f9a-9bf6-a3013e46ba89"
      unitRef="usd">640510000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTMtMS0xLTEwMTQyMA_2fdea8a0-f439-4792-84d4-faf228866137"
      unitRef="usd">197726000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZToyZGZjMDkxZTAzNTY0MWU0ODM4MWYyNjMyNTI3NDU1Yy90YWJsZXJhbmdlOjJkZmMwOTFlMDM1NjQxZTQ4MzgxZjI2MzI1Mjc0NTVjXzctMTUtMS0xLTEwMTQyMA_e4427901-9972-4721-8ab6-38a8054c0f24"
      unitRef="usd">442784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUzMjg_eae7bb01-e997-400e-b9c0-19d1ca5dacad"
      unitRef="usd">21100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzUzMzI_2f14b509-c4e3-46ab-907e-991881925e99"
      unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90ZXh0cmVnaW9uOjE5OWIyNTU2ODliYTRkYWNhZWNkYjZmZDQ5YzY4ZGQ2XzU5MzI_2c37c676-89de-4c8d-b9d0-249669032514">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of March&#160;31, 2023, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzAtMS0xLTEtMTAxNDIw_cf8719d4-6f98-441e-b166-54aa98cbe12d"
      unitRef="usd">69945000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzEtMS0xLTEtMTAxNDIw_dde4f547-47f5-44dd-9134-ecf9ba7593e2"
      unitRef="usd">87529000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzItMS0xLTEtMTAxNDIw_1dabd3e7-a64c-4179-bb5a-7dc072d8ce5b"
      unitRef="usd">63641000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzMtMS0xLTEtMTAxNDIw_1f6c97e5-6e90-42a5-bdf5-83b0719c0815"
      unitRef="usd">63293000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzQtMS0xLTEtMTAxNDIw_2a1fac6a-a8a5-4bdb-a632-11242d640d25"
      unitRef="usd">60552000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzUtMS0xLTEtMTAxNDIw_89f9617d-8822-45d4-bf46-4d9c1cde07fb"
      unitRef="usd">480897000</evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDIvZnJhZzoxOTliMjU1Njg5YmE0ZGFjYWVjZGI2ZmQ0OWM2OGRkNi90YWJsZTo0NjA5NjkzMTYzOTE0NWRjOTlkNTNhYjNkNDI4YjI4Zi90YWJsZXJhbmdlOjQ2MDk2OTMxNjM5MTQ1ZGM5OWQ1M2FiM2Q0MjhiMjhmXzYtMS0xLTEtMTAxNDIw_c344d95c-db79-452f-946f-e2deb10a6b61"
      unitRef="usd">825857000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIzNDYy_d52cb4ae-2c71-4020-8cf3-7dd149c582b5">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022 (the &#x201c;IPG Closing Date&#x201d;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, collateral agent and revolver agent (the &#x201c;Existing Credit Agreement&#x201d; and as modified by the Amendment (defined below), the &#x201c;Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) initial term loans in an aggregate principal amount of $175.0&#160;million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) revolving credit commitments in an aggregate principal amount of $50.0&#160;million (the &#x201c;Initial Revolving Facility&#x201d;), the availability of which shall be determined by reference to the lesser of $50.0&#160;million and a borrowing base calculation. The Borrowers borrowed full amount under the Initial Term Loan Facility and the Initial Revolving Facility on the IPG Closing Date. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Initial Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Initial Revolving Facility was paid as of the IPG Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2023, (&#x201c;the NIA Closing Date&#x201d;), the Company entered into Amendment No. 1 to the Credit Agreement (the &#x201c;Amendment&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) additional revolving commitments in an aggregate principal amount equal to $25.0&#160;million (the &#x201c;Incremental Revolving Facility&#x201d; and together with the Initial Revolving Facility, the Revolving Facility&#x201d;), and (ii) additional term loans in an aggregate principal amount equal to $240.0&#160;million, (the &#x201c;Incremental Term Loan Facility&#x201d; and together with the Initial Term Loan Facility, the &#x201c;Term Loan Facility&#x201d;; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the &#x201c;Credit Facilities&#x201d;). The Borrowers borrowed the full amount under the Incremental Term Loan Facility and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) 3.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 3.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facilities are guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain customary exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain customary exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All loans under the Credit Facilities will mature on the date that is the earliest of (a) the sixth anniversary of the NIA Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate for the Loans is calculated, at the option of the Borrowers, (a) in the case of the Term Loan Facility, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of the Revolving Facility, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. The Company recorded $11.1&#160;million in interest expense related to our Credit Agreement for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Credit Facilities may be prepaid at the option of the Company, subject to the following prepayment premium (the &#x201c;Prepayment Premium&#x201d;): (1) 3.00% of the principal amount so prepaid after the NIA Closing Date but prior to the first anniversary of the NIA Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the NIA Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the NIA Closing Date but prior to the third anniversary of the NIA Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the NIA Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction, in each case, subject to application of the Prepayment Premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Loans. We incurred $14.4&#160;million of debt issuance costs in connection with the Loans, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the Credit Agreement. The Company recorded $0.5&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company repaid $37.5&#160;million under the Revolving Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $0.2 million, $1.0 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.2 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#x2019;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. The Company recorded interest expense of $0.6 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.3 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of March&#160;31, 2023. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3f1b4ec02a7342fcb85559bcc229e583_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzYxMQ_9178f13d-70c8-42e6-b0c8-d280f27e0c47"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2b7598f678494d1aab584ad521987519_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY5NA_4d25f711-8b1a-4bab-a5a3-4d7ca3f72a67"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2b7598f678494d1aab584ad521987519_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzc0NQ_f80d6aa3-4e7b-4d67-bf66-fbe459c245d5"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <evh:DebtInstrumentClosingFeePercent
      contextRef="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1Njc_68337f1e-e838-4041-b189-d0aa623fe5fe"
      unitRef="number">0.0200</evh:DebtInstrumentClosingFeePercent>
    <evh:DebtInstrumentClosingFeePercent
      contextRef="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1NzQ_699a3c9c-d776-4c6d-8f9b-c776c28b6838"
      unitRef="number">0.0200</evh:DebtInstrumentClosingFeePercent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8ff112cad23c4514bbfbb8c0655c94d0_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMTAw_032d6af8-1403-437f-9ec9-c0d231abbbd2"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ica07830c52aa4ce3a36a9196d7fd69c8_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMTA0_563752e5-52ad-421c-af6a-5de54f0acf62"
      unitRef="usd">240000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <evh:DebtInstrumentClosingFeePercent
      contextRef="id3f428993e84490da09219c15b871fd2_D20230120-20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1ODE_947832e3-fd3d-4c78-8e72-f43f5a018b3b"
      unitRef="number">0.0300</evh:DebtInstrumentClosingFeePercent>
    <evh:DebtInstrumentClosingFeePercent
      contextRef="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2NDkyNjc0OTc1ODg_a7173abe-5812-4d26-b11c-27164ee57275"
      unitRef="number">0.0300</evh:DebtInstrumentClosingFeePercent>
    <evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity
      contextRef="ib555a608339b4391936bd7315dbe8d6b_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyOTg1MzQ5MTk4OTM_8220c4e0-b397-4896-97b3-836e7653ef31"
      unitRef="day">91</evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i89ea6a7579f0498aaad68c4136be1a8e_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI1Mjc_1af6002c-9f66-42bb-a947-1d8500408006"
      unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie61f8c08dc6542cab575508067f47573_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI1NTM_772aa22f-39f0-4cf0-96bf-b54b97cc2182"
      unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if0d005b9b6f94895a2093108ec4023c1_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2NDA_b1d0ad1a-6cd9-4253-9008-bab1e553af8e"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic49c939410944f6892ee284ba7b362a4_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2NjY_7a604f8c-69ef-487c-80bc-cae98ab3507b"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i70c8a2427eb04e608ae552366bb2a7d3_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI2OTQ_324185ae-2b11-4c86-bfb4-9f87cbbe8d35"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic1ae078bbbfb4460b44df3f990ac91be_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI4MDM_a5b953b9-8db6-4c35-b2c3-8f1f1f754db7"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzI5MzU_618f9f1a-db4e-430a-8ea5-c176f3a2185e"
      unitRef="usd">11100000</us-gaap:InterestExpenseDebt>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent
      contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyMjI_8cab52a4-d522-4069-8c76-eb7178eab564"
      unitRef="number">0.0300</evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent
      contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMzNDI_688abcbf-aecf-402f-9897-c2a558cef48b"
      unitRef="number">0.0200</evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent
      contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzM0ODg_236b018c-f731-4ef9-882e-9eb7b07c1306"
      unitRef="number">0.0100</evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent
      contextRef="i9a27d95f20f74caf87734e8b0d0f0be0_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzM2Mzg_753a2c50-a653-494c-9732-f75fd36fd66b"
      unitRef="number">0.0000</evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i6af1d7c94ffa4dfdb1daac49c0bdcc06_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzQ3NTA_38e851bd-e3ec-486f-8725-ee442d8eba61"
      unitRef="usd">14400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzQ5OTY_b61eaa3d-6389-4bf3-bc83-b6bce9fa5ae0"
      unitRef="usd">500000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="iee0ccfb937d04787b9a2edcb589528a9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzMyOTg1MzQ5MTgwNTE_89f85cfe-cc2a-4ba0-8b2e-3acde0dbec2b"
      unitRef="usd">37500000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzUxNDc_4e042835-d1c4-417e-a9cc-3a549df7992c"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzUxODQ_493307d4-3217-450c-8499-d0ae2fb69351"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0MDI_426d5ca9-b5aa-4731-b823-19d4f493770f"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i86c90a6284344462a51488ae0069e122_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0NzA_d2be7773-a942-4648-b0bc-4dadc4931e28"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie251d99bd74345e1bc9460f66244b376_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU1NTk_994bb731-c735-4ff7-b644-54d1cb20ee6f"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i657a6cf3c44d4a4082d16bcf0b007b3e_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU1NzQ_031dca44-a369-425b-a818-32bef8d8e838"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU2NTQ_df55fef4-4ce0-49a8-8afb-25d25f68e216"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzYyMTA_d4e21623-2fdb-495e-a0d2-737c7fa953a8"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY1MTg_27b028dc-1086-43d2-9619-683174caecdc"
      unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY1MjM_576d9f95-9aa2-4413-8957-bb1a51908650"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzY5ODU_06307783-1c19-44bb-98d6-33a3b32d565d"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzcxMDE_62e40106-f049-43e5-acf7-4c5332a8f5f8"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgwMTY_8abff5b2-cce4-40af-9814-787382462883"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgxNjU_c122eaf5-0835-4218-9f78-e72e40789079"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgyNjA_a09e0db5-a67a-4008-b6f2-a79cd2c81ce9"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6b77390117574b05b6853a2e6cdfd5a0_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgyNjc_9c25516a-2e6c-486e-ada9-ab5b6a687285"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if07c7d644b54454892b0ecdf3263db18_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzgzOTk_f355e21f-5504-4779-8d3e-751d012b0498"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="idee11c2ef7d44c05b143e3c697bfe00b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzg0MDM_8691ea7b-caee-4efb-a1cb-22002e4b9a52"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:StockholdersEquity
      contextRef="i5e0dbffb9cb44a82b9230fee7cbb2e8e_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkwODI_101fe3d2-1a0c-4033-8f42-ca2b523bf244"
      unitRef="usd">-38100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id09a99b6604145a39f0c6f2102806ba5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkxMzA_a2e041c0-7324-4204-8423-6af8071dc57d"
      unitRef="usd">1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7820004852704049885c737ed680c6c8_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzkyNzE_a77b28cb-7d61-44ba-b9f6-b130b7e0322b"
      unitRef="usd">-11700000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i08db4cba39da4c2daa8e8a98eec10995_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1Xzk1NTM_c2b63661-6270-42d3-b6a1-9f9128344bc3"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMDI2_36656f7b-df7a-48d8-bdb4-8ade822fe3ce"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i13ada70841b74e98b6e8c962e9de3e61_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMDI2_40ee3e1e-9ecb-41d7-9e77-34a83bd1a225"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwMzc0_90285e3f-8d48-4891-b01f-cf9dcc1ce3eb"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwNzk1_90232ecf-3379-438f-8215-84c22be6a836"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwODUw_d7fb41dc-9ddc-477c-9e33-6b0d7529b5e0">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzEwOTA2_30ca3350-038d-4352-8ad8-ab9827807034">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i9205f5d91e6d438584e7239706dd3c32_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExMTQ0_8caf042c-9e05-4f3a-b65f-a34e21fa61b2"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="ib6487f01387746f0ba7463b6968f241d_D20220811-20220811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNDMx_a6d4d44c-dacb-4d09-8ffe-c81bffd034f4"
      unitRef="usd">92800000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i97ba4e8ae10c4f378bae69514e2fe2bd_D20220817-20220818"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNjIw_0b9e2577-ba28-4759-8163-635c194e29c5"
      unitRef="shares">5394165</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4b149b5c258542fb966a78ac8c73abec_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzExNzU0_e022a39e-3757-45eb-9555-4e5bdb94e37b"
      unitRef="usd">-10200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE0Nzk3_afe41d61-84b8-47a1-ac8c-f0dd0f5dd75e"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE0ODM0_069f7de9-0e7e-487a-a785-b5261fe41ccc"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MTAy_6f35ed9f-b6e9-4921-9446-43919459c390"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8b58c2da78614c1f968d97ed45d71235_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MTE4_b73a02ac-c7d7-4f32-a16a-a4018d5cd5b7"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7659a2a5a47648a180caf848566c901e_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MjE5_e9cf8351-69a4-4543-9e8c-bbd22361b523"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic12584d85379426290b0c22a08b05259_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1MzQ3_92d7bcf2-9cec-407d-b4cb-538172013a22"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE1Njg3_069f7de9-0e7e-487a-a785-b5261fe41ccc"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0OTc1NTg0MjMyMA_450cdc4c-6a35-42e9-841c-66ed25ada687"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzU0OTc1NTg0MjMyMA_57ef5737-54de-476b-9197-59e0f19580ed"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2Njcz_f39986c3-d6c8-4591-926d-0ed2dc3f81d1"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE2Nzg5_10163995-c4b1-49c6-b8f4-55d5ffe1d553"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE3Njk3_35621025-6a71-456f-ad27-0e2854827de9"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iab32404962a644bdabfcb08801f645a6_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE3ODQ2_d81fa645-69d3-46d9-ba4f-4c6a1fe2d846"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MDU3_0ce2078e-6521-49ed-92e3-6554bac00253"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i512e2046bfad40b18b8f73ffbb1a4ded_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MDY0_2bbfc03a-9ac9-4973-b136-d9d04065bd6b"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iab32404962a644bdabfcb08801f645a6_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MTk1_d81fa645-69d3-46d9-ba4f-4c6a1fe2d846"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8dba2151c89f438db4f1b097c4343947_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4MTk5_0ce2078e-6521-49ed-92e3-6554bac00253"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquity
      contextRef="i2be0a365f4f7429497792fd03ebd83c0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4OTI1_316f0c69-4f1e-441e-9069-8be6891c5455"
      unitRef="usd">-71800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7719930d21144dfb90251ca3af9cdb73_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE4OTcz_f947e75d-1185-4676-b1f0-5cec6aab3fff"
      unitRef="usd">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4eb00e88f2384aedbcc301007edfb9e1_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5MTEz_5c1cb48e-dcc2-451f-896b-fbbf2c79915b"
      unitRef="usd">-28100000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="ib604663c86e447178b86e5bd16de84b7_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5Mzk1_557612ad-18b1-4266-a726-9c9c31734fb4"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i70c248f6f595430cbbb777c579eaa50b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5ODY4_14a17087-ff23-46c9-a705-b155dca5811e"
      unitRef="usd">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4ea30038b4ed4c8d80d30a37fec3889f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzE5ODY4_e546ae68-f4a1-4f48-a03b-f24c618b10cb"
      unitRef="usd">300000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwMjE2_b064df25-dc60-497d-93c9-0686c93e5f83"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNjE1_47d27ddf-f850-4c9b-9118-b900cef88799"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNjcw_55d49d11-e3ee-4dac-9842-a4b619391a16">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwNzI2_3a02ca0e-256a-4974-b0f7-12aa646b60f1">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="ie344619191144b9ab11a9785b7c582ee_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIwOTY0_56db02c7-2f74-4140-91bd-17dc463b99dd"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90ZXh0cmVnaW9uOjkzOTM3OGIxODIyZTQzYzI5ZWQxOWZhNDA0MmU2MTk1XzIzNDYw_10ba2491-5a92-48dc-a3a2-e440d78eef60">The following table summarizes the carrying value of the long-term convertible debt as of March&#160;31, 2023 and December 31, 2022 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzMtMS0xLTEtMTAxNDIw_65856fd4-df31-4535-a718-03fbd599ae5f"
      unitRef="usd">23971000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i16491b7341a141c18afc36d401c76145_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzMtMy0xLTEtMTAxNDIw_e740536f-4128-4f47-b331-c460eb5465e9"
      unitRef="usd">23925000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzQtMS0xLTEtMTAxNDIw_9fce5ec3-0253-4aa8-b1b2-0dd3f60a7410"
      unitRef="usd">310000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i16491b7341a141c18afc36d401c76145_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzQtMy0xLTEtMTAxNDIw_f9a17b95-dff8-4f2a-99bd-11169b6ea36b"
      unitRef="usd">356000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzUtMS0xLTEtMTAxNDIw_0ae3e7d4-8df5-4c3f-94b6-f515032ff583"
      unitRef="usd">24281000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i16491b7341a141c18afc36d401c76145_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzUtMy0xLTEtMTAxNDIw_e99d1709-632d-478b-b13c-d641ed4af1bc"
      unitRef="usd">24281000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i88b11fb976df4da5ae72ddeb8758f9a5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzYtMS0xLTEtMTAxNDIw_0a8edc9f-db9d-4857-985b-e658f2cd6698">P1Y8M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i16491b7341a141c18afc36d401c76145_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzYtMy0xLTEtMTAxNDIw_b80f6398-71c8-4ee6-b968-63247922458b">P1Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="if5726574012447b8981b087a4fceaa8e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzctMS0xLTEtMTAxNDIw_296283fa-f271-482f-bda4-ca1956294d94"
      unitRef="usd">38000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i32d2ca0bd32c485ab1c987f756ff7c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzctMy0xLTEtMTAxNDIw_70a53efc-3634-4bd0-810e-a41fd5c74ad6"
      unitRef="usd">38000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="id9845ada53344e68b0860c3e9255db86_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEwLTEtMS0xLTEwMTQyMA_02144640-1419-4124-bf50-2ee38945f267"
      unitRef="usd">169205000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEwLTMtMS0xLTEwMTQyMA_7d841c27-f0dd-4876-bbb8-c169ba08352b"
      unitRef="usd">168885000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id9845ada53344e68b0860c3e9255db86_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzExLTEtMS0xLTEwMTQyMA_bf8ecfff-5787-495c-8bbd-1f78fc4a23a1"
      unitRef="usd">3295000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzExLTMtMS0xLTEwMTQyMA_0f27b4f9-d274-4094-987c-8a1a3042d6e4"
      unitRef="usd">3615000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id9845ada53344e68b0860c3e9255db86_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEyLTEtMS0xLTEwMTQyMA_bf9b9f6e-2f7d-4da4-8794-88e8cb227726"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEyLTMtMS0xLTEwMTQyMA_c6311bd4-d57a-460b-a676-4a4035e24a08"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="id9845ada53344e68b0860c3e9255db86_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEzLTEtMS0xLTEwMTQyMA_ae90f837-d0dc-4adc-85c1-7dee36c206bb">P2Y6M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i3b0e4886fee54c19a088f62ee322a948_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzEzLTMtMS0xLTEwMTQyMA_8d09b6e4-8170-4274-a4c2-bb5bbdf218b2">P2Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9416432cd74f4712b91100ee7fbc1c94_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzE0LTEtMS0xLTEwMTQyMA_2f5d6e66-4521-4f02-8482-413aa38e90b2"
      unitRef="usd">192605000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie3eb67937fde4b28be9e30e00861878f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNDUvZnJhZzo5MzkzNzhiMTgyMmU0M2MyOWVkMTlmYTQwNDJlNjE5NS90YWJsZTpjOTBhZjQwOGY4ZWQ0ODgyYTE4OTY0OGVlMTMzNjMwNS90YWJsZXJhbmdlOmM5MGFmNDA4ZjhlZDQ4ODJhMTg5NjQ4ZWUxMzM2MzA1XzE0LTMtMS0xLTEwMTQyMA_d98525d6-ff25-45fe-9dc4-fb98cda12e7a"
      unitRef="usd">185546000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODA2_dbe0593a-4dac-4453-ad0b-9af0dd8fabd2">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both March&#160;31, 2023 and December&#160;31, 2022, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million, respectively, in restricted cash and restricted investments as collateral as of March&#160;31, 2023 and 2022, respectively. The letters of credit have current expiration dates between April 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of March&#160;31, 2023, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers. There were no expenses associated with the UPMC Reseller Agreement for the three months ended March 31, 2023, and $0.6&#160;million for the three months ended March 31, 2022. The contract is currently being wound down. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the reduction in the Company&#x2019;s valuation allowance primarily resulting from deferred tax liabilities established as part of the NIA acquisition, the Company has recorded the remaining TRA liability of $66.2&#160;million for the three months ended March 31, 2023, resulting in a total TRA liability of $112.1 million as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#x201c;Derivative Action&#x201d;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March&#160;31, 2023, approximately 99.1% of our $192.0 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.9% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company has not experienced any realized losses on cash and cash equivalents to date; however, no assurances can be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:357.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:86.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:86.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i27fb4a8e6dd3437b85cca6d4d9569ea7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE3NA_5274bd9f-734a-4fab-b8fd-08f7befb5b57"
      unitRef="usd">13100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id016a79790b94258b28de85b550d8edd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE3NA_e174498f-fa20-4210-8d3f-3444befbd0f3"
      unitRef="usd">13100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i507b0865bc8146928bbcd305853a7801_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzMwMA_54606c36-69cd-43c7-9007-f233624ce99a"
      unitRef="usd">13100000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2e2a5beda11b47868eb4cef319a84fbf_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzMwMA_db30049f-9ec9-4cc6-9da9-388708f5bedf"
      unitRef="usd">13100000</us-gaap:RestrictedCashAndCashEquivalents>
    <evh:LineOfCreditFacilityAutomaticExtensionPeriod
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODA4_991e3427-bdd3-4135-baa4-823164522b76">P1Y</evh:LineOfCreditFacilityAutomaticExtensionPeriod>
    <evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODE0_698d0cc8-0f4a-40d1-b6b4-de20003f1bca">P1Y</evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension>
    <evh:NumberOfCustomers
      contextRef="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY0MzM_d7e4e216-d4c6-40a2-b290-c2d0523b76b1"
      unitRef="customer">20</evh:NumberOfCustomers>
    <us-gaap:Revenues
      contextRef="i2117443d9fd0404b9c738c74555c7b46_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE2NDkyNjc0NjU2NjM_345297f4-5fb2-4c14-84a5-8a6195f38b8c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0b19710891c484c82d272a4acf72ba5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY1Nzc_59cd8638-c18b-4a09-88e1-420c51bc8db2"
      unitRef="usd">600000</us-gaap:Revenues>
    <evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzY4ODE_e91925bb-a381-4d92-9a69-ddaf65d8ad69"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzczMzg_a1f66602-dc46-424a-8139-3073f6de6f6d"
      unitRef="usd">66200000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:TaxReceivableAgreementLiability
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzE2NDkyNjc0NjU3MDE_8974d18c-0347-4e16-b623-a45630f2945f"
      unitRef="usd">112100000</evh:TaxReceivableAgreementLiability>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExMzMy_7a03a41d-dd29-445b-bb4d-0794191e805a"
      unitRef="number">0.991</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExMzQy_15a86276-bbcd-4818-84d5-573972949e24"
      unitRef="usd">192000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzExNDkz_af9c4294-3195-4330-a72e-d6144c1e71f6"
      unitRef="number">0.009</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90ZXh0cmVnaW9uOjUyZDhkMzdlZmRkYjQwYWI5NGQ3OGQyOTUwMTNiOGMwXzEzODE1_d57006c4-8707-49aa-8270-5645de47779c">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:357.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:86.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:86.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice83adaf23a14ba0a5a83118b1a20fdb_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzItMS0xLTEtMTAxNDIw_8419abe9-77a5-4467-8543-20bccf7d0c92"
      unitRef="number">0.346</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i637797ac467b47efa165f840c0332476_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzItMy0xLTEtMTAxNDIw_a37fd754-ec93-4263-be1e-3911cb04d06d"
      unitRef="number">0.425</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i25f7148e093b474dadb164557530b7b8_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzQtMS0xLTEtMTAxNDIw_154dc9d4-3cb8-4c89-9a90-b6db52677466"
      unitRef="number">0.178</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ae61262e7624b0d984871d542365619_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzQtMy0xLTEtMTAxNDIw_dee25749-e34c-4312-ac45-72972b6e8bdd"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12b6b23d17104a8e9b6c457000fbeea2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTo2MGY1NzU1ZmRlNWI0ODRjYTlmODJhYTc4YjE5OGU0ZS90YWJsZXJhbmdlOjYwZjU3NTVmZGU1YjQ4NGNhOWY4MmFhNzhiMTk4ZTRlXzUtMy0xLTEtMTAxNDIw_9ecb730f-c917-4d7b-a078-e8934a592187"
      unitRef="number">0.113</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7c0832ebff07400ea476f7c58f11cc67_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzItNS0xLTEtMTAxNDIw_94e29f4a-c528-4980-a879-102e645aec37"
      unitRef="number">0.172</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie192bdf6ff324e978b378295e4252596_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzItNy0xLTEtMTAxNDIw_d6f4ff6a-8384-4b3c-8a2d-337b7e6322b0"
      unitRef="number">0.239</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7f62d774a64e46899704a37239c377c3_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzMtNS0xLTEtMTAxNDIw_bc9f28c0-4390-48dd-bc7a-71ea1472fe95"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib29e30cc2b08429d885dd5e19d4d420c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzMtNy0xLTEtMTAxNDIw_14aa7156-f362-4691-9ede-bac941564197"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34fc6c7947c34d74ac1f466cf78dbd92_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTEvZnJhZzo1MmQ4ZDM3ZWZkZGI0MGFiOTRkNzhkMjk1MDEzYjhjMC90YWJsZTowOGI0NWJjZTgwY2Q0MmQ0YTM3ODMyNDkyNGJjM2EyMy90YWJsZXJhbmdlOjA4YjQ1YmNlODBjZDQyZDRhMzc4MzI0OTI0YmMzYTIzXzQtNS0xLTEtMTExMTQx_53a34e91-42fd-4989-ac20-aab9ccf77425"
      unitRef="number">0.132</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzM_756e6225-740d-4076-be00-6ac52a346c85">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $2.1 million in letters of credit as of both March&#160;31, 2023 and December 31, 2022, respectively. As of March&#160;31, 2023 and December 31, 2022, the Company held $2.1 million and $2.3&#160;million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of March&#160;31, 2023 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of March&#160;31, 2023, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzQyNg_8ee093da-7f25-4eca-a8c0-03fb1abbd553"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i23c68de8493844868847bcbb42b75777_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI2NjE_5ee25ddc-13a3-4c5a-ae7a-e8d144e6b58d"
      unitRef="usd">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic2494b7c3cda44bcb468b99115c25994_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI2NjE_f99e75b3-a8d9-4248-b2ec-ab825802fde9"
      unitRef="usd">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i23c68de8493844868847bcbb42b75777_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzI3NjE_4630a26e-192d-4e6c-b2d8-341453e532c0"
      unitRef="usd">2100000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic2494b7c3cda44bcb468b99115c25994_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzU0OTc1NTgxNzMyMQ_69b4022b-8c90-421a-90b1-3d9acd025329"
      unitRef="usd">2300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzQ_a987717a-c670-4bea-afe4-a57573b11dbe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of March&#160;31, 2023 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of March&#160;31, 2023, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2d1d9ed997744f43b91313620e282985_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtMi0xLTEtMTAxNDIw_fac2157a-52c0-4e09-a879-bfc13a7451a1">P8Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2d1d9ed997744f43b91313620e282985_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtNC0xLTEtMTAxNDIw_78bfa117-8eaa-466c-9e1e-90a0b015b0d3"
      unitRef="usd">28960000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i2d1d9ed997744f43b91313620e282985_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzEtNi0xLTEtMTAxNDIw_0a142a0d-aa9c-4147-98ee-e9b857b909a4"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8f75598fe1bf467ca300361df6965225_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItMi0xLTEtMTAxNDIw_55e462e3-cb70-4092-8e63-098ef9bd0e63">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8f75598fe1bf467ca300361df6965225_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItNC0xLTEtMTAxNDIw_6070a337-3662-4b2e-88d1-791f7fc0919b"
      unitRef="usd">37301000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i8f75598fe1bf467ca300361df6965225_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzItNi0xLTEtMTAxNDIw_21b4de9f-8ae6-4684-b7c3-4ae9cb237fbe"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtMi0xLTEtMTAxNDIw_d5a86232-d82f-4919-8451-2d9ca74e867e">P3Y1M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtNC0xLTEtMTAxNDIw_a958b947-1984-4e69-af08-553b5dbc16bb"
      unitRef="usd">1597000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i4e4e6bb40e5d476b82eaaa93f0f3a389_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzMtNi0xLTEtMTAxNDIw_1e87d46a-cb53-421b-a98f-995c220a5694"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtMi0xLTEtMTAxNDIw_a54ec528-d7bf-4eb0-93f7-cba84a54086d">P2Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtNC0xLTEtMTAxNDIw_3d249412-7431-4c59-b461-db68ae213ab6"
      unitRef="usd">1180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id3a9b81f7de640bfa0d4e787de30fe38_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzQtNi0xLTEtMTAxNDIw_86dd7f2b-8a46-4b35-a2be-6f71626c0a4a"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtMi0xLTEtMTAxNDIw_717648e6-4211-4514-8de6-b3d9b9430ae2">P0Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtNC0xLTEtMTAxNDIw_182ba6bd-b48a-401f-8582-127157108a33"
      unitRef="usd">91000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="idab7706671c44c04b395a1bb53394e0c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzUtNi0xLTEtMTAxNDIw_074d381c-3274-452c-9ac3-1fbf472915ce"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtMi0xLTEtMTAxNDIw_8a7b365e-184e-4696-9ed4-8e2867de0c48">P4Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtNC0xLTEtMTAxNDIw_d4612793-3d83-4c8f-86b6-d040b533f7d0"
      unitRef="usd">4004000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib88940471cab4b9f9504ec2ef053bed2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTpjNDc4Yzc3ZTFkMGE0M2ZiOTk2YmEyNWM1ZDFjODBlMS90YWJsZXJhbmdlOmM0NzhjNzdlMWQwYTQzZmI5OTZiYTI1YzVkMWM4MGUxXzYtNi0xLTEtMTAxNDIw_f8a73708-796e-47b2-805c-433b0a3dcd44"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90ZXh0cmVnaW9uOjU3MDBkYmVlODdkZDRjZTJiMzZmYjRkOWZhZDNkNWQxXzMyNzU_fb23a18b-81e8-473c-b3f9-c3ca227ebea9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzItNS0xLTEtMTAxNDIw_e317acd7-6427-4f5c-86f9-e2f1fb6eb862"
      unitRef="usd">1940000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzItNy0xLTEtMTAxNDIw_5e851c26-8b26-4a6a-a5b5-81105eb78136"
      unitRef="usd">2274000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzUtNS0xLTEtMTAxNDIw_8e5ea141-fe10-4831-8566-fe55a1f63700"
      unitRef="usd">1556000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzUtNy0xLTEtMTAxNDIw_8858c49b-b5a6-4d4c-afd5-24936e4493ec"
      unitRef="usd">1326000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzYtNS0xLTEtMTAxNDIw_af653e21-1223-4d17-8a15-57cef4149801"
      unitRef="usd">3496000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToyYTc3NmU2NzVmNWM0NDBkOGVlZWUzN2Q3ZmU0YjE1Yi90YWJsZXJhbmdlOjJhNzc2ZTY3NWY1YzQ0MGQ4ZWVlZTM3ZDdmZTRiMTViXzYtNy0xLTEtMTAxNDIw_98824367-9b29-471d-9569-b52038402fde"
      unitRef="usd">3600000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzEtMS0xLTEtMTAxNDIw_f619179c-89b4-4f10-9f82-0188f28dbd9e"
      unitRef="usd">5694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzItMS0xLTEtMTAxNDIw_00d9dc44-facd-4847-8539-09df76c86ba2"
      unitRef="usd">10436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzMtMS0xLTEtMTAxNDIw_f8acf4f4-5948-4756-9ce5-9b000c7746fb"
      unitRef="usd">10052000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzQtMS0xLTEtMTAxNDIw_4e80fb59-6d83-4800-96bb-37c5fb739eac"
      unitRef="usd">8997000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzUtMS0xLTEtMTAxNDIw_2c218a40-8f28-4f28-a542-024b6e46ace9"
      unitRef="usd">8685000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <evh:LesseeOperatingLeaseLiabilityAfterYearFour
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzYtMS0xLTEtMTAxNDIw_7fee020d-ff49-4e66-a8a1-13d82a15ec0f"
      unitRef="usd">31692000</evh:LesseeOperatingLeaseLiabilityAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzctMS0xLTEtMTAxNDIw_bdda429b-8f6e-476c-a870-1da091c4b922"
      unitRef="usd">75556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzktMS0xLTEtMTAxNDIw_263b74d4-5a6e-42d1-9b0f-c9b362b505aa"
      unitRef="usd">16674000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZToxZWQ5ZTlkYmRiZGI0NWVmODgzNTQyMGY3ZGFhZDEwNy90YWJsZXJhbmdlOjFlZDllOWRiZGJkYjQ1ZWY4ODM1NDIwZjdkYWFkMTA3XzEwLTEtMS0xLTEwMTQyMA_c1a1230d-bb80-4b16-b1c8-ca16ff83e6aa"
      unitRef="usd">58882000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTphOGEyMDU1MDkxY2E0MDc0OGJkNGUwM2Q5MGVkMGVjOC90YWJsZXJhbmdlOmE4YTIwNTUwOTFjYTQwNzQ4YmQ0ZTAzZDkwZWQwZWM4XzItMS0xLTEtMTAxNDIw_5d28cddc-2bab-401d-90b6-b9298c0dae8c"
      unitRef="number">0.0634</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTQvZnJhZzo1NzAwZGJlZTg3ZGQ0Y2UyYjM2ZmI0ZDlmYWQzZDVkMS90YWJsZTphOGEyMDU1MDkxY2E0MDc0OGJkNGUwM2Q5MGVkMGVjOC90YWJsZXJhbmdlOmE4YTIwNTUwOTFjYTQwNzQ4YmQ0ZTAzZDkwZWQwZWM4XzMtMS0xLTEtMTAxNDIw_7eef5592-e4dc-48d7-8578-ee549e6d0ba2">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <evh:TemporaryEquityDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl8zMjk4NTM0ODkyNjAz_4ff00ee0-89f9-4b63-988d-7742c1b15c1e">Convertible Preferred Equity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the NIA closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#x201c;Securities Purchase Agreement&#x201d;) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company&#x2019;s newly created Cumulative Series A Preferred Shares, par value $0.01 (the &#x201c;Series A Preferred Stock&#x201d;), at a purchase price of  $960.00 per share, resulting in total gross proceeds to the Company of $168.0&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#x2019;s Class A common stock, par value $0.01 per share and all future series of the Company&#x2019;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000.00 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#x2019;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a Change of Control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the NIA closing, the Company entered into an Investors Rights Agreement with the Purchasers named in Schedule I thereto (the &#x201c;Investors Rights Agreement&#x201d;). The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Investors Rights Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the NIA closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders named in Schedule I thereto, which granted certain registration rights to Ares in respect of the shares of the Company&#x2019;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company paid dividends of $3.7&#160;million, or $20.86 per share of Series A Preferred Stock, and accreted $2.6&#160;million of deferred issuance costs in additional paid-in-capital on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</evh:TemporaryEquityDisclosureTextBlock>
    <evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85MzU5_afe2cb1f-6514-464e-9c8b-dcc50bd8540d"
      unitRef="shares">175000</evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85MzY5_3ff66c82-22b7-4cdc-b36d-7dc866a33770"
      unitRef="usdPerShare">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <evh:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare
      contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzcz_b1a22038-e575-43c0-aef3-47ba6ea23d36"
      unitRef="usdPerShare">960.00</evh:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzc3_2e6518c3-c12e-4370-9929-904c36073f58"
      unitRef="usd">168000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1dfbe078bc7f430697d2a7b1b12e6204_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzgx_0f1f9067-8354-4dc5-ac87-d68dc545b251"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzg1_beee4743-7084-47f4-972c-3aed3a466578"
      unitRef="usdPerShare">1000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <evh:TemporaryEquityVariableDividendRateBasisSpread
      contextRef="i401ab859effb48808de07f4a1e3c6d16_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzg5_227f6027-7bf0-4508-8b36-d179cf4fd008"
      unitRef="number">0.0600</evh:TemporaryEquityVariableDividendRateBasisSpread>
    <evh:TemporaryEquityDividendRatePercentageAnnualIncreaseInRate
      contextRef="i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzkz_2f904258-dd90-42e7-a348-fa756d40fd50"
      unitRef="number">0.020</evh:TemporaryEquityDividendRatePercentageAnnualIncreaseInRate>
    <evh:TemporaryEquityConvertibleConversionPrice
      contextRef="i847f8c6b7dfb43bf822806907fa80330_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85Mzk3_d64c28f1-e68d-4c7f-8417-3e5fc97f1195"
      unitRef="usdPerShare">40.00</evh:TemporaryEquityConvertibleConversionPrice>
    <evh:TemporaryEquityRedemptionPricePercentage
      contextRef="i2add3c8d25f94736a9517cf9293a956c_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDAx_647e6484-598a-4a18-887d-458bfff522b9"
      unitRef="number">1.6500</evh:TemporaryEquityRedemptionPricePercentage>
    <evh:TemporaryEquityRedemptionPricePercentage
      contextRef="i9cca87e30358452e84669a73df40af76_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDA1_2b1934f9-d808-4a1c-bbc4-b82a4cb4b79b"
      unitRef="number">1.5000</evh:TemporaryEquityRedemptionPricePercentage>
    <evh:TemporaryEquityRedemptionPricePercentage
      contextRef="i87668a6ea647431c972d8f8fa361cf97_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDA5_49dfb49f-054c-4be1-a3c0-790b68b5f0cf"
      unitRef="number">1.6500</evh:TemporaryEquityRedemptionPricePercentage>
    <evh:TemporaryEquityRedemptionPricePercentage
      contextRef="ie14b7cf7aca4447892720b9d169358bf_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDEz_95098fbb-9c53-428b-aba5-24bddefc28b3"
      unitRef="number">1.5000</evh:TemporaryEquityRedemptionPricePercentage>
    <evh:TemporaryEquityRedemptionPricePercentage
      contextRef="id704c5c418084a8387e935db5922f100_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl85NDE3_d679472e-1107-4825-a877-b65a39020006"
      unitRef="number">1.3500</evh:TemporaryEquityRedemptionPricePercentage>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl82NTk3MDY5Nzc2OTI3_3dcfad11-ad4e-4674-8eef-b9bcde6c3cb6"
      unitRef="usd">3700000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <evh:TemporaryEquityDividendRatePerDollarAmount
      contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl81NDk3NTU4MjQ1Mzg_6e62df11-87f9-4684-80bb-b5593807e8a7"
      unitRef="usdPerShare">20.86</evh:TemporaryEquityDividendRatePerDollarAmount>
    <evh:TemporaryEquityAccretionToRedemptionValueAndDividends
      contextRef="i76d8c1de8f9a4c5e8ebb85e0816da113_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNDgzL2ZyYWc6NjgyNWU0MjVhMjdiNGNkMzgzYzBkMzMzY2YzMGM4ODYvdGV4dHJlZ2lvbjo2ODI1ZTQyNWEyN2I0Y2QzODNjMGQzMzNjZjMwYzg4Nl81NDk3NTU4MjM5MzI_61fd419f-f82c-4f4e-aa90-ae51d9b23b43"
      unitRef="usd">2600000</evh:TemporaryEquityAccretionToRedemptionValueAndDividends>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4Nw_21431bb3-1340-4ae6-b3aa-86c7ad95d692">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4Ng_3516f18e-c526-4c90-bfa6-237212f26ece">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_c24049ed-f3ce-473f-90b1-4c8a63bdcd39"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_c84f3663-43a4-46fd-b1c1-95d6e2698772"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_e7c97b85-bbfe-4c04-b528-64ccc7462a6b"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNS0xLTEtMTAxNDIw_e987f5fa-6d07-42e6-9cc0-ba4138bd2c4f"
      unitRef="usd">-26258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_1980d515-ef65-4c46-96a0-5dc3770d0a47"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_47d5cef9-3e2c-4522-b85f-2df07ec3bc4e"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_8185dac2-be1c-4f17-b3b3-c697c41afdbc"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzQtNy0xLTEtMTAxNDIw_a50c1c3b-fe74-4cfa-924d-bae05b476b79"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNS0xLTEtMTAxNDIw_713b7515-df01-4066-a235-37cc819d23e6"
      unitRef="shares">107783000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNS0xLTEtMTAxNDIw_9c316804-1f36-45f2-beb9-2b2bc60d99aa"
      unitRef="shares">107783000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNy0xLTEtMTAxNDIw_3c84eed5-d87d-45a0-8d09-28bb088d1048"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzYtNy0xLTEtMTAxNDIw_6a850953-589b-406d-9a8b-bf62ff764231"
      unitRef="shares">89509000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTUtMS0xLTEwMTQyMA_a832f1ce-4f6e-4c9f-9657-58b10951bada"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTUtMS0xLTEwMTQyMA_b6527866-453d-4e92-a30a-4bf04344a6d7"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTctMS0xLTEwMTQyMA_4e751178-48c2-47e3-bffc-4aaf15ec3888"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToyZWU3MzY3ZDliYTI0NjQxOWJkMmJiMDlmOWQyNDE4MS90YWJsZXJhbmdlOjJlZTczNjdkOWJhMjQ2NDE5YmQyYmIwOWY5ZDI0MTgxXzE0LTctMS0xLTEwMTQyMA_90d78023-6930-4a04-99c9-2d97279d9b93"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90ZXh0cmVnaW9uOjA0MjJiYzFkY2M0ZjRmMTI5YWNhMmU3N2Y4Mjc5ZWM3XzY4OA_fc457ac4-25f2-4998-9ade-5305e9007081">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:532.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2eba541d136f4310a4704831029d9705_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzItNS0xLTEtMTAxNDIw_059f7e85-eb69-4613-b970-47698759b07c"
      unitRef="shares">1923000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i492d89de66e04f9b8c3db6a93fd81175_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzItNy0xLTEtMTAxNDIw_acb05358-7ccd-45c3-9ff9-cbe8caf6a1aa"
      unitRef="shares">2161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i476893462fa74bf58564ab53bd877692_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzMtNS0xLTEtMTAxNDIw_b2ee6b56-0a93-4661-b848-4671a2c8b4e2"
      unitRef="shares">1260000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i83e4b979a9e74d449368aa622d2794fe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzMtNy0xLTEtMTAxNDIw_e9dd949f-9087-483f-baac-2832cb52e9ac"
      unitRef="shares">1756000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5a52a2247ce344d0bbdf4224e23b18a3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNS0xLTEtMTA3NTU2_5e53241e-c487-4a80-be14-ecf6ad997dc8"
      unitRef="shares">4375000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iede7c70b83d54696aa5c016fe07b1c1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNy0xLTEtMTA3NTU2_39a8d8e1-2641-4055-ad4e-24ac996e65c7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iddcae13946194fcaa1af1a86f752c869_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNS0xLTEtMTAxNDIw_8b04686f-7aad-4ba6-826a-1bc0cf876662"
      unitRef="shares">6188000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib5af55fd09f6415f8a087fe94b7ac65b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzQtNy0xLTEtMTAxNDIw_56aee0f0-4257-4095-ad85-cd89d29586a6"
      unitRef="shares">11582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzUtNS0xLTEtMTAxNDIw_45549b25-a124-478d-bb28-ec1207eb177e"
      unitRef="shares">13746000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNTcvZnJhZzowNDIyYmMxZGNjNGY0ZjEyOWFjYTJlNzdmODI3OWVjNy90YWJsZToxZTNhYjBhNWVmYjg0NWE0OTJkMTk4YjczZjg0NjcyOC90YWJsZXJhbmdlOjFlM2FiMGE1ZWZiODQ1YTQ5MmQxOThiNzNmODQ2NzI4XzUtNy0xLTEtMTAxNDIw_1c776f40-b36a-41df-9eb8-e0f6ff915555"
      unitRef="shares">15499000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyMw_c83454c8-656b-4cdb-a5bd-3a210182ce04">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyNA_8bee4e66-7d40-46ed-8cac-e7d24c0814ec">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:414.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c894fc3e14c4be68a1ebd94daafd420_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzMtNS0xLTEtMTAxNDIw_793520c9-2cf9-4b5a-b0b0-6001a7a1b72a"
      unitRef="usd">60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6eb4a2f5fe174475b5ce81a76c55e2b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzMtNy0xLTEtMTAxNDIw_5d19b182-8930-4cd8-a0e4-a5f286d6b3e2"
      unitRef="usd">162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzQtNS0xLTEtMTAxNDIw_e8267bc4-43a3-46f3-9514-6aa4ce5c8148"
      unitRef="usd">7489000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzQtNy0xLTEtMTAxNDIw_f51b3bcb-2d8f-48e4-9fd4-6458dde951b5"
      unitRef="usd">3301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f5a1eb774c04210a049f40aa3781de8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzUtNS0xLTEtMTAxNDIw_12f6396c-bcc6-4c44-92dc-d9e43cefe587"
      unitRef="usd">284000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if96c354afa0c4e3c9db694479ca3a37d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzUtNy0xLTEtMTAxNDIw_3646119a-de05-4530-b3b0-1a9edc5eea1b"
      unitRef="usd">775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzYtNS0xLTEtMTAxNDIw_82c1712d-868b-44e8-b3f6-401a06bc18e4"
      unitRef="usd">2877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzYtNy0xLTEtMTAxNDIw_49bcd88d-be80-4cc2-93aa-59df1765cecf"
      unitRef="usd">1108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzctNS0xLTEtMTAxNDIw_6ea49f50-b177-450e-a3f9-d14d57ad2c61"
      unitRef="usd">10710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzctNy0xLTEtMTAxNDIw_72455d30-3400-41d6-b4e6-0ec3ed97a50b"
      unitRef="usd">5346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d69bebdcc784d5d883a6d0f4540fe50_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEwLTUtMS0xLTEwMTQyMA_ea24988b-e6be-474c-86b7-91d682b71877"
      unitRef="usd">1540000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id70cae9e2b7d4e58b25f32a9c3d73a3b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEwLTctMS0xLTEwMTQyMA_adc6cf0b-36ae-4410-9c88-b6427730908b"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e6a4f64f12d41fc8e3d1bdb59b392cc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzExLTUtMS0xLTEwMTQyMA_f704b26c-ea99-4854-aa89-53d168b4acea"
      unitRef="usd">9170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie33450827a3f4e9d919295348407f1bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzExLTctMS0xLTEwMTQyMA_e5a4e706-e45b-4ae9-809c-0bb1edc10285"
      unitRef="usd">4546000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEyLTUtMS0xLTEwMTQyMA_371fab01-d07f-448a-81c8-f4a0e0bbfd46"
      unitRef="usd">10710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTpmYzQ3ZDc2ZDRjYjk0NDhkYmVmZTJiMThjMTgwZTFiZi90YWJsZXJhbmdlOmZjNDdkNzZkNGNiOTQ0OGRiZWZlMmIxOGMxODBlMWJmXzEyLTctMS0xLTEwMTQyMA_72455d30-3400-41d6-b4e6-0ec3ed97a50b"
      unitRef="usd">5346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_139149f2-8752-4b6b-b9be-a8d90a46c34b"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6c41447859d3478b9bf4c5cd97653cc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_70703995-6201-4ec2-bfd3-6b8d3413b041"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzE3MQ_985d2e98-807e-4335-804f-482904d652a4"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90ZXh0cmVnaW9uOjZlNmExM2E3MDk0NjRjOTdhMmQxNWRlNmQ2N2E1NGRjXzMyNQ_636ac72d-0b72-4fb4-83ac-b37d28eb9023">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzItNS0xLTEtMTAxNDIw_cefeb6bd-12f2-4be2-a9a4-553d41f4ec63"
      unitRef="shares">996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4265cb3838a84cefb37602e55e2237f8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzItNy0xLTEtMTAxNDIw_c2b7f11a-8c66-4714-a75a-c6e50b01fa0a"
      unitRef="shares">917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i24762e1d5a2a4aacb36ae6ed8a73b24c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzMtNS0xLTEtMTAxNDIw_0722ee10-ee04-4791-a5f4-a9547cea13ff"
      unitRef="shares">424000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib9cce399849d48d6ad93636960e9af86_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzQvZnJhZzo2ZTZhMTNhNzA5NDY0Yzk3YTJkMTVkZTZkNjdhNTRkYy90YWJsZTphNjUwNDIxMDBhZWE0NGYxODgwYmZmY2NhMmMzYjE0ZC90YWJsZXJhbmdlOmE2NTA0MjEwMGFlYTQ0ZjE4ODBiZmZjY2EyYzNiMTRkXzMtNy0xLTEtMTAxNDIw_233c9225-e242-4da1-9f7c-08ffd41d9bf0"
      unitRef="shares">479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzIyMDQ_e707b6d6-3446-44fb-92fd-6ea9ffe05d03">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An income tax provision (benefit) of $(68.2)&#160;million and $1.2&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively, which resulted in effective tax rates of 77.3% and (29.0)%, respectively. The income tax benefit recorded during the three months ended March 31, 2023, primarily relates to $56.1&#160;million for the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the NIA acquisition accounting and $8.3&#160;million for the TRA liabilities that will create current and future tax benefits upon settlement. The income tax expense recorded during the three months ended March 31, 2022, primarily related to state and foreign taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March 31, 2023, the Company had unrecognized tax benefits of $1.6&#160;million that, if recognized, would affect the overall effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above for discussion of our TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzQ1Mw_8e59020b-aea3-4d3a-8f71-e7c316215e9b"
      unitRef="usd">-68200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0OTc1NTgxNjA5Ng_b2962c5b-4d5c-46ed-8368-1986f716c866"
      unitRef="usd">1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0NQ_e861366d-5d23-42f7-a27c-713800aac9e9"
      unitRef="number">-0.773</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU1Mg_8d3660a4-b480-4064-9973-d57591c9dea4"
      unitRef="number">0.290</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzk0Mg_20160b9c-e6af-41de-ac98-1aa760ef02be"
      unitRef="usd">-56100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <evh:TaxReceivablesAgreementTaxExpenseBenefit
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzU0OTc1NTgxODIyNg_81c9a88d-4cf5-46b2-8f19-db283bb92bcd"
      unitRef="usd">8300000</evh:TaxReceivablesAgreementTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzE1MTg_12edeb26-8dc6-4508-8928-91440e3c9fa5"
      unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8yNzcvZnJhZzo2ZTZhNWUzOTliMTI0OWNiYWM5NDMzZDZjYzdhOWU5Yy90ZXh0cmVnaW9uOjZlNmE1ZTM5OWIxMjQ5Y2JhYzk0MzNkNmNjN2E5ZTljXzE5MDg_3cf9f670-ab78-4302-ba1e-3fc55a8d6e01"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIyMTk_9708b7bf-f79c-4abe-8542-87c7c76a1fd8">Investments in Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2023 and December&#160;31, 2022, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain from these investments was approximately $0.4 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $4.8 million and $3.6 million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i0b9a2f209add49c28eaca381d3e00ea3_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNDM_4a973c5d-c542-4115-aebb-76803f6744ac"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i3d01f3131ee44567b61845961fc57356_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNDM_8fe09248-046e-4c25-885e-8f98ffb54b94"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i3b079f58e6d143e9bf0218c70cddb93a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNTA_64809e21-96b0-46c8-a492-8aada77e8aa6"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="ib02f997833034f13959b8d48cf3f413b_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEyNTA_aa3e14d1-59d5-4b0b-ad6f-61cf858d8194"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i3d01f3131ee44567b61845961fc57356_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTE_7599d5da-773b-456b-beec-3f263f5278e0"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i0b9a2f209add49c28eaca381d3e00ea3_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTE_c93450bc-3629-40fe-8134-e750fa4029c8"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="ib02f997833034f13959b8d48cf3f413b_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTg_00f39cc7-9ac8-4b3f-9e2b-d52ef3e60f08"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i3b079f58e6d143e9bf0218c70cddb93a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzEzNTg_24b72873-43a5-4c81-992d-3c1d4b702985"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzE4MDA_d4cb1d82-1d07-4ebe-bbe4-a48199583f12"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzE4MDU_ef75abe3-3ca9-414c-8a16-28fb0817b0ac"
      unitRef="usd">600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i0bafc71fd6ff4258ba1f07d59a2d2c26_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIxMzM_132f8dff-7302-4859-8038-d52a732f9aa8"
      unitRef="usd">4800000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i6a6d740e3f65457ab486cd579e644ba8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzIvZnJhZzo3ODNhMGQ3MWZjNGQ0MjM2OWJmNDc1YjEwZmJkOTRhYS90ZXh0cmVnaW9uOjc4M2EwZDcxZmM0ZDQyMzY5YmY0NzViMTBmYmQ5NGFhXzIxMzg_944542cd-f022-42f7-989f-555e7f5a8978"
      unitRef="usd">3600000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODY_2b2d43a6-34eb-4bcc-9ed5-4a3a4b4fcd2b">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODc_ccc2f4d7-bed0-44ab-b49a-06cb06e2d7e3">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions of NIA and IPG include a provision for additional equity consideration, at the Company&#x2019;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the NIA contingent consideration is the year ending December 31, 2023, and the earnout period for IPG is the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the NIA and IPG contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (gain) loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.80% - 16.64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.85% - 10.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 9 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODg_b51ca5fb-edf7-4807-84ab-6bb2ff8dee62">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic4c3f6529d1a407f9fb18c47de384547_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtMS0xLTEtMTAxNDIw_fef7104d-4ffe-4172-8d09-6ed05bf09735"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie128286c0dfa444dbd95773bf5ec6363_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtMy0xLTEtMTAxNDIw_cd63ec13-244e-4d20-9097-7d8426626a51"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtNS0xLTEtMTAxNDIw_e15d5103-3103-4951-be23-981594e337b5"
      unitRef="usd">122100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzMtNy0xLTEtMTAxNDIw_05141f62-5f62-4f08-b940-605a35c15308"
      unitRef="usd">122100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic4c3f6529d1a407f9fb18c47de384547_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtMS0xLTEtMTAxNDIw_a021c609-df88-4e23-9a80-acb38035f589"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie128286c0dfa444dbd95773bf5ec6363_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtMy0xLTEtMTAxNDIw_1ad30491-92c8-43f2-a3a8-cbfe6ddf7918"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtNS0xLTEtMTAxNDIw_dcd2e02f-44ee-43d8-a993-076a4c1065fa"
      unitRef="usd">122100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i94eed0228a0947b5bf2dc7e6184b79c7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo4Mzg1ZDcwMjRhNTY0ZGE5OGNkZTQ1Yzc1ODJkYWFmNi90YWJsZXJhbmdlOjgzODVkNzAyNGE1NjRkYTk4Y2RlNDVjNzU4MmRhYWY2XzQtNy0xLTEtMTAxNDIw_c6f5cf51-6b88-495d-bcf4-617c400119fc"
      unitRef="usd">122100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2d66187bddab45d98d6021e00200a254_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtMS0xLTEtMTAxNDIw_b64d5fb0-f179-45cf-9c06-84dc26b885fa"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtMy0xLTEtMTAxNDIw_274d70e2-70ec-4365-82ab-9f6e5c4fe1ec"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtNS0xLTEtMTAxNDIw_95155a57-1010-4944-ad04-3e8f8f2803bc"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i98252e4304374eba80127e9339ac00ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzMtNy0xLTEtMTAxNDIw_6d570f88-4744-4034-a531-0b96966af654"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2d66187bddab45d98d6021e00200a254_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtMS0xLTEtMTAxNDIw_db7b5b63-0fe1-4ad3-b488-3a56562aa0c4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibec0e7040e644ea7bf61ec00e9fcbda0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtMy0xLTEtMTAxNDIw_715fda90-787a-446b-895f-3fcef1a76302"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtNS0xLTEtMTAxNDIw_ea3bcee1-a754-4368-a7ef-c19bae046549"
      unitRef="usd">78000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i98252e4304374eba80127e9339ac00ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZToxYjI3ODVlZTA3Nzc0MDkyYTg1MTA5OTBkMjBmZGUyOC90YWJsZXJhbmdlOjFiMjc4NWVlMDc3NzQwOTJhODUxMDk5MGQyMGZkZTI4XzQtNy0xLTEtMTAxNDIw_3547ada1-9991-4bc3-8005-7dc25a640442"
      unitRef="usd">78000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyODk_7fc9fb8c-5215-4628-aa72-aa3a487d9868">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (gain) loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzItMS0xLTEtMTAxNDIw_ec016f1d-2875-40d9-adf5-1eb5bd0f5ee9"
      unitRef="usd">78000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzItMy0xLTEtMTAxNDIw_dc09371f-9106-49fd-9e79-8e93bb6d849b"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzMtMS0xLTEtMTAxNDIw_124efe9a-fdcf-4f6b-8124-de828819eea8"
      unitRef="usd">69761000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzMtMy0xLTEtMTAxNDIw_58e78e9d-7f21-4805-bf76-75d336d366f0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzQtMS0xLTEtMTAxNDIw_4d2686b8-29c1-416b-a9fd-8a161c8dd385"
      unitRef="usd">29961000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzQtMy0xLTEtMTAxNDIw_75bbc39d-a9a1-4304-b73e-2a2225114838"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMC0xLTEtMTAxNDIw_6680a014-a447-4ee0-882e-987f2070330e">Unrealized (gain) loss, net</evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMC0xLTEtMTAxNDIw_a077718b-bb01-4bc0-8853-d4daa5dcac90">Unrealized (gain) loss, net</evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMS0xLTEtMTAxNDIw_0f0e1443-cbc5-4ec2-aad5-04445649a3a7"
      unitRef="usd">-4300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzUtMy0xLTEtMTAxNDIw_9fbb7939-f1a7-4eaf-a19b-0428b40bdcdb"
      unitRef="usd">-3900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzYtMS0xLTEtMTAxNDIw_1a7c2443-aa8f-4a5b-903a-8ae6e78c8c5c"
      unitRef="usd">122100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTozOWQwZDcyMmMzZjU0YmU1OGM2ZWY2OWFkNTg0ZGY1Mi90YWJsZXJhbmdlOjM5ZDBkNzIyYzNmNTRiZTU4YzZlZjY5YWQ1ODRkZjUyXzYtMy0xLTEtMTAxNDIw_2b5076f1-c7c1-4e4c-8657-7b7df2f4eeb2"
      unitRef="usd">32600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90ZXh0cmVnaW9uOjE0ODE3ZjUwZDYzODQxYjVhZDY0MDI5YzgwNmViZGY4XzUyOTA_afd182d4-9a62-4175-85e0-38887bc301af">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.80% - 16.64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.85% - 10.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic7ec04c66a434196a47081e73befb4d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzMtMS0xLTEtMTAxNDIw_1ca51577-56b0-4972-a54b-163a2f47f1a4"
      unitRef="usd">122100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i15f37596d3fb4fd0b55345096a8d3ec5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzMtNy0xLTEtMTAxNDIw_b2308ebe-403b-41f7-a05d-6a534b633938"
      unitRef="usd">122100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i1ea91b69217d4414bf3a0c1862b782c2_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246ZTlkZDI1NGE3ODBmNGVjYTg1MWMxODBmMmY3NDM5ZDFfNA_8ddf9734-a044-48c7-abfe-116e01d8a2ee"
      unitRef="number">0.0880</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iefbfa8e87ea74767877c1bcb1ba75e70_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTplZjI2NDBlZmYxNDc0MjUzOTY5NTY4NWI4ZjE1Y2M4Zi90YWJsZXJhbmdlOmVmMjY0MGVmZjE0NzQyNTM5Njk1Njg1YjhmMTVjYzhmXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246ZTlkZDI1NGE3ODBmNGVjYTg1MWMxODBmMmY3NDM5ZDFfOQ_c885d51b-8528-4862-af50-f69869f90c38"
      unitRef="number">0.1664</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id0025cd927a74c64b32ed1f84552d804_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzMtMS0xLTEtMTAxNDIw_4f2960b6-7c33-400e-bb9f-b881df5694fd"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i7838e8cce0d84e3c96376f68234721cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzMtNy0xLTEtMTAxNDIw_3af5377b-dffe-41a6-9419-5108b7fbda29"
      unitRef="usd">77946000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibb07d39ed99e4b5493f3f1a76480c9b4_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246YzI0M2ZlNzYyZDY5NDkxODhjNzBhYjMyM2VlZjI5NDRfMTY0OTI2NzQ0MTY4Ng_ca507cbf-5105-46a6-82e4-bfb1e7821fd9"
      unitRef="number">0.0985</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i424e2672ed5c47d6a7f0e6908df8f4fa_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzUvZnJhZzoxNDgxN2Y1MGQ2Mzg0MWI1YWQ2NDAyOWM4MDZlYmRmOC90YWJsZTo2ZDljZDhiMzk0YTc0MzBhYmM5ZDY5ZWQyZjM4ODA4ZS90YWJsZXJhbmdlOjZkOWNkOGIzOTRhNzQzMGFiYzlkNjllZDJmMzg4MDhlXzQtNy0xLTEtMTAxNDIwL3RleHRyZWdpb246YzI0M2ZlNzYyZDY5NDkxODhjNzBhYjMyM2VlZjI5NDRfMTY0OTI2NzQ0MTcwMg_2c5e2181-05a8-46ab-8abe-3ed486c755ed"
      unitRef="number">0.1001</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90ZXh0cmVnaW9uOmQxNWMwMjJiMjdhMDQyYWI5NDliNzIxN2VlZjg3ODgwXzExNzc_68dbaa93-1d6d-48fd-86c2-7d9225cab91b">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our interim consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90ZXh0cmVnaW9uOmQxNWMwMjJiMjdhMDQyYWI5NDliNzIxN2VlZjg3ODgwXzExNzQ_a51396ea-e880-4646-9f21-566e1e3fe689">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzQtMS0xLTEtMTAxNDIw_bf292416-de58-4981-aa9a-40d38e64825d"
      unitRef="usd">9360000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzQtMy0xLTEtMTAxNDIw_3e321c85-7677-4a46-b20f-aac591615190"
      unitRef="usd">8787000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzktMS0xLTEtMTAxNDIw_f374bd85-ca7b-4d01-b3d7-76f1fcc56d80"
      unitRef="usd">2000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzktMy0xLTEtMTAxNDIw_4c177473-41d2-4a18-b5ed-563bb2977e16"
      unitRef="usd">27000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i110024d501a54ed99a65ed852a158dd2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzEwLTEtMS0xLTEwMTQyMA_f6958d7d-fc0f-4fa7-87ed-fe83cf42d03e"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i95e0bc79b1d147a88d91c60dc1a05426_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTo0OGU4YzIyOWU2ZjI0YThhOGM2ODZlOGMwYjI3NTMxNy90YWJsZXJhbmdlOjQ4ZThjMjI5ZTZmMjRhOGE4YzY4NmU4YzBiMjc1MzE3XzEwLTMtMS0xLTEwMTQyMA_e72b7eaf-3f44-4757-8441-0d483f12a439"
      unitRef="usd">192000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Revenues
      contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzItNS0xLTEtMTAxNDIw_55d965be-3292-4217-bc3d-5fa7293571ec"
      unitRef="usd">54721000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzItNy0xLTEtMTAxNDIw_47f6d7a2-6db0-4e35-a091-bc35f995ca96"
      unitRef="usd">32064000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzUtNS0xLTEtMTAxNDIw_84fd8430-407e-4d07-ace6-174a592ebd69"
      unitRef="usd">47506000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzUtNy0xLTEtMTAxNDIw_193eb81b-7839-4500-9650-b4dd70e02cee"
      unitRef="usd">26461000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzYtNS0xLTEtMTAxNDIw_2ebed1e7-18af-481d-a7a7-6164d9102ef4"
      unitRef="usd">242000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i35963def0f354878a0aee255acad57ba_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xNzgvZnJhZzpkMTVjMDIyYjI3YTA0MmFiOTQ5YjcyMTdlZWY4Nzg4MC90YWJsZTpkZjEyN2FmYjQwOWU0MmRlYjk4YTgyZjJjMDQwYTIzNS90YWJsZXJhbmdlOmRmMTI3YWZiNDA5ZTQyZGViOThhODJmMmMwNDBhMjM1XzYtNy0xLTEtMTAxNDIw_f9772122-1ef7-48eb-82cf-5d58a2e48cea"
      unitRef="usd">66000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90ZXh0cmVnaW9uOmM0ZjQ4M2Q1NjFiYzRmM2I4OTk4NmIxZGVhN2Y1NjRhXzQ0OTc_f4ef5420-4df3-44ae-92b3-1bd72d05a1ba">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 10.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:357.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90ZXh0cmVnaW9uOmM0ZjQ4M2Q1NjFiYzRmM2I4OTk4NmIxZGVhN2Y1NjRhXzQ0OTk_e728b932-7910-4aae-82c2-a66532b21913">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:357.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iedeac599ed134eeeb0c936f4c013dbc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzMtNS0xLTEtMTAxNDIw_8ea43cff-d5c5-418c-9900-64c1fb7d11f0"
      unitRef="usd">199730000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i206feaffcac24ac0925bec2bf51079f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzMtMTEtMS0xLTEwMTQyMA_0dff02ac-f8d0-41e8-b526-5003557fc852"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzUtNS0xLTEtMTAxNDIw_35e42b51-7dd1-46af-87aa-334282a03ddd"
      unitRef="usd">180675000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzUtMTEtMS0xLTEwMTQyMA_ef2434a5-9430-4038-97c6-1d6cde52e9eb"
      unitRef="usd">102664000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzYtNS0xLTEtMTAxNDIw_7488469a-905f-42d8-adb6-c430da2ea2db"
      unitRef="usd">-19914000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzYtMTEtMS0xLTEwMTQyMA_d4d8b47a-1b12-4b15-9038-d0faa40bc402"
      unitRef="usd">6511000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzctNS0xLTEtMTAxNDIw_5faec6e6-d463-4d94-a393-fbf263628202"
      unitRef="usd">160761000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzctMTEtMS0xLTEwMTQyMA_7dced8d5-d71a-4b69-82ee-b3935f945264"
      unitRef="usd">109175000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzktNS0xLTEtMTAxNDIw_f5008dc7-af3f-47e9-be2f-2ae3eafb902b"
      unitRef="usd">64870000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzktMTEtMS0xLTEwMTQyMA_bcc2445d-89a0-458a-a58e-ba17d3950883"
      unitRef="usd">47724000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEwLTUtMS0xLTEwMTQyMA_da281773-caac-4ebf-b4ee-58f4891776ad"
      unitRef="usd">98424000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEwLTExLTEtMS0xMDE0MjA_4502d1e2-7ea8-4074-a57e-2186a07d5b75"
      unitRef="usd">59491000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTUtMS0xLTEwMTQyMA_fc8fdf44-8290-489a-b136-b4de2b1f449d"
      unitRef="usd">163294000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTExLTEtMS0xMDE0MjA_f6d78775-344d-4667-9b52-754a95d9fd1c"
      unitRef="usd">107215000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTEtMS0xLTExMzY5MQ_8ff2a094-855a-4d85-bb2b-44ae00ec7aee"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzExLTMtMS0xLTExMzY5MQ_0b00429b-1c64-4538-9912-01d2d8774611"
      unitRef="usd">9016000</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i586e945bd60d49af85c5c42ff6511bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEyLTUtMS0xLTEwMTQyMA_c11e6499-dc6f-4dad-b953-319e94c32cd0"
      unitRef="usd">197197000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i233880303bb34668b01e60bdc5f1cdd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xODcvZnJhZzpjNGY0ODNkNTYxYmM0ZjNiODk5ODZiMWRlYTdmNTY0YS90YWJsZTphODUwNTY0YmFiMzk0MzEyODVjOTg5MmVjNWI4ZGU5Yy90YWJsZXJhbmdlOmE4NTA1NjRiYWIzOTQzMTI4NWM5ODkyZWM1YjhkZTljXzEyLTExLTEtMS0xMDE0MjA_52c6bb76-49cf-49bc-9f6e-daf28a7fd596"
      unitRef="usd">164238000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90ZXh0cmVnaW9uOmY0ZDUzZTgwMTNmMDQzZjhhY2RkNGU4YmEzNWNlNDllXzEyOA_ce96d356-a5b3-4aaa-ba71-3ea55ec1f2a8">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90ZXh0cmVnaW9uOmY0ZDUzZTgwMTNmMDQzZjhhY2RkNGU4YmEzNWNlNDllXzEzMA_a8c4c907-8b4d-4ae0-a6f8-0774cf1df323">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:358.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:85.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzMtMS0xLTEtMTAxNDIw_78ecb15d-cce1-43a7-9a81-ca7e10fe5b0c"
      unitRef="usd">30000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzMtMy0xLTEtMTAxNDIw_8118d72e-3220-40c2-85eb-b404a9b576a7"
      unitRef="usd">670000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzgtMS0xLTEtMTAxNDIw_f728943b-a9f5-423a-83d1-74f681e8c593"
      unitRef="usd">261271000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzgtMy0xLTEtMTAxNDIw_f5a21860-80f9-4875-b2cb-573bd4fbc798"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzExLTEtMS0xLTEwMTQyMA_4b2df67c-7758-4f61-8d37-d0e86db6daf8"
      unitRef="usd">1098000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzExLTMtMS0xLTEwMTQyMA_2afa8789-1948-4a7e-a2e3-770b8262df39"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:OperatingLeasePayments
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzEzLTEtMS0xLTEwMTQyMA_e4510555-39fd-4936-8884-128c885e9661"
      unitRef="usd">3528000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzEzLTMtMS0xLTEwMTQyMA_6ea401cd-9f1c-4e68-bd10-b0a6c0841310"
      unitRef="usd">3830000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzE0LTEtMS0xLTEwMTQyMA_7d06583c-4bac-4669-a0bb-83776c879521"
      unitRef="usd">3076000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i86218da0e0884c94a088b193ed670843_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xOTMvZnJhZzpmNGQ1M2U4MDEzZjA0M2Y4YWNkZDRlOGJhMzVjZTQ5ZS90YWJsZToxMDVmNmU3MWI2YmM0MWQ2Yjg2ZTMxYzIxNjg5NDYwMy90YWJsZXJhbmdlOjEwNWY2ZTcxYjZiYzQxZDZiODZlMzFjMjE2ODk0NjAzXzE0LTMtMS0xLTEwMTQyMA_00ceb68f-ba72-482e-8523-2548f2429381"
      unitRef="usd">3000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNS0xLTEtMTAxNDIw_3becb7ce-adf6-4f78-aec3-ce3636b88558"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNS0xLTEtMTAxNDIw_c657b9ba-d51e-4a5c-b4e5-e6c7cc4ded82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzMtNy0xLTEtMTAxNDIw_47c9cbd2-9772-4ad2-a19a-6a9e8c9bd16c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNy0xLTEtMTAxNDIw_8c3c15ee-3602-4122-9a7d-8acaf76fbfa5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzYtNS0xLTEtMTAxNDIw_51823a66-5af4-46bf-afa9-31cfae70e443"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90YWJsZTo4NzAyMjNmZTA4ZTk0MDk1ODE2Njc4ODJmMDA1Yjc0NC90YWJsZXJhbmdlOjg3MDIyM2ZlMDhlOTQwOTU4MTY2Nzg4MmYwMDViNzQ0XzUtNy0xLTEtMTAxNDIw_3ba58fb6-0998-42ff-a289-e64d84c25796"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDMvZnJhZzo0MmU5ODIwZjE5N2E0NWEzOTNhMTBmZTA2OWNmMzA4ZC90ZXh0cmVnaW9uOjQyZTk4MjBmMTk3YTQ1YTM5M2ExMGZlMDY5Y2YzMDhkXzM3NQ_3d416b36-a15f-46c3-a3d2-c61d3aed3d2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMy0xLTEtMTAxNDIw_52868666-e1a5-400b-a3c3-0e6f1ebc9bd5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTEtMS0xLTEwMTQyMA_fa570c08-3513-4740-98ff-1f33a3f49754"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTEtMS0xLTEwMTQyMA_2ba3b832-8ddd-4d51-9ab8-788d1ee75865"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTMtMS0xLTEwMTQyMA_9661a4b0-b4df-498c-a6a4-e245a2ac3f91"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTMtMS0xLTEwMTQyMA_18fe26ee-d09f-4d8f-9448-fb29369cfe2f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIyLTMtMS0xLTEwMTQyMA_4277679f-0066-437b-9b12-f5707ae72264"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMy0xLTEtMTAxNDIw_3d1d3f23-0b86-4519-9cd5-bafbbfce0d7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzE0LTMtMS0xLTEwMTQyMA_b68cb08a-c882-4d4b-a353-d67537246467"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzIzLTEtMS0xLTEwMTQyMA_f29abeb9-ff5b-4929-bb31-28bb1d7b8002"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzctMS0xLTEtMTAxNDIw_d025c7ee-4c90-4897-8c0c-8cb9278c6eff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzgtMS0xLTEtMTAxNDIw_c876efa8-9fe8-40ca-b9ee-fce401d81afe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90YWJsZTo0NGQ3M2M1NThkMTA0NWJhODk0ZmM4ODIzNWVjMmVjYy90YWJsZXJhbmdlOjQ0ZDczYzU1OGQxMDQ1YmE4OTRmYzg4MjM1ZWMyZWNjXzI3LTEtMS0xLTEwMTQyMA_d5c93415-5b84-4470-82ae-7d2c9c79b600"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmZkNTIxMjBiMTkxZTQ2MjdhMzM5NTdkNjdjNjhiYjdmL3NlYzpmZDUyMTIwYjE5MWU0NjI3YTMzOTU3ZDY3YzY4YmI3Zl8xMDAvZnJhZzpkZjNkODRlZjUyZDY0ZTI5OWM0ZDQ3ODFhMDJhOTExNS90ZXh0cmVnaW9uOmRmM2Q4NGVmNTJkNjRlMjk5YzRkNDc4MWEwMmE5MTE1XzE3OQ_6521a3bf-50b9-42af-bab6-8c8e13326e21"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI,HDB,<)S&(%!:9K1PR$2OR$^G6;'-"#@**D9$6U51&P3]K.6)USV!JZ/;1
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MBOHH9^L"\K05JJ7X3^(TRXS',Q;#,(UWVS'[@ >-0?T: ZJ83;4IF6XS=X\
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M9R*%G=4->MI9SR6/OQBY=47L'(,TD#8W@YWO^CW]3AJU(W:UFQZ'!ND*W'D
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MAJ,17-LJH;$'+8X,=4;/!'E?J5KV '5+W%7*D[7[@8[F.)UG9#["Z;+#E'B
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M>'AVF@G??5MTD^B:])ZCYO%UD(;,CSP?P'[A7#Q,^(+^ V_Y'U!+ P04
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M^DXMBI/3!?^[.'^6+\07/2H71-'V0Z!U\9#\FN+9^3G_<T(4".01^Q%40""
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M S%#BDMCV_"TBCFF+!!142NPD &FK/9&B^-.P4N6!$L.$-"_Z%!/XZ0@:#$
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MUZUU$[B(/%%P+;.0G6USYV[Z36R#X,L.%4G<&SD!%$Z6G%8(?E8!8]F9PX"
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M"P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*56;6_;-A#^*P>U*%K
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MHG.'V" O2Z=/$'(%O)1=4:RLL2^XM"?PYN_OOJ;KXRCSAKE1'O_)D)%P*-]
M]1\E2I4H]NQ\.)OV9I'A6NC#_0]<6!IHW2T(2MC TQYU:.)APF;):#I*QM-)
M*TCO*FS"%EQJ[Q/0NF7G@TG:&]8L>B\^333>1DQP73Y"FHA"$W,D=9[+D+X.
M9<.S:D,>>IZ.^[U^?<R&[_F\$!0^3B,@GQ W76+$[B$)I,;]+VG?_65G#VAE
M2$#7*)K@GD+_NLUR3$@]).!N5?CCNG=3S!XK>#+I3:+@/?9.P-,48CB=(L/H
MMNIDZ1L\WVLMN7:A3,<U)-'M6*'7L8P&Z0_-$IGQCKNI=+9"H(3 H#A"]E<9
M#VG%I2^?NIV/ZU ,"LGG$CF.DB^>5TA:!P$'C@0<8.WH- R:FUT(JE$X>6?(
MY4%"508'F8>/V=O(XP'_C]DU^<8Y0Q0EL\&0?=.H 2=TFCA4,SAU,IBF1SNR
MQFJ';CJ9))-^/V2NPT?G#$DGF5R.V'M>+B4Y[9&V'J.%R52%V(35,B&WSK,'
MLZ0_&;.W6FRXS%TB+ZF:N#H+]5'NU)I8">0FTW%@P-YP$-&<COKL58YM<B%#
M!-VT'.J+V5F+PK<9*[DQ;#@:)RF)*[)5Z8H58BJ9XLZUTDCD5&%07'+!2HZJ
M,DL&M6[DW8YFH_XHZ6/77TZ=R*E+DY':'C9.1OW+^@FU,E!7TRH*M#9JC] )
ME1OJ2M+ID+T4"Z'I0,L_MNGY(@,AD]%LTJR*Q2P=#8) 75Z>IH-DD/;9MTKE
M.\0M&UY"89,1>R/LB:0M_S@,U!":C4LTFUPLF)7:E;%_L$ZA?*ZV(FG7$..>
M+K6"IY/W4F]<475=>X<CW1RU"7.*HL+ES)!A%U51]#[I-;'=S'V)SSI]!]FO
M<1HZW%7>+J]QB@,OX%1;^:M/&]QU+32D/:(6F?()N(?0.F04=.Z%I.R&S-%D
M%[1AD &VVOJ$GX[9'BD/W-07Q,L@?D!=('U@>;'W2;!;&FK;*"UB%):HUMQ:
M+>>5MP4T*3Z&"A<U;Z)J?.!&HK%U:S03JJ-I$0?;L"H^HQ>$<$8M[(Z.=ZVF
MJ3;40!GJ5>L2!K5"0W%8@%,4:!Y#MU:V6[FX)HC:90V,V>01WIV\?X:&&C8J
M),+"MT!HE>>:J+M=Z!%=[QV<%))\$+9W@Z.?NA25FEBNG!5C.4/#X]I5\G.>
MK6I'(N.+!5MHM69:[9UP<9$_]GAG])%VU?5E-<PCASVB&PQAN:8B4(%9N)H$
MBC^W@XCZ<NW<#\-,721[R.AQ76LS63*7QI4!7_8YI DIPK?LF V$K708+@X,
MXIT2-M#2N D+HL$F45WM<X*F(+5HI$#Y$\'1;U-A2UOVQ(2-PF@V*#"Y<.?[
MR%*89)R1&"40T-NI"B/>BF]=E, /2Z<SS!Z&9A"# ,9X$/559U%$>B1,*O),
MY'*!W"S*C!S1[H0(\U2KV\Y)?:?^9CN*=53/Z>JR(W73:I1G[Q-!)Q5,A'X*
M9-5:9DVYB='B,ZT?QU8N;JB?HHQ3%38>UN+>6R6.Z+X8.-?1>N_S'@J73X-Q
ME Q<'K=@@>LG- <JUQH6^T,  -35LG2YEL3-;ZB-)ZG^%CL0E!?8JUVO9ICB
M[ X<>Q4L6VY0*N(NKT*)<G1 %9TJIAZ!/'95-\4D(W>AA>@)AX?A'<H^'T]Z
M:3U44+XA'>B\ 0C(/S"6YDY:8_'/35&T66V"VWC6J>?08D58Y[9.- \P@)F'
MM:1VI=&#K#W>)@AO8Z\Y6M<:+DO"H$YYH-Y%CAC\D]I?3DI&G(K0E(<"X9)
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M^:/DZT/[Q^"]&+9'$_>2U3D;3@;);."'\LZO'"+81+#@2A4YX<@0]>NM*BA
M#M][3L?)=-A_B(M^,ACAXE.I<\6]^[E .'3=. &U\UQH4X/&0T$XUJT+>KF^
MPQ= NW ZE4.-9[VN=^@O6K]YP)RY=+_LH#R-1.9__E#?K7\\<N5_,]$L][\\
M@5&0<@UZ\P6V]GO3\1F&#/=K#O_!JHW[!<5<60RU[G+EOB^A!7B^4,K&#W1
M_9.:Y_\"4$L#!!0    ( !:=HU9G@B<Y+@X  &\I   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;,U:6W/;-A;^*Q@W[20SM*R[K33QC./T-K/99I)L
M^["S#Q )26A(0@5(V^JOW^\<@""IB^/,/FQ?;(D$SOU\YQQ K^Z-_>PV2E7B
MH<A+]_IL4U7;EQ<7+MVH0KJ!V:H2;U;&%K+"5[N^<%NK9,:;BOQB/!S.+PJI
MR[/K5_SLO;U^9>HJUZ5Z;X6KBT+:W1N5F_O79Z.SYL$'O=Y4].#B^M56KM5'
M5?UK^][BVT6DDNE"E4Z;4EBU>GUV,WKY9DKK><%O6MV[SF=!FBR-^4Q??LE>
MGPU)()6KM"(*$O_NU*W*<R($,?X,-,\B2]K8_=Q0_Y%UARY+Z=2MR7_76;5Y
M?79U)C*UDG5>?3#W/ZN@SXSHI29W_%?<^[73RS.1UJXR1=@,"0I=^O_R(=BA
ML^%J>&+#.&P8L]R>$4OY5E;R^I4U]\+2:E"C#ZPJ[X9PNB2G?*PLWFKLJZX_
MJ#M5UDI\4*E9EYHL]>JB F%Z?9$&(F\\D?$)(A/QSI35QHD?RDQE_?T7$"A*
M-6ZD>C-^E. [:0=B,DK$>#B>/$)O$K6<,+W)%[1<65.(6\AJ$0VP=+41MVQC
M9<6_;Y:.G__GF $\_>EQ^I0Y+]U6INKU&5+#*7NGSJZ_^V8T'W[_B/33*/WT
M,>I/]=%7$Q&_UA:)Y9^GP2I.2*M$M=OJ5.;Y3A0(;WV^4]+BA97E6B$EL8J-
MEP;C.5$9L;7F3F=*W$FK3>U$"A&(B)!E)F2&X-5D8,I"X4Q>DPANP$+$K\P\
M4TZO2Y4148 &?%-ME"A4QM34 P#)*2?,2ACLW4I;E20"L=%EFM>0@5Y4IL+R
MU+B*EJ9$F9:XK4JUS*N=?U3(4GJ=!/E-I\HE4974%/#GAC (0F\4MFW$-I>E
M "J2*BPRB*:YU(6C?=CO=+GN$&/U<V>B<# ""+('#!Q0E^= R[B!M(YV]>8!
M+X;?,H5FRUROF3/HD6&<ZCM&]YPA:5FEUA 6!G6UKA19HY7."T42RY1DI\UL
MUEQ6Q!0L9$5$O4SZ+^^7@@H&N268DY^72F71+VULD $*52Q9GY\4G$61E8A[
MA2C*$1_;+0*-B2FK88%UK3-6%HSH\0G]I2,2&WE'(5,IBP@CX4A>)=.-J% ]
M2#_KW0L=,D0@'E0#\3NH6HTZI,$:L4<*",FQ*Y<YD$)!FLK6:54C2, ]F+KU
M$K%ITR3X%LJ*@K 0C[9RQWRC 66>UCG[@>I()D@%;[^5QE=H&<SD/Q(907Y+
M?!)N<UJU])8J:UX(6P?+>C;]A&C"F[Q; YHM:YC7ZMP+X'.B#1X*1TG,4WQ!
M5A!YCG8D0:'K(H1C+]P*N>M'MX%XMF=(!Y#Q>L.?P8 B!^[ ]6NK/*%$N W$
MR6*>.WD'N5V?&X629]"-B4))!S=!O-\:MH SA_BW(5.<4/!\P4+4G)\,*80-
MN?ZLX"U9F!H6B)XA2VX0+L9&U$%L$C>280ERXH\Z6[/9I$\%BK>!>%O'N"TE
M1T](B*XBB4B5K= S1;F\)9=><B $Q[)>"<VQ@W1>LE[L940- !)1DTIP)P2W
M#C*"3X/FG%<F3<'V'O#%TM1EX GHT^03H.Z=RC@7K*\*?ZE(P=P1[E(&M?;B
MKW#EEFU45UO 5J&JC0&1'_4#1=2^V2/AC$(9*NP"Y4U;<@3E[D#\0CU::JQ/
M?:XO1S"!80,I9U(8K0VS/N,6-[3AJ+O?Z-23Z\3C(+8"H9R]\VFFQ/M.</T:
M <=Q]*?]/2W,D?_H)7FU:"@=ARXN,0WZ1 <UI !I).*?-6*#,AX!+W0!:A0Z
M ?I*#M*UZ98: L0]E.)R&D#/=S^FI CF'(+GB;5L'4&,ORQZUP$<%E3/I.^R
MH9;';4;@$\ =DXQVLR^X)ZB@E<Q)0'3M.6GFJ;4!2%F85AQGR#_8#]!&Y<,:
M<!N(3TC8^)4MJ!'EG12S:BTM%SLV*I'T.(3442N(6E&^<?)4\C/KX2"<6^V^
M6(>HCCD?79RC3&3)F:6@718 F,C$H"7U2)C"9"KG/&0D9=9(4[,7U3$^,E48
M5/0M@IJ0I+:64 CF^(RBC#V9#I[B_$G1JW1KO@\>1#(E(AP9Q>#N3*UW?L'R
M#\43D_,!VE38QA6GO#40[RVB36\!2'= Y)LUR0;5@$:21CDNE[6CT-$VXVJE
M?=<CT3G!K7!I,#H1-2?['\>0 ;P@LYJV!2!YN410G%H?HMLH$Y4X%LEW3UU4
MYL@&_M$LZ1L(DO"<)-R%, 77C=[ZRAVS9KGK?(:.I#6W)K'S0J*:S!L^>B%T
M:*&B=TW!KN\Z*.QA^9@3QL0 C7NT O#%2('>AJVC@5<(,OC3[E@\5Z>;Y+B)
M2,RF-SM2&$CWM35H%8.R\$)3S>!B%1 "QI"D<C W$<V, /(<5X'!J6^'I8+7
M5:B 0?A#'3G*K5KNHJP4-CUI2Q4=\U8[N5X3#OC^>R6:P>@3%0<#7+OG$.<$
MM8K'.>H\?K@S.3Y\]\W5>'3YO8L,LI:@]Z4JL_.0BJ0S7)/5*;>*ZJ7XT3>2
M8(:^IS<U"\R\"+EFZ*4_8_&.>R&=B6=B=#5)AI,I?9H,D]EP%%["0*/Q93*?
M+\1H.$TFBP6J6@&[4%?>Z9=&HWFRN+H4\W$RFEV*3SP</1-3VKL8XM-X<9D,
M\:9;^S[RO(!WDT5R=3DAYI>C9#2?BH]QBOJDTDUI<A-PXV/C4+]W/DLFHSED
M3F970W'3GP+C6M)M?@D%YLG5# I0% GPG$+A63*=31^1]U.G^KSG>G$3BE,,
ME0^*CJ?(K:<*._EEK[!+;DL0Z0JDR&LT]0%=:!1.XN A(R^N.P]<: !PSZ:3
MP94HD$(AS(X6R1/ %KH\2SV;AT+J_"6/5OTPX:(1TJIIP$_U1&$,:25&.*,^
MTN@%[ 5J&D;F#L=3]0Y=&GIE+*"YJ*UK^]-;0-AF[L%61AY)K2>:#%^>EC+G
MQ9U4\S4RK[EJ<<]VK+?T+3H*T/J<'=6ZS]??IEOH5N*F%95M_E(#(58U-^JA
M7Z0P5@]AGN,Y0?Z!,0"Q'CKYL#<);27WYTTW!P&YW,<>YX0[)$^C #%:!B'^
M:9 M8_9GD!M>.8Z^O4";+[Y-Q&+\+4L]&@Z_#49SM*<)^U-Q!KAZB_Z$1\DF
MI/COE,GAPRPA;VU]*Y"C=/QL[FG>2&#15%(9)X.H!^XQUQTG--,,\<S)$F2V
M4JU-I3GXVG.'%;^2C@3"4$$V\@<(ODSX, GC66?$:;P,;C7W%*'3:C@75#M
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M17NS[\='?US-?7#H@S_W!9KL'.VWP]QXXFN1RXL!FM]+=RL'EP_O34\F3^]
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M=@[T?J.4/4[< L.7T/)O4$L#!!0    ( !:=HU9D:*$/B@L  -X=   9
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M.DD(MS$[3IY(K'H!5E]B=C]L; ,XN&92#==JB ^M@?8Z -BV-^;43\J2HD)
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MW)BDAUOOWR/%H0D".Z[9>D%.8#QB/S8:W1F&@@OC3%MD5CN\I/%IE\5K"-L
MH6IB$:M"L#K'-4I,M 6+285> @HI%B#1V%=P[N"Q".+;=08 #)DL@Z<BZUQ
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MPB<R@,1D#!LDKAK,E(:0Z+''3FD@7*@DOFZ1HV&_;LBJK^<,1GD9YBZQ-P,
MUF%D@3FO-J*'W2V54N;HVH=*/1^Q8=?KRBO.5':#?;F" )2LO:5=5KW*N5Y5
MJ+2+$!FJ&]N4$K[<NTX5AJ"3R*G&05P&\:5]W%M:]4PX!U57RAXKACU=,FV
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MQ*5*7^X242J$AGZ5<H>C,6D#2.Z8A&-/2A!VJ$EH@;'5([+H,?-==HTB*4$
MMC8K[16U]OK&4O>OG14TPF;O4V QI/#JV<C\\J_7Y@J&7(<&HO]R'2JZTVM4
M]XC'MV\OM<)%<JMM^K4 VR/DL6)L[K*HFYX]T>?R9?+DQQN9"\$)R[9$$X _
ML'>7Y>Y2L#T:YN+J(M/)44_8H=>H>K%"DA3T-N2=>D\D6,XG/+?<><_?\Y/#
M-5.**U#8HTT=#'_H:]GT_LZ7^B7OT$\4UFMS2- <4_D?W;K5!F]RR !#9;.F
MX-@G"RT@8@M%B#V5S 3ZS4Z!A_1ZB?B"_+V-4J!^@6%!VSI<9Z]60BSR;U5P
M@^W3/OOU6^Y=A$[*Q&AZD.P2I%TS+M?"1RIT]X'Z*YSN;(\H"=U".6)3 $M2
MS6,DFJH*FQQ,-YG=,\+,+>"T'(WQ=1'P<!>\5^LX\W>X=%=\VJ*+)WQJBIM#
M7[&#[5"[YW#Y^W^9E^_?]*8 <91JF0IX+$T9-@+%[&GHFBG1)NG80T*J21_Q
MTF5S3X5OVPZH0-W09MPSR(C5<H+YQ.4^#MRH/1<900Y-"$1TD4BP#ZQ&M 0T
M^YY6,XAO!0K[ZB'7U>Z:C.RM\*E89^,!RBL.7*F0G6S#Q+!'5><.MZ8!(]9&
M=J796GK]&?OY>2=P.BAC>H''4D"C6(]$BV: 78/65NP@[[&LDM2IF4@:$EDX
MVODU7ZY#?8]]A&N]3EIW99,V$:F>4<8GDV$!)-,#5_9SD2$&Y+VE@*J=F?XD
MZ\_1].X6#F-$ZDO-H^HAR46/2)U]%FKI(8]5:\R.<&2=]B'2?Z&;#+[.J-9K
MD-T;M8(.H>HB 2&K;HCG68E[-=37NX%!F97<[0B?&=TB "J56MGC;XXQ#A7
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MW[/QSW?VZ<E!K"(Q@$S6,:'[RNW!'0MI9J H.'5<F\+0[AR7L.G;3JTCSY:
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M(PVDL0">SRW(J?G"&W2O>$__#5!+ P04    "  6G:-6S[B552D$  !Y"0
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M;"]W;W)K<VAE971S+W-H965T,C N>&ULK55M;]LV$/XK!VT8-D"-7FW9F6W
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M1B]/!\*E3X+T$FP5QW#<.ACJXV.!KRAR? #[*XN[K'UA@NZ[;/$74$L#!!0
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M5R^=72O'JT&-+T15V0WA3,-.^1 <WAKL"U<_:./4;[IJ2;TC[5M'L'AX>1Q
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METO2"$!>@/=S"S'3#3/HO\M>_1=02P,$%     @ %IVC5M=P3]&[!   I0H
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MLS#OD]K!6%4-?9D55)/TY%JDIX)'/VMJG8D3V7KS@\Q_;8F)2,&IH/BWCOQ
M+!W QOA & :+T[X1=5!=NZRT"P,I+$#1GI^"W:HE1!6Z83?/3MG"2G\.&6KR
M-O/NH'J__^YRFB[>P-FFU-G_,9B0 :(02&OX,E#P4P_CT1(#0!XK#9,RN'&'
M7&>%%#M(]?C-(\\V5$/,H+T,*(J)T._H&"*(>:+VD,[VB_V3-.^K)^81RHA9
MJZ*!DE*"N&S7)]V7J>\2L5O._2QJ0G+*)YP$ 3K33)U$KJKKQ,^ZEI,#_BQ+
M)B$*PJHM@9RS#S:170?JF7?/!+XT8)>E)D&]+=CH0B^E/;5"M0B:U]BN)14F
M\<FVH"+R_ O81$FN7:V ^-BX 'AW$+$GWDD87!\<IBAVF24F9(!HJAMB"6SJ
MVSLE*2<*X^V9K31 R"FS3RUV7FR9;K\T5F&8F/#7>V7K87L' +611)&#+&1J
MSN,]P%.3:3'+6/V[#-]^4>V9>/<4ZP'I#:FFLRM6E&@]DK*72"U=>Q8T:+)R
MM5+=_CT=A:PF=_/&R V=_*6JU4IS9UDA@ >CFZ[A! HBK&I]O!Z.Q;L0JX [
MY#K<%UR&+RUPC\88!*<,T/2TUO7/L'RP@CR*)+<049FUE4VAL[B(W_!L >"8
M$K7!A]C]L^XF1;]R@(.7PNA$"X;+'64_C9ZM8^<$.J7%NI]F-"81>(/(B>A_
M'<=BVG@@*Y:MCC,9$;ZC:'3U=NRFY-!'?419;U?;/):A$#4:Q:"\6:95TG.N
M]A-63B$,E?SL<'586Z%C0AKUL^'8UKK0 \!CF&.U*^+L^$T#*N3$CQ&J-(L<
MRM29^*50]=/GL);2$"JLJ4@I&L@ 6/*M&+@ZNGCXPIIV71SQ'^C-4^Z;"NCN
M\S"7R;+<'?'11I8MAZ#GC57K6ZN&,U3 !-TT=ZZ[_L5U6LFNSH^]'II2-Z1U
M(<@56 AS(!'LP8!H,5QJ&YM6APX;*OD)R6 !G\H;WRPT$_*P-VASDDS=F'*S
MSQO^8,&(LJZXX",]=IUM0P-PU*QKHOJ:1% 85"8=KXM^.*#18!6BN-=.L2CT
MNBAIGH)N^H@BX$>,%4WZ\Y/L3,+\L2+[XA?:\=C&E7S,M8!R3\=PP81OS:0M
MOI0D;2I+LW7BA-$&]G"GUUQYA/YC@6^K@V,G\4Y:5&1W:D0_4_$@2U*4@,V0
M*4PS-+>%A/R32*^NDL7YA*X6:3*]FHFWW2 R_*YD@KL6CS&?=TI:3AV:<Z.L
M]'*2S!<7^)2;)O/Y3+S'4_OLRI/T*KE*,4C.DXLT%1_#"'@T!J7S2;*8IQ!W
ME:00&P]JN-?O9\C7(9W,9\GE8G(J3F:+9#&%QE= 75TF,UIR<G&5S*XP7Q_@
M"@<"Z?R<?(1%Z6213-.+4_%3^"SGR@_Q.\%>'H&G;R UF:3STWT4J",?^G^1
MX!]= >ST_++;^M5_6.]3-#S5_$_G/(.JB><3X3OWZ4G$_JPA-+;A 0%>F];2
M:FK,TOJ:27B/B#V,$J-5U'G+U=ES9XKCP6$PL1\?>5,'AJIP+MP_[4_5[\-A
M\GYY.))_QQ_M8#RUPM;)V>)B)&PXY@XWWC1\M+PTWIN*+U$48#):@/<K8WQW
M0PKZ_VNX^P]02P,$%     @ %IVC5FS3W0 H P  'P<  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULI55K3]LP%/TK5]DT@=21-"FE8VTE8* A[8%@
MCP_3/KC)3>/AV,'7H>S?[]HI69F@TK8OCA_W')]S;=],5\9>4X7HX*Y6FF91
MY5QS&,>45U@+VC,-:EXIC:V%XZ%=QM18%$4 U2I.DV0<UT+J:#X-<Q=V/C6M
M4U+CA05JZUK8G\>HS&H6#:/[B4NYK)R?B.?31BSQ"MWGYL+R*.Y9"EFC)FDT
M6"QGT='P\'CDXT/ %XDKVNB#=[(PYMH/SHM9E'A!J#!WGD'PYQ9/4"E/Q#)N
MUIQ1OZ4';O;OV<^"=_:R$(0G1GV5A:MFT22" DO1*G=I5F]Q[6??\^5&46AA
MU<6.L@CREIRIUV!64$O=?<7=.@\;@$GR!"!= ]*@N]LHJ'PCG)A/K5F!]=',
MYCO!:D"S.*G]H5PYRZN2<6Y^U3:-0LZR$PI.!%5PQN<$Y[H[;T[<-':\CX^.
M\S7G<<>9/L&9P7NC745PJ@LL'N)CUM>+3.]%'J=;"=\+NP?9< !IDF9;^++>
M=!;XLK\S?=K-$7P[6I"S?&&^/V:^XQX]SNT?T2$U(L=9Q*^$T-YB-'_Q;#A.
M7F]1/NJ5C[:Q_^-Q_2\G?*H02J-X6NHEO\7@S&>*-K&YQY8>*S>P.U*#JTQ+
M0A>T>PC\F'B,S&D1']P4X'/.J_Z@?9/" W5O).7*4&L13 D?C'X9]CS7MTC.
M2^,]X$QJH7,_.O)/7CJ)Q-W<MKQ%8[F>6?<S1.)-*QM/#4W+._/C)G@.6<+-
M^""!$R6(D9";NF8C_!;S:Y!$GH=-Y4;K=6U925?!HB7.+",X?L$:_ I!.AX.
MTH,AO'@V28?IZUZ(YH+K"Y;7F8M&>GNB^,$O/@C:PC@<)*\F/=]I6;((\OEX
MA\'!1S8H7,>[/A""TIH:3+^BNM!LL)].N)VPYX N@"TCTQ62&N/'S+MC%H[+
M>W"]"WC'F=)+?R'LGXR@I%A(U:5\)QLD!^-=_NX^=O/CC:)5HUV&TNRMMMIU
M]:N?[:O_45?T?H=WOPZ^-TO)F5%8,C39.]B/P';EN!LXTX02N#"."VKH5OP'
M0^L#>+TTQMT/_ ;]/W'^"U!+ P04    "  6G:-61OXTQ7H>   78   &0
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M]0TTO<XE*DPHI =.\?EIX//3DZRY1I#&60H^O")5)3G"4J>X_)5#9;]'?>9
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ML&). X/5"M =C1;W[+>="]Z$)-_'2--K1'Z^XAS^A >97\0Z[,5)'^+E9;)
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M7=W\R#N(?HB;W_B7,R!,R0BKD7"^3DZJ\T'W$*?QT93L%<,B0=C>W-6J 9E
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MO>254-%4.EK?1,T1<+:TJ[XI0K":T\"-O=7KNAH:^F#L YK0"R?Z*/EGOT0
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M,^C@C+#7*)E3>M;CA*(MR=T,4V]BH0/L#=6UMHNJQF2'@D4*,A\F0XDMT+(
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MCG+ZA2)8A$1^/(I0=(!])$XC(I '>1;1M+9<+EB*38+SN3\' 1)H#BVAUG8
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M<-GO>:#J158+1I9N>2RDH57DCAGM?E36@/1+*<U.L &:?Y/)7U!+ P04
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MC.$II(QY:1K!;<**KZW4A,?&$.:Q%R018*%B&398.%J+IK@!S%AC*NX:0/I
M%7*IV QD0AV!%P2IET?Q3VP*>ILBEG@L3X]K/6'A^)ABM@="YYX]R5C 7OSK
M/V</52J"%VW=DNIK@7DJQ-898164W.)*O>528T]U1Y_&:3R)L:M4E6N0CR2
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MZ/V'VDV@[[DB'4W'+="^*.?_ 5!+ P04    "  6G:-6$WRU0DX#  #_!P
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MEA7=T*BL /T_2&E.&VM@O/-7?P-02P,$%     @ %IVC5K&!_\J^!   DPT
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULQ5=1;]LV$/XKA+L4":#8
MLNS(=F(;L)-V"] 4@9.T#\,>:.EL$:%(E:3B=+]^1TJ6Y41U,Z##7B12).^^
M.W[?D1IOI'K4"8 ASRD7>M)*C,G..QT=)9!2W989"!Q92952@UVU[NA, 8W=
MHI1W M\/.REEHC4=NV^W:CJ6N>%,P*TB.D]3JK[/@<O-I-5M;3\LV#HQ]D-G
M.L[H&N[ /&2W"GN=RDK,4A":24$4K":M6?=\'MKY;L(7!AM=:Q,;R5+*1]NY
MCB<MWP("#I&Q%BB^GN 2.+>&$,:WTF:K<FD7UMM;ZQ]=[!C+DFJXE/PKBTTR
M:0U;)(85S;E9R,T?4,9S9NU%DFOW))MB[@ ]1KDV,BT78S]EHGC3YS(/M05#
M_P<+@G)!X' 7CAS**VKH=*SDAB@[&ZW9A@O5K49P3-A-N3,*1QFN,]./E"GR
MA?(<R U0G2O C!MR?$^7'/3)N&/0B9W:B4J#\\)@\ .#/7(CA4DT^2!BB/?7
M=Q!<A3#8(IP'!PW>4-4FO:Y' C_H';#7JR+N.7N]GT=\Q73$I0U:DS]G2VT4
MDN2OII@+D_UFDU8XYSJC$4Q:J P-Z@E:T_?ONJ%_<0!POP+</V1]>H="C',.
M1*[(3&LPFE 1DT^,+AEGAB%XI/<"HEPI)M9D3C7334$<=G.? %E)CBJU1HS=
M_U*J[&]T87#X4J89%=_?OQL&W<$%PMBAX34T:4&DF%!#5C;;3R[;5H.HXRW,
MI85)CIE TS+7:$2?G!/<[2BIMIM\@B?@I%N^@_+=(_?24+Z7@DMD'9JUY(TD
MUHP8%'6Z/^Z>D-^(PQQ<[+6Z0>!U?;_6*LS6,:^:(VN,Y:U>KB""= EJ&V;P
M*\)L=CX8>K[S73;^BP!?^BA'_O7+[=0"G(*$*1BWCQ2H$J=XLKP(70&G!C$;
MZ=9<W_[N*/GY>D90T4)3=P!8NF*]UI%B2YR,O/LL#9!^^X!$SRJ)GKU9HI<)
MQ?W1UD%MLR[W$-_4%+*K1TV:/>BWN?!8(4<[$#)7;U$GGN]DDS 47TWI)->X
M8LM&)K+<[HO$-!I0>!KM;1!58%-<U)#7RL9#U)F^3Q3 WB'Q4O1.$G/*J8B<
M14SJ$M9,",M$[&2@F(SKS N&W@ ;LSAFQ5:'(V\0=BN2XMW"<'>R(:Y@Y(U"
MI-IV\$'@;89CD8O)\1JO,2<$SP3M$8%7HK[70[L];X3/?42 #*MCV<F\%W@A
M-@[0*JQH%;Z95I8A!7GN(4H$^Y9#47GOV%JP%8LHLNQ!R*5E@2O>UVZ[FDAU
MV.L;#H+:KN]OL^>^%CC-/DY=PYG7<9:TPA@M5;=DJ[E(=Q<376;?@BA2KTE9
M,"!^=7I4TBH U3.%!VF>9NZSW%X'JL0VY;%XD46AJP-E>$N$!9**R*PL/5FF
M)$5L"Z8?3P7D6)@X@><,+Z?(.UO87M>UG:VO[G)I-?N$@VL@,=Y<9([><2J0
M87OH'Y%3T@W;8?^HX7SY7Q)1JO-7Y&$P\$;]\&=I&+6'9RX-?MOO'C7IKU.[
M**>@UNYW0!-GH[@S5U^K/XY9<='>32]^5Y!J6)(TX;#"I7Y[@)5:%;\ 1<?(
MS%V[E]+@)=XU$_QK F4GX/A*XO%3=JR#ZC]L^@]02P,$%     @ %IVC5O2<
MF4H6 P  ^P8  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULG551;]LV
M$/XK![4H&D"(9$J1W=0VX*0=-F %@B3;'H8]T-+9(DJ1&DG%R7[]CJ2M.H5K
M#'NPR2/OOON.Y'V:[[3Y:EM$!\^=5':1M,[UUUEFZQ8[;B]UCXIV-MITW)%I
MMIGM#?(F!'4R8WE>91T7*EG.P]J=6<[UX*10>&? #EW'S<L-2KU;))/DL' O
MMJWS"]ERWO,M/J#[K;\S9&4C2B,Z5%9H!08WBV0UN;XIO7]P^%W@SA[-P5>R
MUOJK-WYI%DGN":'$VGD$3L,3WJ*4'HAH_+W'3,:4/O!X?D#_*=1.M:RYQ5LM
M_Q"-:Q?)+($&-WR0[E[O?L9]/5<>K];2AG_81=^"G.O!.MWM@XE!)U0<^?/^
M'(X"9OD/ M@^@ 7>,5%@^8D[OIP;O0/CO0G-3T*I(9K(">4OY<$9VA44YY;W
M*+G#!NZX<0(MO'_D:XGV8IXY0O<^6;U'NHE([ =(!7S1RK46/JL&F]?Q&;$:
MJ;$#M1MV%O +-Y=03%)@.2O.X!5CJ47 *_Y#J2_P:+BR/#P-"W^NUM89LOXZ
M57>$+4_#^JZYMCVO<9%06U@T3Y@LW[V95/G',Z3+D71Y#GWY0%W8#!)!;^"[
MNSI%]2S8::J/+<)&2^I.H;;@_/5#V%7. K<6_: :D(*OA13AE7#GC%@/T=EI
MT(.A#HWL^L-+$@I<JP=+P?;B&N@ZZW:\3_B$-79K-(<5!JN8:U77>O"Y#7F(
M)Y\B!47R]!8^I$65TSA+I[,I_'I$: SJ^4L@]1:8_TW]CAGP-?UW;V9LPC["
MY .#L^4;?$(U8#P ?"8EM/^S>I(0LI'2&<17G?+]P82SN(^)J82K,IVR"4T*
MEN95"9\/+&ZU=?Y5[#G">WRNY6!)X_QJ@U1$+7B4/F+/.TW,_HD+AU(NH)RF
M5WD%K$K+:@(/I(YT#"EL4:'A,D8VI#O"]X<7T&_'P$H&506G'GEV)$@=FFV0
M70OACJ(VC:NCLJ^BH'USCY\%.IVMH!:5N*'0_')ZE8")4AL-I_L@;VOM2"S#
MM*6O$QKO0/L;K=W!\ G&[]WR7U!+ P04    "  6G:-64P0(D8X#   5"
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M&M\5XP!T=PEU&ZOV?O!OE*5KQ"^I*2K43H"^;Y6R_<89./T36/X#4$L#!!0
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M3&O^9Z'U!GQ>&>.>%S[ \!=<_PU02P,$%     @ %IVC5H TKH+  @  X@<
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK57?3]LP$/Y7K Q-("'R
MJX&.I9%H,\0>V"HZMH=I#VYR;2P<.]A.RZ;]\;.=-&M96C&)E\2^W/?Y[COG
M+EYS\2 + (6>2LKDR"F4JBY=5V8%E%B>\0J8_K+@HL1*;\72E94 G%M02=W
M\\[=$A/F)+&U3442\UI1PF JD*S+$HN?8Z!\/7)\9V.X(\M"&8.;Q!5>P@S4
M?345>N=V+#DI@4G"&1*P&#E7_F4:&7_K\)7 6FZMD<EDSOF#V7S,1XYG @(*
MF3(,6+]6, %*#9$.X['E=+HC#7![O6&_MKGK7.98PH33;R17Q<@9.BB'!:ZI
MNN/K&VCSL0%FG$K[1.O6UW-05DO%RQ:L(R@):][XJ=5A"Q#N P0M('@&"((]
M@+ %A"\%#%K P"K3I&)U2+'"22SX&@GCK=G,PHIIT3I]PDS99TKHKT3C5/)9
M+#$CO[ MPG$*"A,J3] 1(@Q]*7@M,<ME["I]E &X64L[;FB#/;0ANN5,%1)]
M8#GDNWA7A]C%&6SB' <'"6^Q.$.A?XH"+PC1_2Q%QT<G2,)27T'5$]_D,%T*
M64<7;.AZ:-*71[6'9B?;L*M*:'G#%U3E%$TXDYR2O"F2+@B:"I Z[\; %^B:
M,,PR@BF::2,8323Z?C672N@?ZT=?_9H !OT!F&9S*2N<P<BIS%EB!4[R]HU_
M[KWO$_LUR=)7(ML1?M )/SC$GGRJRSD((ZF B@N%YQ0VMTRBWP<NW+@ACBRQ
M:;:KQ(_=U;9*!X_^7Y5>B6Q'I:A3*3JHT@3+PM[#S"S@L28K3%N%COJT:>C.
MM[6)+B+_W3.!>MR&0SW =MW2?]T"W_.C8>?6).5N=<42Q-).%XDR7C/5-,C.
MV@VP*]NWW;_NS?33__F2,(DH+#34.[O0(8AFHC0;Q2O;8^=<Z8YMEX4>PB",
M@_Z^X%QM-N: ;JPG?P!02P,$%     @ %IVC5A3O=+HD!   \14  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&ULO5A=;]LV%/TKA%8,+=!&HKX<9[:!
MQEJQ .M@Q.WV,.R!D6F+*$6J)&VW_WZDI,B2+&NVI^;%)JE[#^\Y_+KD9,_%
M%YE@K,"WE#(YM1*ELCO;EG&"4R1O>(:9_K+F(D5*5\7&EIG :)4[I=1V'2>T
M4T28-9OD;0LQF_"MHH3AA0!RFZ9(?+_'E.^G%K2>&Q[))E&FP9Y-,K3!2ZP^
M9PNA:W:%LB(I9I)P!@1>3ZWW\"Z"H7'(+?XD>"]K96"H/''^Q50>5E/+,1%A
MBF-E()#^V^$YIM0@Z3B^EJ!6U:=QK)>?T3_DY#69)R3QG-._R$HE4^O6 BN\
M1ENJ'OG^-UP2"@Q>S*G,?\&^M'4L$&^EXFGIK"-("2O^T;=2B)H#]$\XN*6#
M>ZZ#5SIXYSKXI8.?*U-0R76(D$*SB>![((RU1C.%7,S<6],GS(S[4@G]E6@_
M-;M'DDC UV AL,1,(3,:;\&RF ;FPY)L&%F3&#$%WL<QWS)%V 8L."4QP1(@
MM@+S!+$-!H0U+ 1A,<FHMGD''K%4@L0*:V,DD]RKUO; =KJBYY.2X'6$%2)4
MOM%NGY<1>/WJ#7AEL#\E?"NUHYS82E,W!.RXI'E?T'1/T/R(Q WPX%O@.J[7
MX3[O=X]P7+F['>[1^;VWW&T]7M6@N=6@N3F>=P*O2\R\\.O7+=DAFLOXH' J
MP=^_:]^B_$^7;$5'?G='9M.YDQF*\=3*S/P0.VS-?OX)ALXO72(."18-!-80
MV*L$]OK0ZP+'SP*+0QLYS-8N30OL,,<V^^YNYOE^ "?VKB[6L94;CH/;IE5T
M;!6XH7NP:M#S*WI^+[WY5@@=?)V2H=G%I0 *ZE'"L>>VN!Q;0=\?MZRBWJ"N
M'-&@HAST4O[$%:)Z0^TD?N'X!F=I<FS5I4EOU%=J$E::A+V:_,'9NQ.*=-$.
MCPFY 1RW:'=9^6'8HMT;V)6T1Q7MT1E3@9TF?^%T&)VE2Y?5L2Z]D5^IRVVE
MRVW_KL I10H++8[.)P'%2E?RW" 6>$54WKI&,:%$?=>?=;;5J4=O+Y<>*4."
M10.!-=0=5^J.7^K,'@\I\)!@T4!@#8&A<TAEG1]X:I?@S6W]:%?OLM+G=FL9
M]P=ZK1"UG!Z>NY+W1"5@31C2J;BN$B8545N3Y'>+T M\Z=P:%"T:"JTIZB'G
MAB^6=,-!L^Y!T:*AT)HJ'Q)O^",S[Q*\<<HZX_8I.^\V@^W<K#_4:Z4X).GP
M/[)TBHB>3)G@,9;2W*A-'R3N/G7[P2Z>4T.B14.A-84\I/XP>+&5.U"^7JH\
M)%HT%%I3Y<-E O;?)O[GR@V/K\/0"[SVRCTV@]YH-&JOW$'O%W;M><T\AGY$
M8J,/4IT"KS6\<S/2PHOB?;&H*)[E+VY/7"F>YL4$HQ46QD!_7W.NGBOF$:]Z
MY9W]"U!+ P04    "  6G:-6Z^%!L" #  #/"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6RM5EMOVC 8_2M65DVMU#7DQJ6#2"UAVAXF(6BWAVD/
M)GP0JXZ=V@:Z?S_;25,N :&J+^#+.2?^CC]_=G_#Q9/, !1ZR2F3 R=3JKAU
M79EFD&-YPPM@>F;!18Z5[HJE*PL!>&Y).77]5JOMYI@P)^[;L;&(^WRE*&$P
M%DBN\AR+?_= ^6;@>,[KP(0L,V4&W+A?X"5,03T68Z%[;JTR)SDP23A# A8#
MY\Z['44&;P&_"&SD5AN92&:</YG.C_G :9D% 854&06L_]8P!$J-D%[&<Z7I
MU)\TQ.WVJ_HW&[N.988E##G]3>8J&SA=!\UA@5=43?CF.U3QV 6FG$K[BS85
MMN6@="45SRNR7D%.6/F/7RH?M@A>>(3@5P3_7$)0$8)S"6%%",\E1!7!ANZ6
ML5OC$JQPW!=\@X1!:S73L.Y;MO:+,),G4R7T+-$\%=]C223B"S06(($I;+;O
M&DW+M#$34[)D9$%2S!2Z2U.^8HJP)1IS2E("$F$V1\,,LR4@PG80@K"4%%1C
MOJ AEAF:0,KU$"7V*^@R 84)E5=Z_G&:H,N+*W1A1!XROI):5_9=I6,T*W73
M*I[[,A[_2#P_L;A!@7>-_)8?--"'I^D)I#7=;Z GYW^]B3XZ_^O>+MW5^UIO
MKE]OKF_U@B-Z3=OUYVXFE=#G\V^3N:5>V*QG:M:M+' * Z<PZ2+6X,2?/WGM
MUM<FJS]2+/E(L=$'B>UL2E!O2G!*/;8GP1R:U#3@>476F.J3UYCLI53;2IF2
MOXZ]J!-YO;Z[WG:Z =;MZJMB%Y8<PGROY47=7=CHY/K?Z4Y8NQ.>=&<".CM)
MJJ#RQQ@EWL8(6^M.?LRN4CO:"C (P\C;<^L0Y;=[^RXDAZC(;_O[7IV,YIU>
M1;57T4FO'KC"],VF_7S:]\[.RXQOF*FQ*@.DJ['4=6&.S;34M1^LLZ;J6_!"
MOR(:?8X.\ZWG]3I[^38\A/E>=)!O20.L[7>Z[3VK#V%!%/9"OX:5)KI;EZ%Y
MZNB:O"1,(@H+36S==+2.*)\/94?QPMZ/,Z[T;6N;F7YQ@3  /;_@7+UVS)5;
MO^'B_U!+ P04    "  6G:-6M].<SMT"  #)!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6RM55UOVC 4_2M6)DV;U)&0 *VZ$ GHIO6A$RK:]C!-
ME9-<$JN.G=D&VG_?:R=D4*5,G?8"_KCG^)Q[X^MX)]6]+@$,>:BXT%.O-*:^
M]'V=E5!1/9 U"-Q92U51@U-5^+I60','JK@?!L'$KR@37A*[M:5*8KDQG E8
M*J(W5475XQRXW$V]H;=?N&5%:>R"G\0U+6 %YEN]5#CS.Y:<52 TDX(H6$^]
MV?!R,;'Q+N [@YT^&!/K))7RWDZN\ZD76$' (3.6@>+?%A; N25"&;];3J\[
MT@(/QWOVS\X[>DFIAH7D/UANRJEWX9$<UG3#S:W<?8'6S]CR99)K]TMV;6S@
MD6RCC:Q:,"JHF&C^Z4.;AP, \O0#PA80/@>,7@!$+2!R1AMESM85-32)E=P1
M9:.1S0Y<;AP:W3!AJ[@R"G<9XDPRIYII(M=DJ4"#,-0F]XRLFJ+:C14K!%NS
MC I#9EDF-\(P49"EY"QCH D5.5F45!1 F#B*4$QDK.88\X',\IQ9:LK)M6@^
M/EO%=U=@*./Z/8;(VB[=&7FG0,#NC@.6)_8-NK1:_:QU-&\<A2\XBLB-%*;4
MY)/((3_&^YB=+D7A/D7S\"3A#54#$@W/2!B$48^>Q6GX%60=/#PA)^HJ%CF^
MZ 6^OAK\G*7:*+P2O_KRU?"-^OELF[C4-<U@ZM7V&U!;\)*W;X:3X&.?V?]$
M=F1]U%D?G6+?6]?8/C)@6YIR( *,@9S0 CN6-B3CE%6:U/31[O9EHSGBPAUA
M>]PV"0:C\]C?'KK\2]"1^G&G?OQ:]6=6/@'."F:]X+UP"ZF[E!J=<<".:?IL
MC'L4AL]<G-3SC[6:=&XG)]U^W50I*-M W#W6[?7NL](0C0^L#)\9.7G4:XWX
M!]VR E6X1T035YRF<7:KW3LU<^W9_Q/>/'+8&@K\[-#B&J'!X!Q-J.;A:"9&
MUJ[WIM)@)W?#$M]:4#8 ]]=2FOW$'M"]WLD34$L#!!0    ( !:=HU9E<6&W
M;0,  -41   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;+5876_:,!3]
M*U8F39O4-K$IE': 5%I5J]1.J.SC8=J#26X2JXZ=V::TTG[\[$ 3JH&90'DA
M=NQ[<GQS\,GU8"'5H\X!#'HNN-##(#>FO A#'>=04'TB2Q!V))6JH,9V51;J
M4@%-JJ""AR2*>F%!F0A&@^K>1(T&<FXX$S!12,^+@JJ7,7"Y& 8X>+WQP++<
MN!OA:%#2#*9@OI4397MAC9*P H1F4B %Z3"XQ!=C0EQ ->,[@X5>:R.WE)F4
MCZYSFPR#R#$"#K%Q$-1>GN *.'=(EL?O%6A0/],%KK=?T6^JQ=O%S*B&*\E_
ML,3DPZ ?H 12.N?F02X^PVI!78<72ZZK7[18S8T"%,^UD<4JV#(HF%A>Z?,J
M$6L!^'1+ %D%5(D(EP^J6%Y30T<#)1=(N=D6S36JI5;1EAP3[JU,C;*CS,:9
MT9AJII%,T42!!F&HR]41FBY?DAN8LDRPE,54&'09QW(N#!,9FDC.8@8:49&@
MJYR*#! 3;V8H)F)6<COG&-U::)&Q&0=TJ348?82^6,U]N 9#&=<?!Z&QJW&<
MPGC%?+QD3K8POZ?J!'7P$2(1Z;P-#VT2ZDR0.A.DPCO=@G<E52D5-8",H@D@
M00M ?] ]$ZR8%YOX>?'<W^E"ES2&85"ZW*HG"$;OW^%>],G#ME.S[53HG2UL
M;RPM \=W5M+)O\E%/^_L?'1KH-"_-E'OM$#]M*9^ZDWTBCJOJ+.&.G74C]!<
M0SKGB+,4-C'W8Q/T E1I#\MNS;*[EQSH\S8Y>/'VS&FO9MMK4PZ]%JB?U=3/
M6I2#'YM$._70KVGV_7JH]F)0UHIXM4GJG)7:OT%X$?=,ZWG-][Q-19RW0!U'
MC2E%+6IB!SC&.T6!U^P3[RF+[1N%'W+?Y#8^ATF;RL!MV!YN? ][O>E0:?C!
M27>W-!J;PWXO^@IQ+B27V<M&)M[@?=/8N!ONMBJ"-LP.-VZ'O8YTJ C\X/^A
M@<;;L-^ )DH^L<1N#P*,*T]0+(7]GHC-#N?PP^Z;W\;K<+]5=;1A?+AQ/NQU
MIT/5X0?O[%0':6R.^)W(KX[M!N*'W3._I/$\@MM4!VG#_LA:F>>O\PY3QPYP
MS]X1KA7I[L##UJ\9$QIQ2"U4=')FMU2U/$-8=HPLJ[I])HW]Q*B:.=A21+D)
M=CR5TKQVW%% ?9(S^@M02P,$%     @ %IVC5E-^7>*0"   76X  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&ULS9U=<]NX&87_"D;=:9.9=<0O45)J
M:\8K $0Z^^&)-^U%IQ>,!%EL*%)+0O%F9G]\08D1!8E&R>GI:F]L4L+[ #2/
M\9(X!'C[G!>?RK64BORZ2;/R;K!6:OMV."P7:[F)RS?Y5F;ZFU5>;&*E=XNG
M8;DM9+S<!VW2H><XX7 3)]E@=KO_[*&8W>8[E2:9?"A(N=MLXN++=S+-G^\&
M[N#K!^^3I[6J/AC.;K?QDWR4ZL/VH=![PR-EF6QD5B9Y1@JYNAO<NV]%X%4!
M^Q)_3^1S>;)-JD/YF.>?JIUWR[N!4[5(IG*A*D2L?WV6<YFF%4FWXY<:.CC6
M606>;G^E\_W!ZX/Y&)=RGJ?_2)9J?3>8#,A2KN)=JM[GST+6!S2J>(L\+?<_
MR7-=UAF0Q:Y4^:8.UBW8)-GA=_QK_8<X"7"#%P*\.L#K&N#7 7[7@* ."+H&
MC.J 4=> L X(NP:,ZX!QUX!)'3#9G]W#Z=B?2QJK>'9;Y,^DJ$IK6K6Q%\0^
M6I_")*NT^Z@*_6VBX]3LO5S(3*5?R+NRW,DEN5\L\EVFDNR)/*HX6\;%LB2O
MJ%1QDI:OR0WY\$C)JV]>DV](DI&?U_FNU*7*VZ'2C:F0PT5=\7>'BKT7*OXA
M+MX0W_V6>([GMX3/[>%4+H[A7DLX[5Y[6SBSA_\MSMX0Y^5PWKWQ;DMX9 ^_
MWST=PYV6<&$/_VFAOH:[$S-\J-5SE)!WE)"WY_DO\'[4'=2);!Z*/-/;"ZE[
M.%62O"#S=9P]R4HO1K$D6R3;5))_?J^!Y)V2F_)?;3HZU!ZTUU[U[6_+;;R0
M=P/=>9>R^"P'LS__R0V=O[:I"@FC2!A#PC@2%B%A @0SE.H?E>K;Z+-'E2\^
MK?-T*8OR+T3^LDO4ES;%'2CAGE(E_\\SU_7<<:#[J<^G8KHL-QE- W=L%J.7
MQ4+-<Z9F,69M>U\!M-0Y]4/_[ @B9)T"!#-.;7 \M8'UU.JN," _YDJ6Y#?R
M*+-$]SO[W;;S:T7U[5&0,(J$,22,(V$1$B9 ,$-VHZ/L1E?-?2.D4I$PBH0Q
M)(PC81$2)D P0ZGA4:FAM8/\/L^>;I0L-OK.[J/ZEF12M0G."NDK."2,(F$,
M">-(6!1>).[Q9.HX9MX6H"H-)8V/2AK_MU0[ZIQJK:B^>D+"*!+&D#".A$5(
MF #!#-E-CK*;7#753I!*1<(H$L:0,(Z$14B8 ,$,I4Z/2ITB4JT5TE=P2!A%
MPA@2QI&P" D3T\LQ \<9GR1N0TJNTXS/.E8QS7>;71I7 _PW<K62"T7BY;]W
MI:JZ/;(J\HW>S[=['R!?D?O'^7Y4\,8)6X=DK77UU1R41J$T!J5Q*"V"T@2*
M9NKSQ#]PKYJ6Z^I1DD72*)3&H#0.I450FD#13,DV?H5K'63N/ QLQ_26'M1Z
M@-(8E,9KVN@D%]Z$H3\Y'WR&UBI0-%-4C;7@VKV%]Y5%FLDE87&1Z2ZN)*]T
M?W=(WOI3*E?)(E&O6W6&'(6?0VD42F-0&H?2(BA-H&BF&ALWQ VNFY6A%@J4
M1J$T!J5Q*"V"T@2*9DJV<5)<Z_!W]ZP\:LDN7NCZX9D[VUK0"=U1<.;/MA4<
M33T_.!MU9?8CZ*V%]@,9CZ?G>1)J0J!HYFEN; C7[D-TS)/D-X*]\X4:&U :
MA=(8E,:AM A*$RB:J>3&!G''U\VQ4.\$2J-0&H/2.)0606D"13,EVU@HKG7<
MNWN.A9HA4!J%TAB4QFO::4KWI^/)14*'6ATHFJFIQNQP[6['_7*95$DX3LE#
MG"QOWF5D'F\3%:>MRH*Z'E :A=(8E,:AM A*$RB:^?1QXY!XSE7SL <U3: T
M"J4Q*(U#:1&4)E T4[*-:>)91[@[Y^$:8[B*XW RG9YEE'E;P6 23D;GSR*W
M%?2\P!N=W^O:CZ"W%MR+Q.CJ^^OI16J$5BM0-/,T-T:#9S<:7DZ-Z-M;>T-Z
M]U'861+8:1+8>1+8B1+8F1+_#T/#:PP-S[]N6H6Z'E :A=(8E,:AM A*$RB:
M*=G&]?"L0]3=TRK4O8#2*)3&H#1>TTXO'FY<)W3'WGD6AQH3*)JIJL:8\.S&
M1.N4V _;9:SDUY3\OZ1S'=MK\I*]M;W%"YT4 J4Q*(U#:1&4)E T4^&-)^.%
MUTWU4/,%2J-0&H/2.)0606D"13,EVY@OGGT22L=GK.V4WLJ#>BA0&JMII[G9
M&[GG$X<XM-((2A,HFBFIQASQ[.;([Y+GN\^<LK>VMW2A'@R4QJ T#J5%4)I
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M&U#N9J=-S=&%IF2V,<"+ *HEBZ-HRFHN%,V2<+8V6:+W*(6"M2%V7]?<_%Z
MU&U*Q_1X<"?*"OT!RY*&E[ !O&_6QD5L8"E$#<H*K8B!74KGX]EBXO-#PC<!
MK3W9$^]DJ_6##U9%2B,O""3DZ!FX6PYP U)Z(B?C5\])AY(>>+H_LG\(WIV7
M+;=PH^5W46"5TG>4%+#C>XEWNKV%WL^5Y\NUM.%)VBYW>DU)OK>HZQ[L%-1"
M=2M_[-_#"2".GP#$/2 .NKM"0>62(\\2HUMB?+9C\YM@-:"=.*'\1]F@<;?"
MX3#[J'71"BD)5P59*>2J%%L)9&XMH+TDGUU?O"&KNN'"N&^!Y"M8%*HD%TM
M+J1]G3!T.CP;R_N:BZYF_$3-+SF.R&1\2>(HCLG]9DDN7OY#PYR-P4L\>(D#
M[^2_O)"EL+G4=F^ _)AO+1K7$3_/J>^JO#U?Q4_)S#8\AY2Z,;!@#D"S5R_&
MT^C],QXF@X?)<^Q_/8CAE9^3V)%, XF?NT,6)>QP6I>=](0?KT_<E$)9(F'G
M,-'H^HH2T[5L%Z!N0IML-;JF"]O*33D8G^#N=UKC,?"=-_PWLC]02P,$%
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M%K!5<X\_,2"- 7[?"J&?.V:"]K<H^A]02P,$%     @ %IVC5J:2&\">!@
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M<II?H+Y?,28?#O($54?Q_']02P,$%     @ %IVC5D(":D3= @  R@D  !D
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M)#:WSAF?F/C1O)FAK1S5?%03K38];'*S=\[1@\$"=*,AJD6H)E%-49I>#UU
M.S&/19996J7QZJ OWW;:=X6Q;_]--1@J 8UL4<U'-3$YG<79FXQ&I[T;=+,A
MJD6H)E%-49I>"UT:.S&GL=T#DILL]HV5);VGKF9E<(-'$UA4$Y/3!'8ZFY\V
M=S2"1;4(U22J*4K3FWL7P4[,$6S/J>NNS;_9WXJPR->;/$OZ+]^8Z<$U@":R
MJ"9:3;O(/CTM 31I1;4(U22J*4K32^#@@<+&J.I?>KBKF1Y< FCJBFH"U8)6
MTX*AD_/<2Q:*T/V2J*8H36_8748Z,6>D/R2;;;%XBLOF#_N7I&[,]9_UHGMS
M?^Z[W"96E5L/VVP9-Q?LF_. ISA[3*QX=S*\:-ZK7]654:]0U\.F7N+\-7WS
M/@VN"#1Y1371:K/#+X7C;P1T*#&J1:@F44U1FEXX780[,4>XO853QJOGDJD+
M(SXJC<71):7>TD"#7U3S44VTFE8:[TXN%J&I+ZI%J"9135&:7AQ=ZCMY;=QQ
M3W%41;QL.DK+^-?Z_&&=9NEZN^ZM 33R134?U<0K'Z,SVGU8O9TC- 5&M0C5
M)*HI2M,+HTN!)^84^#[/RF2Q;<;9#Z@'-!-&-1_5Q"N?WMA0#VA.C&H1JDE4
M4Y2FUT.7$T_,.?&@TX_VE*.)&[1^UF_H9:'1,ZKYJ"9:S7@"@HX,1K4(U22J
M*4K32L?M FK7'%!_EY>E53?RY)=FYI5M6CXU9^;7=?'LQXH]#Q4[&T^8_:%%
M@&J^VS=!\\F%'8%N-$"U$-4B5).HIBA-+X0NF7;-R?39$6+_GFF-S'L[N*S0
MF!O5!*H%J!:B6H1J$M44I>G5UV7A+COSMHN&XJCFHYI M0#50E2+4$VBFJ(T
MO3RZ[-PU9^<7WBIB5@97!1J3HYI M0#50E2+4$VZIS-S.^[)$#Y%;51O[EU.
M[IIS<F-?;!779RQWUGV^7M?]K=V$7[VU@.;EJ.:CFD"U -5"5(M03:*:HC2]
M9+H$WF6G[';1\!S5?%03J!:@6HAJ$:I)5%.4II='E[.[YIS]PG%S9F5P5:"Y
M.:H)]W2N:'M\<I\ANLT0U2)4DZBF*$UO[5UP[IH3WT]%ODB29;F_-O72[-M+
MN;T-'PW+4<U'->&>CH\>STXGL4 W&J):A&H2U12EZ2V_2\9=<[8[],RA>7O_
MLOW7WN) DW-4\U%-H%J :B&J1:@F44U1FEY#79KNLL^/=M$8'-5\5!.H%J!:
MB&H1JDE44Y2FE8?7)>:>.3'O&<+:S+^T&\W]C=4,C[_H[G7S5H96#:KYJ"9:
MS;8/NERC=R-W,O.\Z5&W"]URB&H1JDE44Y2FUT07GGN_/3R_6R[3)AJOJ^%3
MG"[?RKJO%6_29O3'[YZLUTN)W3,@FE[>?GAAXS1QBO7G)D[QSYP/F8]W<'6B
M\3NJ"50+4"U$M0C5)*HI2M/KMXO?/39^]]#X'=5\5!.H%J!:B&H1JDE44Y2F
MET<7OWO,@Z_-S."R0/-W5!.H%J!:B&H1JDFOY\G8/9<?%;55O<%W ;SWVP/X
M?W-_SG\>,Q^\C)D/DOZI@LP'.;@<T5L 4$V@6H!J(:I%J"9135&:7K3=+0 >
M>PN A]X"@&H^J@E4"U M1+4(U22J*4K3RZ.[!<!CGMIM9@:7!7H/ *H)5 M0
M+42U"-5DJVFSHI[<.Z&H;>K-O;L'P'MMU/?Y+MS_ZP=ZFX]K</VAMR*@FD"U
M -5"5(M03:*:HC2]3KL[%CSV@=X>>C,"JOFH)E M0+40U2)4DZBF*$TOC^YF
M!(]YH+>9&5P6Z$T(J"90+4"U$-4B5).M=GCCWUO[=&Y-16U5:_#3[O:"J?GV
M@KIG9%_\I$JS-;35HYJ/:@+5 E0+42U"-8EJBM+TVNAN,YBRC_>>HBD^JOFH
M)E M0+40U2)4DZBF*$TOCR[%GYHGE#]Y2EI>I(]I$]3L1PV?OQG-# \NE--Y
MW.?.[/B+UD<W*GHVVO?<,W2C(:I%J"9135&:WK2[!'YZP>3Q!W=<-F-:DF7W
MT!#S,T.FIZFK.YY/;._H\9#WYKT8_"<>C=Q1+4"U$-4B5).HIBA-KX,NF)^:
M@_D_)5\O/SE XV]4\U%-H%J :B&J1:@F44U1FEX:7?P]9>/O*1I_HYJ/:@+5
M E0+42U"-8EJBM+T\NCB[^D%(^#_E4<HF_W!]8+FXJ@FIJ=CX\>GYR\!NM$0
MU2)4DZBF*&U?"-?E4Y)4?ES%MS?KI'A,[I/5JK1VT7/S97'PKE4D#W6AV._O
MG*OKD_=]^[VP>]X/[/?A[OWKCK^]V<2/R?=Q49]>E]8J>:@W-7K75'A]QOWT
M\J+*-Q^N["OKI[RJ\O7NQZ<D7B9%LT#][P]YW7=K7S0;^)H7/^\.Y_:?4$L#
M!!0    ( !:=HU93 #>?W T  !V[   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8U+GAM;,W=77.;V!T&\*_"J#MM=B:V>)>4VIY)Q'GK;-I,TK07G5X0Z=BF
MD4 +*-YT]L,7)*RC8XY/8/MLMS>[L0(_P'X4_<TCT-5#47ZN[J6LG9^VF[RZ
MGMS7]>[5=%JM[N4VK2Z+G<R;O[DMRFU:-U^6=]-J5\IT?5AINYGZKAM/MVF6
M3VZN#H^]*V^NBGV]R7+YKG2J_7:;EE_?R$WQ<#WQ)H\/O,_N[NOV@>G-U2Z]
MDQ]D_7'WKFR^FIZ4=;:5>945N5/*V^O):^^5B&?M"H<E_I;)A^KLSTY[*)^*
MXG/[A5A?3]QVC^1&KNJ62)O_?9%+N=FT4K,?/W;HY+3-=L7S/S_J]'#PS<%\
M2BNY+#9_S];U_?5D/G'6\C;=;^KWQ0.7W0%%K;<J-M7AO\Y#MZP[<5;[JBZV
MW<K-'FRS_/C_]*?N&W&V0OC<"GZW@O]D!=]_9H6@6R$8ND+8K1 .72'J5HB&
MKA!W*\1#5YAU*\R&KC#O5I@/76'1K; XQ.'X\SO\\).T3F^NRN+!*=NE&ZW]
MPR%!A[6;GWF6MV'_4)?-WV;->O7-#T5^=U'+<NLD\E/M7#B^ZT?.GXM:5LZ+
M1-9IMJF^=[YSIDYUGY;-@UGN?,RSNGIY]L#;;+-IDEM=3>MFEUIXNNHV_^:X
M>?^9S7O.VR*O[RN'Y&NY-JR_M*\?6-:?-M^*T_?#?_Q^O/&MX%]6]:43>"^;
M[X,W=SY^2)P7WWW_>*CJVV#:4SO\-BT?83]XA U,,ISQ+0RQ,XE<#6*HG?E3
MFE\Z[K<9-GQO/ O#!_SL_%#_V1D8,83Q;8P6K>#T5 L.;O#L439/,)%7=;EO
M7BUJYQ\_- LXHI;;ZI^F9\Y1"\U:^R+XJMJE*WD]:5[E*EE^D9.;W__.B]T_
MFL*)Q!(D1I 816(,B7$D)D"8%N/P%./0IM]\J(O5Y_MBLY9E]0='_KC/ZJ^F
M^%J5L?$]8O$!:^>W+S>>YWNS,'!=]VKZY3R<_47C9EEWT5N2])><1XO0F_66
MI,AC888=7 1QT#\4CMRL &%:9J)39B)K9EYOB[+._IT>YMOBMIU&95G*M7.;
MY6F^RO([9U54M7& L,IC<W3$HK/O_<+S^AGJ+Q8%A@ A=XTB,8;$.!(3($R+
M87R*86R-X7*_W6_2]K>K"WE[V_RZY:3K?S4S]N'E^+8LMLW7Q>XQI*\_+-N!
MQ+UP8U,NK9L:FTLDEB Q@L0H$F-(C",Q <*TC,].&9]!I\P9,L9(+$%B!(E1
M),:0&$=B H1I,9Z?8CR'3)E696Q\D5B"Q @2HTB,S7NCTD4<!W/#-(O<K !A
M6C87IVPN[&/$)JTJY[6S++;;9E0X1-643:LR-IM(+$%B!(E1),:0&$=B H1I
M\?5<=<[7A<X('0=*,E1+H!J!:A2J,:C&H9I :7J@STH,#S(MV)G10?9ZKWV>
MYT?]TPF&!1<-VCN?8 )=KP]2Z'$PT^ZY\_X+.'2K J7ID?%59'S[*:GU.FM_
MTT\WSKLT6U^(W%FFNZQ.-\;@6+'1P4%J"50C4(U"-0;5.%03*$V/L^J6/&RY
MY$';):B60#4"U2A48U"-0S6!TO1 JY;)P]1,=F9TD,/^*_ LGB\6_;/_B6E9
MWP\/ T#OE=VP;#B/YY&A;((>$3-M.0C=Q;Q_1!RZ98'2] "IRLG[1N?T[ N\
M\[,#;0+L.S(Z@D@M@6H$JE&HQJ :AVH"I>E/!55[>3%V.(!V6U M@6H$JE&H
MQJ :AVH"I>F!5AV79^T>A@\'T'8+JB50C4 U"M58IVD=@>?&WLPWC"#0!@NE
MZ3%5'99G+[%^G1&D6??U:E7L\[I]W\R'.LW7:;FNG(^[=5I+ZZ ";<N@6@+5
M"%2C4(U!-0[5!$K3GS"J6/,6V$$%6K%!M02J$:A&H1J#:ARJ"92F7TR@FC;?
M6GP,'E3LS-@@0[4$JA&H1CM->V.P&[=SQ=/)@D$WS*&:0&EZ2E5]YMOKL_?M
M=3ZY7#LD+?-FJ*B<%\V$<9Q/FD<3>9NMLMIT*<4;NSPZN$@M@6H$JE&HQJ :
MAVH"I>G95CV?[T-'"A_:]$&U!*H1J$:A&H-J'*H)E*8'6C5]OK5X&3Y20!N^
M3M/?Y^?'7M!_&T-B6C9:^$%H*$:,KAM[4=@O1J!'Q)XYHMG,4(Q MRQ0FAX@
MU:SY]F9MX*L]NB6Q[]7H/"*U!*H1J$:A&H-J'*H)E*8_+U1AZ$?820%:^T&U
M!*H1J$:A&H-J'*H)E*8'6M5^OOURM\&3 K3N@VH)5"-0C4(UUFGGIS*"Q<ST
M-@WH=@5*TT.JJCS?7N7]#Z:17UZ8V/=]]#,#VA]"-0+5*%1C4(U#-8'2]&>/
M:AC].79F@3: 4"V!:@2J4:C&H!J':@*EZ8%6#:!OO[9N\,P";?Z@6@+5"%2C
MG19I4\;<V)= 6SVH)E":?A\GU>H%]E9/W2/-%$W[RF.C"=42J$:@&H5J#*IQ
MJ"90FAY?5?<%'G1H"* ='U1+H!J!:A2J,:C&H9I :7J@5<<7V*_E.P0ZJZI]
MFJ_D\W>2ZI3SW["CA>&E;VG?W.B(0EL[J$:A&H-J'*H)E*9'].S>C]]H[62>
M%65W8]6?G6],$-A;/V+O_8B]^2/V[H_8VS]B[_^(O0'DKU$A!JI"#$+L! 'M
M_J!: M4(5*-0C4$U#M4$2M,#K;J_P'ZQ(&UH)]VVYXB-^8UZDX,W.U[HV9L=
M^O>.?&;1Q+Y/HY,W>!\I=,,,JG'#8?C&HQ"F SXN>+:HG@=5G07VZDSDM6QV
MMG;*M);&1!S7;^][<MJZ>^EZT=,X0-LPJ$:@&H5J#*IQJ"90FIY-U9@%]L;L
ME$WYTT[FE3F>T.(JZ%_ %1O_01NV'('N'85J#*IQJ"90FAX\538%]LO9ED7^
M19:'CSG9E5GS@ODBRYUUL=FD9>7L9'G\;(2VJK5^4,*;;C.S\W/0P648//VG
M$]HN034"U2A48U"-0S6!TO0$JW8IL+=+(L_J+-TX*Y7DX]!WB/(QL6U^+=D]
M;L#SST\B7?I/HPOMDZ :@6H4JC&HQJ&:0&GZARZHSBFT=T[+M"R_MN]?>?ZW
ME-!T,90[,_V68M_8V(!"-0+5*%1C4(U#-8'2]("J5BFT7T3VKBQ64JZKXUNQ
M3F?C#Y_V\,F<5\/M#N/8-#$N[=L>G5=H:035*%1C4(U#-8'2]+RJTBB$E$9A
MOS0Z7LC2BRBT-()J!*I1J,:@&H=J J7I$56E46@OC?Z;C\VQTV// '2:]BPP
MG0$8N!R![AV%:@RJ<:@F4)H>R+./_K*>AK]Y+W?[<G6?5NT_F%]D$\+ZI5.J
M!X^G!=9[Z=2%<[O/UVE;#[6_<-VG^9UTTL-Y@E7[V-UA-&A6:'*\:Y:PC+7'
M?9J?CPE/_^V%-D)0C4 U"M485.-03: T/>JJ$0KMC9 QZE6Z>0QY$^7T29A7
MO?-C:>UL9%J9;YW0[8"6Z\NG)\'L>SDZV=#&":I1J,:@&H=J J7IR5;=5FCO
MMHS)KLMTW<X3Z_1K];+]H.%LN]\:4VO'??= &&<(:!4&U0A4HU"-034.U01*
MTZ.LJK#07H4MB[R2JWU[3=B(!-O-P))@Z 5<4(U -0K5&%3C4$V@-#W!JE,+
M[9W:J(FZFZ+;JD(;1.QCB/$Y,/_V3 VMWZ :@6H4JC&HQJ&:0&EZV%7]%G[C
MXJ[GW@3[VUS=:]_;T:=(H)T?5"-0C4(U!M4X5!,H3?_0;-7Y1=C/:8N@5YY!
MM02J$:A&H1J#:ARJ"92F!UIUA)&](QQ08MN%T1F&]H90C4 U&O7+U- SG7MG
MT.URJ"90FIY/U0E&]D[0.J ,_-17^R9&!QC:*D(U M4H5&-0C4,U@=+TD*M6
M,<)^5%P$;1*A6@+5"%2C4(U!-0[5!$K3 ZU:R<C>2HY_YU$'GM?4,\]T%XRE
M?=.CXPIM%J$:A6H,JG&H)E":'E?5+$;V9G'@&X\BPX50QBO.[)L;'5%H10C5
M*%1C4(U#-8'2](BJBC#ZQITC1\[![</'+[N_-08:>IM)J)9 -0+5*%1C4(U#
M-8'2]-2K-C&:80=CZ$5V4"V!:@2J4:C&H!J':@*EZ8%6Y6)D+Q<-ESNUUS,?
MKM7[SO&:46+0&_"ZK7C>V2CB7KK^8N$%3Z]WMN_1Z!1#6T.H1J$:@VH<J@F4
MIJ=8M8;1+V\-?\M/6&R6(H?[4[:SSZ[(6[5Q?BB:=?XJRZV3//?;)[1WA&H)
M5"-0C4(U!M4X5!,H37O&Q:IWC+&]8PSM':%: M4(5*-0C4$U#M4$2M,#K7K'
MV-X[#KVKL)T9'61H^0C5"%2C<;]\O#"?4&70#7.H)E":GE+5/L:_O'W\C0>=
MY/'*,WJZ\HQ*\QT2[ <Y^CD$[3^A&H%J%*HQJ,:AFD!I^M-,]9\QMO^,H?TG
M5$N@&H%J%*HQJ,:AFD!I>J!5_QG;^\_!TPVR15M"M02J$:A&.^U\NC$V<0RZ
M60[5!$K3,ZI*S]A>>MIFF__KCX"R']?H)PVTJX5J!*I1J,:@&H=J J7ISRS5
MU<8Q=IR!UK!0+8%J!*I1J,:@&H=J J7I@58U;&R_ '/P. .M7Z%: M4(5*.=
M=O[&H@M_[AD'&FBW"M4$2CNF=%K=2UDG:9W>7&UE>2>7<K.IG,/(<#UI3^&<
M'G5*>=NDV'OUVI],>X\OO5>)USX^5<S-U2Z]DV_3\B[+*V<C;QO2O9PUKQME
M=G=_^J(N=M<3;^)\*NJZV![^>"_3YFG0+M#\_6W1#$S=%^T&'HKR\V&W;_X#
M4$L#!!0    ( !:=HU:RW@SSU ,  ,(4   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;*U876^C.!3]*Q8S6LU(;0%#/MI-(K6%T5::KJKISN[#:!Y<
MN$G0@)VQ33+S[]<&2J A;B/Y)3%PS['O.>9B>[9C_(=8 TCTJ\BIF#MK*3=7
MKBN2-11$7+ -4/5DR7A!I+KD*U=L.)"T A6YBSUO[!8DH\YB5MU[X(L9*V6>
M47C@2)1%0?CO&\C9;N[XSO.-+]EJ+?4-=S';D!4\@ORZ>>#JRFU9TJP *C)&
M$8?EW+GVKV(_T( JXM\,=J+31CJ5)\9^Z(N[=.YX>D200R(U!5%_6[B%/-=,
M:AP_&U*G[5,#N^UG]D]5\BJ9)R+@EN7_9:E<SYVI@U)8DC*77]CN+V@2&FF^
MA.6B^D6[.G:B@I-22%8T8#6"(J/U/_G5"-$!^.$1 &X ^"5@= 00-(#@K3V$
M#2!\*V#4 *K4W3KW2KB(2+*8<;9#7$<K-MVHU*_02J^,ZHGR*+EZFBF<7'QF
M='4N@1<H@B>)SA'VL(_^9A($^A"!)%DN/JK;CT SQIL'Y^CK8X0^O/^(WJ.,
MHG_6K!2$IF+F2C4D3>PF3?>W=??X2/<^NF=4K@6*:0II'^^J5-I\\',^-]A(
M>%VN+I#OG^D\\-!XW@ /:K@W (_,\'O"6W@P (_-\ B2%HX-8@2MN4'%%QSE
M4Y;>42%YJ=YMB;Y]5@'H3D(AO@^,[J9F"X?9=,FZ$AN2P-Q1-4D WX*S^..=
M/_;^'!+:)EEDDRRV1-:S)&PM"4WLBP?R6ULA$%NJ>J;LR80H"4T )4S(H3?H
MQDAXJBLUV;@BTQ^1[0*//#73MUVU;?886R+KJ3UJU1X9U=X7LR%AC=A3A;5)
M%MDDBRV1]0P8MP:,K5:@L4U+;))%-LEB2V0]2R:M)1/C.U%9DC"Z!:Y7>V>(
M\6R549)7]>@,D8*55 Z9,SFH'9=X^K)XW-91HT[4-,0')<8XQE/EM$36DW/:
MRCE]K<2$QTN,$7OJ?+9)%MDDBRV1]0RX; VXM%IB+FU:8I,LLDD66R+K6>)[
M^UV%9WPK/BEJ0R4QHT\UH6'K%B;?G_@'-6<@#H=XZO?#XE?#^IIT=EJ^49,[
MJO99("3B1,*@*D;\R:HT&S^ODX=WX06CEZK8[#6VQ=;7&.\UQJ]_W%Y?4IM9
M3E8:'TR8P#N<?3;[C&VQ]77>;RQ]XR;I<!%1MR6D*&M+L6DM8>8_V8'@P(&A
M18?53F-;;+4%;N<,IP"^J@[/A-)5"5@?Y[1WVP.ZZ^I8RMV'UZ=[]X2K!9U
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MYYB#1%51KCJ*K\L:ZYPK%'EE<P4T :$GX/,%YVK7T0Z:NO[T?U!+ P04
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M-LWFBNEL*,H&^OQ]4:CGG;*#9FW?X@=02P,$%     @ %IVC5B?@B)SI @
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M[("0;D@:J4=^^(,6$_*-WII',OL%A_Q:/W# .I6*QT6P=A"S)/\G/XJ%. I
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MO2+/P+69RA0[N:RN[['V.R$-'K=%JF#V\9(2W?52-[&J]?=WHRQV@Q]6^/R
M=@&XOU7*#A/7$N.#EO\%4$L#!!0    ( !:=HU: UUP'<P<  /\_   9
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MXX5]IZV;W,0JJ9=]J[K?FXF*'>/5&GI05US3MF_Z8+Q_TX/Z72B:_9+)&-[
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MW&.&G2DH:X#K&RG-86 W:'K=V7]02P,$%     @ %IVC5C@#>J;3 P  ,Q$
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M:6SERQ]EZ/N&%Y*P1$Y<I;F9-[AQQ>.VY.&?X1&@;YRIC41W+(&DZ>_JF.K
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M) %A#/3S%=>[I)J8%]3?26;_ 5!+ P04    "  6G:-6&F&IZ"@$  "&%P
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M7ZF$\5^R#;X7<43*M;&JZ< 80<-E^+/[K@Y[ .0Y#$@Z0/(4,'P&D': ]*6
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M%LJB['BSQI<$M'/ ]:52=C=P&_1O4_X74$L#!!0    ( !:=HU:5H8WGRP(
M (T)   9    >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;,56:V^;,!3]*Q:3
MIE5:"X&\VA&D)-VCTBI%S;I]F/;!@9N "C:S36C__:X-84E&HDU"VI?XP3W'
MY]Q</_R2BR<9 RCRG*5,3JQ8J?S&MF480T;E%<^!X9<U%QE5.!0;6^8":&1
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M]<>+'J&82+8VU^R"275IF^%*M57 M8'ZGC F#Q,=H&S4PE]02P,$%     @
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M*\5I=;D$G($H!^CW<\[5]J8,T![(Q?\#4$L#!!0    ( !:=HU8Z;.?W2@,
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MH2VTR,R6-:.:3L=2;(DTT<AF+JPV%HW5,&Z6\5I+?,H0IZ>?*)/D&TUR(!=
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M=D(6V$"O%?<%_#+/>)[Q>/*,ME)]UBL 0Q[+0NBQMS)F?>O[.EM!R?2-7(/
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M<1)V7UP8/'UM@_^S6TX:]_L]C<;T*/8.HR0Y$;G5"8<K](D+_5YOG@&0]](
M"0<$-:B]A4H8E [&*#ZO#)L70(PDE<BDT++@N>LHJNDLZT9T<(%7BQ+ Z@FS
MPE(B]BS";8.YZ:HE?T_PE*"63CAJDMG3ZT]7N]J*TSLGR8[6)U:T=JR_"L/;
M2=B]0W''^?*?CJY5,@J()1>:%+# ,(*;/M:/JH5G/3%R[:387!H4=FZX0K$.
MRAK@_D)B,IN)/:"5_^DW4$L#!!0    ( !:=HU8^!^STT@,  #0-   9
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M#2ZQ*"P0A?&]Q?2Z+:WC[O<+^IWC3EQ63.-2%O_PU.0S;^Q!BAFK"_-5;O_
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M<VAE971S+W-H965T.3 N>&ULG51=3]LP%/TK5M[!:4H90FDDZ(J8!%)%!7M
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M]$?I;NA)5N$1HMS/%O?3R6CP.!ZQ+X/I8#8<L\7M>/RX ( ! AB<#9!=S#F
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M<F]P<R]A<' N>&UL4$L! A0#%     @ %IVC5BY _[SO    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %IVC
M5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  6G:-6/@1 J_0%  #8'P  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %IVC
M5N9+.(!5"   LR,  !@              ("!. X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( !:=HU:D023& @,  ,L*   8
M      " @<,6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  6G:-61J%;/R@'  "Q'0  &               @('[&0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ %IVC5HE0"N>T#@  -,8  !@
M             ("!62$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( !:=HU:AHK:23@D  (LG   8              " @4,P  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  6G:-6\8:1[(\$  #L
M"0  &               @(''.0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ %IVC5JU9.)@<%P  >44  !@              ("!C#X
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !:=HU8$AOC\
MO00  #@+   8              " @=Y5  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  6G:-62L^481P.  !>,P  &0
M@('16@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !:=
MHU9G@B<Y+@X  &\I   9              " @21I  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ %IVC5E(C>6[.!@  WQ   !D
M         ("!B7<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  6G:-6G=3C<8L#   5"0  &0              @(&.?@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !:=HU9D:*$/B@L  -X=
M   9              " @5""  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ %IVC5BP/PG  %0  X5@  !D              ("!$8X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  6G:-6+_X^
M\YP1  "T+P  &0              @(%(HP  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( !:=HU: 8R9]5 @  %(4   9
M  " @1NU  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M%IVC5NEI)UR,"0  [AT  !D              ("!IKT  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  6G:-6S[B552D$  !Y"0  &0
M            @(%IQP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( !:=HU;)K- E80,  -H'   9              " @<G+  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %IVC5F;<:+ @!0
MW0L  !D              ("!8<\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  6G:-61CL;#3 %  "C#0  &0              @(&X
MU   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !:=HU:]
MWN&#;PH  *,=   9              " @1_:  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ %IVC5M=P3]&[!   I0H  !D
M     ("!Q>0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M"  6G:-6)Q#D?@@)  !W&   &0              @(&WZ0  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !:=HU9LT]T * ,  !\'   9
M              " @?;R  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ %IVC5D;^-,5Z'@  %V   !D              ("!5?8  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  6G:-62!.RX_ &
M  #/$0  &0              @($&%0$ >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( !:=HU8E)>\]A04   X6   9              "
M@2T< 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ %IVC
M5@2O\ U[!   @PH  !D              ("!Z2$! 'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  6G:-6%6!R..P"  !9!@  &0
M        @(&;)@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( !:=HU9:;!'Y_P(  (,&   9              " @;XI 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ %IVC5@R/-S1C!0  @@T
M !D              ("!]"P! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  6G:-6^B!S^6P#  #B!P  &0              @(&.,@$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !:=HU8X/_33
M4@,   \(   9              " @3$V 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ %IVC5E)=2E]'!   \0D  !D
M ("!NCD! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  6
MG:-6PA*'7V $  !="@  &0              @($X/@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !:=HU83?+5"3@,  /\'   9
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M970T,BYX;6Q02P$"% ,4    "  6G:-6@#2N@L "  #B!P  &0
M    @(',50$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M !:=HU84[W2Z) 0  /$5   9              " @<-8 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ %IVC5NOA0; @ P  SPD  !D
M             ("!'ET! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  6G:-6M].<SMT"  #)!P  &0              @(%U8 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( !:=HU9E<6&W;0,
M -41   9              " @8EC 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ %IVC5E-^7>*0"   76X  !D              ("!
M+6<! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  6G:-6
M>9$OL(8)   K7P  &0              @('T;P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !:=HU;G)0&FO0L  "*.   9
M      " @;%Y 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ %IVC5BXE%U:N @  B08  !D              ("!I84! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  6G:-6L>:;%@H%  "A'
M&0              @(&*B $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( !:=HU:-GCBX6P,  'T.   9              " @<N- 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ %IVC5@FC/)^X
M P  00T  !D              ("!79$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  6G:-6<\W'*D@#   S#0  &0
M@(%,E0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !:=
MHU8,%E)1E@,  +82   9              " @<N8 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ %IVC5@Q"FI@* P  B @  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( !:=HU9" FI$W0(  ,H)   9
M  " @8NQ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M%IVC5NEWJ32J!P  ED$  !D              ("!G[0! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  6G:-6(+>MP5D0  #'Z@  &0
M            @(& O $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( !:=HU93 #>?W T  !V[   9              " @1#- 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ %IVC5K+>#//4 P
MPA0  !D              ("!(]L! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    "  6G:-6 J _L3X%  "'*0  &0              @($N
MWP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( !:=HU9@
MX@#@JP0  .,7   9              " @:/D 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ %IVC5M6 [0:(!0  YR<  !D
M     ("!A>D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !:=HU99\==+) (  -P$   9              "
M@8;\ 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ %IVC
M5H#77 =S!P  _S\  !D              ("!X?X! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    "  6G:-6D-U O&0#  #W"@  &0
M        @(&+!@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( !:=HU8X WJFTP,  #,1   9              " @28* @!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ %IVC5AIAJ>@H!   AA<
M !D              ("!, X" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    "  6G:-6WZW61W<"  "G!@  &0              @(&/$@(
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( !:=HU:5H8WG
MRP(  (T)   9              " @3T5 @!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ %IVC5JR4B8XF P  M D  !D
M ("!/Q@" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    "  6
MG:-6*2G:Z,D#  "<$P  &0              @(&<&P( >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( !:=HU8Z;.?W2@,  ,,/   9
M          " @9P? @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#
M%     @ %IVC5HV]9O5# P  KPD  !D              ("!'2," 'AL+W=O
M<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    "  6G:-6;-Q-U8L#  "O
M$   &0              @(&7)@( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM
M;%!+ 0(4 Q0    ( !:=HU8KDF3A@ ,  +@-   9              " @5DJ
M @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ %IVC5MJY
M^&&4 P  "@P  !D              ("!$"X" 'AL+W=O<FMS:&5E=',O<VAE
M970X-RYX;6Q02P$"% ,4    "  6G:-6/@?L]-(#   T#0  &0
M    @(';,0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    (
M !:=HU;O.NR%=0,   <*   9              " @>0U @!X;"]W;W)K<VAE
M971S+W-H965T.#DN>&UL4$L! A0#%     @ %IVC5I]2 8GH 0  6@0  !D
M             ("!D#D" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"
M% ,4    "  6G:-651A>UDX#  #R%   #0              @ &O.P( >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !:=HU:7BKL<P    !,"   +
M      "  2@_ @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !:=HU;K>2,7T08
M !X[   /              "  1%  @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  6G:-6YN*DT* "   %-0  &@              @ $/1P( >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  6G:-6PH ,:SH"  !H
M,P  $P              @ 'G20( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    8@!B .4:  !23 (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>267</ContextCount>
  <ElementCount>385</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Convertible Preferred Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ConvertiblePreferredEquity</Role>
      <ShortName>Convertible Preferred Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LossPerCommonShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsNarrativeDetails</Role>
      <ShortName>Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails</Role>
      <ShortName>Transactions - Allocation of Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Transactions - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails</Role>
      <ShortName>Transactions - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails</Role>
      <ShortName>Long-term Debt - 2022 Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Commitments and Contingencies - Credit and Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Credit and Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Convertible Preferred Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails</Role>
      <ShortName>Convertible Preferred Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ConvertiblePreferredEquity</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeTaxes</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - evh-20230331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - evh-20230331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  evh-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="evh-20230331.htm">evh-20230331.htm</File>
    <File>a33123exhibit311.htm</File>
    <File>a33123exhibit312.htm</File>
    <File>a33123exhibit321.htm</File>
    <File>a33123exhibit322.htm</File>
    <File>evh-20230331.xsd</File>
    <File>evh-20230331_cal.xml</File>
    <File>evh-20230331_def.xml</File>
    <File>evh-20230331_lab.xml</File>
    <File>evh-20230331_pre.xml</File>
    <File>exhibit106.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="858">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 858,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 267,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 649,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 11
   },
   "keyCustom": 58,
   "keyStandard": 327,
   "memberCustom": 43,
   "memberStandard": 52,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.evolenthealth.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Transactions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Credit Losses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Long-term Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Convertible Preferred Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.evolenthealth.com/role/ConvertiblePreferredEquity",
     "shortName": "Convertible Preferred Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Loss Per Common Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Investments in Equity Method Investees",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Supplemental Cash Flow Information",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Transactions (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenue Recognition (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Credit Losses (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Long-term Debt (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Related Parties (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Organization (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
       "span",
       "div",
       "evh:RightOfOffsetPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
       "span",
       "div",
       "evh:RightOfOffsetPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ifa977c28de4e47168b48e484eaede4c5_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ifa977c28de4e47168b48e484eaede4c5_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Recently Issued Accounting Standards (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Transactions - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
     "shortName": "Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ib409c87cf89b4073a5635cf8c0a310ba_I20230120",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "icd5eb55aee214a3a80aef01f773385a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "icd5eb55aee214a3a80aef01f773385a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
     "shortName": "Transactions - Allocation of Acquisition Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i83ab5f7f3263476a8a74baffa52d8ad2_D20230120-20230120",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Transactions - Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails",
     "shortName": "Transactions - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i3f67a07bd78748978db5d7cb7db253a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iff8f75c2d42f44b8955b09ce1c30ffde_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i69e4c48265fb470aaff1f7302eec43f0_D20221031-20221031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
     "shortName": "Long-term Debt - 2022 Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iae3d6c55001b4c1da1d82fff2848586c_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iba3704b56ea6468cb880afa5c10b8d15_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i8b58c2da78614c1f968d97ed45d71235_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie251d99bd74345e1bc9460f66244b376_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i88b11fb976df4da5ae72ddeb8758f9a5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i88b11fb976df4da5ae72ddeb8758f9a5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:LineOfCreditFacilityAutomaticExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:LineOfCreditFacilityAutomaticExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Commitments and Contingencies - Credit and Concentration Risk (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Credit and Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "evh:NumberOfOptionsToRenewLeases",
      "reportCount": 1,
      "unitRef": "option_to_renew_lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i23c68de8493844868847bcbb42b75777_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Leases - Primary Office Leases (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i2d1d9ed997744f43b91313620e282985_I20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Convertible Preferred Equity (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
     "shortName": "Convertible Preferred Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i8c131a04ae43496793f1aa657b4cf18d_D20230120-20230120",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i7a5e09b6d1694a739ec1ccab8decce92_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Investments in Equity Method Investees (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i0bafc71fd6ff4258ba1f07d59a2d2c26_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i94eed0228a0947b5bf2dc7e6184b79c7_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i94eed0228a0947b5bf2dc7e6184b79c7_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i94eed0228a0947b5bf2dc7e6184b79c7_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i15f37596d3fb4fd0b55345096a8d3ec5_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i586e945bd60d49af85c5c42ff6511bc0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "i110024d501a54ed99a65ed852a158dd2_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ic0cac623727540dc8037eb20bb80cfce_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "iedeac599ed134eeeb0c936f4c013dbc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Recently Issued Accounting Standards",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230331.htm",
      "contextRef": "ie6ac53fa164e483ea5d6e0989b4e9f6d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - evh-20230331.htm",
     "menuCat": "Cover",
     "order": "90",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - evh-20230331.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 98,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r903"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_A2022CreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Credit Facilities",
        "label": "2022 Credit Facilities [Member]",
        "terseLabel": "2022 Credit Facilities"
       }
      }
     },
     "localname": "A2022CreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "label": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "negatedTerseLabel": "NIA acquisition"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BrightHealthManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bright Health Management, Inc",
        "label": "Bright Health Management, Inc [Member]",
        "terseLabel": "Bright Health Management, Inc."
       }
      }
     },
     "localname": "BrightHealthManagementIncMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Percentage Allowed To Be Paid In Equity Consideration",
        "label": "Business Combination, Contingent Consideration, Percentage Allowed To Be Paid In Equity",
        "terseLabel": "Percentage of contingent consideration allowed to be paid in equity interest (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationPercentageAllowedToBePaidInEquity",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cases",
        "label": "Cases [Member]",
        "terseLabel": "Cases"
       }
      }
     },
     "localname": "CasesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ChangesInTaxReceivablesAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Tax Receivables Agreement Liability",
        "label": "Changes In Tax Receivables Agreement Liability",
        "negatedTerseLabel": "Change in tax receivable agreement liability",
        "terseLabel": "Recognition of remaining TRA liability",
        "verboseLabel": "Change in tax receivable agreement liability"
       }
      }
     },
     "localname": "ChangesInTaxReceivablesAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CustomerDiscountsFromPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Discounts From Performance Obligations",
        "label": "Customer Discounts From Performance Obligations",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CustomerDiscountsFromPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtInstrumentClosingFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee, Percent",
        "label": "Debt Instrument, Closing Fee, Percent",
        "terseLabel": "Closing fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeePercent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "label": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "terseLabel": "Number of days prior to any junior debt maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "terseLabel": "Prepayment penalty on or after third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodFourPercent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "terseLabel": "Prepayment penalty prior to first anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodOnePercent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "terseLabel": "Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodThreePercent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "terseLabel": "Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodTwoPercent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_December312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2023",
        "label": "December 31, 2023 [Member]",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "December312023Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2024",
        "label": "December 31, 2024 [Member]",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "December312024Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2025",
        "label": "December 31, 2025 [Member]",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "December312025Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DeferredFinancingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Fees",
        "label": "Deferred Financing Fees [Member]",
        "terseLabel": "Deferred Financing Fees"
       }
      }
     },
     "localname": "DeferredFinancingFeesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityComponentOfLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component of Long Term Debt",
        "label": "Equity Component of Long Term Debt [Member]",
        "terseLabel": "Equity Component of Long Term Debt"
       }
      }
     },
     "localname": "EquityComponentOfLongTermDebtMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services Segment"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "label": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "terseLabel": "Unrealized (gain) loss, net"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ImplantableProviderGroupIMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implantable Provider Group (\"IMP\")",
        "label": "Implantable Provider Group (\"IMP\") [Member]",
        "terseLabel": "IPG"
       }
      }
     },
     "localname": "ImplantableProviderGroupIMPMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Services Agreement",
        "label": "Income (Loss) From Equity Method Investments, Services Agreement",
        "verboseLabel": "Revenue related to services agreements"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LesseeOperatingLeaseLiabilityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, After Year Four",
        "label": "Lessee, Operating Lease, Liability, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Leveraged Stock Units (LSUs)",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance - based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Other Adjustments",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Other Adjustments",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOtherAdjustments",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LineOfCreditFacilityAutomaticExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Automatic Extension Period",
        "label": "Line Of Credit Facility, Automatic Extension Period",
        "terseLabel": "Automatic extension period"
       }
      }
     },
     "localname": "LineOfCreditFacilityAutomaticExtensionPeriod",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "label": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "terseLabel": "Automatic extension after each period"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodBeforeEachAutomaticExtension",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NationalImagingAssociatesIncNIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Imaging Associates Inc. (NIA)",
        "label": "National Imaging Associates Inc. (NIA) [Member]",
        "terseLabel": "NIA"
       }
      }
     },
     "localname": "NationalImagingAssociatesIncNIAMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Customers",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_NumberOfOptionsToRenewLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Renew Leases",
        "label": "Number Of Options To Renew Leases",
        "terseLabel": "Number of leases option"
       }
      }
     },
     "localname": "NumberOfOptionsToRenewLeases",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs",
        "verboseLabel": "Performance-Based Restricted Stock Units (PSUs)"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PerformanceSuiteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Suite",
        "label": "Performance Suite [Member]",
        "terseLabel": "Performance Suite"
       }
      }
     },
     "localname": "PerformanceSuiteMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SpecialtyTechnologyAndServicesSuiteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Technology And Services Suite",
        "label": "Specialty Technology And Services Suite [Member]",
        "terseLabel": "Specialty Technology and Services Suite"
       }
      }
     },
     "localname": "SpecialtyTechnologyAndServicesSuiteMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_StockIssuedDuringPeriodSharesEarnOuts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Earn-outs",
        "label": "Stock Issued During Period, Shares, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockIssuedDuringPeriodValueEarnOuts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Earn-outs",
        "label": "Stock Issued During Period, Value, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Liability",
        "label": "Tax Receivable Agreement Liability",
        "terseLabel": "Tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "label": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "terseLabel": "Amount of tax benefit percent"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentOfTaxSavingsToBePaid",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Tax Expense (Benefit)",
        "label": "Tax Receivables Agreement, Tax Expense (Benefit)",
        "terseLabel": "Tax expense (benefit) from TRA"
       }
      }
     },
     "localname": "TaxReceivablesAgreementTaxExpenseBenefit",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TemporaryEquityAccretionToRedemptionValueAndDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Accretion To Redemption Value And Dividends",
        "label": "Temporary Equity, Accretion To Redemption Value And Dividends",
        "terseLabel": "Accretion of Series A preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAndDividends",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TemporaryEquityConvertibleConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Convertible, Conversion Price",
        "label": "Temporary Equity, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollar per share)"
       }
      }
     },
     "localname": "TemporaryEquityConvertibleConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_TemporaryEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Disclosure",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Equity"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureTextBlock",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_TemporaryEquityDividendRatePerDollarAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Dividend Rate, Per-Dollar-Amount",
        "label": "Temporary Equity, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityDividendRatePerDollarAmount",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_TemporaryEquityDividendRatePercentageAnnualIncreaseInRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Dividend Rate, Percentage, Annual Increase In Rate",
        "label": "Temporary Equity, Dividend Rate, Percentage, Annual Increase In Rate",
        "terseLabel": "Annual increase in dividend rate"
       }
      }
     },
     "localname": "TemporaryEquityDividendRatePercentageAnnualIncreaseInRate",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Redemption Period",
        "label": "Temporary Equity Redemption Period [Axis]",
        "terseLabel": "Preferred Stock Redemption Period [Axis]"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodAxis",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Redemption Period [Domain]",
        "label": "Temporary Equity Redemption Period [Domain]",
        "terseLabel": "Preferred Stock Redemption Period [Domain]"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodDomain",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Redemption, Period Five",
        "label": "Temporary Equity, Redemption, Period Five [Member]",
        "terseLabel": "Change of control after January 20, 2025"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodFiveMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Redemption, Period Four",
        "label": "Temporary Equity, Redemption, Period Four [Member]",
        "terseLabel": "Change of control prior to January 20, 2025"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodFourMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption, Period One",
        "label": "Temporary Equity, Redemption, Period One [Member]",
        "terseLabel": "Called by company on or after January 20, 2025"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodOneMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Redemption, Period Three",
        "label": "Temporary Equity, Redemption, Period Three [Member]",
        "terseLabel": "Refinancing or replacement of debt"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodThreeMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Redemption, Period Two",
        "label": "Temporary Equity, Redemption, Period Two [Member]",
        "terseLabel": "Called by holder on or after January 20, 2030"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPeriodTwoMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TemporaryEquityRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Redemption Price Percentage",
        "label": "Temporary Equity, Redemption Price Percentage",
        "terseLabel": "Redemption price percentage"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePercentage",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of series A preferred stock, net of issuance costs (in shares)",
        "verboseLabel": "Aggregate shares of preferred stock sold (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_TemporaryEquityVariableDividendRateBasisSpread": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Variable Dividend Rate, Basis Spread",
        "label": "Temporary Equity, Variable Dividend Rate, Basis Spread",
        "terseLabel": "Quarterly dividend rate, basis spread on variable rate"
       }
      }
     },
     "localname": "TemporaryEquityVariableDividendRateBasisSpread",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_UPMCResellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPMC Reseller Agreement",
        "label": "UPMC Reseller Agreement [Member]",
        "terseLabel": "UPMC Reseller Agreement"
       }
      }
     },
     "localname": "UPMCResellerAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_WeightedAverageCommonSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Common Shares Outstanding",
        "label": "Weighted Average Common Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageCommonSharesOutstandingAbstract",
     "nsuri": "http://www.evolenthealth.com/20230331",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r210",
      "r257",
      "r267",
      "r273",
      "r341",
      "r349",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r555",
      "r556",
      "r558",
      "r560",
      "r561",
      "r565",
      "r568",
      "r571",
      "r572",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative-effect adjustment from adoption of ASC 2020-06"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r210",
      "r257",
      "r267",
      "r273",
      "r341",
      "r349",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r555",
      "r556",
      "r558",
      "r560",
      "r561",
      "r565",
      "r568",
      "r571",
      "r572",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r210",
      "r257",
      "r267",
      "r273",
      "r341",
      "r349",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r555",
      "r556",
      "r558",
      "r560",
      "r561",
      "r565",
      "r568",
      "r571",
      "r572",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r323",
      "r872",
      "r963",
      "r985",
      "r986"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r469",
      "r646",
      "r716",
      "r758",
      "r759",
      "r819",
      "r821",
      "r823",
      "r824",
      "r826",
      "r848",
      "r849",
      "r861",
      "r869",
      "r882",
      "r887",
      "r959",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r469",
      "r646",
      "r716",
      "r758",
      "r759",
      "r819",
      "r821",
      "r823",
      "r824",
      "r826",
      "r848",
      "r849",
      "r861",
      "r869",
      "r882",
      "r887",
      "r959",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r323",
      "r872",
      "r963",
      "r985",
      "r986"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r320",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r852",
      "r870",
      "r886",
      "r914",
      "r955",
      "r956",
      "r963",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r320",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r852",
      "r870",
      "r886",
      "r914",
      "r955",
      "r956",
      "r963",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r461",
      "r469",
      "r497",
      "r498",
      "r499",
      "r645",
      "r646",
      "r716",
      "r758",
      "r759",
      "r819",
      "r821",
      "r823",
      "r824",
      "r826",
      "r848",
      "r849",
      "r861",
      "r869",
      "r882",
      "r887",
      "r890",
      "r953",
      "r959",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r461",
      "r469",
      "r497",
      "r498",
      "r499",
      "r645",
      "r646",
      "r716",
      "r758",
      "r759",
      "r819",
      "r821",
      "r823",
      "r824",
      "r826",
      "r848",
      "r849",
      "r861",
      "r869",
      "r882",
      "r887",
      "r890",
      "r953",
      "r959",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r321",
      "r322",
      "r755",
      "r756",
      "r757",
      "r820",
      "r822",
      "r825",
      "r827",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r853",
      "r871",
      "r890",
      "r963",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r321",
      "r322",
      "r755",
      "r756",
      "r757",
      "r820",
      "r822",
      "r825",
      "r827",
      "r833",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r853",
      "r871",
      "r890",
      "r963",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "Alpharetta, GA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r260",
      "r261",
      "r262",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r382",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r539",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r603",
      "r604",
      "r608",
      "r609",
      "r610",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r324",
      "r860"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29",
      "r885"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Changes in Allowance for Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r776",
      "r836",
      "r891",
      "r984"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r75",
      "r220",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r43",
      "r134",
      "r228",
      "r685",
      "r724",
      "r728"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r129",
      "r885",
      "r988"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r743",
      "r931",
      "r932",
      "r933",
      "r965",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r260",
      "r261",
      "r262",
      "r264",
      "r273",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r382",
      "r506",
      "r507",
      "r508",
      "r523",
      "r524",
      "r525",
      "r526",
      "r539",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r603",
      "r604",
      "r608",
      "r609",
      "r610",
      "r611",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r654",
      "r655",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r87",
      "r88",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdministrativeServiceMember": {
     "auth_ref": [
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative assistance, including, but not limited to, accounting, tax, legal, regulatory filing, and share registration of managed fund and investment account of independent third party, and related and affiliated entity.",
        "label": "Administrative Service [Member]",
        "terseLabel": "Administrative Services"
       }
      }
     },
     "localname": "AdministrativeServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r501",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total compensation expense by financial statement line item"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r229",
      "r326",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Charge-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r138",
      "r423",
      "r606",
      "r927"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r423",
      "r606",
      "r867",
      "r868",
      "r927"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of the debt discount and the issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r10",
      "r69",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r5",
      "r15",
      "r43",
      "r921",
      "r922",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r177",
      "r223",
      "r249",
      "r298",
      "r312",
      "r318",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r546",
      "r548",
      "r588",
      "r679",
      "r781",
      "r885",
      "r897",
      "r957",
      "r958",
      "r974"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r216",
      "r230",
      "r249",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r546",
      "r548",
      "r588",
      "r885",
      "r957",
      "r958",
      "r974"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r537",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r90",
      "r92",
      "r537",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r911",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Adjustments"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r535",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r535",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r1",
      "r2",
      "r12"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r1",
      "r2"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r1",
      "r2",
      "r98",
      "r543"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r545",
      "r926"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r3",
      "r99",
      "r544"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or input ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Total identifiable intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r13",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r850"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Net capitalized internal-use software development costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r218",
      "r854"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r53",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash and Restricted Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r52",
      "r148",
      "r247"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r4",
      "r148"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r227",
      "r249",
      "r279",
      "r280",
      "r287",
      "r289",
      "r295",
      "r296",
      "r336",
      "r392",
      "r394",
      "r395",
      "r396",
      "r399",
      "r400",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r588",
      "r734",
      "r735",
      "r736",
      "r737",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r768",
      "r790",
      "r813",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r905",
      "r928",
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r119",
      "r681",
      "r767"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r386",
      "r387",
      "r838",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r888",
      "r889",
      "r890",
      "r892",
      "r893",
      "r894",
      "r895",
      "r931",
      "r932",
      "r965",
      "r987",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Class A common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r128",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Class A common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Class A common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r128",
      "r683",
      "r885"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 112,552,160 and 101,500,558 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r232",
      "r234",
      "r240",
      "r673",
      "r693"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r323",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r323",
      "r729",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r323",
      "r837",
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r64",
      "r111",
      "r174",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r323",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r437",
      "r438",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r437",
      "r438",
      "r458"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r437",
      "r438",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r27",
      "r179",
      "r982"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Carrying value"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r161",
      "r402",
      "r403",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r915",
      "r916"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r141",
      "r249",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r588",
      "r957"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r327",
      "r328",
      "r351",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r62",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion issued (in share)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r248",
      "r401",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r417",
      "r424",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r124",
      "r125",
      "r178",
      "r179",
      "r253",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r607",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r162",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r35",
      "r80",
      "r164",
      "r165",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r35",
      "r80",
      "r164",
      "r165",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r114",
      "r116",
      "r402",
      "r607",
      "r865",
      "r866"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r34",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r253",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r607",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36",
      "r253",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r607",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r80",
      "r81",
      "r113",
      "r114",
      "r116",
      "r120",
      "r163",
      "r165",
      "r253",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r607",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r115",
      "r413",
      "r428",
      "r865",
      "r866"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r115",
      "r960"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r514",
      "r515",
      "r680"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r10",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r10",
      "r74"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r10",
      "r303"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [
      "r457",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r457",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r963"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r470",
      "r474",
      "r503",
      "r504",
      "r505",
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r241",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r276",
      "r279",
      "r287",
      "r288",
      "r289",
      "r293",
      "r572",
      "r573",
      "r674",
      "r694",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r241",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r279",
      "r287",
      "r288",
      "r289",
      "r293",
      "r572",
      "r573",
      "r674",
      "r694",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r275",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTerseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r16",
      "r210",
      "r235",
      "r236",
      "r237",
      "r254",
      "r255",
      "r256",
      "r261",
      "r270",
      "r272",
      "r294",
      "r341",
      "r349",
      "r436",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r571",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r632",
      "r719",
      "r720",
      "r721",
      "r743",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r661",
      "r663",
      "r665",
      "r667",
      "r669",
      "r671",
      "r971",
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r334",
      "r337",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Valuation Techniques and Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r106",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r415",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r580",
      "r642",
      "r643",
      "r644",
      "r865",
      "r866",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r579",
      "r580",
      "r582",
      "r583",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r415",
      "r462",
      "r467",
      "r580",
      "r642",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r415",
      "r462",
      "r467",
      "r580",
      "r643",
      "r865",
      "r866",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r415",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r580",
      "r644",
      "r865",
      "r866",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r106",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r18",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Unrealized (gain) loss, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r415",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r642",
      "r643",
      "r644",
      "r865",
      "r866",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r578",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r200",
      "r354",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r200",
      "r354",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r222",
      "r378"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r652",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r155",
      "r659"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r155",
      "r652"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r10",
      "r77",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment/repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r221",
      "r364",
      "r672",
      "r863",
      "r885",
      "r943",
      "r950"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r368",
      "r863"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r363",
      "r375",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r367",
      "r374",
      "r863"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r10",
      "r365",
      "r371",
      "r375",
      "r863"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r102",
      "r140",
      "r150",
      "r265",
      "r266",
      "r267",
      "r268",
      "r285",
      "r289"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss before dividends declared and accretion of Series A preferred stock",
        "totalLabel": "Loss before preferred dividends and accretion of Series A Preferred Stock"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r135",
      "r182",
      "r298",
      "r311",
      "r317",
      "r319",
      "r675",
      "r691",
      "r859"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r10",
      "r136",
      "r181",
      "r305",
      "r331",
      "r690"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Gain from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r380",
      "r383",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r383",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r512",
      "r518",
      "r520",
      "r522",
      "r530",
      "r532",
      "r533",
      "r534",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r189",
      "r203",
      "r271",
      "r272",
      "r306",
      "r516",
      "r531",
      "r695"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Discrete tax benefit",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r647",
      "r926"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r913",
      "r926"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r677",
      "r678",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r72",
      "r648",
      "r649",
      "r650",
      "r652",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r115",
      "r184",
      "r238",
      "r302",
      "r605",
      "r798",
      "r896",
      "r989"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r144",
      "r421",
      "r430",
      "r867",
      "r868"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r143",
      "r301"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r917"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r620",
      "r884"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Primary Office Leases and Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r970"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r968"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r249",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r547",
      "r548",
      "r549",
      "r588",
      "r766",
      "r858",
      "r897",
      "r957",
      "r974",
      "r975"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r133",
      "r180",
      "r687",
      "r885",
      "r930",
      "r939",
      "r967"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, mezzanine equity and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r217",
      "r249",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r547",
      "r548",
      "r549",
      "r588",
      "r885",
      "r957",
      "r974",
      "r975"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r122",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]",
        "terseLabel": "Claims paid related to:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedTerseLabel": "Current year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedTerseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total claims incurred"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]",
        "terseLabel": "Incurred health care costs:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r27",
      "r179",
      "r414",
      "r429",
      "r865",
      "r866",
      "r982"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r148",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r137",
      "r150",
      "r183",
      "r215",
      "r231",
      "r233",
      "r237",
      "r249",
      "r260",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r285",
      "r298",
      "r311",
      "r317",
      "r319",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r573",
      "r588",
      "r692",
      "r789",
      "r811",
      "r812",
      "r859",
      "r896",
      "r957"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r243",
      "r265",
      "r266",
      "r267",
      "r268",
      "r276",
      "r277",
      "r286",
      "r289",
      "r298",
      "r311",
      "r317",
      "r319",
      "r859"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc - Basic",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r243",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r289"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r201",
      "r202",
      "r204",
      "r213",
      "r258",
      "r259",
      "r262",
      "r263",
      "r273",
      "r274",
      "r342",
      "r343",
      "r527",
      "r528",
      "r529",
      "r559",
      "r569",
      "r575",
      "r576",
      "r577",
      "r593",
      "r594",
      "r595",
      "r612",
      "r613",
      "r633",
      "r656",
      "r657",
      "r658",
      "r723",
      "r724",
      "r725",
      "r726",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r257",
      "r260",
      "r261",
      "r262",
      "r264",
      "r267",
      "r273",
      "r293",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r382",
      "r506",
      "r507",
      "r508",
      "r523",
      "r524",
      "r525",
      "r526",
      "r539",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r603",
      "r604",
      "r608",
      "r609",
      "r610",
      "r611",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r654",
      "r655",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r57",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r257",
      "r260",
      "r261",
      "r262",
      "r264",
      "r267",
      "r273",
      "r293",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r382",
      "r506",
      "r507",
      "r508",
      "r523",
      "r524",
      "r525",
      "r526",
      "r539",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r603",
      "r604",
      "r608",
      "r609",
      "r610",
      "r611",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r654",
      "r655",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Accrued net working capital adjustment with business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r298",
      "r311",
      "r317",
      "r319",
      "r859"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r621",
      "r884"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r617",
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r626",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r625",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r171",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r7",
      "r14",
      "r172"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash outflows, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r8",
      "r22"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total claims paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "negatedTerseLabel": "Payment of preferred dividends",
        "terseLabel": "Payment of preferred dividends"
       }
      }
     },
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r46",
      "r542"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r58",
      "r904",
      "r937"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Dividends and accretion of Series A Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r920"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r176",
      "r917"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r245",
      "r924"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross proceeds from sale of temporary equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r925"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r47",
      "r734"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r21"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r193",
      "r198",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r158",
      "r219",
      "r689"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r676",
      "r689",
      "r885"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r242",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r468",
      "r637",
      "r638",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r786",
      "r788",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r637",
      "r638",
      "r639",
      "r640",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r786",
      "r788",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r637",
      "r638",
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r793",
      "r794",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r468",
      "r637",
      "r638",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r786",
      "r788",
      "r818",
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r634",
      "r635",
      "r636",
      "r638",
      "r641",
      "r740",
      "r741",
      "r742",
      "r795",
      "r796",
      "r797",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r50",
      "r737"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "verboseLabel": "Repaid under the revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r52",
      "r175",
      "r218",
      "r247",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r218",
      "r247"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r52",
      "r190",
      "r247"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r834",
      "r835"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesCashReconciliationDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r834",
      "r835",
      "r920"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r834",
      "r835"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r130",
      "r166",
      "r686",
      "r723",
      "r728",
      "r738",
      "r769",
      "r885"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r210",
      "r254",
      "r255",
      "r256",
      "r261",
      "r270",
      "r272",
      "r341",
      "r349",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r556",
      "r557",
      "r561",
      "r571",
      "r719",
      "r721",
      "r743",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r310",
      "r315",
      "r316",
      "r320",
      "r321",
      "r323",
      "r456",
      "r457",
      "r651"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r323",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r206",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r239",
      "r249",
      "r299",
      "r300",
      "r310",
      "r315",
      "r316",
      "r320",
      "r321",
      "r323",
      "r336",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r588",
      "r675",
      "r957"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r624",
      "r884"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "negatedTerseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r90",
      "r92",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
      "http://www.evolenthealth.com/role/TransactionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r90",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Purchase Price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [
      "r249",
      "r332",
      "r333",
      "r335",
      "r336",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r215",
      "r249",
      "r332",
      "r333",
      "r335",
      "r336",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r70",
      "r72",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets",
        "verboseLabel": "Schedule of Intangible Assets Details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r863",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Activity in Claims Reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r793",
      "r794",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r24",
      "r175",
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r24",
      "r175",
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r19",
      "r20",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Awards Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r471",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r64",
      "r111",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Major Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r384",
      "r385",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r863",
      "r914",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r918",
      "r919",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r471",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofStockBasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.",
        "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]",
        "terseLabel": "Series A Senior Convertible Preferred Shares"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r214",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r381",
      "r384",
      "r385",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r863",
      "r914",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r227",
      "r249",
      "r279",
      "r280",
      "r287",
      "r289",
      "r295",
      "r296",
      "r336",
      "r392",
      "r394",
      "r395",
      "r396",
      "r399",
      "r400",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r588",
      "r734",
      "r735",
      "r736",
      "r737",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r768",
      "r790",
      "r813",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r905",
      "r928",
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r39",
      "r210",
      "r235",
      "r236",
      "r237",
      "r254",
      "r255",
      "r256",
      "r261",
      "r270",
      "r272",
      "r294",
      "r341",
      "r349",
      "r436",
      "r506",
      "r507",
      "r508",
      "r525",
      "r526",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r571",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r632",
      "r719",
      "r720",
      "r721",
      "r743",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r294",
      "r651",
      "r733",
      "r754",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r768",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r791",
      "r792",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r813",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r294",
      "r651",
      "r733",
      "r754",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r768",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r791",
      "r792",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r813",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Class A common stock issued in connection with business combinations"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r127",
      "r128",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r166",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r16",
      "r39",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Shares issued for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r85",
      "r127",
      "r128",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r39",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r128",
      "r131",
      "r132",
      "r152",
      "r770",
      "r787",
      "r814",
      "r815",
      "r885",
      "r897",
      "r930",
      "r939",
      "r967",
      "r990"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "verboseLabel": "Current year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r26",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r392",
      "r394",
      "r395",
      "r396",
      "r399",
      "r400",
      "r509",
      "r684"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 shares issued"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Preferred class A common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred class A common stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Preferred class A common stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of series A preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesCreditandConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINMEZZANINEEQUITYANDSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares issued"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r41",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r260",
      "r261",
      "r262",
      "r264",
      "r273",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r382",
      "r506",
      "r507",
      "r508",
      "r523",
      "r524",
      "r525",
      "r526",
      "r539",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r603",
      "r604",
      "r608",
      "r609",
      "r610",
      "r611",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r654",
      "r655",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r513",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r191",
      "r192",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Reduction of valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r622",
      "r884"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/ConvertiblePreferredEquityDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r278",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r276",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//944-40/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org//230/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org//805/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org//250/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org//323/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "50",
   "Subparagraph": "(a)",
   "Topic": "405",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org//944/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)(4)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)(4)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r898": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r899": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r901": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r902": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r903": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(f)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001628908-23-000066-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-23-000066-xbrl.zip
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MLY1/@!F82)ABN7"IM.RGDAL,#C5C[Z'0!L&9L_]HD[&HW?B)D'HUT8J*S/?
ME4OK[#J/F[BZ)P^O[B[+]/=;[\[>K?=K;G&5<3VS&;O-]52!&$,]++L)BRTT
MFI!KI! X I<YX_F,E;DS): '2"H\OT 4<);ADY%<L813"C-,9]+G9"^W(9!#
M#-9R,R.1C-\")>NE3HOO!!J#0RI/3D(V9[$T2$90+,?N:(D PZ:IC%-F2_I9
M]I^"@4H).9!)JY"U$ &:2DQ+!FR!Q8)&)[T%FJ8%NCG!;H*-9JO3\ @X=X_^
M(7#N/ATX TMDCH A["T!4D<LHS@VFY5VF2>8W *QD'FL2H$Z$80K:*@C@"4E
MQ (Q1/"GL%!JB>\*6O;>T!A"PA/[.DF4"@40U!J1YX>SWIZ8VY0E2D_M'/$&
MQM(Z0P2'T\M@-UI97P&NG1NS8>TW[&YBM[=WV+U96^AG!\>=:'!J*W16O(E2
METZ0]H(YM"\\"JX9-^#QAOB1(P6$"P8(\I&2-J4>))9AYJ;L3<]"VEAI6V(_
MRNE&JP"\PN@8!+ZV[!!Q)@"!&\!T=1>G/!^#IZ;O2X42N)UK1/U#"%9$?1&>
MPJ,D,IT'P)-^1CEU)0X"+LF6G0=*U@9*<"#R\WYTH 01F,=2RS584@P\'O /
M1,[> )[O#^"C9GM \W )%F<*%][7[4^CLDZ4(N:EW;T+U?81(,*JD0);T*5!
M!9@V)]+Z9(Q2D'L]M#%9IO'54F! <0_9BBXL85>OR@0U2DSI:(O52@I_X&++
MD95"<B/) 1E(C2]..6DJ+1$-'^36LQ*?NK4%-,AAJ:!.!=)O&9>*4\5!M[P1
M2\*"/0+]665M^-<(2!"+ O8'\36*P+['Q&A_8J(J NLAL7,:W8B,W1/PS@&"
M0361@G#/K<XY51IN,6:(AE,P<"/FP,10D7PDE70SHC#;AJ4P]1CV\ P1MB:Z
M0N-]0;NK'"I*4V!X6$^YXE@;X0WPA'X,.3(IA5&"+5!0^)$(;E9")&"8R@)K
MRL=CX9^ _'A_D#^O!E<3KDJ?,@D7D"1TCC?!%;5;>/""'NU0 L+C=FKLD8X=
M,7W;0,!'NG0/6[!+D>(+::#=1?+IS24;S?<M/G@AS 3:XX%* WQ+W&OP%?L#
MWWGB#L#8!!B=EE2<UK=L1?$CTC7Q$QW'I2$8K9"!+5HS;1V^IZ-MU&5C5/1;
M.,ICA^M=GE.2+0VFT'MRE<FX)05_Q$.G/WFYL.A%L"?E=L&9*/GZR 'AJY*?
MB:IBS)B2MZ"J\YY[\O7/GIRO%2W[OM?M[UVT_.&]KC^=%O-8JR\3)^7Q5;PO
M<RCA]A%$:H/=+ZSCR/"=-G;!7?P+5)EETCF CU2ID49V1.U"HGU>R2'&!A8%
M2T4'_Z=]QCR4X;=2HOD^;,O<?\VR+[YM:9_"EO:50N:*<^4_3:)-=+012T"4
M541DL;6< K\E9A&8K.<6GH/[8_/Y@>"CL%OM L-QT):,RP5VM+!(N _BO&+N
MV 7!B@2['NB-16YCRRS#K>SOX)VI2MS6H]-')N,O]@UHWT&[?WO.5\A0$H/)
MK(X( I^"$8/^@TD%UGHH\S*?:#4!JO4Y'U???4R5M2$KE)X!MDY3'?(T7PL%
MA.X7H4#-+[UQVY(HG=_>5NTC# $P#5PBQ0L+P_D?IUB'"L5G0YG[B?:=3C$\
MQC)OC+1S.AO2_9,)U3,D595I?KC07-UT.8F:)[T>779Q:*83\X&K>S!-?P^F
MY<1F6[]Y<G+R8&N[&3W8]C&MT:#9[AQ]<;6=HV;[Y.'F/ZJV=]3L'?=W4MOR
M\QOF&%?1%CQ_6>O6[N618:>X8]%Z%J& N;^080W_^C3B[T5=TD[9<P*V ';E
M_A/W[$<^8]VZOXGV-_/LV4$/,YW_9>L78Q[A:)O<?"2@U_I\MFB5#YTNABC+
M_%$WF\_>4UJ/-SP+7XJ>\FH\I0F_H;NCU8Q?I!(2=G4'<4F';.QMV.I]UMRW
M? E^Y&VYU9NGA0[W;H?A8\\$-NZB+H/ U_?VL@L?8224;K/+)ZZO5K_A)JV_
MTWO^?U!+ P04    "  6G:-6RT0'L#D(   J+   %    &$S,S$R,V5X:&EB
M:70S,3(N:'1M[5I;<]NV$GX_OP*5YR3.C"[4Q3?9\4QJNU.?:9,T=2?3IS,@
ML11Q#!(L $I6?_W9!:B;)2=6DS9RFSPH)K%8[ +?[GX <?;-Y9N+FU_?7K',
MY8J]_>7;'ZXO6*/5Z;SO7W0ZES>7[/N;'W]@@W;493>&%U8ZJ0NN.IVKUPW6
MR)PKAYW.9#)I3_IM;4:=FW<=4C7H**TMM(43C?,S>H._P,7YO\Z^:;78I4ZJ
M' K'$@/<@6"5E<6(O1=@;UFK54M=Z')JY"ASK!?U^NR]-K=RS$.[DT[!^4S/
M62<\GW7\(&>Q%M/S,R''3(J7#1F='/&DG_1Z(A6#^"B.TY@/C@\.3HZB* 71
M_V\7C>R@>.ACW53!RT8NBU8&-/ZP>URZTXD4+AMVH^C?#2]W?I;JPN%@!CN'
M/X..-4TE%P+]:RE(W; W:!\=H#H'=Z[%E1P50^]D>"$+@?X,6[U>&X4:88R9
MGD0K;89[D?]W2BVME.=238?/;V0.EKV&"7NG<UX\;UI<K)8%(],@:.7O@,;C
MP/YQ$AS#"3A5LH"YHSWR[NHND[%TK-]M]U9=F[O]YYDTV&C2L[WN872Z9LS,
MC*7)3'#^P'RAF;L XV0J$TYAPMY6QE8<K7":_0R)?]>/>DRGS&6P\\[\S$W,
M"["M-W<*INQ5XLCR7A0]!(H-L;#9K?]5%J=I^J?[M1E+UTWV'YT5_L?JHLD2
MOVI37!3NGNT='#\*9ZL^?-CUE03@D\FZHM7X)Z$O-#W=]LR/OW[TT]69BD(2
MO&89'P,S,)8PP6KA,FG93Q4W&!MJRMY!J0UBLV#?:9.S;M3ZB8!Z-=:*:LSW
MP)7+FNRZ2-JXNB</K^YCENGOM]Z]G5OO;[G%5<;US*?LMM 3!6($S;#L)BRV
MT&A"H9%!X A<%HP74U85SE2 'B"G\/0"4<!9CD]&<L523AG,,)U+GY*]W)I
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M\!0>)7'I(@">]#/*J4MQ$'!)MCQZH'1EH!0'(C_O1P=*$('9EEJNP))B8'O
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MP9,O!4Z7H4W!,< 5-X6SJMC')5?,;KO:SGP.BRVR#3AU--RBVV?08ME2(6E
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M _N7.[DY0L)Y-__U,#=^DKKE/A?V"89(?-@G78[KM0$<PU:V<14-UR4)FL=
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MK[9^A+U.R22Y*E9$S3;77VW,(Q5'S3,Q;YNB5D"4/"BC%(%3FPP$YL4TP ^
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M.7JB@8>#GF^5Q>J2+E8V370/!R^[=..$YR=4S)X7F2.+-#Y2S=$['K03W"0
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MQX:#8G2JDNGYN&&Q2D=.FKM.$4=X>Y*1$W1B@"EE3*O_UA^<@N/!Z6S=5!1
M-PHY]3.M5Q(A5TU(KR,[55).O])T50>]&I1V/13IASJG:;%U2D-]9'/OFK1Y
M'=B*#1(]T R_.5#)6W$>#JZ:7I?&G__$96AC]B1+!'TJ*=N+#IL0O/ X1,W4
MDVE/L)AB>IE<T)H%_;,O5UIS7F!CY/JT/S4I8O@R?BQVG9MT7*@MRDFB<F*
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M:DF"'ZK';M$;J\):=S6^7[Q$+PN<)(E^;(F^#DV,)5A@R8#7R!Z:!,M)4T1
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M'4^0^<RGJF]X!2\_HO1PT!V/;O[(S**-\P)3UL*\]4]=_KIU-2)RAX\]H@[
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ME:*?K)T& L./KNM?/&IE1Z[O2M6-16#*]CK]SG!41GR6N=HL6DU6TTIAX\M
MC>O;AO(I46/-^K]7C+_=M]M7V+YV!J2#:'D'T:=Y.,F0P$3E.6"JH*%:S!]$
MA9* (%,HQZ&CE&QL"7\.X?G^LFD6V;.1[J6CR23=3R#=UV&F,,0@YAP@.<2
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M?EA+_6"NZP<D2)[;(LP"" /NO>D%5.[U Z1,0*$=Y5!O;.4MN&#X==/T0P/
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M#G)$C+,,R8)02) ,F*" S$(-L<0NZ;AFZ+C].20'!4(B]^HMAQ)02#70W&$
M6>$*+ICPJB[H."KREF \Z;FDYYZ=GKM/@P#-*8&26*JUH<(1Y1&=0SGCFN6Y
M1>AF17=#7X"D\5:L\:ZC.ETXS!73@#%N %62 )5[5&=,'M">9-YL#1H/\24T
MDD^*+BFZYCSWO12=DZ'NG(2^?K100BAMA$-<.0A% 9.B:YJB.[@.[9PAP=^
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MA0IW6 #E42 H<L_3AG-*C=C8HF2^B4<2[?44[2>.3"2Q7H587P]40*F-=;8
MU(6 HT48:,(I"$UG*<^EDH6'^DFHUTRH[]-_9@F1BML:T3Q(O).AOSS9GZ^K
MP%HBB1!P0@M <\V M-3Y#29Y;K0N4$XWMD0K)_G#>]8DT4\&5:)2HE*B4J+2
M$X*=)40O$MA9 ["S(*I!,.328@N0S#W<H<H";]Q   EF7-N<"5[#'=P,N/,"
MJB:\C$2N#T-='RVBL;91VA1+3U1*5'J*B ;3BOIC S%D">4YDD9!)A7)_7_8
M&K/DXHKP\U_72S 3!K@7!CB:C6% _YWLB\@91=840+$P,1!Y&""-Y2!D9)LB
MUT)QN;'E"=B@K(8DS,N-83R6)%?I2TF0ER+(Y]<$&6LN'94$$*,AH!(SH!'U
MH+X0%D*DB XCSY,8KYD8W\N0]_\K*"P*Q@FEN1 &6R=HSG*G*2-Z-8;\30*=
M3/?E2?O^]6/;,(FED_[$SF5H=5!((*G_#1F-+?4"+T/W:=*2?+[W]-T-]R3L
MR4Q*5$I42E1*5'IZ>(.];8(=LDQA194RFN3*Y<YZ$Y5H3.]BIB1XTTAX,QN9
MV-\QIP?OOVB$42Y0 3S-D4<YN0:20 FL)M! EEL/;BN ,S_C^TD S@LHM7CK
M_&+44:JT2&'R1*5$I:=W92Z,2TA&2&$1XP7)*:162VD+3ARFF,$"\127:!P"
M^#8?EW!*H!QA#IQP><A,$$ R1P%!4E")(34PW]CB>9-:.B9A7FY<XK$D.<4E
MEBC(U^,2O-"*%;  0B()J",": X=0)1RP8S*,2XVMA[<#R:)<7,-][P@TD&#
MK2P4A=QH+;0E@E(!/1?D=ZF16J+AG@3Z7@(]%WH05M$"6P>@TP10(;QH$UN
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M:"NLIEE5KSNNL+J.8/N0S.J*THEMU93[<S5-T54[ZJ(-'#'E.>(PCY$UE"&
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M<K]MXJF")3IBD=S&)F4=HF_30*_M9_0H8>;N&%X+,^L,,PO,,#*!I<,6IBR
M"U=)@36I%6+&$V(DPTJKC4U#.T3<I?^N\?SP7R/K>A'^#=VOF_\-/R[1129!
MAT\&PVX>F-^JWBS=K_'WTVX8'4T].'-GU4_]&SX_Q3H8C?'HZE/F!L+'W&=\
MU3!D?H9"-#_2VQ@+Z_W@&&Y]EK=/]P:C6!5K>)YK-8! JZXT$U^\[15O1_!!
M%3TQFRV7Q[ AKR8N/N#\SZ.9>7!B#R-R@%M?D$WPJ+_9WJD]&V[\Z\(;'7?[
M:'YF7!9J_7Z;_^U*.&_)7><O9<M#N%K6&7%QB9J-534WSZ=6I6,P9CU[,HR_
M37_Y?3JWN_WJU:N3?I]<?3(?\PTNZ5=UO_KKR5L(RI]145M'Y;S:3U[R&;ZP
M9%_XDG'\#/_@^Q^>_,,OM9H^U(HO3)ZI.[GN#1_XGLS>'_;6^BDK,PN'+F%6
M];1M5 ^XEX.R&!W%XN"H!'C;A>./AL6+?@X:V;6E/RH8Z5Q8ZW[!9[!.KH':
M0;S<3;R,QM>0,P&1Q97]VCZAAD^3;)%??SA^\+K7Z<SW=,:47F-,&^#B6\-=
MV.<W<>D5=ICW:UT$0M"'-T2#A$XJ@^V))1;<Q)T7HO7"F!@(XS%&A[UA,G&/
M"0O.ZT\[>7X3^K,=UEOND+1&\LJ,Y&7= H6-P1#CD0'NB[@F&FDL+8K<*RN3
M(T8'0#(BP$I>=,8U+2F]S2SX977/F^K1IN2MI]QZ;*APT5.7!,'*)%&I.VG5
M?:W4?;%<%R.$,>I!O[E$/%F"'/$4)2.IBR919W.S0,$[AM/&JWL#F-,/4@M4
M95T_.A(5X>6OI$_7])).J#\8Y$48C+.'Y_]<G_@OQ=[&#>U_/<C0/)KE2&@9
M#1<N2!QXSG427GA.4Y*"$.=QM1Q=([ZO78Z:LAS1)>P3F(6,0$"1$RP@[HU&
MUG&#,O'DSE'C?2Y_9DC'J%6U,%J%GCWP5G&+LBW*KH;T,Z8U!AAUCG$IM<,D
M2NR"%XGX$%1MX[<HNU8HN]@AG%OA<H\X&W.NFV 2.0:@FVB0C =.6.1@XTO:
M47IQ)_RQH.Q=[I3//=_G\7#436<;5V^#MCOLZ[7#_G/8K=Y-7KW%GI^V J\4
M!(6C'3":R"55EC$C5)#* _8ZE3X10C<:L#%_]V-*?K:#4HWIB[_W_WRQ=U#\
M^\76GP?_[A0[>\^?/>!$N-Y#[^T?O'A;'.P7S_?WWN[_N;.]=?!BNWBYL[>U
M]WQGZ\_B[0%\L NO];98?)?K3A.Q,7?6O6]OU>\)NEN09\6$;^R-C^$Z?@4Q
MP1>YQ7YY:/O=[U71D7.4@#_JRFU#$'7UYWZ:P<8Y:FQWA[XW&([+> #/]$>O
M*N_VL#SBX-V41QSM;__]>?]@B^X='&+@%'CW^\MNQ0OH?WJ[GP_9Q\\OSH!3
M'.^^-?CC_QQA?_QWW[XWX_WC%WSO_:[8W?Y ]K=?G\)_WW??[V1>\/G#\;NS
M_>UP#,_#/K[Z\.U_O@,/V/[RR1NB%3 [Y'5RB"=/D-6$(IH()S$",Q"R9H?=
M_CB&K4S'O*?:6>5 +H%KJDW2-E$B)7/6!H<WB@CL["3K7CF&I7)>5,642$SF
MQ>(B>#4>P8F3!ZDO50GLYP]S\>&QT$D'X;62G&,E+15:I.1AZF&KL+UR@;RX
M@M_W,O+BZR"SXN+?T?9&1P!Y??^L.+7#HMOW@_)D4%8K9+=?;$<?CUTL"XH)
MSQ_D*(_AJ,I$3?!M+U=.BY4C;W0$%.WPJ.B.AL5P[(;=T+5E-^8_3N"*\.E1
M=3>?3X";5_GE>57N'N<*([&Z]/^.87A&9_GBU7$A]H"DY/JUN7#;21R< +O+
M5=V*O+[WXK<LC]"=-#R:/$%UN7Y1L97)%W94'-LO<?((];6'W7R%LGKXXT%^
MBP0W"9E]70O_;T3"&B/Z QCEYS4W@B$)(,<Y?0(R5$<0#SMY*M11Q449400S
M*NL)_)7E6\8LT3IJ+AY6(-C)GEN;W;GC7I6W#(S]%(8:YLQ@7!;Y?* 7N<!3
M,3R)&4!!S)4<W'@(3SF$*P#G/)H\#]#NWMF%>64]6',U%1T^*^KP9I@;11A7
MO1[R[!E5X4?'=?A1O!A^5&3H[U2'35^_?M5PU1OEN5G&U,MYV)-1F6H $*/J
M+'_4C:D8G,2R'IML3PXSF.3)5A:34<O3'$Z"HRH;=-*](I\_.1/>J /G?HV]
MP0GHRRBKWV']]C , U]= C"P.P(!P0C#@/H(@_ V#V2JQ^K2JTV"%NN7.RGC
MU^Y@/"PNZGWQ-I9?NW"EZD[/8:[D2Q5O9WHS&XEN'\;B2I-_<MAJ,W5V]EXN
ME*T89RC:3V]FLGH[>< +UCUHAL\6_BDH,RS<,^,>/[U%F>YM?SG;^^SQ7G7L
MAT^*$(<#,\@Y%A'/C=VM5Q@E[G RDF6[>F,33-(%"WTZ&9X5<PCR?P'4N\/1
MH*PF3ICQ(/C8@FJZ"#!<1F^'HZQ,+N89,H03\ARL4#S/63\NR_S!R1S/>L0
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M/RORB:_<1*RU:@G%+;;=B:);>=.'=6'HN(?A6Y3!U \G9\')&.K#U2%VBY7
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MU.>]$/Y].YF@&4V+@FGJF><@%%I0G8B$)S;1U*3)1B;N7";HP?'!"6@A,,C
M=E">6\(56+TZ23QAF: V$=Q2X_"T0VZSZX6B#JVK0 +!*.26KJXKC%6TPS?@
M!Q'\3+=&D21WA@.0I,II;IG3.O>Y5KGWEB9*B9M*S._ (HZ!0KP$A;61E76R
M<O3RS8EE1J924B)9EA#.7$J,U)2H0E&6IYP;FV)#IVUZ U&YS5(;F7 I4YM+
MP(:,9KF!GX1Q5#J?<Y-MEOI.E_IX[T2(3%*F':&YH;#4V#LR8Y(HJVQ*LY07
MAF_M<+J=?EE5U*2C?_DCBK<^&'-]M4_N9CZVY>]]T7^#[H$C.QE5/0OH6O\
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MIA%8*[-OMIZP'= S7EQ6U5HCX2K1JS]HC@F ,>()0%,.$DL\%T!^1M=TZ'K
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M9PV(%O+"FDJ4[0JL\\J\7N='Z32^[Q1>>^;=M ^TH*DXX/:;1E/Q>+HRW9'
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M+QSWT%!0_VMI:H*CV5I![FYPC];;IO!*;H3]%.=?=^[V3\M9L-H;?:R'IZ&
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M_D8J5TGE*3V\.%$*"(_.--%97A">IJ!TA9(D%5I:D4LJ%=_:84+>Q.0+T+:
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M/*J:L55:<>P+U,Q1K4>>$(9S@3'Y_9[_Y,,G^W^\[I@QWC]\R^KQ& \;*[(
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M./9GL&RHD"N^\5-_5)8_-X"';+7S$K!\8 #!4]KMH(!THU8('*"Y%)50I9L
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M[1%=>6?)CYNTZ0>=.7.+Q!DMK55)DDN>ISR7N>(YIE6D*M5<Z5S<NG#$%T+
M]SY7\8#8"03^A]7!'TGFS%?ZIF+FS.@2OG_Q?@!CN;*7[]B[Y.CUX4=XSM4A
M>Y,>L/<][&H&W_W\OK>0.?-A_^K@Y;\&[ZX^IH=7OWUX_^$-?\?>P#L=P!CM
MU?O!/G8U$P<O7PW^<W4P.6KRXW8_'[[<OSA1CBE1Y)QDSJ:$,YL0Q8N4,.5!
M?+)$B51L[= \[28I?RQIU)M"$AM$O*=2.KF3.J>2)9)RP0 7BU1KQIWA3C*7
MW[J0Q 81?S B'BSW<A14"IL)3A)G<\*YY41I3XGT&;7":,=RC4WADZY(Z./&
MQ ?)1!_%E?=1JN,Q:(EHCHV7ZLX]BD5[C%=>E[^_0GX>2?[^+72ND3233JJ<
M>LVM,KFCF3$9!1WLJ;5L8X4\+IW[9MD*D5G.K,\$,07\AZ<L([E@E#@J+8=9
M%ED.>X.RK"NE^E:-NQIT[]70N&DII&>_UZ4UJ33&%DDF.6.9RGTJ;98(JWFN
MM-CPZ\>VUU?P:^J\D$)9DBCM8+=33O)4*\+S(E&"&BLMUN1)>#=5#W^W/VSV
M\)"O?*XG&B]& X">4(*DR;+;T.D'0*<?;SFL6ZA89@5U:6(U!80%)JT,T"M?
M4)%3P;7B&SK]N%3LW\MTFB4ZI;D%W2J=)IP6!5%YH0D54B?.I<;F"2A8*KLJ
MOZO:J _(;[_9Z[,#O,0SEV>,RX)KQHWTS N;,=CMDBF]H=./;:^OH--:,^NP
ML"67N20<:T8I:V#+I]86DFFJJ=K:D:Q+Q</?[ ^;/#SD*^_1(1W6-WO@K/H8
M:TEM:/0/"A*J!.=FT8Q/[3S\=B__9-A%4>1%)BQSG!6<FUP)81)E/;5I4A3.
M;RR)Q\4NWBU;$IIGFKF"$<<BMS!$:Y,0H!9I+@V3N<"^\>B85]_<9^96V^@'
MN^PW0+@!P@8('4\-+[A*M*9<:F.<3;7B3'F:%KG>F%F/#@A7F5FIY-YDDF0N
M*0@7GI'<"$443323GBJKQ-8.4UDW^78[ZP="X8/DG8_BROLXS]ADL7W_++8;
MQ.BEL.7<:(KIZK=.^+J#);_G(3Z6E7IX5S[7J,!VQ<&_L-#SQA'S8QTQS\#*
M>)JV1)'EJ9!42RD<1UK)<Y7J3#HFC#?IQJGRR&P)VW*J[-&CEZ<7)WE28"WN
ME'!/*>%%YHG*?4),HG3A59)*9\&22%4WS](''_]TYZZ3#70]I'>[!719:75B
M$TN5S+GBQEB9F81IY5E>%,)NW""/#;I:;I#/A\>G_/#-B<=.!9)*DB2A[Z[4
M1#.?$I&[# ^;.<7.XS2C72J_.6%T$[SY8*]\KL&;?S6]B8Z]/1O"4ZMRR7_5
M]4(W]L\FGO-[&@R^8+FQGB<>BS-D6NB$.Y,ZGVCM"KHQ&!Z7UCU=-AB<3EV:
M)3GAV@@"$D-)+J4EE'&3&Y%E8!=N[4C13:E\\!%>FW#.K][JE"EX3Z8X$PD7
M7AL'\I#37,"=E$_\AF _MJV^@F G3EI5<$%DEBK"I2J(TBHG3N&Q,G?><([5
M![HB_^:(BTTXYX.]\KF>).S.=R&M6?6&3S\ /OTL4I"MX9FS5O)4:9X6.G?<
M4E4PRIC)194SL>'3CT;)?ESFTYYB%\U$$^H=)SQWGN293F ]E<B%I)DKQ-8.
MUCR3=Q7)\X#\[YNM7F_U/"]4(0L+S(KS(BV,-)RJ5!5&I*FVF[B]1[?55_#I
M(DL4&,M@-[/<$^Y]2G226N)@-9U5+-/<8;4!V05T?_"[_6&3AX=\Y7-U6+_
MQE<;^OP Z/.S\%'Q+&-.2Y.EF>-4%EJE4F;:VLQXFWBYH<^/2Z?N7?Q^_'%.
MIQ[LGG#K:5:(G(@\3PG/C".:9AG)A#+<%-Y;EV[MI*K+[ZQH\,8A_0 WN\NU
MLBG6Y3,^% ;/I7#6@?V,6YL5&P+]^#;[7K258<,?'/_-CU[^?:)9EE+**?&6
M@[G,F2:Z4)I(ZW/)?&Y=0;=V1)>+A[_9'S9[>,A7;NH+;.H+_/"P]BJ_I6KS
MN)CBLDFZ_=:I>3+,9%.;X(DQD\\KS! J,U707!$C,#A&>DF4R!31W%.A*?6T
M4/=4G>";MMD##\#?@.P&9#=U#YXIR"Z;?TJ8-,LS3IAG"1:92XC.C2.<9DRD
M1ALEZ3T5/GA */L@Z?*CN#(8CO\,;=IWJK[PE9 <3F%3]^RM^\3?+RPN]3=E
MP?P;PY<K2/P#!NT[N_W^R.J)=YW)*'0U_M,/=&\(XM=IIT,?&1B]QN_-3F'"
M)#RHEU[2!:SNUVPK("X[%P#%'=V9^/&@<SKV\.K8S1E&!8O=N?1ZW.U<^,Z9
M_N0[NID;?7X^'GT&,)[X_F7G'[?0+B*77G%AG$P<5[K(A146Z'PA!:7&)B?[
M*YF[6*-4FM5I+<YL;6ZF1N0C52/O_W.6V,&_A_JMFAY]..P!W/?@WNS=6U A
M'^ >KP][H%X^'U[M@BKX^^K]ZW=P[SWVGZLWET?''T]8+A,F'25>6$EXD>98
M!LP3F@O-;(']LF"[\W0[7\+_#HAE'U=Z5'0FK3UT'O80[)SSUEX9S?8*2M:D
MH\<>1*2$/Y5%#Z6IQ/N$7N%1L:2TVT$QV.Z\]: C.L/1I-,;(DWPG4]ZW$/4
M0;$J>Z QPIWCC7ME2T;]<-(;HWC"<'3GXFS4AY_;CUT]QHZV%G07W@$^A2\X
M']N;XVZ#37@Z[;GPE=XP_!EDR$[[X:O;G5T80&?LRVE_T@V?&MT/%X_].?P9
MAE2&/W_2_:D/DP>_%+W/WBV\#MQ\-!UW^J/A*0E;<[9APYO"EO2?S[V%GV E
M.@:?8$>G0X"!,)_CN#WP/KI33"=3F')XW][(A;0F'SB7CX,9Z ^C<6]RB>/!
MAU;?A7U_UK-G.*FPK !F@$2P)<>]3_ (HX&H 42L6PX8 F@-.T4^AX,X'$U\
MAX7UK,8-J](,N1DN?G,.6M8B"VQFX\<+X*(R)S'T@_/"<4>Y*A)79-(((9U3
MW*\&%_95V )_Q(;=^M0W0$+8\T,2<7!\>I(89@Q5.2DR1?$LP1'EM23>V223
MJ84E2+9V5C3Y^9_N+5>82XF-1*PQN> ^+U0J6"*<2IQ(N.%VL\+WL,(?]D^$
M4AZTMB*>%CD8"0)TA9 I,1PFGQ?>%)9M[2BVO,(!;VZWR(;GVF2IQ/8%7*8J
M9]I+QV!/&Y/X0FX6^3X6^>-);C*@8R8C60K_X<HR8J10A,+$.\<83:G'H+IE
MK]O_5+JL1"BO^?(Z#F N.R^]];CPG5K3A__R("OP@^BB$D4U <JF?[G=^=_1
M!2PF4%'CK9["4U!/^<\]H-'PH)EN'.A+U(46G]E'!87:;.A/1Y->X 211.!W
MBO"1+G% H^D$55>X:;C7J!^UMQX@$\!WJQ54K7SA:5.-A )TF,>4ANK)@Q$H
M6KAUWY=EI-&3,U"@'@:*&BV\(-X9?L51A#L')1BV!=X$N0[<"!1H5)3>;<];
M&#CW.,K><!HF=,[F6&MD[/P_,_[GSEI;I3(04@D6Q/FH#,/Y!=A3R-?X]:+G
M)F>U)ZGUK<J23V9?T0;L]NED_5=: \1]!WO_QQA!5"S,:NN_9\UYZ#G@ C$@
M)Q^)+F"PO^C^A;XLM_XY;^B!E=>>P,5W7[\"\;\+"QK!1\I<R%P54KH$ ]M-
M[M-"\=QB"(9.LHB9\!WO=M' 44*XW-*TT#SCB4ESJ:20, AN<V>T7KL,/]8"
MKSV"G7]%IKS>G/Y:T7XP=G?SJI514$;.7 : J:R.L@(4I-3=!M@ #4H/GR%Z
M.%_X\1BPK(*D[<Z+Q:O&T1H8.[CJXLQ'.R7XR)!USQ-UQ,&R+G+0"T-R82OK
M/K+Q<C3P@& (5=C0JH8T,";@8; Y N[#)"V/(H('?!$>.1T:L%+"F.N7B\,,
MMF/U/FBF+4_"%U\ -,((%VDZ; T]&!JV#T.!Y5Z>1GC-*3P3H7T,@#LD]:^-
M63./T<$JPL>7M5=H[FDP&9<#M.VV.T?3\?+CX$5/00N-@\*H1E79O?6#<65G
M:];#*0>KRY_KG@MZ8%CZ<M97;/:U^(31L-9=P6L:5%UM>99GWC<CJ[^V/,]Q
MF*W!58-8*9=#/[G!,^-XI_,SO&J)5S_YFM>?N^&-I^#I(LO+!4RHG24P9^Y3
MF );';8THAIF$W<EB'B)%KK_;)&SM+C.S*,POYT6$>CV^RGLZ8MK70'S KOT
MR%ZYM%V6KKFAA+;'>Y/G1!&<>6;Z/0WS"%#@OZ,4SKG:YZTG+[450 .HY)[G
MJ=?"29^H7!GN@4ZXE4$2\Y;3JF,Z/)V;[ [=[]7K7A[CWCV&Q_ZK/[(?GYW)
M]#$Y/-X]D9AHIKDF19&!R91CAZ:<&9+1E*5.,>F\V +Z;_4Y+O%XZG\X#UL-
M(<?HB!SU^Z.+H+,#+I^/1Y]ZB"*]8?2C!\^> 7.IK3AN1E,ZQ7@T6#QVJ%&I
M7.\"#C=;-!=9YZ?@?1U-X95=^?,O-SV#J4X2"<8L_*)6'LK$/_6&#O#@%Z)B
M(&28CL;H">>4L#!]?5[Z7^H??JV/R7K#,+WA2[]6 Z@L)1S#PC%E>%S\N#(<
M!$^VDR0^>-P^6*WLBNUD5>!'_# 5?)N)]9]?^^5K/\SS>E!W?&.ZG?WP :\)
M@^77A,'>HO+V-8EET0;^0:$B2Q99L%C#)FP<,S>(C7VR,[$$.W.3\1!2#QOG
MPO>.)_KK;#2>1/[3MB'J";K3(<EM<8,QK7!;(>J3='L%Z"(OQ1ML[?Q$?UYP
MR=PPF^%Y1LS=[N6?3$S<5T8M+(7"[5;6+QZ'EDBF1S#^/YL-=.@G+Z(E\BP"
MX*X.WNY=O/_P[\'!Z_W/[S_L)T=O_SUX]W;_ZNCMP<7[P3Y__W+_ZOWQGCAZ
ML1@ =_#YW?&_!H=OW\$X7PT./KP1[]^^/WOWX4"\N_K7X-V'LX\''P[[\,[\
M/U?[=81QJY=RIFGF5$9R(Q.@[5(0I7)'TLREU(DTRZS9VF&2=O-,W%'ZT\.(
M(OY"%N0&]3:H-_,D.*\MGOPZFG+OO4FL2F7!;4)39VP>4(]1MD&]AXEZETL=
MY M74$.)D 5VD!>"Y,REA F;4>DS&Q*\&9==EGQST93O@GH5!__1P; /(M_R
M06-MRUY8] RMM3"??26KNV*=J]RYC1MW [UW#KUOE@FG3KR35!@B-0/H52DE
MNO"<Y"Z11AE;)(IO[63=9$60W$.K5K6I3??#&=5F1W_W';U$IKSA2CA%LKQP
MA#.NB-:J(,ZQE*<<_DD$UL_(Q'+X_(_;T0_!:?DC]NCOS7'MG="/9U$'Z+O0
MC\/1T&[PZJ[QZN]E!F(8+YA/$Z) G GW&+R=)2E)8#]0@*,D2='EU:7JF[O3
M;8I[/=Q-_5T8R&93W].F7B0AFG%G4R8(+*?"SI.>:.8L$861.C'&2XU9W%V1
M/J1-O2)WN!6R\94Q&C\B:.;__I\<MLJOM_YG;;C*W+O3_ 8OCQ?=]=N+;7:#
MUU]WX,JV\QL>N-[IH/,;#7EN?NFV"A$>>W4VY/F9!K"R(4BW-YB/41TZC$@=
M]*9S?W_"0:4OSO3P- 1_K0CF&L6<V,G9V&/2RW!R5G;\$*,DY\-'NB&X5Y=5
M;%GYM8%;*V?E\81E\32]IR@GFK";!WP]?>MO72#/#6V^KZ68S]6M7R7M5.&;
MQL.>PM0_,BI(S#;_IA[*3^P4^4FWB?XN=L5SL";.@?6_^0P6!=SW; !C2XY>
M[UT>'1_0@Y=_GATRN/;JE,$=KM[_M6!-#-[W#E_N@47A/AZ]?M\_?/F&OSO>
M%P=7?U\<OMY+WPWVTJ.7[P<'5X?]_USM+;L(5)*+5&&I/99) I:%(+DO-$FE
MY]PZRH156SMYERGZ/%R:L81MT-P/&H/^]'7ZE*VJH8QF53STK"8)@O2ZK.RF
M+LHS<XC^=!N0^YK4FJ]&NZ9^09V&M8&_NX._%4&!KI %Y2XC.D\XX2E-B/%9
M2I)"9=I;YKUC6SMI5^7+!?%^_F%^E/LLWOWPD>^%+L_J&@RAT%"=\ A(%Q&M
MVM7KD6\3?W+O<.<_G7WAR!J6\<]J%?>'NW$-CXJ_6BMX5*RLWU)N0/'N0/%@
M&11IJDRF1.BLEA&N&2?:*48*851A4YT88;=V>%=MCKD?P.:>M\<])LP7G5M:
MXO.!FZN+M2;7U6M]7M'@=S%!3T9C?)>0@0WBWQWBKPA5S"U5B4H9D07'-F#,
M$(#ZG.0\T5Q+5R26;^VH+I/+U=Z^*4;\#G;2'9Y(7E/-^-$?[1ROJFW6K:J"
MAHIJ=;D0+.(9Z[7 A;>I\_NMW%',<<=J."_KT6 M^6^A@\^OY.\[>@3W._SP
M$38_ ,#Q_@GS(J$\E026",Q=RB6!U8%?P="56E#%"MCG='M=_EM5 KC;KCP;
MBCQ\T</4^6F$A6A@/X:*2,W??X[E:L]!('NC:5D7K+T -O-#1.\Z;;12^OZJ
MWV1_^$?U$G^$=]A(Y6JIQ'L=G.BT2$PN&#'.)X0;^$^>):" $B83244!? )L
MC!5UJ.<D\3:GTF[J6U6-)Z-0TNI4@_R59]6)]87O]T-IH]DY>"S]4Q=S?!H5
MI;Y0EN_%J)QT0NV?IUR9#[@!KKT9#:=UI3$[&@QZ91F0R^OQ$"LY78;J3J7&
M4@<3KP>Q<EE5CBZ6%QU[+*^E^_#G,FK-D9E4!5'UK%).576_T;,+1;U!(*N2
MWD!;0IQ)YSC4&C_OP;T#U,Z*[MC_3GLQ$J=ZZ$(]-9#A%0735E6<:^Z)][E-
M<;G=P0C0_"H>/E0%VU;5SBI]*#C6K>OAA5%H-X#Y*2?C$$0TJ_=6E0W#BG$#
M$(K+JM3K;!3E!/Z)U<QPGL^KDH#-^H$B.8-;X4UA96">.S_U1V7Y<ZC3?DVY
M(3RIC 5@7\0G=\ZTNY4*HI0S#_JF8,QP:HS*)74\L=H[F[.,W;3+P8O9@M<[
M$C?DH;]A8.4SU"C ;]Z<Y&"ZJ$0+DK'"$C! !8'5R(F1A5("S XCQ=9.NKW<
MVK3I;(""<)LEYXGRU+M4%-YRX;PQMK#.ZMQ(F1M+XP'X9LGO9<F/]TX291(K
M>4:\1[.5NHPHFA7 *:3+69HGPAA<\N7\NDZ+R<Z*3G<1(=:"; 6.52G,4+YU
M.L V$(BW;3!L$/ :> UM)*Z#UWT\UXC51N=QJ;G[JI#*M1[6[Z56ZXFXEWC/
M&XYA3B/=UH9E$K@H0#;ECF?>*&5RSI7P-$V]]?SVAL3JO=W6GIM-OGJ3GU[
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MLP<X_^[70^"&[E1WZ#:UJ2V,<B,-V[EH>'O6 @,+[@Z-_UHE?8UA*9PW%A@
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M+B9J0NIU3T$M #X]$M!7WQCDOQ\I0MET.:ZLG5D)-M6DQEJ)CS%S_] "NW$
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M/SK%QG&O>PX+P0N$>!;+Q.4,S/-6IZ!A!]B>'S]SN_%NV*L<207_9CQ'LQX
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MPZ23* IO@(1S>PA"+)(^,NJ)!.Z<,_WJ'DN/+!YUL-2IA /!G !3=5ASD3"
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M6V_4]F+X>P)_.-[&X"3"?[T8&Z< ZI-^(W8",(P]V_,G#4::C4S*!5,R2)O
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M:8B.8"N=)/<M]7UX8EISXO)LC]\7E;;<;YS9WB"+BIR*V.T=V\Y(?(!0\2=
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M<%[P12=6/&'RM+PYF\>@5ZKKM7O.KPQ+Y;R.3G_$6%+,:2KPQ:CU7G\M7H+
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MB&N9D%94H!@YIT%'9W-+3,*W^2U>F8+(;C!ACX +_<H=N"PQOJ!6<Y2]E3V
M%>I6J0_M29^NO&*FX(I.1N NPFG8*YGXN5EF<?PXVRY/[9_$.!(&TU:(I?)N
MP6<T:>77;J5);'7><[2)KL>K0\[?E6*'7 *4#SP3P>B<GLVX\T?'?'%P^.G(
M21*M90%)I@WB+C'DO(9_I//1)"MLQ%F%NF[.Y1W=D<5O/M?"NN0"9F*9H/0X
M%7B.>FJWY=:;W=(D\V['<+7P=J3+KD*K,6+ODS-,!<R55@X,G1B\$]H(JJU9
MF5;_&&MM_8.4^P_F<%J.6_7'@:N:2&]/M#P^WS]\F_OV:^%31-[3TI0((^W
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M-IGK1B:]4B[@LF;#1;"@.@5ZG9FKFB/?9YXC5Y4"3OH9UEZN#9;'GW+3PJ/
ML\2E#-$4',AC$9'%@2+%E%?)&L&LOM;+=5;:YW1RMM#A522=:PXSARV\.6X>
M436(Z>5HVK#G3_)0Q)PR$[(;J_1,\6/ENR"LSQ'R(N['HKW5&[5(F:0HEK&&
MH62+?<RY79.N%TO3TD;TU2F['A4E]..@$->WELV3(7H+LXHFS91^;=M^[NB7
M:Y3R1,7<O:@HII-8_F)BP&I6+H@/A;D3,EK))4@:D!\V6>$)=B"!1%U:]( 4
M0F#](ZH<ICIX1+"6B#,@#B.)01(844Y/C3[X',J_WDG27 GBA-E@%=:<.,6C
MT4Y&[8VDT83(HAS7Q)-Q]FL-\;5"_,O>D5 RF&0$,M92Q#EA2!NAD'/$"F(
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M69"^&D_169X3JUA.C#>>4\5%X<2KU^+Z?D+7=;20#]G10CY01POYDCI:W'J
M\KKIP4W8>F_[0!Q28:G*M"(%( L 5=X 6V<2D)64P5NI*5VMH\6MYQ:L-_?&
MFQNER"W83:2 70:+2FAB,PZ0A0F?HQP'WL/@\UF1O0X^O]4<N2?6T>(G8QK7
M'2WNC+%WSNLG;]FARW(1"B;!%LDS/"D+Q' 0W5FN08+S* O-GV-'"SG=T6(R
MZ2$K+:B?[&PAE^AL,?>YCZO#Q?TP\;K#Q0J\"V/00Z$"4R$4I- 2>-<;S BC
MFCB393X66BMC[J_#Q8VH9-WAXI;(P9^#71V$"922R&,D(EA/C!:,6.%@7[BA
MEN;WT^'BCDEAW>%B2:JXQ$:#-F/>9I$PF5M4\(*XK%"$,HM=(%V>%?1E=+A8
MH1CLRROJRA]/4=>YQ5D?;['5*]?UMKJJW+<=M>ZJLKR8W=L_R YE'AP(6D58
M 1)64)$!%G.!4!4\-L P)H1U5Y6'+'5,&?#CPG*?;P:9.O]@'L237I)E,KB'
M_;9+S]KX8<70G8]6:K^3@H22DL7561PQTQTET&.$S63F4[>J+)#\>J6IRX?-
M(__3/H\I?:]W[=RJ4H( #! PX!0NKBNS^LM-ZZS^.D@%@#<:9<B4\_@+)MRL
M,7CB6;_7'9;^633S9K<-1CC@J BB/>"\QZRNTBG0'0O9.DK)#,.Z5PAMNF41
MAQ+XI*$0FR>C?KA?L,3=>&93HN5XV-@PNW?S:M">6R]Y 4:"B$+S:&7(8V:T
M<2*:(@]SW>V3#O8Q[D(5LX_YJ?OP@#^:;?_MY6F&R]WM@_-#FCG+A*%$6L.P
MT[<GEEM&HA!94#K&(L^F2\M3)JUT,M(< [LM<UC8-ZBHC=:<<O&J%D'CGJ%@
M >E?<G71;C;;YPDJES71L$-.!T3#("EV7BHB!L>1=((XD_&UD&,3I6X#+D><
M,G#2,S0(8,AV'Z13Z/[ZV[0]L40!_FO?>A)FVLX1(,U>^^PW":)OKH2M5F(
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M!TM95!;DG98;4MQ67<.[EW<):O\[M5B:TR9OJJ=3]4""XN<W,[?)4_E1HQ7
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M?]IJ%,!?*&:?MK?DRC?='UG]Z>1"_0YZ$F;4!B(;@]NU(T#NG21L&BW?[ <
MY[6S3OM[ YF[YBYJY\<-D#OC3H1T=Q<I+L0"*:[1*[T*+=2A]L@V6NAD/VYT
M BF=#;YI&Z?=VB_VUZ3H0K0]P/>N'1KIN2?]#JA]_,*>VJ,D!T%&=I,:A+G
M[SB&[7>!=&%&@WFTXA$L=$0//-R+HK3H-VNG&,_7"GW?VZC]XG[%&U!"P5O#
M10.-/A@BGIXUVQ<QG2+ &X,EDO@.[8\:; %,)M1@ [XWX!FC18.!??DF#1"_
M363"_OA4&ZT"K9IT,?!L@&<CX@"R0SP#DTLZOO1__A+*D08S^MYH-TNH 6#$
MGIT!72<'3=.>PW/Q#O3<5&1\@?MR.EQRO+]<PG+L5$BA9L]M)R30A,]NQ1)M
M)X].>L]R<P (M9- F'08'=M2O !QX-*%](Q3!%LH5ZH'P/\CJ.HWDP&8!JUF
MB*9?FLI@'.M]IU\-TVQ8AUH&KTE'4S&]7+J_[6!K2Q[%B>.4X-9R4KA-N/"=
MQBF^44H,2#<7C99M>9Q8,C-+>_*ZHYA;8/J*\7B.1Z SAVWGC= ['@0#C-U5
M'=IFHUNL@W?I]Q;?,C9!'W$%'DBX,#&UJF/_'G=&)Z)'D3BP^[^1A&!^L\US
M>]%]]>_)TZY&BXPOX/2[+]Z!*_S^U_KQIT\Q0#U'%2. IB@DY5H)QK##E8F9
MRJEY.+__B@KN0R>2G0][M9UD(8%<^12/&F WE6OS":_LUK8&DNSYJK\O )R0
M09+<0UR-?JG10G3*A1B*]%(<HL[<"J#ZT'GU1QO$YD;M\X?ZFXW:_H?W28Q9
MD&''L5,9H.C\:E<#PX<HQKNV&2N1CS+K[PABLY1P6[Y70W=73&9FNP\BOVD!
MS&T!*9Z>MG&%VO[;1J6&4<:!C=C%H^TF2)'R10"X^6,+FJ54&>G^/R;N+\_4
M)K] QPK(][_[[@2$/T[9@YJRI3X8UT7-QBD06OH;M4!C?($2)@@Q@<]N'"Y
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MI S -8D$((M6N9/GR/$PSJ"ZU0",G0(T[0Z9#1\!0[2Z!=YL?Z"/O#MBT86
M<8Q)%[//B#$J5#\ _[9S,42/E1$T@OO=<>DS?14P#I(7LDH#RUVD5YSE*CR+
MG2/72N0*&P$@O]&!=P31 2M7P/#):(!O1U@<('N_6[G$ ":VNUU<G!*G;@P1
M+GP]CB!+K^%96CYD9(3/K3#:7EC3D@D2+P\F?@I4X"+,- X7?Y'TWB@Y#Y$X
M/COM^GFC"Q8TD%1HA!%.KHSM<;JJH&W$S<0]@#>/:"-TAT,EU3&^DK **#2&
MJB:MXV#>H=\I501*-]CK&JQT[[A;*^W[TA%YG>OS2?/XBKCH?=\FC1*?L<F_
M5TE]E/>PW=E&[>T__ZE] &8\:W> ?-]^;^,I1^T_T39!6?SUUYO2:PWV4\M6
MGWH@O0U CWZS]@OZ#5CV>_E]^H/^_NL4K +- =S90U4'R 2 P1!;UGY!XIP8
MH[;U86LPSD E)0\F<'[)(G!'0E! ^^-S1]ZIAD 7?04V+#YY0F8-OIEOEE>R
M$4:8&!O78/R#H;NDNGXD#X:WU&, L=@HHY=0HV_68/'_CF>],@Z0SMN \<5&
ML[5_>CI\Z:0(RK.1[N22N(1+:J,%G+>N;T!&POL/]Z@2ME=,.$&!5OO[0#*5
M VW"SL\X"<8>7SUGTD4PM*22WZ:$B34; (E5:ND[RM:S-(_*ES*I;*^9Z6CO
M0=*U^T?EC-#O!#N)R[P)**C93-$!<R<[L0DN'@'1GK<[W_#R](+S3ZPG@'BL
M_3\@Z;[_=E';CJ@"2_Q5P'IU^YT4.CI@E_]W4-O>VQEN!0P.=L1@%)ACJ(7V
M>5*GZ#9#TJQ08/5V>"X$;T6'4CN=B.,S2Q5L>V.CP'+#:G8G-F0#'3*5JJYF
M.2D'I@RCHX%HG'>:GUX]O5'27S#5;G&1]-O$J@X4\4529T-H.W#=Q.\XD8D[
M&I4_*(7IMFNG&'>+"S)ZMW'E/C%J&2,P_YAO ]%[68>K"ME-X;I%/^G%,: ]
M?.M9-?CHI/Z*N@Y-5K#[NR@".R_!V!_S=2>N20N %EH"JR7V2Q[*M"(;(RF$
M%[?:+8*.Q=A+('O< BN]BI5I5%(8I>.V5#J_C6%X/#TNL0?/3K98*]:82O?S
MVB]C-XY+M&2JELBUY.=*H"S8SH&$V:Q]'BHH-("[ [9=<%_ITD@.60M"N=$:
MZ*#A"J([%U<E_@ !V$7Q/5BZ<>T[6,0)J^5ZQ\*885,)AP7S'.BB+JB3RK@9
MR*?I<XUYMO3"<4N/Q)53!G/)=QJN7)=.;+3&UPS'"8,C-QQ\. ((8SQV*%]Y
M2&.EN=.\*(DP@&!M15R1;I*O"X-@!F<UTY$P%$.[>#!%R$0FG/&*:Z^$E-(K
M)_*Y9[RCD)B=W7?C1[Z[?80K>\6;ZF'=88Q+]N+.;@\RF/MA4%%$1G,2A,^)
MR"PCCIF,>!8RR;A3N:/8DF8FHF7 =8O.W$IC'632.?ZS2NS3S^WXO" HT,;]
M.!7L5#1^Q$ N8Z?]@FG@+=O=_G:Q>^)A7I_9[DG]D O)C"H$D85C1'@JB!96
M$FUS:F3!M=/^U>M6>Y8>AO8_()ZV;R35,,33BV330,)=:].71X&K1$9ZS 52
M--.&>J&%URPPQ:RPOE#,69GHB WH:*E@NGETM Z:&PH4NGOI#Z7Q0><<FQ)H
M1X3-#!:)I$2PS$OJO Z8!9]M+LH(K6+DEJ8,5CH%!ZYFQ-G5H7<3/5W)Z,%$
MTH2Q7U;PQ[[] 3SG8^,[6ATOXAAL@3F_5WD?83G:';"'J[)'DW;]A)F(7RQ<
MOPF7Q/ZGH8]G\FRHLGB')T<#(#T\61J0^)F]2*-60'HPGW(6$V=/5P&H5L(V
MT^'A.H]&2!?R+ AC"RV]]((512XI,&,V/SQ\"C7!.HPMPW 5/L0.'LKO%?#]
MW_8[.G?WVW_$#[81AE*0L)<G!L7>]MO#:*AATCEBN0;A%PPCQN:&A&!A[8.V
M(3>O7L_ITO*O ; JC?K!7SV@Q<I-@1Y ]/5?;)3>D7&::2"8A]VISNB )2_C
M=+Q*H^7AFVYYA( >]S2V[38F7/>#D]>Q$X[) U8<]AS- ?2^C,VN9GL],";Z
MO8&K ^=7]'M]@(']7J,Y*+\(PYY5A_>[>W]UG[AHOE(J;??C* <;3:8Q5]$T
M?L9T[W*!+/KXDJOMK .,V<'8L7(7AW%;&(^6HI1P \;]1VB;@Y'8/49C?=R;
M%FN[.ULUZ__;;Y1!.+/A3V"^M3NA,I([P]J9(.?&W5[%2F#L1J&Z\\ 8RJ,W
M)6'NM!8(IK\&LUPCM?DBRE_6+X\.+2WR/,\8"5Z Z<>$)9IR0WBF.&Q)S.&?
M5Z_S?)/=$E3C&V/TB^<9P!2 97Z.LFZFX28):H*.UF1T(^N1PYB'VB@1J/8D
MXT(1$6E.7,XXL4+F/"L8]DQ\]9I2-B=GIC8@IX4I+4_[ '>I( T\XJL"WDOM
M/<85R6<Z+O#+\T#0MV6J1"?B04,J_Y&R&$J3V=:J"*I*V8-F:. YW" H:\1X
M\^QV?$QGR!IC81881U!!"H07HS2>1JMDEA1-G0(-NJ,")>-GE^7=97#8Z%"H
MT1I@A?(EAC$?2RX&@)A8JE#T3%N,H"Y5::V,.OU>)F.VXE%Y4!<1BH..'9]9
M-8$.V/N=+H@+?%[\T>B6YW?V1PELXBDL-X8VA 9:%S@((#, ]^AHQ>#<<I3!
M]3 \K,5&FNM9T[:23DWGA?%H$#2,*PUK.W=EUG&]=Q'7*Q]Y7.^U<;I3<;T6
M-+A7TAN=,Q%SJ9VW,2LXU<R;3,9'6\]CK"C*DY;RJU;T (:ICH[K-N5D/NFW
MOT['E5&D1RG-I$SX@@<DTPA_XJ%4Y3MI@GQN8D#A6;\WEJQ2V4QM##! T>M!
M@W63*G-]N"!%!HSD>!E@E]35(.?CRW$LAV@VOL5FX[C=3E$5-@7=5;R$9'@Q
MU%T@T%VI^ZH8DTF[O+S/HJY#)84Y/ X3&2LM&U)8:YD$@D\9*ML!9IY^;@JN
M&T^0!"W4@/5/0Z N2CH]X$Z6N3#ID@)C?T#1';7QO4&YM7N-05PSJ,5><Y#'
MT^DWT4\#T""D'!]XBW*I,7"S&YLE9BCC\T#P@RI-(95#E9ZR9LHLO1ZN:PNF
M-J[Q&W@XB3L8*_B!$ -?()T+)V?78#W;_5ZYPGC&6H4Z=OO)O5&BH&K*I?=K
M>-Z)49!IQBD4)(844UA"G(W:P&5189U!\LVX97S>[C=#N5N5F5L1596E"G^-
MA4V&.(BQKM[NU(8Y$13/AD?WJL/[%$?- '?;,CJS#,.<.O,;AFNG:G0EGK(3
MSHUMP [GR/1HL@-O8RY;'R/#J@2N+L:A#G+4D%RJS+64BU [3<%E%<D/L^QF
M#NYQ>YI5:I[%\WY >X"I4@32I'MLZ&0IQT\A855.'5)Y&:"$H ]79-$!9XF'
M@!2/&V<E4![&^%2!AA\ WE6G$A@A"%3S%Z*_)MX":_&AW436^U#F$]?>]3'H
M>K2$(#T2=#ZVS2+%,DU$,9:QBANU[YNU/YK6?VO&BXW:%[2<+#+0WQ[ V$;M
M/VF[-FKO;*>%/[>KV6\!F[;ASWY1P&WO8A.N_1O,X'2+LQ@LA8O] = ->H92
MI."<QP]CO[9'&[^5-GX4I#$=HY+(H8J$)MN#S>H.:>BTG0@'DRP;70P<3W=@
MH K(AC+VOPI,*0-+$G'B7-/7 ,&[*=BWG=P.+M%F*K32&L:>3(RU!_/ R$56
MQH[2S=K2<YH[WK D(E6# <=F=LU+(I4,2B2<=>()J"^T2$9Q-X/LD.J$8!%;
M8>B-!?P('\C*9(9]2%(+L449@W:.Z]1N?H_A6<BQ!8"RK&I1%=Q#&V.8$=;]
M]AQ>^_K L$9W(KT")I=R&Q ,C:_(>!$0+%$T?@8P+$62?HFCNC&E2/95ML?(
M07!EH*(] Y7](\$BD''W<8[%)[S&\ [OMG?>I A6,)<2C*O.L "0ON0CJ[=8
MZOGB4-F,6T$#"8$9+(?IB',BD$P9@655=2;MJ]?&S''>_6O@3KI/U^VPV"GL
M[%1AHYG"1Y,?K$L@+443'R\.J;0Z9RHG6%>,"$TUT2)((A4WBAEA(A.IJ<'F
MG!"Q@4<7)<PB4;*Q2NVC%$N6:J0!6DL504),7J<J+1/Y>RIC"Z^JY-7#RY__
MP-1W6COH\2I-"MO\ ^>W%D,ER>UN?[L\M(6!I36"<&HD$9QGQ"H62<BI$)Y&
M18L<(XC,'"DT02"-\74N"0$] (UFG# C\( 33=9NPO^+=5ZBL%')!31'&KU^
MJ4/3=\>@B8>J-%$?FJ]H2("M//:8,JIC2+GH\HYA6)0D::=%SRE3HO&( 'AJ
M]JX4=]R=!-^-J@XX7';:!B)OIT"8@:\@92JD(!6 A/A!&B(-!:\.;W*!MDEA
MT2&]D:*DP4Y.$K,J0U+Z"FQ LPE?"@R8]EG)K67B<,JZ7?0^PP'*4A=57F.*
M&!C5MAA$%C=: =!5)^5<7'?)L,S+Y&(,RG)@L&*G@3[[,C&U"I4(5?(E(NG%
MA- K"X?\7CMNG^,909F#T:T28X;NH"K.YWG [*7P)@B]]E*@,_G<9N%C"4"3
M60^C8(G>5,TI'6N5-Z5P%2Q%/_?V%/TR7AB_UCW%HY]2I _N'U3NN?,B['_[
MXQCZS=C=*R:,D+T"K9 _+O#?=Q8-XI==B?TM/0P2[+C<8U?Q3!'0L)9HIC(B
M<R%#%$HIXZ?/.C3-+!<J:LJD8#H8&V,AA<DS)G+'^'0E=B368I0X5Y:!QJ3$
M#E#\,(.L+.IT?HQNU3/, TF&-PBR9K18,"#;S(9@=Z(83_<8R)2D6F8+*72C
MEG),RAX-QQ:DJ!\6BQH_9@6I \\^;?0G/O_MVFKQ-Q(L<P^>KE_<R<W(-&,%
MM;G7,1<9J'!!)?51R,@+#VRRQ,%3M2.#0\74Z"55NCSKQM\&O_R.9P)->_%;
MHY7$4;KI]ZJ#1'42.:<C7WI@^75U,"<%[&16-E#LC/>>J<[M-K-Y_:O*+[D4
MFTPN_O[*FZ_\4NO!I&YY8+JI'GS"-^AB^93:3,_O:+3:2Y6GX0_T6C.NM/1:
MDR%<*[S>$GU^G]9*S+2]>70]6A^"[-^TV]_0_]SJ70P.0%!__:?=/<-C\&[M
M[XMN+Y[>J'/T9-<O;!"$;;V2SIW;\>O1$-"*K?'F^AQ\U-P&6S!NJ7 VL])J
M3JEVU+*L".Z:F-F9+GD3&!2QY\CK0)^^VZ%LB-=F]?>8A_29 O1L[G[9R?:V
M/YT<[#=/L;G=P;X7.(>]]Y^SK],-\4X.SK^>?.:[^_^<?GW_F0)L%;OO=X_W
MOAR(^NF[X[(QWS?Q=?]3\W\O=P;-\'KU_:T?N]L[YX=:4&-=-$0I*XD0N2):
M"@Y[X[PO5,B\8:]><S$G\^E?/\,</]56_44S6,[!K%#6PU8Y@+IHZ\E"B\P#
M*S&A\JD,P>E^'FL&NUL&NYAB,(M]0I44)'K#B6 Y)R[22+BAU+M,A SCU07;
MG)-4,T]3+^*2@84! \2K^>F^KKP5:%&D_STI:#%3J>E&<O+Z%W_RDHS)0E&A
M8V8X2#(1;'!8F%\JR3.GG%Y#A8>39!]GH0*5(G@3!.'>:2*\-L18DQ&7!R=9
MKI3(\U>OJ=K4MP05IEC@1E#A!;"1LC&G+&=1Y4RX+!@MM*)!"L9SF5.S!@0/
MRD;3@"#$R*02AD0N/!&<,@)@3A+%C&(NC]H%  1TWM'T7$#PXDSW/U+%OX'5
M7D_U_\N221CE=QM&R=.0$O_?0]M?3VNY5A.J%%C1,1ZHHAFVQ30N!R95,,7"
MQ6C96J@^G%#]/"M43?1.\:P@WE!%1%".V$QI$K7APDK#J%:8PKG)EQ&J_T[G
M,W-.J);M^7V/M$UE<N*GKO<K_WC L_IE&LR#C*N5YQ.S_WX:G'-V:U6W)9C<
M\)QS?N/X^\A&? PT,2@J,TAPG:R6L&2(;=DE-!6/6B["87#Q]?$,XQ7VQQ,3
MJH@D'*Q*(<43YT'@PQV>&]_".?!#!;)<&1N G2E^)CJ@VM+?%B[],@+Q*9V0
MJY5.R)^$&VZU@_%\4SZMD_S5)GQ/3D[&EX@.6 )ZWQZ-F"=Z>OVNBIK<3U5:
MZF65EK>355J6L8K98]N0N[WRZ1V-S=_^)8,WKG_=9>S<Y[-F;(DU>P2'.T_0
M^;1DW$CWSC?@'F7)^OQ]PMWN,\U9=$61*1@O6J'R0GFI"TJ]S]7ZU&J.9^A\
M#Z[;_?+GR=?]H_,#]C&#,3)X%M_;KE^D>ESO_SRIL[<7]8MIS]"6.#CY2 ].
M=YM[VW^<?-W^>/%U^Q.\EQ?URYUL;W\G.SBM7Q[L[USB^?ON]*F5$9$9;/#L
M)=-$&)T1JY4A-&-@ZTD;/5?IU&JV7MPZP.5!&"Q2PUPH\J+@3$2CM.-*,R.C
M8))),QW@LF:P^V6PF?.LO!!%D5NBN19$..Z)MBP0SI53,>>,N0Q "9^7^?90
M,.4J:^!9Q*"\@\<T@JW]T>S'JEG3H&/8LT8F+^&XO\A94$I83/'*M3$J$Y8K
MQ@UH,N7Y&G\\G'BLS^(/YTW!M,^(X ;^T2$0YY4EBD9+A6)%-#*=3-U,/*ZC
M9F[(1HZ9R#/O03MIP4S06H8@ 7L$$;#KPQIE/"@;3:,,*JQ55.:DX#DC(C>4
MF!@B =K%PYI<4*-^@HT> <IX@LZ0FT2Z/EUL\0*B7K@H?.Z5$8 C1 ",X6DA
M\MP72@<7#%MCBX<3BA_'L,7;'_7]CS\.);<<+&1L4U0$]&T88CW+B+7.8/:.
M HL9A")_C+Z-I\5&R\3:W8H.>9S"<'WEG,U:1XD]SRBQZX+$K@P;>WG%Z//'
M4XS^!CSX5*+YYL>M75\X_TNL@O$P#&\LU&]^[%ZWC-A+'39@ 6.W-U9W:+\J
M_+U1&Z\NW<:;QVIWCT8<*SC<[HQ:':80/XQ#G)A.^12\\!1;[9PUQP+7JMI:
M]N@(V[3WL+XN5L-.?<,M5HF%%[3-836O6-;N:D]TJOH_W;'"6\,FPH.J?7,;
M5TRS^52EC)\NBU6V2@@21"PV_:11Y$Q9SHU4(5<^U\ZI K.N7CT.PIQ?LW:W
M#1L"=O==EZ7Z"\1WC'N#L-"_4B^XQU.!ZN/0@MB]W#K_^O[/)E@#_.M[L 38
MYXL#P/]?3W>RK]O-TX,O'R^_;O_SK?[W3 4J7M_^X]O!Z3]@#81O8 F 1?%G
MHW[Y]?3@Y-.WO2]?C[]N[W[;_?+QQ_]>@F5Q63]4,H\Y8Y(HD8$!D&'%RYAE
M!)>;@6V0>RVG:QX!4162^2"L*X22T2AO6>0A6!45S]UT :IRI>^QB-/U$YQ\
M(:"E/$@M:<:=T+D%XBJ8R'*>@S&;9^81!^].-/'LECT\O]M.H]U'<51@P768
M&E;5#K9G:Z6B+RN(8VF_5+$P!?&.-3E*\A(E'';LP^X3/2P>V#G%8I)5NXEQ
M.5?;*HO--P#YG VKW+4NA@)[JMUHU::H*BH^[*R$U06KK@.Q=GX<4WG$WGB+
M6_PE%9*TY8PW:SO%U5=,/KF'33 F'Y_*EN%BC#^P7 ZLZ]<:BR('Q5+*_SAX
M>KW=K=:N6W7?N*+A=SLMS6&O?8C*[OPPW7>[W0(7-'W?2T_N[K<_X8-+9IRH
M_@OTY[$"\'F[$P#I/J*^X/<M$S]>[!X=ZHCYY,$258!<%-%;8O'X)>.%H]:Y
M("5_]1ILN3F]X0%\M#NQ5FYVMVQ2@KU"\ M[,0 <$^CGK.HO,D:H0S[HCM-E
M=S2N[4QT71ETCX''.6Q1$CN^D3J =5+13SN'/X=T#DPTGN:1.E-4-%UQ4Y+F
M)13#FGU]^&K0G*S5&[0_KS7*!IH R"ZKWF,U[/*%XHJ@Z*HZK59(;+*"8 ]^
ME()GLBE:JD(*:]*)Q]@TXON@FUCM%T21OZ:>%2,VGGRKDLX'6!%N;*2,D\&5
ME T:-J;&*MUR37&UAOU1VJW9=(;*P*MUCV/LW59"R6/4+5M=6)]N;]@MKUS-
MT$Y+5%5X3>MZ>M9L^++P;TQ-?_I(IW!+:K>+NXIJH]WIE"DF>-FH/UU)EJ,V
M.L.&>4BSV'07*]4F[8#+C\0S8(VRS0D6FTW&>6H?6[7UL=UA:^EN:BN$,TI/
M&I\K<E8+F2A@?]EAOYM4S/]=OX-,-Z4]X%KL -!L#O0E]M-KMTCY%](IR(16
MV2 83:7643-][+ K4&WJJM0("<?R35M6WBU 5X"AU;Q([3M25[^I;B)8979<
MSW?[;D9SX[")AZLNW.F", $%@.-/AR9/I]R@BJ^F6Q@/GI#Z"\(8,*EA1YH)
M[I_@Q.X<ST@YS'-N=CR^5=6BC:_Z4)CUL2/)J-O4"(6E[1\#'#-["XO=2$6L
M;6^(\4(%93KM_M%QC66<;=8^IX%&2&8TQ$9J/UL)^Z0N\/M.2GV?2O ;%I*N
MVLMT&T@32%ZC&>);I/+>L<1%'B3&H*-CV4RCB+CI?V.U:*"RDBRFH68)G-(8
M/>11$"XESP\;0:=B^?#!<9+#%]W*9=";JYE2J[/4Q*J!8=1)KE</"67WW:E5
M25*KE/JIIU/57+/LS81\F%3$J$_OM6H!]Q153=DQ;-0F$Y1S[SPFJ3/&.JG]
M4]DS$^7::?]T2H;50C_.4;AC_4K*12U?=TD]/)]A!UPZ1LO#_D]E,^Z+ 5&#
MS3QL#@:KNM7!MD,]A!#_--!QUK"#1CY8>QP+E9<MN5.M^78'>XCVL&2]#;!8
MG234NHA0@(8I+V<P9\SAT],*)88H2Z</^O^4'/!FV$XO\6%J^]V9;0G^#Q8V
MA]&J,'Q8IE9WV,BKHIAA ]1%TG9J/=)LWL"+VZ/V1FVG":_0;CQKP;>3C,56
M+!<N :Z!=)J5/U-2IA.KG0$J'C0*6*F7"N,^UR%J8;@68+MK+93SS@GFE%1*
M+=M+Y:^8NE#N%64'I;U^#Y.4\7RQ;)CS5-JEW+?%M,-V3]X>2JQ($X(GE%M.
MA)=@,D5E2=2!"A%S)W6X(I)@=EL]$T8XY;D/5@C84)%K9PRETC-IC$C;.E,S
M8[VMM[NMA3%12<?!_@V&""8T<2QZ8IUF4F>L"-&\>CVOJ?GBGCA)*J=-&6O
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M\./KEX_RZW[SV\'II\;7]SO9[I=_3O>VCRYAW(OZ^P,8Y]WQU^VWY[L7TV;
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ME;R/"+!H>!P$.',[=F')$C=T)RYWL=D^__77VEFSWUWLE9E[W"\R:IV6)A;
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M"5;12XK;+DJ5??5!"!#]8*"Y80SP>6&_MX<CC5XZS;0[>2U&2,0-1*((:U.
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M91E]T+R5"Z?4SZ=G_5Y)JJ#K,?'%EXE')3U@X%FBE_'$[^^VT4R#I9.YL3(
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M!UG;[??#X+>S%/$ZZ"PZ'5"M=B,1A,].OX!B"VRU0S!?,1WR# @0!E8X8Z3
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ME?-F52>?O9-+T:_O9/O(W'A<$55[W-&]*N=QPW,>J1>"*&F]-Y9QKY47F)*
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M?.VVOB91F&(+]^$TC3X\>$34#0\R%VEN<KKS:54U\/=X/[V@(1^$7L>T\D?
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M170(1FV]$WI;"K)"Y[>75'"B H,1&"A!B?(&!ZP4<YH9^&F)SH(7$BN6Y6!
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M4NLFBK]AS,]E?Y21@7O?^N[Q5G8_IK[[*0HQ5OLYOG3B5/YQYOXK\SG)^Y/
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MTA,!$%:\PI_.A1. &,1?L3!W 7< ;+-@94TSDNN3E>6DC1@EPY)#,-8B@C5
M(L..I! FP3>+2=P1%9)X :$(9#HOO$4^$">F4,+>O%AN30U%YB! 0&R$+&_E
ML\DJ <D'#X&POQ%!@/^EQJ^%=>2/00673T?4O!8WWY@()\;?1/',"?U_L]BQ
M60UP5)$9[.$U;MM?X#Y%8>?_RAQTD4@)E<(3<+< U@#U"R^C!CUNE*0$%U0
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M'.0NXZ%A[B@',\)" M?%PG5"XI33W -'9?+N2@C6"]&<-0'BH+O!UI*7[&[
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MU-&9BKV+N \P][L"E4UJ])(_A!RL,YH24$P!?\SCSLB+A$H/2S#=LH=#NL!
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M)IUCB2(V#9>;Q;;CPN@Z'KI!AB]TELLX^NXOG%3 :L_[@^:HV )\#@#  LK
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MUZ,^_)X,\P*ED0"RD4K-49]]ZTD_9S'+7CRMLKT*XU3+EAOJ">= ZWYJG<V
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MVDP^::DRE^(@MKD+:^XDN5SD_2X</\07?OURIE^Q(C_U8-#L%/V5>QDHZB0
M"$>ZRM;? 0!LMDNN4K),*OI!/RG*NHRC:[)R".@O?I6Q(T2+E]9%Z$8+@31W
MRBZS,XRNF$"8%(#@,Q!2! +ATHO!J-EY6=3(VH9&=B.1?Q;")KP?5]! _YG[
M\#M&=5(T+3&=\M=$LNAGIKT-A\TNN\U?=,;-ULN_E56]^[M%W_O/9_[4ZW<
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MR2<%G*M.Y,9G%_EXG:.&RE8"^U(:GET:J&V.&*)A,3U#)_03D_1X]&#HY?8
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M,IV^9%A1T^XZC7;_A7A)OV[W/?E7'IR_XG(#E&!:@SQSR8'2'G=[Y,9P%B1
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M)D -N)#)B@JY,Y68F=Y$],J(5*!HB;@#?\//C*IP1/.8T*R *6S_>!3+4K4
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M\2+;^H>/XSY]1T7SJ1NPFZ4OI6("LAPWNSG%_.DE.HV/J_KS9\.GP B0M%0
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M>(-4@4[596^IGZMN_GJ%1:)8!'$>A737F)-V28H>U?F13JSJ)5C;M*4:S--
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M>Z99(O..DE)Q8'F8>(/0M2F^I(Z:7KJ)>/71% K"7F])'8US<O^"C#@&:7:
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M%=.E1!8T9A9*2(+;DHL+C<G1$=IQ,V8(_0P00GF6__-LOJAGZ/SC]%G.2PW
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M<?,$E?[H$C<7O9R?3^>+IE?"UG[P<$F5A]=Q(T62LG:FJ#J.BA0C;(Q*^6R
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M/)G(0J%E9NN%R$Y[R7%7WL\EK'TEQ(>A0U>':$NU[-)AK@#/8^Y=( Z4"N\
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M$*WU?@O%[H_\%OJYI]YM"^$.8-'?=C&\4,I(;9CC8&A]]2);[8;GHS21!V?
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M![3*Y11=?@(MJ]ME^#:7ZJ&TK%YSLPR]"5H*9";7"T@J1P:I]G>2V4 $$^+
MDR,/[=;M1GI]^-;M)O+=Y27++KB>ZJW;C736];;E-@+?)2&68^>D%<Q)56\B
M>LM\T8I%D81&D\#BL!O!X=VZ'80'F\BY>3>5.N#X:H'*\M+A&=8+B!<=O&S,
M7BO/C'%(KGG(S,=8F#+6!)-L*>K&Y>L[.JD\^*A]FX3;ZF0ZG$ ;7I2K\*X
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M'%Q2&KAURH4Z,%0.L0X&+_AB%:2/R!M.4+JGQ0] $[Q@<5E!]M5+1JXA^*B
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MU^9]Z<_/D0P4//_/[.+39C#KK&:IKRYF%Y>5K2U(F9+QWFO0"DDZK+8"43H
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MEC'4+I1A39WHZV]I!_UVHQD/KWRLN&H+*A?-1-K0+*AH:B?.=^4;3-LFR0-
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MEOF+^;JXY]7\8I9FYY=U!N Z0D(+'=0_?N0*S=K)'_)D=QID,)ZT9YXIQLC
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MV^-KQ,E<MOP'E^D/^L?KV)/S4DAEZ!VUD2SK.L7%8WT@&1.]PTEXWSQ?X#:
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MH8MZS(Z$ANZ'T;>$:PM 8P)H;&C=KJMU2)0VI'G 8PC3)3AZ8KA>*HQ*?Y>
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M2&0PRX0)])'<!/K$D*B 2<9XFA+K\JS/FYX:_YDD-+5Z]L<4>UB=/]3IC\#
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MT8RS.!,QE"Q$$,G4Y!-3%,J "(HXC3+E='3^(E9,C>Y:78%LE*VVZ7[7.]N
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M-AI>U6G?BQ48G+GG(CJ!6.9\/Z/RR45W#YGC\@/7W/>JKCG=-%]GQ$12"%7
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M<:P@13R"F$5I0@E#E*/YDURSU43&I&O+*XT*>">WM%R,,#IVP?_ B _]-NY
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M,?7 S0E>/<PFVR6, IB146YJU#GH*#N/63^?#CT28ZSDNVOVSJ@TYL^:6T+
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M,;W!&)K?_'"PIK*3?O<1CWZ@0SKZ7WO">=G6*/1PTOQV,I_^HZ>D,]7#8HA
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M4 Z90@)J\DE%KB+.(NIV3V%PFUVFXSBW'.K+LLO5$C:&>ETK&7ZP+3>LIC2
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MI3#5E0-D1Q3#PSXPIW11;FJA=PL&S=HKK3I.J'P8IO3-=3 &XBM/(T:EMNN
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MJAG@9C?_*UEI"/YW]+<H!@]T#9Z,U?\&<!;-HJCZ_YHD-H ^;N]6:W-B]]]
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M=2Q-]*\PYF5V11C=! F2P+PY;]7NDSLS3Z9W5_39#PI<G:R2)0\E9:;KUP_
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M8.,.76_7JSJ5[6_E]OO;W6:[OI=5MXT^MC=^>@==:U/^GU*8THBQ8E@"2J@
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M;R7_OEHOUW>/FG2_R>I'R<W58;F5[2U(D@H,,<I %C,.$,<98%)2(!&'<5)
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M:/2<G"46F RX0H:>GLS18:%"WXUA\_$Q77UX/40*-4A9^]6,59+D4"I >48
M(BH')$VDJ>]?%"@15#*KAM.G)I@;*W8R1BF\BHR8+MU>CN!WG@@O124P [X
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M!,@S$@N9IMRR")#MA'.CY*;9]G7$U_?WZU6T,2K417AE4R'CH:W)8"ID:!7
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ME"O#+"M9NTZBG^7V>\2Z,K3\4-'3U4W5A]K2_S02P-"67:\NED='T1%E?7F
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MV[P1>K92E?3@Z#6ND4J*ZU6_Z+W^FQ9,M!5F>G]X)YL"^5^;L_^"9CP7F4R
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MFNI/7?^DE?@DMY_5(2I[LRB0*G*4*) S@@#"ANH3PH"$6<$D+"16U$/TB;5
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MRAENQYL=F8MR8\RE3_]I1R8=+,-L/$+9P 3[Z?W?HO]\__7;^_^^_+5]IMU
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M)_7DW 1L/OOO;Q.*;YB'RU3%RA)RKZ-RZ"I##!)=Y<B)CTD3YFT&_(XZX2L
MYHGE=X**;1TJ-63;!$C.4D(5S%;_>3<< T.D:V\4M<1:1Q'?&8@W+)!HJ4F.
M.\#PJ@) MBR]$SA<Z^ X5J:- H,/($&*3&NB!"@T@2P31Z4C*5M+LV=62-8)
M,/ANZ2OZXR%C/Z&VA(QS_/)B^GGR^W@@J4X!/$;9 3"R4DB]-]$3GQ.G"7B.
MSM;#Q?W"NZ&BX:QF#8&VA(F%TW0Q_3"=?!N.(PQH$CGP;(EC&&_)X JV#1!N
M@W%X% K-CDMB/+?Z;NAH.-=93;0M0>3#9#;WHW\??ETZU3SIB'23&+@FTMA
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M$;R'^1TO#*C7C!)AC""26UUXX81G#BDY \P^=^EWT)'W##W]=%KI#D[59-\
MCCY,X:L?IM??O\)X!K@U+C#:F3Z0V< JZK)PB00N,]I=$"1XT$3XK#FC(J=G
M&S8= J<=R.JG64MWJ*JMB0; ]9#XI *ZG-H0+C):6"G1^P2A"&<6J'$!M\9S
M;9Z.=L3[Z>O2H1DZ6+J'0V,R]Z/.G:/WDW%<<453=M1G24PH_294#"0D1#UP
MRY/+UHAGG]?6]H_N*6O!1:H2S76@B(/A]0VF85+)]JRQ\79\EO-P-/1SF'VZ
M#K-A&OKI$&8HQ4E<_!39_I^3X7C^-_SU:]3E0#).<S&OW&>*ISCR'*1CQ%HJ
MN>$@6*J=3CN*X!9<K"IP/)W:FD#IA^GD*TSG-Q]&'D^%<2K1[]?"/7J4 YY\
MJ0U@I;FG)Q(<)2%2@R%)SMHG)[6O[W<]34\+#E<5C%43>@,NU@5RXLM+AW?@
M9_"Q=*N^R+^A_UC$-4"7H%PO26)53D1FE8DS'HTX2YDZ8P!]C\H(>I:@%ERP
M*A"J)_8&,/1<Y+'F D@=>0:-7*6(P4?PG'B>&5'.4I5,-E*ZZN9H%\KZ:=77
MB6&JKH@F3KES_W6(@</P'^AD3L8+.9U/9L7<KG$E) ^>86SK1>&J7(W['#T1
MD=GD34FJU';U=Z&KG_Y^'8"KNA(:L%QO417CRV$8P6J3P/SU]SBZ+G6V?YE,
MTN_#T6@ 1B3)2FML7<HDRKN_X*,E40AJ9;8:6*[NR[],5S_= #MQV2LKH0%@
MW=$MD.Q<:JZ,0X,K;90D0$+I@*)XN+/2;J8R>/8"2/6"M@X <I P&P#!4@2#
MZ!(H WC<2ENN';W'H!(L8518Q'%PZMD>'8?G+7OJ_-=9R<!>DFP@1_ENZ,-P
M-)P/%YF&Q6N.+Y,12GU6(L;YS9UH!%..4[1KZ/B7AF04D$/TRDRV2+ER.;+:
MV:)=:>LW3]EYP5(G*FK ]*SS=<L"UTDDX3C)QN$Y6JJ!@T17S;D(- )02FO[
M,5O(Z+?TI!M]/P.J0X3?%GXVKYPL'L*. YI>[1F1X ,)I:C&&"N8$]X[_URC
MN2-AU%11W-&*?AHXQTB] ?S<ECA\\#>EON'VDA'WD0V&9T)9*&\1F"?.&$<@
M."V .L7M<Y,8CBDL>4A),[@Y2L]/U)4<(?0FTCW(Q_0:UWTDI4$RQD-2AG"&
M!SQ*!UD)R!G3":))%D!6K\5]BIA^/:/N(%1!]$V@Z&&*_9:CVPY/ Q:\YQX/
M>".9*$E03;S'@#)Q9HR*@CW?J?_XJXU-BOJ]@NT(3Q65T,"I]OKJZVAR _ 1
M1F7^ZY9=(I,VW@B*%A:WBK34D4"3(-$IJP(HP=-SPZ8.0=6+1/5[[]H1L.JJ
MH@%LW>;4_SZ<?SF_GLTG5S!]M%^$#0XE)(@K0[AD:142@J:$26F=\\I&6?M&
M?Q>Z^KV6[0AAU172(\C@VY<[,=V\F4S?7)=ZEP^3T3#>_ )CR,-YB8=_&Y?K
MP_.1'UZ5;U=?I/^X7E;4W-\K?H!IGDRORF#G7]"NI[/IM+337)3=#$*F8-'#
M))EYP C(*PR=LR L.2V59SJ'C19BCQYAGI+>?F]_*X.W644W8&&WG!%!\)B9
M-L2$TBJ#!4X\!NC$*@Y611JH[C EMH_U[.R&N"/K>:2P6\C>3\:7GV%Z]0K"
M^@VWI,S04M7%@5HB.7[E,CH8Y9&/8M9H39]KD'@09+92TDS\62?U=;RT&S Q
MBWJ;-=&L<6*2%R;'1+2#,F2"X[;RBA,G%95445"IMNOV-#7-Q)I5L%-)ZCW[
M9Y_]]_L'86>74UB<LG>'^4 PXWE,@#:XU"9+P%B9,TN\@9Q ,NH-W\&M>F&9
M9H+%HY!16YXMF);MF90UK"< X%QP8H5#K#O%B-7HDRF(-$6,@L6SK7LK9K3V
M-#2GB SK&)JJ.F@ 5*]6RY;QO5> .V;=B@)Z@"D9&6DF.15A42I)X-$3:C1N
MFEQ*;FI#Z@62FHG6J@"JIOP;@-,:]0,*S#MN*8D^>"*MC<0+W EE=V2%SC_G
M'5X3-Q-3U;X7WDNN#411I9/M</D>JR0:)N-B/F$<"RN1QH F41'!2O=CK2-Q
MEN%7/D7-F9>&U;8NSY#33CS566%*+64T8&H^PU49-S^]V1"/81EM9L!C-QH,
M&*40Q)JL"7 ?H@&G\4RNC*DG2&DGQNH,3S64T!Z6;IL&G5V5:HJS^7PZ#-?S
M$D5\GGSPRU26EXI[H8B/)945K4 C;"T13E@.V400S[6CK("REXGLM\2E"C2>
MAUME/34 Q,?;%!W#Y4.(#V4>%:KN 9<E\"BW5),1?N+E8C 1S.[SMRDP'W3)
MFUFNB.3&$S3CE% 4M-8V:9=J-\RHRT$[R8C.3&B/*F\ \&MS#I8MVI!$)1/:
M Q^*[V$M(R[D1(Q6RE/-#0^U"P0W:>B[16=_>-CB+1ZLG ; =9;2XJ& 'WWP
M0PRQ5P\8!R8$EA7N3\=3F=2&QX,U/N"W(D;+/,5M7+N(<#LI?3^N: 9J-535
M N)BO+ZZ7A0D+>XDRIB?*7R!\6SX#98YGG>36<GL7.3/_OL@:9D5+9/!(@T8
M:05#K-5 LK720>F*8VH'P'N2V&\0TQ)".U1M \C]"',_'$-Z[:=C%-ULC=U7
MD(=Q.!]0035+FA+-549?.B7B*3K4.DME64@J/SO=Z;!66B]1U:^'V! ^*RNP
M 4A^GH*?74]O%D)>^B*K-KZ::LVX(!Q2Z;"3RWL_JDE243$!RD/UMD9/T=+O
M]59#\*NBK/U!YY:@&\-E ?KG#@/Q03+62="1:.MQ]UAM2J=%0P"YB#P[:I^=
MKETGF.[W]JLAO!VIH 8N1E[*+@RL"M9[,$09*&\C(HJ'6TNL5\8*YP.'VKWC
M7Z*IG=O\D[S=/5HMU6!VTJ$YR]SI%Y@/(X:H#U@Y;H+.PP\^P3B=9S@YY6P=
MJ[@ )AFQS/(RL%/@&9@-84G@H4B9@NHOID\Q6^>I%+^@7EG-2W5O&52E%6X.
M$27)U!J-(N<AULZO'',%U^^TG7VPL>OUVSX*:,'1?\@&;MJ+Z4)V:>%"?H#I
M8@;NP&@;@G;H+WCJB'14$*\3,FA3#MXJF7GMMW4[DM;F5=M>,'@>6E5TTA[4
MEK.5SZ[G7R;3TM=N8+G@-N >C)FCY\!ER=I(01(ZCTZEX*BK_;[\!9+Z31&?
M %I'Z:!52+V=S:Z1E:@][@*#8M(8C<@@-+&EQ!@T<TZF;#.OW?SM&7+ZS>6>
M#$H'R+X!&%6.K1F+2CC-2 @.HY28+?&0' &'!AL MY"NC;P>KO[[[3MVC.O6
MH[H; /O:S?*3GD5V(<32T$UDELOCTD!"-I%XR0QNYAA\JGT4[T!6WQ%%?ZAY
MNCB@B@K;0N4CIR1D 90Z(#1D9(5G11SU*#2=-!42'1->O_'"D^3T;1Q;1.%1
M*FL1?2L_1F3GF0H, :*1>%8:'\=H"7,Z>V%HM+9VU_PG2/E#U0)41=T!JFH
M<5ON[);L##!H-X:BX2X3;XA4$HC/GI-(,:)WR44J:[=%>)*8/]0-_S&HJZ.N
M:KCK^DKBTV?\\]?7[S]_NGAS\>'UQ[//;_%OS]Z_.K_X]</'UW]]_?[3V[^]
M?OL>OWW][N+3IR,O*O9>KIOKB^.XKG2IL2QGNHN![M"+L;EUO!32B^+/!02;
M!0S5#7?>*6.4B+6OP)\@Y?ARIV\POH8WN-^WM7FZ&S]0^H[C_Z52T66YYXG1
M6"9FIL*]Q[UK%8$@J'<975U3^Q;G #+[#5!J(.=Q95.WNFK@)+Y[5[YJO'3_
M:E1*"]8QC5XK0^DI%H@7+A-(S,FH//?5O;\GB>DWZN@"6G7DW@" RB">B[S:
M*0.1HJ&EW(K[DOI4IO@#W!#OH@J49HN2J1XRK!'0KPVJI-1'/O^A$FX 'I]@
MX8[^!<8HFM'9.)VEJ^%X6,0R'WZ#E: &UDI+(W "TJ#5E&@_+56<!%?*9QP%
MJVL_OMF-LGXM3S> ZD G3;1=?@6X=AFO6K2#7%V5,.D?BV\'D#TU5FHBLBY%
M\8P2JZ4C0<B$L8^U@=7.HCU#3K_YC&Y054OZ#1BM7ZYGPS%Z=!CJAN%XP<)=
MQX(Y?C4;IH4$B[KNFU*>?RE?OATO'P5?Y"?^R5WO'C9PJCQ)3IDPR="6@T:Q
M@*<D4"^3==9 KCTW\$2L]9LZZ0;@+:*B@<U2W)-2L'HKZX'Q+$J>2I/^4F$M
M2V&. $_ !9<%. 90.X6W24._U<+=N8$'R[F!JO,[J=P_61NP*"2&Q(R@+Z%*
M#9<CKDR'I2Q']#Y"CKQVH?D6,OH]C3N-+@^4=0-P>3O^!LN6T$L>;A/:@Q2,
M3<Y28FR!O5%EIHPT!(RG/JE@,ZV=#'N*EGY/N2Z 4T7J#1Q*MW3?QC)H'1E*
M0Q'A'<8RB0NTFD82(3%H5DJR&&O'EQLD]'LD=8.5PV7<SGN[>PM9TKS+B[9?
M8?YEDN[WPFR X:Y5&>64/4<Y"6.(%<@;#TXG&4!X7?N@VHFP?E_E=8.JVOKH
MN;GR,@"8O1T_Z H\V](66#.M3-*,J"1%F6!>RH\%$&V5XIGCZ>TVC-36-LL[
M+]AOI\J:X.E.SNT8JD7OA_>3\>2A;W=K?:-+RC/A24R:E\>!0$).DD2* 20W
M,@&K?EWS+$7]#HGOQ*NNIX$F7*1U0[M,2UPC4ZO883*>_0)Y,H6[!L$P>_T=
MA8B:&X[]].8M2G:VO>ADH),'#"J )&%+[WLCB/4\$LL]<"%#LK;V.[P.V>EW
MFGWWAVQ_NF\BSERQN-K&JU%% \>5D0$YT!I**]J@B,N.DV MEP+/C%C]*>D3
MI.QVITE_//P=)_0?PH0.0-CL!/48*)=7BC8FXA,RF%V.RO)R--1N7?0R5;LA
MZH<JU:FLB@8,TX?;=1=5EZ^&WX8)QJED@!=^R/W(M-D Z1=*,$JHH6ARA:+$
MLIR($Y[%!)+&4/MR<W?J=@/;#U6\TY%JVHDUWL/\?D.=??/#T;+&>*W\?%69
M_(N?#>,@)T,M58*D$D?)Q#2QFD:2+03#@U5>U4Z/[$GB;BC\H9+\72JI ?NW
M.WNOAJ-KA/\@9Z8]@T1HLA2%J3/Q&) 1C/:#YLZ9^N_V]B9R-QS^4'<&W2JJ
M 23>-C:\?5UX)S5'A71  ^&F/"#/W**[BKZ%CA"CM11H=;/W%"V[X>J'NE^H
M(O8&HH1-/I;6V$3OD@9%E)0*F:"<>)",F,"X8BH)4_WJ>RLA_5;,UM'Q"\#9
M7^ -HN;6=DJA,\C%( F+.\HX26S6BO@L%%#PP*N_A'F"E'Y+8T^"G$.$WO-U
MT]]A>/D%:3[[AH'O):R_UKNXGL_F?KQXL7(K+2_1\XL>I153&;3,D+.H- $9
M.-=91= ;^8FM=T[[K;J;S?DAKBT[%GD#AFB#N_?75P&F%_D1?TLK:U%0U(5(
M#$83R)SQ)%A76J&:E!ECW.O:G=+V(K"?XZYKE$Q.I;(FZOR?8&]EK!]Q.:"E
M';XUC'!6AH=(C#F\\YR <#PR#R'0VD?FGB3V<Y2V@<HJ:FL"EUL&,]P.93CJ
MZ3[7(1CF([$L++I5&V(=?NL259*%%'6JW5&K(U9VL[X_1,E)2TIOP$MXD 0:
MR)0,:+00S**%6 P/]AI=<NT=NLV6YQ1K7T@\(*#?H+8)2#R7I-M+/PV :Y>Q
M-QBR#4N-8"R]2N 5+/][W_X$#PL4F"_O9#613GCB=*!$^C(4QW(;+*V,R..I
M[C?";A'&)T9"P]A_,YFB/S4^OT::QO'F\]2/9\C>\O'EXKO1$BEWEY%W\MFF
ML]74TBA2=-XG8ERRZ-^5)!G7GJ!.1!#@0U*U'U><E,&>^P.<&+T[;I[^H=3
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MB2)6I5*/R40(5J#<3MB?ZR%Q_4YG[ ADW:BF <QM<O-F.![.X=WP&Z050\D
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M,<-YF4%UQ"7@E@^I.'+O!0IKS1>^6^8^'ZB3 9&+?JDJH%+$:4F)THHG&I)
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M<,5KFPD53C)MP&97?5KT5DHJ7!:@!9T7J-])<BVUG!1E3G(2359$:A5(,&5
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MY\>4KVW]F)J-7EZBLEJ3E[N%;M8[&ZY=OB86%1I&"[P,'=2!V#)'ASF?6**
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MG*HVK7XZ1P&F. E)N@(^NVJ2T#*'3>9\;/O=>;L<I@37Y%H8_4(]L=9[C):
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M [7-!/C?YXL+>E?KZB2@L;7M9!*)^$!IER%2#6 UEA(PJ)1[M\MM2>+, ?6
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MSY=?J/%R<S)(%R(?6##"M29L42%I5,#&MQJ,3I;2N[OT&7+F3<9.#:E>>AC
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MV6M6.(/(/BK$ZK'&22W4OHMV#CZ@N9^!ZJ67XP#<]4(7*3Q?Z!B@JNJ9L2@
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M:JM$#JEW-\*+1(W9NML/7_OJ80!@O<>OZP[CJ_O[YC:_ZK"HJ!U58Z%B*TE
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MK\<:K[X]"=\L-(DUL%>@0%-JLT:JA""+!"]D"#D+@=A[4_M3M(P&IWTTOIQ
M_ / Z+IL[@U+K[W:M>>Y_UY<?+RYX&\VSIEBHU89:J:V!5Y&2#98\)*R*]F*
M:B8J8'R>L,'"OIX ZZ^8 =!V<VK62PW?+O&LO19?CS\X^_#M+/WT]=NOO\5
MP:N:E0+,@KU6S 3!8 &LE2B$B**[<[\/O?,6]4_@H!U,>0, ]7L.KH\S<N""
M->3_U]Z7-;>5[&B^SW_!=.[+RT38+KO:';Z6PW;=CGYB(#>;TS+I)BE7N7_]
M($EJL21*7/+HI&KZ1263JG.P?(D$D$@ D)%]IY57R/W(')@STMCBM&O>$.\^
M.L;=59\.!7<,XHDJZ0!6GQ>8\D[7@0L;C2L"#"^J'AU8"#7UK)@JD6N.RK1N
M%_4@06/?ZSU5W_.AA-\!DN[8]W=7]:7).^4YET"+C=>)AK4;5IT[5ER./.:8
MFH\^VDW-N#>5GB)-<9S@QRXDP>77-[^]??5V5@OSTF9\T_:: W[)$U^[;?O,
M@*?(:#5(!V@Y+3;FO9<LNA+V.?I[Y#6=Q8=':G(^C%A[,#+$SJU:]CNU[K]^
M</-.NO->V$"Q2=84_RI?-*"IL8D+ 9/RUF-K=^DD@CL+)D]#X].K</2V I7X
M?\WGZ>WL[8S6P PW4WU>XNP_ES?6H/;U@F",D"1+H+3V@,([2 EU%!B#P\=N
M#.S_MLZR]&TL7&,A]V#H;@OJFA4^8;623V<*6C!)4%E4HTU<12&E55YG9EJW
MG'N(GL[R"HW,5"L%-+1"0UQM>I=QF9?O<5$Y_9&/O[2TXT'MKB/M0VFCBT:;
M5UW=#A%!>TTN.L14<YK%4"060@13@G1>NV1*^Y$G-RDX?9#+<IGS^IF_Y65<
M3+]7'6Q"#RVXS8%ER%@KP+RF'=4I Z4PQB5#%PHV9VXG.2,WRS]>[W<'NK01
M>0=[T;VM/7G@G->\AXG5!**1%+$&"8RE8+4TD:?6N>^C6^@.B)=&2MZG7>XA
M$N\0-=M\69%)B%@R>"'KG6 5ZD#F ,*9Q!DBHWUT8-STD+0^7</[M<L]1-P=
M@&:]E*YNDE^V'&?9:8=,  5_M)301G"*9RC2DENOD/AHG8:^EY"^('.,AN]L
M4J>*NPO,W&>$KZ. XFU4(3CP41=0C$(!9-R )<]5)]K@>6S>J_1ADL;-ZPRU
M:;740R=]T\[6+"P_SS_F6?YSXQU.2"#,Y.C!.TLRXJP.0) %;&)"))O=G2SB
M@RW4[GM'CU[-D8J\IWW:R5+MPNC4>8W+R_:!9Q>K96V',9U]V:38)TZ6I%TN
M@)9^*(X!O$P(/EAC1;!>A]8S51^CJ4>S<QJJ!M'&J&GCZ[/F1_KK<BY\+HP#
M*WQ=T%Z[4#H/#K-Q3EK??@I[D^;'@Z66A\174VT\BX3@A\7T&RY^GI4RC1NA
M+D]-#3[PR-9)PGVI'R9=:#7G,LH,VA4#JF3RS1-YY"IS(U2BG0Z;C[Q]LG0A
M\]%JXRD:T)8!<:-IQS8)>-&\F)Q0\?:QV/-(%QZB]T/2A8>(?.26,9](^.M8
M\O<\_[+ [U^G$<_7N0W#9-91DH5$JT#57DOHZWW!))BDT$(;N5<-T",M8W82
M,#92&JEWWEK68P,F?[G-PN6$6J([F* AA[1>0Q(P<0Z%*QN8=^CVZV/V&&!V
M$3!>!YE&BIVWEO*84%E]7TS^^6+"59(VVT0<K]O^>T,N%D<P7GMF36+:/G1#
M;9GC__XR__$O]7$;4-3?;@!B\YH15=]&4?/CI3:VDM^^FW#F>8XUX8CUV-XG
M"^0_(V@>*&8K)2OST(GD7DI^^VZ\#D #*/E J8VMY/?_-JG.D%UWJ&*"=CWF
M Z#)#BR&HHU1^DY#Y\.5_/[?QFOO,X"2#Y3:V$K^_<4D^V!M'2O/G2?#8TH"
MIPB=(EB=@@I.EH>2%'LI^??]S/4@_7H&4/*!4AM1R>MK"XN?D[?O)S+ZDK7E
MH"7M,BKG""%P!5:SI#U:(\H^V_+VB1M5;_]QK>WK]XU3PM]>X4=*<.R%_>K%
MQ$N/II /RKT21&XA;ITG;KW74DB12G2G+NQ7^RWLYJ-"!EK8!TJMBS..AS.J
MQHJ8>&THF%,AMU(S<,$7"DYRXMI2X(JM&VX]VX/58X+\(?30#:S.ON=:QSG[
MLN;K<UY\.RN7U\HGSB8MDPG@R:.IOJP!'VFA,!5C=MP5LHF#(.LAJGK,(!T)
M@GL!UDPCG6+L:B[%!_RY*:"YR)-4I+',"6!>:% ZD-B$Y.!TED$&R_, I;W[
MT=:C,1L.;R=KIPO4/7(,S5+VI7IY3@02&@H'KD[5(5<O"N&B=Z+UH6V3HH#1
M#FU/0UE#;70]GF9S#O5J_NW[?%:7SKRL/WG]U_<\6YY\I>.QY[8^O#V(CV%.
M< D+@5QR!YX5<O)U/<Y7R"%+$9'<?VL>3#./?X+[JVU]-5^N)I:QY!EMWDP2
MQI4*"GSV$6IKJ.!116-;GTK?I6)L'^IH+=\IMSY-P!UL5O_$Q;2&)M<,%(:U
MP#< KD-;9S390TN6,4?M.2;R]UI?C[Y#Q-A.3S. G";>#O!Q37@4LEA$1DAV
M=<BM(V#7B0(R< PB&B52^U+&0_ PH'O2# _'B?-X',Q7>/XD;L<_<'6Q(+]]
MNUE?^O'3TPO&'G]R:]?C0%Z&<3Y*%-IK+J"H$LE.* 9>*U$O%\<L@DH$FZZ=
MC[W"NX^YIE-3K0=_,UU&//^/C(M)S(5K%!3P$:-U$J4#Y-'6H<E&*A,%5ZUO
MAQU/;5?.S"&H.2H>/UUA76QJ^V4>WM/2_OQG/O^1_S$G8[$DTQ^1*R: S#,9
M;9X\.*4L>..MJJW% QLK3W2;UJY<J,%A>:JRGA$HZX+[_.=\LFX^$8DIP2VY
M(=PF<!Q%/4:2/"7BO'G[CP-)[,IK>PH('J.:YX8\@E*N(^9*1"W BE)OFT8$
MYUF"G*S&'+VVOG4KOX.)'+<?S5CH.U@]SPQ_;^87BPG31F55FV#ZVB?1R@"^
M&%DC,!\Q^U)RZZX3A](X;G_)D=!WL')&ON#[(&\O"KWDBBLN?;'1&9 Z95!2
M!4#- SF\%KW26J3;%N_>Z[[[OW&<JI>& !I0P,_(9DT\:I52KI5"@427E*?0
M*#MPHEB6K//1M$ZG-CU:MAU#;%!E-$NZM3J_N9&'^GTQ7RY_FY(I)4G'O#G)
MO!(EEL)C00N!U2,(9CB$0*(TQB@ID@V.M?;.CJ-T+P"Z9P# )U!4[S;OCUF:
M+M>EK#F]_BO2GV[/UP472:>$D!T%WTKQVGY16#"6,1U"-LZT/S<X@M"1V_H\
M 8(.L9I-U-D!9G>P-]&:U9H2#\752FO',GB.#ECTM3E$2.V;0.\@92_<^6=K
M! \3]3,HL'GT=&ARJURHY5G7A#_]:==M?J[.N_ZE@33_/=?)U#GA#P+/E_S;
MUNA\Q%7&6;K\=K$^=;A9E'KRL>+)+VZMA[:2&.90DEO/& I:RKD.D1=&@3?(
MP3"=T'FME6]?ZS]<1=2E4%_<%?FVS_,DNQ2X6S=RJ0,=5<Z 21EP6M8,+R:7
M6Y_X'$IC5P>0AR#DX0VDL7*Z\T5N\??QSL+F$XG)6\$DH/<*% \:0A((QF54
MEND8=.LCGD-I[.J8<3#PG:J<KMV:5_,9<;F:AO/\X9*XVM5J]?/X/?;Q9[;;
M/@^DO]'.^#E_^SY?X.+G]E5DGL[G=;K.=9V8DAD#>= 12P:5HJK)I@1.\E1(
MPU:%UB'&HT2=/"CNUQ>\_/GJ')?+L_)I-8_;(5;:\8@2)5@6*$!,CA''QH&U
M9*NE4\%AZT[RCU,U[A[9%BMWYL>UU4D'&^55ZYN;G*Q;WT13)Q5;"S$X7^=K
M&T",!@+)1XHZ<".VK@S;24Q7F#I9Z_,A5- !EF[2O[V\S;UQG'Q'D+3L0 6?
M:>=& XDGY%9D&9LWK[M+Q;CH::3>V]-R3I-U!VCYE!=3<BBO_(@U*]N&Z+%D
MEYEDD#)QH93'.M-:@O-1K"O"I6N]L3U SL@S"D_4]&UKTTCL'2"HMN:?S];R
M>;'E(.18E-4,I*X#9+2D"-4FD@PJ@2S(G&/K>^QWJ1AYBF!;O)PHY Y@<GDQ
MJ*8SUG971,ZTY@ZRB$1_]!909P,L:DV28MF7H:Y=7=(P+D0&=FA.$GAG@-FN
MH*"#<\4P"+RFOZP2X(NH=YA=1.L,4[SU2(N[5(R[#YVFU0<@<H2(1RYF^Y1C
MG>U[]B,O9C5Y]68ZPUF<SKY4=CZ=O?FX-92.HRHQ&."<-E5E8JYC?LGX1O3U
MKGO0XI;W>V\EVYZOZP<>QVAT/JQX1T;,+8O[,2?ZH*KF [EC\[3I-:L%1IL5
M!-I$:5O-M?<+-^"#BTPECD+Z/="RQZO&O2TPT.XSA)C[1LUVF?E05Q)G9'TM
M>>U:U:&)WD.6-FF5?- ,3\?-F%O0(*K='S9'R+EOX)S-\N7D,704\A4&5O%:
M05Y[LRBC:0\W(<O,T=\^<ST&.U?OZQ8^QZAX?P =)^^^,?3YS_GE-IP*5RI:
MX@F)IRQI_7$*![/&0JZ@$2GO4Z^_[_O&"9U&Q]!Q\NX<0_4*U98KJ4VQ62C0
MZ_)*SCP$P7D=Q6F#CR)$L<^0M_W?.(X3-#Z.CI1YWTBJ]UJV3'E?8HPET?+(
M@GS'XNK1G@?CO<Y:JZR"/AU(UR\<Y_+CZ#@Z4N*=PVCZXW)M".5E2#6KZ2F"
M55)Y\)([$*B3=!I#2 VBL>L7CG.+<7P8'2?Q#K*$MQA[=]5"L0YN38PY(&[J
M:#JE* HQMEX4R(%I+F7S:62[:!GW8O; :>8F"NC+'JTE\W:YO,CIMXO%=/9E
MLT@^?25Y+]_G/]=?+2=1&VFS01"U/Z=*HHXMSW6\3#!&:"E3C(?;IOU>WE4I
MQI$ZWVV>!E! %]--;['Y 1=GBW5A0OHGGE_4*M\UBQ-;@@PND)5/:X^0:_!!
M:I ^B,R+\(FWKL'>D[2N3LQ.P]V02GD6]FS-WM5J^K"8QFMFLY3:U:1^B)&<
M24][ S(9*2;QA>FHR3<XPGT_G)"N<N1/9>=:*:8#]^S#8AYS3LLW)-O*#LYB
M7K?7OU/ O);%Q&GKBD)R-V/QH((5@&@+<)70>EZ83:U+C@XDL2MGKHT%'%))
M'6!P4SNS)GVG<1?%:ZUYANAYG6'+$J!!"RYDE9+-VIKF%9*/DS5N3YU!L-9:
M&1W@ZXZ<Z#]IK:7-NJFWV*^]B!R$2F2_67$4:J'V@#$$,%QK&Y/0O'F7TT/H
M&[<)SU/X=^W4TY>3=UGY\=OTQS3E6:I5&B]Q.5U^(N(P34A\Y,'6H#Z8M?N:
M@&(E!C'Q**00@M^^G+./1_?(6\=MN#.T^]92Y'V!Z29'V[NG^"6_F,TN\/SM
M+"[JI<"WL_KM1,7$'!:*NG5M=B!J6^^@'?!,\7@PBGMWQ+GC_@2,VU)G:(@-
MI(B^T';#T]S\NEP;9PI[)L&5%!RW=1)2K"5K&D)1$1Q*)F)$68H['%V[7SAN
M;Y*AT=1(T'VAY\99QC92WJZ226"*PF%+F[F26"ODR?ZZ4GGR2FC)L(AT.'AV
MOF^_G"Q[KN!I(^<._/7+_GAGY=*Z+G\-<%_,TK5KN EY#5E6J4H =$F#DIE"
MWA D6*>TTK84[UMG9(\@<S\$/H]C@:?25E_&[-9^_]O\_!P7EW/;HA?.1 =>
MUK2+# 4",P$<CY9G6G:L[%/'OO\;]X/3\\CV#RCKOA#T(I)7N![ .[^VV.O\
M"BV4JR4T$4PG%S""%:K>>LT,@A,!HHM.1"^S]/QP,.WW\OUP]6RS^@-HH.MV
M*N_FRR6MGVUFKZ91ZBC#B\W3Y^4U+FHCF>7W;8[EA#YFQ[VH8=^R!IPVZL9R
M^:[+S-6-AH8Q,($>G*$?BM6\:5$2<HF%0(7(;>L[<KMH.=51>Y]7%./.O^4J
M]Q<_2)8UV_)Y?B.'_'5^3M9B6;,N<2(CK9S:H,AZ+2B&89$< $X+3"=5G#8U
MY]*8]0-)'+=LHPEF;OMG0RJI@V!A?_9^FYY?K'*:2!6$,9IB(%'' ?!@ZSQ,
M"9B#0>Z(1]&Z\.Q@(L<MXQ@9A\<HJ@,DWNK0]OZBEFN>E4U1U(TIS]ME1HO*
M\R2 6:UHF7E;;V4J2&A0B,*BC:W/F0XB<-S"CD$0.)R"^D7?=BW=X7'"++=>
M< V!>S+SQ0@(B1%[FD<6BY5&MVZ"?B")XQ9R/"4"FRBI PS>EMEZ(5T)SF(0
MR,B2<QXR,1,S.,MJL_:8'5=<:6S=JO=!@L8MWA@$7^T4T"N:)D+K8)20P$0I
MH$*LO79U!(]:FL(=$H=/@:*^(H43%+T/A Z2>H?0N?0HK28F-(G#2FE I>P!
M=?# M"'/,J?  A\8/%TZ^,/!YQC)/[-DVHO9:IHJF],?>=V3Y=0AXP>^8<CT
MV0&\#9TWDT8&RV. J.H(4R9#W2$9>"XRP3+YTGP$]U!YLT_Q:TX7Y_FLW"_?
MUW_%\PL29:WWO9' /"NW"=K<#C.)S+,J'H35Y#%8I\$K-! DBRJ**!EOW92]
M+0=][:5'(>Y._\CQ5-S!_GLBSR]_WO^ =?<:7QQM')Q#4E44*#/X)!$D0QE+
M*3G+UFT)!V1GY*:[(Z)TWB=DNET][_';9<<XK2)'PR,D+ Q4U(ILDBP@G/+)
M.&.3;!U)/T;3N#CN!CQ[@?I(38Y<QO QT[8XC:MM5<\?L^EJ^?'3'U6(9;[X
M5N\D41B1TWU_]^%E_<L7L_0N;S)?-[Y[1]]L6QMHFW6R04&46M99;P+0) 3&
M<]+".;(?^]0\#$]ICV@_%E7S;E7<@2E^3?':_&?>E*V=K0M%+MM+Y>AEO<RN
M1-:@?+UWK!!!*)]K2TU.H&P=CNPB9MQDPB!P;*N #I!T51/Y2X_PY"G J'DU
M%5@DT00!(4@#.EC/E)=:Q-8)J7L)&?>T;U $G2[X#M!SXV+ ;SFL+AN3F9Q9
M\!:X(!.JF*( 5:("E72@-<"8M>W;^-]#R+@G=8.BYW3!=X">$]WC=U<%F%):
MIIGUD+TE29)4B>]4SZ8L^IBE8J'UH7$KVL?=(_\^@?9Q8'C^BV!;=ZXQ1)1<
M %M?XBO)DO]*RU]S';.30I;8NO]%$\)[C%B&QEQ;X!\!@*X/LM8>=:CA7&4[
MSY;KQ][_Z>N_ZJ\G5(:?\+)VQUNM.&YTTG4]=+'V<KE^]<=\7EMNO)HO5\LU
M\M;$75ZSNCJ=<#;9K)"6@N6T%!QR\+$HJ%<DN,Z!!]YZ+SZ-XG:G9E=!85[\
MF,9\>83]JP9?G*\?N5[+'W.<?YE-_YN(6C=P6E.ZW4J=*>A0UILDAL1H X3L
M.) ,4RKT[\1;^]"#,#*N@7]"+.\^:1L+%CTX-W_B(GVF/UZGK)VG?4B93)YA
MI."V6 IXL/(B8Z*]*PGOF[OI-PGHY5!K-$#<]CR.UDX'T-HAM<4"9U_6 SN7
M+W]>_\UV::\YOF9[ECZ<X^Q&2.ZRQNQ+A.Q4[;P2Z_21=4(XNBC)DXJE><G"
M 'R,[%4?#ZO;-G1L'7> \]V99N.%Y<XXB,H3(]()\$[7ZP LF6!]\;QYY=%)
MJ?[A3.OH.-G[>. 0I76 OAU';Y?Y1BD2,\8"S_4N"G$&Z)R%S"WQJ8NGZ+<Q
M A\D:.1D6F\H;*>\D<_X'SZ[Q2B"M<& JR<EY/+0DN*Q'IQ$8VCOR?KVJ/M[
MC^=//UD?[""J&V2U5<:HO=4K*WL5$%SS%D4JC%L-5@9R912R.F"; P\12W3,
M!1;V -IA;QWW$*LKY VHK@ZVVLTMY'5?VRK$=]OH;S.L-]CLE> 4Y7D/RCM'
M3C1GD(M*)B7%F6J=WG^ G%[.K'J)HUMIKE\0;A>NL2BMDAGX^I@#ZZBH7&I4
MQXM+*5JG6X?'#Q(T;M313.W[P>D('70 J+K$SLHG/,^79MG4+AXR1V"1I*(X
MS^ **Y!8"$;+H+UIW6CF#A%= N<8!=\I"SE%VAW Y5,^IZ^^_)YGY&.>D^OP
M(GV;SJ8U'U_/1[?'7Y?,Y:)3KMP807ZFBI[,-T,#.@<*K-%&[ULWJSB(P'$W
MRN%@-IR6.H!@&Z_BNC9 27)H=<B@+;JZ%10(/ 30(BC/I2_I=L>\=FFZ-BR,
M'/QVY^^-B9 .%LB6LVUCD#N,;U?_A.P+C^@#+?N<B2MO*E<)6"H9=62^8.O1
M*/M1-O*USC'!<_L L+TFGV%MT8N4IO6_M3/^.K^PWB4;UQ0]^)*A:XGVY["3
M&B(CC=;: EI9YXH6#\CI-^ZBR<E[ ESK2RSCUA"U,0JO\/MTA>?UTVU5H(G:
MFD"+UL420)&W7YT\13\$>INRR]BG[W&'E>==1W0 GH=Q-DZ#QC,TZI=>XWPS
MKW@ML75*>OG[ F>DL^9%H_N^</#"T:,X[\/P%Q9TUL:#2<E3*$I!*6%1@1<N
M!EI!R%'_K0S_=7!S_$G+)J!A,<@B26J6UPEDBED(6D3@3!A>C*!5WGK21#/B
MG[5Q/P2SNXM$GU+]/<20O]2(>84^N7I;05"4H;A-@(%S,"S64?*YZ-+\]DJ/
MA:%/"H('BT$/T4@'<!KDF%I'KW1B%.P*'4%9$H3/G,)>"K=3#%'EU+J^[N]>
M#'H0K)ZB&/00'7> \X<KNJRWC 5$*&I=\, D>%-K"VUM2AZ2$,U=@-/+\9Y7
M4>A!>#FH'.\0Y8U<CG=@'8Y)UO%H(K@DZMCO3)PA1;]UG)8443COU",AUT!E
M4\^K%/08[ VLK@Y,XJ.BWB7IZQ0Z<A6$4Z9.%:D<%W+>;120?732Z*R*:WTO
MZ72J>RG"&M-G?6+=/V>T;T:,O9W1TK_8S$5<?<V+SU]QMKF>L$D.+=_.-DG#
M"8F=9V5H.\J&U)*UA. Q "8O:NVD8:QU)N:I>.O<+6F,V59+9D@ =9U?WI31
M?,:_3FF>?<]#VN6!'Z.P46[WZC77";.K)%B(4BC!#0BI:NNS$B!PR2 $Z[/F
MUAC6.E9^@)PV5;#TZ.T)^,L\RV5*7*(4@M.:,RP3IG5"0*T21(8&G43,O'6#
MTQVD]%# >#H2[J]\/4WN'6S2KTO)L1;"7?%31\6^FL]6T]G%=/;E['M>K'6U
MG%CK21[6 LM,U%,X 0$] Z^Y+YH7*5CKD'U_ZGHH7VP/LH&T<SCN_ 9WL_RE
M'C-\;@:_.C+VZE3XSQKV_;:EAWA]L5SFU:NO=;=_.]L>!?L4%1=!@Y?)@8JT
M2_O$&12#T6;)0BZMRV@/I7'<$L2AH#BHIDX%Y,EIHKJR<LS3'S7.6[[XLLAK
M!_.N>9?)<![(2Y1>*5!%%W(53:A,YD0!8#3&/.)?'?*^<6_4M<;28)+N8"/]
M8[:X*F8A9K9<+"?.::&C=&"5KP6)+E-806)SVA4=K. \MKY"LH.4<8>U#667
M6LA][.GV-Y?$U8J@V#32?\[**UQ^_80_UHWT<)H^S]=![W;0ZX1+I:P5@6)7
MS8C/(FG+)X,;R-FTDEL6;B<_'C=(!]*P%[#,<P'6DVJD\VS"C[Q<K1,HT]DF
MI_*/O/HZ3YLO\FE)AGV?W3+W<!0_K:9RW7GAIC9GEOYM/IVM_DG_(.A>U^H$
MDR/WA"!;> '%:?_S:!04';UQ01D,S:<T'D9BPVZ$][]XDW6WR3"M,H)TG!P!
M62,;+P6(&)C"%!-+S6_.[479R)<S!L33 PT"6VEJQ#UWN5A-/M9895WG0?$(
M%D3R$03W52Z&M@<BOP23K#0AQ[C7B1H]]0:TZ%_7L/KEA;T4<+73Y/Q4L?:
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MJ<T207NL01_FFI$L2H#+2H'S(J*HQP]6#26K ?CI)*5]*BIWFO.Q(=!31/)
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M(/ ]E=I:9Z1W9ONV7]0?@:C]/__K_P%02P,$%     @ %IVC5DOJ ^6#,P
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M[18^'6=P-ODXRI(L?_&7 _KO)7ZR-U8SDRQ>_->UF>DBN-2WP<=LIM+_"@N
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MIBP(_\3@2L31^-_")H:^RG ;@GN S5C%R?FMZ.PTF#[?W&.)S:QMC<0\*PK
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M4$L! A0#%     @ %IVC5LM$![ Y"   *BP  !0              ( != @
M &$S,S$R,V5X:&EB:70S,3(N:'1M4$L! A0#%     @ %IVC5EP K;?<!
M8!4  !0              ( !WQ   &$S,S$R,V5X:&EB:70S,C$N:'1M4$L!
M A0#%     @ %IVC5N2Q4(O,!   -!4  !0              ( ![14  &$S
M,S$R,V5X:&EB:70S,C(N:'1M4$L! A0#%     @ %IVC5JG#[J=;IP( ;WD;
M !               ( !ZQH  &5V:"TR,#(S,#,S,2YH=&U02P$"% ,4
M"  6G:-6[UH81;,8   Y'@$ $               @ %TP@( 979H+3(P,C,P
M,S,Q+GAS9%!+ 0(4 Q0    ( !:=HU8MS7.M/B8  .>& 0 4
M  "  57; @!E=F@M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( !:=HU9]
MM&<[]7\  $K !0 4              "  <4! P!E=F@M,C R,S S,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( !:=HU:3(UY)U34! ,?1#  4              "
M >R! P!E=F@M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !:=HU:J!HN!
MS\X  ,]0"0 4              "  ?.W! !E=F@M,C R,S S,S%?<')E+GAM
M;%!+ 0(4 Q0    ( !:=HU9+Z@/E@S,  %U) 0 .              "  ?2&
F!0!E>&AI8FET,3 V+FAT;5!+!08     "P + ,@"  "CN@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
